PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for obesity in adults: Recommendations and rationale	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENTION	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for obesity in adults based on the USPSTF's examination of evidence specific to obesity and overweight in adults and updates the 1996 recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. The summary of the evidence is also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse.	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Agency for Healthcare Research & Quality	Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							*AM AC FAM PHYS, PER HLTH EX REC GEN; Douketis JD, 1999, CAN MED ASSOC J, V160, P513; Franz MJ, 2002, DIABETES CARE, V25, P148, DOI 10.2337/diacare.25.1.148; Nawaz H, 2001, AM J PREV MED, V21, P73, DOI 10.1016/S0749-3797(01)00317-8; *US DEP HHS PUBL H, 1998, NIH PUBL	5	233	236	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					930	932		10.7326/0003-4819-139-11-200312020-00012	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644896				2022-12-28	WOS:000186884800007
J	Pauly, D; Alder, J; Bennett, E; Christensen, V; Tyedmers, P; Watson, R				Pauly, D; Alder, J; Bennett, E; Christensen, V; Tyedmers, P; Watson, R			The future for fisheries	SCIENCE			English	Article							MARINE; MANAGEMENT	Formal analyses of long-term global marine fisheries prospects have yet to be performed, because fisheries research focuses on local, species-specific management issues. Extrapolation of present trends implies expansion of bottom fisheries into deeper waters, serious impact on biodiversity, and declining global catches, the last possibly aggravated by fuel cost increases. Examination of four scenarios, covering various societal development choices, suggests that the negative trends now besetting fisheries can be turned around, and their supporting ecosystems rebuilt, at least partly.	Univ British Columbia, Fisheries Ctr, Sea Around Us Project, Vancouver, BC V6T 1Z4, Canada; Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA; Dalhousie Univ, Sch Resource & Environm Studies, Halifax, NS B3H 3J5, Canada	University of British Columbia; University of Wisconsin System; University of Wisconsin Madison; Dalhousie University	Pauly, D (corresponding author), Univ British Columbia, Fisheries Ctr, Sea Around Us Project, Vancouver, BC V6T 1Z4, Canada.	d.pauly@fisheries.ubc.ca	Bennett, Elena/A-9553-2008; Tyedmers, Peter H/I-7490-2012; Pauly, Daniel Marc/AAY-2316-2021; Watson, Reg A/F-4850-2012; Tyedmers, Peter/N-1334-2019; Christensen, Villy/C-3945-2009	Tyedmers, Peter H/0000-0002-5150-0756; Watson, Reg A/0000-0001-7201-8865; Tyedmers, Peter/0000-0002-5150-0756; Bennett, Elena/0000-0003-3944-2925; Pauly, Daniel/0000-0003-3756-4793; Christensen, Villy/0000-0003-0688-2633				Bennett EM, 2003, FRONT ECOL ENVIRON, V1, P322, DOI 10.2307/3868093; Christensen V, 2003, FISH FISH, V4, P1, DOI 10.1046/j.1467-2979.2003.00103.x; Christensen V, 1998, J FISH BIOL, V53, P128, DOI 10.1006/jfbi.1998.0809; CHRISTENSEN V, IN PRESS B MAR SCI; Cury P, 2001, FISH FISH, V2, P162, DOI 10.1046/j.1467-2960.2001.00044.x; HEINBERG R, 2003, PARTYS OVER OIL WAR; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Macinko Seth, 2002, WHO OWNS AM FISHERIE; Morgan LE, 2003, SHIFTING GEARS ADDRE; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; Okey TA, 2003, MAR POLICY, V27, P193, DOI 10.1016/S0308-597X(03)00002-2; Parrish RH, 1998, GLOBAL VERSUS LOCAL CHANGES IN UPWELLING SYSTEMS, P525; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; Pauly D, 2002, NATURE, V418, P689, DOI 10.1038/nature01017; Pauly D., 2003, PERFECT OCEAN STATE; Pauly Daniel, 2000, P227; Peterson GD, 2003, CONSERV BIOL, V17, P358, DOI 10.1046/j.1523-1739.2003.01491.x; *PEW OC COMM, 2003, AM LIV OC CHART COUR; Pitcher TJ, 2001, ECOL APPL, V11, P601; Pitcher TJ, 2002, FISH FISH, V3, P317, DOI 10.1046/j.1467-2979.2002.00093.x; POPE J, 1989, DANA-J FISH MAR RES, V8, P33; TYEDMERS P, 2003, IN PRESS ENCY ENERGY, V2; *UN ENV PROGR, 2002, GLOB ENV OUTL, V3; Watson R, 2001, NATURE, V414, P534, DOI 10.1038/35107050	26	333	347	1	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1359	1361		10.1126/science.1088667	http://dx.doi.org/10.1126/science.1088667			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631031				2022-12-28	WOS:000186683500041
J	Schlechte, JA				Schlechte, JA			Prolactinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SECRETING PITUITARY-ADENOMAS; LONG-TERM THERAPY; HYPERPROLACTINEMIC AMENORRHEA; FOLLOW-UP; DOPAMINE AGONISTS; BROMOCRIPTINE TREATMENT; CABERGOLINE TREATMENT; PLASMA PROLACTIN; NATURAL-HISTORY; WOMEN		Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa	Schlechte, JA (corresponding author), Univ Iowa Hosp & Clin, Dept Internal Med, MRF 157, 200 Hawkins Dr, Iowa City, IA 52242 USA.	janet-schlechte@uiowa.edu		Schlechte, Janet/0000-0002-4089-0445				ARAFAH BM, 1995, J CLIN ENDOCR METAB, V80, P3507, DOI 10.1210/jc.80.12.3507; ARON DC, 1995, WESTERN J MED, V162, P340; BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220; BRODSKY JB, 1980, AM J OBSTET GYNECOL, V138, P1165, DOI 10.1016/S0002-9378(16)32785-5; CARTER JN, 1978, NEW ENGL J MED, V299, P847, DOI 10.1056/NEJM197810192991602; Colao A, 2003, NEW ENGL J MED, V349, P2023, DOI 10.1056/NEJMoa022657; Colao A, 1997, J CLIN ENDOCR METAB, V82, P876, DOI 10.1210/jc.82.3.876; CORENBLUM B, 1993, FERTIL STERIL, V59, P671; David SR, 2000, CLIN THER, V22, P1085, DOI 10.1016/S0149-2918(00)80086-7; DERIVERA JL, 1976, CLIN ENDOCRINOL, V5, P273, DOI 10.1111/j.1365-2265.1976.tb01953.x; Di Somma C, 1998, J CLIN ENDOCR METAB, V83, P807, DOI 10.1210/jc.83.3.807; DORRINGTON J, 1981, NATURE, V290, P600, DOI 10.1038/290600a0; FAHY UM, 1992, GYNECOL ENDOCRINOL, V6, P183, DOI 10.3109/09513599209015553; FEARRINGTON EL, 1983, AM J CARDIOL, V51, P1466, DOI 10.1016/0002-9149(83)90336-3; GEN M, 1984, J CLIN ENDOCR METAB, V59, P463, DOI 10.1210/jcem-59-3-463; GOLD EB, 1983, FERTIL STERIL, V39, P753; JARRELL J, 1980, FERTIL STERIL, V33, P49; Jasonni VM, 1991, ACTA OBSTET GYN SCAN, V70, P493, DOI 10.3109/00016349109007166; Jeffcoate WJ, 1996, CLIN ENDOCRINOL, V45, P299, DOI 10.1046/j.1365-2265.1996.00824.x; JOHNSTON DG, 1984, LANCET, V2, P187; KLETZKY OA, 1989, FERTIL STERIL, V51, P269; KLIBANSKI A, 1988, J CLIN ENDOCR METAB, V67, P124, DOI 10.1210/jcem-67-1-124; KONOPKA P, 1983, AM J OBSTET GYNECOL, V146, P935, DOI 10.1016/0002-9378(83)90968-7; LIUZZI A, 1985, NEW ENGL J MED, V313, P656, DOI 10.1056/NEJM198509123131103; Losa M, 2002, J CLIN ENDOCR METAB, V87, P3180, DOI 10.1210/jc.87.7.3180; MARCH CM, 1981, AM J OBSTET GYNECOL, V139, P835, DOI 10.1016/0002-9378(81)90553-6; Melmed S., 2002, PITUITARY; Molitch ME, 2002, PITUITARY, SECOND EDITION, P455; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; MOLITCH ME, 1985, NEW ENGL J MED, V23, P1364; MOULT PJA, 1982, CLIN ENDOCRINOL, V16, P153, DOI 10.1111/j.1365-2265.1982.tb03159.x; Naidich MJ, 1999, ENDOCRIN METAB CLIN, V28, P45, DOI 10.1016/S0889-8529(05)70057-8; Passos VQ, 2002, J CLIN ENDOCR METAB, V87, P3578, DOI 10.1210/jc.87.8.3578; RASMUSSEN C, 1987, FERTIL STERIL, V48, P550; Ricci E, 2002, REPROD TOXICOL, V16, P791, DOI 10.1016/S0890-6238(02)00055-2; Robert E, 1996, REPROD TOXICOL, V10, P333, DOI 10.1016/0890-6238(96)00063-9; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; SCHLECHTE J, 1987, J CLIN ENDOCR METAB, V64, P1021, DOI 10.1210/jcem-64-5-1021; Schlechte J, 1980, Endocr Rev, V1, P295; SCHLECHTE JA, 1986, J CLIN ENDOCR METAB, V62, P1296, DOI 10.1210/jcem-62-6-1296; SERRI O, 1983, NEW ENGL J MED, V309, P280, DOI 10.1056/NEJM198308043090505; SIEVERTSEN GD, 1980, J CLIN ENDOCR METAB, V50, P846, DOI 10.1210/jcem-50-5-846; SISAM DA, 1987, FERTIL STERIL, V48, P67; SLUIJMER AV, 1992, FERTIL STERIL, V58, P72; SNYDER PJ, 1973, J CLIN INVEST, V52, P2324, DOI 10.1172/JCI107421; STEINER J, 1976, BRIT MED J, V1, P1186, DOI 10.1136/bmj.1.6019.1186; StJean E, 1996, CLIN ENDOCRINOL, V44, P305, DOI 10.1046/j.1365-2265.1996.663486.x; URBAN RJ, 1991, AM J OBSTET GYNECOL, V164, P147, DOI 10.1016/0002-9378(91)90645-8; VANTVERLAAT JW, 1991, CLIN ENDOCRINOL, V34, P175, DOI 10.1111/j.1365-2265.1991.tb00289.x; Verhelst J, 1999, J CLIN ENDOCR METAB, V84, P2518, DOI 10.1210/jc.84.7.2518; WANG C, 1987, CLIN ENDOCRINOL, V27, P363, DOI 10.1111/j.1365-2265.1987.tb01163.x; WARFIELD A, 1984, ANN INTERN MED, V101, P783, DOI 10.7326/0003-4819-101-6-783; WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403; YEN SSC, 1974, J CLIN INVEST, V53, P652, DOI 10.1172/JCI107600; ZARATE A, 1983, ACTA ENDOCRINOL-COP, V104, P139, DOI 10.1530/acta.0.1040139	55	154	162	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2035	2041		10.1056/NEJMcp025334	http://dx.doi.org/10.1056/NEJMcp025334			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627789				2022-12-28	WOS:000186642900009
J	Ziemelis, K				Ziemelis, K			Hydrocarbon reservoirs	NATURE			English	Editorial Material																			0	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					317	317		10.1038/426317a	http://dx.doi.org/10.1038/426317a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628059	Bronze			2022-12-28	WOS:000186660800051
J	Arroll, B; Khin, N; Kerse, N				Arroll, B; Khin, N; Kerse, N			Screening for. depression in primary care with two verbally asked questions: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL LITERATURE; MENTAL-DISORDERS; DIAGNOSTIC-TEST; USERS GUIDES; ARTICLE; CIDI	Objective To determine the diagnostic accuracy, of two verbally asked questions for screening for depression. Design Cross sectional criterion standard validation study. Setting 15 general practices in New Zealand. Participants 421 consecutive patients not taking psychotropic drugs. Main outcome measures Sensitivity, specificity, and likelihood ratios of the two questions compared with the computerised composite international diagnostic interview. Results The two screening questions showed a sensitivity and specificity of 97% (95% confidence interval, 83% to 99%) and 67% (62% to 72%), respectively. The likelihood ratio for a positive test was 2.9 (2.5 to 3.4) and the likelihood ratio for a negative test was 0.05 (0.01 to 0.35). Overall, 37% (157/421) of the patients screened positive for depression. Conclusion Two verbally asked questions for screening for depression would detect most cases of depression in general practice. The questions have the advantage of brevity As treatment is more likely when doctors make the diagnosis, these questions may have even greater utility.	Univ Auckland, Fac Med & Hlth Sci, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; Univ Auckland, Dept Psychiat, Auckland 1, New Zealand	University of Auckland; University of Auckland	Arroll, B (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Gen Practice & Primary Hlth Care, PB 92019, Auckland 1, New Zealand.	b.arroll@auckland.ac.nz	Kerse, Ngaire/AFF-8119-2022					ANDERSEN SM, 1989, MED CARE, V27, P869, DOI 10.1097/00005650-198909000-00003; ANDREWS G, 1995, AUST NZ J PSYCHIAT, V29, P124, DOI 10.3109/00048679509075901; Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Dowrick C, 1995, FAM PRACT, V12, P461, DOI 10.1093/fampra/12.4.461; Gilbody SM, 2001, BRIT MED J, V322, P406, DOI 10.1136/bmj.322.7283.406; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; Nease DE, 2003, J FAM PRACTICE, V52, P118; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Steer RA, 1999, GEN HOSP PSYCHIAT, V21, P106, DOI 10.1016/S0163-8343(98)00070-X; *WHO, COMP INT DIAGN INT; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Wittchen HU, 1998, SOC PSYCH PSYCH EPID, V33, P568, DOI 10.1007/s001270050095	15	319	329	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	2003	327	7424					1144	1146		10.1136/bmj.327.7424.1144	http://dx.doi.org/10.1136/bmj.327.7424.1144			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615341	Green Published, Bronze			2022-12-28	WOS:000186622100022
J	Vatten, LJ; Skjaerven, R				Vatten, LJ; Skjaerven, R			Effects on pregnancy outcome of changing partner between first two births: prospective population study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERINATAL-MORTALITY; RISK; PREECLAMPSIA; RECURRENCE; SMOKING	Objective To compare the effects on pregnancy outcomes of changing partner between the first two births with having the same partner for both births. Design Prospective population study. Setting Norway. Participants 31683 women who changed partner between their first two births and 456 458 women with the same partner for both births. Results After adjustment for maternal age and education, interval between births, and decade of birth, the risk of adverse pregnancy outcomes was higher for the second birth for women who changed partner between their first two births compared with those who had the same partner for both births: preterm birth (<37 weeks; relative risk 2.0, 95% confidence interval 1.9 to 2.1), low birth weight (<2500 g; 2.5, 2.3 to 2.6), and infant mortality (1.8, 1.6 to 2.1). For the first birth, the risk of these adverse pregnancy outcomes was only slightly higher for mothers who subsequently had a second birth with another partner. Conclusion Women who change partner between their first two births are at an increased risk of delivering a preterm, low birthweight baby with an increased risk of infant mortality compared with women who have the same partner for both births.	Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, NO-7489 Trondheim, Norway; Univ Bergen, Dept Publ Hlth & Primary Care, NO-5021 Bergen, Norway	Norwegian University of Science & Technology (NTNU); University of Bergen	Vatten, LJ (corresponding author), Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, NO-7489 Trondheim, Norway.	lars.vatten@medisin.ntnu.no	Vatten, Lars/AFK-2073-2022; Vatten, Lars/AAF-9380-2022					Basso O, 1999, AM J EPIDEMIOL, V150, P598; Dekker G A, 1998, Obstet Gynecol Surv, V53, P377, DOI 10.1097/00006254-199806000-00023; Heck K E, 1997, Matern Child Health J, V1, P81, DOI 10.1023/A:1026218322723; Hoffman S, 1996, PAEDIATR PERINAT EP, V10, P380, DOI 10.1111/j.1365-3016.1996.tb00063.x; Jacobsen G, 1997, ACTA OBSTET GYN SCAN, V76, P14; Li DK, 1999, EPIDEMIOLOGY, V10, P148, DOI 10.1097/00001648-199903000-00011; Lie RT, 1998, BRIT MED J, V316, P1343, DOI 10.1136/bmj.316.7141.1343; McMunn AM, 2001, SOC SCI MED, V53, P423, DOI 10.1016/S0277-9536(00)00346-4; Melve KK, 1999, AM J EPIDEMIOL, V150, P756; Parker Jennifer D., 1994, Annals of Epidemiology, V4, P271; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; Skjaerven R, 2002, NEW ENGL J MED, V346, P33, DOI 10.1056/NEJMoa011379; *STAT NORW, 2000, C617 NOS; WILCOX AJ, 1993, AM J EPIDEMIOL, V137, P1098, DOI 10.1093/oxfordjournals.aje.a116613	14	25	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	2003	327	7424					1138	+		10.1136/bmj.327.7424.1138	http://dx.doi.org/10.1136/bmj.327.7424.1138			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615338	Green Published, Bronze			2022-12-28	WOS:000186622100019
J	Bradshaw, HD; Schemske, DW				Bradshaw, HD; Schemske, DW			Allele substitution at a flower colour locus produces a pollinator shift in monkeyflowers	NATURE			English	Article							QUANTITATIVE TRAIT LOCI; REPRODUCTIVE ISOLATION; FLORAL TRAITS; MIMULUS; EVOLUTION; GENETICS; ADAPTATION	The role of major mutations in adaptive evolution has been debated for more than a century(1,2). The classical view is that adaptive mutations are nearly infinite in number with infinitesimally small phenotypic effect(3), but recent theory suggests otherwise(4). To provide empirical estimates of the magnitude of adaptive mutations in wild plants, we conducted field studies to determine the adaptive value of alternative alleles at a single locus, YELLOW UPPER5-7 (YUP). YUP controls the presence or absence of yellow carotenoid pigments in the petals of pink-flowered Mimulus lewisii, which is pollinated by bumblebees(5,8-10), and its red-flowered sister species(11) M. cardinalis, which is pollinated by hummingbirds(5,8-10). We bred near-isogenic lines (NILs) in which the YUP allele from each species was substituted into the other. M. cardinalis NILs with the M. lewisii YUP allele had dark pink flowers and received 74-fold more bee visits than the wild type, whereas M. lewisii NILs with the M. cardinalis yup allele had yellow-orange flowers and received 68-fold more hummingbird visits than the wild type. These results indicate that an adaptive shift in pollinator preference may be initiated by a single major mutation.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Michigan State Univ, WK Kellogg Biol Stn, Hickory Corners, MI 49060 USA	University of Washington; University of Washington Seattle; Michigan State University; Michigan State University	Bradshaw, HD (corresponding author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.							Beardsley PM, 2003, EVOLUTION, V57, P1397, DOI 10.1111/j.0014-3820.2003.tb00347.x; BRADSHAW HD, 1995, NATURE, V376, P762, DOI 10.1038/376762a0; Bradshaw HD, 1998, GENETICS, V149, P367; Fisher, 1958, GENETICAL THEORY NAT; Gillham NW, 2001, GENETICS, V159, P1383; GRANT V, 1994, P NATL ACAD SCI USA, V91, P10407, DOI 10.1073/pnas.91.22.10407; HIESEY WM, 1971, CARNEGIE I WASH PUBL, V628; Hodges SA, 2002, AM NAT, V159, pS51, DOI 10.1086/338372; Mauricio R, 2001, NAT REV GENET, V2, P370, DOI 10.1038/35072085; ORR HA, 1992, AM NAT, V140, P725, DOI 10.1086/285437; Orr HA, 1998, EVOLUTION, V52, P935, DOI [10.2307/2411226, 10.1111/j.1558-5646.1998.tb01823.x]; Ramsey J, 2003, EVOLUTION, V57, P1520, DOI 10.1111/j.0014-3820.2003.tb00360.x; Schemske DW, 1999, P NATL ACAD SCI USA, V96, P11910, DOI 10.1073/pnas.96.21.11910; VICKERY RK, 1995, GREAT BASIN NAT, V55, P177	14	543	568	6	297	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					176	178		10.1038/nature02106	http://dx.doi.org/10.1038/nature02106			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614505				2022-12-28	WOS:000186517200042
J	Buvanendran, A; Kroin, JS; Tuman, KJ; Lubenow, TR; Elmofty, D; Moric, M; Rosenberg, AG				Buvanendran, A; Kroin, JS; Tuman, KJ; Lubenow, TR; Elmofty, D; Moric, M; Rosenberg, AG			Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTOPERATIVE PAIN; PREEMPTIVE ANALGESIA; RADICAL PROSTATECTOMY; EPIDURAL ANALGESIA; ROFECOXIB; SURGERY; MORPHINE; ARTHROPLASTY; REHABILITATION	Context Controlling postoperative pain after knee replacement while reducing opiod-induced adverse effects and improving outcomes remains an important challenge. Objective To assess the effect of combined preoperative and postoperative administration of a selective inhibitor of cyclooxygenase 2 on opioid consumption and outcomes after total knee arthroplasty (TKA). Design, Setting, and Patients Randomized, placebo-controlled, double-blind trial conducted June 2001 through September 2002, enrolling 70 patients aged 40 to 77 years and undergoing TKA at a university hospital in the United States. Interventions Patients were randomly assigned to receive 50 mg of oral rofecoxib at 24 hours and at 1 to 2 hours before TKA, 50 mg daily for 5 days postoperatively, and 25 mg daily for another 8 days, or matching placebo at the same times. Main Outcome Measures Postoperative outcomes including postsurgical analgesic consumption and pain scores achieved, nausea and vomiting, joint range of motion, sleep disturbance, patient satisfaction with analgesia, and hematologic and coagulation parameters. Results Total epidural analgesic consumption and in-hospital opioid consumption were less in the group receiving rofecoxib compared with the group receiving placebo (P<.05). Median pain score (visual analog scale [VAS], 0-10) achieved for the knee was lower in the rofecoxib group compared with the placebo group during hospital stay (2.2 [inter-quartile range {IQR}, 1.4-3.2] vs 3.5 [IQR, 2.7-4.3], P<.001) and 1 week after discharge (2.6 [IQR, 1.4-3.5] vs 3:7 [IQR, 2:9-4.7], P=.03). There was less postoperative vomiting in the rofecoxib group (6%) compared with the placebo group (26%) (P=.047), as well as a decrease in sleep disturbance compared with the placebo group on the night of surgery (P=.006) and on the first (P=.047) and second (P<.001) days postoperatively. Knee flexion was increased in the rofecoxib group compared with the placebo group at discharge (active flexion: mean [SD], 84.2&DEG; [11.1&DEG;] vs 73.2&DEG; [13.6&DEG;], P=.03; passive flexion: 90.5&DEG; [6.8&DEG;] vs 81.8&DEG; [13:4&DEG;], P=.05) and at 1 month postoperatively (109.3&DEG; [8.5&DEG;] vs 100.8&DEG; [11.8&DEG;], P=.01), with shorter time in physical therapy to achieve effective joint range of motion. The rofecoxib group was more satisfied with analgesia and anesthesia at discharge compared with the placebo group (median satisfaction score, 4.3 [IQR, 3.0-4.7] vs 3.3 [IQR, 2.3-4.3], respectively; P=.03), and the differences persisted at 2-week and at 1-month follow-up. There was no intergroup difference in surgical blood loss (P>.05 for both intraoperative and postoperative blood loss). Conclusion Perioperative use of an inhibitor of cyclooxygenase 2 is an effective component of multimodal analgesia that reduces opioid consumption, pain, vomiting, and sleep disturbance, with improved knee range of motion after TKA.	Rush Presbyterian St Lukes Med Ctr, Dept Anesthesiol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA	Rush University; Rush University	Buvanendran, A (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Anesthesiol, Chicago, IL 60612 USA.		Rosenberg, Anna/AAL-1075-2021; Moric, Mario/A-5637-2016	Rosenberg, Anna/0000-0003-1456-7991; Moric, Mario/0000-0003-2844-8168				ARROYO JL, 1985, EUR J ANAESTH, V2, P401; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Borgeat A, 2003, ANESTHESIOLOGY, V98, P530, DOI 10.1097/00000542-200302000-00036; BUVANENDRAN A, 2002, ANESTHESIOLOGY, V97, pA465; BUVANENDRAN A, 2001, ANESTHESIOLOGY, V95, pA868; Capdevila X, 1999, ANESTHESIOLOGY, V91, P8, DOI 10.1097/00000542-199907000-00006; Cheng J C, 1997, Am J Ther, V4, P62, DOI 10.1097/00045391-199702000-00002; Chiu K Y, 2002, J Orthop Surg (Hong Kong), V10, P194; DAHL JB, 1991, BRIT J ANAESTH, V66, P703, DOI 10.1093/bja/66.6.703; DIERKING GW, 1992, BRIT J ANAESTH, V68, P344, DOI 10.1093/bja/68.4.344; Dolan S, 2003, ANESTHESIOLOGY, V98, P170, DOI 10.1097/00000542-200301000-00027; Giercksky KE, 2000, SCAND J GASTROENTERO, V35, P1121; Girod V, 2000, NEUROPHARMACOLOGY, V39, P2329, DOI 10.1016/S0028-3908(00)00091-5; Gordon SM, 2002, CLIN PHARMACOL THER, V72, P175, DOI 10.1067/mcp.2002.126501; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Halpin RA, 2002, DRUG METAB DISPOS, V30, P684, DOI 10.1124/dmd.30.6.684; Huang JJ, 2001, J CLIN ANESTH, V13, P94, DOI 10.1016/S0952-8180(01)00219-7; JEVSEVAR DS, 1993, PHYS THER, V73, P229, DOI 10.1093/ptj/73.4.229; Katz J, 2001, CAN J ANAESTH, V48, P105, DOI 10.1007/BF03019721; KEHLET H, 1989, BRIT J ANAESTH, V63, P189, DOI 10.1093/bja/63.2.189; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Kroin JS, 2002, REGION ANESTH PAIN M, V27, P451, DOI 10.1053/rapm.2002.35521; KROIN JS, 2003, ANESTH ANALG, V96, pS190; Laubenthal K N, 1972, Phys Ther, V52, P34; LUBENOW TR, 2000, CLIN ANESTH, P1403; McCrory C, 2002, J CARDIOTHOR VASC AN, V16, P607, DOI 10.1053/jcan.2002.126957; McCrory CR, 2002, ANESTH ANALG, V95, P169, DOI 10.1097/00000539-200207000-00030; MURPHY DF, 1993, BRIT J ANAESTH, V70, P298, DOI 10.1093/bja/70.3.298; Myles PS, 2000, BRIT J ANAESTH, V84, P6, DOI 10.1093/oxfordjournals.bja.a013383; NORKIN CC, 1995, MEASUREMENT JOINT MO, P142; O'Brien RG, 1998, PROCEEDINGS OF THE TWENTY-THIRD ANNUAL SAS USERS GROUP INTERNATIONAL CONFERENCE, P1346; PARKER RK, 1994, ANESTHESIOLOGY, V80, P6, DOI 10.1097/00000542-199401000-00005; Reuben SS, 2000, ANESTH ANALG, V91, P1221, DOI 10.1097/00000539-200011000-00032; Reuben SS, 2002, J ARTHROPLASTY, V17, P26, DOI 10.1054/arth.2002.27677; Reuben SS, 2002, ANESTH ANALG, V94, P55, DOI 10.1097/00000539-200201000-00010; Robinson C M, 1993, J Arthroplasty, V8, P607, DOI 10.1016/0883-5403(93)90007-Q; RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552, DOI 10.1093/bja/76.4.552; Schwartz JI, 2000, CLIN PHARMACOL THER, V68, P626, DOI 10.1067/mcp.2000.112244; SRIWATANAKUL K, 1983, CLIN PHARMACOL THER, V34, P234, DOI 10.1038/clpt.1983.159; STANDING JA, 2001, AM J HEALTH-SYST PH, V58, P2076; Turan A, 2002, ANESTH ANALG, V95, P1308, DOI 10.1097/00000539-200211000-00039; Varrassi G, 1999, ANESTH ANALG, V88, P611, DOI 10.1097/00000539-199903000-00028; Wang H, 2002, REGION ANESTH PAIN M, V27, P139, DOI 10.1053/rapm.2002.29253; Westfall P.H., 1993, RESAMPLING BASED MUL; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Worland RL, 1998, J ARTHROPLASTY, V13, P784, DOI 10.1016/S0883-5403(98)90031-6; Worwag E, 1998, ANESTH ANALG, V87, P62, DOI 10.1097/00000539-199807000-00014; Yao M, 2003, CANCER RES, V63, P586; 1999, JT COMM PERSPECT, V19, P6	50	240	267	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2411	2418		10.1001/jama.290.18.2411	http://dx.doi.org/10.1001/jama.290.18.2411			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612477				2022-12-28	WOS:000186518300027
J	Cock, TA; Auwerx, J				Cock, TA; Auwerx, J			Leptin: cutting the fat off the bone	LANCET			English	Review							MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RECOMBINANT LEPTIN; FOOD-INTAKE; OBESE GENE; MASS; DEFICIENCY; ADIPOSITY; RECEPTORS; THERAPY	Context Leptin was initially proposed to be the antiobesity hormone. Now it is realised that leptin is more a signal molecule that communicates nutritional status to the brain, and that it is involved in bone formation by having an antiosteogenic action. Starting point Recently, Florent Elefteriou and colleagues (Endocrinology 2003;144: 3842-47) found that hypothalamic neurons control bone mass. These researchers, used monosodium glutamate to obliterate neurons in the arcuate nucleus Previously, this group (Cell 2002; 101: 305-17) had shown that leptin inhibits bone formation by modulating the sympathetic nervous system. Although leptin influences both energy balance and bone mass by acting on the hypothalamus, the two processes involve different proteins and neurons. Where next? Leptin has antiosteogenic activity in mice, mediated by hypothalamic nervous pathways and the sympathetic nervous system. Yet some human studies dispute leptin's antiosteogenic role. Large clinical studies are necessary to consolidate leptin's role in the physiology of human bone. In mice the P blocker propranolol, a widely used drug with no major deleterious effects, significantly increases bone formation and bone mass without affecting bodyweight, a finding that may provide novel opportunities to design efficient bone-forming drugs for human beings.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Genopole Strasbourg, Inst Clin Souris, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.		Auwerx, Johan/ABE-9307-2021	Auwerx, Johan/0000-0002-5065-5393; Cock, Terrie-Anne/0000-0002-2928-0080				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Blum M, 2003, CALCIFIED TISSUE INT, V73, P27, DOI 10.1007/s00223-002-1019-4; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elefteriou F, 2003, ENDOCRINOLOGY, V144, P3842, DOI 10.1210/en.2003-0369; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Iwamoto I, 2000, ACTA OBSTET GYN SCAN, V79, P1060, DOI 10.1034/j.1600-0412.2000.0790121060.x; Martini G, 2001, BONE, V28, P113, DOI 10.1016/S8756-3282(00)00408-7; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Odabasi E, 2000, EUR J ENDOCRINOL, V142, P170, DOI 10.1530/eje.0.1420170; Rauch F, 1998, CALCIFIED TISSUE INT, V63, P453, DOI 10.1007/s002239900556; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; Sainsbury A, 2003, MOL CELL BIOL, V23, P5225, DOI 10.1128/MCB.23.15.5225-5233.2003; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Sato M, 2001, J CLIN ENDOCR METAB, V86, P5273, DOI 10.1210/jc.86.11.5273; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 2002, ANN ENDOCRINOL-PARIS, V63, P117; Simha V, 2002, J CLIN ENDOCR METAB, V87, P4942, DOI 10.1210/jc.2002-020792; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	68	72	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1572	1574		10.1016/S0140-6736(03)14747-2	http://dx.doi.org/10.1016/S0140-6736(03)14747-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615115				2022-12-28	WOS:000186464500025
J	Fuchizaki, U; Miyamori, H; Kitagawa, S; Kaneko, S; Kobayashi, K				Fuchizaki, U; Miyamori, H; Kitagawa, S; Kaneko, S; Kobayashi, K			Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease)	LANCET			English	Editorial Material							RECEPTOR-LIKE KINASE-1; GENE		Keiju Med Ctr, Dept Internal Med, Nanao, Ishikawa 9268605, Japan; Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 920, Japan	Kanazawa University	Fuchizaki, U (corresponding author), Keiju Med Ctr, Dept Internal Med, 94 Tomioka Cho, Nanao, Ishikawa 9268605, Japan.							Bliss Michael, 2007, WILLIAM OSLER LIFE M; Cushing H., 1925, LIFE W OSLER; GIBBS DD, 1986, J ROY SOC MED, V79, P742; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Haitjema T, 1996, ARCH INTERN MED, V156, P714, DOI 10.1001/archinte.156.7.714; Hall LA, 2001, MED HIST, V45, P523, DOI 10.1017/S002572730006840X; Hanes FA, 1909, B JOHNS HOPKINS HOSP, V20, P63; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Osler W, 1901, B JOHNS HOPKINS HOSP, V12, P333; Rendu Henri, 1844, JAMA-J AM MED ASSOC, V197, P583; RENDU HJ, 1896, GAZ HOPITAUX, P1322; Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; Weber FP, 1907, LANCET, V2, P160	15	63	66	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1490	1494		10.1016/S0140-6736(03)14696-X	http://dx.doi.org/10.1016/S0140-6736(03)14696-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602446				2022-12-28	WOS:000186356600027
J	Winegarden, N				Winegarden, N			Microarrays in cancer: moving from hype to clinical reality	LANCET			English	Editorial Material							DNA MICROARRAYS; INFORMATION; DISCOVERY		Univ Hlth Network, Microarray Ctr, Max Bell Res Ctr, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Winegarden, N (corresponding author), Univ Hlth Network, Microarray Ctr, Max Bell Res Ctr, 5R421, Toronto, ON M5G 2M9, Canada.			Winegarden, Neil/0000-0001-5964-5899				Braxton S, 1998, CURR OPIN BIOTECH, V9, P643, DOI 10.1016/S0958-1669(98)80144-4; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Ciro M, 2003, CURR OPIN CELL BIOL, V15, P213, DOI 10.1016/S0955-0674(03)00007-3; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hughes TR, 2001, CURR OPIN CHEM BIOL, V5, P21, DOI 10.1016/S1367-5931(00)00163-0; Meltzer PS, 2001, CURR OPIN GENET DEV, V11, P258, DOI 10.1016/S0959-437X(00)00187-8; PEROU CM, 2000, NEW TECHNOLOGIES LIF, V6, P67; van Berkum NL, 2001, CURR OPIN BIOTECH, V12, P48, DOI 10.1016/S0958-1669(00)00173-7	8	18	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1428	1428		10.1016/S0140-6736(03)14724-1	http://dx.doi.org/10.1016/S0140-6736(03)14724-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602430				2022-12-28	WOS:000186356600002
J	Hsieh, JJD; Cheng, EHY; Korsmeyer, SJ				Hsieh, JJD; Cheng, EHY; Korsmeyer, SJ			Taspase1: A threonine aspartase required for cleavage of MLL and proper HOX gene expression	CELL			English	Article							DROSOPHILA-TRITHORAX; CHROMOSOMAL TRANSLOCATIONS; PROTEOLYTIC CLEAVAGE; MAMMALIAN TRITHORAX; BITHORAX COMPLEX; HOMEOBOX GENES; PROTEIN; LEUKEMIA; MECHANISM; ACTIVATION	The Mixed-Lineage Leukemia gene (MLL/HRX/ALL1) encodes a large nuclear protein homologous to Drosophila trithorax that is required for the maintenance of HOX gene expression. MLL is cleaved at two conserved sites generating N320 and C180 fragments, which heterodimerize to stabilize the complex and confer its subnuclear destination. Here, we purify and clone the protease responsible for cleaving MLL. We entitle it Taspase1 as it initiates a class of endopeptidases that utilize an N-terminal threonine as the active site nucleophile to proteolyze polypeptide substrates following aspartate. Taspase1 proenzyme is intramolecularly proteolyzed generating an active 28 kDa alpha/22 kDa beta heterodimer. RNAi-mediated knockdown of Taspase1 results in the appearance of unprocessed MLL and the loss of proper HOX gene expression. Taspase1 coevolved with MLL/trithorax as Arthropoda and Chordata emerged from Metazoa suggesting that Taspase1 originated to regulate complex segmental body plans in higher organisms.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Korsmeyer, SJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, 44 Binney St, Boston, MA 02115 USA.	stanley_korsmeyer@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P01CA068484, K01CA102594] Funding Source: NIH RePORTER; NCI NIH HHS [CA102594, CA68484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BREEN TR, 1993, DEVELOPMENT, V117, P119; Breen TR, 1999, GENETICS, V152, P319; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buske C, 2000, INT J HEMATOL, V71, P301; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Downing J R, 1996, Cancer Treat Res, V84, P73; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; FIAR K, 2001, MOL CELL BIOL, V21, P3589; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; FURIE B, 1992, NEW ENGL J MED, V326, P800; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Oinonen C, 2000, PROTEIN SCI, V9, P2329, DOI 10.1110/ps.9.12.2329; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; SEDKOV Y, 1994, DEVELOPMENT, V120, P1907; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; Ye YH, 2000, SEMIN CELL DEV BIOL, V11, P211, DOI 10.1006/scdb.2000.0167; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	49	205	211	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					293	303		10.1016/S0092-8674(03)00816-X	http://dx.doi.org/10.1016/S0092-8674(03)00816-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636557	Bronze			2022-12-28	WOS:000186415000009
J	Temple, S				Temple, S			Embryonic stem cell self-renewal, analyzed	CELL			English	Editorial Material							SIGNALING PATHWAY; DIFFERENTIATION	Maintaining the pluripotency of mouse ES cells requires both LIF (leukemia inhibitory factor) and unknown factors in serum. The paper from Ying et al. in this issue of Cell shows that BMP (bone morphogenetic protein) can replace serum in this capacity, defining molecular requirements for ES cell self-renewal.	Albany Med Coll, Albany, NY 12208 USA	Albany Medical College	Temple, S (corresponding author), Albany Med Coll, Albany, NY 12208 USA.							Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Norton JD, 2000, J CELL SCI, V113, P3897; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780	8	6	7	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 31	2003	115	3					247	248		10.1016/S0092-8674(03)00853-5	http://dx.doi.org/10.1016/S0092-8674(03)00853-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636550	Bronze			2022-12-28	WOS:000186415000002
J	Vaux, DL; Silke, J				Vaux, DL; Silke, J			HtrA2/Omi, a sheep in wolf's clothing	CELL			English	Editorial Material							APOPTOSIS; PROTEASE; IDENTIFICATION; PROTEINS; BINDING		Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Vaux, DL (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.		Silke, John/B-7622-2008; Vaux, David L/C-7249-2013	Silke, John/0000-0002-7611-5774; Vaux, David L/0000-0003-2703-1651				Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	8	36	40	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 31	2003	115	3					251	253		10.1016/S0092-8674(03)00851-1	http://dx.doi.org/10.1016/S0092-8674(03)00851-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636553	Bronze			2022-12-28	WOS:000186415000005
J	Linkins, LA; Choi, PT; Douketis, JD				Linkins, LA; Choi, PT; Douketis, JD			Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; INTRAVENOUS UNFRACTIONATED HEPARIN; MECHANICAL HEART-VALVE; PULMONARY-EMBOLISM; RISK-FACTORS; INITIAL TREATMENT; 1ST EPISODE; LONG-TERM; INTRACRANIAL HEMORRHAGE	Background: Clinicians should consider the clinical impact of anticoagulant-related bleeding when deciding on the duration of anticoagulant therapy in patients with venous thromboembolism. Purpose: To provide reliable estimates of the clinical impact of anticoagulant-related bleeding, defined as the case-fatality rate of major bleeding and the risk for intracranial bleeding. Data Sources: MEDLINE (January 1989 to May 2003), Cochrane Controlled Trial Registry, thromboembolism experts, and reference lists; English-language literature only. Study Selection: Randomized, controlled trials and prospective cohort studies that investigated patients with venous thromboembolism who received oral anticoagulant therapy (target international normalized ratio, 2.0 to 3.0) for at least 3 months and that reported major bleeding and death as primary study outcomes. Data Extraction: Two reviewers independently extracted data on the number of anticoagulant-related major and intracranial bleeding episodes and on whether these events were fatal or nonfatal. Data Synthesis: The authors analyzed 33 studies involving 4374 patient-years of oral anticoagulant therapy. For all patients, the case-fatality rate of major bleeding was 13.4% (95% CI, 9.4% to 17.4%) and the rate of intracranial bleeding was 1.15 per 100 patient-years (CI, 1.14 to 1.16 per 100 patient-years). For patients who received anticoagulant therapy for more than 3 months, the case-fatality rate of major bleeding was 9.1% (CI, 2.5% to 21.7%), and the rate of intracranial bleeding was 0.65 per 100 patient-years (CI, 0.63 to 0.68 per 100 patient-years) after the initial 3 months of anticoagulation. Conclusion: The clinical impact of anticoagulant-related major bleeding in patients with venous thromboembolism is considerable, and clinicians should take this into account when deciding whether to continue long-term oral anticoagulant therapy in an individual patient.	McMaster Univ, Hamilton, ON, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	McMaster University; University of British Columbia	Douketis, JD (corresponding author), St Josephs Healthcare, Room F-541,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	jdouket@mcmaster.ca	Douketis, James/AAO-5659-2021					Agnelli G, 2003, ANN INTERN MED, V139, P19, DOI 10.7326/0003-4819-139-1-200307010-00008; Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Bauer KA, 2001, ANN INTERN MED, V135, P367, DOI 10.7326/0003-4819-135-5-200109040-00013; Boccalon H, 2000, ARCH INTERN MED, V160, P1769, DOI 10.1001/archinte.160.12.1769; Bounameaux H, 1997, THROMB HAEMOSTASIS, V78, P997; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902; Buller HR, 2000, CIRCULATION, V102, P2726; CAPPELLERI JC, 1995, AM HEART J, V130, P547, DOI 10.1016/0002-8703(95)90365-8; Charbonnier BA, 1998, THROMB HAEMOSTASIS, V79, P897; Das SK, 1996, WORLD J SURG, V20, P521, DOI 10.1007/s002689900081; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Devereaux PJ, 2001, BMJ-BRIT MED J, V323, P1218, DOI 10.1136/bmj.323.7323.1218; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; Douketis JD, 1999, CHEST, V116, P1240, DOI 10.1378/chest.116.5.1240; Douketis JD, 2000, ARCH INTERN MED, V160, P3431, DOI 10.1001/archinte.160.22.3431; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FLEISS JL, 1973, STATISTICAL METHODS, P43; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; Gonzalez-Fajardo JA, 1999, J VASC SURG, V30, P283, DOI 10.1016/S0741-5214(99)70139-4; Harenberg J, 2000, THROMB HAEMOSTASIS, V83, P652; Harrison L, 1997, ANN INTERN MED, V126, P133, DOI 10.7326/0003-4819-126-2-199701150-00006; Hart RG, 1999, CEREBROVASC DIS, V9, P215, DOI 10.1159/000015958; Hull RD, 2000, ARCH INTERN MED, V160, P229, DOI 10.1001/archinte.160.2.229; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; Hylck EM, 2000, ARCH INTERN MED, V160, P1612, DOI 10.1001/archinte.160.11.1612; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Kovacs MJ, 2000, THROMB HAEMOSTASIS, V83, P209; Kovacs MJ, 1998, HAEMOSTASIS, V28, P62; Kovacs MJ, 2003, ANN INTERN MED, V138, P714, DOI 10.7326/0003-4819-138-9-200305060-00007; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; Leroyer C, 1998, HAEMOSTASIS, V28, P70; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S; LEVINE MN, 1986, CHEST, V89, pS16, DOI 10.1378/chest.89.2_Supplement.16S; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; Lindmarker P, 1996, J INTERN MED, V240, P395, DOI 10.1046/j.1365-2796.1996.81877000.x; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; Lopaciuk S, 1999, THROMB HAEMOSTASIS, V81, P26; McManus RJ, 1998, BMJ-BRIT MED J, V317, P1562, DOI 10.1136/bmj.317.7172.1562; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; Monreal M, 1998, HAEMOSTASIS, V28, P236; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Pinede L, 2001, CIRCULATION, V103, P2453; Pinede L, 2000, J INTERN MED, V247, P553, DOI 10.1046/j.1365-2796.2000.00631.x; PINI M, 1994, THROMB HAEMOSTASIS, V72, P191; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Punthakee X, 2002, THROMB RES, V108, P31, DOI 10.1016/S0049-3848(02)00398-5; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Tsai AW, 2002, ARCH INTERN MED, V162, P1182, DOI 10.1001/archinte.162.10.1182; van den Belt AGM, 2000, THROMB HAEMOSTASIS, V84, P758, DOI 10.1055/s-0037-1614111; Wells PS, 1998, ARCH INTERN MED, V158, P1809, DOI 10.1001/archinte.158.16.1809; Yusuf S, 2002, LANCET, V359, P294; 1997, COLL AM PATHOLOGISTS	68	575	592	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					893	900		10.7326/0003-4819-139-11-200312020-00007	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644891				2022-12-28	WOS:000186884800002
J	Basu, AR; Petaev, MI; Poreda, RJ; Jacobsen, SB; Becker, L				Basu, AR; Petaev, MI; Poreda, RJ; Jacobsen, SB; Becker, L			Chondritic meteorite fragments associated with the Permian-Triassic boundary in Antarctica	SCIENCE			English	Article							GIGANTIC RELEASE; SIBERIAN TRAPS; BOLIDE IMPACT; CATASTROPHE; FULLERENES; EXTINCTION; SULFUR	Multiple chondritic meteorite fragments have been found in two sedimentary rock samples from an end-Permian bed at Graphite Peak in Antarctica. The Ni/Fe, Co/Ni, and P/Fe ratios in metal grains; the Fe/Mg and Mn/Fe ratios in olivine and pyroxene; and the chemistry of Fe-, Ni-, P-, and S-bearing oxide in the meteorite fragments are typical of CM-type chondritic meteorites. In one sample, the meteoritic fragments are accompanied by more abundant discrete metal grains, which are also found in an end-Permian bed at Meishan, southern China. We discuss the implications of this finding for a suggested global impact event at the Permian-Triassic boundary.	Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Calif Santa Barbara, Dept Geol, Inst Crustal Studies, Santa Barbara, CA 93106 USA	University of Rochester; Harvard University; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of California System; University of California Santa Barbara	Basu, AR (corresponding author), Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA.	abasu@earth.rochester.edu	Jacobsen, Stein/B-1759-2013; Jacobsen, Stein/ABA-1063-2021	Jacobsen, Stein/0000-0003-2164-0720				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; BASU AR, 1995, SCIENCE, V269, P822, DOI 10.1126/science.269.5225.822; Becker L, 2001, SCIENCE, V291, P1530, DOI 10.1126/science.1057243; Becker L, 2000, P NATL ACAD SCI USA, V97, P2979, DOI 10.1073/pnas.050519397; BECKERLING W, 1995, PLANET SPACE SCI, V43, P435, DOI 10.1016/0032-0633(94)00175-Q; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; BREARLEY AJ, 1998, REV MINERAL, V36, P3; Brownlee DE, 1997, METEORIT PLANET SCI, V32, P157, DOI 10.1111/j.1945-5100.1997.tb01257.x; CAMPBELL IH, 1992, SCIENCE, V258, P1760, DOI 10.1126/science.258.5089.1760; ERWIN DH, 1993, GREATEST PALEOZOIC C; Farley KA, 2001, SCIENCE, V293, P2343; Hallam A., 1997, MASS EXTINCTIONS THE; Jessberger EK, 2001, ASTR AST LI, P253; Jin YG, 2000, SCIENCE, V289, P432, DOI 10.1126/science.289.5478.432; Kaiho K, 2001, GEOLOGY, V29, P815, DOI 10.1130/0091-7613(2001)029<0815:EPCBAB>2.0.CO;2; Koeberl C, 2002, GEOLOGY, V30, P855, DOI 10.1130/0091-7613(2002)030<0855:EPCBBI>2.0.CO;2; Krull ES, 2000, GEOL SOC AM BULL, V112, P1459, DOI 10.1130/0016-7606(2000)112<1459:CDPFPA>2.0.CO;2; KURAT G, 1994, GEOCHIM COSMOCHIM AC, V58, P3879, DOI 10.1016/0016-7037(94)90369-7; Kyte FT, 1998, NATURE, V396, P237, DOI 10.1038/24322; KYTE FT, 2002, LUNAR PLANETARY SCI, V31; Miono S, 1999, NUCL INSTRUM METH B, V150, P516, DOI 10.1016/S0168-583X(98)00917-3; Poreda RJ, 2003, ASTROBIOLOGY, V3, P75, DOI 10.1089/153110703321632435; RAUP DM, 1979, SCIENCE, V206, P217, DOI 10.1126/science.206.4415.217; RENNE PR, 1991, SCIENCE, V253, P176, DOI 10.1126/science.253.5016.176; RENNE PR, 1995, SCIENCE, V269, P1413, DOI 10.1126/science.269.5229.1413; RETALLACK GJ, 1995, SCIENCE, V267, P77, DOI 10.1126/science.267.5194.77; Retallack GJ, 1998, GEOLOGY, V26, P979, DOI 10.1130/0091-7613(1998)026<0979:SFEOIA>2.3.CO;2; Rietmeijer F. J. M., 1998, REV MINERAL, V36, P1; Schmitz B, 2003, SCIENCE, V300, P961, DOI 10.1126/science.1082182; Schmitz B, 2001, EARTH PLANET SC LETT, V194, P1, DOI 10.1016/S0012-821X(01)00559-3; Sheldon ND, 2002, GEOLOGY, V30, P919, DOI 10.1130/0091-7613(2002)030<0919:LOLIET>2.0.CO;2; Shukolyukov A, 1998, SCIENCE, V282, P927, DOI 10.1126/science.282.5390.927; SUN Y, 1984, 27 INT GEOL C	33	106	122	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1388	1392		10.1126/science.1090852	http://dx.doi.org/10.1126/science.1090852			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631038				2022-12-28	WOS:000186683500050
J	Seewald, JS				Seewald, JS			Organic-inorganic interactions in petroleum-producing sedimentary basins	NATURE			English	Review							THERMOCHEMICAL SULFATE REDUCTION; CARBON-DIOXIDE; LIGHT-HYDROCARBONS; HYDROUS PYROLYSIS; HYDROTHERMAL REACTIVITY; METASTABLE EQUILIBRIUM; LABORATORY EXPERIMENTS; THERMAL-DECOMPOSITION; SMACKOVER FORMATION; NATURAL GASES	Petroleum deposits form as a consequence of the increased temperatures that accompany progressive burial of organic matter deep within sedimentary basins. Recent advances in petroleum geochemistry suggest that inorganic sedimentary components participate in organic transformations associated with this process. Water is particularly important because it facilitates reaction mechanisms not available in dry environments, and may contribute hydrogen and oxygen for the formation of hydrocarbons and oxygenated alteration products. These findings suggest that petroleum generation and stability is influenced by subsurface chemical environments, and is a simple function of time, temperature and the composition of sedimentary organic matter.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Seewald, JS (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, MS 4, Woods Hole, MA 02543 USA.	jseewald@whoi.edu						ANDRESEN B, 1994, ORG GEOCHEM, V21, P1229, DOI 10.1016/0146-6380(94)90166-X; BARKER C, 1990, AAPG BULL, V74, P1254; BASKIN DK, 1986, ORG GEOCHEM, V10, P499; Bell J. LS., 1994, ORGANIC ACIDS GEOLOG, P227; BORGUND AE, 1994, ORG GEOCHEM, V21, P943, DOI 10.1016/0146-6380(94)90053-1; BROOKS BT, 1952, IND ENG CHEM, V44, P2570, DOI 10.1021/ie50515a032; BURNHAM AK, 1995, COMPOSITION GEOCHEMI, P211; CLAYPOOL GE, 1989, AAPG BULL, V73, P904; COOLES GP, 1986, ORG GEOCHEM, V10, P235, DOI 10.1016/0146-6380(86)90026-4; COOLES GP, 1987, MINERAL MAG, V51, P483, DOI 10.1180/minmag.1987.051.362.03; Crossey L J, 1986, SEPM SPECIAL PUBLICA, V38, p147~156; EGLINTON TI, 1987, MINERAL MAG, V51, P495, DOI 10.1180/minmag.1987.051.362.04; Espitalie J., 1984, ORG GEOCHEM, V6, P365, DOI [DOI 10.1016/0146-6380(84)90059-7, 10.1016/0146-6380(84)90059-7]; FRANKS SG, 1984, CLASTIC DIAGENESIS, P63; GILES MR, 1994, ORGANIC ACIDS GEOLOG, P449; Goldhaber MB, 1995, ACS SYM SER, V612, P412; GOLDSTEIN TP, 1983, AAPG BULL, V67, P152; HELGESON HC, 1993, GEOCHIM COSMOCHIM AC, V57, P3295, DOI 10.1016/0016-7037(93)90541-4; Hoering T., 1984, ORG GEOCHEM, V5, P267, DOI DOI 10.1016/0146-6380(84)90014-7; HORSFIELD B, 1980, GEOCHIM COSMOCHIM AC, V44, P1119, DOI 10.1016/0016-7037(80)90066-6; HUIZINGA BJ, 1987, ORG GEOCHEM, V11, P591, DOI 10.1016/0146-6380(87)90012-X; Hunt J.M., 1996, PETROLEUM GEOLOGY GE; Hunt JM, 1998, AAPG MEMOIR, V70, P87; HUNT JM, 1984, SCIENCE, V226, P1265, DOI 10.1126/science.226.4680.1265; HUTCHEON I, 1993, GEOCHIM COSMOCHIM AC, V57, P1017, DOI 10.1016/0016-7037(93)90037-W; HUTCHEON I, 1990, GEOLOGY, V18, P541, DOI 10.1130/0091-7613(1990)018<0541:CDICRA>2.3.CO;2; JENDEN PD, 1988, CHEM GEOL, V71, P117, DOI 10.1016/0009-2541(88)90110-6; JENDEN PD, 1988, GEOCHIM COSMOCHIM AC, V52, P851, DOI 10.1016/0016-7037(88)90356-0; KARLSEN DA, 1993, GEOCHIM COSMOCHIM AC, V57, P3641, DOI 10.1016/0016-7037(93)90146-N; KISSIN YV, 1987, GEOCHIM COSMOCHIM AC, V51, P2445, DOI 10.1016/0016-7037(87)90296-1; KROUSE HR, 1988, NATURE, V333, P415, DOI 10.1038/333415a0; LAFARGUE E, 1990, ORG GEOCHEM, V16, P121, DOI 10.1016/0146-6380(90)90032-U; LAIDLER KJ, 1962, PROC R SOC LON SER-A, V270, P242, DOI 10.1098/rspa.1962.0215; Lewan MD, 1998, NATURE, V391, P164, DOI 10.1038/34391; Lewan MD, 1997, GEOCHIM COSMOCHIM AC, V61, P3691, DOI 10.1016/S0016-7037(97)00176-2; LEWAN MD, 1985, PHILOS T R SOC A, V315, P123, DOI 10.1098/rsta.1985.0033; LUNDEGARD PD, 1984, GEOLOGY, V12, P399, DOI 10.1130/0091-7613(1984)12<399:POSPFF>2.0.CO;2; LUNDEGARD PD, 1986, ROLES ORGANIC MATTER, P129; Machel HG, 1998, AAPG BULL, V82, P1870; Machel HG, 1995, ACS SYM SER, V612, P439; MANGO FD, 1994, NATURE, V368, P536, DOI 10.1038/368536a0; Mango FD, 1997, ORG GEOCHEM, V26, P417, DOI 10.1016/S0146-6380(97)00031-4; Mango FD, 2000, GEOCHIM COSMOCHIM AC, V64, P1265, DOI 10.1016/S0016-7037(99)00389-0; Manzano BK, 1997, ORG GEOCHEM, V27, P507, DOI 10.1016/S0146-6380(97)00070-3; McCollom TM, 2003, GEOCHIM COSMOCHIM AC, V67, P3645, DOI 10.1016/S0016-7037(03)00135-2; McCollom TM, 2003, GEOCHIM COSMOCHIM AC, V67, P3625, DOI 10.1016/S0016-7037(03)00136-4; McCollom TM, 2001, GEOCHIM COSMOCHIM AC, V65, P455, DOI 10.1016/S0016-7037(00)00533-0; McNeil RI, 1996, ENERG FUEL, V10, P60, DOI 10.1021/ef9501399; MIKNIS FP, 1987, ENERG FUEL, V1, P477, DOI 10.1021/ef00006a004; ONEIL JR, 1969, J CHEM PHYS, V51, P5547, DOI 10.1063/1.1671982; ORR WL, 1986, ORG GEOCHEM, V10, P499, DOI 10.1016/0146-6380(86)90049-5; ORR WL, 1974, AAPG BULL, V58, P2295; Pittman E.D., 1994, ORGANIC ACIDS GEOLOG, P115, DOI [10.1007/978-3-642-78356-2_5, DOI 10.1007/978-3-642-78356-2_5]; PRICE LC, 1995, NATURE, V378, P368, DOI 10.1038/378368a0; PRICE LC, 1992, ORG GEOCHEM, V19, P141, DOI 10.1016/0146-6380(92)90033-T; PRICE LC, 1993, GEOCHIM COSMOCHIM AC, V57, P3261, DOI 10.1016/0016-7037(93)90539-9; Price LC, 2001, GEOCHIM COSMOCHIM AC, V65, P3791, DOI 10.1016/S0016-7037(01)00762-1; SASSEN R, 1988, ORG GEOCHEM, V12, P351, DOI 10.1016/0146-6380(88)90009-5; Schimmelmann A, 2001, ORG GEOCHEM, V32, P1009, DOI 10.1016/S0146-6380(01)00059-6; SCHMIDT V, 1979, ASPECTS DIAGENESIS, P175; Seewald JS, 1998, GEOCHIM COSMOCHIM AC, V62, P1599, DOI 10.1016/S0016-7037(98)00000-3; SEEWALD JS, 1994, NATURE, V370, P285, DOI 10.1038/370285a0; Seewald JS, 2001, GEOCHIM COSMOCHIM AC, V65, P1641, DOI 10.1016/S0016-7037(01)00544-0; Shock E. L., 1994, ORGANIC ACIDS GEOLOG, P270; SISKIN M, 1991, SCIENCE, V254, P231, DOI 10.1126/science.254.5029.231; SMITH JT, 1989, MAR PETROL GEOL, V6, P129, DOI 10.1016/0264-8172(89)90016-0; STALKER L, 1994, ORG GEOCHEM, V22, P477, DOI 10.1016/0146-6380(94)90120-1; SUGISAKI R, 1994, GEOCHIM COSMOCHIM AC, V58, P2527, DOI 10.1016/0016-7037(94)90029-9; SURDAM RC, 1993, AAPG BULL, V77, P1509; SURDAM RC, 1989, AAPG BULL, V73, P1; SURDAM RC, 1985, PHILOS T R SOC A, V315, P135, DOI 10.1098/rsta.1985.0034; SWEENEY JJ, 1995, AAPG BULL, V79, P1515; TANNENBAUM E, 1986, AAPG BULL, V70, P1156; TANNENBAUM E, 1985, NATURE, V317, P708, DOI 10.1038/317708a0; Taylor P, 2001, ORG GEOCHEM, V32, P341, DOI 10.1016/S0146-6380(00)00176-5; Tissot B.P., 1984, PETROLEUM FORMATION, DOI 10.1007/978-3-642-96446-6; TOLAND WG, 1960, J AM CHEM SOC, V82, P1911, DOI 10.1021/ja01493a020; TOLAND WG, 1958, J AM CHEM SOC, V80, P5423, DOI 10.1021/ja01553a026; TOMIC J, 1995, ORG GEOCHEM, V23, P647, DOI 10.1016/0146-6380(95)00043-E; TREIBER LE, 1972, SOC PETROL ENG J, V12, P531, DOI 10.2118/3526-PA; UNGERER P, 1990, ORG GEOCHEM, V16, P1, DOI 10.1016/0146-6380(90)90022-R; WORDEN RH, 1995, AAPG BULL, V79, P854; ZIEGEL ER, 1980, TECHNOMETRICS, V22, P139	83	383	467	9	178	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					327	333		10.1038/nature02132	http://dx.doi.org/10.1038/nature02132			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628062				2022-12-28	WOS:000186660800054
J	Garcia-Ruiz, JM; Hyde, ST; Carnerup, AM; Christy, AG; Van Kranendonk, MJ; Welham, NJ				Garcia-Ruiz, JM; Hyde, ST; Carnerup, AM; Christy, AG; Van Kranendonk, MJ; Welham, NJ			Self-assembled silica-carbonate structures and detection of ancient microfossils	SCIENCE			English	Article							EARTHS EARLIEST FOSSILS; ARRHENIUS EQUATION; WESTERN-AUSTRALIA; LIFE	We have synthesized inorganic micron-sized filaments, whose microstucture consists of silica-coated nanometer-sized carbonate crystals, arranged with strong orientational order. They exhibit noncrystallographic, curved, helical morphologies, reminiscent of biological forms. The. laments are similar to supposed cyanobacterial microfossils from the Precambrian Warrawoona chert formation in Western Australia, reputed to be the oldest terrestrial microfossils. Simple organic hydrocarbons, whose sources may also be abiotic and indeed inorganic, readily condense onto these. laments and subsequently polymerize under gentle heating to yield kerogenous products. Our results demonstrate that abiotic and morphologically complex microstructures that are identical to currently accepted biogenic materials can be synthesized inorganically.	Univ Granada, Fac Ciencias, Inst Andaluz Ciencias Tierra, CSIC, Granada 18002, Spain; Australian Natl Univ, Res Sch Phys Sci, Dept Appl Math, Canberra, ACT 0200, Australia; Geol Survey Western Australia, Perth, WA 6004, Australia	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Andaluz de Ciencias de la Tierra (IACT); University of Granada; Australian National University; Geological Survey of Western Australia	Garcia-Ruiz, JM (corresponding author), Univ Granada, Fac Ciencias, Inst Andaluz Ciencias Tierra, CSIC, Campus Fuentenueva, Granada 18002, Spain.		García-Ruiz, Juan Manuel/U-1085-2019; Hyde, Stephen/F-9248-2010; Garcia-Ruiz, Juan Manuel/C-4389-2015; Van Kranendonk, Martin J/J-8755-2012; Christy, Andrew/C-3205-2013; Hyde, Stephen T/N-2928-2019	García-Ruiz, Juan Manuel/0000-0002-4743-8718; Hyde, Stephen/0000-0003-2003-9992; Garcia-Ruiz, Juan Manuel/0000-0002-4743-8718; Van Kranendonk, Martin J/0000-0002-0611-2703; Christy, Andrew/0000-0002-2203-1444; Hyde, Stephen T/0000-0003-2003-9992; Welham, Nicholas/0000-0002-4716-9837				AWRAMIK SM, 1983, PRECAMBRIAN RES, V20, P357, DOI 10.1016/0301-9268(83)90081-5; BAIRD T, 1992, MATER RES BULL, V27, P1031, DOI 10.1016/0025-5408(92)90241-Q; Brasier MD, 2002, NATURE, V416, P76, DOI 10.1038/416076a; BUICK R, 1990, Palaios, V5, P441, DOI 10.2307/3514837; Cartwright JHE, 2002, J COLLOID INTERF SCI, V256, P351, DOI 10.1006/jcis.2002.8620; CLOUD P, 1979, PRECAMBRIAN RES, V9, P81, DOI 10.1016/0301-9268(79)90052-4; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; GARCIA-RUIZ J.M., 2002, ASTROBIOLOGY, V2, P335; Garcia-Ruiz J. M., 2000, CARBONATE SEDIMENTAT, V67, P75; Garcia-Ruiz JM, 1998, GEOLOGY, V26, P843; GarciaRuiz JM, 1997, AN QUIM, V93, P1; Garrels R.M., 1965, SOLUTIONS MINERALS E; Hofmann BA, 2000, PLANET SPACE SCI, V48, P1077, DOI 10.1016/S0032-0633(00)00081-7; HUNT JM, 1991, AAPG BULL, V75, P795; Ko TH, 2000, POLYM COMPOSITE, V21, P745, DOI 10.1002/pc.10229; Lowenstam HA, 1989, BIOMINERALIZATION; McCollom TM, 2003, GEOCHIM COSMOCHIM AC, V67, P311, DOI 10.1016/S0016-7037(02)00945-6; Pasteris JD, 2002, NATURE, V420, P476, DOI 10.1038/420476b; SCHOPF JW, 1987, SCIENCE, V237, P70, DOI 10.1126/science.11539686; Schopf JW, 2002, NATURE, V416, P73, DOI 10.1038/416073a; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; SCHOPF JW, 1983, EARTHS EARLIEST BIOS, pCH9; SVENSSON IL, 1986, J CHEM SOC FARAD T 1, V82, P3635, DOI 10.1039/f19868203635; THORPE RI, 1992, ARCHAEAN TERRAINS PR, V22, P395; Ueno Y, 2001, INT GEOL REV, V43, P196, DOI 10.1080/00206810109465008; VANKRANENDONK MJ, UNPUB; WOOD DA, 1988, AAPG BULL, V72, P115; Yang H, 1997, NATURE, V386, P692, DOI 10.1038/386692a0	28	336	346	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1194	1197		10.1126/science.1090163	http://dx.doi.org/10.1126/science.1090163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615534	Green Submitted			2022-12-28	WOS:000186544300049
J	Marmorstein, R				Marmorstein, R			Transcription initiation at its most basic level	CELL			English	Editorial Material							RNA-POLYMERASE-II; BINDING-PROTEIN; SITE SELECTION; RECOGNITION; IBP39; MOTIF	The structure of the initiator binding protein from the primitive eukaryote Trichomonas vaginalis reveals how a single protein can orchestrate promoter recognition, RNA polymerase 11 recruitment, and start site selection, and provides an evolutionary link with transcription initiation in higher eukaryotes.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.							Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Hirose Y, 2000, GENE DEV, V14, P1415; Keeling PJ, 2000, NATURE, V405, P635, DOI 10.1038/35015167; Lau AOT, 2003, MOL BIOCHEM PARASIT, V130, P167, DOI 10.1016/S0166-6851(03)00172-5; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Liston DR, 2001, MOL CELL BIOL, V21, P7872, DOI 10.1128/MCB.21.22.7872-7882.2001; Schumacher MA, 2003, CELL, V115, P413, DOI 10.1016/S0092-8674(03)00887-0; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520	10	3	3	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					370	372		10.1016/S0092-8674(03)00888-2	http://dx.doi.org/10.1016/S0092-8674(03)00888-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622590	Bronze			2022-12-28	WOS:000186627100002
J	Villegas, JE; Savel'ev, S; Nori, F; Gonzalez, EM; Anguita, JV; Garcia, R; Vicent, JL				Villegas, JE; Savel'ev, S; Nori, F; Gonzalez, EM; Anguita, JV; Garcia, R; Vicent, JL			A superconducting reversible rectifier that controls the motion of magnetic flux quanta	SCIENCE			English	Article							BROWNIAN MOTORS; VORTEX DYNAMICS; REGULAR ARRAY; FILMS; RATCHET; LATTICE; DEFECTS; DOTS	We fabricated a device that controls the motion of flux quanta in a niobium superconducting film grown on an array of nanoscale triangular pinning potentials. The controllable recti. cation of the vortex motion is due to the asymmetry of the fabricated magnetic pinning centers. The reversal in the direction of the vortex flow is explained by the interaction between the vortices trapped on the magnetic nanostructures and the interstitial vortices. The applied magnetic field and input current strength can tune both the polarity and magnitude of the rectified vortex flow. Our ratchet system is explained and modeled theoretically, taking the interactions between particles into consideration.	Univ Complutense Madrid, Fac Ciencias Fis, Dept Fis Mat, E-28040 Madrid, Spain; RIKEN, Inst Phys & Chem Res, Frontier Res Syst, Wako, Saitama 3510198, Japan; Univ Michigan, Dept Phys, Ctr Theoret Phys, Ann Arbor, MI 48109 USA; CSIC, Ctr Nacl Microelect, Inst Microelect Madrid, Madrid 28760, Spain	Complutense University of Madrid; RIKEN; University of Michigan System; University of Michigan; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Microelectronica (CNM); CSIC - Instituto de Microelectronica de Barcelona (IMB-CNM); CSIC - Instituto de Microelectronica de Madrid (IMM)	Vicent, JL (corresponding author), Univ Complutense Madrid, Fac Ciencias Fis, Dept Fis Mat, E-28040 Madrid, Spain.	jlvicent@fis.ucm.es	Garcia, Ricardo/B-3124-2013; Savel'ev, Sergey E/A-5876-2011; Villegas, Javier E./C-7200-2011; Gonzalez, Elvira/M-6160-2018; Nori, Franco/B-1222-2009	Garcia, Ricardo/0000-0002-7115-1928; Savel'ev, Sergey E/0000-0003-2771-230X; Villegas, Javier E./0000-0002-2096-3360; Nori, Franco/0000-0003-3682-7432; Gonzalez, Elvira M./0000-0001-9360-3596; Microelectronica de Madrid, Instituto de/0000-0003-4211-9045				Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Astumian RD, 2002, PHYS TODAY, V55, P33, DOI 10.1063/1.1535005; BAERT M, 1995, PHYS REV LETT, V74, P3269, DOI 10.1103/PhysRevLett.74.3269; DALDINI O, 1974, PHYS REV LETT, V32, P218, DOI 10.1103/PhysRevLett.32.218; Fasano Y, 1999, PHYS REV B, V60, P15047, DOI 10.1103/PhysRevB.60.R15047; Harada K, 1996, SCIENCE, V274, P1167, DOI 10.1126/science.274.5290.1167; Jaque D, 2002, APPL PHYS LETT, V81, P2851, DOI 10.1063/1.1512947; Kwok WK, 2002, PHYSICA C, V382, P137, DOI 10.1016/S0921-4534(02)01213-3; Lee CS, 1999, NATURE, V400, P337, DOI 10.1038/22578; Linke H, 1999, SCIENCE, V286, P2314, DOI 10.1126/science.286.5448.2314; Linke H., 2002, APPL PHYS A, V75; Martin JI, 1999, PHYS REV LETT, V83, P1022, DOI 10.1103/PhysRevLett.83.1022; Martin JI, 1997, PHYS REV LETT, V79, P1929, DOI 10.1103/PhysRevLett.79.1929; Metlushko V, 1999, PHYS REV B, V60, pR12585, DOI 10.1103/PhysRevB.60.R12585; Morgan DJ, 1998, PHYS REV LETT, V80, P3614, DOI 10.1103/PhysRevLett.80.3614; Nori F, 1996, SCIENCE, V271, P1373, DOI 10.1126/science.271.5254.1373; OTANI Y, 1993, J MAGN MAGN MATER, V126, P622, DOI 10.1016/0304-8853(93)90705-7; PRUYMBOOM A, 1988, PHYS REV LETT, V60, P1430, DOI 10.1103/PhysRevLett.60.1430; Reimann P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3; Rosseel E, 1996, PHYS REV B, V53, pR2983, DOI 10.1103/PhysRevB.53.R2983; Savel'ev S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.010601; Savel'ev S, 2002, NAT MATER, V1, P179, DOI 10.1038/nmat746; Velez M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.094509; Velez M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.104511; Wambaugh JF, 1999, PHYS REV LETT, V83, P5106, DOI 10.1103/PhysRevLett.83.5106; Weiss S, 2000, EUROPHYS LETT, V51, P499, DOI 10.1209/epl/i2000-00365-x; WORDENWEBER R, UNPUB; Zapata I, 1996, PHYS REV LETT, V77, P2292, DOI 10.1103/PhysRevLett.77.2292; Zhu BY, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.014514; Zhu BY, 2003, PHYSICA E, V18, P318, DOI 10.1016/S1386-9477(02)01062-7; Zhu BY, 2003, PHYSICA E, V18, P322, DOI 10.1016/S1386-9477(02)01066-4	31	413	413	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1188	1191		10.1126/science.1090390	http://dx.doi.org/10.1126/science.1090390			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615532				2022-12-28	WOS:000186544300047
J	Schulz, R; Mendelsohn, AB; Haley, WE; Mahoney, D; Allen, RS; Zhang, S; Thompson, L; Belle, SH				Schulz, R; Mendelsohn, AB; Haley, WE; Mahoney, D; Allen, RS; Zhang, S; Thompson, L; Belle, SH		REACH Investigators	End-of-life care and the effects of bereavement on family caregivers of persons with dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; PREVALENCE	Background: Although family caregiving has been intensively studied in the past decade, little attention has been paid to the impact of end-of-life care on caregivers who are family members of persons with dementia or to the caregivers' responses to the death of the patient. Methods: Using standardized assessment instruments and structured questions, we assessed the type and intensity of care provided by 217 family caregivers to persons with dementia during the year before the patient's death and assessed the caregivers' responses to the death. Results: Half the caregivers reported spending at least 46 hours per week assisting patients with activities of daily living and instrumental activities of daily living. More than half the caregivers reported that they felt they were ``on duty'' 24 hours a day, that the patient had frequent pain, and that they had had to end or reduce employment owing to the demands of caregiving. Caregivers exhibited high levels of depressive symptoms while providing care to the relative with dementia, but they showed remarkable resilience after the death. Within three months of the death, caregivers had clinically significant declines in the level of depressive symptoms, and within one year the levels of symptoms were substantially lower than levels reported while they were acting as caregivers. Seventy-two percent of caregivers reported that the death was a relief to them, and more than 90 percent reported belief that it was a relief to the patient. Conclusions: End-of-life care for patients with dementia was extremely demanding of family caregivers. Intervention and support services were needed most before the patient's death. When death was preceded by a protracted and stressful period of caregiving, caregivers reported considerable relief at the death itself.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Aging, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA; Univ S Florida, Dept Gerontol, Tampa, FL USA; Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA; Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA; Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Tuscaloosa; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Schulz, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 121 Univ Pl,6th Fl, Pittsburgh, PA 15260 USA.	schulz@pitt.edu	Haley, William E/B-6133-2017	Haley, William E/0000-0003-0780-3482; Mahoney, Diane/0000-0002-6415-475X; Allen, Rebecca Sue/0000-0002-2563-4996; Mendelsohn, Aaron/0000-0002-0560-1177	NIA NIH HHS [AG 13305] Funding Source: Medline; NINR NIH HHS [NR 13269] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG013255, U01AG013305] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown H., 1999, APPL MIXED MODELS ME; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grant I, 2002, PSYCHOSOM MED, V64, P477, DOI 10.1097/00006842-200205000-00012; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Hurley AC, 2002, JAMA-J AM MED ASSOC, V288, P2324, DOI 10.1001/jama.288.18.2324; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; *OFF ASS SECR PLAN, 1998, INF CAR COMP ACT; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/jama.285.24.3123; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375	19	338	342	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1936	1942		10.1056/NEJMsa035373	http://dx.doi.org/10.1056/NEJMsa035373			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742EA	14614169				2022-12-28	WOS:000186502400010
J	Horton, R				Horton, R			21st-century biomedical journals: failures and futures	LANCET			English	Editorial Material							OPEN-ACCESS; QUALITY		The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							ADAM D, 2003, GUARDIAN        1006, P3; Bok D, 2003, U MARKETPLACE; Brown PO, 2003, PLOS BIOL, V1, P1, DOI 10.1371/journal.pbio.0000036; Butler D, 2003, NATURE, V425, P554, DOI 10.1038/425554a; Crawford BD, 2003, LANCET, V362, P1578, DOI 10.1016/S0140-6736(03)14749-6; HELD MJ, 2003, J CELL BIOL; HENDERSON M, 2003, TIMES           0912, P16; Horton R, 2003, LANCET, V361, P712, DOI 10.1016/S0140-6736(03)12665-7; Jefferson T, 2002, JAMA-J AM MED ASSOC, V287, P2786, DOI 10.1001/jama.287.21.2786; Jefferson T, 2002, JAMA-J AM MED ASSOC, V287, P2784, DOI 10.1001/jama.287.21.2784; Kareiva P, 2002, NATURE, V420, P15, DOI 10.1038/420015a; Lawrence PA, 2003, NATURE, V422, P259, DOI 10.1038/422259a; Tamber PS, 2003, LANCET, V362, P1575, DOI 10.1016/S0140-6736(03)14748-4; *WELLC TRUST, 2003, EC AN SCI RES PUBL	14	20	21	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1510	1512		10.1016/S0140-6736(03)14775-7	http://dx.doi.org/10.1016/S0140-6736(03)14775-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615101				2022-12-28	WOS:000186464500002
J	Zeng, N				Zeng, N			Drought in the Sahel	SCIENCE			English	Editorial Material							TROPICAL NORTH-AFRICA; SUMMER RAINFALL; VARIABILITY; CLIMATE		Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA; Univ Maryland, Earth Syst Sci Interdisciplinary Ctr, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Zeng, N (corresponding author), Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA.		Zeng, Ning/A-3130-2008	Zeng, Ning/0000-0002-7489-7629				CHARNEY JG, 1975, Q J ROY METEOR SOC, V101, P193, DOI 10.1002/qj.49710142802; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Giannini A, 2003, SCIENCE, V302, P1027, DOI 10.1126/science.1089357; GRAHAM NE, 1995, SCIENCE, V267, P666, DOI 10.1126/science.267.5198.666; LAMB PJ, 1978, TELLUS, V30, P240, DOI 10.1111/j.2153-3490.1978.tb00839.x; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; OTTERMAN J, 1974, SCIENCE, V186, P531, DOI 10.1126/science.186.4163.531; Prospero JM, 2003, SCIENCE, V302, P1024, DOI 10.1126/science.1089915; ROWELL DP, 1995, Q J ROY METEOR SOC, V121, P669, DOI 10.1256/smsqj.52310; Taylor CM, 2002, J CLIMATE, V15, P3615, DOI [10.1175/1520-0442(2002)015<3615:TIOLUC>2.0.CO;2, 10.1175/1520-0442(2002)015&lt;3615:TIOLUC&gt;2.0.CO;2]; Ward MN, 1998, J CLIMATE, V11, P3167, DOI 10.1175/1520-0442(1998)011<3167:DASLTP>2.0.CO;2; XUE Y, 1993, J CLIMATE, V5, P2232; Zeng N, 1999, SCIENCE, V286, P1537, DOI 10.1126/science.286.5444.1537	13	135	144	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					999	1000		10.1126/science.1090849	http://dx.doi.org/10.1126/science.1090849			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605358				2022-12-28	WOS:000186396300033
J	Lerman, BB; Basson, CT				Lerman, BB; Basson, CT			High-risk patients with ventricular preexcitation - A pendulum in motion	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PARKINSON-WHITE-SYNDROME; CATHETER ABLATION		Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, New York, NY 10021 USA	Cornell University	Lerman, BB (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, New York, NY 10021 USA.							Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Calkins H, 1999, CIRCULATION, V99, P262, DOI 10.1161/01.CIR.99.2.262; MARKELL RL, 1995, PACE, V18, P1474, DOI 10.1111/j.1540-8159.1995.tb06733.x; Todd DM, 2003, J AM COLL CARDIOL, V41, P245, DOI 10.1016/S0735-1097(02)02707-9; Vaughan CJ, 2003, J CARDIOVASC ELECTR, V14, P263, DOI 10.1046/j.1540-8167.2003.02394.x	5	9	10	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1787	1789		10.1056/NEJMp038137	http://dx.doi.org/10.1056/NEJMp038137			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602876				2022-12-28	WOS:000186353800001
J	Perfit, MR; Cann, JR; Fornari, DJ; Engels, J; Smith, DK; Ridley, WI; Edwards, MH				Perfit, MR; Cann, JR; Fornari, DJ; Engels, J; Smith, DK; Ridley, WI; Edwards, MH			Interaction of sea water and lava during submarine eruptions at mid-ocean ridges	NATURE			English	Article							EAST PACIFIC RISE; MID-ATLANTIC RIDGE; DE-FUCA RIDGE; KILAUEA VOLCANO; SHEET FLOWS; PILLARS; FLOOR; CALIBRATION; MORPHOLOGY; INFLATION	Lava erupts into cold sea water on the ocean floor at mid-ocean ridges ( at depths of 2,500 m and greater), and the resulting flows make up the upper part of the global oceanic crust(1). Interactions between heated sea water and molten basaltic lava could exert significant control on the dynamics of lava flows and on their chemistry. But it has been thought that heating sea water at pressures of several hundred bars cannot produce significant amounts of vapour(2-5) and that a thick crust of chilled glass on the exterior of lava flows minimizes the interaction of lava with sea water. Here we present evidence to the contrary, and show that bubbles of vaporized sea water often rise through the base of lava flows and collect beneath the chilled upper crust. These bubbles of steam at magmatic temperatures may interact both chemically and physically with flowing lava, which could influence our understanding of deep-sea volcanic processes and oceanic crustal construction more generally(6). We infer that vapour formation plays an important role in creating the collapse features that characterize much of the upper oceanic crust and may accordingly contribute to the measured low seismic velocities in this layer.	Univ Florida, Dept Geol Sci, Gainesville, FL 32611 USA; Univ Leeds, Dept Earth Sci, Leeds LS2 9JT, W Yorkshire, England; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Dept Geol & Geophys, Honolulu, HI 96822 USA; Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; US Geol Survey, Mineral Resources Team, Lakewood, CO 80225 USA	State University System of Florida; University of Florida; University of Leeds; Woods Hole Oceanographic Institution; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; United States Department of the Interior; United States Geological Survey	Perfit, MR (corresponding author), Univ Florida, Dept Geol Sci, Gainesville, FL 32611 USA.			Perfit, Michael/0000-0002-1399-8928				BALLARD RD, 1979, J GEOPHYS RES, V84, P5407, DOI 10.1029/JB084iB10p05407; BATIZA R, 2000, ENCY VOLCANOLOGY, P383; Berndt ME, 1997, GEOCHIM COSMOCHIM AC, V61, P2849, DOI 10.1016/S0016-7037(97)00134-8; CHADWICK WW, IN PRESS J GEOPHYS R; Clague DA, 2000, B VOLCANOL, V61, P437, DOI 10.1007/PL00008910; Dixon JE, 1995, J PETROL, V36, P1607; DIXON JE, 1988, EARTH PLANET SC LETT, V90, P87, DOI 10.1016/0012-821X(88)90114-8; EMBLEY RW, 1994, J GEOPHYS RES-SOL EA, V99, P4741, DOI 10.1029/93JB02038; ENGELS J, 2003, GEOCHEM GEOPHY GEOSY, V4, P1078, DOI DOI 10.1029/2003GC000560; Fornari DJ, 1998, J GEOPHYS RES-SOL EA, V103, P9827, DOI 10.1029/98JB00028; Fouquet Y, 1998, TERRA NOVA, V10, P280; FRANCHETEAU J, 1979, NATURE, V281, P209, DOI 10.1038/281209a0; GREGG TKP, 1995, GEOLOGY, V23, P73, DOI 10.1130/0091-7613(1995)023<0073:QOSLFM>2.3.CO;2; Gregg TKP, 1996, GEOLOGY, V24, P981, DOI 10.1130/0091-7613(1996)024<0981:SLFIAM>2.3.CO;2; Gregg TKP, 2000, EARTH PLANET SC LETT, V178, P195, DOI 10.1016/S0012-821X(00)00085-6; GRIFFITHS RW, 1992, J GEOPHYS RES-SOL EA, V97, P19729, DOI 10.1029/92JB01594; HAYMON RM, 1993, EARTH PLANET SC LETT, V119, P85, DOI 10.1016/0012-821X(93)90008-W; Head JW, 2003, J VOLCANOL GEOTH RES, V121, P155, DOI 10.1016/S0377-0273(02)00425-0; HON K, 1994, GEOL SOC AM BULL, V106, P351, DOI 10.1130/0016-7606(1994)106<0351:EAIOPS>2.3.CO;2; Klingelhofer F, 1999, J VOLCANOL GEOTH RES, V92, P215, DOI 10.1016/S0377-0273(99)00092-X; LEROUS PJ, 2002, GOLDSCHMIDT C ABST A, V437; Maicher D, 2001, B VOLCANOL, V63, P482, DOI 10.1007/s004450100165; Michael PJ, 1998, J GEOPHYS RES-SOL EA, V103, P18325, DOI 10.1029/98JB00791; PERFIT MR, 1999, AGU MONOGRAPH, V106, P59; Peterson D. W., 1974, STUDIES SPELEO, V2, p209 ; Sharapov VN, 2001, GEOL ORE DEPOSIT+, V43, P76; SINTON J, 2000, J GEOPHYS RES, V107; Smith DK, 1999, J GEOPHYS RES-SOL EA, V104, P25379, DOI 10.1029/1999JB900177; SOURIRAJAN S, 1962, AM J SCI, V260, P115, DOI 10.2475/ajs.260.2.115; TRIBBLE GW, 1991, GEOLOGY, V19, P633, DOI 10.1130/0091-7613(1991)019<0633:UOOALF>2.3.CO;2; WATTERS AC, 1960, AM J SCI A, V258, P350	31	44	44	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					62	65		10.1038/nature02032	http://dx.doi.org/10.1038/nature02032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603316				2022-12-28	WOS:000186370800040
J	Pizzari, T; Cornwallis, CK; Lovlie, H; Jakobsson, S; Birkhead, TR				Pizzari, T; Cornwallis, CK; Lovlie, H; Jakobsson, S; Birkhead, TR			Sophisticated sperm allocation in male fowl	NATURE			English	Article							GALLUS-GALLUS; COMPETITION; STRATEGIES; EJACULATE; BEHAVIOR; CHOICE; EXPENDITURE	When a female is sexually promiscuous, the ejaculates of different males compete for the fertilization of her eggs(1); the more sperm a male inseminates into a female, the more likely he is to fertilize her eggs(2). Because sperm production is limited and costly, theory predicts that males will strategically allocate sperm (1) according to female promiscuity(1,3-5), (2) saving some for copulations with new females(3,6,7), and (3) to females producing more and/or better offspring(3,8). Whether males allocate sperm in all of these ways is not known, particularly in birds where the collection of natural ejaculates only recently became possible. Here we demonstrate male sperm allocation of unprecedented sophistication in the fowl Gallus gallus. Males show status-dependent sperm investment in females according to the level of female promiscuity; they progressively reduce sperm investment in a particular female but, on encountering a new female, instantaneously increase their sperm investment; and they preferentially allocate sperm to females with large sexual ornaments signalling superior maternal investment. Our results indicate that female promiscuity leads to the evolution of sophisticated male sexual behaviour.	Swedish Univ Agr Sci, Dept Anim Environm & Hlth, SE-53223 Uppsala, Sweden; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	Swedish University of Agricultural Sciences; University of Sheffield	Pizzari, T (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	t.pizzari@leeds.ac.uk	Cornwallis, Charlie/A-6276-2012					Bakst M.R., 1997, TECHNIQUES SEMEN EVA; BIRKHEAD TR, 1988, NATURE, V334, P60, DOI 10.1038/334060a0; CLUTTONBROCK TH, 1979, ANIM BEHAV, V27, P211, DOI 10.1016/0003-3472(79)90141-6; DER G, 2001, HDB STAT ANAL USING; DEWSBURY DA, 1982, AM NAT, V119, P601, DOI 10.1086/283938; Evans JP, 2003, BEHAV ECOL, V14, P268, DOI 10.1093/beheco/14.2.268; Fumihito A, 1996, P NATL ACAD SCI USA, V93, P6792, DOI 10.1073/pnas.93.13.6792; Hunter FM, 2000, P ROY SOC B-BIOL SCI, V267, P1541, DOI 10.1098/rspb.2000.1176; ISHIKAWA H, 1930, P WORLD POULT J C, P90; MARTIN PA, 1974, J REPROD FERTIL, V39, P251, DOI 10.1530/jrf.0.0390251; Parker G.A., 1998, SPERM COMPETITION SE, P3, DOI DOI 10.1016/B978-012100543-6/50026-X; Parker J. E., 1942, MISS AGR EXP STATION, V347, P3; Pilastro A, 2002, P NATL ACAD SCI USA, V99, P9913, DOI 10.1073/pnas.152133499; PITNICK S, 1994, AM NAT, V143, P785, DOI 10.1086/285633; Pizzari T, 2000, NATURE, V405, P787, DOI 10.1038/35015558; Pizzari T, 2002, TRENDS ECOL EVOL, V17, P456, DOI 10.1016/S0169-5347(02)02591-0; Pizzari T, 2001, ANIM BEHAV, V61, P601, DOI 10.1006/anbe.2000.1620; Pizzari T, 2001, P ROY SOC B-BIOL SCI, V268, P181, DOI 10.1098/rspb.2000.1348; PIZZARI T, IN PRESS BEHAV ECOL; Reinhold K, 2002, J EVOLUTION BIOL, V15, P201, DOI 10.1046/j.1420-9101.2002.00390.x; Schutz KE, 2001, ETHOLOGY, V107, P753, DOI 10.1046/j.1439-0310.2001.00703.x; Wedell N, 2002, TRENDS ECOL EVOL, V17, P313, DOI 10.1016/S0169-5347(02)02533-8; Westneat DF, 1998, BEHAV ECOL SOCIOBIOL, V43, P161, DOI 10.1007/s002650050477; WILSON JR, 1963, J COMP PHYSIOL PSYCH, V56, P636, DOI 10.1037/h0042469; ZUK M, 1995, P ROY SOC B-BIOL SCI, V260, P205, DOI 10.1098/rspb.1995.0081	25	246	249	4	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					70	74		10.1038/nature02004	http://dx.doi.org/10.1038/nature02004			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603319	Green Accepted			2022-12-28	WOS:000186370800043
J	Li, SX; Chen, W; Srinivasan, SR; Bond, MG; Tang, R; Urbina, EM; Berenson, GS				Li, SX; Chen, W; Srinivasan, SR; Bond, MG; Tang, R; Urbina, EM; Berenson, GS			Childhood cardiovascular risk factors and carotid vascular changes in adulthood - The Bogalusa Heart Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTIMA-MEDIA THICKNESS; ARTERIAL-WALL THICKNESS; BLACK-WHITE DIFFERENCES; B-MODE ULTRASOUND; YOUNG-ADULTS; INSULIN-RESISTANCE; ATHEROSCLEROTIC LESIONS; ADIPOSE-TISSUE; SERUM-LIPOPROTEINS; CHOLESTEROL LEVELS	Context Carotid artery intima-media thickness (IMT) is associated with cardiovascular risk factors and is recognized as an important predictive measure of clinical coronary atherosclerosis events in middle-aged and elderly populations. However, information on the association of carotid IMT in young adults with different risk factors measured in childhood, adulthood, or as a cumulative burden of each of the risk factors measured serially from childhood to adulthood is limited. Objective To examine the association between carotid IMT in young adults and traditional cardiovascular risk factors measured since childhood. Design, Setting, and Participants A cohort study of 486 adults aged 25 to 37 years from a semirural black and white community in Bogalusa, La (71% white, 39% men), who had at least 3 measurements of traditional risk factors since childhood, conducted between September 1973 and December 1996. Main Outcome Measure Association of carotid IMT with risk factors, including systolic blood pressure, lipoprotein levels, and body mass index. Results Male vs female (0.757 mm Vs 0.719 mm) and black vs white (0.760 mm vs 0.723 mm) participants had increased carotid IMT (P<.001 for both). In multivariable analyses, significant predictors for being in top vs lower 3 quartiles of carotid IMT in young adults were childhood measures of low-density lipoprotein cholesterol (LDL-C) level (odds ratio [OR], 1.42, corresponding to 1-SD change specific for age, race, and sex; 95% confidence interval [CI], 1.14-1.78) and body mass index (BMI; OR, 1.25; 95% CI, 1.01-1.54); adulthood measures of LDL-C level (OR, 1.46; 95% CI, 1.16-1.82), high-density lipoprotein cholesterol (HDL-C) level (OR; 0.67; 95% CI, 0.51-0.88), and systolic blood pressure (OR, 1.36; 95% CI, 1.08-1.72); and long-term cumulative burden of LDL-C (OR, 1.58; 95% CI, 1.24-2.01) and HDL-C (OR, 0.75; 95% CI, 0.58-0.97) levels measured serially from childhood to adulthood. An increasing trend in carotid IMT across quartiles of LDL-C level measured in childhood was observed, with a mean value of 0.761 mm (95% CI, 0.743-0.780 mm) for those at the top quartile vs 0.724 mm (95% CI, 0.715-0.734 mm) for those in the lower 3 quartiles (P<.001). Conclusions Childhood measures of LDL-C level and BMI predict carotid IMT in young adults: The prevention implications of these findings remains to be explored.	Tulane Univ, Hlth Sci Ctr, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Epidemiol, New Orleans, LA 70112 USA; Wake Forest Univ, Bowman Gray Sch Med, Div Vasc Ultrasound Res, Winston Salem, NC USA	Tulane University; Tulane University; Wake Forest University; Wake Forest Baptist Medical Center	Berenson, GS (corresponding author), Tulane Univ, Hlth Sci Ctr, Tulane Ctr Cardiovasc Hlth, 1440 Canal St,Suite 1829, New Orleans, LA 70112 USA.		Li, Shengxu/D-8915-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD043820] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL038844, R01HL038844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016592] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38844] Funding Source: Medline; NIA NIH HHS [AG-16592] Funding Source: Medline; NICHD NIH HHS [HD-043820] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKERBLOM HK, 1991, ANN MED, V23, P35, DOI 10.3109/07853899109147928; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Bao WH, 1996, ARCH INTERN MED, V156, P1315, DOI 10.1001/archinte.156.12.1315; Berenson G.S., 1986, CAUSATION CARDIOVASC; Berenson GS, 2002, AM J CARDIOL, V90, p3L, DOI 10.1016/S0002-9149(02)02953-3; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BUCULO G, 1973, CLIN CHEM, V19, P476; BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; Chambless LE, 2002, AM J EPIDEMIOL, V155, P38, DOI 10.1093/aje/155.1.38; Chobanian AV, 1996, ARCH INTERN MED, V156, P1952, DOI 10.1001/archinte.156.17.1952; Crouse JR, 2002, CIRCULATION, V106, P2061, DOI 10.1161/01.CIR.0000033833.54884.34; DAgostino RB, 1996, STROKE, V27, P1744, DOI 10.1161/01.STR.27.10.1744; Davis PH, 2001, CIRCULATION, V104, P2815, DOI 10.1161/hc4601.099486; DONAHUE RP, 1989, ARTERIOSCLEROSIS, V9, P656, DOI 10.1161/01.ATV.9.5.656; Engeli S, 2000, HYPERTENSION, V35, P1270, DOI 10.1161/01.HYP.35.6.1270; Greenlund KJ, 1998, ANN EPIDEMIOL, V8, P22, DOI 10.1016/S1047-2797(97)00127-0; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hulthe J, 1997, STROKE, V28, P1189, DOI 10.1161/01.STR.28.6.1189; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAUER RM, 1988, PEDIATRICS, V82, P309; LAUER RM, 1980, CHILDHOOD PREVENTION; Lipid Research Clinics Program, 1974, DHEW PUBL; Mannami T, 2000, ARCH INTERN MED, V160, P2297, DOI 10.1001/archinte.160.15.2297; MANOLIO TA, 1995, J CLIN EPIDEMIOL, V48, P1141, DOI 10.1016/0895-4356(94)00240-Q; McGill HC, 1998, ARTERIOSCL THROM VAS, V18, P1108, DOI 10.1161/01.ATV.18.7.1108; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; MORRISON JA, 1979, METABOLISM, V28, P241, DOI 10.1016/0026-0495(79)90070-2; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; O'Leary DH, 2002, AM J CARDIOL, V90, p18L, DOI 10.1016/S0002-9149(02)02957-0; PORKKA KVK, 1994, AM J EPIDEMIOL, V140, P1096, DOI 10.1093/oxfordjournals.aje.a117210; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Riley WA, 1991, J NEUROIMAGING, V1, P168, DOI DOI 10.1111/JON199114168; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG; SRINIVASAN SR, 1975, BIOCHIM BIOPHYS ACTA, V388, P58, DOI 10.1016/0005-2760(75)90062-4; SRINIVASAN SR, 1991, PREV MED, V20, P671, DOI 10.1016/0091-7435(91)90063-A; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STOUT RW, 1987, LANCET, V1, P1077; Tang R, 2000, J HYPERTENS, V18, P197, DOI 10.1097/00004872-200018020-00010; Urbina EM, 2002, AM J CARDIOL, V90, P953, DOI 10.1016/S0002-9149(02)02660-7; Wilson PWF, 1997, NEW ENGL J MED, V337, P516, DOI 10.1056/NEJM199708213370802; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; 1995, AM J MED SCI S1, V310, pS1	49	716	749	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2271	2276		10.1001/jama.290.17.2271	http://dx.doi.org/10.1001/jama.290.17.2271			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600185	Bronze			2022-12-28	WOS:000186356800021
J	Michalsen, A; Klotz, S; Ludtke, R; Moebus, S; Spahn, G; Dobos, GJ				Michalsen, A; Klotz, S; Ludtke, R; Moebus, S; Spahn, G; Dobos, GJ			Effectiveness of leech therapy in osteoarthritis of the knee - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MEDICINAL LEECHES; HIRUDO-MEDICINALIS; TOPICAL DICLOFENAC; VENOUS CONGESTION; SYNOVIAL-FLUID; CLINICAL-TRIAL; DOUBLE-BLIND; PLASMA; INHIBITION	Background: Leech therapy was commonly used in traditional medicine for treating localized pain. Clinically significant pain relief after leech therapy for osteoarthritis of the knee has been demonstrated by preliminary data. Objective: To evaluate the effectiveness of leech therapy for symptomatic relief of osteoarthritis of the knee. Design: Randomized, controlled trial. Setting: Outpatient department for integrative medicine of an academic teaching hospital. Patients: 51 patients with osteoarthritis of the knee (leech therapy: 24 patients, mean age [+/-SD], 62.5 +/- 10.2 years; topical diclofenac therapy: 27 patients, mean age [+/-SD], 65.5 +/- 6.7 years). Intervention: A single treatment with 4 to 6 locally applied leeches (leech therapy group) or a 28-day topical diclofenac regimen (control group). Measurements: mean of the pain, function, and stiffness subscores of the Western Ontario and McMaster Universities Osteoarthritis Index and physical sum score of the Medical Outcomes Study 36-Item Short-Form Health Survey with group comparisons at days 3, 7, 28, and 91. Results: The primary end point, pain at day 7, was reduced from a mean (+/-SD) of 53.5 +/- 13.7 to 19.3 +/- 12.2 after leech therapy compared with 51.5 +/- 16.8 to 42.4 +/- 19.7 with topical diclofenac (estimated group difference, -23.9 [95% Cl, -32.8 to -15.1]; P < 0.001). Although the difference between group pain scores was no longer significant after day 7, differences for function, stiffness, and total symptoms remained significant in favor of leech therapy until the end of study and for quality of life until day 28. Results were not affected by outcome expectation. Conclusions: Leech therapy helps relieve symptoms in patients with osteoarthritis of the knee. The potential of leech therapy for treating osteoarthritis and the pharmacologic properties of leech saliva remain to be clarified.	Univ Duisburg Essen, Acad Teaching Hosp, Kliniken Essen Mitte, Essen, Germany; Univ Duisburg Essen, Veronica Carstens Fdn, Essen, Germany; Univ Duisburg Essen, Inst Med Informat Biometry & Epidemiol, Essen, Germany	Kliniken Essen-Mitte; University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Dobos, GJ (corresponding author), Kliniken Essen Mitte, Dept Internal Med 5, Deimelsberg 34 A, D-45276 Essen, Germany.	gustav.dobos@uni-essen.de		Moebus, Susanne/0000-0002-0072-5410				ADAMS SL, 1988, ANN INTERN MED, V109, P399, DOI 10.7326/0003-4819-109-5-399; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; BASKOVA IP, 1992, THROMB RES, V67, P721, DOI 10.1016/0049-3848(92)90076-M; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bruhlmann P, 2003, CLIN EXP RHEUMATOL, V21, P193; Claude A, 1940, P SOC EXP BIOL MED, V43, P684; DABB RW, 1992, ANN PLAS SURG, V29, P250, DOI 10.1097/00000637-199209000-00010; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Eldor A, 1996, BLOOD REV, V10, P201, DOI 10.1016/S0268-960X(96)90000-4; FIELDS WS, 1991, HAEMOSTASIS, V21, P3; FOWLER PD, 1986, EUR J CLIN PHARMACOL, V31, P469, DOI 10.1007/BF00613526; GIACOMETTI L, 1987, AM J CARDIOL, V60, P1128, DOI 10.1016/0002-9149(87)90366-3; Grace D, 1999, J RHEUMATOL, V26, P2659; Guthrie DA, 1946, HIST MED; KELLGREN JA, 1993, ATLAS STANDARD RADIO; LINEAWEAVER WC, 1992, ANN PLAS SURG, V29, P238, DOI 10.1097/00000637-199209000-00008; LINEAWEAVER WC, 1991, BLOOD COAGUL FIBRIN, V2, P201, DOI 10.1097/00001721-199102000-00032; Mackay DR, 1999, ANN PLAS SURG, V42, P275, DOI 10.1097/00000637-199903000-00008; Markwardt F, 2002, SEMIN THROMB HEMOST, V28, P405, DOI 10.1055/s-2002-35292; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; Michalsen A, 2002, ALTERN THER HEALTH M, V8, P84; Michalsen A, 2001, ANN RHEUM DIS, V60, P986, DOI 10.1136/ard.60.10.986; Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Muller IW, 2000, HDB BLUTEGELTHERAPIE; Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936; RADERMACHER J, 1991, BRIT J CLIN PHARMACO, V31, P537, DOI 10.1111/j.1365-2125.1991.tb05576.x; RIGBI M, 1987, COMP BIOCHEM PHYS C, V88, P95, DOI 10.1016/0742-8413(87)90052-1; RIGBI M, 1987, COMP BIOCHEM PHYS B, V87, P567, DOI 10.1016/0305-0491(87)90053-8; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SAWYER R.T., 1986, LEECH BIOL BEHAV, VII; Schaible HG, 2002, ANN NY ACAD SCI, V966, P343, DOI 10.1111/j.1749-6632.2002.tb04234.x; Shah S, 1998, LANCET, V352, P2014, DOI 10.1016/S0140-6736(98)09291-5; van Haselen RA, 2000, RHEUMATOLOGY, V39, P714, DOI 10.1093/rheumatology/39.7.714; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinfeld AB, 2000, ANN PLAS SURG, V45, P207, DOI 10.1097/00000637-200045020-00021; Whitehead J., 1999, DESIGN ANAL SEQUENTI; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	38	89	93	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					724	730		10.7326/0003-4819-139-9-200311040-00006	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738XJ	14597456				2022-12-28	WOS:000186312900002
J	Blutt, SE; Kirkwood, CD; Parreno, V; Warfield, KL; Ciarlet, M; Estes, MK; Bok, K; Bishop, RF; Conner, ME				Blutt, SE; Kirkwood, CD; Parreno, V; Warfield, KL; Ciarlet, M; Estes, MK; Bok, K; Bishop, RF; Conner, ME			Rotavirus antigenaemia and viraemia: a common event?	LANCET			English	Article							POLYMERASE-CHAIN-REACTION; CEREBROSPINAL-FLUID; REVERSE TRANSCRIPTION; LYMPHOID-TISSUES; GASTROENTERITIS; INFECTION; IMMUNODEFICIENCY; ENCEPHALOPATHY; CHILD; VP7	Background Rotavirus infection is thought to be confined to the intestine. Reports of rotavirus RNA in the cerebral spinal fluid and serum of children infected with rotavirus suggest the possibility that rotavirus escapes the intestine into the circulatory system. We assessed whether rotavirus antigen, RNA, or both, were present in serum samples from immunocompetent rotavirus-infected children and animals. Methods We obtained sera from immunocompetent mice, rats, rabbits, and calves 1-10 days after inoculation with rotavirus or matched vehicle. We obtained sera retrospectively from immunocompetent children diagnosed with rotavirus diarrhoea (n=33), healthy children (n=6) and adults (n=12), children convalescing from rotavirus (n=6), and children with non-rotavirus diarrhoea (n=11). Samples were analysed for the presence of rotavirus antigen or RNA by EIA or RT-PCR, respectively. Findings Rotavirus antigen was present in sera from rotavirus-infected animals, but not in sera from control animals. Infectious rotavirus or rotavirus RNA was detected in sera of mice and calves, respectively. Antigen was present in 22 of 33 serum samples from children with confirmed rotavirus infection but in none of 35 samples from controls. Detection of serum antigen was inversely related to the number of days between symptom onset and sample collection, and directly related to stool antigen concentration. Rotavirus RNA was detected by RT-PCR in three of six rotavirus-positive sera. Interpretation Rotavirus can escape the gastrointestinal tract in children, resulting in antigenaemia and possible viraemia. This finding is important for the understanding of the pathogenesis, immunology, and clinical manifestations of rotavirus infection.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Murdoch Childrens Res Inst,Enter Virus Res Grp, Melbourne, Vic, Australia; INTA, CICVyA, Inst Virol, Buenos Aires, DF, Argentina; INEI ANLIS, Dept Virol, Lab Gastroenteritis Virales, Buenos Aires, DF, Argentina; Vet Affairs Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Instituto Nacional de Tecnologia Agropecuaria (INTA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Conner, ME (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.		Conner, Margaret E./I-7230-2019	parreno, viviana/0000-0003-0385-5592	NIAID NIH HHS [F32-AI10604, R01 AI24998] Funding Source: Medline; NIDDK NIH HHS [DK56338] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010604, R01AI024998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown KA, 1998, MICROB PATHOGENESIS, V24, P327, DOI 10.1006/mpat.1997.0198; Conner Margaret E., 1997, P713; COULSON BS, 1987, J CLIN MICROBIOL, V25, P509, DOI 10.1128/JCM.25.3.509-515.1987; DHARAKUL T, 1988, CLIN EXP IMMUNOL, V74, P14; ESTES MK, 1997, FIELDS VIROLOGY, P1625; GILGER MA, 1992, J PEDIATR-US, V120, P912, DOI 10.1016/S0022-3476(05)81959-6; Goldwater PN, 2001, J PAEDIATR CHILD H, V37, P206, DOI 10.1046/j.1440-1754.2001.00596.x; GOUVEA V, 1994, J CLIN MICROBIOL, V32, P1338, DOI 10.1128/JCM.32.5.1338-1340.1994; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; Iturriza-Gomara M, 2002, J CLIN MICROBIOL, V40, P4797, DOI 10.1128/JCM.40.12.4797-4799.2002; KRAFT LM, 1958, YALE J BIOL MED, V31, P122; Limbos MAP, 1996, CLIN INFECT DIS, V22, P834, DOI 10.1093/clinids/22.5.834; Lynch M, 2001, CLIN INFECT DIS, V33, P932, DOI 10.1086/322650; MCCORMACK JG, 1982, J INFECTION, V4, P167, DOI 10.1016/S0163-4453(82)93777-X; Morrison C, 2001, HUM PATHOL, V32, P216, DOI 10.1053/hupa.2001.21565; Mossel EC, 2002, J VIROL, V76, P6502, DOI 10.1128/JVI.76.13.6502-6509.2002; Nigrovic LE, 2002, CLIN INFECT DIS, V34, P130, DOI 10.1086/323560; NISHIMURA S, 1993, BRAIN DEV-JPN, V15, P457, DOI 10.1016/0387-7604(93)90088-P; ONeal CM, 1997, J VIROL, V71, P8707, DOI 10.1128/JVI.71.11.8707-8717.1997; Pang XL, 1996, PEDIATR INFECT DIS J, V15, P543, DOI 10.1097/00006454-199606000-00015; SAULSBURY FT, 1980, J PEDIATR-US, V97, P61, DOI 10.1016/S0022-3476(80)80131-4; Takahashi S, 1999, EUR J PEDIATR, V158, P133, DOI 10.1007/s004310051033; USHIJIMA H, 1994, J CLIN MICROBIOL, V32, P2893, DOI 10.1128/JCM.32.12.2893-2897.1994; YOSHIDA A, 1995, PEDIATR INFECT DIS J, V14, P914	24	164	179	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1445	1449		10.1016/S0140-6736(03)14687-9	http://dx.doi.org/10.1016/S0140-6736(03)14687-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602437				2022-12-28	WOS:000186356600009
J	Mallucci, G; Dickinson, A; Linehan, J; Klohn, PC; Brandner, S; Collinge, J				Mallucci, G; Dickinson, A; Linehan, J; Klohn, PC; Brandner, S; Collinge, J			Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; KNOCKOUT MICE; PROTEIN PRP; SCRAPIE; EXPRESSION; RESISTANT; STRAINS	The mechanisms involved in prion neurotoxicity are unclear, and therapies preventing accumulation of PrPSc, the disease-associated form of prion protein (PrP), do not significantly prolong survival in mice with central nervous system prion infection. We found that depleting endogenous neuronal PrPc in mice with established neuroinvasive prion infection reversed early spongiform change and prevented neuronal loss and progression to clinical disease. This occurred despite the accumulation of extraneuronal PrPSc to levels seen in terminally ill wild-type animals. Thus, the propagation of non-neuronal PrPSc is not pathogenic, but arresting the continued conversion of PrPc to PrPSc within neurons during scrapie infection prevents prion neurotoxicity.	MRC, Prion Unit, London WC1, England; Inst Neurol, Dept Neurodgenerat Dis, London WC1, England		Collinge, J (corresponding author), MRC, Prion Unit, Queen Sq, London WC1, England.		Kloehn, Peter/AAS-3719-2021; Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Mallucci, Giovanna/0000-0001-8504-1191	Medical Research Council [MC_U132692719, MC_U123160654] Funding Source: Medline; MRC [MC_U123160654] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Baker CA, 1999, J VIROL, V73, P5089, DOI 10.1128/JVI.73.6.5089-5097.1999; Baker CA, 2002, J VIROL, V76, P10905, DOI 10.1128/JVI.76.21.10905-10913.2002; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; Collins SJ, 2002, ANN NEUROL, V52, P503, DOI 10.1002/ana.10336; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Goelz MF, 1998, LAB ANIM SCI, V48, P34; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MEDORI R, 1992, PRION DIS HUMANS ANI, pCH18; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; Tremblay P, 1998, P NATL ACAD SCI USA, V95, P12580, DOI 10.1073/pnas.95.21.12580	22	529	551	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					871	874		10.1126/science.1090187	http://dx.doi.org/10.1126/science.1090187			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593181				2022-12-28	WOS:000186258000051
J	Meyer, G; Brose, N				Meyer, G; Brose, N			SPARring with spines	SCIENCE			English	Editorial Material							SYNAPTIC PLASTICITY; MORPHOLOGY; UBIQUITIN; PROTEIN		Max Planck Inst Expt Med, Dept Mol Neurosci, D-37075 Gottingen, Germany	Max Planck Society	Meyer, G (corresponding author), Max Planck Inst Expt Med, Dept Mol Neurosci, D-37075 Gottingen, Germany.							Ackermann M, 2003, NAT NEUROSCI, V6, P1194, DOI 10.1038/nn1135; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; MEYER G, UNPUB; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; PARK DTS, 2003, SCIENCE, V302, P1368, DOI DOI 10.1126/SC2ENCE.1082475	9	12	13	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1341	+		10.1126/science.1092039	http://dx.doi.org/10.1126/science.1092039			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631024				2022-12-28	WOS:000186683500034
J	Wilson, JF				Wilson, JF			The crucial link between literacy and health	ANNALS OF INTERNAL MEDICINE			English	Article							KNOWLEDGE; ASSOCIATION; CARE						Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Kalichman SC, 2000, J ACQ IMMUN DEF SYND, V25, P337, DOI 10.1097/00126334-200012010-00007; Lindau ST, 2002, AM J OBSTET GYNECOL, V186, P938, DOI 10.1067/mob.2002.122091; Parker RM, 2003, HEALTH AFFAIR, V22, P147, DOI 10.1377/hlthaff.22.4.147; Rudd Rima E., 1999, ANN REV ADULT LEARNI, P175; Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; SCILLINGER D, IN PRESS PATIENT ED; Tappe MK, 2001, J SCHOOL HEALTH, V71, P477, DOI 10.1111/j.1746-1561.2001.tb07284.x; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008	10	49	51	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					875	878		10.7326/0003-4819-139-10-200311180-00038	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00038			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744ZV	14623636				2022-12-28	WOS:000186663500031
J	Dabis, F				Dabis, F			Children and HIV in Africa: what is next?	LANCET			English	Editorial Material									Univ Victor Segalen, INSERM, U593, Inst Sante Publ Epidemiol & Dev, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Dabis, F (corresponding author), Univ Victor Segalen, INSERM, U593, Inst Sante Publ Epidemiol & Dev, F-33076 Bordeaux, France.		DABIS, FRANCOIS/S-9298-2019	DABIS, FRANCOIS/0000-0002-1614-8857				ASSIIMWEOKIROR G, 1997, AIDS, V11, P1757; *COL U MAILM SCH P, MTCT PLUS EXP HIV AI; Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2; DABIS F, 2003, ANTIVIR THER S, V8, pS236; Foster G, 2002, NEW ENGL J MED, V346, P1907, DOI 10.1056/NEJMsb020718; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; NEWELL ML, 2003, 13 INT C AIDS SEX TR; OTIENO P, 2003, 13 INT C AIDS SEX TR; Rouet F, 2003, PEDIATRICS, V112, pE289, DOI 10.1542/peds.112.4.e289; *UNAIDS, 2002, HIV AIDS EP SURV UPD; *WHO, 2003, GLOB AIDS TREATM STR	11	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1597	1598		10.1016/S0140-6736(03)14839-8	http://dx.doi.org/10.1016/S0140-6736(03)14839-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630437				2022-12-28	WOS:000186637400005
J	Geiger, HJ; Borchelt, G				Geiger, HJ; Borchelt, G			Racial and ethnic disparities in US health care	LANCET			English	Editorial Material									Phys Human Rights, Washington, DC 20005 USA; CUNY, Sch Med, New York, NY 10031 USA	City University of New York (CUNY) System	Borchelt, G (corresponding author), Phys Human Rights, 1156 15th St NW,Suite 1001, Washington, DC 20005 USA.							*I MED, 2003, UN TREATM CONFR RAC; Ibrahim SA, 2003, AM J PUBLIC HEALTH, V93, P1689, DOI 10.2105/AJPH.93.10.1689; KHIMM S, 2003, ALTERNET        1016; MURPHY D, 2003, NY TIMES        0803; *PHR, 2003, RIGHT EQ TREATM ACT; *RAC PRIV IN, CLASS RAC ETHN COL N	6	12	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1674	1674		10.1016/S0140-6736(03)14806-4	http://dx.doi.org/10.1016/S0140-6736(03)14806-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744MZ	14631976				2022-12-28	WOS:000186637400031
J	Lang, AE				Lang, AE			Subthalamic stimulation for Parkinson's disease - Living better electrically?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Toronto, ON, Canada	University of Toronto	Lang, AE (corresponding author), Univ Toronto, Toronto, ON, Canada.		Lang, Anthony/ABF-8114-2021	Lang, Anthony/0000-0003-1229-3667				Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4	3	10	10	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1888	1891		10.1056/NEJMp038160	http://dx.doi.org/10.1056/NEJMp038160			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614163				2022-12-28	WOS:000186502400002
J	Bruera, E; Kim, HN				Bruera, E; Kim, HN			Cancer pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORPHINE; SYSTEM; TRIAL		Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil med, Unit 008, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bruera, E (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil med, Unit 008, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Bennett, Sally/B-3367-2010; Bruera, Eduardo/AAA-1550-2022	Bennett, Sally/0000-0002-4353-5027; 				BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; Bruera E, 1996, J PAIN SYMPTOM MANAG, V11, P147, DOI 10.1016/0885-3924(95)00161-1; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera E, 1989, J Pain Symptom Manage, V4, P3, DOI 10.1016/0885-3924(89)90057-2; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Bruera E, 1999, SUPPORT CARE CANCER, V7, P321, DOI 10.1007/s005200050269; BRUERA E, IN PRES J CLIN ONCOL; BRUERA E, 2003, CLIN PAIN MANAGEMENT, P63; BRUERA E, IN PRESS J PAIN SYMP; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Centeno C, 2003, HDB ADV CANC CARE, P27; CHERNEY IN, 2002, PRINCIPLE PRACTICE P, P3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Foley KM, 2000, HOSP PRACT, V35, P101, DOI 10.3810/hp.2000.04.193; Hassenbusch SJ, 2003, CANCER PAIN: ASSESSMENT AND MANAGEMENT, P261, DOI 10.1017/CBO9780511550096.016; Mancini I, 2002, GASTROINTESTINAL SYM, P193; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P338, DOI 10.1016/S0885-3924(01)00250-0; PEREIRA J, 1998, TOPICS PALLIATIVE CA, V3, P79; RAWLINS MC, 1998, PALLIATIVE MED, P355; Ripamonti C, 2003, CANCER PAIN: ASSESSMENT AND MANAGEMENT, P124, DOI 10.1017/CBO9780511550096.009; Ripamonti C, 1998, TUMORI J, V84, P289, DOI 10.1177/030089169808400302; Ross JR, 2003, BMJ-BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; STRASSER F, 2003, IN PRESS CANC PAIN; WHO, 1996, WORLD HLTH REP 1996; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; GUIDELINES USING EDM	27	124	133	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2476	2479		10.1001/jama.290.18.2476	http://dx.doi.org/10.1001/jama.290.18.2476			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612485				2022-12-28	WOS:000186518300035
J	Bruynseels, P; Jorens, PG; Demey, HE; Goossens, H; Pattyn, SR; Elseviers, MM; Weyler, J; Bossaert, LL; Mentens, Y; Ieven, M				Bruynseels, P; Jorens, PG; Demey, HE; Goossens, H; Pattyn, SR; Elseviers, MM; Weyler, J; Bossaert, LL; Mentens, Y; Ieven, M			Herpes simplex virus in the respiratory tract of critical care patients: a prospective study	LANCET			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; DISTRESS SYNDROME; SURGICAL PATIENTS; INFECTION; PATHOGENESIS; MECHANISMS	Background Herpes simplex virus (HSV) is occasionally detected in the lower respiratory tract of patients in intensive care, but its clinical importance in such situations remains unclear. We did a prospective cohort study to define the prevalence, origin, risk factors, and clinical relevance of HSV in the respiratory tract of patients undergoing critical care. Methods We tested 764 patients admitted to intensive care for the presence of HSV in the respiratory tract, and assessed statistical relations between this virus and clinical variables. Findings HSV was detected by oropharyngeal swab in the upper respiratory tract of 169 (22%) of 764 patients, within 10 days of admission for 150 (89%) of these individuals. The virus was isolated in 58 (16%) of 361 patients whose lower respiratory tract was sampled. The presence of HSV in the throat was a risk factor for development of HSV infections in the lower respiratory tract (p<0-001). HSV was isolated most frequently in patients with severe disease. HSV in the throat was associated with acute respiratory distress syndrome (p<0-001) and with increased length of stay in intensive care (P<0-001). Interpretation Our data suggest that HSV reactivation or infection of the upper respiratory tract is frequent among patients in intensive care, and is a risk factor for development of lower respiratory tract infection with this virus, possibly by means of aspiration.	Univ Antwerp Hosp, Dept Microbiol, B-2650 Antwerp, Belgium; Univ Antwerp Hosp, Dept Intens Care Med, B-2650 Antwerp, Belgium; Univ Antwerp Hosp, Dept Resp Med, B-2650 Antwerp, Belgium; Univ Antwerp, Dept Epidemiol & Community Med, B-2020 Antwerp, Belgium	University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp	Bruynseels, P (corresponding author), Univ Antwerp Hosp, Dept Microbiol, Wilrijkstr 10, B-2650 Antwerp, Belgium.		Weyler, Joost JJ/O-8594-2016	Weyler, Joost JJ/0000-0001-7271-5492; Elseviers, Monique/0000-0001-9415-6900				AURELIAN L, 2000, CLIN VIROLOGY MANUAL; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BEYERS RJ, 1996, EUR RESPIR J, V9, P2313; Cook CH, 1998, AM J SURG, V176, P357, DOI 10.1016/S0002-9610(98)00205-0; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Hart GD, 2001, REV MED VIROL, V11, P73, DOI 10.1002/rmv.309; JORENS PG, 1997, YB INTENSIVE CARE EM, P83; Kingreen D, 1997, BONE MARROW TRANSPL, V20, P989, DOI 10.1038/sj.bmt.1700995; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koerner RJ, 1997, J HOSP INFECT, V35, P83, DOI 10.1016/S0195-6701(97)90096-7; LEVEN M, 1996, J INFECT DIS, V173, P1445; Livingston BM, 2000, CRIT CARE MED, V28, P389, DOI 10.1097/00003246-200002000-00017; MCINTOSH K, 1990, FIELDS VIROLOGY; MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P280, DOI 10.1097/00006454-199304000-00004; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P781, DOI 10.1056/NEJM197310112891505; PORTEOUS C, 1984, CRIT CARE MED, V12, P626, DOI 10.1097/00003246-198408000-00003; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; TUXEN DV, 1982, AM REV RESPIR DIS, V126, P416; TUXEN DV, 1987, AM REV RESPIR DIS, V136, P402, DOI 10.1164/ajrccm/136.2.402; Ursi D, 1998, MOL CELL PROBE, V12, P235, DOI 10.1006/mcpr.1998.0180; WARREN KG, 1978, NEW ENGL J MED, V298, P1068, DOI 10.1056/NEJM197805112981907; Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9	23	116	116	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1536	1541		10.1016/S0140-6736(03)14740-X	http://dx.doi.org/10.1016/S0140-6736(03)14740-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615108				2022-12-28	WOS:000186464500009
J	Butler, CC; Kinnersley, P; Hood, K; Robling, M; Prout, H; Rollnick, S; Houston, H				Butler, CC; Kinnersley, P; Hood, K; Robling, M; Prout, H; Rollnick, S; Houston, H			Clinical course of acute infection of the upper respiratory tract in children: cohort study	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT		Univ Wales Coll Med, Dept Gen Practice, Llanedeyrin Hlth Ctr, Cardiff CF23 9PN, S Glam, Wales	Cardiff University	Butler, CC (corresponding author), Univ Wales Coll Med, Dept Gen Practice, Llanedeyrin Hlth Ctr, Cardiff CF23 9PN, S Glam, Wales.		Butler, Christopher C/B-5048-2009; Robling, Michael/B-5516-2009; Hood, Kerenza/C-2528-2008	Robling, Michael/0000-0002-1004-036X; Hood, Kerenza/0000-0002-5268-8631; Butler, Christopher/0000-0002-0102-3453				Butler CC, 2002, LANCET, V359, P2153, DOI 10.1016/S0140-6736(02)09091-8; Jacobs B, 2000, J CLIN EPIDEMIOL, V53, P793, DOI 10.1016/S0895-4356(99)00238-3; STOTT NCH, 1979, BRIT MED J, V1, P29, DOI 10.1136/bmj.1.6155.29	3	20	21	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1088	1089		10.1136/bmj.327.7423.1088	http://dx.doi.org/10.1136/bmj.327.7423.1088			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604932	Green Published, Bronze			2022-12-28	WOS:000186530400021
J	Salonen, JT				Salonen, JT			Liver damage and protective effect of high density lipoprotein cholesterol	BRITISH MEDICAL JOURNAL			English	Article									Univ Kuopio, Publ Hlth Res Inst, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland	University of Eastern Finland	Salonen, JT (corresponding author), Univ Kuopio, Publ Hlth Res Inst, Dept Publ Hlth & Gen Practice, Box 1627, FIN-70211 Kuopio, Finland.				NHLBI NIH HHS [HL 44199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Liinamaa MJ, 1997, ARTERIOSCL THROM VAS, V17, P2940, DOI 10.1161/01.ATV.17.11.2940; Perova Natalia V., 1995, Annals of Epidemiology, V5, P179, DOI 10.1016/1047-2797(94)00104-2; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; *SOC CLIN CHEM CLI, 1976, SCAND J CLIN LAB INV, V36, P119	5	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1082	1083		10.1136/bmj.327.7423.1082	http://dx.doi.org/10.1136/bmj.327.7423.1082			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604929	Green Published, Bronze			2022-12-28	WOS:000186530400018
J	Inatani, M; Irie, F; Plump, AS; Tessier-Lavigne, M; Yamaguchi, Y				Inatani, M; Irie, F; Plump, AS; Tessier-Lavigne, M; Yamaguchi, Y			Mammalian brain morphogenesis and midline axon guidance require heparan sulfate	SCIENCE			English	Article							NERVOUS-SYSTEM; PROTEOGLYCANS; GENE; NEUROGENESIS; DISRUPTION; EXPRESSION; RECEPTOR; EXT1; MICE	Heparan sulfate (HS) is required for morphogen signaling during Drosophila pattern formation, but little is known about its physiological importance in mammalian development. To de. ne the developmental role of HS in mammalian species, we conditionally disrupted the HS-polymerizing enzyme EXT1 in the embryonic mouse brain. The EXT1-null brain exhibited patterning defects that are composites of those caused by mutations of multiple HS-binding morphogens. Furthermore, the EXT1-null brain displayed severe guidance errors in major commissural tracts, revealing a pivotal role of HS in midline axon guidance. These findings demonstrate that HS is essential for mammalian brain development.	Burnham Inst, La Jolla, CA 92037 USA; Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94035 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; Stanford University	Yamaguchi, Y (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NICHD NIH HHS [P01 HD25938] Funding Source: Medline; NINDS NIH HHS [R01 NS33117] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033117] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; IRIE F, UNPUB; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin X, 1998, BIOCHEM BIOPH RES CO, V248, P738, DOI 10.1006/bbrc.1998.9050; Liu AM, 2001, ANNU REV NEUROSCI, V24, P869, DOI 10.1146/annurev.neuro.24.1.869; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Yamaguchi Y, 2001, SEMIN CELL DEV BIOL, V12, P99, DOI 10.1006/scdb.2000.0238	19	332	340	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1044	1046		10.1126/science.1090497	http://dx.doi.org/10.1126/science.1090497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605369				2022-12-28	WOS:000186396300048
J	Joseph, DG				Joseph, DG			Uses of Jacobson v Massachusetts in the age of bioterror	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH		Yale Univ, New Haven, CT 06520 USA	Yale University	Joseph, DG (corresponding author), Yale Univ, New Haven, CT 06520 USA.							Albert MR, 2001, NEW ENGL J MED, V344, P375, DOI 10.1056/NEJM200102013440511; Annas GJ, 2002, NEW ENGL J MED, V346, P1337, DOI 10.1056/NEJM200204253461722; Gostin LO, 2002, JAMA-J AM MED ASSOC, V288, P622, DOI 10.1001/jama.288.5.622; Gostin LO, 2001, PUBLIC HLTH LAW POWE; Gussow Z., 1989, LEPROSY RACISM PUBLI; Hammonds Evelynn, 1999, CHILDHOODS DEADLY SC; LEAVITT JW, 1996, TYPHOID MARY CAPTIVE; LUECK S, 2002, WALL STREET J   0107, pA26; MODEL PUBLIC HLTH LA	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2331	2331		10.1001/jama.290.17.2331	http://dx.doi.org/10.1001/jama.290.17.2331			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600197	Bronze			2022-12-28	WOS:000186356800033
J	Man, SFP; McAlister, FA; Anthonisen, NR; Sin, DD				Man, SFP; McAlister, FA; Anthonisen, NR; Sin, DD			Contemporary management of chronic obstructive pulmonary disease - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SMOKING INTERVENTION; HEALTH; COPD	The presentation of chronic obstructive pulmonary disease (COPD) usually is insidious, and many patients are undiagnosed until the disease is far advanced. Therefore, the early use of spirometry is recommended for anyone who is suspected to have COPD. In the early stages of the disease, the patient is only mildly symptomatic (cough and sputum production). As COPD becomes more advanced, functional impairment in the form of chronic dyspnea occurs and acute exacerbations of symptoms become more frequent, contributing to overall morbidity and mortality. The single most important known causative factor of COPD is cigarette smoking. Smoking cessation remains, therefore, the mainstay of COPD therapy. In patients with advanced disease, symptomatic treatment with the regular use of either short- or long-acting sympathomimetic and/or anticholinergic bronchodilators, singly or in combination, should be added to smoking cessation and influenza and pneumococcal vaccination therapies. An inhaled corticosteroid, either alone or more commonly in combination with a long-acting bronchodilator, can further reduce exacerbations and improve the health status of these patients. Furthermore, patients with severe COPD, particularly those who are debilitated, should be considered for pulmonary rehabilitation because these programs have been proven useful in maintaining, or in some cases improving, health status for these patients. Finally, correction of resting arterial hypoxemia with oxygen therapy for more than 15 h/d prolongs survival of COPD patients for those with a resting Pao(2) lower than 55 to 60 mm Hg.	Univ Alberta, Walter C Mackenzie Ctr 2E4 29, Div Pulm Med, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Div Gen Med, Edmonton, AB T6G 2B7, Canada; Inst Hlth Econ, Edmonton, AB, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada	University of Alberta; University of Alberta; University of Manitoba	Sin, DD (corresponding author), Univ Alberta, Walter C Mackenzie Ctr 2E4 29, Div Pulm Med, Edmonton, AB T6G 2B7, Canada.	don.sin@ualberta.ca	McAlister, Finlay/C-4151-2013; Sin, Don/AAC-2219-2021	McAlister, Finlay/0000-0001-7435-3341; 				Abbot N. C., 1998, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001008; [Anonymous], 1980, Ann Intern Med, V93, P391; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Centers for Medicaid and Medicare Services, MED COV DAT; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372, DOI 10.1164/ajrccm.164.3.2004029; Dewan NA, 2002, CHEST, V122, P1118, DOI 10.1378/chest.122.4.1118; Fabbri LM, 2003, EUR RESPIR J, V22, P1, DOI 10.1183/09031936.03.00063703; FIORE MC, 2000, TREATING TOBACCO USE; FLENLEY DC, 1981, LANCET, V1, P681; Hogg JC, 2002, THORAX, V57, P830, DOI 10.1136/thorax.57.9.830; HUGHES JR, 2002, COCHRANE DB SYST REV, V1, P31; LANCASTER T, 2002, COCHRANE DB SYST REV, V3; Muller NL, 2002, THORAX, V57, P982, DOI 10.1136/thorax.57.11.982; Murray RP, 2002, PREV MED, V35, P314, DOI 10.1006/pmed.2002.1087; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pearson MG, 1997, THORAX, V52, pS1; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SILAGY C, 2002, COCHRANE DB SYST REV, V4; White AR, 2002, COCHRANE DB SYST REV, V2	22	28	32	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2313	2316		10.1001/jama.290.17.2313	http://dx.doi.org/10.1001/jama.290.17.2313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600190	Bronze			2022-12-28	WOS:000186356800026
J	Riverol, M; Irimia, P; Martinez-Vila, E				Riverol, M; Irimia, P; Martinez-Vila, E			Cerebellitis	LANCET			English	Editorial Material									Univ Navarra, Univ Navarra Clin, Dept Neurol, Pamplona 31008, Spain	University of Navarra	Riverol, M (corresponding author), Univ Navarra, Univ Navarra Clin, Dept Neurol, Ave Pio XII S-N, Pamplona 31008, Spain.		Martinez-Vila, Eduardo/A-2695-2012; Sieira, Pablo/I-3259-2017; Riverol, Mario/C-3049-2012	Sieira, Pablo/0000-0002-7238-0036; Riverol, Mario/0000-0002-4383-9127; Martinez-Vila, Eduardo/0000-0003-3422-4726					0	2	2	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1449	1449		10.1016/S0140-6736(03)14688-0	http://dx.doi.org/10.1016/S0140-6736(03)14688-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602438				2022-12-28	WOS:000186356600010
J	Dekosky, ST; Marek, K				Dekosky, ST; Marek, K			Looking backward to move forward: Early detection of neurodegenerative disorders	SCIENCE			English	Review							MILD COGNITIVE IMPAIRMENT; SUBCLINICAL DOPAMINERGIC DYSFUNCTION; FAMILY-HISTORY DATA; E TYPE-4 ALLELE; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; ELDERLY SUBJECTS; AMYLOID PLAQUES; FRONTAL-CORTEX	Early detection of neurodegenerative disorders would provide clues to the underlying pathobiology of these diseases and would enable more effective diagnosis and treatment of patients. Recent advances in molecular neuroscience have begun to provide the tools to detect diseases like Alzheimer's disease, Parkinson's disease, and others early in their course and potentially even before the development of clinical manifestations of disease. These genetic, imaging, clinical, and biochemical tools are being validated in a number of studies. Early detection of these slowly progressive diseases offers the promise of presymptomatic diagnosis and, ultimately, of disease-modifying medications for use early in disease and during the presymptomatic period.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Alzheimer Dis Res Ctr, Pittsburgh, PA 15261 USA; Inst Neurodegenerat Disorders, New Haven, CT USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dekosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.	DeKoskyST@upmc.edu		Marek, Kenneth/0000-0002-4197-5627; DeKosky, Steven/0000-0003-3743-2758				Arvanitakis Z, 2002, ALZ DIS ASSOC DIS, V16, P187, DOI 10.1097/00002093-200207000-00009; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Benveniste H, 1999, P NATL ACAD SCI USA, V96, P14079, DOI 10.1073/pnas.96.24.14079; Berendse HW, 2001, ANN NEUROL, V50, P34, DOI 10.1002/ana.1049; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brooks DJ, 2000, ADV NEUROL, V82, P209; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Chen P, 2000, NEUROLOGY, V55, P1847, DOI 10.1212/WNL.55.12.1847; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Davis KL, 1999, JAMA-J AM MED ASSOC, V281, P1401, DOI 10.1001/jama.281.15.1401; Dawson VL, 2000, SCIENCE, V288, P631, DOI 10.1126/science.288.5466.631; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; Dekker M, 2003, MOVEMENT DISORD, V18, P751, DOI 10.1002/mds.10422; DeKosky ST, 2003, ANN NEUROL, V53, P81, DOI 10.1002/ana.10414; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; Djousse L, 2003, AM J MED GENET A, V119A, P279, DOI 10.1002/ajmg.a.20190; DOTY RL, 1995, NEURODEGENERATION, V4, P93, DOI 10.1006/neur.1995.0011; EIDELBERG D, 1995, NEUROLOGY, V45, P1995, DOI 10.1212/WNL.45.11.1995; Eidelberg D, 2002, NEUROLOGY, V58, P997, DOI 10.1212/WNL.58.7.997; Elbaz A, 2003, NEUROLOGY, V61, P11, DOI 10.1212/01.WNL.0000068007.58423.C2; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fox NC, 2001, LANCET, V358, P201, DOI 10.1016/S0140-6736(01)05408-3; Frank RA, 2003, NEUROBIOL AGING, V24, P521, DOI 10.1016/S0197-4580(03)00002-2; Gasser T, 2003, ADV NEUROL, V91, P143; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; Jenkins BG, 1998, NEUROLOGY, V50, P1357, DOI 10.1212/WNL.50.5.1357; Kanehisa M, 2003, NAT GENET, V33, P305, DOI 10.1038/ng1109; Khan NL, 2002, ANN NEUROL, V52, P849, DOI 10.1002/ana.10417; Klunk WE, 2003, J NEUROSCI, V23, P2086; Kung MP, 2002, J MOL NEUROSCI, V19, P7, DOI 10.1007/s12031-002-0003-9; Larrieu S, 2002, NEUROLOGY, V59, P1594, DOI 10.1212/01.WNL.0000034176.07159.F8; Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851; Marder K, 2003, NEUROLOGY, V61, P18, DOI 10.1212/01.WNL.0000074784.35961.C0; Marek K, 1999, NEUROSCIENTIST, V5, P333, DOI 10.1177/107385849900500519; Marek KL, 1996, NEUROLOGY, V46, P231, DOI 10.1212/WNL.46.1.231; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Miller RJ, 2003, TRENDS PHARMACOL SCI, V24, P18, DOI 10.1016/S0165-6147(02)00011-1; Montgomery EB, 2000, MOVEMENT DISORD, V15, P467, DOI 10.1002/1531-8257(200005)15:3<467::AID-MDS1007>3.0.CO;2-#; Montine TJ, 2002, ANN NEUROL, V52, P175, DOI 10.1002/ana.10272; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; MORRISH PK, 1995, J NEUROL NEUROSUR PS, V59, P597, DOI 10.1136/jnnp.59.6.597; Mufson EJ, 2002, J COMP NEUROL, V443, P136, DOI 10.1002/cne.10122; NEARY D, 1986, J NEUROL NEUROSUR PS, V49, P229, DOI 10.1136/jnnp.49.3.229; NIZNIK HB, 1991, J NEUROCHEM, V56, P192, DOI 10.1111/j.1471-4159.1991.tb02580.x; Oliveira SA, 2003, ARCH NEUROL-CHICAGO, V60, P975, DOI 10.1001/archneur.60.7.975; Pankratz N, 2003, AM J HUM GENET, V72, P1053, DOI 10.1086/374383; Paulsen JS, 2001, NEUROLOGY, V57, P658, DOI 10.1212/WNL.57.4.658; Petersen R. C., 2003, MILD COGNITIVE IMPAI; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Piccini P, 1997, ANN NEUROL, V41, P222, DOI 10.1002/ana.410410213; Piccini P, 1999, ANN NEUROL, V45, P577, DOI 10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O; Poduslo JF, 2002, NEUROBIOL DIS, V11, P315, DOI 10.1006/nbdi.2002.0550; Pullman SL, 1998, MOVEMENT DISORD, V13, P85; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Riley KP, 2002, ANN NEUROL, V51, P567, DOI 10.1002/ana.10161; Ritchie K, 2000, COMPR PSYCHIAT, V41, P61, DOI 10.1016/S0010-440X(00)80010-3; Rosas HD, 2003, NEUROLOGY, V60, P1615, DOI 10.1212/01.WNL.0000065888.88988.6E; SCHEFF SW, 1990, NEUROBIOL AGING, V11, P29, DOI 10.1016/0197-4580(90)90059-9; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schmidt R, 2002, ANN NEUROL, V52, P168, DOI 10.1002/ana.10265; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; Skipper L, 2002, NEUROTOXICOLOGY, V23, P503, DOI 10.1016/S0161-813X(02)00038-4; SMALL GW, 1995, JAMA-J AM MED ASSOC, V273, P942, DOI 10.1001/jama.273.12.942; SNOW BJ, 1993, ANN NEUROL, V34, P324, DOI 10.1002/ana.410340304; Sunderland T, 2003, JAMA-J AM MED ASSOC, V289, P2094, DOI 10.1001/jama.289.16.2094; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tiraboschi P, 2000, NEUROLOGY, V55, P1278, DOI 10.1212/WNL.55.9.1278; Tuokko H, 2003, ARCH NEUROL-CHICAGO, V60, P577, DOI 10.1001/archneur.60.4.577; van Dyck CH, 2002, AM J GERIAT PSYCHIAT, V10, P36, DOI 10.1176/appi.ajgp.10.1.36; Van Heertum RL, 2003, SEMIN NUCL MED, V33, P77, DOI 10.1053/snuc.2003.127294; Weckwerth W, 2002, CURR OPIN BIOTECH, V13, P156, DOI 10.1016/S0958-1669(02)00299-9; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Zoghbi HY, 2002, TRENDS GENET, V18, P463, DOI 10.1016/S0168-9525(02)02729-4	81	278	291	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					830	834		10.1126/science.1090349	http://dx.doi.org/10.1126/science.1090349			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593169				2022-12-28	WOS:000186258000039
J	Kinoshita, T; Miura, A; Choi, YH; Kinoshita, Y; Cao, XF; Jacobsen, SE; Fischer, RL; Kakutani, T				Kinoshita, T; Miura, A; Choi, YH; Kinoshita, Y; Cao, XF; Jacobsen, SE; Fischer, RL; Kakutani, T			One-way control of FWA imprinting in Arabidopsis endosperm by DNA methylation	SCIENCE			English	Article							CYTOSINE METHYLTRANSFERASE; EPIGENETIC ALLELES; POLYCOMB GENE; THALIANA; GLYCOSYLASE; MAINTENANCE; MUTATIONS; MUTANTS; MEA; DRM	The Arabidopsis FWA gene was initially identified from late-flowering epigenetic mutants that show ectopic FWA expression associated with heritable hypomethylation of repeats around transcription starting sites. Here, we show that wild-type FWA displays imprinted (maternal origin-specific) expression in endosperm. The FWA imprint depends on the maintenance DNA methyltransferase MET1, as is the case in mammals. Unlike mammals, however, the FWA imprint is not established by allele-specific de novo methylation. It is established by maternal gametophyte-specific gene activation, which depends on a DNA glycosylase gene, DEMETER. Because endosperm does not contribute to the next generation, the activated FWA gene need not be silenced again. Double fertilization enables plants to use such "one-way" control of imprinting and DNA methylation in endosperm.	Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4118540, Japan; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; University of California System; University of California Berkeley; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kinoshita, T (corresponding author), Natl Inst Genet, Mishima, Shizuoka 4118540, Japan.	tekinosh@lab.nig.ac.jp; tkakutan@lab.nig.ac.jp			NIGMS NIH HHS [GM60398] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060398, R37GM060398] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartee L, 2001, GENE DEV, V15, P1753, DOI 10.1101/gad.905701; BIRCHLER JA, 1993, ANNU REV GENET, V27, P181, DOI 10.1146/annurev.ge.27.120193.001145; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Cao XF, 2002, P NATL ACAD SCI USA, V99, P16491, DOI 10.1073/pnas.162371599; Cao XF, 2000, P NATL ACAD SCI USA, V97, P4979, DOI 10.1073/pnas.97.9.4979; Choi YH, 2002, CELL, V110, P33, DOI 10.1016/S0092-8674(02)00807-3; Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Kakutani T, 1997, PLANT J, V12, P1447, DOI 10.1046/j.1365-313x.1997.12061447.x; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; Kankel MW, 2003, GENETICS, V163, P1109; Kinoshita T, 1999, PLANT CELL, V11, P1945, DOI 10.1105/tpc.11.10.1945; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Luo M, 2000, P NATL ACAD SCI USA, V97, P10637, DOI 10.1073/pnas.170292997; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Stokes TL, 2002, GENE DEV, V16, P171, DOI 10.1101/gad.952102; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Vielle-Calzada JP, 1999, GENE DEV, V13, P2971, DOI 10.1101/gad.13.22.2971; Xiao WY, 2003, DEV CELL, V5, P891, DOI 10.1016/S1534-5807(03)00361-7	24	428	465	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	2004	303	5657					521	523		10.1126/science.1089835	http://dx.doi.org/10.1126/science.1089835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765XM	14631047				2022-12-28	WOS:000188316400037
J	Serizawa, S; Miyamichi, K; Nakatani, H; Suzuki, M; Saito, M; Yoshihara, Y; Sakano, H				Serizawa, S; Miyamichi, K; Nakatani, H; Suzuki, M; Saito, M; Yoshihara, Y; Sakano, H			Negative feedback regulation ensures the one receptor-one olfactory neuron rule in mouse	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY; ODORANT RECEPTORS; GENE-EXPRESSION; LIGHT-CHAIN; ORGANIZATION; PROJECTION	In the mouse olfactory system, each olfactory sensory neuron (OSN) expresses only one odorant receptor (OR) gene in a monoallelic and mutually exclusive manner. Such expression forms the genetic basis for OR-instructed axonal projection of OSNs to the olfactory bulb of the brain during development. Here, we identify an upstream cis-acting DNA region that activates the OR gene cluster in mouse and allows the expression of only one OR gene within the cluster. Deletion of the coding region of the expressed OR gene or a naturally occurring frame-shift mutation allows a second OR gene to be expressed. We propose that stochastic activation of only one OR gene within the cluster and negative feedback regulation by that OR gene product are necessary to ensure the one receptor - one neuron rule.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130032, Japan; Japan Sci & Technol Corp, CREST Programs, Kawaguchi, Saitama 3320012, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8620976, Japan; RIKEN, Brain Sci Inst, Lab Neurobiol Synapse, Wako, Saitama 3510198, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Kumamoto University; RIKEN	Sakano, H (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130032, Japan.	sakano@mail.ecc.u-tokyo.ac.jp	Miyamichi, Kazunari/AAO-3705-2021; Yoshihara, Yoshihiro/N-6481-2015	Yoshihara, Yoshihiro/0000-0002-0319-7166				BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Ishii T, 2001, GENES CELLS, V6, P71, DOI 10.1046/j.1365-2443.2001.00398.x; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nakatani H, 2003, EUR J NEUROSCI, V18, P2425, DOI 10.1046/j.1460-9568.2003.02998.x; Pyrski M, 2001, J NEUROSCI, V21, P4637, DOI 10.1523/JNEUROSCI.21-13-04637.2001; Qasba P, 1998, J NEUROSCI, V18, P227; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rouquier S, 2000, P NATL ACAD SCI USA, V97, P2870, DOI 10.1073/pnas.040580197; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Schweighoffer E, 2003, IMMUNITY, V18, P523, DOI 10.1016/S1074-7613(03)00082-7; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; SERIZAWA S, UNPUB; SMITH AFA, REPEATMASKER; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	28	385	393	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	2003	302	5653					2088	2094		10.1126/science.1089122	http://dx.doi.org/10.1126/science.1089122			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	755CB	14593185				2022-12-28	WOS:000187385200034
J	Keren, K; Berman, RS; Buchstab, E; Sivan, U; Braun, E				Keren, K; Berman, RS; Buchstab, E; Sivan, U; Braun, E			DNA-templated carbon nanotube field-effect transistor	SCIENCE			English	Article							ROOM-TEMPERATURE; SEPARATION; MOLECULES; RECOGNITION; CIRCUITS; LOGIC; WIRE	The combination of their electronic properties and dimensions makes carbon nanotubes ideal building blocks for molecular electronics. However, the advancement of carbon nanotube-based electronics requires assembly strategies that allow their precise localization and interconnection. Using a scheme based on recognition between molecular building blocks, we report the realization of a self-assembled carbon nanotube field-effect transistor operating at room temperature. A DNA scaffold molecule provides the address for precise localization of a semiconducting single-wall carbon nanotube as well as the template for the extended metallic wires contacting it.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Braun, E (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	erez@physics.technion.ac.il		Keren, Kinneret/0000-0002-2962-6977				Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Avouris P, 2002, ACCOUNTS CHEM RES, V35, P1026, DOI 10.1021/ar010152e; Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; Bockrath M, 2002, NANO LETT, V2, P187, DOI 10.1021/nl0100724; Bradley K, 2003, NANO LETT, V3, P639, DOI 10.1021/nl025941j; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Chattopadhyay D, 2003, J AM CHEM SOC, V125, P3370, DOI 10.1021/ja028599l; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Dieckmann GR, 2003, J AM CHEM SOC, V125, P1770, DOI 10.1021/ja029084x; Eichen Y, 1998, ACTA POLYM, V49, P663, DOI 10.1002/(SICI)1521-4044(199810)49:10/11<663::AID-APOL663>3.0.CO;2-4; Gomez-Navarro C, 2002, P NATL ACAD SCI USA, V99, P8484, DOI 10.1073/pnas.122610899; Heath JR, 2003, PHYS TODAY, V56, P43, DOI 10.1063/1.1583533; Javey A, 2002, NANO LETT, V2, P929, DOI [10.1021/nl025647r, 10.1021/n1025647r]; Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247; Krupke R, 2003, SCIENCE, V301, P344, DOI 10.1126/science.1086534; Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Niemeyer CM, 2000, CURR OPIN CHEM BIOL, V4, P609, DOI 10.1016/S1367-5931(00)00140-X; Pantarotto D, 2003, J AM CHEM SOC, V125, P6160, DOI 10.1021/ja034342r; Postma HWC, 2001, SCIENCE, V293, P76, DOI 10.1126/science.1061797; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; Shim M, 2002, NANO LETT, V2, P285, DOI 10.1021/nl015692j; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Williams KA, 2002, NATURE, V420, P761, DOI 10.1038/420761a; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Zheng M, 2003, NAT MATER, V2, P338, DOI 10.1038/nmat877	27	671	701	5	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1380	1382		10.1126/science.1091022	http://dx.doi.org/10.1126/science.1091022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631035				2022-12-28	WOS:000186683500047
J	Singh, AK; Harris, NL; Bazari, H; Steele, DJR; Colvin, RB				Singh, AK; Harris, NL; Bazari, H; Steele, DJR; Colvin, RB			A 68-year-old woman with impaired renal function - Acute granulomatous interstitial nephritis with tubular injury and minimal-change disease, due to a reaction to ibuprofen.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THE-COUNTER IBUPROFEN; NEPHROTIC SYNDROME; GLOMERULONEPHRITIS; PROTEINURIA; FAILURE; HYPERSENSITIVITY; THERAPY		Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Singh, AK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.							BANDER SJ, 1985, AM J KIDNEY DIS, V6, P233, DOI 10.1016/S0272-6386(85)80178-5; Becker-Cohen R, 2001, EUR J PEDIATR, V160, P293, DOI 10.1007/s004310100729; BENDER WL, 1984, AM J MED, V76, P1006, DOI 10.1016/0002-9343(84)90849-0; BODEM CR, 1983, MEDICINE, V62, P372, DOI 10.1097/00005792-198311000-00003; Chen CY, 1996, RENAL FAILURE, V18, P31, DOI 10.3109/08860229609052772; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; Dharnidharka VR, 1998, PEDIATR NEPHROL, V12, P576, DOI 10.1007/s004670050508; EBERT TH, 1983, NEW ENGL J MED, V309, P970; ENRIQUEZ R, 1995, AM J NEPHROL, V15, P270, DOI 10.1159/000168845; Fervenza FC, 2000, AM J KIDNEY DIS, V36, P1034; Henao J, 2002, AM J KIDNEY DIS, V39, P1313, DOI 10.1053/ajkd.2002.33412; JUSTINIANI FR, 1986, ANN INTERN MED, V105, P303, DOI 10.7326/0003-4819-105-2-303_1; LAURO S, 1994, ANTICANCER RES, V14, P2171; MAGIL AB, 1983, HUM PATHOL, V14, P36, DOI 10.1016/S0046-8177(83)80044-6; MANIGLIA R, 1988, ANN CLIN LAB SCI, V18, P240; Miller BW, 1997, AM J KIDNEY DIS, V30, P586, DOI 10.1016/S0272-6386(97)90323-1; MORGENSTERN SJ, 1989, AM J KIDNEY DIS, V14, P50, DOI 10.1016/S0272-6386(89)80093-9; Ravnskov U, 1999, BRIT J CLIN PHARMACO, V47, P203, DOI 10.1046/j.1365-2125.1999.00869.x; REGESTER RE, 1988, J TENNESSEE MED ASS, V73, P709; RENNKE HG, 1980, NEW ENGL J MED, V302, P691; RETTMAR K, 1995, AM J HEMATOL, V49, P355, DOI 10.1002/ajh.2830490417; Segal A, 1998, HUM PATHOL, V29, P1246, DOI 10.1016/S0046-8177(98)90252-0; Singh AK, 1996, AM J KIDNEY DIS, V27, P273, DOI 10.1016/S0272-6386(96)90553-3; Stoves J, 1998, NEPHROL DIAL TRANSPL, V13, P227, DOI 10.1093/ndt/13.1.227-b; Tam VKK, 1996, AM J KIDNEY DIS, V27, P715, DOI 10.1016/S0272-6386(96)90108-0; TOLINS JP, 1987, MINN MED, V70, P509; Tomita N, 2001, ANTI-CANCER DRUG, V12, P677, DOI 10.1097/00001813-200109000-00005; Tse WY, 1997, NEPHROL DIAL TRANSPL, V12, P1017, DOI 10.1093/ndt/12.5.1017; VIERO RM, 1995, HUM PATHOL, V26, P1347, DOI 10.1016/0046-8177(95)90300-3; WATTAD A, 1994, PEDIATRICS, V93, P693	30	11	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2055	2063		10.1056/NEJMcpc030028	http://dx.doi.org/10.1056/NEJMcpc030028			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627791				2022-12-28	WOS:000186642900011
J	McConnell, J				McConnell, J			Mattresses for a pain in the back	LANCET			English	Editorial Material							DOUBLE-BLIND; SLEEP; QUALITY		Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia	University of Melbourne	McConnell, J (corresponding author), Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia.	jennymcconnell@bigpond.com						Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; DERMAN KL, 1995, S AFR MED J, V85, P278; Enck P, 1999, SCHMERZ, V13, P205, DOI 10.1007/s004820050200; Ernst E, 2001, J PAIN SYMPTOM MANAG, V22, P879, DOI 10.1016/S0885-3924(01)00337-2; Furlan A D, 2001, Spine (Phila Pa 1976), V26, pE155, DOI 10.1097/00007632-200104010-00018; GARFIN SR, 1981, PAIN, V10, P87, DOI 10.1016/0304-3959(81)90049-X; Hides J A, 2001, Spine (Phila Pa 1976), V26, pE243, DOI 10.1097/00007632-200106010-00004; Jacobson BH, 2002, J MANIP PHYSIOL THER, V25, P88, DOI 10.1067/mmt.2002.121410; Monsein M, 2000, MedGenMed, V2, pE36; Price P, 2003, CLIN REHABIL, V17, P488, DOI 10.1191/0269215503cr640oa; SCHONSTEIN E, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001822; ZUSSMAN M, 1998, AUST J PHYSIOTHER, V44, P13	12	2	2	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1594	1595		10.1016/S0140-6736(03)14836-2	http://dx.doi.org/10.1016/S0140-6736(03)14836-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630434				2022-12-28	WOS:000186637400002
J	Singh, JA				Singh, JA			Is donor aid allocation to Iraq fair?	LANCET			English	Editorial Material									Univ Natal, Howard Coll, Sch Law, ZA-4041 Durban, South Africa	University of Kwazulu Natal	Singh, JA (corresponding author), Univ Natal, Howard Coll, Sch Law, King George V Ave, ZA-4041 Durban, South Africa.							Kapp C, 2003, LANCET, V362, P1467, DOI 10.1016/S0140-6736(03)14736-8; LABBE T, 2003, WASHINGTON POST 1030, P1; RICKS TE, 2002, WASHINGTON POST 0806, pA1; The Global Fund, 2022, BMJ, DOI DOI 10.1136/BMJ.O2320; WHO, COUNTR INF	5	1	1	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1672	1673		10.1016/S0140-6736(03)14804-0	http://dx.doi.org/10.1016/S0140-6736(03)14804-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14631973				2022-12-28	WOS:000186637400029
J	Kelman, CW; Kortt, MA; Becker, NG; Li, Z; Mathews, JD; Guest, CS; Holman, CD				Kelman, CW; Kortt, MA; Becker, NG; Li, Z; Mathews, JD; Guest, CS; Holman, CD			Deep vein thrombosis and air travel: record linkage study	BRITISH MEDICAL JOURNAL			English	Article							VENOUS THROMBOSIS; PULMONARY-EMBOLISM; RISK; EVENTS	Objective To investigate the time relations between long haul air travel and venous thromboembolisin. Design Record linkage study using the case crossover approach. Setting Western Australia. Participants 5408 patients admitted to hospital with venous thromboembolism and matched with data for arrivals of international flights during 1981-99. Results ne risk of venous thromboembolism is increased for only two weeks after a long haul flight; 46 Australian citizens and 200 non-Australian citizens had an episode of venous thromboembolism during this so called hazard period. The relative risk during this period for Australian citizens was 4.17 (95% confidence interval, 2.94 to 5.40), with 76% of cases (n=35) attributable to the preceding flight. A "healthy traveller" effect was observed, particularly for Australian citizens. Conclusions The annual risk of venous thromboembolism is increased by 12% if one long haul flight is taken yearly. The average risk of death from flight related venous thromboembolisin is small compared with that from motor vehicle crashes and injuries at work. The individual risk of death from flight related venous thromboembolism for people with certain pre-existing medical conditions is, however, likely to be greater than the average risk of 1 per 2 million for passengers arriving from a flight. Airlines and health authorities should continue to advise passengers on how to minimise risk.	Commonwealth Dept Hlth & Ageing, Canberra, ACT 2601, Australia; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Australian National University; University of Western Australia	Kelman, CW (corresponding author), Commonwealth Dept Hlth & Ageing, GPO Box 9848, Canberra, ACT 2601, Australia.		Holman, Cashel DJ/B-6173-2009	Kortt, Michael/0000-0002-3556-3001; Kelman, Chris/0000-0001-5126-8179				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Ansell JE, 2001, NEW ENGL J MED, V345, P828, DOI 10.1056/NEJM200109133451110; *AUSTR BUR STAT, 1999, 1998 CAUS DEATH; *DEP TRANSP REG DE, 1999, ROAD FAT AUSTR 1998; Eekhoff EMW, 2000, THROMB HAEMOSTASIS, V83, P408, DOI 10.1055/s-0037-1613828; Ferrari E, 1999, CHEST, V115, P440, DOI 10.1378/chest.115.2.440; Gallus AS, 2001, MED J AUSTRALIA, V174, P264, DOI 10.5694/j.1326-5377.2001.tb143263.x; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; HOMANS J, 1954, NEW ENGL J MED, V250, P148, DOI 10.1056/NEJM195401282500404; *INT CIV AV ORG, 2000, 1999 AN REP COUNC IN; Kelman CW, 2002, AUST NZ J PUBL HEAL, V26, P251, DOI 10.1111/j.1467-842X.2002.tb00682.x; Kesteven PJL, 2001, AVIAT SPACE ENVIR MD, V72, P125; Kraaijenhagen RA, 2000, LANCET, V356, P1492, DOI 10.1016/S0140-6736(00)02878-6; Lapostolle F, 2001, NEW ENGL J MED, V345, P779, DOI 10.1056/NEJMoa010378; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LORD RSA, 2000, HAWAII MED J, V59, P155; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MARSHALL RJ, 1993, STAT MED, V12, P2333, DOI 10.1002/sim.4780122409; *NAT TRANSP SAF BO, 2001, ACC FAT RAT 1982 200; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Scurr JH, 2001, LANCET, V357, P1485, DOI 10.1016/S0140-6736(00)04645-6	22	79	80	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1072	1075		10.1136/bmj.327.7423.1072	http://dx.doi.org/10.1136/bmj.327.7423.1072			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604926	Green Published, Bronze			2022-12-28	WOS:000186530400015
J	Krimigis, SM; Decker, RB; Hill, ME; Armstrong, TP; Gloeckler, G; Hamilton, DC; Lanzerotti, LJ; Roelof, EC				Krimigis, SM; Decker, RB; Hill, ME; Armstrong, TP; Gloeckler, G; Hamilton, DC; Lanzerotti, LJ; Roelof, EC			Voyager 1 exited the solar wind at a distance of similar to 85 AU from the Sun	NATURE			English	Article							ENERGETIC PARTICLE EVENTS; OUTER HELIOSPHERE; COSMIC-RAYS; TERMINATION SHOCK; PICKUP IONS; ACCELERATION; PROPAGATION; SPACECRAFT; OXYGEN	The outer limit of the Solar System is often considered to be at the distance from the Sun where the solar wind changes from supersonic to subsonic flow(1). Theory predicts that a termination shock marks this boundary, with locations ranging(2) from a few to over 100 AU (1 AU approximate to 1.5 x 10(8) km, the distance from Earth to the Sun). 'Pick-up ions' that originate(3,4) as interstellar neutral atoms should be accelerated to tens of MeV at the termination shock, generating anomalous cosmic rays(5-7). Here we report a large increase in the intensity of energetic particles in the outer heliosphere, as measured by an instrument on the Voyager 1 spacecraft. We argue that the spacecraft exited the supersonic solar wind and passed into the subsonic region ( possibly beyond the termination shock) on about 1 August 2002 at a distance of similar to85 AU (heliolatitude similar to34degrees N), then re-entered the supersonic solar wind about 200 days later at, 87 AU from the Sun. We show that the composition of the ions accelerated at the putative termination shock is that of anomalous cosmic rays and of interstellar pick-up ions.	Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Fundamental Technol, Lawrence, KS 66046 USA; Bell Labs, Murray Hill, NJ 07974 USA; New Jersey Inst Technol, Ctr Solar Terr Res, Newark, NJ 07102 USA	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University System of Maryland; University of Maryland College Park; AT&T; New Jersey Institute of Technology	Krimigis, SM (corresponding author), Johns Hopkins Univ, Appl Phys Lab, Johns Hopkins Rd, Laurel, MD 20723 USA.	tom.krimigis@jhuapl.edu	Krimigis, Stamatios/G-4591-2019; Hill, Matthew/H-4312-2016; Roelof, Edmond/G-6654-2019	Krimigis, Stamatios/0000-0003-2781-2386; Hill, Matthew/0000-0002-5674-4936; Roelof, Edmond/0000-0002-2270-0652; Hamilton, Douglas/0000-0001-6103-8019				BURLAGA LF, IN PRESS GEOPHYS RES; CARGILL PJ, 1988, COMETARY SOLAR PLASM; DECKER RB, 1993, J GEOPHYS RES-SPACE, V98, P33, DOI 10.1029/92JA01841; DECKER RB, 1995, SPACE SCI REV, V72, P347, DOI 10.1007/BF00768804; Decker RB, 2000, AIP CONF PROC, V528, P161; DECKER RB, 2003, GEOPH RES ABSTR, V5; Fahr HJ, 2000, ASTRON ASTROPHYS, V357, P268; Fahr HJ, 1999, ASTRON ASTROPHYS, V350, P1071; Fichtner H, 2001, SPACE SCI REV, V95, P639, DOI 10.1023/A:1010376901322; FISK LA, 1974, ASTROPHYS J, V190, pL35, DOI 10.1086/181498; Fisk LA, 1996, J GEOPHYS RES-SPACE, V101, P15547, DOI 10.1029/96JA01005; GLEESON LJ, 1968, ASTROPHYS SPACE SCI, V2, P431, DOI 10.1007/BF02175919; Gloeckler G, 2001, AIP CONF PROC, V598, P281, DOI 10.1063/1.1434012; Hill ME, 2002, ASTROPHYS J, V572, pL169, DOI 10.1086/341668; Izmodenov V, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016127; Kane M, 1998, J GEOPHYS RES-SPACE, V103, P267, DOI 10.1029/97JA02776; KRIMIGIS SM, 1977, SPACE SCI REV, V21, P329, DOI 10.1007/BF00211545; le Roux JA, 2000, GEOPHYS RES LETT, V27, P2873, DOI 10.1029/2000GL000096; McDonald FB, 2003, NATURE, V426, P48, DOI 10.1038/nature02066; NEUGEBAUER M, 1990, REV GEOPHYS, V28, P231, DOI 10.1029/RG028i002p00231; PARKER EN, 1965, PLANET SPACE SCI, V13, P9, DOI 10.1016/0032-0633(65)90131-5; PARKER EN, 1961, ASTROPHYS J, V134, P20, DOI 10.1086/147124; PESSES ME, 1981, ASTROPHYS J, V246, pL85, DOI 10.1086/183559; ROELOF EC, 1999, SPACE SCI REV, V89, P225; ROELOF EC, 1969, NASA, pCH7; SARRIS ET, 1985, ASTROPHYS J, V298, P676, DOI 10.1086/163651; Schwadron NA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016499; Steenberg CD, 1999, J GEOPHYS RES-SPACE, V104, P24879, DOI 10.1029/1999JA900336; Stone EC, 2001, SCIENCE, V293, P55, DOI 10.1126/science.1060090; ZWICKL RD, 1981, J GEOPHYS RES-SPACE, V86, P5449, DOI 10.1029/JA086iA07p05449	30	163	166	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					45	48		10.1038/nature02068	http://dx.doi.org/10.1038/nature02068			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603311				2022-12-28	WOS:000186370800035
J	Westhoff, C				Westhoff, C			Emergency contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YUZPE REGIMEN; UNINTENDED PREGNANCY; ADVANCE PROVISION; US WOMEN; LEVONORGESTREL; PROBABILITY; CONCEPTION; SURVIVAL; PILLS; YOUNG		Columbia Univ, Dept Obstet & Gynecol, New York, NY 10032 USA	Columbia University	Westhoff, C (corresponding author), Columbia Univ, Dept Obstet & Gynecol, 630 W 168 St, New York, NY 10032 USA.	clw3@columbia.edu						*ACOG, 2001, ACOG PRACT B, V25, P1; Arab L, 2003, J AM DIET ASSOC, V103, P1008, DOI 10.1016/S0002-8223(03)00474-7; Baird DD, 1999, FERTIL STERIL, V71, P40, DOI 10.1016/S0015-0282(98)00419-1; Berg AO, 2002, AM J NURS, V102, P87; BRACKEN MB, 1990, OBSTET GYNECOL, V76, P552; CROXATTO HB, 2002, IPPF MED B, V36, P1; D'Souza RE, 2003, J FAM PLAN REPROD H, V29, P23, DOI 10.1783/147118903101197485; Dunson DB, 2002, HUM REPROD, V17, P1399, DOI 10.1093/humrep/17.5.1399; Ellertson C, 2003, OBSTET GYNECOL, V101, P1168, DOI 10.1016/S0029-7844(03)00352-1; Ellertson C, 2003, OBSTET GYNECOL, V101, P1160, DOI 10.1016/S0029-7844(03)00353-3; Ellertson C, 2001, OBSTET GYNECOL, V98, P570, DOI 10.1016/S0029-7844(01)01506-X; FARLEY TMM, 1995, LANCET, V346, P1582; FASOLI M, 1989, CONTRACEPTION, V39, P459, DOI 10.1016/0010-7824(89)90123-6; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Grimes DA, 2002, NEW ENGL J MED, V347, P846, DOI 10.1056/NEJMsb020913; Grimes DA, 1999, OBSTET GYNECOL, V94, P471, DOI 10.1016/S0029-7844(99)80049-0; *GYN INC, 2000, PREV EM CONTR PACK I; Hamandi K, 2003, J NEUROL, V250, P615, DOI 10.1007/s00415-003-1043-y; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Jackson RA, 2003, OBSTET GYNECOL, V102, P8, DOI 10.1016/S0029-7844(03)00478-2; Jones RK, 2002, PERSPECT SEX REPRO H, V34, P294, DOI 10.2307/3097748; Lake SR, 1999, BRIT J OPHTHALMOL, V83, P630; NG E, 2003, OBSTET GYNECOL S, V101, pS13; Nielsen CL, 2000, CONTRACEPTION, V62, P275, DOI 10.1016/S0010-7824(00)00178-5; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Piaggio G, 1999, LANCET, V353, P721, DOI 10.1016/S0140-6736(98)05718-3; Raine T, 2000, OBSTET GYNECOL, V96, P1, DOI 10.1016/S0029-7844(00)00830-9; Raymond EG, 2000, OBSTET GYNECOL, V95, P271, DOI 10.1016/S0029-7844(99)00550-5; Rodrigues I, 2001, AM J OBSTET GYNECOL, V184, P531, DOI 10.1067/mob.2001.111102; Sanchez-Guerra M, 2002, J NEUROL, V249, P774, DOI 10.1007/s00415-002-0681-9; Sanchez-Ojanguren J, 1998, REV NEUROLOGIA, V27, P604, DOI 10.33588/rn.27158.97381; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Sheffer-Mimouni G, 2003, CONTRACEPTION, V67, P267, DOI 10.1016/S0010-7824(02)00539-5; Speroff L, 2001, CLIN GUIDE CONTRACEP; Stewart FH, 2001, JAMA-J AM MED ASSOC, V285, P2232, DOI 10.1001/jama.285.17.2232; Stratton P, 2000, HUM REPROD, V15, P1092, DOI 10.1093/humrep/15.5.1092; *TASK FORC POST ME, 1998, LANCET, V353, P428; Trussell J, 1997, AM J PUBLIC HEALTH, V87, P932, DOI 10.2105/AJPH.87.6.932; Trussell J, 1999, CONTRACEPTION, V59, P147, DOI 10.1016/S0010-7824(99)00018-9; Trussell J, 1999, OBSTET GYNECOL, V93, P872, DOI 10.1016/S0029-7844(98)00380-9; Trussell J, 2000, OBSTET GYNECOL, V95, P267, DOI 10.1016/S0029-7844(99)00518-9; Trussell J, 1996, OBSTET GYNECOL, V88, P150, DOI 10.1016/0029-7844(96)00036-1; Vasilakis C, 1999, CONTRACEPTION, V59, P79, DOI 10.1016/S0010-7824(99)00011-6; von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3; von Hertzen H, 2000, CONTRACEPTION, V61, P303, DOI 10.1016/S0010-7824(00)00116-5; Westhoff C, 2002, CONTRACEPTION, V66, P141, DOI 10.1016/S0010-7824(02)00351-7; *WHO, 2000, IMPR ACC QUAL CAR FA; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301; Wilcox AJ, 2000, BRIT MED J, V321, P1259, DOI 10.1136/bmj.321.7271.1259; *WOM CAP CORP, 2003, PLAN B PACK INS; YUZPE AA, 1982, FERTIL STERIL, V37, P508	51	21	25	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1830	1835		10.1056/NEJMcp031990	http://dx.doi.org/10.1056/NEJMcp031990			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602882				2022-12-28	WOS:000186353800008
J	Pastor-Barriuso, R; Banegas, JR; Damian, J; Appel, LJ; Guallar, E				Pastor-Barriuso, R; Banegas, JR; Damian, J; Appel, LJ; Guallar, E			Systolic blood pressure, diastolic blood pressure, and pulse pressure: An evaluation of their joint effect on mortality	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; FOLLOW-UP; REGRESSION DILUTION; RISK-FACTOR; METAANALYSIS; HYPERTENSION; STROKE; MEN	Background: The relative importance of blood pressure components (systolic blood pressure, diastolic blood pressure, and pulse pressure) on cardiovascular risk is currently being debated. Many studies, however, are limited by inadequate statistical methods to separate these effects. Objective: To evaluate the joint effect of blood pressure components on all-cause and cardiovascular mortality by using nonparametric and change point models. Design: Prospective cohort study. Setting: 15-year mortality follow-up of participants in the Second National Health and Nutrition Examination Survey. Participants: 7830 white and African-American men and women 30 to 74 years of age, apparently free of cardiovascular disease at baseline. Measurements: Baseline blood pressure, corrected for measurement error. Results: Of the 1588 patients who died, 582 died of cardiovascular disease. Systolic blood pressure was linearly related to all-cause and cardiovascular mortality in younger and elderly participants. The association of diastolic blood pressure with all-cause and cardiovascular mortality was hockey stick-shaped (flat then increasing) in younger participants and J-shaped in elderly participants. Increased pulse pressure was associated with increased risk, decreased risk, or no change in risk depending on age and systolic and diastolic blood pressure. Conclusions: on the basis of these and previous data, the evidence for a monotonic association of systolic blood pressure with all-cause and cardiovascular mortality is compelling, but a J-shaped association for diastolic blood pressure may develop at older age. The complexity of the association of pulse pressure with mortality discourages its use for prognostic or therapeutic decisions.	Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain; Univ Autonoma Madrid, Madrid, Spain	Johns Hopkins University; Johns Hopkins Medicine; Instituto de Salud Carlos III; Autonomous University of Madrid	Guallar, E (corresponding author), Johns Hopkins Med Inst, Dept Epidemiol, 2024 E Monument St,Room 2-639, Baltimore, MD 21205 USA.	eguallar@jhsph.edu	Appel, Larry/GLT-2608-2022; Guallar, Eliseo/D-3807-2014; Pastor-Barriuso, Roberto/AAA-6746-2019	Guallar, Eliseo/0000-0002-4471-9565; Pastor-Barriuso, Roberto/0000-0002-7325-3960; Damian, Javier/0000-0002-6258-8220				Benetos A, 2001, J AM COLL CARDIOL, V37, P163, DOI 10.1016/S0735-1097(00)01092-5; Boutitie F, 2002, ANN INTERN MED, V136, P438, DOI 10.7326/0003-4819-136-6-200203190-00007; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Dart AM, 2001, J AM COLL CARDIOL, V37, P975, DOI 10.1016/S0735-1097(01)01108-1; Domanski M, 2002, JAMA-J AM MED ASSOC, V287, P2677, DOI 10.1001/jama.287.20.2677; Franklin SS, 2001, CIRCULATION, V103, P1245; GOETGHEBEUR EJT, 1995, J ROY STAT SOC A STA, V158, P107, DOI 10.2307/2983406; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; HUGHES MD, 1992, J CLIN EPIDEMIOL, V45, P985, DOI 10.1016/0895-4356(92)90114-3; Kannel WB, 1996, JAMA-J AM MED ASSOC, V275, P1571, DOI 10.1001/jama.275.20.1571; KANNEL WB, 1971, AM J CARDIOL, V27, P335, DOI 10.1016/0002-9149(71)90428-0; Kannel WB, 1997, AM HEART J, V134, P758, DOI 10.1016/S0002-8703(97)70061-9; Kuchenhoff H, 1997, STAT MED, V16, P169, DOI 10.1002/(SICI)1097-0258(19970130)16:2<169::AID-SIM478>3.0.CO;2-M; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LORIA CM, 1999, VITAL HLTH STAT 1, V38, P1; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *MATHS, 1999, MATHS S PLUS 2000 US; McDowell A, 1981, Vital Health Stat 1, P1; Pastor R, 1998, AM J EPIDEMIOL, V148, P631, DOI 10.1093/aje/148.7.631; Pastor-Barriuso R, 2003, STAT MED, V22, P1141, DOI 10.1002/sim.1045; Port S, 2000, LANCET, V355, P175, DOI 10.1016/S0140-6736(99)07051-8; Psaty BM, 2001, ARCH INTERN MED, V161, P1183, DOI 10.1001/archinte.161.9.1183; Staessen JA, 2000, LANCET, V355, P865, DOI 10.1016/S0140-6736(99)07330-4; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; VATTEN LJ, 1995, EPIDEMIOLOGY, V6, P70, DOI 10.1097/00001648-199501000-00014; White WB, 2001, AM J CARDIOL, V87, P1278, DOI 10.1016/S0002-9149(01)01519-3	30	148	149	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					731	739		10.7326/0003-4819-139-9-200311040-00007	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738XJ	14597457				2022-12-28	WOS:000186312900003
J	Borrill, Z; Houghton, C; Sestini, P; Sullivan, PJ				Borrill, Z; Houghton, C; Sestini, P; Sullivan, PJ			Retrospective analysis of evidence base for tests used in diagnosis and monitoring of disease in respiratory medicine	BRITISH MEDICAL JOURNAL			English	Article							ARTICLE; GUIDES; INTERVENTIONS; BIAS	Objectives To determine how many common clinical tests used in a respiratory medicine outpatient clinic are based on high quality evidence. Design Retrospective review of case notes. Record of first three tests for each patient. Diagnostic tests, tests used to assess existing condition, explicit trials of therapy were included. Literature search for supporting evidence and grading of best evidence for each test. Setting Inner city university teaching hospital in the United Kingdom. Participants All new outpatients referred to a single respiratory medicine team over a period of three months. Main outcome measures Proportion of tests supported by level 1a-1c evidence (scale developed by Centre for Evidence Based Medicine). Results Only half the tests that were used to make or exclude a diagnosis and a fifth of the tests used to assess a known condition were supported by level 1a-1c evidence. There was no evidence to support trials of therapy. Conclusions A large proportion of clinical tests in respiratory medicine are not supported by level 1a-1c evidence. None of the therapeutic trials that were used were supported by evidence.	Hope Hosp, Dept Cardioresp Med, Manchester M6 8HD, Lancs, England; Univ Siena, Dept Clin Med & Immunol Sci, Div Resp Dis, I-53100 Siena, Italy	University of Siena	Sullivan, PJ (corresponding author), Hope Hosp, Dept Cardioresp Med, Manchester M6 8HD, Lancs, England.		Sestini, Piersante/AAF-8570-2019	Sestini, Piersante/0000-0002-8195-0811				ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Geddes JR, 1996, QUAL HEALTH CARE, V5, P215, DOI 10.1136/qshc.5.4.215; Gill P, 1996, BRIT MED J, V312, P819; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Howes N, 1997, BRIT J SURG, V84, P1220; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; McSherry R, 1999, Br J Nurs, V8, P113; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Reid MC, 1998, AM J MED, V104, P374, DOI 10.1016/S0002-9343(98)00054-0	13	16	18	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1136	1138		10.1136/bmj.327.7424.1136	http://dx.doi.org/10.1136/bmj.327.7424.1136			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615337	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000186622100018
J	Murphy, DJ; Pope, C; Frost, J; Liebling, RE				Murphy, DJ; Pope, C; Frost, J; Liebling, RE			Women's views on the impact of operative delivery in the second stage of labour: qualitative interview study	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; CESAREAN-SECTION; CHILDBIRTH; EXPERIENCE; POSTPARTUM; MORBIDITY; SYMPTOMS; COHORT; BIRTH	Objective To obtain the views of women on the impact of operative delivery in the second stage of labour. Design Qualitative inter-view study. Setting Two urban teaching hospitals in the United Kingdom. Participants Purposive sample of 27 women who had undergone operative delivery in the second stage of labour between January 2000 and January 2002. Key themes Preparation for birth, understandings of the indications for operative delivery, and explanation or debriefing after birth. Results The women felt unprepared for operative delivery and thought that their birth plan or antenatal classes had not catered adequately for this event. They emphasised the importance of maintaining an open mind about the management of labour. They had difficulty understanding the need for operative delivery despite a review by medical and midwifery staff before discharge. Operative delivery had a noticeable impact on women's views about future pregnancy and delivery. Conclusions Women consider postnatal debriefing and medical review important deficiencies in current care. Those who experienced operative delivery in the second stage of labour would welcome the opportunity to have a later review of their intrapartum care, physical recovery, and management of future pregnancies.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Southmead Gen Hosp, N Bristol NHS Trust, Womens Ctr, Bristol BS10 5NB, Avon, England	University of Dundee; University of Bristol; North Bristol NHS Trust; Southmead Hospital	Murphy, DJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland.		Frost, Julia/GSI-4196-2022	Murphy, Deirdre/0000-0001-6074-6718; Frost, Julia/0000-0002-3503-5911; Pope, Catherine/0000-0002-8935-6702				Creedy DK, 2000, BIRTH-ISS PERINAT C, V27, P104, DOI 10.1046/j.1523-536x.2000.00104.x; Czarnocka J, 2000, BRIT J CLIN PSYCHOL, V39, P35, DOI 10.1348/014466500163095; Department of Health (DoH), 1993, CHANGING CHILDBIRTH; DIMATTEO MR, 1993, BIRTH-ISS PERINAT C, V20, P204, DOI 10.1111/j.1523-536X.1993.tb00228.x; EKEOCHA CEO, 1985, BRIT J OBSTET GYNAEC, V92, P97, DOI 10.1111/j.1471-0528.1985.tb01055.x; Fisher J, 1997, AUST NZ J PSYCHIAT, V31, P728, DOI 10.3109/00048679709062687; Graham WJ, 1999, BRIT J OBSTET GYNAEC, V106, P213, DOI 10.1111/j.1471-0528.1999.tb08233.x; Lavender T, 1998, BIRTH-ISS PERINAT C, V25, P215, DOI 10.1046/j.1523-536X.1998.00215.x; Mackey MC, 1998, NURS CONNECT, V11, P19; Main DM, 2000, AM J OBSTET GYNECOL, V182, P1312, DOI 10.1067/mob.2000.106249; Maternity Center Association, 2002, LIST MOTH REP 1 NAT; MENAGE J, 1997, CMAJ, V156, P831; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; MUHR T, 1997, ATLAS LI WINDOWS; Murphy DJ, 2001, LANCET, V358, P1203, DOI 10.1016/S0140-6736(01)06341-3; Murphy DJ, 2003, AM J OBSTET GYNECOL, V188, P542, DOI 10.1067/mob.2003.67; Nolan ML, 1997, MIDWIFERY, V13, P179, DOI 10.1016/S0266-6138(97)80004-6; Small R, 2000, BRIT MED J, V321, P1043, DOI 10.1136/bmj.321.7268.1043; Statham H, 2001, LANCET, V357, P635, DOI 10.1016/S0140-6736(05)71425-2; Thomas J., 2001, NATL SENTINEL CAESAR; THOMAS J, 2001, NAT SENTINEL CAESARE; Tucker JS, 1996, BRIT MED J, V312, P554, DOI 10.1136/bmj.312.7030.554; WEAVER J, 2000, MIDIRS MIDWIFERY DIG, V10, P487; Wijma K, 1997, J ANXIETY DISORD, V11, P587, DOI 10.1016/S0887-6185(97)00041-8	24	46	46	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1132	+		10.1136/bmj.327.7424.1132	http://dx.doi.org/10.1136/bmj.327.7424.1132			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744HL	14615336	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000186622100017
J	Tsong, AE; Miller, MG; Raisner, RM; Johnson, AD				Tsong, AE; Miller, MG; Raisner, RM; Johnson, AD			Evolution of a combinatorial transcriptional circuit: A case study in yeasts	CELL			English	Article							MATING-TYPE GENES; CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; HOMEODOMAIN PROTEINS; PODOSPORA-ANSERINA; OPAQUE-PHASE; HOX PROTEIN; WHITE-PHASE; ALPHA-LOCUS; IDENTIFICATION	Developing new regulation of existing genes is likely a key mechanism by which organismal complexity arises in evolution. To examine plasticity of gene regulation over evolutionary timescales, we have determined the transcriptional circuit regulating mating type in the human fungal pathogen Candida albicans, and compared it to that of Saccharomyces cerevisiae. Since the two yeasts last shared an ancestor 100-800 million years ago, several major differences in circuitry have arisen. For example, a positive regulator of mating type was retained in C. albicans but lost in S. cerevisiae; this circuit branch was replaced by the modification of an existing negative regulator, thereby conserving the circuit output. We also characterize a tier of mating type transcriptional regulation that is present only in C. albicans, and likely results from the vastly different environmental selections imposed on the two yeasts-in this case, the pressure on C. albicans to survive in a mammalian host.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnson, AD (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ajohnson@cgl.ucsf.edu			NIAID NIH HHS [R01 AI49187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Astrom SU, 2000, GENETICS, V156, P81; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; Bennett RJ, 2003, MOL CELL BIOL, V23, P8189, DOI 10.1128/MCB.23.22.8189-8201.2003; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Calderone RA., 2002, CANDIDA CANDIDIASIS; Carroll S.B., 2001, DNA DIVERSITY; Carroll SB, 2000, CELL, V101, P577, DOI 10.1016/S0092-8674(00)80868-5; Casselton LA, 1998, MICROBIOL MOL BIOL R, V62, P55, DOI 10.1128/MMBR.62.1.55-70.1998; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Coppin E, 1997, MICROBIOL MOL BIOL R, V61, P411, DOI 10.1128/.61.4.411-428.1997; Davidson E. H., 2001, DEV EVOLUTION; deBono M, 1996, GENETICS, V144, P587; DEBUCHY R, 1993, MOL GEN GENET, V241, P667, DOI 10.1007/BF00279909; Doebley J, 1998, PLANT CELL, V10, P1075, DOI 10.1105/tpc.10.7.1075; Duboule D, 1998, TRENDS GENET, V14, P54, DOI 10.1016/S0168-9525(97)01358-9; FONZI WA, 1993, GENETICS, V134, P717; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gow NAR, 2002, MOL CELL, V10, P217, DOI 10.1016/S1097-2765(02)00608-1; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Haag ES, 2002, CURR BIOL, V12, P2035, DOI 10.1016/S0960-9822(02)01333-7; Harrington TC, 1997, CURR GENET, V32, P52, DOI 10.1007/s002940050247; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Hull CM, 2000, SCIENCE, V289, P307, DOI 10.1126/science.289.5477.307; Hull CM, 1999, SCIENCE, V285, P1271, DOI 10.1126/science.285.5431.1271; Johnson A, 2003, NAT REV MICROBIOL, V1, P106, DOI 10.1038/nrmicro752; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; Keogh RS, 1998, YEAST, V14, P443, DOI 10.1002/(SICI)1097-0061(19980330)14:5<443::AID-YEA243>3.0.CO;2-L; Kjaerulff S, 1997, EMBO J, V16, P4021, DOI 10.1093/emboj/16.13.4021; Kronstad JW, 1997, ANNU REV GENET, V31, P245, DOI 10.1146/annurev.genet.31.1.245; Kurischko C, 1999, MOL GEN GENET, V262, P180, DOI 10.1007/s004380051073; Kvaal C, 1999, INFECT IMMUN, V67, P6652; Kvaal CA, 1997, INFECT IMMUN, V65, P4468, DOI 10.1128/IAI.65.11.4468-4475.1997; Lachke SA, 2003, INFECT IMMUN, V71, P4970, DOI 10.1128/IAI.71.9.4970-4976.2003; Lan CY, 2002, P NATL ACAD SCI USA, V99, P14907, DOI 10.1073/pnas.232566499; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lockhart SR, 2003, EUKARYOT CELL, V2, P847, DOI 10.1128/EC.2.5.847-855.2003; Lockhart SR, 2002, GENETICS, V162, P737; Magee BB, 2000, SCIENCE, V289, P310, DOI 10.1126/science.289.5477.310; Magee BB, 2002, MOL MICROBIOL, V46, P1345, DOI 10.1046/j.1365-2958.2002.03263.x; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; McGuire IC, 2001, FUNGAL GENET BIOL, V34, P131, DOI 10.1006/fgbi.2001.1295; Mead J, 1996, MOL CELL BIOL, V16, P2135; Miller MG, 2002, CELL, V110, P293, DOI 10.1016/S0092-8674(02)00837-1; ONEIL MT, 1992, GENETICS, V131, P113; PICARD M, 1991, GENETICS, V128, P539; PTASHNE M, 2002, GENES SIGNALS; Ronshaugen M, 2002, NATURE, V415, P914, DOI 10.1038/nature716; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; SILICIANO PG, 1986, P NATL ACAD SCI USA, V83, P2320, DOI 10.1073/pnas.83.8.2320; SLUTSKY B, 1987, J BACTERIOL, V169, P189, DOI 10.1128/JB.169.1.189-197.1987; Soll DR, 2003, EUKARYOT CELL, V2, P390, DOI 10.1128/EC.2.3.390-397.2003; SOLL DR, 1992, CLIN MICROBIOL REV, V5, P183, DOI 10.1128/CMR.5.2.183-203.1992; Souciet JL, 2000, FEBS LETT, V487, P3, DOI 10.1016/S0014-5793(00)02272-9; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Srikantha T, 2003, EUKARYOT CELL, V2, P328, DOI 10.1128/EC.2.2.328-340.2003; TURGEON BG, 1993, MOL GEN GENET, V238, P270; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; Wilson RB, 2000, YEAST, V16, P65, DOI 10.1002/(SICI)1097-0061(20000115)16:1&lt;65::AID-YEA508&gt;3.0.CO;2-M; Witthuhn RC, 2000, CURR GENET, V38, P48, DOI 10.1007/s002940000131; Wong S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r10; Wong S, 2002, P NATL ACAD SCI USA, V99, P9272, DOI 10.1073/pnas.142101099; Yun SH, 2000, FUNGAL GENET BIOL, V31, P7, DOI 10.1006/fgbi.2000.1226	73	201	248	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2003	115	4					389	399		10.1016/S0092-8674(03)00885-7	http://dx.doi.org/10.1016/S0092-8674(03)00885-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622594	Bronze			2022-12-28	WOS:000186627100006
J	Ule, J; Jensen, KB; Ruggiu, M; Mele, A; Ule, A; Darnell, RB				Ule, J; Jensen, KB; Ruggiu, M; Mele, A; Ule, A; Darnell, RB			CLIP identifies Nova-regulated RNA networks in the brain	SCIENCE			English	Article							4 SPLICE VARIANTS; MESSENGER-RNAS; PROTEIN; BINDING; GEPHYRIN; RECEPTOR; DISEASE; CHANNELS; DOMAIN; MOUSE	Nova proteins are neuron-specific antigens targeted in paraneoplastic opsoclonus myoclonus ataxia (POMA), an autoimmune neurologic disease characterized by abnormal motor inhibition. Nova proteins regulate neuronal pre-messenger RNA splicing by directly binding to RNA. To identify Nova RNA targets, we developed a method to purify protein-RNA complexes from mouse brain with the use of ultraviolet cross-linking and immunoprecipitation (CLIP). Thirty-four transcripts were identified multiple times by Nova CLIP. Three-quarters of these encode proteins that function at the neuronal synapse, and one-third are involved in neuronal inhibition. Splicing targets confirmed in Nova(-/-) mice include c-Jun N-terminal kinase 2, neogenin, and gephyrin; the latter encodes a protein that clusters inhibitory gamma-aminobutyric acid and glycine receptors, two previously identified Nova splicing targets. Thus, CLIP reveals that Nova coordinately regulates a biologically coherent set of RNAs encoding multiple components of the inhibitory synapse, an observation that may relate to the cause of abnormal motor inhibition in POMA.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Univ Amsterdam, Ctr Res Expt Econ & Polit Decis Making, NL-1018 WB Amsterdam, Netherlands	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; University of Amsterdam	Darnell, RB (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.		Ule, Jernej/C-6315-2013; Jensen, Kirk/B-4756-2008; Darnell, Robert B/B-9022-2008; Jensen, Kirk/AAL-5883-2020	Ule, Jernej/0000-0002-2452-4277; Jensen, Kirk/0000-0002-2084-1734; Darnell, Robert B/0000-0002-5134-8088; Jensen, Kirk/0000-0002-2084-1734; Ruggiu, Matteo/0000-0002-6404-1210	NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH064753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040955, R01NS034389] Funding Source: NIH RePORTER; NIMH NIH HHS [K01 MH64753] Funding Source: Medline; NINDS NIH HHS [NS40955, R01 NS34389] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Billups D, 2000, J NEUROSCI, V20, P8643; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; Butler MH, 2000, NEURON, V26, P307, DOI 10.1016/S0896-6273(00)81165-4; Casanova E, 1996, NEUROREPORT, V7, P1320, DOI 10.1097/00001756-199605170-00021; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Dredge BK, 2003, MOL CELL BIOL, V23, P4687, DOI 10.1128/MCB.23.13.4687-4700.2003; Dredge BK, 2001, NAT REV NEUROSCI, V2, P43, DOI 10.1038/35049061; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Jensen KB, 2000, P NATL ACAD SCI USA, V97, P5740, DOI 10.1073/pnas.090553997; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Lerche H, 2001, AM J MED GENET, V106, P146, DOI 10.1002/ajmg.1582; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LERNER MR, 1981, CELL, V25, P298, DOI 10.1016/0092-8674(81)90047-7; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Musunuru K, 2001, ANNU REV NEUROSCI, V24, P239, DOI 10.1146/annurev.neuro.24.1.239; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; RUGGIU M, UNPUB; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; ULE J, UNPUB; Villanueva A, 2001, EMBO J, V20, P5114, DOI 10.1093/emboj/20.18.5114; VONMUHLEN CA, 1995, SEMIN ARTHRITIS RHEU, V24, P323, DOI 10.1016/S0049-0172(95)80004-2; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25	33	791	818	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1212	1215		10.1126/science.1090095	http://dx.doi.org/10.1126/science.1090095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615540				2022-12-28	WOS:000186544300055
J	Mitrofanov, IG				Mitrofanov, IG			Astrophysics - A constraint on canonical quantum gravity?	NATURE			English	Editorial Material									Space Res Inst, Moscow 117997, Russia	Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences	Mitrofanov, IG (corresponding author), Space Res Inst, Profsojuznaya Str 84-32, Moscow 117997, Russia.			Mitrofanov, Igor/0000-0001-7204-2101				Amelino-Camelia G, 1998, NATURE, V393, P763, DOI 10.1038/31647; Cambini R., 1999, PHYS REV D, V59; COLBURN W, 2003, NATURE, V423, P415; Gonzalez MM, 2003, NATURE, V424, P749, DOI 10.1038/nature01869; Jacobson T, 2003, NATURE, V424, P1019, DOI 10.1038/nature01882	5	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					139	139		10.1038/426139a	http://dx.doi.org/10.1038/426139a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614493				2022-12-28	WOS:000186517200030
J	Crawford, BD				Crawford, BD			Open-access publishing: where is the value?	LANCET			English	Article									John Wiley & Sons, Hoboken, NJ 07030 USA	Wiley	Crawford, BD (corresponding author), John Wiley & Sons Ltd, Off Vice President, Atrium,So Gate, Chichester PO19 8SQ, W Sussex, England.							BRAND STEWART, 1987, MEDIA LAB INVENTING, P202; VARIAN H, INFORMATION EC EC IN	2	16	17	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1578	1580		10.1016/S0140-6736(03)14749-6	http://dx.doi.org/10.1016/S0140-6736(03)14749-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615117				2022-12-28	WOS:000186464500027
J	Turnbull, F; Neal, B; Algert, C; Chalmers, J; Woodward, M; MacMahon, S; MacMahon, S; Baigent, C; Cutler, J; Fagard, R; Neal, B; Whelton, P; Yusuf, S; Algert, C; Chalmers, J; Chapman, N; MacMahon, S; Neal, B; Turnbull, F; Woodward, M; Agodoa, L; Baigent, C; Black, H; Boissel, JP; Brenner, B; Brown, M; Bulpitt, C; Byington, R; Chalmers, J; Collins, R; Cutler, J; Dahlof, B; Davis, B; Dens, J; Estacio, R; Fagard, R; Fox, K; Hansson, L; Holman, R; Hunsicker, L; Kostis, J; Kuramoto, K; Lewis, E; Lindholm, L; Lubsen, J; MacMahon, S; Malacco, E; Mancia, G; Neal, B; Pepine, C; Pfeffer, M; Pitt, B; Poole-Wilson, P; Remuzzi, G; Rodgers, A; Ruggenenti, P; Schrier, R; Sever, P; Sleight, P; Staessen, J; Tco, K; Turner, R; Whelton, P; Wing, L; Yui, Y; Yusuf, S; Zanchetti, A				Turnbull, F; Neal, B; Algert, C; Chalmers, J; Woodward, M; MacMahon, S; MacMahon, S; Baigent, C; Cutler, J; Fagard, R; Neal, B; Whelton, P; Yusuf, S; Algert, C; Chalmers, J; Chapman, N; MacMahon, S; Neal, B; Turnbull, F; Woodward, M; Agodoa, L; Baigent, C; Black, H; Boissel, JP; Brenner, B; Brown, M; Bulpitt, C; Byington, R; Chalmers, J; Collins, R; Cutler, J; Dahlof, B; Davis, B; Dens, J; Estacio, R; Fagard, R; Fox, K; Hansson, L; Holman, R; Hunsicker, L; Kostis, J; Kuramoto, K; Lewis, E; Lindholm, L; Lubsen, J; MacMahon, S; Malacco, E; Mancia, G; Neal, B; Pepine, C; Pfeffer, M; Pitt, B; Poole-Wilson, P; Remuzzi, G; Rodgers, A; Ruggenenti, P; Schrier, R; Sever, P; Sleight, P; Staessen, J; Tco, K; Turner, R; Whelton, P; Wing, L; Yui, Y; Yusuf, S; Zanchetti, A		Blood Pressure Lowering Treatment	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials	LANCET			English	Article							CONVERTING-ENZYME-INHIBITORS; DOUBLE-BLIND; ANTIHYPERTENSIVE THERAPIES; 1ST-LINE AGENTS; HEART-FAILURE; HYPERTENSION; MORBIDITY; MORTALITY; OUTCOMES; CORONARY	Background The benefits of reducing blood pressure on the risks of major cardiovascular disease are well established, but uncertainty remains about the comparative effects of different blood-pressure-lowering regimens. We aimed to estimate effects of strategies based on different drug classes (angiotensin-converting-enzyme [ACE] inhibitors, calcium antagonists, angiotensin-receptor blockers [ARBs], and diuretics or P blockers) or those targeting different blood pressure goals, on the risks of major cardiovascular events and death. Methods We did seven sets of prospectively-designed overviews with data from 29 randomised trials (n=162 341). The trial eligibility criteria, primary outcomes, and main hypotheses were specified before the result of any contributing trial was known. Findings In placebo-controlled trials the relative risks of total major cardiovascular events were reduced by regimens based on ACE inhibitors (22%; 95% Cl 17-27) or calcium antagonists (18%; 5-29). Greater risk reductions were produced by regimens that targeted lower blood pressure goals (15%; 5-24). ARB-based regimens reduced the risks of total major cardiovascular events (10%; 4-17) compared with control regimens. There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or P blockers, although ACE-inhibitor-based regimens reduced blood pressure less. There was evidence of some differences between active regimens in their effects on cause-specific outcomes. For every outcome other than heart failure, the difference between randomised groups in achieved blood pressure reduction was directly related to the observed difference in risk. Interpretation Treatment with any commonly-used regimen reduces the risk of total major cardiovascular events, and larger reductions in blood pressure produce larger reductions in risk.	Univ Sydney, George Inst Int Hlth, Blood Pressure Lowering Treatment Trialists Colla, Sydney, NSW 2042, Australia	University of Sydney	Turnbull, F (corresponding author), Univ Sydney, George Inst Int Hlth, Blood Pressure Lowering Treatment Trialists Colla, POB 576, Sydney, NSW 2042, Australia.	fturnbull@iih.usyd.edu.au	Staessen, Jan A/A-1065-2011; Woodward, Mark/D-8492-2015; Woodward, Mark/L-6817-2017; Remuzzi, Giuseppe/V-9766-2017	Staessen, Jan A/0000-0002-3026-1637; Chalmers, John/0000-0002-9931-0580; Remuzzi, Giuseppe/0000-0002-6194-3446; MacMahon, Stephen/0000-0003-2064-7699; Neal, Bruce/0000-0002-0490-7465				Alderman M, 1997, J HYPERTENS, V15, P105; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Carson PA, 2000, J AM COLL CARDIOL, V36, P541, DOI 10.1016/S0735-1097(00)00728-2; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COHN JN, 1995, CIRCULATION S1, V92, P1; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dens JA, 2001, AM J CARDIOL, V87, P28, DOI 10.1016/S0002-9149(00)01267-4; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Kuramoto K, 1999, HYPERTENSION, V34, P1129; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; MacMahon S, 1997, J HYPERTENS, V15, P1201, DOI 10.1097/00004872-199715110-00002; MacMahon S, 2000, J AM COLL CARDIOL, V36, P438, DOI 10.1016/S0735-1097(00)00736-1; Malacco E, 2003, BLOOD PRESSURE, V12, P160, DOI 10.1080/08037050310009545; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; Murray CJ, 1996, GLOBAL BURDEN DIS; Neal B, 2000, LANCET, V356, P1955; Pahor M, 2000, LANCET, V356, P1949, DOI 10.1016/S0140-6736(00)03306-7; Pitt B, 2000, CIRCULATION, V102, P1503, DOI 10.1161/01.CIR.102.13.1503; Pitt B, 2001, AM J CARDIOL, V87, P1058, DOI 10.1016/S0002-9149(01)01461-8; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Teo KK, 2000, CIRCULATION, V102, P1748; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WHO, 2002, RED RISKS PROM HLTH; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Woodward M., 2014, EPIDEMIOLOGY STUDY D; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; YUI Y, 2002, CIRC J S, V66, P357; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zanchetti A, 1998, J HYPERTENS, V16, P1667, DOI 10.1097/00004872-199816110-00014; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD	51	1885	1967	2	88	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	2003	362	9395					1527	1535						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615107				2022-12-28	WOS:000186464500008
J	Grathwohl, KW; Derdak, S				Grathwohl, KW; Derdak, S			Buffalo chest	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA	San Antonio Military Medical Center; United States Department of Defense; United States Army; United States Department of Defense; United States Air Force	Grathwohl, KW (corresponding author), Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA.								0	15	15	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1829	1829		10.1056/NEJMicm010281	http://dx.doi.org/10.1056/NEJMicm010281			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602881				2022-12-28	WOS:000186353800007
J	Batavia, AI				Batavia, AI			Accounting for the health-care bill	LANCET			English	Editorial Material									Florida Int Univ, Miami Beach, FL USA	State University System of Florida; Florida International University	Batavia, AI (corresponding author), Care of Batavia M, NYU, Dept Phys Therapy, 380 2nd Ave, New York, NY 10010 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1495	1497		10.1016/S0140-6736(03)14697-1	http://dx.doi.org/10.1016/S0140-6736(03)14697-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602447				2022-12-28	WOS:000186356600028
J	Martinowich, K; Hattori, D; Wu, H; Fouse, S; He, F; Hu, Y; Fan, GP; Sun, YE				Martinowich, K; Hattori, D; Wu, H; Fouse, S; He, F; Hu, Y; Fan, GP; Sun, YE			DNA methylation-related chromatin remodeling in activity-dependent Bdnf gene regulation	SCIENCE			English	Article							BINDING PROTEIN MECP2; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; CALCIUM REGULATION; RETT-SYNDROME; CNS NEURONS; EXPRESSION; LOCALIZATION; REGIONS	In conjunction with histone modi. cations, DNA methylation plays critical roles in gene silencing through chromatin remodeling. Changes in DNA methylation perturb neuronal function, and mutations in a methyl-CpG-binding protein, MeCP2, are associated with Rett syndrome. We report that increased synthesis of brain-derived neurotrophic factor (BDNF) in neurons after depolarization correlates with a decrease in CpG methylation within the regulatory region of the Bdnf gene. Moreover, increased Bdnf transcription involves dissociation of the MeCP2-histone deacetylase-mSin3A repression complex from its promoter. Our findings suggest that DNA methylation-related chromatin remodeling is important for activity-dependent gene regulation that may be critical for neural plasticity.	Univ Calif Los Angeles, ACCESS Program, Neurosci Interdept Program, Los Angeles, CA USA; Univ Calif Los Angeles, ACCESS Program, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Calif Los Angeles, ACCESS Program, Dept Psychiat & Behav Sci, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fan, GP (corresponding author), Univ Calif Los Angeles, ACCESS Program, Neurosci Interdept Program, Los Angeles, CA USA.	gfan@mednet.ucla.edu; ysun@mednet.ucla.edu	Wu, Hao/G-4145-2013; Martinowich, Keri/F-9841-2012	Wu, Hao/0000-0002-1256-6891; Wu, Hao/0000-0003-4395-6929; Fan, Guoping/0000-0001-5235-6410; Martinowich, Keri/0000-0002-5237-0789	NINDS NIH HHS [NS44405] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044405] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Chen WG, 2003, J NEUROSCI, V23, P2572; Fan GP, 2001, J NEUROSCI, V21, P788, DOI 10.1523/JNEUROSCI.21-03-00788.2001; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; GOTO K, 1994, DIFFERENTIATION, V56, P39, DOI 10.1046/j.1432-0436.1994.56120039.x; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Herman H, 2003, NAT GENET, V34, P199, DOI 10.1038/ng1162; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	28	1074	1117	4	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					890	893		10.1126/science.1090842	http://dx.doi.org/10.1126/science.1090842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593184				2022-12-28	WOS:000186258000056
J	Shepherd, A; Wingham, D; Payne, T; Skvarca, P				Shepherd, A; Wingham, D; Payne, T; Skvarca, P			Larsen ice shelf has progressively thinned	SCIENCE			English	Article							ANTARCTIC PENINSULA; MODEL; TEMPERATURE; VARIABILITY; COLLAPSE; GLACIER; RETREAT; SURFACE; TRENDS; MOTION	The retreat and collapse of Antarctic Peninsula ice shelves in tandem with a regional atmospheric warming has fueled speculation as to how these events may be related. Satellite radar altimeter measurements show that between 1992 and 2001 the Larsen Ice Shelf lowered by up to 0.27 +/- 0.11 meters per year. The lowering is explained by increased summer melt-water and the loss of basal ice through melting. Enhanced ocean-driven melting may provide a simple link between regional climate warming and the successive disintegration of sections of the Larsen Ice Shelf.	Univ Cambridge, Scott Polar Res Inst, Ctr Polar Observat & Modelling, Cambridge CB2 1ER, England; UCL, Ctr Polar Observat & Modelling, London WC1E 6BT, England; Univ Bristol, Ctr Polar Observat & Modelling, Bristol BS8 1SS, Avon, England; Inst Antartico Argentino, RA-1010 Buenos Aires, DF, Argentina	University of Cambridge; University of London; University College London; University of Bristol; Instituto Antartico Argentino	Shepherd, A (corresponding author), Univ Cambridge, Scott Polar Res Inst, Ctr Polar Observat & Modelling, Cambridge CB2 1ER, England.	aps46@cam.ac.uk	payne, antony/A-8916-2008	payne, antony/0000-0001-8825-8425; Shepherd, Andrew/0000-0002-4914-1299				BROWN GS, 1977, IEEE T ANTENN PROPAG, V25, P67, DOI 10.1109/JOE.1977.1145328; Comiso JC, 2000, J CLIMATE, V13, P1674, DOI 10.1175/1520-0442(2000)013<1674:VATIAS>2.0.CO;2; Doake CSM, 1998, NATURE, V391, P778, DOI 10.1038/35832; DOAKE CSM, 1984, ANN GLACIOL, V5, P47, DOI 10.3189/1984AoG5-1-47-50; Fahnestock MA, 2002, ANN GLACIOL, V34, P127, DOI 10.3189/172756402781817798; FERRIGNO JG, 2001, 12560 USGS; Joughin I, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016941; K Herterich, 1987, DYNAMICS W ANTARCTIC; Lythe MB, 2001, J GEOPHYS RES-SOL EA, V106, P11335, DOI 10.1029/2000JB900449; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; NICHOLLS K, COMMUNICATION; Patterson W.S.B, 1994, PHYS GLACIERS, Vthird, P496; POTTER JR, 1985, BR ANTARCT SURV B, V68, P1; RACK W, 2000, THESIS LEOPOLDFRANZE; Raymond C, 1996, J GLACIOL, V42, P510, DOI 10.3189/S002214300000349X; Reeh N, 2000, ANN GLACIOL, V31, P111, DOI 10.3189/172756400781820408; REEH N, 1991, POLARFORSCHUNG, V0059; RIDLEY JK, 1988, INT J REMOTE SENS, V9, P601, DOI 10.1080/01431168808954881; Rignot E, 2002, SCIENCE, V296, P2020, DOI 10.1126/science.1070942; Robertson R, 2002, DEEP-SEA RES PT II, V49, P4791, DOI 10.1016/S0967-0645(02)00159-5; Rott H, 1998, ANN GLACIOL-SER, V27, P86; Rott H, 1996, SCIENCE, V271, P788, DOI 10.1126/science.271.5250.788; Scambos TA, 2000, J GLACIOL, V46, P516, DOI 10.3189/172756500781833043; Shepherd A, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2001JC001152; Shepherd A, 2001, SCIENCE, V291, P862, DOI 10.1126/science.291.5505.862; SPERONI JO, 2001, GEOACTAS, V25, P1; Turner J, 1998, ANN GLACIOL, V27, P591; Vaughan DG, 1996, NATURE, V379, P328, DOI 10.1038/379328a0; Vaughan DG, 2001, SCIENCE, V293, P1777, DOI 10.1126/science.1065116; WARWICK RA, 1996, CLIMATE CHANGE 1995, P359; WEERTMAN J, 1973, PUBLICATION ASS INT, V95, P139; Whitehouse MJ, 1996, DEEP-SEA RES PT I, V43, P425, DOI 10.1016/0967-0637(96)00020-9; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456	33	223	228	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					856	859		10.1126/science.1089768	http://dx.doi.org/10.1126/science.1089768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593176				2022-12-28	WOS:000186258000046
J	Fliers, E; Sauerwein, HP; Romijn, JA; Reiss, P; van der Valk, M; Kalsbeek, A; Kreier, F; Buijs, RM				Fliers, E; Sauerwein, HP; Romijn, JA; Reiss, P; van der Valk, M; Kalsbeek, A; Kreier, F; Buijs, RM			HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy	LANCET			English	Article							VIRUS-INFECTED PATIENTS; PROTEASE INHIBITORS; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; INSULIN-RESISTANCE; LIPODYSTROPHY; GLUTAMATE; INNERVATION; NUCLEUS; TISSUE	Abnormal body-fat distribution in HIV-1-associated adipose redistribution syndrome (HARS) remains unexplained at present. White adipose tissue is controlled by humoral factors and by neural regulation. Sympathetic innervation stimulates lipolysis, whereas parasympathetic innervation has an anabolic influence on white adipose tissue. Results of neuroanatomical studies showed a clear somatotopy with respect to autonomic control of white adipose tissue by both the sympathetic and parasympathetic branch, with separate sets of autonomic neurons innervating either the subcutaneous or the visceral fat compartment. Thus, the CNS is likely to be a key player in regulation of body-fat distribution. We propose that HARS is mediated by effects of antiretroviral treatment on the CNS and could indicate a change in autonomic balance resulting in redistribution of adipose tissue.	Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Int Antiviral Therapy Evaluat Ctr, NL-1100 DE Amsterdam, Netherlands; Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol & Metab, NL-2300 RC Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Fliers, E (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, F5-168,POB 22700, NL-1100 DE Amsterdam, Netherlands.		van der valk, marc/AAQ-9026-2020; Kalsbeek, Andries/H-3076-2019; Kreier, Felix/C-3371-2008; Buijs, Rudolf/AAD-5707-2020	van der valk, marc/0000-0002-8290-6425; Kalsbeek, Andries/0000-0001-9606-8453; Fliers, Eric/0000-0001-8048-9050				Bartness TJ, 1998, AM J PHYSIOL-REG I, V275, pR1399, DOI 10.1152/ajpregu.1998.275.5.R1399; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; Buijs RM, 2001, J COMP NEUROL, V431, P405, DOI 10.1002/1096-9861(20010319)431:4<405::AID-CNE1079>3.0.CO;2-D; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Chen DL, 2002, J CLIN ENDOCR METAB, V87, P4845, DOI 10.1210/jc.2002-020794; Christeff N, 2002, EUR J CLIN INVEST, V32, P775, DOI 10.1046/j.1365-2362.2002.01068.x; Dawson R, 1997, AM J PHYSIOL-ENDOC M, V273, pE202, DOI 10.1152/ajpendo.1997.273.1.E202; Flier JS, 2000, J CLIN INVEST, V105, P859, DOI 10.1172/JCI9725; GRIPSHOVER B, 2003, P 10 C RETR OPP INF; Kreier F, 2002, J CLIN INVEST, V110, P1243, DOI 10.1172/JCI200215736; Ledru E, 2000, BLOOD, V95, P3191, DOI 10.1182/blood.V95.10.3191.010k10_3191_3198; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Morris MJ, 1998, REGUL PEPTIDES, V75-6, P441, DOI 10.1016/S0167-0115(98)00100-1; van der Valk M, 2002, J CLIN ENDOCR METAB, V87, P5066, DOI 10.1210/jc.2002-020892; van der Valk M, 2001, AIDS, V15, P847, DOI 10.1097/00002030-200105040-00005; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Wulff EA, 2000, DRUGS, V59, P1251, DOI 10.2165/00003495-200059060-00005; Wynn HE, 2002, CNS DRUGS, V16, P595, DOI 10.2165/00023210-200216090-00002; Yanovski JA, 1999, J CLIN ENDOCR METAB, V84, P1925, DOI 10.1210/jc.84.6.1925	21	43	46	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1758	1760		10.1016/S0140-6736(03)14858-1	http://dx.doi.org/10.1016/S0140-6736(03)14858-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643128				2022-12-28	WOS:000186767700027
J	Verheugt, FWA				Verheugt, FWA			Can we pull the plug on warfarin in atrial fibrillation?	LANCET			English	Editorial Material							ORAL ANTICOAGULATION; XIMELAGATRAN		Radboud Univ Nijmegen Med Ctr, Heartctr, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Radboud Univ Nijmegen Med Ctr, Heartctr, NL-6500 HB Nijmegen, Netherlands.	f.verheugt@cardio.umcn.nl	Verheugt, F.W.A./H-8105-2014					Blackshear JL, 1996, LANCET, V348, P633; Brouwer MA, 2002, CIRCULATION, V105, P1270, DOI 10.1161/hc1102.105594; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; HALPERIN JL, 2003, SPORTIV 5 AM HEART A; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; Wallentin L, 2003, LANCET, V362, P789, DOI 10.1016/S0140-6736(03)14287-0	8	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1686	1687		10.1016/S0140-6736(03)14880-5	http://dx.doi.org/10.1016/S0140-6736(03)14880-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643112				2022-12-28	WOS:000186767700002
J	Vuylsteke, P; Knockaert, DC; Blockmans, D; Arnout, J; Vanderschueren, S				Vuylsteke, P; Knockaert, DC; Blockmans, D; Arnout, J; Vanderschueren, S			Abdominal pain, hypertension, and thrombocytopenia	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; PURPURA		Univ Hosp Gasthuisberg, Dept Gen Internal Med, B-3000 Louvain, Belgium; Univ Hosp Gasthuisberg, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Vanderschueren, S (corresponding author), Univ Hosp Gasthuisberg, Dept Gen Internal Med, B-3000 Louvain, Belgium.		Vuylsteke, peter/GXW-1169-2022; Vanderschueren, Steven/AAB-5739-2021	Vuylsteke, Peter/0000-0001-6401-3722				Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; George JN, 1998, J CLIN APHERESIS, V13, P120, DOI 10.1002/(SICI)1098-1101(1998)13:3<120::AID-JCA5>3.0.CO;2-E; LAMBERT SR, 1985, ARCH OPHTHALMOL-CHIC, V103, P1172; RIDOLFI RL, 1981, MEDICINE, V60, P413, DOI 10.1097/00005792-198111000-00003; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1720	1720		10.1016/S0140-6736(03)14876-3	http://dx.doi.org/10.1016/S0140-6736(03)14876-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643121				2022-12-28	WOS:000186767700011
J	Fitch, JP; Raber, E; Imbro, DR				Fitch, JP; Raber, E; Imbro, DR			Technology challenges in responding to biological or chemical attacks in the civilian sector	SCIENCE			English	Review							WARFARE AGENTS; DECONTAMINATION	Increasingly sophisticated technologies are needed for counterterrorism responses to biological and chemical warfare agents. Recently developed detection and identification systems are characterized by increased sensitivity, greater automation, and fewer false alarms. Attempts are also under way to reduce the cost and complexity of field-deployable systems. A broad range of decontamination reagents for equipment and personnel is emerging, but decontamination of large buildings, inaccessible spaces, and sensitive equipment remains problematic.	Lawrence Livermore Natl Lab, Nonproliferat Arms Control & Int Secur Directorat, Livermore, CA 94551 USA; Lawrence Livermore Natl Lab, Environm Protect Dept, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Fitch, JP (corresponding author), Lawrence Livermore Natl Lab, Nonproliferat Arms Control & Int Secur Directorat, Livermore, CA 94551 USA.	fitch2@llnl.gov; raber1@llnl.gov						Allwine KJ, 2002, B AM METEOROL SOC, V83, P521, DOI 10.1175/1520-0477(2002)083<0521:OOUAMF>2.3.CO;2; BARRETT JA, 1999, WIDE AREA DECONTAMIN; CARLSEN TM, 2001, UCRLAR143245; COLE S, 2003, HOMELAND SECURITY SO; Colton RJ, 2003, SCIENCE, V299, P1324, DOI 10.1126/science.1080688; EMANUEL P, 2001, NATO S OP MED ISS CH; Fitch JP, 2002, P IEEE, V90, P1708, DOI 10.1109/JPROC.2002.804680; *FOOD DRUG ADM, 2003, MED LETT CDC FDA, P12; FRUCHEY I, 2002, 23 ARM SCI C ORL FL; GORDON SP, 2003, CHEM BIOL NAT SEC PR; Herrmann HW, 2002, IEEE T PLASMA SCI, V30, P1460, DOI 10.1109/TPS.2002.804196; HOLMES P, 1997, P 1997 ERDEC SCI C 1, P367; HOVERSTEN P, 2002, AVIATION WEEKS HOMEL, V1, P7; IMBRO DR, 2003, CHEM BIOL NAT SEC PR; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Koller D, 2001, STAT ENG IN, P445; LARSON L, 2002, ABBREVIATED TEST REP; LEE RL, 2002, 4 AM MET SOC S URB E; McBride MT, 2003, ANAL CHEM, V75, P1924, DOI 10.1021/ac026379k; McGuire R, 2001, UCRLAR143212 LAWR LI; MILANOVICH FP, 2000, P SOC PHOTO-OPT INS, V4200, P55; Nagao M, 1997, TOXICOL APPL PHARM, V144, P198, DOI 10.1006/taap.1997.8110; *NAT EN BOARD, 1999, CAND EN SUPPL DEM 20, P43; Okumura T, 1998, ACAD EMERG MED, V5, P613, DOI 10.1111/j.1553-2712.1998.tb02470.x; Raber E, 2002, J HAZARD MATER, V93, P339, DOI 10.1016/S0304-3894(02)00051-1; Raber E, 2002, RISK ANAL, V22, P195, DOI 10.1111/0272-4332.00026; Raber E, 2001, INT J ENVIRON HEAL R, V11, P128, DOI 10.1080/09603120020047519; RABER E, IN PRESS INT J ENV H; TAYLOR MT, 2001, P MICR TOT AN SYST M, P670; *US EPA, 2002, CHALL FAC ENV PROT A; *US EPA AEGL NAT A, 2000, AC EXP GUID LEV NERV; *US GEN ACC OFF, 2003, CAP HILL ANTHR INC E; *US GEN ACC OFF, 2003, GAO PUBL; Whyte P, 2002, J FOOD SAFETY, V22, P55, DOI 10.1111/j.1745-4565.2002.tb00330.x	34	118	130	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1350	1354		10.1126/science.1085922	http://dx.doi.org/10.1126/science.1085922			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631029				2022-12-28	WOS:000186683500039
J	Mah, TF; Pitts, B; Pellock, B; Walker, GC; Stewart, PS; O'Toole, GA				Mah, TF; Pitts, B; Pellock, B; Walker, GC; Stewart, PS; O'Toole, GA			A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance	NATURE			English	Article							MOLECULAR-WEIGHT; SUCCINOGLYCAN; PENETRATION; LIMITATION; EXPRESSION	Biofilms are surface-attached microbial communities with characteristic architecture and phenotypic and biochemical properties distinct from their free-swimming, planktonic counterparts(1). One of the best-known of these biofilm-specific properties is the development of antibiotic resistance that can be up to 1,000-fold greater than planktonic cells(2). We report a genetic determinant of this high-level resistance in the Gram-negative opportunistic pathogen, Pseudomonas aeruginosa. We have identified a mutant of P. aeruginosa that, while still capable of forming biofilms with the characteristic P. aeruginosa architecture, does not develop high-level biofilm-specific resistance to three different classes of antibiotics. The locus identified in our screen, ndvB, is required for the synthesis of periplasmic glucans. Our discovery that these periplasmic glucans interact physically with tobramycin suggests that these glucose polymers may prevent antibiotics from reaching their sites of action by sequestering these antimicrobial agents in the periplasm. Our results indicate that biofilms themselves are not simply a diffusion barrier to these antibiotics, but rather that bacteria within these microbial communities employ distinct mechanisms to resist the action of antimicrobial agents.	Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Hanover, NH 03755 USA; Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA; MIT, Dept Biol, Cambridge, MA 02412 USA	Dartmouth College; Montana State University System; Montana State University Bozeman; Massachusetts Institute of Technology (MIT)	O'Toole, GA (corresponding author), Dartmouth Coll Sch Med, Dept Microbiol & Immunol, Hanover, NH 03755 USA.	georgeo@Dartmouth.edu		/0000-0001-7243-8261; Stewart, Philip/0000-0001-7773-8570				Anderl JN, 2000, ANTIMICROB AGENTS CH, V44, P1818, DOI 10.1128/AAC.44.7.1818-1824.2000; Bhagwat AA, 1996, J BACTERIOL, V178, P4635, DOI 10.1128/jb.178.15.4635-4642.1996; Bloemberg GV, 1997, APPL ENVIRON MICROB, V63, P4543, DOI 10.1128/AEM.63.11.4543-4551.1997; BREEDVELD MW, 1994, MICROBIOL REV, V58, P145, DOI 10.1128/MMBR.58.2.145-161.1994; CAETANOANOLLES G, 1993, PCR METH APPL, V3, P85; Chen RJ, 2002, CAN J MICROBIOL, V48, P1008, DOI 10.1139/W02-099; Christensen BB, 1999, METHOD ENZYMOL, V310, P20; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Davey ME, 2000, MICROBIOL MOL BIOL R, V64, P847, DOI 10.1128/MMBR.64.4.847-867.2000; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Gonzalez JE, 1998, P NATL ACAD SCI USA, V95, P13477, DOI 10.1073/pnas.95.23.13477; Hentzer M, 2001, J BACTERIOL, V183, P5395, DOI 10.1128/JB.183.18.5395-5401.2001; Heydorn A, 2000, MICROBIOL-UK, V146, P2409, DOI 10.1099/00221287-146-10-2409; Hoyle B D, 1991, Prog Drug Res, V37, P91; LOEWUS FA, 1952, ANAL CHEM, V24, P219, DOI 10.1021/ac60061a050; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; SIMON R, 1989, GENE, V80, P161, DOI 10.1016/0378-1119(89)90262-X; SZEJTLI J, 1990, CARBOHYD POLYM, V12, P375, DOI 10.1016/0144-8617(90)90088-A; Walters MC, 2003, ANTIMICROB AGENTS CH, V47, P317, DOI 10.1128/AAC.47.1.317-323.2003; Wang LX, 1999, J BACTERIOL, V181, P6788, DOI 10.1128/JB.181.21.6788-6796.1999; Whiteley M, 2001, NATURE, V413, P860, DOI 10.1038/35101627	24	799	864	6	228	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					306	310		10.1038/nature02122	http://dx.doi.org/10.1038/nature02122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628055	Green Published			2022-12-28	WOS:000186660800048
J	O'Brien, JL; Pryde, GJ; White, AG; Ralph, TC; Branning, D				O'Brien, JL; Pryde, GJ; White, AG; Ralph, TC; Branning, D			Demonstration of an all-optical quantum controlled-NOT gate	NATURE			English	Article							COMMUNICATION; ENTANGLEMENT; REALIZATION; COMPUTATION; GENERATION; PHOTONS	The promise of tremendous computational power, coupled with the development of robust error-correcting schemes(1), has fuelled extensive efforts(2) to build a quantum computer. The requirements for realizing such a device are confounding: scalable quantum bits (two-level quantum systems, or qubits) that can be well isolated from the environment, but also initialized, measured and made to undergo controllable interactions to implement a universal set of quantum logic gates(3). The usual set consists of single qubit rotations and a controlled-NOT (CNOT) gate, which flips the state of a target qubit conditional on the control qubit being in the state 1. Here we report an unambiguous experimental demonstration and comprehensive characterization of quantum CNOT operation in an optical system. We produce all four entangled Bell states as a function of only the input qubits' logical values, for a single operating condition of the gate. The gate is probabilistic (the qubits are destroyed upon failure), but with the addition of linear optical quantum non-demolition measurements, it is equivalent to the CNOT gate required for scalable all-optical quantum computation(4).	Univ Queensland, Dept Phys, Ctr Quantum Comp Technol, Brisbane, Qld 4072, Australia; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Queensland; University of Illinois System; University of Illinois Urbana-Champaign	O'Brien, JL (corresponding author), Univ Queensland, Dept Phys, Ctr Quantum Comp Technol, Brisbane, Qld 4072, Australia.	job@physics.uq.edu.au	White, Andrew G./AAI-1062-2020; Pryde, Geoff J/A-8067-2008; Ralph, Timothy C/A-1858-2011; White, Andrew G/A-1088-2009; O'Brien, Jeremy L/A-6290-2008	Pryde, Geoff J/0000-0003-3324-6579; Ralph, Timothy C/0000-0003-0692-8427; White, Andrew G/0000-0001-9639-5200; O'Brien, Jeremy/0000-0002-3576-8285				CLARK RG, 2001, QUANTUM INF COMPUT, V1, P1; DiVincenzo DP, 1998, SUPERLATTICE MICROST, V23, P419, DOI 10.1006/spmi.1997.0520; DODD JL, 2003, IN PRESS PHYS REV A; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Imamoglu A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.163602; James DFV, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.183601; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Koashi M, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.030301; Kok P, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.063814; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Kurtsiefer C, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.023802; Kuzmich A, 2003, NATURE, V423, P731, DOI 10.1038/nature01714; Leibfried D, 2003, NATURE, V422, P412, DOI 10.1038/nature01492; Munro WJ, 2001, J MOD OPTIC, V48, P1239, DOI 10.1080/095003400110034532; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pan JW, 2001, NATURE, V410, P1067, DOI 10.1038/35074041; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; Pittman TB, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.062311; PITTMAN TB, 2003, QUANTPH0303095; Ralph TC, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.062324; Schmidt-Kaler F, 2003, NATURE, V422, P408, DOI 10.1038/nature01494; Takeuchi S, 2001, OPT LETT, V26, P843, DOI 10.1364/OL.26.000843; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Vandersypen LMK, 2001, NATURE, V414, P883, DOI 10.1038/414883a; [No title captured]	30	685	710	9	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					264	267		10.1038/nature02054	http://dx.doi.org/10.1038/nature02054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628045	Green Submitted, Green Published			2022-12-28	WOS:000186660800037
J	Mofenson, LM; Harris, DR; Moye, J; Bethel, J; Korelitz, J; Read, JS; Nugent, R; Meyer, W				Mofenson, LM; Harris, DR; Moye, J; Bethel, J; Korelitz, J; Read, JS; Nugent, R; Meyer, W		NICHD IVIG Clinical Trial Study Gr	Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings	LANCET			English	Article								Cheaper, simpler alternatives to CD4 lymphocyte count and HIV-1 RNA detection for assessing the prognosis of HIV-1 infection are needed for resource-poor settings. However, little is known about the predictive value of alternative assays, in particular in children. We assessed the prognostic value of total lymphocyte count, immune complex-dissociated p24 antigen, white blood cell count, packed-cell volume (haematocrit), and serum albumin for mortality in 376 HIV-1-infected, mainly African-American or Hispanic children enrolled during March, 1988 to January, 1991. In a Cox proportional hazards model, including all assay-alternatives to CD4 and RNA, total lymphocyte count (p<0.0001) and serum albumin (p=0.0107) independently predicted mortality. Further assessment of these markers is warranted in resource-poor settings.	NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD 20852 USA; WESTAT Corp, Rockville, MD 20850 USA; Quest Diagnost, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Westat	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, 6100 Execut Blvd, Rockville, MD 20852 USA.	LM65D@nih.gov	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; moye, john/0000-0001-9976-8586	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD033162] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; Rabkin M, 2002, LANCET, V360, P1503, DOI 10.1016/S0140-6736(02)11478-4; Taha TE, 2000, AIDS, V14, P453, DOI 10.1097/00002030-200003100-00021	5	34	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1625	1627		10.1016/S0140-6736(03)14825-8	http://dx.doi.org/10.1016/S0140-6736(03)14825-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630444				2022-12-28	WOS:000186637400012
J	Pavic, M; Francina, A; Durand, DV; Rousset, H				Pavic, M; Francina, A; Durand, DV; Rousset, H			Polycythaemia and iron deficiency	LANCET			English	Editorial Material									Ctr Hosp Lyon Sud, Serv Med Interne, F-69495 Pierre Benite, France; Hop Edouard Herriot, Unite Pathol Mol & Hemoglobine, F-69437 Lyon 03, France	CHU Lyon; CHU Lyon	Rousset, H (corresponding author), Ctr Hosp Lyon Sud, Serv Med Interne, F-69495 Pierre Benite, France.							BELLINGHAM AJ, 1976, BRIT MED BULL, V32, P234, DOI 10.1093/oxfordjournals.bmb.a071368; Blacklock HA, 2001, BRIT J HAEMATOL, V115, P774, DOI 10.1046/j.1365-2141.2001.03168.x; Kralovics R, 2000, CURR OPIN PEDIATR, V12, P29, DOI 10.1097/00008480-200002000-00006; STEPHENS AD, 1977, BRIT J HAEMATOL, V36, P153; WAJEMAN H, 1996, HEMATOL CELL THER, V38, P305	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1624	1624		10.1016/S0140-6736(03)14796-4	http://dx.doi.org/10.1016/S0140-6736(03)14796-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630443				2022-12-28	WOS:000186637400011
J	Wolff, EW				Wolff, EW			Whither Antarctic sea ice?	SCIENCE			English	Editorial Material									British Antarctic Survey, Cambridge CB3 0ET, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Wolff, EW (corresponding author), British Antarctic Survey, High Cross,Madingley Rd, Cambridge CB3 0ET, England.		Wolff, Eric W/D-7925-2014; Wolff, Eric/AAB-1097-2021	Wolff, Eric W/0000-0002-5914-8531; Wolff, Eric/0000-0002-5914-8531				Curran MAJ, 2003, SCIENCE, V302, P1203, DOI 10.1126/science.1087888; Delmas RJ, 2003, TELLUS B, V55, P71, DOI 10.1034/j.1600-0889.2003.00032.x; Gersonde R, 2000, PALAEOGEOGR PALAEOCL, V162, P263, DOI 10.1016/S0031-0182(00)00131-0; Rankin AM, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002492; Stephens BB, 2000, NATURE, V404, P171, DOI 10.1038/35004556; Vaughan DG, 2003, CLIMATIC CHANGE, V60, P243, DOI 10.1023/A:1026021217991; WELCH KA, 1993, GEOPHYS RES LETT, V20, P443, DOI 10.1029/93GL00499; ZWALLY HJ, 2002, J GEOPHYS RES, V107	8	6	7	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1164	1164						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615525				2022-12-28	WOS:000186544300039
J	Tovar, J; Leon-Avila, G; Sanchez, LB; Sutak, R; Tachezy, J; van der Giezen, M; Hernandez, M; Muller, M; Lucocq, JM				Tovar, J; Leon-Avila, G; Sanchez, LB; Sutak, R; Tachezy, J; van der Giezen, M; Hernandez, M; Muller, M; Lucocq, JM			Mitochondrial remnant organelles of Giardia function in iron-sulphur protein maturation	NATURE			English	Article							PARASITE ENTAMOEBA-HISTOLYTICA; TRICHOMONAS-VAGINALIS; LAMBLIA; HYDROGENOSOMES; INTESTINALIS; EUKARYOTES; GENE; GENOME; PHYLOGENY; EVOLUTION	Giardia intestinalis (syn. lamblia) is one of the most widespread intestinal protozoan pathogens worldwide, causing hundreds of thousands of cases of diarrhoea each year(1). Giardia is a member of the diplomonads, often described as an ancient protist group whose primitive nature is suggested by the lack of typical eukaryotic organelles (for example, mitochondria, peroxisomes), the presence of a poorly developed endomembrane system and by their early branching in a number of gene phylogenies(1,2). The discovery of nuclear genes of putative mitochondrial ancestry in Giardia(3-7) and the recent identification of mitochondrial remnant organelles in amitochondrial protists such as Entamoeba histolytica(8,9) and Trachipleistophora hominis(10) suggest that the eukaryotic amitochondrial state is not a primitive condition but is rather the result of reductive evolution. Using an in vitro protein reconstitution assay and specific antibodies against IscS and IscU-two mitochondrial marker proteins involved in iron sulphur cluster biosynthesis-here we demonstrate that Giardia contains mitochondrial remnant organelles (mitosomes) bounded by double membranes that function in iron-sulphur protein maturation. Our results indicate that Giardia is not primitively amitochondrial and that it has retained a functional organelle derived from the original mitochondrial endosymbiont.	Univ London, Royal Holloway, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Rockefeller Univ, New York, NY 10021 USA; Charles Univ, Fac Sci, Dept Parasitol, CR-12844 Prague, Czech Republic; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of London; Royal Holloway University London; Rockefeller University; Charles University Prague; University of Dundee	Tovar, J (corresponding author), Univ London, Royal Holloway, Sch Biol Sci, Egham TW20 0EX, Surrey, England.		van der Giezen, Mark/J-9550-2019; sutak, robert/R-4369-2017; Tachezy, Jan/R-4945-2017	van der Giezen, Mark/0000-0002-1033-1335; sutak, robert/0000-0001-5588-1683; Tachezy, Jan/0000-0001-6976-8446; lucocq, john/0000-0002-5191-0093				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Andersson JO, 2003, CURR BIOL, V13, P94, DOI 10.1016/S0960-9822(03)00003-4; Arisue N, 2002, PARASITOL INT, V51, P9, DOI 10.1016/S1383-5769(01)00093-9; Cochran W.G., 2007, SAMPLING TECHNIQUES; Doolittle WE, 1998, TRENDS GENET, V14, P307; Dyall SD, 2000, CURR OPIN MICROBIOL, V3, P404, DOI 10.1016/S1369-5274(00)00112-0; Embley TM, 2003, PHILOS T R SOC B, V358, P191, DOI 10.1098/rstb.2002.1190; Hashimoto T, 1998, P NATL ACAD SCI USA, V95, P6860, DOI 10.1073/pnas.95.12.6860; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lloyd D, 2002, MICROBIOL-SGM, V148, P1349, DOI 10.1099/00221287-148-5-1349; Lloyd D, 2002, TRENDS MICROBIOL, V10, P122, DOI 10.1016/S0966-842X(02)02306-5; Lloyd D, 2002, MICROBIOL-SGM, V148, P727, DOI 10.1099/00221287-148-3-727; Mai ZM, 1999, MOL CELL BIOL, V19, P2198; Martin W, 2001, BIOL CHEM, V382, P1521, DOI 10.1515/BC.2001.187; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; Morrison HG, 2001, MOL BIOL EVOL, V18, P530, DOI 10.1093/oxfordjournals.molbev.a003832; Muller M., 2003, MOL MED PARASITOLOGY, P125, DOI DOI 10.1016/B978-012473346-6/50008-9; Philippe H, 2000, P ROY SOC B-BIOL SCI, V267, P1213, DOI 10.1098/rspb.2000.1130; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; RIORDAN CE, 2003, CURR GENET      0820; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; SOLTYS BJ, 1994, J PARASITOL, V80, P580, DOI 10.2307/3283195; Strong WB, 2000, MOL BIOCHEM PARASIT, V107, P1, DOI 10.1016/S0166-6851(99)00225-X; Tachezy J, 2001, MOL BIOL EVOL, V18, P1919, DOI 10.1093/oxfordjournals.molbev.a003732; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Vidakovic MS, 1996, J BIOL CHEM, V271, P14734, DOI 10.1074/jbc.271.25.14734; Williams BAP, 2002, NATURE, V418, P865, DOI 10.1038/nature00949	31	369	389	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					172	176		10.1038/nature01945	http://dx.doi.org/10.1038/nature01945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614504				2022-12-28	WOS:000186517200041
J	Mantyselka, PT; Turunen, JHO; Ahonen, RS; Kumpusalo, EA				Mantyselka, PT; Turunen, JHO; Ahonen, RS; Kumpusalo, EA			Chronic pain and poor self-rated health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BACK-PAIN; GENERAL-POPULATION; MUSCULOSKELETAL PAIN; DEPRESSIVE SYMPTOMS; PRIMARY-CARE; PREVALENCE; COMMUNITY; COMPLAINTS; IMPACT; ADULTS	Context Chronic pain is common in Western societies. Self-rated health is an important indicator of morbidity and mortality, but little is known about the relation between chronic pain and self-rated health in the general population. Objective To analyze the association between chronic pain and self-rated health. Design, Setting, and Population A questionnaire survey carried out during the spring of 2002 of an age- and sex-stratified population sample of 6500 individuals in Finland aged 15 to 74 years, with a response rate of 71% (N=4542) after exclusion of those with unobtainable data (n=38). Chronic pain was defined as pain with a duration of at least 3 months and was graded by frequency: (1) at most once a week; (2) several times a week; and (3) daily or continuously. On the basis of a 5-item questionnaire on self-rated health; individuals were classified as having good, moderate, or poor health. Multinominal logistic regression analysis was used to assess the determinants of health. Analysis included sex, age, education, working status, chronic diseases, and mood. Main Outcome Measures Perceived chronic pain graded by,frequency and self-rated health status. Results The prevalence of any chronic pain was 35.1%; that of daily chronic pain, 14.3%. The prevalence of moderate self-rated health was 26.6% and of poor health, 7.6%. For moderate self-rated health among individuals having chronic pain at most once a week compared with individuals having no chronic pain, the adjusted odds were 1.36 (95% confidence interval [CI], 1.05-1.76); several times a week, 2.41 (95% CI, 1.94-3.00); and daily, 3.69 (95% CI, 2.97-4.59). Odds for poor self-rated health were as follows: having chronic pain at most once a week, 1.16 (95% CI, 0.65-2.07); several times a week, 2.62 (95% CI, 1.76-3.90); and daily, 11.82 (95% CI, 8.67-16.10). Conclusion Chronic pain is independently related to low self-rated health in the general population.	Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Unit Gen Practice, Kuopio, Finland; Univ Kuopio, Dept Social Pharm, FIN-70211 Kuopio, Finland	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	Mantyselka, PT (corresponding author), Univ Kuopio, Dept Publ Hlth & Gen Practice, POB 1627, FIN-70211 Kuopio, Finland.	pekka.mantyselka@uku.fi		Turunen, Juha/0000-0002-9913-1240				Andersson HI, 1999, SCAND J PRIM HEALTH, V17, P87, DOI 10.1080/028134399750002700; ARINEN S, 1998, HLTH USE HLTH SERVIC; Blyth FM, 2001, PAIN, V89, P127, DOI 10.1016/S0304-3959(00)00355-9; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; Buskila D, 2000, J RHEUMATOL, V27, P1521; Cott CA, 1999, J EPIDEMIOL COMMUN H, V53, P731, DOI 10.1136/jech.53.11.731; CROFT P, 1993, J RHEUMATOL, V20, P710; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Elliott AM, 2002, PAIN, V99, P299, DOI 10.1016/S0304-3959(02)00138-0; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; Frolund F, 1986, Scand J Prim Health Care, V4, P97; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; MAGNI G, 1990, PAIN, V43, P299, DOI 10.1016/0304-3959(90)90027-B; Mantyselka P, 2001, PAIN, V89, P175, DOI 10.1016/S0304-3959(00)00361-4; Mantyselka PT, 2002, EUR J PAIN, V6, P141, DOI 10.1053/eujp.2001.0311; Molarius A, 2002, J CLIN EPIDEMIOL, V55, P364, DOI 10.1016/S0895-4356(01)00491-7; *NAT AG MED SOC IN, 2002, FINN STAT MED 2001; Ohayon MM, 2003, ARCH GEN PSYCHIAT, V60, P39, DOI 10.1001/archpsyc.60.1.39; Reyes-Gibby CC, 2002, PAIN, V95, P75, DOI 10.1016/S0304-3959(01)00375-X; SALOKANGAS RKR, 1995, ACTA PSYCHIAT SCAND, V92, P10, DOI 10.1111/j.1600-0447.1995.tb09536.x; Salokangas RKR, 2002, J AFFECT DISORDERS, V68, P215, DOI 10.1016/S0165-0327(00)00315-3; Smith BH, 2001, FAM PRACT, V18, P292, DOI 10.1093/fampra/18.3.292; VANTULDER MW, 1995, PAIN, V62, P233, DOI 10.1016/0304-3959(94)00272-G; Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1; WEBSTER BS, 1994, SPINE, V19, P1111, DOI 10.1097/00007632-199405001-00001; *WHO, REG OFF EUR COUNTR I	29	221	229	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2435	2442		10.1001/jama.290.18.2435	http://dx.doi.org/10.1001/jama.290.18.2435			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742LH	14612480	Bronze			2022-12-28	WOS:000186518300030
J	Stewart, WF; Ricci, JA; Chee, E; Morganstein, D; Lipton, R				Stewart, WF; Ricci, JA; Chee, E; Morganstein, D; Lipton, R			Lost productive time and cost due to common pain conditions in the US workforce	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; UNITED-STATES; MUSCULOSKELETAL DISORDERS; BACK-PAIN; WORK LOSS; AMERICAN MIGRAINE; HEALTH LITERACY; ECONOMIC COST; DOUBLE-BLIND; IMPACT	Context Common pain conditions appear to have an adverse effect on work, but no comprehensive estimates exist on the amount of productive time lost in the US workforce due to pain. Objective To measure lost productive time (absence and:reduced performance due to common pain conditions) during a 2-week period. Design,and Setting Cross-sectional study using survey data from the American Productivity Audit (a telephone survey that uses the Work and Health Interview) of working adults between August 1, 2001, and July 30, 2002. Participants Random sample of 28902 working adults in the United States. Main Outcome Measures Lost productive time due to common pain conditions (arthritis, back, headache, and other musculoskeletal) expressed in hours per worker per week and calculated in US dollars. Results Thirteen percent of the total workforce experienced a loss in productive time during a 2-week period due to a common pain condition. Headache was the most common (5.4%) pain condition resulting in lost productive time. It was followed by back pain (3.2%), arthritis pain (2.0%), and other mosculoskeletal pain. (2.0%) Workers who experienced lost productive time from a pain condition lost a mean (SE) of 4.6 (0.09) h/wk. Workers who had a headache had a mean (SE) loss in productive time of 3.5 (0.1) h/wk. Workers who reported arthritis or back pain had mean (SE) lost productive times of 5.2 (0.25) h/wk. Other common pain conditions resulted in a mean (SE) loss in productive time of 5.5 (0.22) h/wk. Lost productive time from common pain conditions among active workers costs an estimated $61.2 billion per year. The majority (76.6%) of the lost productive time was explained by reduced performance while at work and not work absence. Conclusions Pain is an inordinately common and disabling condition in the US work-force. Most of the pain-related lost productive time occurs while employees are at work-force. Most of the pain-related lost productive time occurs while employees are at work and is in the form of reduced. performance.	Geisinger Hlth Syst, Ctr Hlth Res & Rural Advocacy, Danville, PA 17822 USA; AdvancePCS Ctr Work & Hlth, Hunt VAlley, MD USA; WESTAT Corp, Stat Grp, Rockville, MD 20850 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA	Geisinger Health System; Westat; Yeshiva University; Albert Einstein College of Medicine	Stewart, WF (corresponding author), Geisinger Hlth Syst, Ctr Hlth Res & Rural Advocacy, 100 N Acad Ave, Danville, PA 17822 USA.		Bannuru, Raveendhara/G-2601-2011	Bannuru, Raveendhara/0000-0002-8069-5783				Berger ML, 2001, J OCCUP ENVIRON MED, V43, P18, DOI 10.1097/00043764-200101000-00005; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; *BUR LAB STAT BUR, CURR POP SURV; Cady RC, 1998, ARCH INTERN MED, V158, P1013, DOI 10.1001/archinte.158.9.1013; Clark RG, 2002, INT STAT REV, V70, P289, DOI 10.2307/1403911; Cockburn I M, 1999, Bus Health, V17, P49; Cole DC, 2001, OCCUP ENVIRON MED, V58, P728, DOI 10.1136/oem.58.11.728; Coyte PC, 1998, ARTHRIT CARE RES, V11, P315, DOI 10.1002/art.1790110503; Crystal-Peters J, 2000, AM J MANAG CARE, V6, P373; Cull RE, 1992, BRIT J EC, V2, P103; Dartigues JF, 1998, CEPHALALGIA, V18, P26, DOI 10.1177/0333102498018S2107; Dasbach EJ, 2000, CEPHALALGIA, V20, P830, DOI 10.1046/j.1468-2982.2000.00126.x; Fautrel B, 2002, CURR OPIN RHEUMATOL, V14, P121, DOI 10.1097/00002281-200203000-00008; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Gerth WC, 2001, PHARMACOECONOMICS, V19, P197, DOI 10.2165/00019053-200119020-00006; Greenberg P E, 1995, Bus Health, V13, P27; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; GROVES RM, 1988, TELEPHONE SURVEY MET, P208; Guo HR, 1999, AM J PUBLIC HEALTH, V89, P1029, DOI 10.2105/AJPH.89.7.1029; Henke CJ, 2000, AM J GASTROENTEROL, V95, P788; HILDEBRANDT VH, 1995, ERGONOMICS, V38, P1283, DOI 10.1080/00140139508925188; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; KARASEK R, 1986, JOB CONTENT INSTRUME; Kessler RC, 2001, ANN ALLERG ASTHMA IM, V87, P289, DOI 10.1016/S1081-1206(10)62242-9; LEE P, 1994, QUAL LIFE RES, V3, pS85, DOI 10.1007/BF00433381; Lerner D, 2002, J CLIN EPIDEMIOL, V55, P197, DOI 10.1016/S0895-4356(01)00424-3; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lipton RB, 2000, NEUROLOGY, V55, P629, DOI 10.1212/WNL.55.5.629; McCunney RJ, 2001, J OCCUP ENVIRON MED, V43, P30, DOI 10.1097/00043764-200101000-00007; Merkesdal S, 2001, ARTHRITIS RHEUM-US, V44, P528, DOI 10.1002/1529-0131(200103)44:3<528::AID-ANR100>3.0.CO;2-U; Michel P, 1997, HEADACHE, V37, P71, DOI 10.1046/j.1526-4610.1997.3702071.x; Osterhaus J T, 1992, Pharmacoeconomics, V2, P67, DOI 10.2165/00019053-199202010-00008; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; RASMUSSEN BK, 1992, J EPIDEMIOL COMMUN H, V46, P443, DOI 10.1136/jech.46.4.443; RICCI JA, 2001, VALUE HEALTH, V4, P460, DOI DOI 10.1016/S1098-3015(11)71634-5; Rizzo JA, 1998, MED CARE, V36, P1471, DOI 10.1097/00005650-199810000-00006; Schulman EA, 2000, MAYO CLIN PROC, V75, P782, DOI 10.4065/75.8.782; Schwartz BS, 1997, J OCCUP ENVIRON MED, V39, P320, DOI 10.1097/00043764-199704000-00009; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; Stang P, 2001, PHARMACOECONOMICS, V19, P231, DOI 10.2165/00019053-200119030-00002; STANG PE, 1993, HEADACHE, V33, P29, DOI 10.1111/j.1526-4610.1993.hed3301029.x; Stewart W, 2002, CNS DRUGS, V16, P5, DOI 10.2165/00023210-200216001-00002; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Stewart WF, 1996, CEPHALALGIA, V16, P231, DOI 10.1046/j.1468-2982.1996.1604231.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; STEWART WF, IN PRESS J OCCUP ENV; STEWART WF, IN PRESS U OCCUP ENV; *US OFF PERS MAN, 1999, FED CIV WORKF STAT O; Von Korff M, 1998, NEUROLOGY, V50, P1741, DOI 10.1212/WNL.50.6.1741; YELIN E, 1992, ARTHRITIS RHEUM, V35, P489, DOI 10.1002/art.1992.35.5.489; YELIN E, 1995, ARTHRITIS RHEUM, V38, P1351, DOI 10.1002/art.1780381002; Yelin EH, 1995, ARTHRIT CARE RES, V8, P311, DOI 10.1002/art.1790080417	52	1029	1048	1	56	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2443	2454		10.1001/jama.290.18.2443	http://dx.doi.org/10.1001/jama.290.18.2443			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742LH	14612481	Bronze			2022-12-28	WOS:000186518300031
J	Metz, L; Page, S				Metz, L; Page, S			Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?	LANCET			English	Editorial Material									Foothills Med Ctr, Dept Clin Neurosci, Calgary, AB T2N 2T9, Canada; Univ Calgary, Off Med Bioeth, Calgary, AB, Canada	University of Calgary; University of Calgary	Metz, L (corresponding author), Foothills Med Ctr, Dept Clin Neurosci, Calgary, AB T2N 2T9, Canada.		Page, Stacey/ABC-4571-2021					ASHWORTH B, 1964, PRACTITIONER, V192, P540; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Hinderer SR, 1996, ARCH PHYS MED REHAB, V77, P1083, DOI 10.1016/S0003-9993(96)90073-8; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; MARTYN CN, 1995, LANCET, V345, P579, DOI 10.1016/S0140-6736(95)90485-9; Page SA, 2003, CAN J NEUROL SCI, V30, P201, DOI 10.1017/S0317167100002584; PETRO DJ, 1981, J CLIN PHARMACOL, V21, pS413, DOI 10.1002/j.1552-4604.1981.tb02621.x; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39; Wade DT, 2003, CLIN REHABIL, V17, P21, DOI 10.1191/0269215503cr581oa	10	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1513	1513		10.1016/S0140-6736(03)14776-9	http://dx.doi.org/10.1016/S0140-6736(03)14776-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615102				2022-12-28	WOS:000186464500003
J	Noris, M; Brioschi, S; Caprioli, J; Todeschini, M; Bresin, E; Porrati, F; Gamba, S; Remuzzi, G				Noris, M; Brioschi, S; Caprioli, J; Todeschini, M; Bresin, E; Porrati, F; Gamba, S; Remuzzi, G		Int Registry Recurrent Familial	Familial haemolytic uraemic syndrome and an MCP mutation	LANCET			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-H GENE; IDENTIFICATION; HYPOCOMPLEMENTEMIA; REGION; CR-1	Background Mutations in factor H (HF1) have been reported in a consistent number of diarrhoea-negative, non-Shiga toxin-associated cases of haemolytic uraemic syndrome (DHUS). However, most patients with DHUS have no HF1 mutations, despite decreased serum concentrations of C3. Our aim, therefore, was to assess whether genetic abnormalities in other complement regulatory proteins are involved. Methods We screened genes that encode the complement regulatory proteins-ie, factor H related 5, complement receptor 1, and membrane cofactor protein (MCP)-by PCR-single-strand conformation polymorphism (PCR-SSCP) and by direct sequencing, in 25 consecutive patients with DHUS, an abnormal complement profile, and no HF1 mutation, from our International Registry of Recurrent and Familial HUS/TTP (HUS/thrombotic thrombocytopenic purpura). Findings We identified a heterozygous mutation in MCP, a surface-bound complement regulator, in two patients with a familial history of HUS. The mutation causes a change in three aminoacids at position 233-35 and insertion of a premature stop-codon, which results in loss of the transmembrane domain of the protein and severely reduced cell-surface expression of MCP. Interpretation Results of previous studies on HF1 indicate an association between HF1 deficiency and DHUS. Our findings of an MCP mutation in two related patients suggest that impaired regulation of complement activation might be a factor in the pathogenesis of genetic forms of HUS. MCP could be a second putative candidate gene for DHUS. The protein is highly expressed in the kidney and plays a major part in regulation of glomerular C3 activation. We propose, therefore, that reduced expression of MCP in response to complement-activating stimuli could prevent restriction of complement deposition on glomerular endothelial cells, leading to microvascular cell damage and tissue injury.	Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis, I-24100 Bergamo, Italy; Osped Riuniti Bergamo, Dept Nephrol & Dialysis, Azienda Osped, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Noris, M (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24020 Ranica, BG, Italy.	noris@marionegri.it	Gamba, Sara/ABF-8859-2020; NORIS, MARINA/ABG-2219-2020; Bresin, Elena/ABG-2409-2020; Todeschini, Marta/ABF-4705-2020; Remuzzi, Giuseppe/V-9766-2017	Gamba, Sara/0000-0002-4887-890X; NORIS, MARINA/0000-0001-7651-5033; Bresin, Elena/0000-0003-4198-2891; Todeschini, Marta/0000-0003-3422-8815; Remuzzi, Giuseppe/0000-0002-6194-3446	Telethon [GGP02161] Funding Source: Medline	Telethon(Fondazione Telethon)		Artz MA, 2003, TRANSPLANTATION, V76, P821, DOI 10.1097/01.TP.0000085083.74065.1B; BERGSTEIN J, 1974, TRANSPLANTATION, V17, P487, DOI 10.1097/00007890-197405000-00007; BERNS JS, 1992, AM J KIDNEY DIS, V19, P331, DOI 10.1016/S0272-6386(12)80449-5; Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297; CAPRIOLI J, IN PRESS HUM MOL GEN; Ferraris JR, 2002, PEDIATR NEPHROL, V17, P809, DOI 10.1007/s00467-002-0936-9; FITZPATRICK MM, 1993, J PEDIATR-US, V122, P532; Kaplan B. S., 1992, HEMOLYTIC UREMIC SYN; Kaplan BS, 1998, J AM SOC NEPHROL, V9, P1126; KIRCHNER KA, 1982, NEPHRON, V30, P28, DOI 10.1159/000182427; Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; Loirat C, 2003, PEDIATR NEPHROL, V18, P1095, DOI 10.1007/s00467-003-1289-8; McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200; MILLER RB, 2002, NEPHROL DIAL TRANSPL, V17, P809; Moulds JM, 2001, BLOOD, V97, P2879, DOI 10.1182/blood.V97.9.2879; NAKANISHI I, 1994, EUR J IMMUNOL, V24, P1529, DOI 10.1002/eji.1830240711; Nangaku M, 1998, KIDNEY INT, V54, P1419, DOI 10.1046/j.1523-1755.1998.00130.x; Neuhaus TJ, 1997, ARCH DIS CHILD, V76, P518, DOI 10.1136/adc.76.6.518; Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676; Noris M, 1999, J AM SOC NEPHROL, V10, P281; Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201; PIRSON Y, 1987, CLIN NEPHROL, V28, P250; Proesmans W, 1996, KIDNEY BLOOD PRESS R, V19, P205, DOI 10.1159/000174075; Remuzzi G, 2002, BLOOD, V100, P778, DOI 10.1182/blood-2001-12-0166; Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203; Ruggenenti P, 2001, KIDNEY INT, V60, P831, DOI 10.1046/j.1523-1755.2001.060003831.x; RUGGENENTI P, 2003, THERAPY NEPHROLOGY H; THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110; Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1111/j.1523-1755.1998.00824.x; WILSON JG, 1986, J EXP MED, V164, P50, DOI 10.1084/jem.164.1.50; Xiang LB, 1999, J IMMUNOL, V163, P4939	32	239	254	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	2003	362	9395					1542	1547		10.1016/S0140-6736(03)14742-3	http://dx.doi.org/10.1016/S0140-6736(03)14742-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615110				2022-12-28	WOS:000186464500011
J	Hatton, RD; Weaver, CT				Hatton, RD; Weaver, CT			T-bet or not T-bet	SCIENCE			English	Editorial Material							CYTOKINE GENE-EXPRESSION; TRANSCRIPTION FACTOR; LINEAGE COMMITMENT; CELLS; GAMMA; CD4		Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Hatton, RD (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.			Hatton, Robin/0000-0002-4797-9899; Weaver, Casey/0000-0002-2180-1793				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Cho JY, 2003, INT IMMUNOL, V15, P1149, DOI 10.1093/intimm/dxg113; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Wilson V, 2002, GENOME BIOL, V3, P30081, DOI [10.1186/gb-2002-3-6-reviews3008, DOI 10.1186/GB-2002-3-6-REVIEWS3008]; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	14	31	33	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					993	994		10.1126/science.1092040	http://dx.doi.org/10.1126/science.1092040			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605354				2022-12-28	WOS:000186396300029
J	Bradley, C; Craigie, R				Bradley, C; Craigie, R			MoMLV reverse transcriptase regulates its own expression	CELL			English	Editorial Material							RNA	A precise ratio of Gag:Gag-Pol expression is required for assembly of infectious retroviral virions. In this issue of Cell, Orlova et al. show that MoMLV reverse transcriptase binds the translation release factor eRF1, and that this interaction promotes translation readthrough to make Gag-Pol.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bradley, C (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036108] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Orlova M, 2003, CELL, V115, P319, DOI 10.1016/S0092-8674(03)00805-5; Shehu-Xhilaga M, 2001, J VIROL, V75, P1834, DOI 10.1128/JVI.75.4.1834-1841.2001; Swanstrom R., 1997, P263	5	0	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 31	2003	115	3					250	251		10.1016/S0092-8674(03)00850-X	http://dx.doi.org/10.1016/S0092-8674(03)00850-X			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636552	Bronze			2022-12-28	WOS:000186415000004
J	Lund, E; Guttinger, S; Calado, A; Dahlberg, JE; Kutay, U				Lund, E; Guttinger, S; Calado, A; Dahlberg, JE; Kutay, U			Nuclear export of microRNA precursors	SCIENCE			English	Article							RNA-INTERFERENCE; TRANSPORT; DICER; MATURATION	MicroRNAs (miRNAs), which function as regulators of gene expression in eukaryotes, are processed from larger transcripts by sequential action of nuclear and cytoplasmic ribonuclease III-like endonucleases. We show that Exportin-5 (Exp5) mediates efficient nuclear export of short miRNA precursors (pre-miRNAs) and that its depletion by RNA interference results in reduced miRNA levels. Exp5 binds correctly processed pre-miRNAs directly and specifically, in a Ran guanosine triphosphate-dependent manner, but interacts only weakly with extended pre-miRNAs that yield incorrect miRNAs when processed by Dicer in vitro. Thus, Exp5 is key to miRNA biogenesis and may help coordinate nuclear and cytoplasmic processing steps.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	University of Wisconsin System; University of Wisconsin Madison; Swiss Federal Institutes of Technology Domain; ETH Zurich	Dahlberg, JE (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA.	dahlberg@wisc.edu; ulrike.kutay@bc.biol.ethz.ch	Calado, Ângelo Miguel Silva/Y-2296-2019	Calado, Ângelo Miguel Silva/0000-0003-0182-2615	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030220, R37GM030220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee D, 2002, BIOESSAYS, V24, P119, DOI 10.1002/bies.10046; Bollman KM, 2003, DEVELOPMENT, V130, P1493, DOI 10.1242/dev.00362; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kidner CA, 2003, TRENDS GENET, V19, P13, DOI 10.1016/S0168-9525(02)00011-2; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; LUND E, UNPUB; Moss EG, 2002, CURR BIOL, V12, pR688, DOI 10.1016/S0960-9822(02)01206-X; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	29	1889	2080	4	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					95	98		10.1126/science.1090599	http://dx.doi.org/10.1126/science.1090599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14631048				2022-12-28	WOS:000187710600042
J	Oniscu, GC; Schalkwijk, AAH; Johnson, RJ; Brown, H; Forsythe, JLR				Oniscu, GC; Schalkwijk, AAH; Johnson, RJ; Brown, H; Forsythe, JLR			Equity of access to renal transplant waiting list and renal transplantation in Scotland: cohort study	BRITISH MEDICAL JOURNAL			English	Article							SEX-DIFFERENCES; CANDIDATES; SELECTION; BARRIERS; SURVIVAL; DIALYSIS; WOMEN; RACE	Objective To examine the access to the renal transplant waiting list and renal transplantation in Scotland. Design Cohort study. Setting Renal and transplant units in Scotland. Participants 4523 adults starting renal replacement therapy in Scotland between 1 January 1989 and 31 December 1999. Main outcome measures Impact of age, sex, social deprivation, primary renal disease, renal or transplant unit, and geography on access to the waiting list and renal transplantation. Results 1736 of 4523 (38.4%) patients were placed on the waiting list for renal transplantation and 1095 (24.2%) underwent transplantation up to 31 December 2000, the end of the study period. Patients were less likely to be placed on the list if they were female, older, had diabetes, were in a high deprivation category, and were treated in a renal unit in a hospital with no transplant unit. Patients living furthest away from the transplant centre were listed more quickly. The only factors governing access to transplantation once on the list were age, primary renal disease, and year of listing. A significant centre effect was found in access to the waiting list and renal transplantation. Conclusions A major disparity exists in access to the renal transplant waiting list and renal transplantation in Scotland. Comorbidity may be an important factor.	New Royal Infirm Edinburgh, Transplant Unit, Edinburgh EH16 4SA, Midlothian, Scotland; Glasgow Royal Infirm, Scottish Renal Registry, Glasgow G4 0SF, Lanark, Scotland; United Kingdom Transplant Serv, Bristol BS34 8RR, Avon, England; Scottish Natl Hlth Serv, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland	University of Glasgow	Forsythe, JLR (corresponding author), New Royal Infirm Edinburgh, Transplant Unit, Edinburgh EH16 4SA, Midlothian, Scotland.		Oniscu, Gabriel/AAY-3200-2020	Oniscu, Gabriel/0000-0003-1714-920X; Johnson, Rachel/0000-0001-9199-3455				AARONSON KD, 1995, CIRCULATION, V91, P2753, DOI 10.1161/01.CIR.91.11.2753; Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; Bloembergen WE, 1997, AM J KIDNEY DIS, V30, P733, DOI 10.1016/S0272-6386(97)90076-7; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; *DEP HLTH SOC SERV, 1980, IN HLTH BLACK REP; Eggers P W, 1995, Health Care Financ Rev, V17, P89; European Best Practice Guidelines, 2000, NEPHROL DIAL TRANSPL, V15, P3; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Johnson RWG, 1996, TRANSPLANT P, V28, P36; Kasiske BL, 1998, J AM SOC NEPHROL, V9, P2142; KASISKE BL, 1995, J AM SOC NEPHROL, V6, P1; McCauley J, 1997, AM J KIDNEY DIS, V30, P739, DOI 10.1016/S0272-6386(97)90077-9; MCMILLAN MA, 1995, NEPHROL DIAL TRANSPL, V10, P855; Meier-Kriesche HU, 2000, KIDNEY INT, V58, P1311, DOI 10.1046/j.1523-1755.2000.00287.x; Miceli A, 2000, J EPIDEMIOL COMMUN H, V54, P157; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; Purdy A, 1999, J WOMEN HEALTH GEN-B, V8, P631, DOI 10.1089/jwh.1.1999.8.631; *REN ASS, 1997, TREATM AD PAT REN FA; Sassi F, 2001, Health Technol Assess, V5, P1; Sassi F, 2001, BRIT MED J, V323, P762, DOI 10.1136/bmj.323.7316.762; Schaubel DE, 2000, ARCH INTERN MED, V160, P2349, DOI 10.1001/archinte.160.15.2349; *SCOTT REN REG, 2001, 2000 ANN REP; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; Wolfe RA, 2000, AM J KIDNEY DIS, V36, P1025, DOI 10.1053/ajkd.2000.19106	24	109	110	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 29	2003	327	7426					1261	1263		10.1136/bmj.327.7426.1261	http://dx.doi.org/10.1136/bmj.327.7426.1261			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644969	Bronze, Green Published			2022-12-28	WOS:000186948800018
J	Coulter, DM; Clark, DWJ; Savage, RL				Coulter, DM; Clark, DWJ; Savage, RL			Lesson of the week - Celecoxib, rofecoxib, and acute temporary visual impairment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IBUPROFEN		Univ Otago, Dunedin Sch Med,Intens Med Monitoring Programme, Dept Prevent & Social Med, New Zealand Pharmacovigilance Ctr, Dunedin 9000, New Zealand; New Zealand Pharmacovigilance Ctr, Ctr Adverse React Monitoring, Dunedin, New Zealand	University of Otago	Coulter, DM (corresponding author), Univ Otago, Dunedin Sch Med,Intens Med Monitoring Programme, Dept Prevent & Social Med, New Zealand Pharmacovigilance Ctr, POB 913, Dunedin 9000, New Zealand.	david.coulter@stonebow.otago.ac.nz						Coulter DM, 2002, DRUG SAFETY, V25, P433, DOI 10.2165/00002018-200225060-00007; HAEFLIGER IO, 1994, SURV OPHTHALMOL, V39, P123, DOI 10.1016/0039-6257(94)90157-0; Lund BC, 2001, PHARMACOTHERAPY, V21, P114, DOI 10.1592/phco.21.1.114.34445; NICASTRO NJ, 1989, ANN OPHTHALMOL, V21, P447; TULLIO CJ, 1981, AM J HOSP PHARM, V38, P1362, DOI 10.1093/ajhp/38.9.1362	5	17	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	2003	327	7425					1214	1215		10.1136/bmj.327.7425.1214	http://dx.doi.org/10.1136/bmj.327.7425.1214			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630760	Green Published			2022-12-28	WOS:000186784300023
J	Trumbore, SE; Gaudinski, JB				Trumbore, SE; Gaudinski, JB			The secret lives of roots	SCIENCE			English	Editorial Material							NORTHERN HARDWOOD FOREST; FINE ROOTS; TURNOVER; CARBON; TREES		Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; Univ Calif Santa Cruz, Dept Environm Studies, Santa Cruz, CA 95064 USA	University of California System; University of California Irvine; University of California System; University of California Santa Cruz	Trumbore, SE (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.		Trumbore, Susan/B-1948-2013; Gaudinski, Julia/GXZ-6661-2022	Gaudinski, Julia/0000-0001-7419-6761				Gaudinski JB, 2001, OECOLOGIA, V129, P420, DOI 10.1007/s004420100746; Giardina CP, 2002, ECOSYSTEMS, V5, P487, DOI 10.1007/s10021-002-0130-8; Gill RA, 2000, NEW PHYTOL, V147, P13, DOI 10.1046/j.1469-8137.2000.00681.x; HENDRICK RL, 1992, ECOLOGY, V73, P1094, DOI 10.2307/1940183; Luo YQ, 2003, GLOBAL CHANGE BIOL, V9, P1118, DOI 10.1046/j.1365-2486.2003.00642.x; MAJDI H, UNPUB; Matamala R, 2003, SCIENCE, V302, P1385, DOI 10.1126/science.1089543; Pregitzer KS, 2002, NEW PHYTOL, V154, P267, DOI 10.1046/j.1469-8137.2002.00413_1.x; Pregitzer KS, 2002, ECOL MONOGR, V72, P293, DOI 10.1890/0012-9615(2002)072[0293:FRAONN]2.0.CO;2; Tierney GL, 2002, CAN J FOREST RES, V32, P1692, DOI [10.1139/x02-123, 10.1139/X02-123]; Vogt KA, 1998, PLANT SOIL, V200, P71, DOI 10.1023/A:1004313515294	11	102	143	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1344	1345		10.1126/science.1091841	http://dx.doi.org/10.1126/science.1091841			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631025				2022-12-28	WOS:000186683500035
J	Bhushan, V; Collins, RH				Bhushan, V; Collins, RH			Chronic graft-vs-host disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW-TRANSPLANTATION; STEM-CELL; RISK-FACTORS; PREDNISONE; COMPLICATIONS; CYCLOSPORINE		Univ Texas, SW Med Ctr, Dept Internal Med, Hematopoiet Cell Transplantat Program, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Collins, RH (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Hematopoiet Cell Transplantat Program, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	robert.collins@utsouthwestern.edu						Akpek G, 2003, BLOOD, V102, P802, DOI 10.1182/blood-2002-10-3141; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Antin JH, 2002, NEW ENGL J MED, V347, P36, DOI 10.1056/NEJMcp010518; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; Arvin AM, 2000, BIOL BLOOD MARROW TR, V6, P219, DOI 10.1016/S1083-8791(00)70004-8; ATKINSON K, 1990, BLOOD, V75, P2459; *CDCP, 2000, MMWR RECOMM REP, V49, pCE1; Cutler C, 2001, J CLIN ONCOL, V19, P3685, DOI 10.1200/JCO.2001.19.16.3685; Dickinson AM, 2002, NAT MED, V8, P410, DOI 10.1038/nm0402-410; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Hess A, 2001, TRANSPLANT P, V33, P1754, DOI 10.1016/S0041-1345(00)02668-3; Ho VT, 2001, BLOOD, V98, P3192, DOI 10.1182/blood.V98.12.3192; Koc S, 2002, BLOOD, V100, P48, DOI 10.1182/blood.V100.1.48; Kulkarni S, 2000, BLOOD, V95, P3683; Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P215, DOI 10.1053/bbmt.2003.50026; Maury S, 2001, BRIT J HAEMATOL, V115, P630, DOI 10.1046/j.1365-2141.2001.03135.x; Michalek J, 2003, LANCET, V361, P1183, DOI 10.1016/S0140-6736(03)12917-0; Osarogiagbon RU, 2000, BIOL BLOOD MARROW TR, V6, P280, DOI 10.1016/S1083-8791(00)70010-3; Parkman R, 1998, Curr Opin Hematol, V5, P22, DOI 10.1097/00062752-199801000-00004; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; Sokos DR, 2002, BIOL BLOOD MARROW TR, V8, P117, DOI 10.1053/bbmt.2002.v8.pm11939601; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1988, BLOOD, V72, P555; Teshima T, 2002, SEMIN HEMATOL, V39, P15, DOI 10.1053/shem.2002.29246; WINGARD JR, 1989, BLOOD, V74, P1428; Zhang Y, 2002, J IMMUNOL, V168, P3088, DOI 10.4049/jimmunol.168.6.3088	27	56	57	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2599	2603		10.1001/jama.290.19.2599	http://dx.doi.org/10.1001/jama.290.19.2599			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744DQ	14625337				2022-12-28	WOS:000186613000030
J	Frenk, J; Sepulveda, J; Gomez-Dantes, O; Knaul, F				Frenk, J; Sepulveda, J; Gomez-Dantes, O; Knaul, F			Evidence-based health policy: three generations of reform in Mexico	LANCET			English	Article							AIDS	The Mexican health system has evolved through three generations of reform. The creation of the Ministry of Health and the main social security agency in 1943 marked the first generation of health reforms. In the late 1970s, a second generation of reforms was launched around the primary health-care model. Third-generation reforms favour systemic changes to reorganise the system through the horizontal integration of basic functions-stewardship, financing, and provision. The stability of leadership in the health sector is emphasised as a key element that allowed for reform during the past 60 years. Furthermore, there has been a transition in the second generation of reforms to a model that is increasingly based on evidence; this has been intensified and extended in the third generation of reforms. We also examine policy developments that will provide social protection in health for all. These developments could be of interest for countries seeking to provide their citizens with universal access to health care that incorporates equity, quality, and financial protection.	Inst Nacl Salud Publ, Colonia Santa Maria Ahuacatitian, Cuernavaca 62508, Morelos, Mexico; Mexican Minist Hlth, Mexico City, DF, Mexico; Minist Publ Educ Mexico, Mexico City, DF, Mexico	Instituto Nacional de Salud Publica	Sepulveda, J (corresponding author), Inst Nacl Salud Publ, Colonia Santa Maria Ahuacatitian, Cuernavaca 62508, Morelos, Mexico.	jsepulveda@insp.mx		Knaul, Felicia/0000-0002-0512-4788				BUSTAMANTE E, 1972, GAC MED MEX, V103, P43; del Rio C, 2002, AIDS, V16, P1445, DOI 10.1097/00002030-200207260-00001; Frenk J., 1989, Health Policy and Planning, V4, P29, DOI 10.1093/heapol/4.1.29; FRENK J, 1994, EC SALUD PROPUESTA A; Gomez-Dantes O, 1999, REV SAUDE PUBL, V33, P401, DOI 10.1590/S0034-89101999000400012; Gutierrez G, 1996, B WORLD HEALTH ORGAN, V74, P189; HERNANDEZ P, 1997, OBSERVATORIO SALUD N, P119; Instituto Nacional de Salud Publica, 2000, ENC NAC SAL 2000; KARL T, 1996, ESTE PAIS        DIC, P46; Londono JL, 1997, HEALTH POLICY, V41, P1, DOI 10.1016/S0168-8510(97)00010-9; LOZANO R, 1997, OBSERVATORIO SALUD N, P23; MARTINEZ P. D., 1970, Scdud Publ. Mex., V12, P37; *POD EJ FED, 1995, PROGR REF SECT SAL 1; RIVERADOMMARCO J, 1995, SALUD PUBLICA MEXICO, V37, P95; *SECR SAL, 1996, PROGR AMPL COB LIN O; *SECR SAL, 2001, B INF EST, V21; SEPULVEDA J, 1989, AIDS PROFILE EPIDEMI, P159; Sepulveda J., 2001, ENCUESTA NACL NUTR 1; SepulvedaAmor J, 1995, SALUD PUBLICA MEXICO, V37, P624; SOBERON G, 1986, AM J PUBLIC HEALTH, V76, P673, DOI 10.2105/AJPH.76.6.673; *WHO, 2000, WHO FRAM CONV TOB CO, P15; Williams A, 2001, HEALTH ECON, V10, P93, DOI 10.1002/hec.594; World Health Organization, 2000, WORLD HLTH REP 2000	23	82	85	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1667	1671		10.1016/S0140-6736(03)14803-9	http://dx.doi.org/10.1016/S0140-6736(03)14803-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744MZ	14630451				2022-12-28	WOS:000186637400028
J	Wenstrom, KD				Wenstrom, KD			Fetal surgery for congenital diaphragmatic hernia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Alabama, Sch Med, Div Maternal Fetal Med & Reprod Genet, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Wenstrom, KD (corresponding author), Univ Alabama, Sch Med, Div Maternal Fetal Med & Reprod Genet, Birmingham, AL 35233 USA.							HARRISON MR, 1978, J PEDIATR SURG, V13, P227, DOI 10.1016/S0022-3468(78)80391-1; Reickert CA, 1998, SURGERY, V123, P305, DOI 10.1016/S0039-6060(98)70183-7; WENSTROM KD, 1991, AM J OBSTET GYNECOL, V165, P838, DOI 10.1016/0002-9378(91)90425-Q	3	8	10	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1887	1888		10.1056/NEJMp038151	http://dx.doi.org/10.1056/NEJMp038151			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614162				2022-12-28	WOS:000186502400001
J	D'Alessandro, U; Coosemans, M				D'Alessandro, U; Coosemans, M			Is it feasible to give insecticide-treated bednets free to pregnant women?	LANCET			English	Editorial Material							MALARIA CONTROL; KENYA; PYRIMETHAMINE; PREVALENCE; EFFICACY; AREAS; NETS		Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Institute of Tropical Medicine (ITM)	D'Alessandro, U (corresponding author), Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				BRABIN B, 1992, ANN TROP PAEDIATR, V12, P303, DOI 10.1080/02724936.1992.11747589; Brabin B, 2002, MATERNAL MORBIDITY M, P65; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; DAlessandro U, 1996, T ROY SOC TROP MED H, V90, P487, DOI 10.1016/S0035-9203(96)90289-8; Guyatt HL, 2002, TROP MED INT HEALTH, V7, P409, DOI 10.1046/j.1365-3156.2002.00879.x; Mushi AK, 2003, HEALTH POLICY PLANN, V18, P163, DOI 10.1093/heapol/czg021; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50, DOI 10.4269/ajtmh.2003.68.50; Verhoeff FH, 1999, TROP MED INT HEALTH, V4, P5, DOI 10.1046/j.1365-3156.1999.00349.x; Verhoeff FH, 2001, EUR J CLIN NUTR, V55, P682, DOI 10.1038/sj.ejcn.1601200	12	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1515	1516		10.1016/S0140-6736(03)14778-2	http://dx.doi.org/10.1016/S0140-6736(03)14778-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615104				2022-12-28	WOS:000186464500005
J	Michael, TP; Salome, PA; Yu, HJ; Spencer, TR; Sharp, EL; McPeek, MA; Alonso, JM; Ecker, JR; McClung, CR				Michael, TP; Salome, PA; Yu, HJ; Spencer, TR; Sharp, EL; McPeek, MA; Alonso, JM; Ecker, JR; McClung, CR			Enhanced fitness conferred by naturally occurring variation in the circadian clock	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; ABERRANT EXPRESSION; GENE; LIGHT; RHYTHMS; PACEMAKER; RESPONSES; PLANTS; TIME	Natural variation in clock parameters is necessary for the circadian clock to contribute to organismal fitness over a broad geographic range. Considerable variation is evident in the period, phase, and amplitude of 150 Arabidopsis accessions, and the period length is correlated with the day length at the latitude of origin, implying the adaptive significance of correctly regulated circadian timing. Quantitative trait loci analysis of recombinant inbred lines indicates that multiple loci interact to determine period, phase, and amplitude. The loss-of-function analysis of each member of the ARABIDOPSIS PSEUDO-RESPONSE REGULATOR family suggests that they are candidates for clock quantitative trait loci.	Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA	Dartmouth College; Salk Institute	McClung, CR (corresponding author), Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA.	mcclung@dartmouth.edu	Alonso, Jose M/K-6826-2014; Ecker, Joseph R/B-9144-2008; McPeek, Mark/AAE-2784-2022; Salome, Patrice/E-5702-2017	Alonso, Jose M/0000-0001-7087-1571; Ecker, Joseph R/0000-0001-5799-5895; Michael, Todd/0000-0001-6272-2875; McClung, C. Robertson/0000-0002-7875-3614				Beaver LM, 2002, P NATL ACAD SCI USA, V99, P2134, DOI 10.1073/pnas.032426699; Borevitz JO, 2002, GENETICS, V160, P683; CLARKE JH, 1995, MOL GEN GENET, V248, P278, DOI 10.1007/BF02191594; Costa R, 1998, CURR OPIN NEUROBIOL, V8, P659, DOI 10.1016/S0959-4388(98)80096-2; Daido H, 2002, J THEOR BIOL, V217, P425, DOI 10.1006/jtbi.2002.3050; DeCoursey PJ, 2000, J COMP PHYSIOL A, V186, P169, DOI 10.1007/s003590050017; Green RM, 1999, P NATL ACAD SCI USA, V96, P4176, DOI 10.1073/pnas.96.7.4176; Green RM, 2002, PLANT PHYSIOL, V129, P576, DOI 10.1104/pp.004374; Li B, 1998, OECOLOGIA, V115, P293, DOI 10.1007/s004420050519; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Makino S, 2002, PLANT CELL PHYSIOL, V43, P58, DOI 10.1093/pcp/pcf005; Maloof JN, 2001, NAT GENET, V29, P441, DOI 10.1038/ng777; Mas P, 2003, PLANT CELL, V15, P223, DOI 10.1105/tpc.006734; Matsushika A, 2000, PLANT CELL PHYSIOL, V41, P1002, DOI 10.1093/pcp/pcd043; Matsushika A, 2002, PLANT CELL PHYSIOL, V43, P833, DOI 10.1093/pcp/pcf118; MCCLUNG CR, 2002, ARABIDOPSIS BOOK, P1, DOI DOI 10.1199/TAB.0044; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Miyashita NT, 1999, GENETICS, V152, P1723; PITTENDRIGH CS, 1989, J BIOL RHYTHM, V4, P217; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Rieseberg LH, 1999, HEREDITY, V83, P363, DOI 10.1038/sj.hdy.6886170; Roden LC, 2002, P NATL ACAD SCI USA, V99, P13313, DOI 10.1073/pnas.192365599; Sato E, 2002, PLANT CELL PHYSIOL, V43, P1374, DOI 10.1093/pcp/pcf166; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; Shimomura K, 2001, GENOME RES, V11, P959, DOI 10.1101/gr.171601; Somers DE, 1998, DEVELOPMENT, V125, P485; Swarup K, 1999, PLANT J, V20, P67, DOI 10.1046/j.1365-313X.1999.00577.x; Weinig C, 2003, MOL ECOL, V12, P1153, DOI 10.1046/j.1365-294X.2003.01787.x; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	30	330	339	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1049	1053		10.1126/science.1082971	http://dx.doi.org/10.1126/science.1082971			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605371				2022-12-28	WOS:000186396300050
J	Walvoord, MA; Phillips, FM; Stonestrom, DA; Evans, RD; Hartsough, PC; Newman, BD; Striegl, RG				Walvoord, MA; Phillips, FM; Stonestrom, DA; Evans, RD; Hartsough, PC; Newman, BD; Striegl, RG			A reservoir of nitrate beneath desert soils	SCIENCE			English	Article							TERRESTRIAL ECOSYSTEMS; GLOBAL PATTERNS; NITROGEN-CYCLE; WATER; IMPACTS; STATES	A large reservoir of bioavailable nitrogen (up to -10(4) kilograms of nitrogen per hectare, as nitrate) has been previously overlooked in studies of global nitrogen distribution. The reservoir has been accumulating in subsoil zones of arid regions throughout the Holocene. Consideration of the subsoil reservoir raises estimates of vadose-zone nitrogen inventories by 14 to 71% for warm deserts and arid shrublands worldwide and by 3 to 16% globally. Subsoil nitrate accumulation indicates long-term leaching from desert soils, impelling further evaluation of nutrient dynamics in xeric ecosystems. Evidence that subsoil accumulations are readily mobilized raises concern about groundwater contamination after land-use or climate change.	US Geol Survey, Lakewood, CO 80225 USA; New Mexico Inst Min & Technol, Dept Earth & Environm Sci, Socorro, NM 87801 USA; US Geol Survey, Menlo Pk, CA 94025 USA; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Univ Nevada, Grad Program Hydrol Sci, Reno, NV 89557 USA; Desert Res Inst, Reno, NV 89512 USA; Los Alamos Natl Lab, Div Earth & Environm Sci, Los Alamos, NM 87545 USA	United States Department of the Interior; United States Geological Survey; New Mexico Institute of Mining Technology; United States Department of the Interior; United States Geological Survey; Washington State University; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; United States Department of Energy (DOE); Los Alamos National Laboratory	Walvoord, MA (corresponding author), US Geol Survey, Lakewood, CO 80225 USA.	walvoord@usgs.gov	Walvoord, Michelle/AAQ-1137-2020; Hartsough, Peter C./B-6104-2008; Evans, Raymond D/A-8829-2010; Stonestrom, David/E-9125-2011	Walvoord, Michelle/0000-0003-4269-8366; Evans, Raymond D/0000-0002-0446-2806; Stonestrom, David/0000-0001-7883-3385; Hartsough, Peter/0000-0001-7888-8028				Ainsworth CC, 2000, VADOSE ZONE SCIENCE AND TECHNOLOGY SOLUTIONS, VOLS I AND II, P829; [Anonymous], [No title captured]; BORING LR, 1988, BIOGEOCHEMISTRY, V6, P119, DOI 10.1007/BF00003034; BOWDEN WB, 1986, BIOGEOCHEMISTRY, V2, P249, DOI 10.1007/BF02180161; BOYCE JS, 1976, FARM RANCH HOME Q, V22, P2; Canter LW., 1997, NITRATES GROUNDWATER; Cleveland CC, 1999, GLOBAL BIOGEOCHEM CY, V13, P623, DOI 10.1029/1999GB900014; EVANS RD, 1994, OECOLOGIA, V99, P233, DOI 10.1007/BF00627735; EVANS RD, 1993, OECOLOGIA, V94, P314, DOI 10.1007/BF00317104; EVANS RML, UNPUB; Galloway JN, 2003, BIOSCIENCE, V53, P341, DOI 10.1641/0006-3568(2003)053[0341:TNC]2.0.CO;2; Gebauer RLE, 2000, ECOLOGY, V81, P1415, DOI 10.1890/0012-9658(2000)081[1415:WANUPF]2.0.CO;2; GUTIERREZ JR, 1987, ECOLOGY, V68, P2032, DOI 10.2307/1939894; Hartsough P, 2001, GEOPHYS RES LETT, V28, P2955, DOI 10.1029/2000GL011823; HESS JW, 1977, PUBLICATION U NEVADA, V32; Jobbagy EG, 2001, BIOGEOCHEMISTRY, V53, P51, DOI 10.1023/A:1010760720215; KLEIN JM, 1979, 7960 US GEOL SURV; LAJTHA K, 1987, BIOGEOCHEMISTRY, V4, P265, DOI 10.1007/BF02187370; McMahon P.B., 2003, WATER MOVEMENT THICK, DOI [10.3133/wri034171, DOI 10.3133/WRI034171]; NEWMAN B, UNPUB; Nolan BT, 2000, ENVIRON SCI TECHNOL, V34, P1156, DOI 10.1021/es9907663; PETERJOHN WT, 1990, BIOGEOCHEMISTRY, V10, P67; PHILLIPS FM, 1994, SOIL SCI SOC AM J, V58, P15, DOI 10.2136/sssaj1994.03615995005800010003x; POST WM, 1985, NATURE, V317, P613, DOI 10.1038/317613a0; RICE RC, 1989, GROUND WATER, V27, P813, DOI 10.1111/j.1745-6584.1989.tb01045.x; SCHLESINGER WH, 1990, SCIENCE, V247, P1043, DOI 10.1126/science.247.4946.1043; SCHMIDT S, UNPUB; Stonestrom D.A., 2003, 03104 US GEOL SURV; Van Devender T. R., 1987, N AM ADJACENT OCEANS, P323; Vitousek PM, 1997, ECOL APPL, V7, P737, DOI 10.2307/2269431; Walvoord MA, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR000824; Walvoord MA, 2002, THESIS NEW MEXICO I; West NE, 1978, NITROGEN DESERT ECOS; ZINKE PJ, 1984, TM8857 ORNL	34	266	279	3	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1021	1024		10.1126/science.1086435	http://dx.doi.org/10.1126/science.1086435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605364				2022-12-28	WOS:000186396300040
J	Fischer, A				Fischer, A			Have we seen the last variant of severe combined immunodeficiency?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hop Necker Enfants Malad, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), Hop Necker Enfants Malad, Paris, France.								0	15	16	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1789	1792		10.1056/NEJMp038153	http://dx.doi.org/10.1056/NEJMp038153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602877				2022-12-28	WOS:000186353800002
J	Kovats, RS; Bouma, MJ; Hajat, S; Worrall, E; Haines, A				Kovats, RS; Bouma, MJ; Hajat, S; Worrall, E; Haines, A			El Nino and health	LANCET			English	Review							SOUTHERN-OSCILLATION INDEX; 4 CORNERS REGION; DENGUE-FEVER; HANTAVIRUS INFECTION; MALARIA EPIDEMICS; HIGHLAND MALARIA; UNITED-STATES; CLIMATE; DISEASE; CHOLERA	El Nino Southern Oscillation (ENSO) is a climate event that originates in the Pacific Ocean but has wide-ranging consequences for weather around the world, and is especially associated with droughts and floods. The irregular occurrence of El Nino and La Nina events has implications for public health. On a global scale, the human effect of natural disasters increases during El Nino. The effect of ENSO on cholera risk in Bangladesh, and malaria epidemics in parts of South Asia and South America has been well established. The strongest evidence for an association between ENSO and disease is provided by time-series analysis with data series that include more than one event. Evidence for ENSO's effect on other mosquito-borne and rodent-borne diseases is weaker than that for malaria and cholera. Health planners are used to dealing with spatial risk concepts but have little experience with temporal risk management. ENSO and seasonal climate forecasts might offer the opportunity to target scarce resources for epidemic control and disaster preparedness.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Ctr Global Change & Hlth, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Deans Off, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Kovats, RS (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Ctr Global Change & Hlth, Keppel St, London WC1E 7HT, England.	sari.kovats@lshtm.ac.uk	Worrall, Eve/O-4845-2019; Worrall, Eve/J-2564-2015	Worrall, Eve/0000-0001-9147-3388; Worrall, Eve/0000-0001-9147-3388; Kovats, Sari/0000-0002-4823-8099; Haines, Andy/0000-0002-8053-4605				Akhtar R, 1996, LANCET, V348, P1457, DOI 10.1016/S0140-6736(04)70109-9; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; [Anonymous], 1997, PUBLIC HLTH CONSEQUE; Anyamba A, 2001, Cad Saude Publica, V17 Suppl, P133, DOI 10.1590/S0102-311X2001000700022; Bangs Michael J., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P608; Bi P, 2000, J EPIDEMIOL COMMUN H, V54, P69, DOI 10.1136/jech.54.1.69; Bouma MJ, 1997, TROP MED INT HEALTH, V2, P1122, DOI 10.1046/j.1365-3156.1997.d01-210.x; Bouma MJ, 1997, LANCET, V350, P1435, DOI 10.1016/S0140-6736(97)04509-1; Bouma MJ, 1997, JAMA-J AM MED ASSOC, V278, P1772, DOI 10.1001/jama.278.21.1772; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; Bouma MJ, 1996, AM J TROP MED HYG, V55, P131, DOI 10.4269/ajtmh.1996.55.131; Bouma MJ, 2001, HYDROBIOLOGIA, V460, P147, DOI 10.1023/A:1013165215074; BOUMA MJ, 1994, LANCET, V343, P302, DOI 10.1016/S0140-6736(94)91152-5; BOUMA MJ, 1994, LANCET, V344, P1638, DOI 10.1016/S0140-6736(94)90432-4; BOUMA MJ, 1995, LANCET, V373, P132; BOUMA MJ, 1995, EPIDEMIOLOGY CONTROL; BROOM AK, 1995, AM J TROP MED HYG, V53, P95, DOI 10.4269/ajtmh.1995.53.95; BUCHANONSMITH M, 1996, FAMINE EARLY WARNING; CAIRNCROSS AM, 1993, ENV HLTH ENG TROPICS; Chatfield C., 2016, ANAL TIME SERIES INT; Checkley W, 2000, LANCET, V355, P442, DOI 10.1016/S0140-6736(00)82010-3; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Corwin AL, 2001, T ROY SOC TROP MED H, V95, P257, DOI 10.1016/S0035-9203(01)90229-9; DAVIES FG, 1985, B WORLD HEALTH ORGAN, V63, P941; Davis Mike, 2000, LATE VICTORIAN HOLOC; DILLEY M, 1995, DISASTERS, V19, P181, DOI 10.1111/j.1467-7717.1995.tb00338.x; Ebi KL, 2001, AM J PUBLIC HEALTH, V91, P1200, DOI 10.2105/AJPH.91.8.1200; Engelthaler DM, 1999, EMERG INFECT DIS, V5, P87, DOI 10.3201/eid0501.990110; *EUR CTR MED RANG, 1999, WORKSH APPL SEAS FOR; Franke CR, 2002, EMERG INFECT DIS, V8, P914, DOI 10.3201/eid0809.010523; GABALDON A, 1949, T ROY SOC TROP MED H, V43, P113, DOI 10.1016/0035-9203(49)90037-1; Gagnon AS, 2002, INT J BIOMETEOROL, V46, P81, DOI 10.1007/s00484-001-0119-6; Gagnon AS, 2001, CLIM RES, V19, P35, DOI 10.3354/cr019035; Glantz M. H., 1996, CURRENTS CHANGE EL N; Glantz M.H., 2001, ONCE BURNED TWICE SH; Hales S, 1996, LANCET, V348, P1664, DOI 10.1016/S0140-6736(05)65737-6; Hales S, 1999, ENVIRON HEALTH PERSP, V107, P99, DOI 10.2307/3434364; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; Harley DO, 1996, MED J AUSTRALIA, V165, P531, DOI 10.5694/j.1326-5377.1996.tb138630.x; Hay SI, 1998, PARASITOL TODAY, V14, P306, DOI 10.1016/S0169-4758(98)01285-X; Hay SI, 2000, P NATL ACAD SCI USA, V97, P9335, DOI 10.1073/pnas.97.16.9335; Hirsch A., 1883, HDB GEOGRAPHICAL HIS; Hjelle B, 2000, J INFECT DIS, V181, P1569, DOI 10.1086/315467; Hopp MJ, 2001, CLIMATIC CHANGE, V48, P441, DOI 10.1023/A:1010717502442; IPCC, 2001, ADV CLIM CHANG RES; Kovats RS, 2000, B WORLD HEALTH ORGAN, V78, P1127; KOVATS RS, 2000, CLIMATE VECTOR BORNE, P50; KOVATS RS, 1999, EL NINO HLTH; Kuhnel I, 2000, NAT HAZARDS, V22, P117, DOI 10.1023/A:1008187117471; Lindblade KA, 1999, T ROY SOC TROP MED H, V93, P480, DOI 10.1016/S0035-9203(99)90344-9; Lindsay SW, 2000, LANCET, V355, P989, DOI 10.1016/S0140-6736(00)90022-9; Linthicum KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/science.285.5426.397; Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; Maelzer D, 1999, ENVIRON HEALTH PERSP, V107, P817, DOI 10.2307/3454579; Mills JN, 1999, EMERG INFECT DIS, V5, P95, DOI 10.3201/eid0501.990111; Murphy SJ, 2001, NAT HAZARDS, V23, P171, DOI 10.1023/A:1011160904414; Myers MF, 2000, ADV PARASIT, V47, P309, DOI 10.1016/S0065-308X(00)47013-2; Najera JA., 1998, MALARIA EPIDEMICS DE; NICHOLLS N, 1993, SOUTH-EAST ASIA'S ENVIRONMENTAL FUTURE, P154; NICHOLLS N, 1988, B AM METEOROL SOC, V69, P173, DOI 10.1175/1520-0477(1988)069<0173:ENOIP>2.0.CO;2; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; ONORI E, 1980, B WORLD HEALTH ORGAN, V58, P91; *PAHO, 2000, CRON DES FEN EL NIN; Parmenter RR, 1999, AM J TROP MED HYG, V61, P814, DOI 10.4269/ajtmh.1999.61.814; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; Pascual M, 2002, MICROBES INFECT, V4, P237, DOI 10.1016/S1286-4579(01)01533-7; Patz J. A., 2002, ECOSYSTEM CHANGE PUB; Poveda G., 2000, NINO SO OSCILLATION, P183; Poveda G., 2001, ENVIRON HEALTH PERSP, V109, P307; PROTHERO RM, 1994, INT J EPIDEMIOL, V23, P657, DOI 10.1093/ije/23.4.657; Reiter P, 1998, LANCET, V351, P839, DOI 10.1016/S0140-6736(05)78979-0; Rodo X, 2002, P NATL ACAD SCI USA, V99, P12901, DOI 10.1073/pnas.182203999; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Schwartz J B, 1996, PDA J Pharm Sci Technol, V50, P197; SPENNEMANN DHR, 1995, DISASTERS, V19, P194, DOI 10.1111/j.1467-7717.1995.tb00339.x; SWAROOP S, 1946, AM J TROP MED HYG, V29, P1; Thomson MC, 2000, LANCET, V355, P1559, DOI 10.1016/S0140-6736(05)74616-X; Thomson MC, 1996, ANN TROP MED PARASIT, V90, P243, DOI 10.1080/00034983.1996.11813050; Timmermann A, 1999, NATURE, V398, P694, DOI 10.1038/19505; Tong SL, 1998, LANCET, V351, P1100, DOI 10.1016/S0140-6736(05)79379-X; VINNIKOV KY, 2002, GEOPHYS RES LETT, V29, P10; Walker G T, 1932, MEM R METEOROL SOC, V4, P53; WENZEL RP, 1994, NEW ENGL J MED, V330, P1004, DOI 10.1056/NEJM199404073301410; *WHO, 2001, ROLL BACK MAL TECHN; WHO, 1999, HLTH GUID VEG FIR EV; *WHO AFRO ICP, 2001, RBM TSN MAL EP PREV; *WMO UNESCO UNEP I, 1999, 905 WMOUNESCOUNEPICS; Woodruff RE, 2002, EPIDEMIOLOGY, V13, P384, DOI 10.1097/00001648-200207000-00005; WORRALL E, 2001, THESIS LIVERPOOL SCH; YACOB KBM, 1946, J MALAR I INDIA, V6, P273; YIP R, 1997, PUBLIC HLTH CONSEQUE, P305; Zurbrigg S., 1994, Parassitologia (Rome), V36, P121; 1998, SISTEMA NACL VIGILAN	94	288	298	3	100	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2003	362	9394					1481	1489		10.1016/S0140-6736(03)14695-8	http://dx.doi.org/10.1016/S0140-6736(03)14695-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602445				2022-12-28	WOS:000186356600026
J	Malin, MC; Edgett, KS				Malin, MC; Edgett, KS			Evidence for persistent flow and aqueous sedimentation on early Mars	SCIENCE			English	Article							CHANNELS; WATER; MORPHOLOGY; SCALE	Landforms representative of sedimentary processes and environments that occurred early in martian history have been recognized in Mars Global Surveyor Mars Orbiter Camera and Mars Odyssey Thermal Emission Imaging System images. Evidence of distributary, channelized flow (in particular, flow that lasted long enough to foster meandering) and the resulting deposition of a fan-shaped apron of debris indicate persistent flow conditions and formation of at least some large intracrater layered sedimentary sequences within fluvial, and potentially lacustrine, environments.	Malin Space Sci Syst, San Diego, CA 92191 USA		Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.			Edgett, Kenneth/0000-0001-7197-5751				[Anonymous], 1983, GEOL SOC AM BULL, V94, P1035; Baker V.R., 1992, CHANNELS VALLEY NETW, P493; Baker VR, 2001, NATURE, V412, P228, DOI 10.1038/35084172; BLAIR TC, 1994, J SEDIMENT RES A, V64, P450; Cabrol NA, 2001, ICARUS, V149, P291, DOI 10.1006/icar.2000.6530; Carr M.H, 1996, WATER MARS; Carr MH, 2000, ICARUS, V146, P366, DOI 10.1006/icar.2000.6428; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; Galloway W.E., 1975, DELTAS MODELS EXPLOR, P87; KOMAR PD, 1979, ICARUS, V37, P156, DOI 10.1016/0019-1035(79)90123-4; MAIZELS J, 1990, PALAEOGEOGR PALAEOCL, V76, P241, DOI 10.1016/0031-0182(90)90115-N; Malin MC, 2000, SCIENCE, V290, P1927, DOI 10.1126/science.290.5498.1927; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; Miller RP, 1937, J GEOL, V45, P432, DOI 10.1086/624550; MILTON DJ, 1973, J GEOPHYS RES, V78, P4037, DOI 10.1029/JB078i020p04037; MILTON DJ, 1974, ICARUS, V23, P27; Nemec W., 1990, SPECIAL PUBLICATION, V10, P3; Ori GG, 2000, J GEOPHYS RES-PLANET, V105, P17629, DOI 10.1029/1999JE001219; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; WEIHAUPT JG, 1974, J GEOPHYS RES, V79, P2073, DOI 10.1029/JB079i014p02073; Wessel P, 1991, EOS T AM GEOPHYS UN, V72, P445, DOI [10.1029/90EO00319, DOI 10.1029/90EO00319, DOI 10.1029/90E000319]	23	351	358	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	2003	302	5652					1931	1934		10.1126/science.1090544	http://dx.doi.org/10.1126/science.1090544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	752NL	14615547				2022-12-28	WOS:000187174000051
J	Shaevitz, JW; Abbondanzieri, EA; Landick, R; Block, SM				Shaevitz, JW; Abbondanzieri, EA; Landick, R; Block, SM			Backtracking by single RNA polymerase molecules observed at near-base-pair resolution	NATURE			English	Article							ESCHERICHIA-COLI; TRANSCRIPT CLEAVAGE; ELONGATION; DNA; FIDELITY; FORCE; GREA; MECHANISM; COMPLEXES; ARREST	Escherichia coli RNA polymerase ( RNAP) synthesizes RNA with remarkable fidelity in vivo(1). Its low error rate may be achieved by means of a ' proofreading' mechanism comprised of two sequential events. The first event ( backtracking) involves a transcriptionally upstream motion of RNAP through several base pairs, which carries the 30 end of the nascent RNA transcript away from the enzyme active site. The second event ( endonucleolytic cleavage) occurs after a variable delay and results in the scission and release of the most recently incorporated ribonucleotides, freeing up the active site. Here, by combining ultrastable optical trapping apparatus with a novel two- bead assay to monitor transcriptional elongation with near- base- pair precision, we observed backtracking and recovery by single molecules of RNAP. Backtracking events (similar to 5 bp) occurred infrequently at locations throughout the DNA template and were associated with pauses lasting 20 s to > 30 min. Inosine triphosphate increased the frequency of backtracking pauses, whereas the accessory proteins GreA and GreB, which stimulate the cleavage of nascent RNA, decreased the duration of such pauses.	Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Stanford University; Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison	Block, SM (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.				NIGMS NIH HHS [R01 GM057035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; deCastro MJ, 2000, NAT CELL BIOL, V2, P724, DOI 10.1038/35036357; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FENG GH, 1994, J BIOL CHEM, V269, P22282; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; Marr MT, 2000, MOL CELL, V6, P1275, DOI 10.1016/S1097-2765(00)00126-X; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; Neuman KC, 2003, CELL, V115, P437, DOI 10.1016/S0092-8674(03)00845-6; Nishiyama M, 2001, NAT CELL BIOL, V3, P425, DOI 10.1038/35070116; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	28	289	303	4	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 11	2003	426	6967					684	687		10.1038/nature02191	http://dx.doi.org/10.1038/nature02191			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	752DY	14634670	Green Accepted			2022-12-28	WOS:000187132800047
J	Monje, ML; Toda, H; Palmer, TD				Monje, ML; Toda, H; Palmer, TD			Inflammatory blockade restores adult hippocampal neurogenesis	SCIENCE			English	Article							NEURAL STEM-CELLS; DENTATE GYRUS; RAT-BRAIN; RECEPTOR ACTIVATION; MAMMALIAN FOREBRAIN; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; EXPRESSION; INTERLEUKIN-6; DIFFERENTIATION	Cranial radiation therapy causes a progressive decline in cognitive function that is linked to impaired neurogenesis. Chronic inflammation accompanies radiation injury, suggesting that inflammatory processes may contribute to neural stem cell dysfunction. Here, we show that neuroinflammation alone inhibits neurogenesis and that inflammatory blockade with indomethacin, a common nonsteroidal anti-inflammatory drug, restores neurogenesis after endotoxin-induced inflammation and augments neurogenesis after cranial irradiation.	Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA	Stanford University	Palmer, TD (corresponding author), Stanford Univ, Dept Neurosurg, MSLS P309,Mail Code 5487,1201 Welche Rd, Stanford, CA 94305 USA.		Palmer, Theo/GSI-6635-2022; Toda, Hiroki/C-6932-2016	Toda, Hiroki/0000-0002-1596-4131; Palmer, Theo/0000-0002-6266-1862	NIMH NIH HHS [MH20016-05] Funding Source: Medline; NINDS NIH HHS [F30 NS04696701] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brew BJ, 1999, NEUROL CLIN, V17, P861, DOI 10.1016/S0733-8619(05)70170-5; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; CALVO W, 1988, BRIT J RADIOL, V61, P1043, DOI 10.1259/0007-1285-61-731-1043; Cameron HA, 1998, CURR OPIN NEUROBIOL, V8, P677, DOI 10.1016/S0959-4388(98)80099-8; Cameron HA, 1998, NEUROSCIENCE, V82, P349; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Chojnacki A, 2003, J NEUROSCI, V23, P1730; Dickson DW, 2001, CLIN GERIATR MED, V17, P209, DOI 10.1016/S0749-0690(05)70066-5; EKDAHL CT, 2003, P NATL ACAD SCI US; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gould E, 1997, J NEUROSCI, V17, P2492; Hodges H, 1998, BEHAV BRAIN RES, V91, P99, DOI 10.1016/S0166-4328(97)00108-3; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Luskin MB, 1998, J NEUROBIOL, V36, P221; Mackenzie IRA, 2000, NEUROLOGY, V55, P132, DOI 10.1212/WNL.55.1.132; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARKS JE, 1981, INT J RADIAT ONCOL, V7, P243, DOI 10.1016/0360-3016(81)90443-0; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nakashima K, 2002, MOL NEUROBIOL, V25, P233; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; REICHMAN HR, 1986, J NEUROSURG, V65, P233, DOI 10.3171/jns.1986.65.2.0233; Reyes TM, 1998, AM J PHYSIOL-REG I, V274, pR139, DOI 10.1152/ajpregu.1998.274.1.R139; Shaw KN, 2001, BEHAV BRAIN RES, V124, P47, DOI 10.1016/S0166-4328(01)00232-7; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; SHINTANI F, 1995, J NEUROSCI, V15, P1961, DOI 10.1523/JNEUROSCI.15-03-01961.1995; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Tanapat P, 1998, INT J DEV NEUROSCI, V16, P235, DOI 10.1016/S0736-5748(98)00029-X; Terrazzino S, 2002, J NEUROIMMUNOL, V124, P45, DOI 10.1016/S0165-5728(02)00013-9; Turrin NP, 2001, BRAIN RES BULL, V54, P443, DOI 10.1016/S0361-9230(01)00445-2; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Watanabe D, 1996, EUR J NEUROSCI, V8, P1630, DOI 10.1111/j.1460-9568.1996.tb01307.x; Weaver JD, 2002, NEUROLOGY, V59, P371, DOI 10.1212/WNL.59.3.371; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x	51	1809	1882	4	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 5	2003	302	5651					1760	1765		10.1126/science.1088417	http://dx.doi.org/10.1126/science.1088417			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	750AX	14615545				2022-12-28	WOS:000186970100047
J	Alatrakchi, N; Koziel, MJ				Alatrakchi, N; Koziel, MJ			A tale of two viruses: hepatitis C in the age of HAART	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; COINFECTED PATIENTS; INFECTED PATIENTS; LIVER FIBROSIS; PROGRESSION; MORTALITY; HEPATOTOXICITY; DISEASE; IMPACT		Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Koziel, MJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.							Aceti A, 2002, J ACQ IMMUN DEF SYND, V29, P41, DOI 10.1097/00042560-200201010-00005; Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332; Babik JM, 2003, J VIROL, V77, P1940, DOI 10.1128/JVI.77.3.1940-1950.2003; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; den Brinker M, 2000, AIDS, V14, P2895, DOI 10.1097/00002030-200012220-00011; Einav S, 2002, Transpl Infect Dis, V4, P85, DOI 10.1034/j.1399-3062.2002.t01-2-02001.x; Ghany MG, 2003, GASTROENTEROLOGY, V124, P97, DOI 10.1053/gast.2003.50018; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Macias J, 2002, EUR J CLIN MICROBIOL, V21, P775, DOI 10.1007/s10096-002-0823-0; Martin-Carbonero L, 2002, AIDS, V16, P1423, DOI 10.1097/00002030-200207050-00016; Martinez-Sierra C, 2003, CLIN INFECT DIS, V36, P491, DOI 10.1086/367643; Nunez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Tedaldi EM, 2003, CLIN INFECT DIS, V36, P363, DOI 10.1086/345953	15	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1687	1688		10.1016/S0140-6736(03)14881-7	http://dx.doi.org/10.1016/S0140-6736(03)14881-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643113				2022-12-28	WOS:000186767700003
J	van Balen, FAM; Smit, WM; Zuithoff, NPA; Verheij, TJM				van Balen, FAM; Smit, WM; Zuithoff, NPA; Verheij, TJM			Clinical efficacy of three common treatments in acute otitis externa in primary care: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							EAR; ETIOLOGY; RISK	Objective To compare the clinical efficacy of ear drops containing acetic acid, corticosteroid. and acetic acid, and steroid and antibiotic in acute otitis externa in primary care. Design Randomised controlled trial. Setting 79 general practices, Netherlands. Participants 213 adults with acute otitis externa. Main outcome measures Primary outcome: duration of symptoms (days) according to patient diaries. Secondary outcome: cure rate according to general practitioner completed questionnaires and recurrence of symptoms between days 21 and 42. Results Symptoms lasted for a median of 8.0 days (95% confidence interval 7.0 to 9.0) in the acetic acid group, 7.0 days (5.8 to 8.3) in the steroid and acetic acid group, and 6.0 days (5.1 to 6.9) in the steroid and antibiotic group. The overall cure rates at seven, 14, and 21 days were 38%, 68%, and 75%, respectively. Compared with the acetic acid group, significantly more patients were cured in the steroid and acetic acid group and steroid and antibiotic group at day 14 (odds ratio 2.4, 1.1 to 5.3, and 3.5, 1.6 to 7.7, respectively) and day 21 (5.3, 2.0 to 13.7, and 3.9, 1.7 to 9.1, respectively). Recurrence of symptoms between days 21 and 42 occurred in 29% (50/172) of patients and was seen significantly less in the steroid and acetic acid group (0.3, 0.1 to 0.7) and steroid and antibiotic group (0.4, 0.2 to 1.0) than in the acetic acid group. Conclusions Ear drops containing corticosteroids are more effective than acetic acid ear drops in the treatment of acute otitis externa in primary care. Steroid and acetic acid or steroid and antibiotic ear drops are equally effective.	Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands		van Balen, FAM (corresponding author), Julius Ctr Hlth Sci & Primary Care, POB 80560, NL-3508 AB Utrecht, Netherlands.							AGIUS AM, 1992, CLIN OTOLARYNGOL, V17, P150, DOI 10.1111/j.1365-2273.1992.tb01063.x; CALDERON R, 1982, ARCH ENVIRON HEALTH, V37, P300, DOI 10.1080/00039896.1982.10667583; CANNON S, 1970, EYE EAR NOSE THROAT, V49, P186; CLAYTON MI, 1990, CLIN OTOLARYNGOL, V15, P7, DOI 10.1111/j.1365-2273.1990.tb00425.x; DIBB WL, 1991, J INFECTION, V22, P233, DOI 10.1016/S0163-4453(05)80004-0; FALSER N, 1984, DERMATOLOGICA, V169, P135, DOI 10.1159/000249653; FREEDMAN R, 1978, EAR NOSE THROAT J, V57, P198; GOODMAN WS, 1984, J OTOLARYNGOL, V13, P183; HIRSCH HH, 1992, EUR J BIOCHEM, V13, P1; JACOBSSON S, 1991, EUR ARCH OTO-RHINO-L, V248, P246; Jobbins D, 1986, Aust Fam Physician, V15, P720; Jones RN, 1997, ARCH OTOLARYNGOL, V123, P1193; KIME CE, 1978, CURR THER RES, V23, pS15; Lambert I J, 1981, J R Coll Gen Pract, V31, P291; NIELSEN PG, 1985, MYKOSEN, V28, P234; ORDONEZ GE, 1978, CURR THER RES, V23, pS3; ORDONEZ GE, 1978, CURR THER RES, V223, pS3; Roland PS, 2002, LARYNGOSCOPE, V112, P1166, DOI 10.1097/00005537-200207000-00005; ROOIJACKERSLEMM.E, 1993, HUISARTS WET, V36, P212; ROOIJACKERSLEMM.E, 1995, HUISARTS WET, V28, P265; Rowlands S, 2001, BRIT J GEN PRACT, V51, P533; RUTH M, 1990, EUR ARCH OTO-RHINO-L, V247, P77; SLACK RWT, 1987, J LARYNGOL OTOL, V101, P533, DOI 10.1017/S0022215100102178; SPRINGER GL, 1985, ARCH ENVIRON HEALTH, V40, P202, DOI 10.1080/00039896.1985.10545918; VANASPEREN IA, 1995, BRIT MED J, V311, P1407, DOI 10.1136/bmj.311.7017.1407	25	42	43	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1201	1203		10.1136/bmj.327.7425.1201	http://dx.doi.org/10.1136/bmj.327.7425.1201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630756	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000186784300019
J	Lynch, M; Conery, JS				Lynch, M; Conery, JS			The origins of genome complexity	SCIENCE			English	Article							DUPLICATE GENES; INTRON; EVOLUTION; SIZE; RECOMBINATION; PRESERVATION; COMMUNITIES; DROSOPHILA; MUTATION; DENSITY	Complete genomic sequences from diverse phylogenetic lineages reveal notable increases in genome complexity from prokaryotes to multicellular eukaryotes. The changes include gradual increases in gene number, resulting from the retention of duplicate genes, and more abrupt increases in the abundance of spliceosomal introns and mobile genetic elements. We argue that many of these modi. cations emerged passively in response to the long-term population-size reductions that accompanied increases in organism size. According to this model, much of the restructuring of eukaryotic genomes was initiated by nonadaptive processes, and this in turn provided novel substrates for the secondary evolution of phenotypic complexity by natural selection. The enormous long-term effective population sizes of prokaryotes may impose a substantial barrier to the evolution of complex genomes and morphologies.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Oregon, Dept Comp & Informat Sci, Eugene, OR 97403 USA	Indiana University System; Indiana University Bloomington; University of Oregon	Lynch, M (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.							Akashi H, 2001, CURR OPIN GENET DEV, V11, P660, DOI 10.1016/S0959-437X(00)00250-1; Carbone C, 2002, SCIENCE, V295, P2273, DOI 10.1126/science.1067994; Carvalho AB, 1999, NATURE, V401, P344, DOI 10.1038/43827; Charlesworth B., 1985, POPULATION GENETICS, P213; Comeron JM, 2000, GENETICS, V156, P1175; CRAIG NL, 2002, MOBILE DNA, V2; Denver DR, 2000, SCIENCE, V289, P2342, DOI 10.1126/science.289.5488.2342; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; Drake JW, 1998, GENETICS, V148, P1667; Enquist BJ, 2001, NATURE, V410, P655, DOI 10.1038/35070500; Finlay BJ, 2002, SCIENCE, V296, P1061, DOI 10.1126/science.1070710; Force A, 1999, GENETICS, V151, P1531; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gregory TR, 2001, BIOL REV, V76, P65, DOI 10.1017/S1464793100005595; Kimura M., 1983, NEUTRAL THEORY MOL E; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Lynch M, 2000, GENETICS, V154, P459; Lynch M, 2001, GENETICS, V159, P1789; Lynch M, 2002, CURR OPIN GENET DEV, V12, P701, DOI 10.1016/S0959-437X(02)00360-X; Lynch M, 2002, P NATL ACAD SCI USA, V99, P6118, DOI 10.1073/pnas.092595699; Lynch Michael, 2003, Journal of Structural and Functional Genomics, V3, P35, DOI 10.1023/A:1022696612931; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; Ohno S., 1970, EVOLUTION GENE DUPLI; OHTA T, 1973, NATURE, V246, P96, DOI 10.1038/246096a0; Petrov DA, 1998, MOL BIOL EVOL, V15, P293, DOI 10.1093/oxfordjournals.molbev.a025926; Schmid PE, 2000, SCIENCE, V289, P1557, DOI 10.1126/science.289.5484.1557; Stoltzfus A, 1999, J MOL EVOL, V49, P169, DOI 10.1007/PL00006540; Vinogradov AE, 1999, J MOL EVOL, V49, P376, DOI 10.1007/PL00006561	30	1111	1134	6	236	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1401	1404		10.1126/science.1089370	http://dx.doi.org/10.1126/science.1089370			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631042				2022-12-28	WOS:000186683500054
J	Ravizza, G; Peucker-Ehrenbrink, B				Ravizza, G; Peucker-Ehrenbrink, B			Chemostratigraphic evidence of Deccan volcanism from the marine osmium isotope record	SCIENCE			English	Article							GLOBAL CLIMATE; TRAPS; AGE; GEOCHEMISTRY; INFERENCES; DURATION; ROCKS	Continental flood basalt (CFB) volcanism is hypothesized to have played a causative role in global climate change and mass extinctions. Uncertainties associated with radiometric dating preclude a clear chronological assessment of the environmental consequences of CFB volcanism. Our results document a 25% decline in the marine Os-187/Os-188 record that predates the Cretaceous-Tertiary boundary (KTB) and coincides with late Maastrichtian warming. We argue that this decline provides a chemostratigraphic marker of Deccan volcanism and thus constitutes compelling evidence that the main environmental consequence of Deccan volcanism was a transient global warming event of 3degrees to 5degreesC that is fully resolved from the KTB mass extinction.	Univ Hawaii, Dept Geol & Geophys, Honolulu, HI 96822 USA; Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	University of Hawaii System; Woods Hole Oceanographic Institution	Ravizza, G (corresponding author), Univ Hawaii, Dept Geol & Geophys, Honolulu, HI 96822 USA.	ravizza@hawaii.edu	Ravizza, Greg/J-5104-2013	Peucker-Ehrenbrink, Bernhard/0000-0002-3819-992X				Allegre CJ, 1999, EARTH PLANET SC LETT, V170, P197, DOI 10.1016/S0012-821X(99)00110-7; Banerjee AC, 2000, J GEOL SOC INDIA, V56, P625; Barrera E, 1999, GEOL S AM S, P245; CALDEIRA K, 1990, GEOPHYS RES LETT, V17, P1299, DOI 10.1029/GL017i009p01299; Cohen AS, 2002, GEOLOGY, V30, P267, DOI 10.1130/0091-7613(2002)030<0267:NGEFTO>2.0.CO;2; Courtillot V, 2000, EARTH PLANET SC LETT, V182, P137, DOI 10.1016/S0012-821X(00)00238-7; Courtillot VE, 2003, CR GEOSCI, V335, P113, DOI 10.1016/S1631-0713(03)00006-3; Dessert C, 2001, EARTH PLANET SC LETT, V188, P459, DOI 10.1016/S0012-821X(01)00317-X; Hassler DR, 2000, CHEM GEOL, V166, P1, DOI 10.1016/S0009-2541(99)00180-1; Hicks JF, 2002, GEOL S AM S, P35; Hofmann C, 2000, EARTH PLANET SC LETT, V180, P13, DOI 10.1016/S0012-821X(00)00159-X; KYTE FT, 1993, GEOCHIM COSMOCHIM AC, V57, P1719, DOI 10.1016/0016-7037(93)90109-A; Li LQ, 1999, MAR GEOL, V161, P171, DOI 10.1016/S0025-3227(99)00078-X; Li LQ, 1998, GEOLOGY, V26, P995, DOI 10.1130/0091-7613(1998)026<0995:ADSWAT>2.3.CO;2; Mahoney JJ, 2002, EARTH PLANET SC LETT, V203, P295, DOI 10.1016/S0012-821X(02)00840-3; McArthur JM, 2001, J GEOL, V109, P155, DOI 10.1086/319243; Mukhopadhyay S, 2001, GEOCHIM COSMOCHIM AC, V65, P653, DOI 10.1016/S0016-7037(00)00555-X; Nordt L, 2002, GEOLOGY, V30, P703, DOI 10.1130/0091-7613(2002)030<0703:PBIEFI>2.0.CO;2; Olsson RK, 2001, J FORAMIN RES, V31, P275, DOI 10.2113/31.3.275; Pande K, 2002, P INDIAN AS-EARTH, V111, P115, DOI 10.1007/BF02981139; Pegram WJ, 1999, GEOCHIM COSMOCHIM AC, V63, P4053, DOI 10.1016/S0016-7037(99)00308-7; Peucker-Ehrenbrink B, 2000, TERRA NOVA, V12, P205, DOI 10.1046/j.1365-3121.2000.00295.x; Ravizza G, 2001, PALEOCEANOGRAPHY, V16, P155, DOI 10.1029/2000PA000541; SUGARMAN PJ, 1995, GEOL SOC AM BULL, V107, P19, DOI 10.1130/0016-7606(1995)107<0019:UCMSIB>2.3.CO;2; Taylor AS, 1999, CHEM GEOL, V161, P199, DOI 10.1016/S0009-2541(99)00087-X; Vonhof HB, 1997, GEOLOGY, V25, P347, DOI 10.1130/0091-7613(1997)025<0347:HRLMED>2.3.CO;2; WARNER TB, 1974, INITIAL REPORTS DEEP, V25, P395; Wignall PB, 2001, EARTH-SCI REV, V53, P1, DOI 10.1016/S0012-8252(00)00037-4; Wilf P, 2003, P NATL ACAD SCI USA, V100, P599, DOI 10.1073/pnas.0234701100; Zachos JC, 1986, PALEOCEANOGRAPHY, V1, P5, DOI 10.1029/PA001i001p00005	30	119	127	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1392	1395		10.1126/science.1089209	http://dx.doi.org/10.1126/science.1089209			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631039				2022-12-28	WOS:000186683500051
J	Lee, DS; Austin, PC; Rouleau, JL; Liu, PP; Naimark, D; Tu, JV				Lee, DS; Austin, PC; Rouleau, JL; Liu, PP; Naimark, D; Tu, JV			Predicting mortality among patients hospitalized for heart failure - Derivation and validation of a clinical model	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOGISTIC-REGRESSION ANALYSIS; ACUTE MYOCARDIAL-INFARCTION; CARDIAC-SURGERY; CARE; COMMUNITY; RULES; INDEX; PROGNOSIS; SURVIVAL; MULTICENTER	Context A predictive model of mortality in heart failure may be useful for clinicians to improve communication with and care of hospitalized patients. Objectives To identify predictors of mortality and to develop and to validate a model using information available at hospital presentation. Design, Setting, and Participants Retrospective study of 4031 community-based patients presenting with heart failure at multiple hospitals in Ontario, Canada (2624 patients in the derivation cohort from 1999-2001 and 1407 patients in the validation cohort from 1997-1999), who had been identitifed as part of the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study. Main Outcome Measures All-cause 30-day and 1-year mortality. Results The mortality rates for the derivation cohort and validation cohort, respectively, were 8.9% and 8.2% in hospital, 10.7% and 10.4% at 30 days, and 32.9% and 30.5% at 1 year. Multivariable predictors of mortality at both 30 days and 1 year included older age, lower systolic blood pressure, higher respiratory rate, higher urea nitrogen level (all P<.001), and hyponatremia (P<.01). Comorbid conditions associated with mortality included cerebrovascular disease (30-day mortality odds ratio [OR], 1.43; 95% confidence interval [CI], 1.03-1.98; P=.03), chronic obstructive pulmonary disease (OR, 1.66; 95 % CI, 1.22-2.27; P=.002), hepatic cirrhosis (OR, 3.22; 95% CI, 1.08-9.65; P=.04), dementia (OR, 2.54; 95% CI, 1.77-3.65; P<.001), and cancer (OR, 1.86; 95% CI, 1.28-2.70; P=.001). A risk index stratified the risk of death and identified low- and high-risk individuals. Patients with very low-risk scores (:560) had a mortality rate of 0.4% at 30 days and 7.8% at 1 year. Patients with very high-risk scores (>150) had a mortality rate of 59.0% at 30 days and 78.8% at 1 year. Patients with higher 1-year risk scores had reduced survival at all times up to 1 year (log-rank, P<.001). For the derivation cohort, the area under the receiver operating characteristic curve for the model was 0.80 for 30-day mortality and 0.77 for 1-year mortality. Predicted mortality rates in the validation cohort closely matched observed rates across the entire spectrum of risk. Conclusions Among community-based heart failure patients, factors identifiable Within hours of hospital presentation predicted mortality risk at 30 days and 1 year. The externally validated predictive index may assist clinicians in estimating heart failure mortality risk and in providing quantitative guidance for decision making in heart failure care.	Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto Gen Hosp, Toronto, ON M5G 1L7, Canada; Toronto Gen Hosp, Univ Hlth Network, Div Cardiol, Dept Hlth Policy, Toronto, ON, Canada; Toronto Gen Hosp, Univ Hlth Network, Div Cardiol, Dept Management, Toronto, ON, Canada; Toronto Gen Hosp, Univ Hlth Network, Div Cardiol, Dept Evaluat Clin Epidemiol, Toronto, ON, Canada; Toronto Gen Hosp, Univ Hlth Network, Div Cardiol, Dept Publ Hlth Sci, Toronto, ON, Canada; Mt Sinai Hosp, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5G 1X5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Tu, JV (corresponding author), Inst Clin Evaluat Sci, Room G-106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	tu@ices.on.ca		Austin, Peter/0000-0003-3337-233X; Naimark, David Malcolm Joseph/0000-0002-0621-0637; Tu, Jack/0000-0003-0111-722X; Lee, Douglas/0000-0001-7078-745X				Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; CAMPANA C, 1993, J HEART LUNG TRANSPL, V12, P756; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chin MH, 1997, AM J CARDIOL, V79, P1640, DOI 10.1016/S0002-9149(97)00214-2; Cleland JGF, 2002, LANCET, V360, P1631, DOI 10.1016/S0140-6736(02)11601-1; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Efron B, 1998, INTRO BOOTSTRAP; Eichhorn Eric J., 2001, American Journal of Medicine, V110, p14S; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fried Terri R, 2003, J Palliat Med, V6, P237, DOI 10.1089/109662103764978489; GOLDBERGER JJ, 1986, ARCH INTERN MED, V146, P489, DOI 10.1001/archinte.146.3.489; Graff L, 1999, ANN EMERG MED, V34, P429, DOI 10.1016/S0196-0644(99)80043-2; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hanratty B, 2002, BRIT MED J, V325, P581, DOI 10.1136/bmj.325.7364.581; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KONSTAM M, 2001, 940612 AHCPR; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Lee DS, 2003, CAN J CARDIOL, V19, P357; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; Masoudi FA, 2003, J AM COLL CARDIOL, V41, P217, DOI 10.1016/S0735-1097(02)02696-7; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Polanczyk CA, 1998, MED CARE, V36, P1489, DOI 10.1097/00005650-199810000-00007; Poses RM, 2000, ANN INTERN MED, V133, P10, DOI 10.7326/0003-4819-133-1-200007040-00003; Reilly BM, 2002, JAMA-J AM MED ASSOC, V288, P342, DOI 10.1001/jama.288.3.342; Rosenthal GE, 2000, HEALTH SERV RES, V34, P1449; Seamark DA, 2002, PALLIATIVE MED, V16, P495, DOI 10.1191/0269216302pm596oa; SELKER HP, 1994, MED CARE, V32, P1040, DOI 10.1097/00005650-199410000-00005; Senni M, 1999, J AM COLL CARDIOL, V33, P164, DOI 10.1016/S0735-1097(98)00523-3; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Sharpe N, 1998, PROG CARDIOVASC DIS, V41, P73, DOI 10.1016/S0033-0620(98)80034-0; Southard P, 1989, J Emerg Nurs, V15, P393; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Tu JV, 1997, J CLIN EPIDEMIOL, V50, P743, DOI 10.1016/S0895-4356(97)89028-2; TU JV, 1994, CAN MED ASSOC J, V151, P177; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; TU JV, 1999, CARDIOVASCULAR HLTH, P111; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868; Zannad F, 1999, J AM COLL CARDIOL, V33, P734, DOI 10.1016/S0735-1097(98)00634-2	53	997	1052	1	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2581	2587		10.1001/jama.290.19.2581	http://dx.doi.org/10.1001/jama.290.19.2581			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744DQ	14625335	Bronze			2022-12-28	WOS:000186613000028
J	Kovacs, FM; Abraira, V; Pena, A; Martin-Rodriguez, JG; Sanchez-Vera, M; Ferrer, E; Ruano, D; Guillen, P; Gestoso, M; Muriel, A; Zamora, J; del Rea, MTG; Mufraggi, N				Kovacs, FM; Abraira, V; Pena, A; Martin-Rodriguez, JG; Sanchez-Vera, M; Ferrer, E; Ruano, D; Guillen, P; Gestoso, M; Muriel, A; Zamora, J; del Rea, MTG; Mufraggi, N			Effect of firmness of mattress on chronic non-specific low-back pain: randomised, double-blind, controlled, multicentre trial	LANCET			English	Article							QUALITY; THERAPY; SLEEP	Background A firm mattress is commonly believed to be beneficial for low-back pain, although evidence supporting this recommendation is lacking. We assessed the effect of different firmnesses of mattresses on the clinical course of patients with chronic non-specific low-back pain. Methods In a randomised, double-blind, controlled, multicentre trial, we assessed 313 adults who had chronic non-specific low-back pain, but no referred pain, who complained of backache while lying in bed and on rising. Mattress firmness is rated on a scale developed by the European Committee for Standardisation. The H-s scale starts at 1.0 (firmest) and stops at 10.0 (softest). We randomly assigned participants firm mattresses (H-s=2.3) or medium-firm mattresses (H-s=5.6). We did clinical assessments at baseline and at 90 days. Primary endpoints were improvements in pain while lying in bed, pain on rising, and disability. Findings At 90 days, patients with medium-firm mattresses had better outcomes for pain in bed (odds ratio 2.36 [95% Cl 1.13-4.93]), pain on rising (1.93 [0.97-3.86]), and disability (2.10 [1.24-3.56]) than did patients with firm mattresses. Throughout the study period, patients with medium-firm mattresses also had less daytime low-back pain (p=0.059), pain while lying in bed (p=0.064), and pain on rising (p=0.008) than did patients with firm mattresses. Interpretation A mattress of medium firmness improves pain and disability among patients with chronic non-specific low-back pain.	Kovacs fdn, Dept Sci, E-07012 Palma de Mallorca, Spain; Hosp Ramon & Cajal, Unit Clin Biostat, E-28034 Madrid, Spain; Hosp Ramon & Cajal, Serv Phys Rehabil, E-28034 Madrid, Spain; Hosp Zarziela, Neurosurg Serv, Madrid, Spain; Clin Luz, Trauma Serv, Madrid, Spain; Univ Barcelona, Hosp Clin, Neurosurg Serv, Barcelona, Spain; Univ Barcelona, Dept Anat, Barcelona, Spain; Clin CEMTRO, Trauma Serv, Madrid, Spain	Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona	Kovacs, FM (corresponding author), Kovacs fdn, Dept Sci, Paseo Mallorca 36, E-07012 Palma de Mallorca, Spain.	kovacs@kovacs.org	Kovacs, Francisco/L-9083-2014; Muriel, Alfonso AM/F-9948-2015; Zamora, Javier/AEO-0608-2022; Zamora, Javier/B-1722-2009	Kovacs, Francisco/0000-0002-2984-4800; Muriel, Alfonso AM/0000-0002-4805-4011; Zamora, Javier/0000-0003-4901-588X; Zamora, Javier/0000-0003-4901-588X; Abraira, Victor/0000-0002-4615-8503				ABRAIRA V, 1984, P C IB BIOING AST SP, V100; *AG HLTH CAR POL R, 1994, CLIN PRACT GUID NUMB; Andersson G, 1997, ADULT SPINE PRINCIPL; Belsley D. A., 1991, CONDITIONING DIAGNOS; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Enck P, 1999, SCHMERZ, V13, P205, DOI 10.1007/s004820050200; *EUR COMM STAND, 1996, CENTC207WG1TG4 EUR C; GARFIN SR, 1981, PAIN, V10, P87, DOI 10.1016/0304-3959(81)90049-X; Hagino C, 1997, J CAN CHIROPR ASS, V41, P16; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jacobson BH, 2002, J MANIP PHYSIOL THER, V25, P88, DOI 10.1067/mmt.2002.121410; Kleinbaum D, 1988, APPL REGRESSION ANAL; Koul P A, 2000, J Assoc Physicians India, V48, P901; Kovacs FM, 2003, PAIN, V103, P259, DOI 10.1016/S0304-3959(02)00454-2; Kovacs FM, 2002, SPINE, V27, P538, DOI 10.1097/00007632-200203010-00016; Kovacs FM, 2002, SPINE, V27, P1149, DOI 10.1097/00007632-200206010-00004; Kovacs FM, 1997, SPINE, V22, P786, DOI 10.1097/00007632-199704010-00017; Lemeshow S., 1990, TITLE ADEQUACY SAMPL; Levy H, 1996, J South Orthop Assoc, V5, P185; Lings S, 2000, INT ARCH OCC ENV HEA, V73, P290, DOI 10.1007/s004200000118; Monsein M, 2000, MedGenMed, V2, pE36; Moses L., 1963, TABLES RANDOM PERMUT; Pocock SJ., 2013, CLIN TRIALS PRACTICA; POPE MH, 1991, ADULT SPINE PRINCIPL; PRONNETT S, 1983, MARATHON EQUILIBRE E; SANDSTROM J, 1986, SCAND J REHABIL MED, V18, P29; SCHMIDT AJM, 1985, J PSYCHOSOM RES, V29, P183, DOI 10.1016/0022-3999(85)90040-6; SCRIVER V, 1994, HEART LUNG, V23, P308; VANTULDER MW, 1996, LOW BACK PAIN PRIMAR; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B	30	54	59	4	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1599	1604		10.1016/S0140-6736(03)14792-7	http://dx.doi.org/10.1016/S0140-6736(03)14792-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630439				2022-12-28	WOS:000186637400007
J	Williams, BL				Williams, BL			A peek into the evolution of the sexual lifestyles of yeast	CELL			English	Editorial Material							CANDIDA-ALBICANS	Tsong et al. (2003; this issue of Cell) characterize the role of mating type genes in Candida, albicans and identify a new regulator of mating type and several mating type target genes. Comparison with Saccharomyces cerevisiae provides an in-depth view into the evolution of a well-characterized genetic regulatory circuit.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	Williams, BL (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.							Bennett RJ, 2003, EMBO J, V22, P2505, DOI 10.1093/emboj/cdg235; Carroll S.B., 2001, DNA DIVERSITY; Haag ES, 2002, CURR BIOL, V12, P2035, DOI 10.1016/S0960-9822(02)01333-7; Hull CM, 2000, SCIENCE, V289, P307, DOI 10.1126/science.289.5477.307; Hull CM, 1999, SCIENCE, V285, P1271, DOI 10.1126/science.285.5431.1271; Madhani HD, 1998, TRENDS CELL BIOL, V8, P348, DOI 10.1016/S0962-8924(98)01298-7; Tsong AE, 2003, CELL, V115, P389, DOI 10.1016/S0092-8674(03)00885-7	7	0	4	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					369	370		10.1016/S0092-8674(03)00891-2	http://dx.doi.org/10.1016/S0092-8674(03)00891-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622589	Bronze			2022-12-28	WOS:000186627100001
J	Boden, G; Hoeldtke, RD				Boden, G; Hoeldtke, RD			Nerves, fat, and insulin resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Temple Univ Hosp & Med Sch, Dept Med, Philadelphia, PA 19140 USA; W Virginia Univ, Morgantown, WV 26506 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; West Virginia University	Boden, G (corresponding author), Temple Univ Hosp & Med Sch, Dept Med, Philadelphia, PA 19140 USA.							Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kreier F, 2002, J CLIN INVEST, V110, P1243, DOI 10.1172/JCI200215736; PETERSON H R, 1988, New England Journal of Medicine, V318, P1077, DOI 10.1056/NEJM198804283181701	4	24	24	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1966	1967		10.1056/NEJMcibr035229	http://dx.doi.org/10.1056/NEJMcibr035229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614173				2022-12-28	WOS:000186502400015
J	Demokritov, SO; Serga, AA; Demidov, VE; Hillebrands, B; Kostylev, MP; Kalinikos, BA				Demokritov, SO; Serga, AA; Demidov, VE; Hillebrands, B; Kostylev, MP; Kalinikos, BA			Experimental observation of symmetry-breaking nonlinear modes in an active ring	NATURE			English	Article							MAGNETIC ENVELOPE SOLITONS; SELF-GENERATION; FILMS; TRAINS	Solitons are large-amplitude, spatially confined wave packets in nonlinear media. They occur in a wide range of physical systems, such as water surfaces, optical fibres, plasmas, Bose-Einstein condensates and magnetically ordered media(1,2). A distinguishing feature of soliton behaviour that is common to all systems, is that they propagate without a change in shape owing to the stabilizing effect of the particular nonlinearity involved(1,3). When the propagation path is closed, modes consisting of one or several solitons may rotate around the ring, the topology of which imposes additional constraints on their allowed frequencies and phases(4,5). Here we measure the mode spectrum of spin-wave solitons in a nonlinear active ring constructed from a magnetic ferrite film. Several unusual symmetry-breaking soliton-like modes are found, such as 'Mobius' solitons, which break the fundamental symmetry of 2pi-periodicity in the phase change acquired per loop: a Mobius soliton needs to travel twice around the ring to meet the initial phase condition.	Tech Univ Kaiserslautern, Fachbereich Phys, D-67663 Kaiserslautern, Germany; Tech Univ Kaiserslautern, Forsch Schwerpunkt MINAS, D-67663 Kaiserslautern, Germany; St Petersburg Electrotech Univ, St Petersburg 197376, Russia	University of Kaiserslautern; University of Kaiserslautern; Saint Petersburg State Electrotechnical University	Demokritov, SO (corresponding author), Tech Univ Kaiserslautern, Fachbereich Phys, Erwin Schrodinger Str 56, D-67663 Kaiserslautern, Germany.		Demokritov, Sergej O/C-4347-2013; Hillebrands, Burkard/C-6242-2008; Serga, Alexander A/J-4646-2017; Kostylev, Mikhail/H-5214-2014	Demokritov, Sergej O/0000-0003-4422-4201; Hillebrands, Burkard/0000-0001-8910-0355; Serga, Alexander A/0000-0003-2634-8569; Kalinikos, Boris/0000-0003-4968-1225; Kostylev, Mikhail/0000-0002-1631-2098				Agrawal G.P., 2006, NONLINEAR FIBER OPTI, V4th; Bagada AV, 1997, PHYS REV LETT, V79, P2137, DOI 10.1103/PhysRevLett.79.2137; Bauer M, 1998, PHYS REV LETT, V81, P3769, DOI 10.1103/PhysRevLett.81.3769; Carr LD, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.063610; Carr LD, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.063611; Kalinikos BA, 2000, PHYS REV LETT, V84, P4697, DOI 10.1103/PhysRevLett.84.4697; Kalinikos BA, 1998, PHYS REV LETT, V80, P4301, DOI 10.1103/PhysRevLett.80.4301; Kalinikos BA, 2002, JETP LETT+, V76, P253, DOI 10.1134/1.1520616; Khaykovich L, 2002, SCIENCE, V296, P1290, DOI 10.1126/science.1071021; KIVSHAR YS, 1989, REV MOD PHYS, V61, P763, DOI 10.1103/RevModPhys.61.763; Kolodin PA, 1998, PHYS REV LETT, V80, P1976, DOI 10.1103/PhysRevLett.80.1976; Li ZH, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.263901; Liu X, 1999, PHYS REV LETT, V82, P4631, DOI 10.1103/PhysRevLett.82.4631; Melkov GA, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.066607; Nash JM, 1998, J APPL PHYS, V83, P2689, DOI 10.1063/1.367033; Remoissenet M., 1994, WAVES CALLED SOLITON, DOI [10.1007/978-3-662-03057-8, DOI 10.1007/978-3-662-03057-8]; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507	17	90	91	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					159	162		10.1038/nature02042	http://dx.doi.org/10.1038/nature02042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614500				2022-12-28	WOS:000186517200037
J	Nathan, DG; Wilson, JD				Nathan, DG; Wilson, JD			Clinical research and the NIH - A report card	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACADEMIC HEALTH CENTERS; INSTITUTES-OF-HEALTH; MEDICAL-SCHOOLS; CHALLENGES; FUTURE		Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA	Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nathan, DG (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.							Campbell EG, 2001, JAMA-J AM MED ASSOC, V286, P800, DOI 10.1001/jama.286.7.800; Crowley WF, 1996, ACAD MED, V71, P1154, DOI 10.1097/00001888-199611000-00013; Gallin JI, 1997, JAMA-J AM MED ASSOC, V277, P651; Hirsch LJ, 2002, SCI ENG ETHICS, V8, P429, DOI 10.1007/s11948-002-0065-7; Ley TJ, 2002, NEW ENGL J MED, V346, P368, DOI 10.1056/NEJM200201313460515; Mark AL, 2001, J INVEST MED, V49, P486, DOI 10.2310/6650.2001.33624; Nathan DG, 2000, NAT MED, V6, P1201, DOI 10.1038/81282; Nathan DG, 2002, NEW ENGL J MED, V346, P372, DOI 10.1056/NEJM200201313460516; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; Nathan DG, 2002, NEW ENGL J MED, V347, P1368, DOI 10.1056/NEJMsb020394; Nathan DG, 2002, JAMA-J AM MED ASSOC, V287, P2424, DOI 10.1001/jama.287.18.2424; Oinonen MJ, 2001, ACAD MED, V76, P700, DOI 10.1097/00001888-200107000-00010; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; Schulman KA, 2002, NEW ENGL J MED, V347, P1335, DOI 10.1056/NEJMsa020349; Shulman LE, 1996, ACAD MED, V71, P362, DOI 10.1097/00001888-199604000-00013; SHULMAN LE, 1996, ACAD MED, V71, P398; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278	17	54	55	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1860	1865		10.1056/NEJMsb035066	http://dx.doi.org/10.1056/NEJMsb035066			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602885				2022-12-28	WOS:000186353800014
J	Sedkov, Y; Cho, E; Petruk, S; Cherbas, L; Smith, ST; Jones, RS; Cherbas, P; Canaani, E; Jaynes, JB; Mazo, A				Sedkov, Y; Cho, E; Petruk, S; Cherbas, L; Smith, ST; Jones, RS; Cherbas, P; Canaani, E; Jaynes, JB; Mazo, A			Methylation at lysine 4 of histone H3 in ecdysone-dependent development of Drosophila	NATURE			English	Article							MORPHOGENETIC FURROW MOVEMENT; POLARITY GENE HEDGEHOG; RETINOID-X-RECEPTOR; NUCLEAR RECEPTOR; ULTRASPIRACLE; PROTEIN; EYE; ECR; PROGRESSION; ENCODES	Steroid hormones fulfil important functions in animal development. In Drosophila, ecdysone triggers moulting and metamorphosis through its effects on gene expression(1). Ecdysone works by binding to a nuclear receptor, EcR, which heterodimerizes with the retinoid X receptor homologue Ultraspiracle(2,3). Both partners are required for binding to ligand or DNA(4-6). Like most DNA-binding transcription factors, nuclear receptors activate or repress gene expression by recruiting co-regulators, some of which function as chromatin-modifying complexes(7,8). For example, p160 class coactivators associate with histone acetyltransferases and arginine histone methyltransferases(9). The Trithorax-related gene of Drosophila encodes the SET domain protein TRR. Here we report that TRR is a histone methyltransferases capable of trimethylating lysine 4 of histone H3 (H3-K4). trr acts upstream of hedgehog (hh) in progression of the morphogenetic furrow, and is required for retinal differentiation. Mutations in trr interact in eye development with EcR, and EcR and TRR can be co-immunoprecipitated on ecdysone treatment. TRR, EcR and trimethylated H3-K4 are detected at the ecdysone-inducible promoters of hh and BR-C in cultured cells, and H3-K4 trimethylation at these promoters is decreased in embryos lacking a functional copy of trr. We propose that TRR functions as a coactivator of EcR by altering the chromatin structure at ecdysone-responsive promoters.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Jefferson University; Indiana University System; Indiana University Bloomington; Southern Methodist University; Weizmann Institute of Science	Mazo, A (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.			Jaynes, James/0000-0001-7943-794X	NIGMS NIH HHS [R01 GM050231-05A2, R01 GM050231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Brennan CA, 1998, DEVELOPMENT, V125, P2653; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chanut F, 2000, GENETICS, V156, P1203; Cherbas L, 2003, DEVELOPMENT, V130, P271, DOI 10.1242/dev.00205; Ghbeish N, 2002, MECH DEVELOP, V111, P89, DOI 10.1016/S0925-4773(01)00610-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hu X, 2003, MOL ENDOCRINOL, V17, P716, DOI 10.1210/me.2002-0287; Katsani KR, 2001, GENE DEV, V15, P2197, DOI 10.1101/gad.201901; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; RIDDIFORD LM, 1993, RECEPTOR, V3, P203; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sedkov Y, 1999, MECH DEVELOP, V82, P171, DOI 10.1016/S0925-4773(98)00246-9; SMITH ST, UNPUB NATURE CELL BI; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Treisman JE, 1997, GENE DEV, V11, P1949, DOI 10.1101/gad.11.15.1949; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Zelhof AC, 1997, DEVELOPMENT, V124, P2499	29	126	136	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					78	83		10.1038/nature02080	http://dx.doi.org/10.1038/nature02080			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603321	Green Accepted			2022-12-28	WOS:000186370800045
J	Orlova, M; Yueh, A; Leung, J; Goff, SP				Orlova, M; Yueh, A; Leung, J; Goff, SP			Reverse transcriptase of Moloney murine leukemia virus binds to eukarvotic release factor 1 to modulate suppression of translational termination	CELL			English	Article							STOP CODON RECOGNITION; PEPTIDYL-TRANSFER-RNA; POL FUSION PROTEIN; GENE AMBER CODON; MESSENGER-RNA; DNA-POLYMERASE; READ-THROUGH; FACTOR ERF1; PRECURSOR POLYPROTEINS; MUTATIONAL ANALYSIS	The pol (for polymerase) gene of the murine leukemia viruses (MuLVs) is expressed in the form of a large Gag-Pol precursor protein by the suppression of translational termination, or enhanced readthrough, of a UAG stop codon at the end of gag. A search for cellular proteins that interact with the reverse transcriptase of Moloney MuLV resulted in the identification of eRF1, the eukaryotic translation release factor 1. The proteins bound strongly in vitro, and the overexpression of eRF1 resulted in the RT-dependent incorporation of the protein into assembling virion particles. The overexpression of RT in trans enhanced the translational readthrough of a reporter construct containing the Gag-Pol boundary region. Noninteracting mutants of RT failed to synthesize adequate levels of Gag-Pol and could not replicate. These results suggest that RT enhances suppression of termination and that the interaction of RT with eRF1 is required for an appropriate level of translational readthrough.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Integrated Program Cell & Mol Biol, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Integrated Program Cell & Mol Biol, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	goff@cancercenter.columbia.edu	Goff, Stephen P/K-6337-2014; Yueh, Andrew/D-2079-2010	Goff, Stephen P/0000-0003-0693-5547; 	NATIONAL CANCER INSTITUTE [R37CA030488, R01CA030488] Funding Source: NIH RePORTER; NCI NIH HHS [CA30488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam SL, 1999, J MOL BIOL, V288, P837, DOI 10.1006/jmbi.1999.2713; Alderete JP, 2001, J VIROL, V75, P7188, DOI 10.1128/JVI.75.15.7188-7192.2001; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; Bacharach E, 2000, J VIROL, V74, P11027, DOI 10.1128/JVI.74.23.11027-11039.2000; BERTEAUX V, 1991, BIOCHIMIE, V73, P1291, DOI 10.1016/0300-9084(91)90091-E; Bertram G, 2000, RNA, V6, P1236, DOI 10.1017/S1355838200000777; BLAIN SW, 1993, J BIOL CHEM, V268, P23585; Carnes J, 2000, RNA, V6, P1468, DOI 10.1017/S1355838200001242; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; DINMAN JD, 1992, J VIROL, V66, P3669, DOI 10.1128/JVI.66.6.3669-3676.1992; Drugeon G, 1997, NUCLEIC ACIDS RES, V25, P2254, DOI 10.1093/nar/25.12.2254; FELSENSTEIN KM, 1988, J VIROL, V62, P2179, DOI 10.1128/JVI.62.6.2179-2182.1988; FELSENSTEIN KM, 1992, J VIROL, V66, P6601, DOI 10.1128/JVI.66.11.6601-6608.1992; FENG YX, 1989, J VIROL, V63, P2870, DOI 10.1128/JVI.63.6.2870-2873.1989; FENG YX, 1989, J VIROL, V63, P2405, DOI 10.1128/JVI.63.5.2405-2410.1989; FENG YX, 1992, J VIROL, V66, P5127, DOI 10.1128/JVI.66.8.5127-5132.1992; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; Grentzmann G, 1998, RNA, V4, P479; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HONIGMAN A, 1991, VIROLOGY, V183, P313, DOI 10.1016/0042-6822(91)90144-Z; Ito K, 1996, P NATL ACAD SCI USA, V93, P5443, DOI 10.1073/pnas.93.11.5443; JACKS T, 1990, CURR TOP MICROBIOL, V157, P93; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; JAMJOOM GA, 1977, VIROLOGY, V78, P11, DOI 10.1016/0042-6822(77)90075-7; Janzen DM, 2002, MOL CELL BIOL, V22, P8562, DOI 10.1128/MCB.22.24.8562-8570.2002; JONES DS, 1989, NUCLEIC ACIDS RES, V17, P5933, DOI 10.1093/nar/17.15.5933; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; KUCHINO Y, 1987, P NATL ACAD SCI USA, V84, P2668, DOI 10.1073/pnas.84.9.2668; LeGoff X, 1997, MOL CELL BIOL, V17, P3164, DOI 10.1128/MCB.17.6.3164; Leung DW, 1989, TECHNIQUE, V1, P11; Levin J. G., 1993, REVERSE TRANSCRIPTAS, P5; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MURPHY EC, 1978, VIROLOGY, V86, P329, DOI 10.1016/0042-6822(78)90074-0; MURPHY EC, 1978, J VIROL, V13, P359; PANET A, 1975, P NATL ACAD SCI USA, V72, P2535, DOI 10.1073/pnas.72.7.2535; PANET A, 1978, J VIROL, V26, P214, DOI 10.1128/JVI.26.2.214-220.1978; PANGANIBAN AT, 1988, J VIROL, V62, P3574, DOI 10.1128/JVI.62.10.3574-3580.1988; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; Shehu-Xhilaga M, 2001, J VIROL, V75, P1834, DOI 10.1128/JVI.75.4.1834-1841.2001; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Stansfield I, 1996, MOL MICROBIOL, V20, P1135, DOI 10.1111/j.1365-2958.1996.tb02634.x; Tachedjian G, 2000, P NATL ACAD SCI USA, V97, P6334, DOI 10.1073/pnas.97.12.6334; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; Telesnitsky A., 1997, P121; TENDAM EB, 1990, VIRUS GENES, V2, P121; Wang WR, 2001, EMBO J, V20, P880, DOI 10.1093/emboj/20.4.880; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618; YOSHINAKA Y, 1985, J VIROL, V55, P870, DOI 10.1128/JVI.55.3.870-873.1985; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	64	49	54	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					319	331		10.1016/S0092-8674(03)00805-5	http://dx.doi.org/10.1016/S0092-8674(03)00805-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636559	Bronze			2022-12-28	WOS:000186415000011
J	Ying, QL; Nichols, J; Chambers, I; Smith, A				Ying, QL; Nichols, J; Chambers, I; Smith, A			BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; SIGNAL-TRANSDUCTION; NEURAL FATE; ES CELLS; ACTIVATION; EXPRESSION; PATHWAY; NEUROGENESIS; RECEPTOR; LINE	The cytokine leukemia inhibitory factor (LIF) drives self-renewal of mouse embryonic stem (ES) cells by activating the transcription factor STAT3. In serum-free cultures, however, LIF is insufficient to block neural differentiation and maintain pluripotency. Here, we report that bone morphogenetic proteins (BMPs) act in combination with LIF to sustain self-renewal and preserve multilineage differentiation, chimera colonization, and germline transmission properties. ES cells can be propagated from single cells and derived de novo without serum or feeders using LIF plus BMP. The critical contribution of BMP is to induce expression of Id genes via the Smad pathway. Forced expression of Id liberates ES cells from BMP or serum dependence and allows self-renewal in LIF alone. Upon LIF withdrawal, Id-expressing ES cells differentiate but do not give rise to neural lineages. We conclude that blockade of lineage-specific transcription factors by Id proteins enables the self-renewal response to LIF/STAT3.	Univ Edinburgh, Inst Stem Cell Res, Edinburgh EH9 3JQ, Midlothian, Scotland	University of Edinburgh	Ying, QL (corresponding author), Univ Edinburgh, Inst Stem Cell Res, Kings Bldg,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.	qilong.ying@ed.ac.uk; austin.smith@ed.ac.uk		Smith, Austin/0000-0002-3029-4682; Chambers, Ian/0000-0003-2605-1597; Nichols, Jennifer/0000-0002-8650-1388				Adelman CA, 2002, DEVELOPMENT, V129, P539; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Baonza A, 2000, DEVELOPMENT, V127, P2383; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Buehr M, 2003, PHILOS T R SOC B, V358, P1397, DOI 10.1098/rstb.2003.1327; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Burdon T, 1999, CELLS TISSUES ORGANS, V165, P131, DOI 10.1159/000016693; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Harland R, 2000, CURR OPIN GENET DEV, V10, P357, DOI 10.1016/S0959-437X(00)00096-4; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nakashima K, 1997, FEBS LETT, V401, P49, DOI 10.1016/S0014-5793(96)01430-5; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Nichols J, 2001, DEVELOPMENT, V128, P2333; Nishinakamura R, 1999, DEV BIOL, V216, P481, DOI 10.1006/dbio.1999.9518; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Norton JD, 2000, J CELL SCI, V113, P3897; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smith A, 2001, COLD SPRING HARBOR M, P205; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUDA Y, 1987, J CELL PHYSIOL, V133, P197, DOI 10.1002/jcp.1041330127; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Wiles MV, 1999, EXP CELL RES, V247, P241, DOI 10.1006/excr.1998.4353; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wilson SI, 2001, NAT NEUROSCI, V4, P1161, DOI 10.1038/nn747; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Ying QL, 2003, METHOD ENZYMOL, V365, P327	62	1579	1747	4	159	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					281	292		10.1016/S0092-8674(03)00847-X	http://dx.doi.org/10.1016/S0092-8674(03)00847-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636556	Bronze			2022-12-28	WOS:000186415000008
J	Donnelly, CA; Woodroffe, R; Cox, DR; Bourne, J; Gettinby, G; Le Fevre, AM; McInerney, JP; Morrison, WI				Donnelly, CA; Woodroffe, R; Cox, DR; Bourne, J; Gettinby, G; Le Fevre, AM; McInerney, JP; Morrison, WI			Impact of localized badger culling on tuberculosis incidence in British cattle	NATURE			English	Article							MELES-MELES; POPULATION; MOVEMENT	Pathogens that are transmitted between wildlife, livestock and humans present major challenges for the protection of human and animal health, the economic sustainability of agriculture, and the conservation of wildlife. Mycobacterium bovis, the aetiological agent of bovine tuberculosis ( TB), is one such pathogen. The incidence of TB in cattle has increased substantially in parts of Great Britain in the past two decades, adversely affecting the livelihoods of cattle farmers and potentially increasing the risks of human exposure. The control of bovine TB in Great Britain is complicated by the involvement of wildlife, particularly badgers (Meles meles), which appear to sustain endemic infection and can transmit TB to cattle(1). Between 1975 and 1997 over 20,000 badgers were culled as part of British TB control policy, generating conflict between conservation and farming interest groups(2). Here we present results from a large-scale field trial(3-5) that indicate that localized badger culling not only fails to control but also seems to increase TB incidence in cattle.	Independent Sci Grp Cattle TB, Dept Environm, Food & Rural Affairs, London SW1P 4PQ, England; Univ London Imperial Coll Sci & Technol, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England; Univ Calif Davis, Dept Wildlife Fish & Conservat Biol, Davis, CA 95616 USA; Univ Oxford Nuffield Coll, Oxford OX1 1NF, England; Univ Strathclyde, Dept Stat & Modelling Sci, Glasgow G1 1XH, Lanark, Scotland; Univ Exeter, Ctr Rural Res, Exeter EX4 6TL, Devon, England; Univ Edinburgh, Royal Dick Sch Vet Studies, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland	Imperial College London; University of California System; University of California Davis; University of Oxford; University of Strathclyde; University of Exeter; University of Edinburgh	Donnelly, CA (corresponding author), Independent Sci Grp Cattle TB, Dept Environm, Food & Rural Affairs, 1A Page St, London SW1P 4PQ, England.		Rehman, Andrea/AAP-3172-2020; Rehman, Andrea M/H-1351-2015	Rehman, Andrea/0000-0001-9967-5822; Rehman, Andrea M/0000-0001-9967-5822; Donnelly, Christl/0000-0002-0195-2463				BOURNE J, 1998, 1 IND SCI GROUP CATT; BOURNE J, 2001, 3 IND SCI GROUP CATT; BOURNE J, 1999, 2 IND SCI GROUP CATT; CHEESEMAN CL, 1988, MAMMAL REV, V18, P51, DOI 10.1111/j.1365-2907.1988.tb00071.x; CRESSWELL WJ, 2001, REPORT INDEPENDENT A; DONCASTER CP, 1993, OIKOS, V66, P88, DOI 10.2307/3545199; Eves JA, 1999, IRISH VET J, V52, P199; EWBANK R, 2003, REPORT 2 INDEPENDENT; GRIFFIN JM, 1996, SELECTED PAPERS, P6; HARDIE RM, 1992, EPIDEMIOL INFECT, V109, P23; HOPKINS FG, 1934, COMMITTEE CATTLE DIS; KING EJ, 1999, ADV VERTEBRATE PEST, P147; KIRKWOOD JK, 2000, REPORT INDEPENDENT A; KREBS J, 1997, PB3423; Krebs JR, 1998, SCIENCE, V279, P817, DOI 10.1126/science.279.5352.817; LEFEVRE AM, 2003, CHANGES BADGER SETTS; MOLLISON D, 2000, TB CATTLE 1 REPORT S; Rogers LM, 1998, P ROY SOC B-BIOL SCI, V265, P1269, DOI 10.1098/rspb.1998.0429; ROPER TJ, 1993, Z SAUGETIERKD, V58, P252; Tuyttens FAM, 2000, J ANIM ECOL, V69, P567, DOI 10.1046/j.1365-2656.2000.00419.x; Woodroffe R, 1999, J APPL ECOL, V36, P494, DOI 10.1046/j.1365-2664.1999.00418.x	21	218	226	1	217	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 18	2003	426	6968					834	837		10.1038/nature02192	http://dx.doi.org/10.1038/nature02192			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	754QM	14634671	Green Published			2022-12-28	WOS:000187342000057
J	Krause, AE; Frank, KA; Mason, DM; Ulanowicz, RE; Taylor, WW				Krause, AE; Frank, KA; Mason, DM; Ulanowicz, RE; Taylor, WW			Compartments revealed in food-web structure	NATURE			English	Article							STABILITY; DIVERSITY; ECOLOGY	Compartments(1) in food webs are subgroups of taxa in which many strong interactions occur within the subgroups and few weak interactions occur between the subgroups(2). Theoretically, compartments increase the stability in networks(1-5), such as food webs. Compartments have been difficult to detect in empirical food webs because of incompatible approaches(6-9) or insufficient methodological rigour(8,10,11). Here we show that a method for detecting compartments from the social networking science(12-14) identified significant compartments in three of five complex, empirical food webs. Detection of compartments was influenced by food web resolution, such as interactions with weights. Because the method identifies compartmental boundaries in which interactions are concentrated, it is compatible with the definition of compartments. The method is rigorous because it maximizes an explicit function, identifies the number of non-overlapping compartments, assigns membership to compartments, and tests the statistical significance of the results(12-14). A graphical presentation(14) reveals systemic relationships and taxa-specific positions as structured by compartments. From this graphic, we explore two scenarios of disturbance to develop a hypothesis for testing how compartmentalized interactions increase stability in food webs(15-17).	Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA; Michigan State Univ, Dept Educ Psychol Counseling & Special Educ, E Lansing, MI 48824 USA; NOAA, Great Lakes Environm Res Lab, Ann Arbor, MI 48105 USA; Univ Maryland, Chesapeake Biol Lab, Solomons, MD 20688 USA	Michigan State University; Michigan State University; National Oceanic Atmospheric Admin (NOAA) - USA; University System of Maryland; University of Maryland Center for Environmental Science	Krause, AE (corresponding author), Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA.	krausean@msu.edu	Ulanowicz, Robert E/G-1021-2013; Krause, Ann/GRT-0163-2022; Mason, Doran/ABF-1415-2020	frank, kenneth/0000-0002-6116-5509; Mason, Doran/0000-0002-6017-4243				Abarca-Arenas LG, 2002, ECOL MODEL, V149, P285, DOI 10.1016/S0304-3800(01)00474-4; Blau P.M., 1977, INEQUALITY HETEROGEN; Dicks LV, 2002, J ANIM ECOL, V71, P32, DOI 10.1046/j.0021-8790.2001.00572.x; Dunne JA, 2002, ECOL LETT, V5, P558, DOI 10.1046/j.1461-0248.2002.00354.x; Frank KA, 1996, SOC NETWORKS, V18, P93, DOI 10.1016/0378-8733(95)00257-X; FRANK KA, 1995, SOC NETWORKS, V17, P27, DOI 10.1016/0378-8733(94)00247-8; Frank KA, 1998, AM J SOCIOL, V104, P642, DOI 10.1086/210083; Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799; GOLDWASSER L, 1993, ECOLOGY, V74, P1216, DOI 10.2307/1940492; Grimm Volker, 1996, Senckenbergiana Maritima, V27, P215; Huxham M, 1996, OIKOS, V76, P284, DOI 10.2307/3546201; Johnson JC, 2001, J SOC STRUCTURE; MARTINEZ ND, 1991, ECOL MONOGR, V61, P367, DOI 10.2307/2937047; May R.M., 1973, STABILITY COMPLEXITY; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; McMahon SM, 2001, SCIENCE, V293, P1604, DOI 10.1126/science.1062026; MCNAUGHTON SJ, 1978, NATURE, V274, P251, DOI 10.1038/274251a0; MOORE JC, 1988, NATURE, V333, P261, DOI 10.1038/333261a0; Neutel AM, 2002, SCIENCE, V296, P1120, DOI 10.1126/science.1068326; PIMM SL, 1979, THEOR POPUL BIOL, V16, P144, DOI 10.1016/0040-5809(79)90010-8; PIMM SL, 1980, J ANIM ECOL, V49, P879, DOI 10.2307/4233; POLIS GA, 1991, AM NAT, V138, P123, DOI 10.1086/285208; RAFFAELLI D, 1992, J ANIM ECOL, V61, P551, DOI 10.2307/5610; Raffaelli D, 2002, SCIENCE, V296, P1035, DOI 10.1126/science.1072080; Simmel G., 1955, CONFLICT WEB GROUP A; SIMON HA, 1965, GEN SYST, V10, P63; Ulanowicz RE, 1999, J MARINE SYST, V19, P159, DOI 10.1016/S0924-7963(98)90017-3; Williams RJ, 2000, NATURE, V404, P180, DOI 10.1038/35004572; Wolff KH., 1950, SOCIOLOGY G SIMMEL; YODIZ P, 1982, AM NAT, V120, P551	30	511	523	2	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					282	285		10.1038/nature02115	http://dx.doi.org/10.1038/nature02115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628050	Green Published			2022-12-28	WOS:000186660800042
J	McCrea, M; Guskiewicz, KM; Marshall, SW; Barr, W; Randolph, C; Cantu, RC; Onate, JA; Yang, JZ; Kelly, JP				McCrea, M; Guskiewicz, KM; Marshall, SW; Barr, W; Randolph, C; Cantu, RC; Onate, JA; Yang, JZ; Kelly, JP			Acute effects and recovery time following concussion in collegiate football players - The NCAA Concussion Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; LONGITUDINAL DATA-ANALYSIS; STANDARDIZED ASSESSMENT; POSTURAL STABILITY; AUSTRALIAN RULES; SPORTS; DEFICITS; SEVERITY	Context Lack of empirical data on recovery time following sport-related concussion hampers clinical decision making about return to play after injury. Objective To prospectively measure immediate effects and natural recovery course relating to symptoms, cognitive functioning, and postural stability following sport-related concussion. Design, Setting, and Participants Prospective cohort study of 1631 football players from 15 US colleges. All players underwent preseason baseline testing on concussion assessment measures in 1999, 2000, and 2001. Ninety-four players with concussion (based on American Academy of Neurology criteria) and 56 noninjured controls underwent assessment of symptoms, cognitive functioning, and postural stability immediately, 3 hours, and 1, 2, 3, 5, 7, and 90 days after injury. Main Outcome Measures Scores on the Graded Symptom Checklist (GSC), Standardized Assessment of Concussion (SAC), Balance Error Scoring System (BESS), and a neuropsychological test battery. Results No player with concussion was excluded from participation; 79 players with concussion (84%) completed the protocol through day 90. Players with concussion exhibited more severe symptoms (mean GSC score 20.93 [95% confidence interval (CI), 15.65-26.21] points higher than that of controls), cognitive impairment (mean SAC score 2.94 [95% CI, 1.50-4.38] points lower than that of controls), and balance problems (mean BESS score 5.81 [95% CI, -0.67 to 12.30] points higher than that of controls) immediately after concussion. On average, symptoms gradually resolved by day 7 (GSC mean difference, 0.33; 95% CI, -1.41 to 2.06), cognitive functioning improved to baseline levels within 5 to 7 days (day 7 SAC mean difference, -0.03; 95% CI, -1.33 to 1.26), and balance deficits dissipated within 3 to 5 days after injury (day 5 BESS mean difference, -0.31; 95% CI, -3.02 to 2.40). Mild impairments in cognitive processing and verbal memory evident on neuropsychological testing 2 days after concussion resolved by day 7. There were no significant differences in symptoms or functional impairments in the concussion and control groups 90 days after concussion. Conclusions Collegiate football players may require several days for recovery of symptoms, cognitive dysfunction, and postural instability after concussion. Further research is required to determine factors that predict variability in recovery time after concussion. Standardized measurement of postconcussive symptoms, cognitive functioning, and postural stability may enhance clinical management of athletes recovering from concussion.	Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; NYU, Sch Med, Dept Neurol, New York, NY USA; Northwestern Univ, Feonberg Sch Med, Chicago Neurol Inst, Chicago, IL 60611 USA; Northwestern Univ, Feonberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; Loyola Univ, Sch Med, Dept Neurol, Maywood, IL 60153 USA; Emerson Hosp, Neurosurg Serv, Concord, MA USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Athlet Training Program, Dept Rehabil Sci, Boston, MA 02215 USA	Medical College of Wisconsin; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; New York University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Loyola University Chicago; Boston University	McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.	michael.mccrea@phci.org	Yang, Jingzhen/N-4786-2014; Onate, James/E-3790-2011	Barr, William/0000-0001-7711-7758; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Benton AL, 1983, MULTILINGUAL APHASIA; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Colorado Medical Society, 1991, REP SPORTS MED COMM; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; DICK R, 2003, NATL COLL ATHLETIC A; DIGGLE PJ, 1994, ANAL LONGITUDINAL DA, pCH11; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golden J.C., 1978, STROOP COLOR WORD TE; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead WC, 1985, HALSTEADREITAN NEURO; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MCCREA M, 2003, J INT NEUROPSYCH SOC, V9, P206; MCCREA M, IN PRESS CLIN J SPOR; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith A., 1991, SYMBOL DIGIT MODALIT; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vastag B, 2002, JAMA-J AM MED ASSOC, V287, P437, DOI 10.1001/jama.287.4.437; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	58	1033	1038	2	207	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2556	2563		10.1001/jama.290.19.2556	http://dx.doi.org/10.1001/jama.290.19.2556			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744DQ	14625332				2022-12-28	WOS:000186613000025
J	Hase, M; Kitajima, M; Constantinescu, AM; Petek, H				Hase, M; Kitajima, M; Constantinescu, AM; Petek, H			The birth of a quasiparticle in silicon observed in time-frequency space	NATURE			English	Article							RAMAN-SCATTERING; TEMPERATURE-DEPENDENCE; LIGHT-SCATTERING; CRITICAL-POINTS; FREE-CARRIERS; SI; SEMICONDUCTORS; INTERFERENCE; ELECTRON; BAND	The concept of quasiparticles in solid-state physics is an extremely powerful tool for describing complex many-body phenomena in terms of single-particle excitations(1). Introducing a simple particle, such as an electron, hole or phonon, deforms a manybody system through its interactions with other particles. In this way, the added particle is 'dressed' or 'renormalized' by a self-energy cloud that describes the response of the many-body system, so forming a new entity - the quasiparticle. Using ultrafast laser techniques, it is possible to impulsively generate bare particles and observe their subsequent dressing by the many-body interactions ( that is, quasiparticle formation) on the time and energy scales governed by the Heisenberg uncertainty principle(2). Here we describe the coherent response of silicon to excitation with a 10-femtosecond (10(-14) s) laser pulse. The optical pulse interacts with the sample by way of the complex second-order nonlinear susceptibility to generate a force on the lattice driving coherent phonon excitation. Transforming the transient reflectivity signal into frequency - time space reveals interference effects leading to the coherent phonon generation and subsequent dressing of the phonon by electron - hole pair excitations.	Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA; Natl Inst Mat Sci, Mat Engn Lab, Tsukuba, Ibaraki 3050047, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institute for Materials Science	Petek, H (corresponding author), Univ Pittsburgh, Dept Phys & Astron, Pittsburgh, PA 15260 USA.		Hase, Muneaki/A-9486-2009; Petek, Hrvoje/A-3912-2009	Hase, Muneaki/0000-0003-4242-2546; Petek, Hrvoje/0000-0001-9605-2590				BAIRAMOV BH, 1993, PHYS REP, V229, P221, DOI 10.1016/0370-1573(93)90090-Z; BALKANSKI M, 1975, PHYS REV B, V12, P4328, DOI 10.1103/PhysRevB.12.4328; Belitsky VI, 1997, J PHYS-CONDENS MAT, V9, P5965, DOI 10.1088/0953-8984/9/27/022; BIGOT JY, 1991, PHYS REV LETT, V67, P636, DOI 10.1103/PhysRevLett.67.636; BUHLEIER R, 1994, PHYS REV B, V50, P2425, DOI 10.1103/PhysRevB.50.2425; Caumes JP, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.047401; CERDEIRA F, 1973, PHYS REV B, V8, P4734, DOI 10.1103/PhysRevB.8.4734; CERDEIRA F, 1972, PHYS REV B, V5, P1440, DOI 10.1103/PhysRevB.5.1440; CHANDRASEKHAR M, 1980, PHYS REV B, V22, P761, DOI 10.1103/PhysRevB.22.761; CONTRERAS G, 1985, PHYS REV B, V32, P924, DOI 10.1103/PhysRevB.32.924; DOWNER MC, 1986, PHYS REV LETT, V56, P761, DOI 10.1103/PhysRevLett.56.761; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; Fischer B, 2000, APPL PHYS LETT, V76, P583, DOI 10.1063/1.125824; GOLDMAN JR, 1994, PHYS REV LETT, V72, P1364, DOI 10.1103/PhysRevLett.72.1364; Huber R, 2001, NATURE, V414, P286, DOI 10.1038/35104522; Johnston MB, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165301; KANEHISA MA, 1982, PHYS REV B, V25, P7619, DOI 10.1103/PhysRevB.25.7619; KHURGIN JB, 1994, J OPT SOC AM B, V11, P2492, DOI 10.1364/JOSAB.11.002492; LAUTENSCHLAGER P, 1987, PHYS REV B, V36, P4821, DOI 10.1103/PhysRevB.36.4821; LAUTENSCHLAGER P, 1986, PHYS REV B, V33, P5501, DOI 10.1103/PhysRevB.33.5501; PFEIFER T, 1992, APPL PHYS A-MATER, V55, P482, DOI 10.1007/BF00348337; Pines D., 1966, THEORY QUANTUM LIQUI; Sabbah AJ, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.165217; SAETA PN, 1993, APPL PHYS LETT, V63, P3482, DOI 10.1063/1.110127; SCHOLZ R, 1993, PHYS REV B, V47, P16229, DOI 10.1103/PhysRevB.47.16229; SIPE JE, 1987, PHYS REV B, V35, P9091, DOI 10.1103/PhysRevB.35.9091; Sjodin T, 1998, PHYS REV LETT, V81, P5664, DOI 10.1103/PhysRevLett.81.5664; Stevens TE, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.144304; WOLFF PA, 1968, PHYS REV, V171, P436, DOI 10.1103/PhysRev.171.436	29	180	181	3	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					51	54		10.1038/nature02044	http://dx.doi.org/10.1038/nature02044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603313	Green Submitted			2022-12-28	WOS:000186370800037
J	Makkar, HS; Frieden, IJ				Makkar, HS; Frieden, IJ			Transillumination of a cystic lymphatic malformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Makkar, HS (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.			Frieden, Ilona/0000-0001-7305-5940					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					E18	E18		10.1056/ENEJMicm020574	http://dx.doi.org/10.1056/ENEJMicm020574			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602894				2022-12-28	WOS:000186353800010
J	Sandidge, JS				Sandidge, JS			Arachnology - Scavenging by brown recluse spiders	NATURE			English	Editorial Material							ARANEAE		Univ Kansas, Dept Ecol & Evolutionary Biol, Lawrence, KS 66045 USA	University of Kansas	Sandidge, JS (corresponding author), Univ Kansas, Dept Ecol & Evolutionary Biol, Lawrence, KS 66045 USA.							ATKINS JA, 1958, AM J TROP MED HYG, V7, P165, DOI 10.4269/ajtmh.1958.7.165; Gertsch W. J., 1983, B AM MUS NAT HIST, V175, P264; HITE JM, 1966, U ARKANSAS AGR EXP S, V711, P1; JACKSON RR, 1982, J ZOOL, V196, P255; KNOST SJ, 1975, AM MIDL NAT, V93, P239, DOI 10.2307/2424125; POLLARD SD, 1993, NAT HIST, V102, P58; SMITH RB, 1984, SCIENCE, V226, P1330, DOI 10.1126/science.226.4680.1330; VERTER R, 2002, J MED ENTOMOL, V39, P948	8	35	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					30	30		10.1038/426030a	http://dx.doi.org/10.1038/426030a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603305				2022-12-28	WOS:000186370800029
J	Lipkowitz, E				Lipkowitz, E			The physicians' dilemma in the 18th-century French smallpox debate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Northwestern Univ, Evanston, IL 60201 USA	Northwestern University	Lipkowitz, E (corresponding author), Northwestern Univ, Evanston, IL 60201 USA.							BERNOULLI D, 1766, MEMOIRES ACAD ROYALE, P29; BRADLEY L, 1971, SMALLPOX INOCULATION, P6; DELACOMDAMINE C, 1764, LETT M CONDAMINE M M, P51; DELACONDAMINE C, 1768, HIST ACAD ROYALE SCI, P517; DENTRECOLLES P, 1763, J MED CHIR PHARMACOL, V16, P387; GATTI A, 1767, NOUVELLES REFLEXIONS, P160; HOPKINS DR, 2002, GREATEST KILLER SMAL, P81; MILLER G, 1957, ADOPTION INOCULATION, P235; PETIT A, 1766, LUS FM PARIS IMPRIME; POINSINET A, 1756, INOCULATION POEME MO, P1; Rusnock Andrea A., 2002, VITAL ACCOUNTS QUANT, P43	11	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2329	2330		10.1001/jama.290.17.2329	http://dx.doi.org/10.1001/jama.290.17.2329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600196				2022-12-28	WOS:000186356800032
J	Lee, A; Ackerman, MJ				Lee, A; Ackerman, MJ			Sudden unexplained death: evaluation of those left behind	LANCET			English	Editorial Material							LONG-QT SYNDROME; MOLECULAR DIAGNOSIS; YOUNG; SCN5A		Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Cardiol, Rochester, MN 55905 USA; Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Ackerman, MJ (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Cardiol, Rochester, MN 55905 USA.							Ackerman MJ, 1999, NEW ENGL J MED, V341, P1121, DOI 10.1056/NEJM199910073411504; Ackerman MJ, 2001, AM J FOREN MED PATH, V22, P105, DOI 10.1097/00000433-200106000-00001; Ackerman MJ, 2001, JAMA-J AM MED ASSOC, V286, P2264, DOI 10.1001/jama.286.18.2264; Ackerman MJ, 1999, MAYO CLIN PROC, V74, P1088, DOI 10.4065/74.11.1088; Davies MJ, 1999, HISTOPATHOLOGY, V34, P93; DRISCOLL DJ, 1985, J AM COLL CARDIOL, V5, P118; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Moss AJ, 1999, AM J CARDIOL, V84, P876, DOI 10.1016/S0002-9149(99)00458-0; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; Schwartz PJ, 2001, LANCET, V358, P1342, DOI 10.1016/S0140-6736(01)06450-9; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178	13	11	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1429	1431		10.1016/S0140-6736(03)14726-5	http://dx.doi.org/10.1016/S0140-6736(03)14726-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602432				2022-12-28	WOS:000186356600004
J	Singleton, AB; Farrer, M; Johnson, J; Singleton, A; Hague, S; Kachergus, J; Hulihan, M; Peuralinna, T; Dutra, A; Nussbaum, R; Lincoln, S; Crawley, A; Hanson, M; Maraganore, D; Adler, C; Cookson, MR; Muenter, M; Baptista, M; Miller, D; Blancato, J; Hardy, J; Gwinn-Hardy, K				Singleton, AB; Farrer, M; Johnson, J; Singleton, A; Hague, S; Kachergus, J; Hulihan, M; Peuralinna, T; Dutra, A; Nussbaum, R; Lincoln, S; Crawley, A; Hanson, M; Maraganore, D; Adler, C; Cookson, MR; Muenter, M; Baptista, M; Miller, D; Blancato, J; Hardy, J; Gwinn-Hardy, K			alpha-synuclein locus triplication causes Parkinson's disease	SCIENCE			English	Article									NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Mayo Clin, Genet Neurodgenerat Lab, Jacksonville, FL 32224 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin, Dept Neurol, Scottsdale, AZ 85259 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Georgetown University	Singleton, AB (corresponding author), NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.		Resource Center, NINDS Human Genetics/AGF-2474-2022; Sander-Effron, Samuel/AAX-2231-2020; Singleton, Andrew B/C-3010-2009; Cookson, Mark/AAW-2516-2021; Johnson, Janel/A-7136-2010; Hardy, John/C-2451-2009; Gwinn, Katrina A/C-2508-2009	Cookson, Mark/0000-0002-1058-3831; Hardy, John/0000-0002-3122-0423; Gwinn, Katrina/0000-0002-8277-651X; Farrer, Matthew/0000-0003-1159-5321	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002974, ZIANS002974, Z01NS003006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000957, ZIAAG000953, ZIAAG000957, Z01AG000953] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Muenter MD, 1998, ANN NEUROL, V43, P768, DOI 10.1002/ana.410430612; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324	5	3209	3296	5	291	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					841	841		10.1126/science.1090278	http://dx.doi.org/10.1126/science.1090278			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593171	Green Submitted			2022-12-28	WOS:000186258000041
J	Tekkis, PP; Poloniecki, JD; Thompson, MR; Stamatakis, JD				Tekkis, PP; Poloniecki, JD; Thompson, MR; Stamatakis, JD		Assoc Coloproctology Great Britain	Operative mortality in colorectal cancer: prospective national study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURGICAL CARE; RISK; PERFORMANCE; RATES; SURGEONS; QUALITY; POSSUM	Objective To develop a mathematical model that will predict the probability of death after surgery for colorectal cancer. Design Descriptive study using routinely collected clinical data. Data source The database of the Association of Coloproctology of Great Britain and Ireland (ACPGBI), encompassing 8077 patients with a new diagnosis of colorectal cancer in 73 hospitals during a 12 month period. Statistical analysis A three level hierarchical logistic regression model was used to identify independent predictors of operative mortality. The model was developed on 60% of the patient population and its validity tested on the remaining 40%. Results Overall postoperative mortality was 7.5% (95% confidence interval 6.9% to 8.1%). Independent predictors of death were age, American Society of Anesthesiology (ASA) grade, Dukes's stage, urgency of the operation, and cancer excision. When tested the predictive model showed good discrimination (area under the receiver operating characteristic curve = (0.775) and calibration (comparison of observed with expected mortality across different procedures; Hosmer-Lemeshow statistic = 6.34, 8 df, P = 0.610). Conclusions Clinicians can predict postoperative death by using a simple numerical table derived from the statistical model of the ACPGBI. The model can be used in everyday practice for preoperative counselling of patients and their carers as a part of multidisciplinary care. It may also be used to compare the outcomes between multidisciplinary teams for colorectal cancer.	Prince Wales Hosp, Dept Surg, Bridgend CF31 1RQ, Wales; St Marks Hosp, Dept Surg, Harrow HA1 3UJ, Middx, England; Univ London St Georges Hosp, Dept Publ Hlth Sci, London SW17 0WT, England; Queen Alexandra Hosp, Dept Surg, Portsmouth, Hants, England	Imperial College London; St Georges University London; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Stamatakis, JD (corresponding author), Prince Wales Hosp, Dept Surg, Bridgend CF31 1RQ, Wales.	jeff.stamatakis@bromor-tr.wales.nhs.uk						Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; Callum KG.AppendixA, 2000, NOW 2000 REPORT NATL, P125; Copeland G P, 1992, J R Coll Surg Edinb, V37, P145; COPELAND GP, 1991, BRIT J SURG, V78, P356; Daley J, 2001, ANNU REV MED, V52, P275, DOI 10.1146/annurev.med.52.1.275; Department of Health, HOSP EP STAT; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P149, DOI 10.2307/2983475; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Holm T, 1997, BRIT J SURG, V84, P657, DOI 10.1046/j.1365-2168.1997.02745.x; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006; Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(01)00938-3; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; Sagar PM, 1996, DIS COLON RECTUM, V39, P654, DOI 10.1007/BF02056945; Spiegelhalter DJ, 2002, J R STAT SOC A STAT, V165, P191, DOI 10.1111/1467-985X.02021; Tekkis PP, 2000, DIS COLON RECTUM, V43, P1528, DOI 10.1007/BF02236732; Treasure T, 2002, THORAX, V57, P3, DOI 10.1136/thorax.57.1.3; TURNBULL RB, 1967, ANN SURG, V166, P420	20	195	202	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	2003	327	7425					1196	1199		10.1136/bmj.327.7425.1196	http://dx.doi.org/10.1136/bmj.327.7425.1196			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630754	Bronze, Green Published			2022-12-28	WOS:000186784300017
J	Colao, A; Di Sarno, A; Cappabianca, P; Di Somma, C; Pivonello, R; Lombardi, G				Colao, A; Di Sarno, A; Cappabianca, P; Di Somma, C; Pivonello, R; Lombardi, G			Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROLACTIN-SECRETING MACROADENOMAS; DOPAMINE AGONIST CABERGOLINE; FOLLOW-UP; MACROPROLACTINOMA SHRINKAGE; BROMOCRIPTINE TREATMENT; MEDICAL-TREATMENT; NATURAL-HISTORY; DRUG-WITHDRAWAL; PITUITARY-TUMOR; AMENORRHEA	Background: Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has been unclear. We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients. Methods: The study population included 200 patients -- 25 patients with nontumoral hyperprolactinemia, 105 with microprolactinomas, and 70 with macroprolactinomas. Withdrawal of cabergoline was considered if prolactin levels were normal, magnetic resonance imaging (MRI) showed no tumor (or tumor reduction of 50 percent or more, with the tumor at a distance of more than 5 mm from the optic chiasm, and no invasion of the cavernous sinuses or other critical areas), and if follow-up after withdrawal could be continued for at least 24 months. Results: Recurrence rates two to five years after the withdrawal of cabergoline were 24 percent in patients with nontumoral hyperprolactinemia, 31 percent in patients with microprolactinomas, and 36 percent in patients; with macroprolactinomas. Renewed tumor growth did not occur in any patient; in 10 female patients (22 percent) and 7 male patients (39 percent) with recurrent hyperprolactinemia, gonadal dysfunction redeveloped. In all diagnostic groups, prolactin levels at the time of recurrence were significantly lower than at diagnosis (P<0.001). The Kaplan-Meier estimated rate of recurrence at five years was higher among patients with macroprolactinomas and those with microprolactinomas who had small remnant tumors visible on MRI at the time of treatment withdrawal than among patients whose MRI scans showed no evidence of tumor at the time of withdrawal (patients with macroprolactinomas, 78 percent vs. 33 percent, P=0.001; patients with microprolactinomas, 42 percent vs. 26 percent, P=0.02). Conclusions: Cabergoline can be safely withdrawn in patients with normalized prolactin levels and no evidence of tumor. However, because the length of follow-up in our study was insufficient to rule out a delayed increase in the size of the tumor, we suggest that patients be closely monitored, particularly those with macroprolactinomas, in whom renewed growth of the tumor may compromise vision.	Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Endocrinol Sect, I-80131 Naples, Italy; Univ Naples Federico II, Dept Neurol Sci, Neurosurg Sect, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Colao, A (corresponding author), Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Endocrinol Sect, Via S Pansini 5, I-80131 Naples, Italy.		Di Somma, Carolina/K-7772-2016	Di Somma, Carolina/0000-0002-5724-1951; CAPPABIANCA, Paolo/0000-0001-8277-498X				BERGH T, 1982, CLIN ENDOCRINOL, V16, P587, DOI 10.1111/j.1365-2265.1982.tb03175.x; BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220; BEVAN JS, 1987, CLIN ENDOCRINOL, V26, P541, DOI 10.1111/j.1365-2265.1987.tb00809.x; Biller BMK, 1996, J CLIN ENDOCR METAB, V81, P2338, DOI 10.1210/jc.81.6.2338; Cannavo S, 1999, J ENDOCRINOL INVEST, V22, P354, DOI 10.1007/BF03343573; Colao A, 1997, J CLIN ENDOCR METAB, V82, P3574, DOI 10.1210/jc.82.11.3574; Colao A, 1998, LANCET, V352, P1455, DOI 10.1016/S0140-6736(98)03356-X; Colao A, 2003, EUR J ENDOCRINOL, V148, P325, DOI 10.1530/eje.0.1480325; Colao A, 2000, J CLIN ENDOCR METAB, V85, P2247, DOI 10.1210/jc.85.6.2247; Colao A, 1997, J CLIN ENDOCR METAB, V82, P876, DOI 10.1210/jc.82.3.876; CROSIGNANI PG, 1992, EUR J OBSTET GYN R B, V44, P175, DOI 10.1016/0028-2243(92)90094-F; CUNNAH D, 1991, CLIN ENDOCRINOL, V34, P231, DOI 10.1111/j.1365-2265.1991.tb00299.x; Delgrange E, 1996, EUR J ENDOCRINOL, V134, P454, DOI 10.1530/eje.0.1340454; Di Sarno A, 2000, CLIN ENDOCRINOL, V53, P53, DOI 10.1046/j.1365-2265.2000.01016.x; Di Sarno A, 2001, J CLIN ENDOCR METAB, V86, P5256, DOI 10.1210/jc.86.11.5256; FERRARI C, 1992, ACTA ENDOCRINOL-COP, V126, P489, DOI 10.1530/acta.0.1260489; Ferrari CI, 1997, CLIN ENDOCRINOL, V46, P409, DOI 10.1046/j.1365-2265.1997.1300952.x; GEN M, 1984, J CLIN ENDOCR METAB, V59, P463, DOI 10.1210/jcem-59-3-463; Jeffcoate WJ, 1996, CLIN ENDOCRINOL, V45, P299, DOI 10.1046/j.1365-2265.1996.00824.x; JOHNSTON DG, 1984, LANCET, V2, P187; Karunakaran S, 2001, CLIN ENDOCRINOL, V54, P295, DOI 10.1046/j.1365-2265.2001.01190.x; KOPPELMAN MCS, 1984, ANN INTERN MED, V100, P115, DOI 10.7326/0003-4819-100-1-115; Losa M, 2002, J CLIN ENDOCR METAB, V87, P3180, DOI 10.1210/jc.87.7.3180; MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698; Molitch ME, 1999, ENDOCRIN METAB CLIN, V28, P143, DOI 10.1016/S0889-8529(05)70061-X; Molitch ME, 1997, J CLIN ENDOCR METAB, V82, P996, DOI 10.1210/jc.82.4.996; MORIONDO P, 1985, J CLIN ENDOCR METAB, V60, P764, DOI 10.1210/jcem-60-4-764; Muratori M, 1997, J ENDOCRINOL INVEST, V20, P537, DOI 10.1007/BF03348016; Orrego J J, 2000, Pituitary, V3, P189, DOI 10.1023/A:1011412028660; PARKES D, 1980, NEW ENGL J MED, V302, P749; Passos VQ, 2002, J CLIN ENDOCR METAB, V87, P3578, DOI 10.1210/jc.87.8.3578; Pinzone JJ, 2000, J CLIN ENDOCR METAB, V85, P3053, DOI 10.1210/jc.85.9.3053; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; SCHLECHTE JA, 1986, J CLIN ENDOCR METAB, V62, P1296, DOI 10.1210/jcem-62-6-1296; SISAM DA, 1987, FERTIL STERIL, V48, P67; THORNER MO, 1981, J CLIN ENDOCR METAB, V53, P480, DOI 10.1210/jcem-53-3-480; VANCE ML, 1984, ANN INTERN MED, V100, P78, DOI 10.7326/0003-4819-100-1-78; VANTVERLAAT JW, 1991, CLIN ENDOCRINOL, V34, P175, DOI 10.1111/j.1365-2265.1991.tb00289.x; Verhelst J, 1999, J CLIN ENDOCR METAB, V84, P2518, DOI 10.1210/jc.84.7.2518; WANG C, 1987, CLIN ENDOCRINOL, V27, P363, DOI 10.1111/j.1365-2265.1987.tb01163.x; WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403; WINKELMANN W, 1985, PROLACTIN BASIC CLIN, P817; ZARATE A, 1983, ACTA ENDOCRINOL-COP, V104, P139, DOI 10.1530/acta.0.1040139	43	198	211	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2023	2033		10.1056/NEJMoa022657	http://dx.doi.org/10.1056/NEJMoa022657			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627787				2022-12-28	WOS:000186642900006
J	Wada, S; Oishi, M; Yamada, TK				Wada, S; Oishi, M; Yamada, TK			A newly discovered species of living baleen whale	NATURE			English	Article							MITOCHONDRIAL-DNA; FIN WHALE; SEQUENCES; REGION	In the late 1970s eight Balaenoptera specimens of unknown identity were caught in the lower latitudinal Indo-Pacific waters by Japanese research whaling vessels(1). The combination of the allozyme patterns and physical maturity of the eight specimens separated them from all acknowledged Balaenoptera species(2). In September 1998 we collected a medium-sized baleen whale carcass on a coastal island in the Sea of Japan. This specimen and the previously collected eight specimens resembled Balaenoptera physalus (fin whale) in external appearance but were much smaller. Comparison of external morphology, osteology and mitochondrial DNA data grouped the nine specimens as a single species but separated them from all known baleen whale species. Therefore, here we describe a new species of Balaenoptera, which is characterized by its unique cranial morphology, its small number of baleen plates, and by its distant molecular relationships with all of its congeners. Our analyses also separated Balaenoptera brydei (Bryde's whale)(3,4) and Balaenoptera edeni (Eden's whale)(5) into two distinct species, raising the number of known living Balaenoptera species to eight.	Natl Res Inst Fisheries Sci, Fisheries Res Agcy, Kanazawa Ku, Yokohama, Kanagawa 2368648, Japan; Iwate Prefectural Museum, Morioka, Iwate 0200102, Japan; Museum Nat Sci, Shinjuku Ku, Tokyo 1690073, Japan	Japan Fisheries Research & Education Agency (FRA)	Wada, S (corresponding author), Natl Res Inst Fisheries Sci, Fisheries Res Agcy, Kanazawa Ku, 2-12-4 Fukuura, Yokohama, Kanagawa 2368648, Japan.		Yamada, Tadasu K./C-3362-2008					ANDERSON J, 1978, ANATOMICAL ZOOLOGICA, V1, P551; Andrews R. C., 1918, Records of the Indian Museum, V15; ARNASON U, 1993, J MOL EVOL, V37, P312; ARNASON U, 1993, MOL BIOL EVOL, V10, P960; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; Arnold P., 1987, SCI REP WHALES RES I, V38, P1; BEST PB, 1985, SCI REP WHALES RES, V36, P1; BEST PB, 1977, REPORTS INT WHALING, V1, P10; HOELZEL AR, 1991, MOL BIOL EVOL, V8, P475; Junge G. C. A., 1950, Zool Verh Leiden 1950, VNo. 9, P1; Kato H., 2002, ENCY MARINE MAMMALS, P171; Kumar S., 1993, MEGA MOL EVOLUTIONAR; LeDuc Richard G., 2002, P100; LONNBERG EINAR, 1931, ARK ZOOL, V23B, P1; Mackintosh N. A., 1929, Discovery Reports Cambridge, V1, P257; MATTHEWS L. HARRISON, 1938, DISCOVERY REPTS [GOVT DEPENDENCIES FALKLAND ISLANDS], V17, P183; Ohsumi S., 1980, REPORT INT WHALING C, V30, P319; OLSEN O, 1913, P ZOOL SOC LOND, P1073; Omura H., 1981, SCI REP WHALES RES, V33, P1; OMURA H, 1966, WHALES DOLPHINS PORP, P70; Pilleri G., 1974, INVEST CETACEA, VV, P95; RICE DW, 1998, MAR MAMMAL SCI, V4, P67; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Soot-Eyen T., 1961, Norsk Hvalfangsttidende Sandefjord, V50, P323; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUE FW, 1904, SMITHSONIAN CONTRIBU, V33, P1; WADA S, 1991, REPORTS INT WHALING, V13, P125	27	135	168	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					278	281		10.1038/nature02103	http://dx.doi.org/10.1038/nature02103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628049				2022-12-28	WOS:000186660800041
J	Abrams, EJ; Kuhn, L				Abrams, EJ; Kuhn, L			Should treatment be started among all HIV-infected children and then stopped?	LANCET			English	Editorial Material							DISEASE PROGRESSION; TRANSMISSION; PREVENTION; INFANTS; LOAD		Columbia Univ, New York, NY 10027 USA	Columbia University	Abrams, EJ (corresponding author), Columbia Univ, New York, NY 10027 USA.	eja1@columbia.edu						Abrams EJ, 1998, J INFECT DIS, V178, P101, DOI 10.1086/515596; Abrams EJ, 2003, AIDS, V17, P867, DOI 10.1097/00002030-200304110-00012; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; Luzuriaga K, 2000, J VIROL, V74, P6984, DOI 10.1128/JVI.74.15.6984-6991.2000; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Scott ZA, 2001, J IMMUNOL, V167, P7134, DOI 10.4049/jimmunol.167.12.7134; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; Taha T E, 2000, Pediatrics, V106, pE77, DOI 10.1542/peds.106.6.e77; Thorne C, 2002, J ACQ IMMUN DEF SYND, V29, P396, DOI 10.1097/00126334-200204010-00011; Tremblay CL, 2003, AIDS, V17, P1086, DOI 10.1097/00002030-200305020-00021; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006; *WORK GROUP ANT TH, 2003, GUID US ANT AG PED H; World Health Organization, 2002, SCAL ANT THER RES LT	17	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1595	1596		10.1016/S0140-6736(03)14837-4	http://dx.doi.org/10.1016/S0140-6736(03)14837-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630435				2022-12-28	WOS:000186637400003
J	Claster, S; Vichinsky, EP				Claster, S; Vichinsky, EP			Managing sickle cell disease	BRITISH MEDICAL JOURNAL			English	Review							ACUTE CHEST SYNDROME; PENICILLIN PROPHYLAXIS; PAINFUL CRISES; CHILDREN; ANEMIA; IMPACT; ABNORMALITIES; HYDROXYUREA; TRANSFUSION; PREVENTION	Advances are being made in the management of sickle cell disease for all age groups. This review discusses the progress in amelioration of symptoms, problems unique to particular age groups, and the types of drugs and treatments currently under investigation.	Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA; Childrens Hosp & Res Ctr Oakland, Dept Hematol & Oncol, Oakland, CA 94609 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Vichinsky, EP (corresponding author), Childrens Hosp & Res Ctr Oakland, Dept Hematol & Oncol, 747 52nd St, Oakland, CA 94609 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				Abbott KC, 2002, CLIN NEPHROL, V58, P9; Adams RJ, 1998, CONTROL CLIN TRIALS, V19, P110, DOI 10.1016/S0197-2456(97)00099-8; Ataga KI, 2000, AM J HEMATOL, V63, P205, DOI 10.1002/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.3.CO;2-#; Ballas SK, 2001, AM J HEMATOL, V68, P127, DOI 10.1002/ajh.1164; Benjamin LJ, 2000, BLOOD, V95, P1130, DOI 10.1182/blood.V95.4.1130.003k03a_1130_1136; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; CASATRO OL, 2002, BLOOD, V3, P3; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Dean D, 2003, J PEDIAT HEMATOL ONC, V25, P46, DOI 10.1097/00043426-200301000-00010; FALLETTA JM, 1995, J PEDIATR-US, V127, P685, DOI 10.1016/S0022-3476(95)70154-0; Hagar R W, 2000, Adv Pediatr, V47, P249; Hord J, 2002, J PEDIAT HEMATOL ONC, V24, P470, DOI 10.1097/00043426-200208000-00012; Lane PA, 2002, PEDIATRICS, V109, P526; Miller GG, 2001, TOOLS, V39, P385; Miller ST, 2000, NEW ENGL J MED, V342, P1612; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; MORRIS CR, 2000, BLOOD 1 S, V6, pA485; Moser FG, 1996, AM J NEURORADIOL, V17, P965; *NIH, 022117 NIH; OHENEFREMPONG K, 1991, SEMIN HEMATOL, V28, P213; Okpala I, 2002, BRIT J HAEMATOL, V118, P918, DOI 10.1046/j.1365-2141.2002.03691.x; Olivieri NF, 1998, J PEDIAT HEMATOL ONC, V20, P26, DOI 10.1097/00043426-199801000-00004; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; SCHMALZER EA, 1987, TRANSFUSION, V27, P228, DOI 10.1046/j.1537-2995.1987.27387235626.x; Smith JA, 1996, OBSTET GYNECOL, V87, P199, DOI 10.1016/0029-7844(95)00367-3; Stuart MJ, 2001, CURR OPIN HEMATOL, V8, P111, DOI 10.1097/00062752-200103000-00009; STYLES LA, 1994, J PEDIATR-US, V125, P909, DOI 10.1016/S0022-3476(05)82006-2; Styles LA, 1996, AM J HEMATOL, V52, P103, DOI 10.1002/(SICI)1096-8652(199606)52:2<103::AID-AJH6>3.3.CO;2-K; Vichinsky E, 2002, LANCET, V360, P629, DOI 10.1016/S0140-6736(02)09776-3; VICHINSKY E, 1988, PEDIATRICS, V81, P749; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; VICHINSKY EP, 1991, SEMIN HEMATOL, V28, P220; Vichinsky EP, 1997, BLOOD, V89, P1787, DOI 10.1182/blood.V89.5.1787.1787_1787_1792; Vichinsky EP, 2001, SEMIN HEMATOL, V38, P14, DOI 10.1053/shem.2001.20140; Walters MC, 2000, BLOOD, V95, P1918; YOUNG NS, 2001, SEMIN HEMATOL, P435	36	101	105	1	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1151	1155		10.1136/bmj.327.7424.1151	http://dx.doi.org/10.1136/bmj.327.7424.1151			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615343	Green Published			2022-12-28	WOS:000186622100024
J	Feldmann, J; Callebaut, I; Raposo, G; Certain, S; Bacq, D; Dumont, C; Lambert, N; Ouachee-Chardin, M; Chedeville, G; Tamary, H; Minard-Colin, V; Vilmer, E; Blanche, S; Le Deist, F; Fischer, A; Saint Basile, GD				Feldmann, J; Callebaut, I; Raposo, G; Certain, S; Bacq, D; Dumont, C; Lambert, N; Ouachee-Chardin, M; Chedeville, G; Tamary, H; Minard-Colin, V; Vilmer, E; Blanche, S; Le Deist, F; Fischer, A; Saint Basile, GD			Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3)	CELL			English	Article							CHEDIAK-HIGASHI-SYNDROME; MEMBRANE-FUSION; CRYSTAL-STRUCTURE; LYMPHOCYTES-T; DOMAIN; EXOCYTOSIS; UNC-13; CELLS; PROTEINS; SYNTAXIN	Secretion of cytolytic granules content at the immunological synapse is a highly regulated process essential for lymphocyte cytotoxicity. This process requires the rapid transfer of perforin containing lytic granules to the target cell interface, followed by their docking and fusion with the plasma membrane. Defective cytotoxicity characterizes a genetically heterogeneous condition named familial hemophagocytic lymphohistiocytosis (FHL), which can be associated with perforin deficiency. The locus of a perforin (+) FHL subtype (FHL3), observed in 10 patients, was mapped to 17q25. This region contains hMunc13-4, a member of the Munc13 family of proteins involved in vesicle priming function. HMunc13-4 mutations were shown to cause FHL3. HMunc13-4 deficiency results in defective cytolytic granule exocytosis, despite polarization of the secretory granules and docking with the plasma membrane. Expressed tagged hMunc13-4 localizes with cytotoxic granules at the immunological synapse. HMunc13-4 is therefore essential for the priming step of cytolytic granules secretion preceding vesicle membrane fusion.	Hop Necker Enfants Malad, INSERM U429, F-75743 Paris, France; Univ Paris 06, CNRS UMR7590, LMCP, F-75005 Paris, France; Univ Paris 07, CNRS UMR7590, LMCP, F-75005 Paris, France; Inst Curie, CNRS UMR 144, Paris, France; Ctr Natl Genotypage, F-91057 Evry, France; Hop Necker Enfants Malad, Unite Immunol Hematol, F-75015 Paris, France; Schneiders Children Med Ctr, Pediat Hematol Unit, IL-49202 Petah Tiqwa, Israel; Hop Robert Debre, Unite Immunohematol, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Saint Basile, GD (corresponding author), Hop Necker Enfants Malad, INSERM U429, F-75743 Paris, France.		; de Saint Basile, Genevieve/G-9731-2017	Raposo, graca/0000-0001-9590-1298; DOGNIAUX, Stephanie/0000-0003-3309-1204; de Saint Basile, Genevieve/0000-0002-1913-5269				Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; BAETZ K, 1995, J IMMUNOL, V154, P6122; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1997, J BIOL CHEM, V272, P2520; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; de Saint Basile G, 2001, CURR OPIN IMMUNOL, V13, P549, DOI 10.1016/S0952-7915(00)00257-0; Dufourcq-Lagelouse R, 1999, AM J HUM GENET, V64, P172, DOI 10.1086/302194; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; FORTIER AH, 1989, CELL IMMUNOL, V124, P64, DOI 10.1016/0008-8749(89)90112-3; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROTHSTEIN TL, 1978, J IMMUNOL, V121, P1652; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sassa T, 1999, J NEUROSCI, V19, P4772; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V251, P158, DOI 10.1006/bbrc.1998.9408; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; Ubach J, 1999, NAT CELL BIOL, V1, P106, DOI 10.1038/10076; Vyas YM, 2002, IMMUNOL REV, V189, P161, DOI 10.1034/j.1600-065X.2002.18914.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	50	657	690	1	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					461	473		10.1016/S0092-8674(03)00855-9	http://dx.doi.org/10.1016/S0092-8674(03)00855-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622600	Bronze			2022-12-28	WOS:000186627100012
J	Gstaiger, M; Luke, B; Hess, D; Oakeley, EJ; Wirbelauer, C; Blondel, M; Vigneron, M; Peter, M; Krek, W				Gstaiger, M; Luke, B; Hess, D; Oakeley, EJ; Wirbelauer, C; Blondel, M; Vigneron, M; Peter, M; Krek, W			Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CYTOSOLIC CHAPERONIN; UNFOLDED PROTEINS; AMINO-ACID; YEAST; EXPRESSION; STARVATION; CELLS; TOR; P45(SKP2)	Prefoldins (PFDs) are members of a recently identified, small-molecular weight protein family able to assemble into molecular chaperone complexes. Here we describe an unusually large member of this family, termed URI, that forms complexes with other small-molecular weight PFDs and with RPB5, a shared subunit of all three RNA polymerases. Functional analysis of the yeast and human orthologs of URI revealed that both are targets of nutrient signaling and participate in gene expression controlled by the TOR kinase. Thus, URI is a component of a signaling pathway that coordinates nutrient availability with gene expression.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR 7100, F-67412 Illkirch Graffenstaden, France	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Krek, W (corresponding author), ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.		Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Peter, Matthias/0000-0002-2160-6824; Luke, Brian/0000-0002-1648-5511				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; LUKE BT, UNPUB; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; WIRBELAUER C, UNPUB; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	25	135	143	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1208	1212		10.1126/science.1088401	http://dx.doi.org/10.1126/science.1088401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615539				2022-12-28	WOS:000186544300054
J	Koechlin, E; Ody, C; Kouneiher, F				Koechlin, E; Ody, C; Kouneiher, F			The architecture of cognitive control in the human prefrontal cortex	SCIENCE			English	Article							WORKING-MEMORY; MAINTENANCE; MECHANISMS; BEHAVIOR; MOTOR; FMRI	The prefrontal cortex (PFC) subserves cognitive control: the ability to coordinate thoughts or actions in relation with internal goals. Its functional architecture, however, remains poorly understood. Using brain imaging in humans, we showed that the lateral PFC is organized as a cascade of executive processes from premotor to anterior PFC regions that control behavior according to stimuli, the present perceptual context, and the temporal episode in which stimuli occur, respectively. The results support an unified modular model of cognitive control that describes the overall functional organization of the human lateral PFC and has basic methodological and theoretical implications.	Univ Paris 06, INSERM, F-75005 Paris, France; Hop La Pitie Salpetriere, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Koechlin, E (corresponding author), Univ Paris 06, INSERM, 9 Quai St Bernard, F-75005 Paris, France.	koechlin@ccr.jussieu.fr	Koechlin, Etienne/E-5061-2016; Koechlin, Etienne/AAF-5717-2021	Koechlin, Etienne/0000-0002-6514-9311; Koechlin, Etienne/0000-0002-6514-9311				Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; BERLYNE DE, 1957, PSYCHOL REV, V64, P329, DOI 10.1037/h0041135; Buckner RL, 1998, P NATL ACAD SCI USA, V95, P891, DOI 10.1073/pnas.95.3.891; Christoff K, 2001, NEUROIMAGE, V14, P1136, DOI 10.1006/nimg.2001.0922; Dove A, 2000, COGNITIVE BRAIN RES, V9, P103, DOI 10.1016/S0926-6410(99)00029-4; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fechner G. T., 1860, ELEMENTE PSYCHOPHYSI; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Friston K. J., 1993, Human Brain Mapping, V1, P69, DOI 10.1002/hbm.460010108; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Fuster J.M., 1989, PREFRONTAL CORTEX; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Koechlin E, 2000, P NATL ACAD SCI USA, V97, P7651, DOI 10.1073/pnas.130177397; Koechlin E, 2002, NEURON, V35, P371, DOI 10.1016/S0896-6273(02)00742-0; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; McIntosh A. R., 1994, Human Brain Mapping, V2, P2; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Nagahama Y, 2001, CEREB CORTEX, V11, P85, DOI 10.1093/cercor/11.1.85; Norwich KH, 1997, PERCEPT PSYCHOPHYS, V59, P929, DOI 10.3758/BF03205509; Pandya DN, 1996, RES PER NEUROSCI, P13; Passingham R. E., 1993, OXFORD PSYCHOL SERIE; Rowe JB, 2000, SCIENCE, V288, P1656, DOI 10.1126/science.288.5471.1656; Sakai K, 2003, NAT NEUROSCI, V6, P75, DOI 10.1038/nn987; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; Veltman DJ, 2003, NEUROIMAGE, V18, P247, DOI 10.1016/S1053-8119(02)00049-6; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033	30	1181	1187	2	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1181	1185		10.1126/science.1088545	http://dx.doi.org/10.1126/science.1088545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615530				2022-12-28	WOS:000186544300045
J	Malissen, B				Malissen, B			Switching off TCR signaling	SCIENCE			English	Editorial Material							CIN85; CD2; CMS		Ctr Immunol Marseille Luminy, CNRS, INSERM, Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Malissen, B (corresponding author), Ctr Immunol Marseille Luminy, CNRS, INSERM, Marseille 9, France.		Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342				Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; LEE KH, 2003, SCIENCE         0925; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; Trautmann A, 2003, CURR OPIN IMMUNOL, V15, P249, DOI 10.1016/S0952-7915(03)00040-2	9	5	6	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1162	1163		10.1126/science.1092675	http://dx.doi.org/10.1126/science.1092675			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615524				2022-12-28	WOS:000186544300038
J	Zhang, B; Ginsburg, D				Zhang, B; Ginsburg, D			Getting secretory granules ready for prime time	CELL			English	Editorial Material								Several rare human diseases have shed important light on the secretory pathway required for lymphocyte cytotoxicity. In this issue of Cell, Feldmann et al. identify mutations in Munc13-4 as a cause of familial hemophagocytic lymphohistiocytosis. Munc13-4 appears to be involved in the priming of cytotoxic granules prior to fusion with the plasma membrane.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zhang, B (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Zhang, Bin/B-8102-2012					Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799	7	3	3	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					372	373		10.1016/S0092-8674(03)00894-8	http://dx.doi.org/10.1016/S0092-8674(03)00894-8			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622591	Bronze			2022-12-28	WOS:000186627100003
J	Prigerson, HG				Prigerson, HG			Costs to society of family caregiving for patients with end-stage Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Dept Psychiat, New Haven, CT 06520 USA	Yale University	Prigerson, HG (corresponding author), Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.		Prigerson, Holly/L-3800-2019; Prigerson, Holly/GWV-3283-2022	Prigerson, Holly/0000-0002-7075-4268; 				CHISHOLM D, 2001, INT J METH PSYCH RES, V10, P59, DOI DOI 10.1002/MPR.101	1	40	41	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1891	1892		10.1056/NEJMp038157	http://dx.doi.org/10.1056/NEJMp038157			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614164				2022-12-28	WOS:000186502400003
J	Block, BM; Liu, SS; Rowlingson, AJ; Cowan, AR; Cowan, JA; Wu, CL				Block, BM; Liu, SS; Rowlingson, AJ; Cowan, AR; Cowan, JA; Wu, CL			Efficacy of postoperative epidural analgesia - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PATIENT-CONTROLLED ANALGESIA; CONTROLLED OPIOID ANALGESIA; PAIN OUTCOME MEASURES; REGIONAL ANESTHESIA; RANDOMIZED-TRIALS; PROSPECTIVE EXPERIENCE; MORPHINE ANALGESIA; SURGICAL-PATIENTS; CLINICAL-TRIALS; AORTIC-SURGERY	Context Whether epidural analgesia is a better method than parenteral opioids for postoperative pain control remains controversial. Objective To systematically review the efficacy of postoperative epidural analgesia vs parenteral opioids, the primary alternative technique. Data Sources Studies were identified primarily by searching the National Library of Medicine's PubMed database (1966 to April 25, 2002) and other sources for studies related to postoperative epidural analgesia. Study Selection Inclusion criteria were a comparison of epidural therapy vs parenteral opioids for postoperative analgesia, measurement of pain using a visual analog scale (VAS) or numeric rating scale, randomization of patients to either therapy, and adult patients (greater than or equal to18 years). A total of 1404 abstracts were identified, 100 of which met all inclusion criteria. Data Extraction Each article was reviewed and data extracted from tables, text, or extrapolated from figures as needed. Weighted mean pain scores, weighted mean differences in pain score, and weighted incidences of complications were determined by using a fixed-effect model. Data Synthesis Epidural analgesia provided better postoperative analgesia compared with parenteral opioids (mean [SE], 19,40 mm [0.17] vs 29.40 mm [0.20] on the VAS; P<.001). When analyzed by postoperative day, epidural analgesia was better than parenteral opioids on each postoperative day (P<.001 for each day after surgery). For all types of surgery and pain assessments, all forms of epidural analgesia provided significantly better postoperative analgesia compared with parenteral opioid analgesia (P<.001 for all), with the exception of thoracic epidural analgesia vs opioids for rest pain after thoracic surgery (weighted mean difference, 0.6 mm; 95% confidence interval, -0.3 to 1.5 mm; P = .12). The complication rates were lower than expected for nausea or vomiting and pruritus but comparable with existing data for lower extremity motor block. Conclusion Epidural analgesia, regardless of analgesic agent, location of catheter placement, and type and time of pain assessment, provided better postoperative analgesia compared with parenteral opioids.	Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Univ Washington, Virginia Mason Med Ctr, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA	Johns Hopkins University; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wu, CL (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Carnegie 280,600 N Wolfe St, Baltimore, MD 21287 USA.			Wu, Christopher/0000-0002-4484-0787				Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Barratt SM, 2002, REGION ANESTH PAIN M, V27, P15, DOI 10.1053/rapm.2002.27850; Basse L, 2002, BRIT J SURG, V89, P446, DOI 10.1046/j.0007-1323.2001.02044.x; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Bois S, 1997, ANESTH ANALG, V85, P1233, DOI 10.1097/00000539-199712000-00010; Boylan JF, 1998, ANESTHESIOLOGY, V89, P585, DOI 10.1097/00000542-199809000-00006; Brodner G, 2000, EUR J ANAESTH, V17, P566, DOI 10.1046/j.1365-2346.2000.00738.x; Brodner G, 2001, ANESTH ANALG, V92, P1594, DOI 10.1097/00000539-200106000-00049; Bucklin BA, 2002, REGION ANESTH PAIN M, V27, P23, DOI 10.1053/rapm.2002.29111; CADE L, 1993, ANAESTH INTENS CARE, V21, P696, DOI 10.1177/0310057X9302100537; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Carr DB, 2001, EUR J PAIN, V5, P91, DOI 10.1053/eujp.2001.0288; Cassady JF, 2000, REGION ANESTH PAIN M, V25, P246; Correll DJ, 2001, REGION ANESTH PAIN M, V26, P444, DOI 10.1053/rapm.2001.26219; DELEONCASASOLA OA, 1994, ANESTHESIOLOGY, V81, P368, DOI 10.1097/00000542-199408000-00015; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Horlocker TT, 2003, REGION ANESTH PAIN M, V28, P172, DOI 10.1053/rapm.2003.50046; Horlocker TT, 1998, REGION ANESTH PAIN M, V23, P129, DOI 10.1016/S1098-7339(98)90137-7; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Kahn L, 1999, CAN J ANAESTH, V46, P415, DOI 10.1007/BF03012939; Kampe S, 2001, ANAESTHESIA, V56, P1189; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Kopacz DJ, 1999, ANESTH ANALG, V89, P1497, DOI 10.1097/00000539-199912000-00034; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Nakata K, 2002, J CLIN ANESTH, V14, P121, DOI 10.1016/S0952-8180(01)00366-X; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; ROSENTHAL R, 1991, PSYCHOSOM MED, V53, P247, DOI 10.1097/00006842-199105000-00001; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; WHITE MJ, 1992, CAN J ANAESTH, V39, P576, DOI 10.1007/BF03008321; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x; Wu CL, 2000, ANESTH ANALG, V91, P1232, DOI 10.1097/00000539-200011000-00035; Wu CL, 2001, REGION ANESTH PAIN M, V26, P196, DOI 10.1053/rapm.2001.22257	52	613	665	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2455	2463		10.1001/jama.290.18.2455	http://dx.doi.org/10.1001/jama.290.18.2455			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612482				2022-12-28	WOS:000186518300032
J	Meldrum, ML				Meldrum, ML			A capsule history of pain management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC TENSION HEADACHE; DOUBLE-BLIND; ELECTRICAL-STIMULATION; MORPHINE; RECEPTOR; AMITRIPTYLINE; ANALGESIA; EFFICACY; RELIEF	Pain is a complex clinical problem. Assessment depends on verbal report, and the patient's physical perceptions may be modified by cognitive and affective factors. The salience of pain as a problem in its own right has grown since 1945 and new therapeutic alternatives have developed from research and from new theoretical perspectives. This short historical review of the highlights of the history of pain management gives particular emphasis to the 20th century and to chronic and cancer pain.	Univ Calif Los Angeles, Dept Hist, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Meldrum, ML (corresponding author), Univ Calif Los Angeles, Dept Hist, 6265 Bunche Hall,Box 951473, Los Angeles, CA 90095 USA.			Meldrum, Marcia/0000-0003-0130-9299				ACKER CJ, 2001, CREATING AM JUNKIE A; AKIL H, 1972, CR ACAD SCI D NAT, V274, P3603; [Anonymous], [No title captured]; Baszanger I., 1998, INVENTING PAIN MED L; Beecher H. K., 1959, MEASUREMENT SUBJECTI; BEECHER HK, 1946, ANN SURG, V123, P96, DOI 10.1097/00000658-194601000-00008; Bonica JJ, 1953, MANAGEMENT PAIN SPEC; Cervetti Nancy, 2003, AM PAIN SOC B, V13, P7; CERVETTI NS, 2003, AM PAIN SOC B, V13, P19; Clark D, 1999, SOC SCI MED, V49, P727, DOI 10.1016/S0277-9536(99)00098-2; DIAMOND S, 1971, HEADACHE, V11, P110, DOI 10.1111/j.1526-4610.1971.hed1103110.x; Dray A, 1996, ANNU REV PHARMACOL, V36, P253; EDDY NB, 1973, SCIENCE, V181, P407, DOI 10.1126/science.181.4098.407; FIELDS HL, 1981, ANN NEUROL, V9, P101, DOI 10.1002/ana.410090202; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; FORDYCE WE, 1973, ARCH PHYS MED REHAB, V54, P399; GRACELY RH, 1992, PAIN, V51, P175, DOI 10.1016/0304-3959(92)90259-E; Hodgkiss Andrew., 2000, LESION METAPHOR CHRO; Horsley V, 1891, Br Med J, V2, P1191; Horsley V, 1891, Br Med J, V2, P1249; Horsley V, 1891, Br Med J, V2, P1139; HOUDE RW, 1979, P S PAIN ADV CANC, P263; HOWARD-JONES N, 1947, J Hist Med Allied Sci, V2, P201; HUGHES J, 1975, BRAIN RES, V88, P295, DOI 10.1016/0006-8993(75)90391-1; Jackson Jean., 2000, CAMP PAIN TALKING CH; Kerr Norman Shanks, 1894, INEBRIETY NARCOMANIA, V3rd; LANCE JW, 1964, LANCET, V1, P1236; Lee Harper, 2005, KILL MOCKINGBIRD; LEE R, 1977, J INT MED RES, V5, P146; Leriche R., 1939, SURG PAIN; Liebeskind JC, 1997, PROG PAIN RES MANAG, V8, P19; Livingston WK, 1998, PAIN AND SUFFERING; LOESER JD, 1975, J NEUROSURG, V42, P308, DOI 10.3171/jns.1975.42.3.0308; Mann CC, 1991, ASPIRIN WARS MONEY M; MAYER DJ, 1971, SCIENCE, V174, P1351, DOI 10.1126/science.174.4016.1351; MCTAVISH JR, 1987, B HIST MED, V61, P343; Meldrum MarciaL., 2003, OPIOIDS PAIN RELIEF; MELDRUM ML, 1999, AM PAIN SOC B, V9, P3; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MEYER GA, 1972, BRAIN, V95, P163, DOI 10.1093/brain/95.1.163; Mitchell S. Weir, 1872, INJURIES NERVES THEI; MODELL W, 1958, JAMA-J AM MED ASSOC, V167, P2190, DOI 10.1001/jama.1958.72990350005006; Morris D. B., 1991, CULTURE PAIN; Morris DB, 1998, CLIN J PAIN, V14, P191, DOI 10.1097/00002508-199809000-00004; Noordenbos W., 1959, PAIN; Pernick, 1985, CALCULUS SUFFERING P; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; Portenoy RK, 2000, J PAIN SYMPTOM MANAG, V19, pS16; Rey R., 1993, HIST PAIN; Rovenstine EA, 1941, J AMER MED ASSOC, V117, P1599, DOI 10.1001/jama.1941.02820450023006; Sang CN, 2000, J PAIN SYMPTOM MANAG, V19, pS21; Saunders, 1964, PRESCRIBERS J, V4, P68; SAUNDERS C, 1964, NURS MIRROR, pR7; Schiffrin MJ, 1956, MANAGEMENT PAIN CANC, P7; SCHMIDT KH, 1985, STUD PSYCHOL, V27, P61; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Spiller WG, 1912, J AMER MED ASSOC, V58, P1489; Sternbach R. A., 1968, PAIN PSYCHOPHYSIOLOG; SWERDLOW M, 1996, JC LIEBESKIND HIST P; SWERDLOW M, 1999, ROYAL COLL ANAESTH N, V47, P165; THORSTEINSSON G, 1977, ARCH PHYS MED REHAB, V58, P8; Turk D, 1983, PAIN BEHAV MED COGNI; TWYCROSS RG, 1977, PAIN, V3, P93, DOI 10.1016/0304-3959(77)90072-0; WATSON CP, 1982, NEUROLOGY, V32, P671, DOI 10.1212/WNL.32.6.671; White J., 1969, PAIN NEUROSURGEON 40; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	67	72	76	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2470	2475		10.1001/jama.290.18.2470	http://dx.doi.org/10.1001/jama.290.18.2470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612484				2022-12-28	WOS:000186518300034
J	Brook, I				Brook, I			Unexplained fever in young children: how to manage severe bacterial infection	BRITISH MEDICAL JOURNAL			English	Review							FEBRILE CHILDREN; OCCULT BACTEREMIA; LOW-RISK; INFANTS; AGE; MENINGITIS; CARE; TEMPERATURE; LESS	Fever with no clear source of infection in children under 3 years old carries a small but important risk of sepsis and meningitis. This review describes the bacterial causes of such infection and the appropriate management in different age groups.	Georgetown Univ, Sch Med, Dept Pediat, Washington, DC 20057 USA	Georgetown University	Brook, I (corresponding author), 4431 Albemarle St NW, Washington, DC 20016 USA.							Bachur R, 2000, PEDIATRICS, V105, P502, DOI 10.1542/peds.105.3.502; BAKER MD, 1993, NEW ENGL J MED, V329, P1437, DOI 10.1056/NEJM199311113292001; BARAFF LJ, 1992, PEDIATR INFECT DIS J, V11, P257, DOI 10.1097/00006454-199204000-00001; Baraff LJ, 1997, PEDIATRICS, V100, P134, DOI 10.1542/peds.100.1.134; BARAFF LJ, 1993, PEDIATRICS, V92, P1; Baraff LJ, 2000, ANN EMERG MED, V36, P602, DOI 10.1067/mem.2000.110820; BASS JW, 1993, PEDIATR INFECT DIS J, V12, P466, DOI 10.1097/00006454-199306000-00003; Black SB, 2001, PEDIATR INFECT DIS J, V20, P1105, DOI 10.1097/00006454-200112000-00002; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P993; DAGAN R, 1988, J PEDIATR-US, V112, P355, DOI 10.1016/S0022-3476(88)80312-3; DAGAN R, 1985, J PEDIATR-US, V107, P855, DOI 10.1016/S0022-3476(85)80175-X; FLEISHER GR, 1994, J PEDIATR-US, V124, P504, DOI 10.1016/S0022-3476(05)83126-9; HOBERMAN A, 1993, J PEDIATR-US, V123, P17, DOI 10.1016/S0022-3476(05)81531-8; JAFFE DM, 1991, PEDIATRICS, V87, P670; JASKIEWICZ JA, 1994, PEDIATRICS, V94, P390; JONES RG, 1993, PEDIATR INFECT DIS J, V12, P179, DOI 10.1097/00006454-199303000-00001; KAPLAN SL, 1981, J PEDIATR-US, V99, P591, DOI 10.1016/S0022-3476(81)80265-X; KLEIN JO, 1984, PEDIATR INFECT DIS J, V3, P75, DOI 10.1097/00006454-198401000-00018; LEVY JC, 1980, PEDIATRICS, V65, P956; MCCARTHY PL, 1980, PEDIATRICS, V65, P1090; MCCARTHY PL, 1977, PEDIATRICS, V59, P663; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501; SHAPIRO ED, 1986, J PEDIATR-US, V109, P15, DOI 10.1016/S0022-3476(86)80564-9; Thuler LCS, 1997, PEDIATR INFECT DIS J, V16, P846, DOI 10.1097/00006454-199709000-00006	24	20	23	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1094	1097		10.1136/bmj.327.7423.1094	http://dx.doi.org/10.1136/bmj.327.7423.1094			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604934	Green Published			2022-12-28	WOS:000186530400023
J	Nystul, TG; Goldmark, JP; Padilla, PA; Roth, MB				Nystul, TG; Goldmark, JP; Padilla, PA; Roth, MB			Suspended animation in C-elegans requires the spindle checkpoint	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; OXYGEN DEPRIVATION; MECHANISMS; HYPOXIA; PROTEIN; ARREST; ANOXIA; VISUALIZATION; DIAPAUSE; ENCODES	In response to environmental signals such as anoxia, many organisms enter a state of suspended animation, an extreme form of quiescence in which microscopically visible movement ceases. We have identified a gene, san-1, that is required for suspended animation in Caenorhabditis elegans embryos. We show that san-1 functions as a spindle checkpoint component in C. elegans. During anoxia-induced suspended animation, embryos lacking functional SAN-1 or a second spindle checkpoint component, MDF-2, failed to arrest the cell cycle, exhibited chromosome missegregation, and showed reduced viability. These data provide a model for how a dynamic biological process is arrested in suspended animation.	Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Univ N Texas, Dept Biol Sci, Denton, TX 76203 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of North Texas System; University of North Texas Denton	Roth, MB (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.		Nystul, Todd/AAA-7344-2022	Nystul, Todd/0000-0002-6250-2394	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270, R01GM048435] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07270, GM48435] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; Buchwitz BJ, 1999, NATURE, V401, P547, DOI 10.1038/44062; Clegg JS, 1997, J EXP BIOL, V200, P467; Douglas RM, 2003, J APPL PHYSIOL, V94, P2068, DOI 10.1152/japplphysiol.01029.2002; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fukushige T, 1999, P NATL ACAD SCI USA, V96, P11883, DOI 10.1073/pnas.96.21.11883; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Jackson DC, 2002, J PHYSIOL-LONDON, V543, P731, DOI 10.1113/jphysiol.2002.024729; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kitagawa R, 1999, NAT CELL BIOL, V1, P514, DOI 10.1038/70309; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; NYSTUL TG, UNPUB; Padilla PA, 2001, P NATL ACAD SCI USA, V98, P7331, DOI 10.1073/pnas.131213198; Padilla PA, 2002, MOL BIOL CELL, V13, P1473, DOI 10.1091/mbc.01-12-0594; Podrabsky JE, 1999, J EXP BIOL, V202, P2567; Renfree MB, 2000, ANNU REV PHYSIOL, V62, P353, DOI 10.1146/annurev.physiol.62.1.353; Safar P, 2000, CRIT CARE MED, V28, pN214, DOI 10.1097/00003246-200011001-00012; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Storey KB, 2002, COMP BIOCHEM PHYS A, V133, P733, DOI 10.1016/S1095-6433(02)00206-4; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1	23	72	78	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1038	1041		10.1126/science.1089705	http://dx.doi.org/10.1126/science.1089705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605367				2022-12-28	WOS:000186396300046
J	Pappone, C; Santinelli, V; Manguso, F; Augello, G; Santinelli, O; Vicedomini, G; Gulletta, S; Mazzone, P; Tortoriello, V; Pappone, A; Dicandia, C; Rosanio, S				Pappone, C; Santinelli, V; Manguso, F; Augello, G; Santinelli, O; Vicedomini, G; Gulletta, S; Mazzone, P; Tortoriello, V; Pappone, A; Dicandia, C; Rosanio, S			A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM-FOLLOW-UP; VENTRICULAR-FIBRILLATION; NATURAL-HISTORY; PATTERN; POPULATION; PATHWAYS; RISK	BACKGROUND: Young age and inducibility of atrioventricular reciprocating tachycardia or atrial fibrillation during invasive electrophysiological testing identify asymptomatic patients with a Wolff-Parkinson-White pattern on the electrocardiogram as being at high risk for arrhythmic events. We tested the hypothesis that prophylactic catheter ablation of accessory pathways would provide meaningful and durable benefits as compared with no treatment in such patients. METHODS: From 1997 to 2002, among 224 eligible asymptomatic patients with the Wolff-Parkinson-White syndrome, patients at high risk for arrhythmias were randomly assigned to radio-frequency catheter ablation of accessory pathways (37 patients) or no treatment (35 patients). The end point was the occurrence of arrhythmic events over a five-year follow-up period. RESULTS: Patients assigned to ablation had base-line characteristics that were similar to those of the controls. Two patients in the ablation group (5 percent) and 21 in the control group (60 percent) had arrhythmic events. One control patient had ventricular fibrillation as the presenting arrhythmia. The five-year Kaplan-Meier estimates of the incidence of arrhythmic events were 7 percent among patients who underwent ablation and 77 percent among the controls (P<0.001 by the log-rank test); the risk reduction with ablation was 92 percent (relative risk, 0.08; 95 percent confidence interval, 0.02 to 0.33; P<0.001). CONCLUSIONS: Prophylactic accessory-pathway ablation markedly reduces the frequency of arrhythmic events in asymptomatic patients with the Wolff-Parkinson-White syndrome who are at high risk for such events.	San Raffaele Univ Hosp, Dept Cardiol, Electrophysiol & Cardiac Pacing Unit, I-20132 Milan, Italy; Univ Hosp Federico II, Dept Cardiol, Naples, Italy; Univ Texas, Med Branch, Dept Internal Med, Div Cardiol, Galveston, TX 77550 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Texas System; University of Texas Medical Branch Galveston	Pappone, C (corresponding author), San Raffaele Univ Hosp, Dept Cardiol, Electrophysiol & Cardiac Pacing Unit, Via Olgettina 60, I-20132 Milan, Italy.		Gulletta, Simone/AGQ-5866-2022; Mazzone, Patrizio/HHC-7625-2022; Vicedomini, Gabriele/K-5182-2018; Augello, Giuseppe/AAM-2338-2021; Santinelli, Vincenzo/J-9927-2016; Pappone, Carlo/J-9853-2016	Vicedomini, Gabriele/0000-0002-2300-3621; Santinelli, Vincenzo/0000-0003-4169-3619; Pappone, Carlo/0000-0002-0901-6135				BECKMAN KJ, 1990, J AM COLL CARDIOL, V15, P640, DOI 10.1016/0735-1097(90)90639-7; BERKMAN NL, 1968, NEW ENGL J MED, V278, P492, DOI 10.1056/NEJM196802292780906; BREMBILLAPERROT B, 1993, EUR HEART J, V14, P511, DOI 10.1093/eurheartj/14.4.511; CSANADI Z, 1995, CIRCULATION, V91, P2614, DOI 10.1161/01.CIR.91.10.2614; Fitzsimmons PJ, 2001, AM HEART J, V142, P530, DOI 10.1067/mhj.2001.117779; Goudevenos JA, 2000, HEART, V83, P29, DOI 10.1136/heart.83.1.29; KLEIN G J, 1989, New England Journal of Medicine, V320, P1229, DOI 10.1056/NEJM198905113201901; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; LEITCH JW, 1991, CIRCULATION, V83, P1124; LEITCH JW, 1990, CIRCULATION, V82, P1718, DOI 10.1161/01.CIR.82.5.1718; LeLorier P, 2001, Curr Cardiol Rep, V3, P301, DOI 10.1007/s11886-001-0084-z; MONTOYA PT, 1991, EUR HEART J, V12, P144; MUNGER TM, 1993, CIRCULATION, V87, P866, DOI 10.1161/01.CIR.87.3.866; Pappone C, 2003, J AM COLL CARDIOL, V41, P239, DOI 10.1016/S0735-1097(02)02706-7; SATOH M, 1989, PACE, V12, P413, DOI 10.1111/j.1540-8159.1989.tb02678.x; TEO WS, 1991, AM J CARDIOL, V67, P889, DOI 10.1016/0002-9149(91)90626-V; TIMMERMANS C, 1995, AM J CARDIOL, V76, P492, DOI 10.1016/S0002-9149(99)80136-2; Todd DM, 2003, J AM COLL CARDIOL, V41, P245, DOI 10.1016/S0735-1097(02)02707-9; ZARDINI M, 1990, AM J CARDIOL, V66, P1388, DOI 10.1016/0002-9149(90)91178-9	19	156	170	1	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1803	1811		10.1056/NEJMoa035345	http://dx.doi.org/10.1056/NEJMoa035345			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602878				2022-12-28	WOS:000186353800004
J	Schuster, DG				Schuster, DG			Neurasthenia and a modernizing America	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Schuster, DG (corresponding author), Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA.							Addams Jane, 1910, 20 YEARS HULL HOUSE; Beard G. M., 1869, BOSTON MED SURGICAL, V80, P245; Beard George Miller, 1881, AM NERVOUSNESS ITS C; BEDELL LG, 1889, WOMANS J, V20, P162; Blumer GA, 1906, J NERV MENT DIS, V33, P336, DOI 10.1097/00005053-190605000-00003; CARROLL JV, 2002, AM LEGION MAGAZINE, V153, P20; Dana CL, 1904, BOSTON MED SURG J, V150, P339, DOI 10.1056/NEJM190403311501301; Gilman CharlottePerkins., 1998, WOMEN EC STUDY EC RE; GILMAN CP, 1916, FORERUNNER       JUL, P202; Gosling F., 1987, FREUD NEURASTHENIA A; Lutz Tom, 1991, AM NERVOUSNESS 1903; Mitchell S. W., 1887, WEAR TEAR HINTS OVER; Mitchell SW, 1878, FAT BLOOD MAKE THEM; MORRIS RT, 1916, DOCTORS VERSUS FOLKS; *NAT ORG RAR DIS, NEUR; ROSENBERG C E, 1962, Bull Hist Med, V36, P245; STRAHORN RE, 1896, COSMOPOLITAN, V21, P473; Wiebe R.H., 1967, SEARCH ORDER 1877 19; Will B, 1998, AM LIT, V70, P293, DOI 10.2307/2902839; WORCESTER E, COMMUNICATION   0118	20	14	14	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2327	2328		10.1001/jama.290.17.2327	http://dx.doi.org/10.1001/jama.290.17.2327			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600195	Bronze			2022-12-28	WOS:000186356800031
J	Barrett, MP; Burchmore, RJS; Stich, A; Lazzari, JO; Frasch, AC; Cazzulo, JJ; Krishna, S				Barrett, MP; Burchmore, RJS; Stich, A; Lazzari, JO; Frasch, AC; Cazzulo, JJ; Krishna, S			The trypanosomiases	LANCET			English	Review							HUMAN AFRICAN TRYPANOSOMIASIS; CHAGAS HEART-DISEASE; POLYMERASE-CHAIN-REACTION; RESEARCH-AND-DEVELOPMENT; SLEEPING-SICKNESS; BRUCEI-GAMBIENSE; GAMBIAN TRYPANOSOMIASIS; AMERICAN TRYPANOSOMES; PARASITE PERSISTENCE; THERAPEUTIC TARGET	The trypanosomiases consist of a group of important animal and human diseases caused by parasitic protozoa of the genus Trypanosoma. In sub-Saharan Africa, the final decade of the 20th century witnessed an alarming resurgence in sleeping sickness (human African trypanosomiasis). In South and Central America, Chagas' disease (American trypanosomiasis) remains one of the most prevalent infectious diseases. Arthropod vectors transmit African and American trypanosomiases, and disease containment through insect control programmes is an achievable goal. Chemotherapy is available for both diseases, but existing drugs are far from ideal. The trypanosomes are some of the earliest diverging members of the Eukaryotae and share several biochemical peculiarities that have stimulated research into new drug targets. However, differences in the ways in which trypanosome species interact with their hosts have frustrated efforts to design drugs effective against both species. Growth in recognition of these neglected diseases might result in progress towards control through increased funding for drug development and vector elimination.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Med Mission Inst, Dept Trop Med & Epidem Control, Wurzburg, Germany; Hosp Pirovano, Div Cardiol, Buenos Aires, DF, Argentina; Univ Nacl Gen San Martin, Inst Invest Biotecnol, San Martin, Buenos Aires, Argentina; Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	University of Glasgow; St Georges University London	Barrett, MP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	m.barrett@bio.gla.ac.uk	Nogueira, Raquel Tayar/F-6475-2019; Burchmore, Richard/A-1896-2011	Nogueira, Raquel Tayar/0000-0002-0581-763X; Barrett, Mike/0000-0001-9447-3519; Krishna, Sanjeev/0000-0003-0066-0634; Frasch, Alberto Carlos/0000-0001-7532-653X; Burchmore, Richard/0000-0003-1663-9004				Acosta-Serrano A, 2001, MOL BIOCHEM PARASIT, V114, P143, DOI 10.1016/S0166-6851(01)00245-6; Ali BRS, 1999, MOL BIOCHEM PARASIT, V104, P67, DOI 10.1016/S0166-6851(99)00131-0; Allsopp R, 2001, TRENDS PARASITOL, V17, P15, DOI 10.1016/S1471-4922(00)01828-6; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; [Anonymous], 1998, WHO TECHN REP SER, V881; [Anonymous], [No title captured]; Aronov AM, 1999, P NATL ACAD SCI USA, V96, P4273, DOI 10.1073/pnas.96.8.4273; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; Barrett Michael P., 2002, Current Topics in Medicinal Chemistry, V2, P471, DOI 10.2174/1568026024607427; Barrett MP, 1997, PARASITOL TODAY, V13, P11, DOI 10.1016/S0169-4758(96)10075-2; Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; BARROW DL, 2000, NEUROSURGERY NEWS, V1, P1; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; Brun R, 2001, TROP MED INT HEALTH, V6, P906, DOI 10.1046/j.1365-3156.2001.00775.x; Buckner FS, 2000, J BIOL CHEM, V275, P21870, DOI 10.1074/jbc.M000975200; Buguet A, 2001, SLEEP MED REV, V5, P139, DOI 10.1053/smrv.2000.0130; Burchmore RJS, 2002, CURR PHARM DESIGN, V8, P257, DOI 10.2174/1381612023396159; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; Caffrey C. R., 2000, Current Drug Targets, V1, P155, DOI 10.2174/1389450003349290; Cattand P, 2001, TROP MED INT HEALTH, V6, P348, DOI 10.1046/j.1365-3156.2001.00669.x; CAZZULO JJ, 1994, J BIOENERG BIOMEMBR, V26, P157, DOI 10.1007/BF00763064; Cazzulo Juan Jose, 2002, Current Topics in Medicinal Chemistry, V2, P1261, DOI 10.2174/1568026023392995; Chimelli L, 1997, BRAIN PATHOL, V7, P599, DOI 10.1111/j.1750-3639.1997.tb01077.x; Clayton CE, 1999, PARASITOL TODAY, V15, P372, DOI 10.1016/S0169-4758(99)01498-2; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; Croft SL, 1999, MEM I OSWALDO CRUZ, V94, P215, DOI 10.1590/S0074-02761999000200017; da Silva AL, 1999, MEM I OSWALDO CRUZ, V94, P343, DOI 10.1590/S0074-02761999000700067; deAndrade ALSS, 1996, LANCET, V348, P1407, DOI 10.1016/S0140-6736(96)04128-1; Degrave WM, 2001, INT J PARASITOL, V31, P532, DOI 10.1016/S0020-7519(01)00144-8; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; Dias JCP, 2002, MEM I OSWALDO CRUZ, V97, P603, DOI 10.1590/S0074-02762002000500002; Docampo R, 2001, CURR PHARM DESIGN, V7, P1157, DOI 10.2174/1381612013397546; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; DUMAS M, 1998, PROGR HUMAN AFRICAN, P215; Enanga B, 2002, CELL MOL LIFE SCI, V59, P845, DOI 10.1007/s00018-002-8472-0; Engman DM, 2002, ACTA TROP, V81, P123, DOI 10.1016/S0001-706X(01)00202-9; Estani SS, 1998, AM J TROP MED HYG, V59, P526, DOI 10.4269/ajtmh.1998.59.526; Etchegorry MG, 2001, TROP MED INT HEALTH, V6, P957, DOI 10.1046/j.1365-3156.2001.00764.x; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Fernandes O, 1998, AM J TROP MED HYG, V58, P807, DOI 10.4269/ajtmh.1998.58.807; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; Gaunt MW, 2003, NATURE, V421, P936, DOI 10.1038/nature01438; Gibson Wendy, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS141, DOI 10.1016/S0035-9203(02)90066-0; Girones N, 2003, TRENDS PARASITOL, V19, P19, DOI 10.1016/S1471-4922(02)00006-5; GLASGOW JP, 1970, AFRICAN TRYPANOSOMIA, P456; Grant IF, 2001, TRENDS PARASITOL, V17, P10, DOI 10.1016/S1471-4922(00)01848-1; Guhl F, 2000, MEM I OSWALDO CRUZ, V95, P553, DOI 10.1590/S0074-02762000000400018; Hager KM, 1997, NATURE, V385, P823, DOI 10.1038/385823a0; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Hargrove JW, 2000, MED VET ENTOMOL, V14, P123, DOI 10.1046/j.1365-2915.2000.00226.x; Hasne MP, 2000, J APPL MICROBIOL, V89, P697, DOI 10.1046/j.1365-2672.2000.01168.x; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jannin J, 2001, Med Trop (Mars), V61, P437; JAUBERTEAU MO, 1991, J NEUROL SCI, V101, P82, DOI 10.1016/0022-510X(91)90020-8; Jennings FW, 2002, PARASITOL INT, V51, P381, DOI 10.1016/S1383-5769(02)00044-2; JENNINGS FW, 1993, ACTA TROP, V54, P205, DOI 10.1016/0001-706X(93)90093-Q; Keiser J, 2001, TRENDS PARASITOL, V17, P42, DOI 10.1016/S1471-4922(00)01829-8; Kelly J M, 1995, Methods Mol Biol, V47, P349; LaCount DJ, 2001, PROTIST, V152, P103, DOI 10.1078/1434-4610-00047; Lakhdar-Ghazal Faouzi, 2002, Current Topics in Medicinal Chemistry, V2, P439, DOI 10.2174/1568026024607472; Laurent JP, 1997, PARASITOLOGY, V114, P213, DOI 10.1017/S0031182096008414; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; Legros D, 1999, T ROY SOC TROP MED H, V93, P439, DOI 10.1016/S0035-9203(99)90151-7; Leon JS, 2001, INT J PARASITOL, V31, P555, DOI 10.1016/S0020-7519(01)00163-1; LeQuesne SA, 1996, BIOCHEM J, V316, P481; Louis F J, 2001, Med Trop (Mars), V61, P340; MacLeod A, 2000, P NATL ACAD SCI USA, V97, P13442, DOI 10.1073/pnas.230434097; MacLeod A, 2001, PHILOS T R SOC B, V356, P1035, DOI 10.1098/rstb.2001.0892; Magez S, 1998, J IMMUNOL, V160, P1949; Marcon GEB, 2002, DIAGN MICR INFEC DIS, V43, P39, DOI 10.1016/S0732-8893(02)00366-8; *MED SANS FRONT, DRUGS NEGL DIS IN; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Miles M., 2003, MANSON TROPICAL DIS, P1325; Mpia B, 2002, TROP MED INT HEALTH, V7, P775, DOI 10.1046/j.1365-3156.2002.00933.x; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Nyakundi JN, 2002, PARASITOLOGY, V124, P589, DOI 10.1017/S0031182002001701; Paul KS, 2001, TRENDS PARASITOL, V17, P381, DOI 10.1016/S1471-4922(01)01984-5; Pays J F, 1998, Med Trop (Mars), V58, P391; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; PENTREATH VW, 1995, T ROY SOC TROP MED H, V89, P9, DOI 10.1016/0035-9203(95)90637-1; PEPIN J, 1991, T ROY SOC TROP MED H, V85, P222, DOI 10.1016/0035-9203(91)90032-T; Pepin J, 2001, ADV PARASIT, V49, P71, DOI 10.1016/S0065-308X(01)49038-5; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Pepin J, 2000, B WORLD HEALTH ORGAN, V78, P1284; Pollevick GD, 2000, J BIOL CHEM, V275, P27671; POLTERA AA, 1985, BRIT MED BULL, V41, P169, DOI 10.1093/oxfordjournals.bmb.a072045; Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2; Rahmathullah SM, 1999, J MED CHEM, V42, P3994, DOI 10.1021/jm990237+; Raper J, 2001, CURR OPIN MICROBIOL, V4, P402, DOI 10.1016/S1369-5274(00)00226-5; Raper Jayne, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS145, DOI 10.1016/S0035-9203(02)90067-2; Rassi A, 2000, CLIN CARDIOL, V23, P883, DOI 10.1002/clc.4960231205; Reina-San-Martin B, 2000, NAT MED, V6, P890, DOI 10.1038/78651; Remme JHF, 2002, TRENDS PARASITOL, V18, P421, DOI 10.1016/S1471-4922(02)02387-5; Rogers DJ, 2002, TRENDS PARASITOL, V18, P534, DOI 10.1016/S1471-4922(02)02422-4; Schmidt Armin, 2002, Current Topics in Medicinal Chemistry, V2, P1239, DOI 10.2174/1568026023393048; Schnaufer A, 2002, INT J PARASITOL, V32, P1071, DOI 10.1016/S0020-7519(02)00020-6; Schofield CJ, 1999, ADV PARASIT, V42, P1, DOI 10.1016/S0065-308X(08)60147-5; Schofield CJ, 2001, INT J PARASITOL, V31, P615, DOI 10.1016/S0020-7519(01)00162-X; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Soares MBP, 2001, AN ACAD BRAS CIENC, V73, P547, DOI 10.1590/S0001-37652001000400008; Stevens JR, 1999, PARASITOLOGY, V118, P107, DOI 10.1017/S0031182098003473; Stevenson H.W., 2000, J PSYCHOL CHIN SOC, V1, P1; Stich A, 2003, TRENDS PARASITOL, V19, P195, DOI 10.1016/S1471-4922(03)00055-2; Stich A, 2002, BRIT MED J, V325, P203, DOI 10.1136/bmj.325.7357.203; Stich A, 2001, MEDICINE, V29, P42; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; Tarleton RL, 2001, INT J PARASITOL, V31, P550, DOI 10.1016/S0020-7519(01)00158-8; Troeberg L, 1999, EXP PARASITOL, V91, P349, DOI 10.1006/expr.1998.4386; Trouiller P, 1999, TROP MED INT HEALTH, V4, P412, DOI 10.1046/j.1365-3156.1999.00420.x; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Urbina JA, 2001, CURR OPIN INFECT DIS, V14, P733, DOI 10.1097/00001432-200112000-00012; Urbina JA, 1997, PARASITOLOGY, V114, pS91, DOI 10.1017/S0031182097001194; Urbina JA, 2002, CURR PHARM DESIGN, V8, P287, DOI 10.2174/1381612023396177; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; Verlinde CLM, 2001, DRUG RESIST UPDATE, V4, P50, DOI 10.1054/drup.2000.0177; Vreysen M J, 2001, Med Trop (Mars), V61, P397; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; Welburn SC, 2001, LANCET, V358, P2017, DOI 10.1016/S0140-6736(01)07096-9; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7	125	593	604	7	163	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2003	362	9394					1469	1480		10.1016/S0140-6736(03)14694-6	http://dx.doi.org/10.1016/S0140-6736(03)14694-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602444				2022-12-28	WOS:000186356600025
J	Scopigno, T; Ruocco, G; Sette, F; Monaco, G				Scopigno, T; Ruocco, G; Sette, F; Monaco, G			Is the fragility of a liquid embedded in the properties of its glass?	SCIENCE			English	Article							HIGH-FREQUENCY DYNAMICS; FORMING LIQUIDS; RELAXATION	When a liquid is cooled below its melting temperature, it usually crystallizes. However, if the quenching rate is fast enough, the system may remain in a disordered state, progressively losing its fluidity upon further cooling. When the time needed for the rearrangement of the local atomic structure reaches approximately 100 seconds, the system becomes "solid" for any practical purpose, and this defines the glass transition temperature T-g. Approaching this transition from the liquid side, different systems show qualitatively different temperature dependencies of the viscosity, and accordingly they have been classified by introducing the concept of "fragility." We report experimental observations that relate the microscopic properties of the glassy phase to the fragility. We find that the vibrational properties of the glass well below T-g are correlated with the fragility value. Consequently, we extend the fragility concept to the glassy state and indicate how to determine the fragility uniquely from glass properties well below T-g.	Univ Roma La Sapienza, Ist Nazl Fis Mat, I-00185 Rome, Italy; Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; Sapienza University Rome; European Synchrotron Radiation Facility (ESRF)	Scopigno, T (corresponding author), Univ Roma La Sapienza, Ist Nazl Fis Mat, I-00185 Rome, Italy.	tullio.scopigno@phys.uniroma1.it	Monaco, Giulio/AAU-2947-2021; Monaco, Giulio/AAW-4387-2020; Scopigno, Tullio/A-1778-2010; Ruocco, Giancarlo/A-6245-2010	Monaco, Giulio/0000-0003-2497-6422; Scopigno, Tullio/0000-0002-7437-4262; Ruocco, Giancarlo/0000-0002-2762-9533				Andreozzi L, 2003, J PHYS-CONDENS MAT, V15; ANGELL CA, 1991, J NON-CRYST SOLIDS, V131, P13, DOI 10.1016/0022-3093(91)90266-9; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; ANGELL CA, 1997, P INT SCH PHYS E FER, V11; BOHMER R, 1993, J CHEM PHYS, V99, P4201, DOI 10.1063/1.466117; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; DYRE JC, PREPRINT; Erwin BM, 2002, J NON-CRYST SOLIDS, V307, P225, DOI 10.1016/S0022-3093(02)01464-3; Fioretto D, 1999, PHYS REV E, V59, P4470, DOI 10.1103/PhysRevE.59.4470; Garrahan JP, 2003, P NATL ACAD SCI USA, V100, P9710, DOI 10.1073/pnas.1233719100; Giordano M, 1999, J PHYS-CONDENS MAT, V11, pU3; GOLDSTEIN M, 1969, J CHEM PHYS, V51, P3728, DOI 10.1063/1.1672587; HALL RW, 1987, J CHEM PHYS, V86, P2943, DOI 10.1063/1.452045; Hansen C, 1998, J CHEM PHYS, V108, P6408, DOI 10.1063/1.476063; Hemmati M, 2001, J CHEM PHYS, V115, P6663, DOI 10.1063/1.1396679; HUANG D, 2001, J CHEM PHYS, V13, P56121; Martinez LM, 2001, NATURE, V410, P663, DOI 10.1038/35070517; Masciovecchio C, 1998, PHYS REV LETT, V80, P544, DOI 10.1103/PhysRevLett.80.544; Masciovecchio C, 1999, PHILOS MAG B, V79, P2013, DOI 10.1080/13642819908223089; Monaco G, 1998, PHYS REV LETT, V80, P2161, DOI 10.1103/PhysRevLett.80.2161; Ngai KL, 1999, J CHEM PHYS, V111, P10403, DOI 10.1063/1.480394; NGAI KL, 2002, J NONCRYST SOLIDS, V307; Ruocco G, 2000, PHYS REV LETT, V84, P5788, DOI 10.1103/PhysRevLett.84.5788; Ruocco G, 1999, PHYS REV LETT, V83, P5583, DOI 10.1103/PhysRevLett.83.5583; Sastry S, 2001, NATURE, V409, P164, DOI 10.1038/35051524; Scopigno T, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.031205; Scopigno T, 2003, J CHEM PHYS, V118, P311, DOI 10.1063/1.1526097; Sette F, 1998, SCIENCE, V280, P1550, DOI 10.1126/science.280.5369.1550; SOKOLOV AP, 1993, PHYS REV LETT, V71, P2062, DOI 10.1103/PhysRevLett.71.2062; Speedy RJ, 1999, J PHYS CHEM B, V103, P4060, DOI 10.1021/jp983830w; STILLINGER FH, 1982, PHYS REV A, V25, P978, DOI 10.1103/PhysRevA.25.978; Tolle A, 1997, PHYS REV E, V56, P809, DOI 10.1103/PhysRevE.56.809; Yannopoulos SN, 2000, PHYS REV B, V62, P3728, DOI 10.1103/PhysRevB.62.3728; ZORN R, 1995, MACROMOLECULES, V28, P8552, DOI 10.1021/ma00129a014	34	247	252	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					849	852		10.1126/science.1089446	http://dx.doi.org/10.1126/science.1089446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593174	Green Submitted			2022-12-28	WOS:000186258000044
J	Cooper, LA; Roter, DL; Johnson, RL; Ford, DE; Steinwachs, DM; Powe, NR				Cooper, LA; Roter, DL; Johnson, RL; Ford, DE; Steinwachs, DM; Powe, NR			Patient-centered communication, ratings of care, and concordance of patient and physician race	ANNALS OF INTERNAL MEDICINE			English	Article							LONGITUDINAL DATA-ANALYSIS; RACIAL-DIFFERENCES; CARDIOVASCULAR PROCEDURES; ETHNIC DISPARITIES; MEDICAL-CARE; GENDER; SATISFACTION; QUALITY; PERCEPTIONS; AMERICANS	Background: African-American patients who visit physicians of the same race rate their medical visits as more satisfying and participatory than do those who see physicians of other races. Little research has investigated the communication process in race-concordant and race-discordant medical visits. Objectives: To compare patient-physician communication in race-concordant and race-discordant visits and examine whether communication behaviors explain differences in patient ratings of satisfaction and participatory decision making. Design: Cohort study with follow-up using previsit and postvisit surveys and audiotape analysis. Setting: 16 urban primary care practices. Patients: 252 adults (142 African-American patients and 110 white patients) receiving care from 31 physicians (of whom 18 were African-American and 13 were white). Measurements: Audiotape measures of patient-centeredness, patient ratings of physicians' participatory decision-making styles, and overall satisfaction. Results: Race-concordant visits were longer (2.15 minutes [95% CI, 0.60 to 3.71]) and had higher ratings of patient positive affect (0.55 point, [95% CI, 0.04 to 1.05]) compared with race-discordant visits. Patients in race-concordant visits were more satisfied and rated their physicians as more participatory (8.42 points [95% CI, 3.23 to 13.60]). Audiotape measures of patient-centered communication behaviors did not explain differences in participatory decision making or satisfaction between race-concordant and race-discordant visits. Conclusions: Race-concordant visits are longer and characterized by more patient positive affect. Previous studies link similar communication findings to continuity of care. The association between race concordance and higher patient ratings of care is independent of patient-centered communication, suggesting that other factors, such as patient and physician attitudes, may mediate the relationship. Until more evidence is available regarding the mechanisms of this relationship and the effectiveness of intercultural communication skills programs, increasing ethnic diversity among physicians may be the most direct strategy to improve health care experiences for members of ethnic minority groups.	Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Cooper, LA (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-500, Baltimore, MD 21205 USA.	lisa.cooper@jhmi.edu	Thornton, Rachel Johnson/V-8078-2019; Roter, Debra L/N-8830-2014	Thornton, Rachel Johnson/0000-0002-9711-1094; 				Andrulis DP, 1998, ANN INTERN MED, V129, P412, DOI 10.7326/0003-4819-129-5-199809010-00012; [Anonymous], 2000, NAT GENET, V24, P97; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; Collins KS, 2002, FINDINGS COMMONWEALT; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; *CTR HLTH PROGR DE, 2001, MAR STUD PHYS EXP MA; Derose KP, 2001, J GEN INTERN MED, V16, P218, DOI 10.1046/j.1525-1497.2001.016004218.x; Doescher MP, 2000, ARCH FAM MED, V9, P1156, DOI 10.1001/archfami.9.10.1156; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Fogarty LA, 1999, J CLIN ONCOL, V17, P371, DOI 10.1200/JCO.1999.17.1.371; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GAMBLE VN, 1993, AM J PREV MED, V9, P35, DOI 10.1016/S0749-3797(18)30664-0; Giron M, 1998, AM J PSYCHIAT, V155, P530, DOI 10.1176/ajp.155.4.530; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Gross DA, 1998, J FAM PRACTICE, V47, P133; HALL JA, 1987, MED CARE, V25, P399, DOI 10.1097/00005650-198705000-00004; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; Hall JA, 2002, PATIENT EDUC COUNS, V48, P69, DOI 10.1016/S0738-3991(02)00071-X; HALL JA, 1981, J HEALTH SOC BEHAV, V22, P18, DOI 10.2307/2136365; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; *I MED, 2003, UN TREATM CONFR RAC; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Krieger N, 1996, AM J PUBLIC HEALTH, V86, P1370, DOI 10.2105/AJPH.86.10.1370; LaVeist TA, 2000, MED CARE RES REV, V57, P146, DOI 10.1177/107755800773743637; Lazare A., 1995, MED INTERVIEW CLIN C, P3; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Makuc DM, 1999, HEALTH SERV RES, V34, P229; Malat J, 2001, J HEALTH SOC BEHAV, V42, P360, DOI 10.2307/3090184; McKinlay JB, 2002, J HEALTH SOC BEHAV, V43, P92, DOI 10.2307/3090247; Mead N, 2000, PATIENT EDUC COUNS, V39, P71, DOI 10.1016/S0738-3991(99)00092-0; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; ROSENHECK R, 1995, AM J PSYCHIAT, V152, P555; Roter D, 2003, LEA COMMUN SER, P121; Roter Debra, 2000, Health Expect, V3, P17, DOI 10.1046/j.1369-6513.2000.00073.x; Roter DL, 1999, OBSTET GYNECOL, V93, P635, DOI 10.1016/S0029-7844(98)00542-0; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; Roter DL, 2002, JAMA-J AM MED ASSOC, V288, P756, DOI 10.1001/jama.288.6.756; Roter DL, 2001, HEALTH COMMUN, V13, P33, DOI 10.1207/S15327027HC1301_04; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; Schmittdiel J, 2000, J GEN INTERN MED, V15, P761, DOI 10.1046/j.1525-1497.2000.91156.x; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; Van Wieringen JCM, 2002, EUR J PUBLIC HEALTH, V12, P63, DOI 10.1093/eurpub/12.1.63; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wiggers JH, 1997, SOC SCI MED, V44, P925, DOI 10.1016/S0277-9536(96)00175-X; Wissow LS, 2003, ARCH PEDIAT ADOL MED, V157, P419, DOI 10.1001/archpedi.157.5.419; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	56	847	848	7	137	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					907	915		10.7326/0003-4819-139-11-200312020-00009	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	748WW	14644893				2022-12-28	WOS:000186884800004
J	Brindle, P; Emberson, J; Lampe, F; Walker, M; Whincup, P; Fahey, T; Ebrahim, S				Brindle, P; Emberson, J; Lampe, F; Walker, M; Whincup, P; Fahey, T; Ebrahim, S			Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDIVIDUAL PATIENT DATA; ISCHEMIC-HEART-DISEASE; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; FOLLOW-UP; POPULATION; VALIDATION; RECOMMENDATIONS; STATEMENT; TRENDS	Objective To establish the predictive accuracy of the Framingham risk score for coronary heart disease in a representative British population. Design Prospective cohort study. Setting 24 towns in the United Kingdom. Participants 6643 British men aged 40-59 years and free from cardiovascular disease at entry into the British regional heart study. Main outcome measures Comparison of observed 10 year coronary heart disease mortality and event rates with predicted rates for each individual, using the relevant Framingham risk equation. Results Of 6643 men, 2.8% (95% confidence interval 2.4% to 3.2%) died from coronary heart disease compared with 4.1% predicted (relative overestimation 47%, P<0.0001). A fatal or non-fatal coronary heart disease event occurred in 10.2% (9.5% to 10.9%) of the men compared with 16.0% predicted (relative overestimation 57%, P<0.0001). These relative degrees of overestimation were similar at all levels of coronary heart disease risk, so that overestimation of absolute risk was greatest for those at highest risk. A simple adjustment provided an improved level of accuracy. In a "high risk score" approach, most cases occur in the low risk group. In this case, 84% of the deaths from coronary heart disease and non-fatal events occurred in the 93% of men classified at low risk (<30% in 10 years) by the Framingham score. Conclusion Guidelines for the primary prevention of coronary heart disease advocate offering preventive measures to individuals at high risk. Currently recommended risk scoring methods derived from the Framingham study significantly overestimate the absolute coronary risk assigned to individuals in the United Kingdom.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England; Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland	University of Bristol; University of London; University College London; UCL Medical School; St Georges University London; University of Dundee	Brindle, P (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	peter.brindle@bristol.ac.uk	Fahey, Tom/C-9367-2012; Lampe, Fiona/I-5826-2019	Fahey, Tom/0000-0002-5896-5783; Lampe, Fiona/0000-0001-6851-5471; Whincup, Peter/0000-0002-5589-4107; Emberson, Jonathan/0000-0001-7792-9422				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Brindle P, 2002, BRIT MED J, V325, P56, DOI 10.1136/bmj.325.7355.56; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Fodor JG, 2000, CAN MED ASSOC J, V162, P1441; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Haq IU, 1999, HEART, V81, P40, DOI 10.1136/hrt.81.1.40; Hense H, 2003, EUR HEART J, V3, P1; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jackson R, 2000, BMJ-BRIT MED J, V320, P709, DOI 10.1136/bmj.320.7236.709; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; LAURIER D, 1994, J CLIN EPIDEMIOL, V47, P1353, DOI 10.1016/0895-4356(94)90079-5; Lawlor DA, 2001, BRIT MED J, V323, P541, DOI 10.1136/bmj.323.7312.541; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; MANTEL N, 1959, J NATL CANCER I, V22, P719; Menotti A, 2000, EUR HEART J, V21, P365, DOI 10.1053/euhj.1999.1864; Packard CJ, 1998, CIRCULATION, V97, P1440; PETERSON S, 2002, CHRISTIAN SCI M 0328, P1; Pocock SJ, 2001, BMJ-BRIT MED J, V323, P75, DOI 10.1136/bmj.323.7304.75; Ramachandran S, 2000, BRIT MED J, V320, P676, DOI 10.1136/bmj.320.7236.676; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; Thomsen TF, 2002, INT J EPIDEMIOL, V31, P817, DOI 10.1093/ije/31.4.817; Vanderpump MPJ, 1996, THYROID, V6, P155; Walker M, 2000, J PUBLIC HEALTH MED, V22, P479, DOI 10.1093/pubmed/22.4.479; Wallis EJ, 2000, BMJ-BRIT MED J, V320, P671, DOI 10.1136/bmj.320.7236.671; Wood D, 1998, ATHEROSCLEROSIS, V140, P199, DOI 10.1016/S0021-9150(98)90209-X; Wood D, 1998, HEART, V80, pS1	32	324	346	2	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	2003	327	7426					1267	1270A		10.1136/bmj.327.7426.1267	http://dx.doi.org/10.1136/bmj.327.7426.1267			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644971	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000186948800020
J	Barrenas, ML; Bratthall, A; Dahlgren, J				Barrenas, ML; Bratthall, A; Dahlgren, J			The thrifty phenotype hypothesis and hearing problems	BRITISH MEDICAL JOURNAL			English	Article							GROWTH; EAR		Univ Gothenburg, Inst Hlth Woman & Child, Dept Pediat, Goteborg Pediat Growth Res Ctr, S-41685 Gothenburg, Sweden	University of Gothenburg	Barrenas, ML (corresponding author), Univ Gothenburg, Inst Hlth Woman & Child, Dept Pediat, Goteborg Pediat Growth Res Ctr, S-41685 Gothenburg, Sweden.		Dahlgren, Jovanna/J-8558-2015	Andersson Barrenas, Marie-Louise/0000-0002-7051-1178				Barrenas ML, 2000, HEARING RES, V144, P21, DOI 10.1016/S0378-5955(00)00040-X; BJORNTORP P, 1995, METABOLISM S2, V44, pS38; Camarero G, 2001, J NEUROSCI, V21, P7630, DOI 10.1523/JNEUROSCI.21-19-07630.2001; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241	5	18	19	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1199	1200		10.1136/bmj.327.7425.1199	http://dx.doi.org/10.1136/bmj.327.7425.1199			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630755	Green Published, Bronze			2022-12-28	WOS:000186784300018
J	Chen, CC; Lamping, KG; Nuno, DW; Barresi, R; Prouty, SJ; Lavoie, JL; Cribbs, LL; England, SK; Sigmund, CD; Weiss, RM; Williamson, RA; Hill, JA; Campbell, KP				Chen, CC; Lamping, KG; Nuno, DW; Barresi, R; Prouty, SJ; Lavoie, JL; Cribbs, LL; England, SK; Sigmund, CD; Weiss, RM; Williamson, RA; Hill, JA; Campbell, KP			Abnormal coronary function in mice deficient in alpha(1H) T-type Ca2+ channels	SCIENCE			English	Article							CALCIUM CHANNELS; VENTRICULAR MYOCYTES; SINOATRIAL NODE; SMOOTH-MUSCLE; GENE FAMILY; EXPRESSION; CURRENTS; ALPHA-1H; CELLS; SUBUNIT	Calcium ion (Ca2+) influx through voltage-gated Ca2+ channels is important for the regulation of vascular tone. Activation of L-type Ca2+ channels initiates muscle contraction; however, the role of T-type Ca2+ channels (T-channels) is not clear. We show that mice deficient in the alpha(1H) T-type Ca2+ channel (alpha(1) 3.2-null) have constitutively constricted coronary arterioles and focal myocardial fibrosis. Coronary arteries isolated from alpha(1) 3.2-null arteries showed normal contractile responses, but reduced relaxation in response to acetylcholine and nitroprusside. Furthermore, acute blockade of T-channels with Ni2+ prevented relaxation of wild-type coronary arteries. Thus, Ca2+ influx through alpha(1H) T-type Ca2+ channels is essential for normal relaxation of coronary arteries.	Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA; Univ Texas, SW Med Ctr, Div Cardiol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Loyola University Chicago; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Campbell, KP (corresponding author), Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.		Lavoie, Julie/F-2288-2013; Sigmund, Curt D./W-1611-2019; Barresi, Rita/AAB-9569-2022; Chen, Chien-Chang/D-2023-2015	Lavoie, Julie/0000-0001-6316-2769; Sigmund, Curt D./0000-0002-1453-0921; Barresi, Rita/0000-0001-7351-959X; Chen, Chien-Chang/0000-0001-8850-4278; Campbell, Kevin/0000-0003-2066-5889				Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Bohn G, 2000, FEBS LETT, V481, P73, DOI 10.1016/S0014-5793(00)01979-7; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Chutkow WA, 2002, J CLIN INVEST, V110, P203, DOI 10.1172/JCI200215672; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Guo W, 1998, J MOL CELL CARDIOL, V30, P1095, DOI 10.1006/jmcc.1998.0675; Gustafsson F, 2001, AM J PHYSIOL-HEART C, V280, pH582, DOI 10.1152/ajpheart.2001.280.2.H582; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; Hansen PB, 2001, CIRC RES, V89, P630, DOI 10.1161/hh1901.097126; Kuga T, 1996, CIRC RES, V79, P14, DOI 10.1161/01.RES.79.1.14; Lamping KG, 2000, AM J PHYSIOL-HEART C, V279, pH1906, DOI 10.1152/ajpheart.2000.279.4.H1906; Lee JH, 1999, J NEUROSCI, V19, P1912; Mangoni ME, 2003, P NATL ACAD SCI USA, V100, P5543, DOI 10.1073/pnas.0935295100; Martinez ML, 1999, J MOL CELL CARDIOL, V31, P1617, DOI 10.1006/jmcc.1999.0998; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; NELSON MT, 1995, AM J PHYSIOL, V268, P799; NUSS HB, 1993, CIRC RES, V73, P777, DOI 10.1161/01.RES.73.4.777; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Schrier AD, 2001, AM J PHYSIOL-CELL PH, V280, pC265, DOI 10.1152/ajpcell.2001.280.2.C265; SEN L, 1994, CIRC RES, V75, P149, DOI 10.1161/01.RES.75.1.149; Son WY, 2002, DEV GROWTH DIFFER, V44, P181, DOI 10.1046/j.1440-169X.2002.00633.x; Talley EM, 1999, J NEUROSCI, V19, P1895	24	271	283	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1416	1418		10.1126/science.1089268	http://dx.doi.org/10.1126/science.1089268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631046				2022-12-28	WOS:000186683500058
J	Colombelli, R; Srinivasan, K; Troccoli, M; Painter, O; Gmachl, CF; Tennant, DM; Sergent, AM; Sivco, DL; Cho, AY; Capasso, F				Colombelli, R; Srinivasan, K; Troccoli, M; Painter, O; Gmachl, CF; Tennant, DM; Sergent, AM; Sivco, DL; Cho, AY; Capasso, F			Quantum cascade surface-emitting photonic crystal laser	SCIENCE			English	Article							DEFECT MODES; OPERATION	We combine photonic and electronic band structure engineering to create a surface-emitting quantum cascade microcavity laser. A high-index contrast two-dimensional photonic crystal is used to form a micro-resonator that simultaneously provides feedback for laser action and diffracts light vertically from the surface of the semiconductor surface. A top metallic contact allows electrical current injection and provides vertical optical confinement through a bound surface plasmon wave. The miniaturization and tailorable emission properties of this design are potentially important for sensing applications, while electrical pumping can allow new studies of photonic crystal and surface plasmon structures in nonlinear and near-field optics.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; New Jersey Nanotechnol Consortium, Murray Hill, NJ 07974 USA; Univ Paris 11, Inst Elect Fondamentale, F-91405 Orsay, France; Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA	Alcatel-Lucent; Lucent Technologies; AT&T; California Institute of Technology; Harvard University; UDICE-French Research Universities; Universite Paris Saclay; Princeton University	Colombelli, R (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Srinivasan, Kartik/D-6369-2010	Colombelli, Raffaele/0000-0002-1540-9920; Painter, Oskar/0000-0002-1581-9209; Troccoli, Mariano/0000-0003-3709-1893				Beck M, 2002, SCIENCE, V295, P301, DOI 10.1126/science.1066408; Capasso F, 2002, IEEE J QUANTUM ELECT, V38, P511, DOI 10.1109/JQE.2002.1005403; COLOMBELLI R, UNPUB; D'Urso B, 1998, J OPT SOC AM B, V15, P1155, DOI 10.1364/JOSAB.15.001155; Gmachl C, 1998, APPL PHYS LETT, V72, P3130, DOI 10.1063/1.121569; Hofstetter D, 1999, APPL PHYS LETT, V75, P3769, DOI 10.1063/1.125450; Imada M, 1999, APPL PHYS LETT, V75, P316, DOI 10.1063/1.124361; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; Kohler R, 2002, NATURE, V417, P156, DOI 10.1038/417156a; Painter O, 1999, J OPT SOC AM B, V16, P275, DOI 10.1364/JOSAB.16.000275; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Park HG, 2001, APPL PHYS LETT, V79, P3032, DOI 10.1063/1.1416163; Sakoda K, 1998, J APPL PHYS, V84, P1210, DOI 10.1063/1.368186; SCHERER A, 1991, OPT PHOT NEWS, V2, P9; Schrenk W, 2000, APPL PHYS LETT, V77, P2086, DOI 10.1063/1.1313807; Sirtori C, 1998, OPT LETT, V23, P1366, DOI 10.1364/OL.23.001366; SRINIVASAN K, UNPUB; SRINIVASAN K, IN PRESS; STRAUB A, UNPUB; Vurgaftman I, 2003, IEEE J QUANTUM ELECT, V39, P689, DOI 10.1109/JQE.2003.811943	21	249	256	3	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1374	1377		10.1126/science.1090561	http://dx.doi.org/10.1126/science.1090561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14593186	Green Accepted			2022-12-28	WOS:000186683500045
J	Wood, E; Hogg, RS; Yip, B; Harrigan, PR; O'Shaughnessy, MV; Montaner, JSG				Wood, E; Hogg, RS; Yip, B; Harrigan, PR; O'Shaughnessy, MV; Montaner, JSG			Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 X 10(9) cells/L	ANNALS OF INTERNAL MEDICINE			English	Article							SOCIETY-USA PANEL; BASE-LINE; UPDATED RECOMMENDATIONS; DISEASE PROGRESSION; VIRAL LOAD; AIDS; TOXICITY; TRIAL; RNA	Background: The safety of delaying highly active antiretroviral therapy (HAART) in HIV-infected patients is uncertain when the CD4(+) cell count declines below 0.350 x 10(9) cells/L. Objective: To evaluate the effect of baseline CD4(+) cell count and adherence to HAART on survival rates. Design: Prospective observational study. Setting: Province-wide Canadian HlV/AIDS treatment program. Patients: 1422 HIV-infected persons initiating HAART between 1 August 1996 and 31 July 2000 and followed through 31 March 2002. Measurements: Patients were stratified by baseline CD4+ cell count and adherence level. Cumulative mortality rates were evaluated by using Kaplan-Meier methods and Cox regression-estimated adjusted relative hazards. Results: Kaplan-Meier analyses showed no survival benefit of starting HAART at a CD4(+) count of 0.200 x 10(9) cells/L or greater among adherent patients. Adjusted analysis showed that compared with adherent patients who initiated HAART at a CD4+ cell count of 0.350 x 10(9) cells/L or greater, nonadherent patients who initiated HAART when the CD4+ cell count was 0.200 to 0.349 x 109 cells/L had statistically elevated mortality rates (adjusted relative hazard, 2.56 [95% Cl, 1.36 to 4.84]; P = 0.004). However, compared with adherent patients who initiated HAART at a CD4(+) cell count of 0.350 x 109 cells/L or greater, adherent patients who initiated HAART when the CD4(+) cell count was 0.200 to 0.349 x 10(9) cells/L had statistically similar mortality rates (adjusted relative hazard, 0.82 [Cl, 0.45 to 1.49]; P > 0.2). Conclusions: Delaying HAART until the CD4(+) cell count falls to 0.200 x 10(9) cells/L does not increase the mortality rate in HIV-infected patients with good medication adherence. Mortality rates increase if HAART is initiated below 0.200 x 10(9) cells/L. Also, nonadherent patients have higher mortality rates than adherent patients with similar CD4(+) cell counts. Above a CD4(+) cell count of 0.200 x 10(9) cells/L, medication adherence is the critical determinant of survival, not the CD4(+) cell count at which HAART is begun.	Univ British Columbia, St Pauls Hosp, AIDS Res Program, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Program, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@hivnet.ubc.ca	Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488				Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; COX DR, 1972, J R STAT SOC B, V34, P187; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; FERRER E, 2003, 10 C RETR OPP INF BO; Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386; Grant LA, 2001, AIDS, V15, P2101, DOI 10.1097/00002030-200111090-00005; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Heath KV, 2001, AIDS, V15, P231, DOI 10.1097/00002030-200101260-00013; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Lane HC, 2003, ANN INTERN MED, V138, P680, DOI 10.7326/0003-4819-138-8-200304150-00018; Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011; Low-Beer S, 2000, J ACQ IMMUN DEF SYND, V23, P360; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; PALELLA F, 2002, 9 C RETR OPP INF SEA; Palepu A, 2001, AIDS, V15, P423, DOI 10.1097/00002030-200102160-00021; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phair JP, 2002, AIDS, V16, P2455, DOI 10.1097/00002030-200212060-00011; Schackman BR, 2002, ARCH INTERN MED, V162, P2478, DOI 10.1001/archinte.162.21.2478; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; STERLING T, 2003, 10 C RETR OPP INF BO; Sterling TR, 2003, CLIN INFECT DIS, V36, P812, DOI 10.1086/367934; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; *US PUBL HLTH SERV, GUID US ANT AG HIV I; Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009; WOOD E, 2003, IN PRESS J INFECT DI; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; 2001, HIV MED, V2, P276	33	303	306	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					810	816		10.7326/0003-4819-139-10-200311180-00008	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744ZV	14623618				2022-12-28	WOS:000186663500004
J	Yang, AS; Estecio, MRH; Garcia-Moreno, G; Kantarjian, HM; Issa, JPJ				Yang, AS; Estecio, MRH; Garcia-Moreno, G; Kantarjian, HM; Issa, JPJ			Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "induction of tumors in mice by genomic hypomethylation"	SCIENCE			English	Editorial Material							GENETIC INSTABILITY; METHYLATION		Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Yang, AS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Issa, Jean-Pierre/0000-0003-2258-5030; Estecio, Marcos/0000-0002-6874-7413				Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	7	60	64	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615517				2022-12-28	WOS:000186544300029
J	Herzig, S; Hedrick, S; Morantte, I; Koo, SH; Galimi, F; Montminy, M				Herzig, S; Hedrick, S; Morantte, I; Koo, SH; Galimi, F; Montminy, M			CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma	NATURE			English	Article							GENE-EXPRESSION; RESPONSIVE ACTIVATOR; PROMOTER ANALYSIS; PROTEIN; GLUCONEOGENESIS; REVEALS; LIVER; HES-1	Fasting triggers a series of hormonal cues that promote energy balance by inducing glucose output and lipid breakdown in the liver(1). In response to pancreatic glucagon and adrenal cortisol, the cAMP-responsive transcription factor CREB activates gluconeogenic and fatty acid oxidation programmes by stimulating expression of the nuclear hormone receptor coactivator PGC-1 (refs 2-5). In parallel, fasting also suppresses lipid storage and synthesis ( lipogenic) pathways(1), but the underlying mechanism is unknown. Here we show that mice deficient in CREB activity have a fatty liver phenotype and display elevated expression of the nuclear hormone receptor PPAR-gamma, a key regulator of lipogenic genes(6,7). CREB inhibits hepatic PPAR-gamma expression in the fasted state by stimulating the expression of the Hairy Enhancer of Split (HES-1) gene, a transcriptional repressor that is shown here to be a mediator of fasting lipid metabolism in vivo. The coordinate induction of PGC-1 and repression of PPAR-gamma by CREB during fasting provides a molecular rationale for the antagonism between insulin and counter-regulatory hormones, and indicates a potential role for CREB antagonists as therapeutic agents in enhancing insulin sensitivity in the liver.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu	Galimi, Francesco/J-4238-2012; Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879; Herzig, Stephan/0000-0003-3950-3652				Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200	27	235	251	0	31	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					190	193		10.1038/nature02110	http://dx.doi.org/10.1038/nature02110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614508				2022-12-28	WOS:000186517200046
J	Moller, S; Perlov, C; Jackson, W; Taussig, C; Forrest, SR				Moller, S; Perlov, C; Jackson, W; Taussig, C; Forrest, SR			A polymer/semiconductor write-once read-many-times memory	NATURE			English	Article							CHALCOGENIDE GLASSES; POLY(3,4-ETHYLENEDIOXYTHIOPHENE); FILMS	Organic devices promise to revolutionize the extent of, and access to, electronics by providing extremely inexpensive, lightweight and capable ubiquitous components that are printed onto plastic, glass or metal foils(1-3). One key component of an electronic circuit that has thus far received surprisingly little attention is an organic electronic memory. Here we report an architecture for a write-once read-many-times (WORM) memory, based on the hybrid integration of an electrochromic polymer with a thin-film silicon diode deposited onto a flexible metal foil substrate. WORM memories are desirable for ultralow-cost permanent storage of digital images, eliminating the need for slow, bulky and expensive mechanical drives used in conventional magnetic and optical memories. Our results indicate that the hybrid organic/inorganic memory device is a reliable means for achieving rapid, large-scale archival data storage. The WORM memory pixel exploits a mechanism of current-controlled, thermally activated un-doping of a two-component electrochromic conducting polymer.	Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Ctr Photon & Optoelect Mat, Princeton, NJ 08544 USA; Hewlett Packard Labs, Palo Alto, CA 94304 USA	Princeton University; Princeton University; Hewlett-Packard	Forrest, SR (corresponding author), Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA.							Asokan S, 2001, J OPTOELECTRON ADV M, V3, P753; FORREST SR, 1995, LASER FOCUS WORLD, V31, P99; Gelinck GH, 2000, APPL PHYS LETT, V77, P1487, DOI 10.1063/1.1290728; Greczynski G, 2001, J ELECTRON SPECTROSC, V121, P1, DOI 10.1016/S0368-2048(01)00323-1; Groenendaal BL, 2000, ADV MATER, V12, P481, DOI 10.1002/(SICI)1521-4095(200004)12:7<481::AID-ADMA481>3.0.CO;2-C; HACK M, 1992, J APPL PHYS, V72, P2331, DOI 10.1063/1.351575; Heuer HW, 2002, ADV FUNCT MATER, V12, P89, DOI 10.1002/1616-3028(20020201)12:2<89::AID-ADFM89>3.0.CO;2-1; Hua ZY, 2001, APPL SURF SCI, V169, P447, DOI 10.1016/S0169-4332(00)00701-7; Johansson T, 2002, SYNTHETIC MET, V129, P269, DOI 10.1016/S0379-6779(02)00086-3; PEI QB, 1994, POLYMER, V35, P1347, DOI 10.1016/0032-3861(94)90332-8; Peumans P, 2003, J APPL PHYS, V93, P3693, DOI 10.1063/1.1534621; Saluel D, 1999, J MAGN MAGN MATER, V193, P488, DOI 10.1016/S0304-8853(98)00480-6; STOCKER HJ, 1969, APPL PHYS LETT, V15, P55, DOI 10.1063/1.1652900; Xing KZ, 1997, SYNTHETIC MET, V89, P161, DOI 10.1016/S0379-6779(97)81212-X	14	695	719	7	305	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					166	169		10.1038/nature02070	http://dx.doi.org/10.1038/nature02070			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614502				2022-12-28	WOS:000186517200039
J	Mosimaneotsile, B; Talbot, EA; Moeti, TL; Hone, NM; Moalosi, G; Moffat, HJ; Lee, EJ; Kenyon, TA				Mosimaneotsile, B; Talbot, EA; Moeti, TL; Hone, NM; Moalosi, G; Moffat, HJ; Lee, EJ; Kenyon, TA			Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana	LANCET			English	Article								To exclude tuberculosis, WHO/UNAIDS recommends considering medical history, symptom screen, and chest radiograph before starting tuberculosis prevention in people infected with Hill. The value of a chest radiograph for this purpose is unknown. We prospectively assessed 935 HIV-Infected outpatients seeking isoniazid preventive therapy. Of 935 patients, 692 (74%) had no signs or symptoms of tuberculosis. Of these 692, 123 (18%) were lost during the chest radiograph process, and one (0.2%) of the remaining 563 was diagnosed with tuberculosis on the basis of the chest radiograph. A screening chest radiograph should not be required routinely for asymptomatic people taking isoniazid as preventive treatment in settings able to screen for signs and symptoms of tuberculosis.	US Ctr Dis Control & Prevent, BOTUSA Project, Gaborone, Botswana; Govt Botswana, Minist Hlth, Gaborone, Botswana		Mosimaneotsile, B (corresponding author), POB 90, Gaborone, Botswana.							ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; Lockman S, 2000, INT J TUBERC LUNG D, V4, P584; MASUPU K, 2001, BOTSWANA 2001 HIV SE; WHO/UNAIDS, 1999, WEEKLY EPIDEMIOLOGIC, V74, P385; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625	5	56	56	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1551	1552		10.1016/S0140-6736(03)14745-9	http://dx.doi.org/10.1016/S0140-6736(03)14745-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615113				2022-12-28	WOS:000186464500014
J	Swingler, GH; Volmink, J; Ioannidis, JPA				Swingler, GH; Volmink, J; Ioannidis, JPA			Number of published systematic reviews and global burden of disease: database analysis	BRITISH MEDICAL JOURNAL			English	Article									Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece; Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, ZA-7700 Rondebosch, South Africa; Univ Cape Town, Fac Hlth Sci, ZA-7925 Cape Town, South Africa	University of Ioannina; University of Cape Town; University of Cape Town	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece.		Ioannidis, John P. A./G-9836-2011					Alderson P, 2000, BRIT MED J, V320, P376, DOI 10.1136/bmj.320.7231.376; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Isaakidis P, 2002, BRIT MED J, V324, P702, DOI 10.1136/bmj.324.7339.702; Mulrow CD, 1997, ANN INTERN MED, V126, P389, DOI 10.7326/0003-4819-126-5-199703010-00008	5	75	79	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1083	1084		10.1136/bmj.327.7423.1083	http://dx.doi.org/10.1136/bmj.327.7423.1083			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604930	Green Published, Bronze			2022-12-28	WOS:000186530400019
J	Raitakari, OT; Juonala, M; Kahonen, M; Taittonen, L; Laitinen, T; Maki-Torkko, N; Jarvisalo, MJ; Uhari, M; Jokinen, E; Ronnemaa, T; Akerblom, HK; Viikari, JSA				Raitakari, OT; Juonala, M; Kahonen, M; Taittonen, L; Laitinen, T; Maki-Torkko, N; Jarvisalo, MJ; Uhari, M; Jokinen, E; Ronnemaa, T; Akerblom, HK; Viikari, JSA			Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood - The Cardiovascular Risk in Young Finns Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; WALL THICKNESS; PRECLINICAL ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; SERUM-CHOLESTEROL; FOLLOW-UP; CHILDREN; MEN; ASSOCIATION	Context Exposure to cardiovascular risk factors during childhood and adolescence may be associated with the development of atherosclerosis later in life. Objective To study the relationship between cardiovascular risk factors measured in childhood and adolescence and common carotid artery intima-media thickness (IMT), a marker of preclinical atherosclerosis, measured in adulthood. Design, Setting, and Participants Population-based, prospective cohort study conducted at 5 centers in Finland among 2229 white adults aged 24 to 39 years who were examined in childhood and adolescence at ages 3 to 18 years in 1980 and reexamined 21 years later, between September 2001 and January 2002. Main Outcome Measures Association between cardiovascular risk variables (levels of low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides; LDL-C/HDL-C ratio; systolic and diastolic blood pressure; body mass index; smoking) measured in childhood and adulthood and common carotid artery IMT measured in adulthood. Results In multivariable models adjusted for age and sex, IMT in adulthood was significantly associated with childhood LDL-C levels (P=.001), systolic blood pressure (P<.001), body mass index (P=.007), and smoking (P=.02), and with adult systolic blood pressure (P<.001), body mass index (P<.001), and smoking (P=.004). The number of risk factors measured in 12- to 18-year-old adolescents, including high levels (ie, extreme age- and sex-specific 80th percentile) of LDL-C, systolic blood pressure, body mass index, and cigarette smoking, were directly related to carotid IMT measured in young adults at ages 33 through 39 years (P<.001 for both men and women), and remained significant after adjustment for contemporaneous risk variables. The number of risk factors measured at ages 3 to 9 years demonstrated a weak direct relationship with carotid IMT at ages 24 to 30 years in men (P=.02) but not in women (P=.63). Conclusions Risk factor profile assessed in 12- to 18-year-old adolescents predicts adult common carotid artery IMT independently of contemporaneous risk factors. These findings suggest that exposure to cardiovascular risk factors early in life may induce changes in arteries that contribute to the development of atherosclerosis.	Univ Turku, Turku PET Ctr, FIN-20500 Turku, Finland; Univ Turku, Dept Clin Physiol, FIN-20500 Turku, Finland; Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, FIN-20500 Turku, Finland; Univ Turku, Dept Med, FIN-20500 Turku, Finland; Univ Tampere, Dept Clin Physiol, FIN-33101 Tampere, Finland; Univ Oulu, Dept Paediat, Oulu, Finland; Univ Kuopio, Dept Clin Physiol, FIN-70211 Kuopio, Finland; Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland	University of Turku; University of Turku; University of Turku; University of Turku; Tampere University; University of Oulu; University of Eastern Finland; University of Helsinki	Raitakari, OT (corresponding author), Univ Turku, Turku PET Ctr, POB 52, FIN-20500 Turku, Finland.	olli.raitakari@utu.fi	Raitakari, Olli/AAQ-7389-2021	Kahonen, Mika/0000-0002-4510-7341; Juonala, Markus/0000-0001-9498-364X				AKERBLOM HK, 1985, ACTA PAEDIATR SCAND, P49; Allan PL, 1997, STROKE, V28, P348, DOI 10.1161/01.STR.28.2.348; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; Davis PH, 2001, CIRCULATION, V104, P2815, DOI 10.1161/hc4601.099486; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gaziano JM, 1998, NEW ENGL J MED, V338, P1690, DOI 10.1056/NEJM199806043382310; HAAPANEN A, 1989, CIRCULATION, V80, P10, DOI 10.1161/01.CIR.80.1.10; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Jarvisalo MJ, 2001, CIRCULATION, V104, P2943, DOI 10.1161/hc4901.100522; Kanters SDJM, 1997, STROKE, V28, P665, DOI 10.1161/01.STR.28.3.665; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAPINLEIMU H, 1995, LANCET, V345, P471, DOI 10.1016/S0140-6736(95)90580-4; MAHONEY LT, 1991, ANN NY ACAD SCI, V623, P120, DOI 10.1111/j.1749-6632.1991.tb43723.x; Mahoney LT, 1996, J AM COLL CARDIOL, V27, P277, DOI 10.1016/0735-1097(95)00461-0; McGill HC, 2000, ARTERIOSCL THROM VAS, V20, P836, DOI 10.1161/01.ATV.20.3.836; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; O'Leary DH, 2002, AM J CARDIOL, V90, p18L, DOI 10.1016/S0002-9149(02)02957-0; Obarzanek E, 2001, PEDIATRICS, V107, P256, DOI 10.1542/peds.107.2.256; PAUCIULLO P, 1994, ARTERIOSCLER THROMB, V14, P1075, DOI 10.1161/01.ATV.14.7.1075; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; Porkka KVK, 1997, AM J EPIDEMIOL, V146, P64, DOI 10.1093/oxfordjournals.aje.a009192; PORKKA KVK, 1994, AM J EPIDEMIOL, V140, P1096, DOI 10.1093/oxfordjournals.aje.a117210; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; Stamler J, 2000, JAMA-J AM MED ASSOC, V284, P311, DOI 10.1001/jama.284.3.311; Tonstad S, 1996, ARTERIOSCL THROM VAS, V16, P984, DOI 10.1161/01.ATV.16.8.984; VIIKARI J, 1991, ANN MED, V23, P53, DOI 10.3109/07853899109147931; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968	32	1278	1318	0	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2277	2283		10.1001/jama.290.17.2277	http://dx.doi.org/10.1001/jama.290.17.2277			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600186	Bronze			2022-12-28	WOS:000186356800022
J	Ball, ED				Ball, ED			Update in hematology	ANNALS OF INTERNAL MEDICINE			English	Review									Univ Calif San Diego, Div Blood & Bone Marrow Transplantat, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ball, ED (corresponding author), Univ Calif San Diego, Div Blood & Bone Marrow Transplantat, 9310 Campus Point Dr, La Jolla, CA 92093 USA.	tball@ucsd.edu						Forrester JS, 2003, CIRCULATION, V108, P1139, DOI 10.1161/01.CIR.0000085305.82019.65	1	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					916	922		10.7326/0003-4819-139-11-200312020-00010	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644894				2022-12-28	WOS:000186884800005
J	Wachtell, K; Ibsen, H; Olsen, MH; Borch-Johnsen, K; Lindholm, LH; Mogensen, CE; Dahlof, B; Devereux, RB; Beevers, G; de Faire, U; Fyhrquist, F; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Nieminen, MS; Okin, PM; Omvik, P; Oparil, S; Wedel, H; Snapinn, SM; Aurup, P				Wachtell, K; Ibsen, H; Olsen, MH; Borch-Johnsen, K; Lindholm, LH; Mogensen, CE; Dahlof, B; Devereux, RB; Beevers, G; de Faire, U; Fyhrquist, F; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Nieminen, MS; Okin, PM; Omvik, P; Oparil, S; Wedel, H; Snapinn, SM; Aurup, P			Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study	ANNALS OF INTERNAL MEDICINE			English	Article							VASCULAR-DISEASE; EXCRETION RATE; FOLLOW-UP; MICROALBUMINURIA; MORTALITY; PREDICTOR; MASS; INTERVENTION; MORBIDITY; COHORT	Background: several studies have shown that albuminuria is associated with increased risk for fatal and nonfatal cardiovascular events, independent of conventional risk factors. The partition values for urine albumin-creatinine ratio (UACR) used to identify microalbuminuria have been based on studies that predicted risk in diabetic patients. Objective: To determine whether the relation between albuminuria and cardiovascular risk can be used to predict cardiovascular morbidity and mortality in hypertensive patients. Design: Multicenter cohort study derived from a randomized, controlled trial. Patients: 8206 patients with stage II or III hypertension randomly assigned to double-blind therapy with losartan or atenolol. Follow-up was 39 122 patient-years. Measurements: Renal glomerular permeability evaluated by UACR. Results: In nondiabetic hypertensive patients with left ventricular hypertrophy, the risk for the composite cardiovascular end point increased continuously as albuminuria increased (P < 0.001 for trend). There was no specific threshold for increased risk. For every 10-fold increase in UACR, hazard ratios in nondiabetic patients increased as follows: composite end point, by 57% (95% CI, 40.6% to 75.0%); cardiovascular mortality, by 97.7% (CI, 66.5% to 235%); all-cause mortality, by 75.2% (CI, 54.0% to 99.4%); stroke, by 51.0% (CI, 28.8% to 76.9%); and myocardial infarction, by 45% (CI, 19.9% to 75.4%) (P < 0.001 for all comparisons). Values were similar in diabetic patients, although for myocardial infarction the trend was weaker and not significant. Conclusion: increased UACR resulted in increasing risk for cardiovascular morbidity and mortality among hypertensive patients with left ventricular hypertrophy. We found no thresholds or plateaus. Risk increases at much lower UACR values than has been reported among diabetic patients.	Glostrup Univ Hosp, Dept Med, DK-2600 Glostrup, Denmark; Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Norrland Univ Hosp, Umea, Sweden; Arhus Univ Hosp, Aarhus, Denmark; Sahlgrenska Univ, Ostra Hosp, S-41345 Gothenburg, Sweden; Nord Sch Publ Hlth, Gothenburg, Sweden; Cornell Univ, Weill Med Coll, New York, NY USA; Univ Birmingham, Dudley Rd Hosp, Birmingham B15 2TT, W Midlands, England; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Helsinki Univ Hosp, Dept Med 4, FIN-00170 Helsinki, Finland; Univ Michigan, Ann Arbor, MI 48109 USA; Ulleval Hosp, Oslo, Norway; Merck Res Labs, Sollentuna, Sweden; Viborg Univ Hosp, Viborg, Denmark; Haukeland Hosp, N-5021 Bergen, Norway; Univ Alabama Birmingham, Birmingham, AL USA; Merck & Co Inc, Whitehouse Stn, NJ USA	University of Copenhagen; Steno Diabetes Center; Umea University; Aarhus University; Sahlgrenska University Hospital; Cornell University; University of Birmingham; Karolinska Institutet; University of Helsinki; Helsinki University Central Hospital; University of Michigan System; University of Michigan; University of Oslo; Merck & Company; University of Alabama System; University of Alabama Birmingham; Merck & Company	Wachtell, K (corresponding author), Glostrup Univ Hosp, Dept Med, M41, DK-2600 Glostrup, Denmark.	kristian@wachtell.net	Olsen, Michael H/H-8176-2014	Olsen, Michael Hecht/0000-0003-2230-5780				Agewall S, 1997, AM J CARDIOL, V80, P164, DOI 10.1016/S0002-9149(97)00312-3; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BIGAZZI R, 1992, NEPHRON, V61, P94, DOI 10.1159/000186842; Borch-Johnsen K, 1999, ARTERIOSCL THROM VAS, V19, P1992, DOI 10.1161/01.ATV.19.8.1992; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; Bulatov VA, 2001, J HYPERTENS, V19, P1473, DOI 10.1097/00004872-200108000-00016; CERASOLA G, 1989, J HYPERTENS, V7, pS332, DOI 10.1097/00004872-198900076-00162; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; Deckert T, 1996, BRIT MED J, V312, P871; Dinneen SF, 1997, ARCH INTERN MED, V157, P1413, DOI 10.1001/archinte.157.13.1413; ESHOJ O, 1987, DIABETIC MED, V4, P531, DOI 10.1111/j.1464-5491.1987.tb00924.x; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Gerstein HC, 2001, INT J CLIN PRACT, P8; GORGELS WJMJ, 1995, AM J EPIDEMIOL, V142, P1157, DOI 10.1093/oxfordjournals.aje.a117574; IRGENSMOLLER L, 1986, CLIN CHIM ACTA, V157, P295, DOI 10.1016/0009-8981(86)90304-9; Jager A, 1999, ARTERIOSCL THROM VAS, V19, P617, DOI 10.1161/01.ATV.19.3.617; Jensen JS, 2000, HYPERTENSION, V35, P898, DOI 10.1161/01.HYP.35.4.898; Jensen JS, 1997, NEPHROL DIAL TRANSPL, V12, P6; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KUUSISTO J, 1995, CIRCULATION, V91, P831, DOI 10.1161/01.CIR.91.3.831; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIAO YL, 1995, JAMA-J AM MED ASSOC, V273, P1592, DOI 10.1001/jama.273.20.1592; Ljungman S, 1996, AM J HYPERTENS, V9, P770, DOI 10.1016/0895-7061(96)00102-1; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; PARVING HH, 1974, LANCET, V1, P1190; Roest M, 2001, CIRCULATION, V103, P3057, DOI 10.1161/hc2501.091353; Wachtell K, 2002, AM HEART J, V143, P319, DOI 10.1067/mhj.2002.119895; Wachtell K, 2002, J HYPERTENS, V20, P405, DOI 10.1097/00004872-200203000-00015; YUDKIN JS, 1988, LANCET, V2, P530	31	432	463	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					901	906		10.7326/0003-4819-139-11-200312020-00008	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644892				2022-12-28	WOS:000186884800003
J	Richmond, JK; Baglole, DJ				Richmond, JK; Baglole, DJ			Lassa fever: epidemiology, clinical features, and social consequences	BRITISH MEDICAL JOURNAL			English	Review							LINKED-IMMUNOSORBENT-ASSAY; SIERRA-LEONE; VIRUS; DIAGNOSIS; VIROLOGY; GUINEA; RISK	Lassa fever is endemic in west Africa, where it probably kills several thousand people each year. With access to the region improving, the opportunity, and the need, to improve our understanding of this disease are increasing.	Merlin, London SE1 1DB, England		Richmond, JK (corresponding author), 24 Llantrisant Rise, Cardiff CF5 2PG, S Glam, Wales.							BAUSCH D, 2000, LASSA FEVER SIERRA L; Bausch DG, 2000, J CLIN MICROBIOL, V38, P2670, DOI 10.1128/JCM.38.7.2670-2677.2000; Chen JP, 2000, BLOOD COAGUL FIBRIN, V11, P461, DOI 10.1097/00001721-200007000-00010; CUMMINS D, 1990, JAMA-J AM MED ASSOC, V264, P2093; CUMMINS D, 1989, BRIT J HAEMATOL, V72, P543, DOI 10.1111/j.1365-2141.1989.tb04321.x; DEMBY AH, 1994, J CLIN MICROBIOL, V32, P2898, DOI 10.1128/JCM.32.12.2898-2903.1994; Fisher-Hoch SP, 2001, REV MED VIROL, V11, P331, DOI 10.1002/rmv.329; FISHERHOCH S, 1988, J MED VIROL, V26, P127, DOI 10.1002/jmv.1890260204; FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857; HEALING T, 2001, REPORT ASSESSMENT VI; JOHNSON KM, 1987, J INFECT DIS, V155, P456, DOI 10.1093/infdis/155.3.456; KEENLYSIDE RA, 1983, AM J TROP MED HYG, V32, P829, DOI 10.4269/ajtmh.1983.32.829; LIAO BS, 1992, OTOLARYNG HEAD NECK, V106, P226, DOI 10.1177/019459989210600303; LUKASHEVICH IS, 1993, J MED VIROL, V40, P210, DOI 10.1002/jmv.1890400308; McCarthy M, 2002, LANCET, V360, P732, DOI 10.1016/S0140-6736(02)09938-5; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; *MERL, 2002, LICKING LASSA FEVER; PRICE ME, 1988, BRIT MED J, V297, P584, DOI 10.1136/bmj.297.6648.584; ter Meulen J, 2001, TROP MED INT HEALTH, V6, P83, DOI 10.1046/j.1365-3156.2001.00676.x; terMeulen J, 1996, AM J TROP MED HYG, V55, P661; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407; *WHO, 2000, 179 WHO; Wilson ME, 1995, BRIT MED J, V311, P1681, DOI 10.1136/bmj.311.7021.1681	25	207	213	1	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 29	2003	327	7426					1271	1275		10.1136/bmj.327.7426.1271	http://dx.doi.org/10.1136/bmj.327.7426.1271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644972	Green Published, Green Submitted			2022-12-28	WOS:000186948800021
J	Samaha-Kfoury, JN; Araj, GF				Samaha-Kfoury, JN; Araj, GF			Recent developments in beta lactamases and extended spectrum beta lactamases	BRITISH MEDICAL JOURNAL			English	Review							KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; RISK-FACTORS; ETEST ESBL; RESISTANCE; IMPACT; ENTEROBACTERIACEAE; COLONIZATION; EPIDEMIOLOGY; INHIBITORS		Amer Univ Beirut, Dept Pathol & Lab Med, Beirut, Lebanon	American University of Beirut	Araj, GF (corresponding author), Amer Univ Beirut, Dept Pathol & Lab Med, POB 113-6044, Beirut, Lebanon.							AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Araj G F, 2000, J Med Liban, V48, P221; ARLET G, 1991, FEMS MICROBIOL LETT, V82, P19; Bisson G, 2002, INFECT CONT HOSP EP, V23, P254, DOI 10.1086/502045; BRADFORD PA, 1994, ANTIMICROB AGENTS CH, V38, P761, DOI 10.1128/AAC.38.4.761; Bradford PA, 2001, CLIN MICROBIOL REV, V14, P933, DOI 10.1128/CMR.14.4.933-951.2001; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610; CASEWELL M, 1977, BRIT MED J, V2, P1315, DOI 10.1136/bmj.2.6098.1315; Cormican MG, 1996, J CLIN MICROBIOL, V34, P1880, DOI 10.1128/JCM.34.8.1880-1884.1996; DBAIBO GS, 2000, LEBAN MED J, V48, P177; DECHAMPS C, 1989, J CLIN MICROBIOL, V27, P2887, DOI 10.1128/JCM.27.12.2887-2890.1989; Ferrara A, 1998, CHEMOTHERAPY, V44, P313, DOI 10.1159/000007128; Kotra L P., 2002, BACTERIAL RESISTANCE, P123; Lautenbach E, 2001, CLIN INFECT DIS, V32, P1162, DOI 10.1086/319757; Leverstein-van Hall MA, 2002, J CLIN MICROBIOL, V40, P3703, DOI 10.1128/JCM.40.10.3703-3711.2002; MartinezMartinez L, 1996, ANTIMICROB AGENTS CH, V40, P342, DOI 10.1128/AAC.40.2.342; *NAT COMM CLIN LAB, 2002, M100S12 NAT COMM CLI; NueschInderbinen MT, 1996, EUR J CLIN MICROBIOL, V15, P398, DOI 10.1007/BF01690097; Page MI, 2002, ASM NEWS, V68, P217; Paterson DL, 2001, J CLIN MICROBIOL, V39, P2206, DOI 10.1128/JCM.39.6.2206-2212.2001; Paterson DL, 2000, CLIN INFECT DIS, V30, P473, DOI 10.1086/313719; STRATTON CW, 2000, LEBAN MED J, V48, P186; Thomson KS, 1999, ANTIMICROB AGENTS CH, V43, P1393, DOI 10.1128/AAC.43.6.1393	24	58	68	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1209	1213		10.1136/bmj.327.7425.1209	http://dx.doi.org/10.1136/bmj.327.7425.1209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630759	Green Published			2022-12-28	WOS:000186784300022
J	Johnson, EJ; Goldstein, DG				Johnson, EJ; Goldstein, DG			Medicine - Do defaults save lives?	SCIENCE			English	Editorial Material							ORGAN DONATION		Columbia Univ, Ctr Decis Sci, New York, NY 10027 USA	Columbia University	Johnson, EJ (corresponding author), Columbia Univ, Ctr Decis Sci, New York, NY 10027 USA.	ejj3@columbia.edu	Goldstein, Daniel G/A-7479-2008; Johnson, Eric/C-5668-2012	Goldstein, Daniel G/0000-0002-0970-5598; Johnson, Eric/0000-0001-7797-8347				American Medical Association, 1993, STRAT CAD ORG PROC M; BARON J, 1994, ORGAN BEHAV HUM DEC, V59, P475, DOI 10.1006/obhd.1994.1070; Bellman S, 2001, COMMUN ACM, V44, P25, DOI 10.1145/359205.359241; Camerer C, 2003, U PENN LAW REV, V151, P1211, DOI 10.2307/3312889; CAMPLAN AL, 1994, JAMA-J AM MED ASSOC, V272, P1708; Clay M., 2002, J SOCIAL POLITICAL E, V27, P227; Conesa C, 2003, TRANSPLANT P, V35, P1276, DOI 10.1016/S0041-1345(03)00468-8; Gabel H, 1997, TRANSPLANT P, V29, P3093, DOI 10.1016/S0041-1345(97)00794-X; Gabel H, 2002, DONOR NONDONOR REGIS; Gimbel Ronald W, 2003, Prog Transplant, V13, P17; Gold SM, 2001, ORGAN DONATION PROCE; Harris CE, 2001, ISSUES LAW MED, V16, P213; Harris J, 2003, J MED ETHICS, V29, P303, DOI 10.1136/jme.29.5.303; Harris J, 2002, BRIT MED J, V325, P114, DOI 10.1136/bmj.325.7356.114; Johnson EJ, 2002, MARKET LETT, V13, P5, DOI 10.1023/A:1015044207315; JOHNSON EJ, 1993, J RISK UNCERTAINTY, V7, P35, DOI 10.1007/BF01065313; Josefson D, 2002, BRIT MED J, V324, P1541, DOI 10.1136/bmj.324.7353.1541; Kahneman D, 2000, CHOICES VALUES FRAME; Klassen AC, 1996, ANN INTERN MED, V125, P70, DOI 10.7326/0003-4819-125-1-199607010-00011; Madrian BC, 2001, Q J ECON, V116, P1149, DOI 10.1162/003355301753265543; Oz MC, 2003, J HEART LUNG TRANSPL, V22, P389, DOI 10.1016/S1053-2498(03)00074-3; PAYNE JW, 1992, ANNU REV PSYCHOL, V43, P87, DOI 10.1146/annurev.ps.43.020192.000511; Samuelson W, 1988, J RISK UNCERTAINTY, V1, P7, DOI 10.1007/BF00055564; SLOVIC P, 1995, AM PSYCHOL, V50, P364, DOI 10.1037/0003-066X.50.5.364; THALER RH, IN PRESS U CHICAGO L; The Gallup Organization, 1993, AM PUBL ATT ORG DON; TVERSKY A, 1991, Q J ECON, V106, P1039, DOI 10.2307/2937956; Wolf JS, 1997, TRANSPL P, V29, P1477, DOI 10.1016/S0041-1345(96)00694-X	28	1004	1023	3	166	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1338	1339		10.1126/science.1091721	http://dx.doi.org/10.1126/science.1091721			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	745HP	14631022				2022-12-28	WOS:000186683500032
J	Song, WH; Kinloch, IA; Windle, AH				Song, WH; Kinloch, IA; Windle, AH			Nematic liquid crystallinity of multiwall carbon nanotubes	SCIENCE			English	Article							DISCLINATIONS		Univ Cambridge, Dept Mat Sci & Met, Cambridge CB2 3QZ, England	University of Cambridge	Windle, AH (corresponding author), Univ Cambridge, Dept Mat Sci & Met, Pembroke St, Cambridge CB2 3QZ, England.		Song, Wenhui/M-9661-2013; Kinloch, Ian/AAI-3965-2021; Song, Wenhui/AAO-8045-2020	Song, Wenhui/0000-0001-8406-472X; Song, Wenhui/0000-0001-8406-472X				CHEN SX, 1993, LIQ CRYST, V15, P247, DOI 10.1080/02678299308031955; FORY PJ, 1956, P ROY SOC LOND A MAT, V243, P66; Gonin D, 1997, LIQ CRYST, V23, P489, DOI 10.1080/026782997208073; Hirsch A, 2002, ANGEW CHEM INT EDIT, V41, P1853, DOI 10.1002/1521-3773(20020603)41:11<1853::AID-ANIE1853>3.0.CO;2-N; JOSEPH AN, 1986, MOL CRYST LIQ CRYST, V138, P211; ONSAGER L, 1949, ANN NY ACAD SCI, V51, P627, DOI 10.1111/j.1749-6632.1949.tb27296.x; Somoza AM, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.081403; WOOD BA, 1986, NATURE, V324, P655, DOI 10.1038/324655a0; [No title captured]	9	259	271	4	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1363	1363		10.1126/science.1089764	http://dx.doi.org/10.1126/science.1089764			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631032				2022-12-28	WOS:000186683500042
J	Dacey, MJ				Dacey, MJ			Tragedy and response - The Rhode Island nightclub fire	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kent Cty Hosp, Dept Crit Care Med, Warwick, RI 02886 USA		Dacey, MJ (corresponding author), Kent Cty Hosp, Dept Crit Care Med, Warwick, RI 02886 USA.								0	27	27	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					1990	1992		10.1056/NEJMp038179	http://dx.doi.org/10.1056/NEJMp038179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627783				2022-12-28	WOS:000186642900002
J	Sharp, D				Sharp, D			Before, under, and after anaesthesia	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1598	1598		10.1016/S0140-6736(03)14840-4	http://dx.doi.org/10.1016/S0140-6736(03)14840-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630438				2022-12-28	WOS:000186637400006
J	Smith, EJ; Marsden, RG; Balogh, A; Gloeckler, G; Geiss, J; McComas, DJ; McKibben, RB; MacDowall, RJ; Lanzerotti, LJ; Krupp, N; Krueger, H; Landgraf, M				Smith, EJ; Marsden, RG; Balogh, A; Gloeckler, G; Geiss, J; McComas, DJ; McKibben, RB; MacDowall, RJ; Lanzerotti, LJ; Krupp, N; Krueger, H; Landgraf, M			The Sun and heliosphere at solar maximum	SCIENCE			English	Review							ULYSSES OBSERVATIONS; MODULATION; LATITUDES; POLE	Recent Ulysses observations from the Sun's equator to the poles reveal fundamental properties of the three-dimensional heliosphere at the maximum in solar activity. The heliospheric magnetic field originates from a magnetic dipole oriented nearly perpendicular to, instead of nearly parallel to, the Sun's rotation axis. Magnetic fields, solar wind, and energetic charged particles from low-latitude sources reach all latitudes, including the polar caps. The very fast high-latitude wind and polar coronal holes disappear and reappear together. Solar wind speed continues to be inversely correlated with coronal temperature. The cosmic ray flux is reduced symmetrically at all latitudes.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; European Space Agcy, European Space Technol Ctr, Dept Space Sci, NL-2200 AG Noordwijk, Netherlands; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2BZ, England; Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Int Space Sci Inst, CH-3012 Bern, Switzerland; SW Res Inst, San Antonio, TX 78238 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Durham, NH 03824 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; New Jersey Inst Technol, Ctr Solar Terr Res, Newark, NJ 07021 USA; Max Planck Inst Aeron, D-37191 Katlenburg Lindau, Germany; Max Planck Inst Kernphys, D-69029 Heidelberg, Germany	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); European Space Agency; Imperial College London; University System of Maryland; University of Maryland College Park; Southwest Research Institute; University System Of New Hampshire; University of New Hampshire; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Alcatel-Lucent; Lucent Technologies; AT&T; New Jersey Institute of Technology; Max Planck Society; Max Planck Society	Smith, EJ (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.		McComas, David J/H-6202-2011; Balogh, Andre/GZK-2076-2022; MacDowall, Robert J/D-2773-2012	McComas, David J/0000-0001-6160-1158; 				Balogh A., 2001, HELIOSPHERE NEAR SOL; CROOKER N, 1997, GEOPHYSICAL MONOGRAP, V99; FISK L, 1998, COSMIC RAYS HELIOSPH; Fisk LA, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2002JA009284; Fisk LA, 2001, SPACE SCI REV, V97, P21, DOI 10.1023/A:1011805606787; FOUKAL PV, 1990, SOLAR ASTROPHYSICS; Gloeckler G, 2003, J GEOPHYS RES-SPACE, V108, DOI 10.1029/2002JA009286; Harvey KL, 2002, SOL PHYS, V211, P31, DOI 10.1023/A:1022469023581; Heber B, 2001, SPACE SCI REV, V97, P309, DOI 10.1023/A:1011889319933; Heber B, 1996, ASTRON ASTROPHYS, V316, P538; Hofer MY, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014944; JOKIPII JR, 1995, GEOPHYS RES LETT, V22, P3385, DOI 10.1029/95GL03458; Ko YK, 1997, SOL PHYS, V171, P345, DOI 10.1023/A:1004943213433; Landgraf M, 2000, J GEOPHYS RES-SPACE, V105, P10303, DOI 10.1029/1999JA900243; LANZEROTTI LJ, 2001, S-P B ASTROPHYS, P259; Marsden RG, 1996, ASTRON ASTROPHYS, V316, P279; McComas DJ, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013940; MCCOMAS DJ, 2003, GEOPHYS RES LETT, V30, DOI [DOI 10.1029/2003GL017136, 10.1029/2003GL017136]; McKibben RB, 2001, SPACE SCI REV, V97, P257, DOI 10.1023/A:1011816715390; McKibben RB, 2001, SPACE SCI REV, V97, P367, DOI 10.1023/A:1011810024476; MCKIBBEN RB, 2001, S-P B ASTROPHYS, P327; NEUGEBAUER M, 2001, S-P B ASTROPHYS, P43; Parker E.N., 1963, ASTROPHYS J SUPPL S, DOI DOI 10.1086/190087; Potgieter MS, 1998, SPACE SCI REV, V83, P147, DOI 10.1023/A:1005014722123; ROELOF EC, 1992, GEOPHYS RES LETT, V19, P1243, DOI 10.1029/92GL01312; Simnett GM, 2001, SPACE SCI REV, V97, P231, DOI 10.1023/A:1011800311755; Simpson JA, 1996, ASTROPHYS J, V465, pL69, DOI 10.1086/310127; Smith EJ, 2001, GEOPHYS RES LETT, V28, P4159, DOI 10.1029/2001GL013471; SMITH EJ, 1995, GEOPHYS RES LETT, V22, P3297, DOI 10.1029/95GL03556; Smith EJ, 2003, AIP CONF PROC, V679, P67, DOI 10.1063/1.1618543; SMITH EJ, 1995, SCIENCE, V268, P1005, DOI 10.1126/science.7754377; SMITH EJ, 1995, GEOPHYS RES LETT, V22, P3317, DOI 10.1029/95GL02826; Smith EJ, 2001, J GEOPHYS RES-SPACE, V106, P15819, DOI 10.1029/2000JA000120; Suess ST, 1996, GEOPHYS RES LETT, V23, P3267, DOI 10.1029/96GL02908; ZIRKER JB, 1977, CORONAL HOLES HIGH S	35	58	58	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1165	1169		10.1126/science.1086295	http://dx.doi.org/10.1126/science.1086295			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615526				2022-12-28	WOS:000186544300040
J	Ballantyne, JC; Mao, JR				Ballantyne, JC; Mao, JR			Opioid therapy for chronic pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC NONMALIGNANT PAIN; CONTROLLED-RELEASE OXYCODONE; LONG-TERM USE; MORPHINE-TOLERANCE; DOUBLE-BLIND; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; ANALGESIC TOLERANCE; RECEPTOR ANTAGONIST; OSTEOARTHRITIS PAIN		Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Pain Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ballantyne, JC (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Pain Ctr, 15 Parkman St,WACC 333, Boston, MA 02114 USA.	jballantyne@partners.org			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008835] Funding Source: NIH RePORTER; NIDA NIH HHS [R01DA08835] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abs R, 2000, J CLIN ENDOCR METAB, V85, P2215, DOI 10.1210/jc.85.6.2215; Altier N, 2001, BURNS, V27, P771, DOI 10.1016/S0305-4179(01)00032-8; Alvarez V, 2001, NEURON, V32, P761, DOI 10.1016/S0896-6273(01)00530-X; *AM SOC ADD MED AM, 2001, DEF REL US OP TREATM; American Academy of Pain Medicine and American Pain Society, 1997, US OP TREATM CHRON P; ARKINSTALL W, 1995, PAIN, V62, P169, DOI 10.1016/0304-3959(94)00262-D; BALLANTYNE J, 2002, MASSACHUSETTS GEN HO, P562; BANKI CM, 1987, PSYCHONEUROENDOCRINO, V12, P3, DOI 10.1016/0306-4530(87)90016-3; BARTOLOME MB, 1983, EUR J PHARMACOL, V95, P231, DOI 10.1016/0014-2999(83)90639-8; Bian D, 1999, BRAIN RES, V831, P55, DOI 10.1016/S0006-8993(99)01393-1; Bouckoms A. J., 1992, ANN CLIN PSYCHIAT, V4, P185; BRODNER RA, 1978, MT SINAI J MED, V45, P233; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BUCKLEY FP, 1986, PAIN, V26, P153, DOI 10.1016/0304-3959(86)90071-0; Bulka A, 2002, PAIN, V95, P103, DOI 10.1016/S0304-3959(01)00382-7; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Caldwell JR, 2002, J PAIN SYMPTOM MANAG, V23, P278, DOI 10.1016/S0885-3924(02)00383-4; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; COLLU R, 1976, EUR J PHARMACOL, V37, P133, DOI 10.1016/0014-2999(76)90016-9; COMPTON MA, 1994, J PAIN SYMPTOM MANAG, V9, P462, DOI 10.1016/0885-3924(94)90203-8; Davis AM, 1999, J PHARMACOL EXP THER, V289, P1048; De Waal EJ, 1998, TOXICOLOGY, V129, P201, DOI 10.1016/S0300-483X(98)00077-8; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; ELLIOTT K, 1994, PAIN, V56, P69, DOI 10.1016/0304-3959(94)90151-1; Federation of State Medical Boards of the United States, 1998, MOD GUID US CONTR SU; Finch PM, 2000, CLIN J PAIN, V16, P251, DOI 10.1097/00002508-200009000-00011; FINLAYSON RE, 1986, PAIN, V26, P175, DOI 10.1016/0304-3959(86)90073-4; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Fishman SM, 2002, PAIN MED, V3, P339, DOI 10.1046/j.1526-4637.2002.02047.x; FISHMAN SM, 2002, MASSACHUSETTS GEN HO; Foley KM, 2003, NEW ENGL J MED, V348, P1279, DOI 10.1056/NEJMe030014; FRANCES A, 2000, DIAGNOSTIC STAT MANU, P191; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; Galski T, 2000, J PAIN SYMPTOM MANAG, V19, P200, DOI 10.1016/S0885-3924(99)00158-X; GardnerNix JS, 1996, J PAIN SYMPTOM MANAG, V11, P321, DOI 10.1016/0885-3924(95)00191-3; Giffard RG, 2000, REGION ANESTH PAIN M, V25, P22, DOI 10.1016/S1098-7339(00)80006-1; Grisel JE, 1996, PSYCHOPHARMACOLOGY, V128, P248, DOI 10.1007/s002130050132; Haythornthwaite JA, 1998, J PAIN SYMPTOM MANAG, V15, P185, DOI 10.1016/S0885-3924(97)00352-7; Hill CS, 1996, J PAIN SYMPTOM MANAG, V11, P287; JADAD AR, 1992, LANCET, V339, P1367, DOI 10.1016/0140-6736(92)91194-D; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; KJAERSGAARDANDERSEN P, 1990, PAIN, V43, P309, DOI 10.1016/0304-3959(90)90028-C; KUSNECOV AW, 1994, INT ARCH ALLERGY IMM, V105, P107, DOI 10.1159/000236812; Lorenz J, 1997, PAIN, V73, P369, DOI 10.1016/S0304-3959(97)00123-1; Maier C, 2002, PAIN, V97, P223, DOI 10.1016/S0304-3959(02)00020-9; MAKMAN MH, 1994, ADV NEUROIMMUNOL, V4, P69, DOI 10.1016/S0960-5428(05)80002-6; Malaivijitnond S, 1998, J MED PRIMATOL, V27, P1, DOI 10.1111/j.1600-0684.1998.tb00061.x; Manning BH, 1996, PAIN, V67, P79, DOI 10.1016/0304-3959(96)81972-5; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Mao JR, 2002, J NEUROSCI, V22, P8312; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mao JR, 2002, J NEUROSCI, V22, P7650; MAO JR, 1995, PAIN, V61, P353, DOI 10.1016/0304-3959(95)00022-K; MAREK P, 1991, BRAIN RES, V558, P163, DOI 10.1016/0006-8993(91)90736-F; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; MCNAIRY SL, 1984, PAIN, V18, P169, DOI 10.1016/0304-3959(84)90884-4; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; MENDELSON JH, 1975, J PHARMACOL EXP THER, V192, P211; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Mitchell JM, 2000, NAT NEUROSCI, V3, P47, DOI 10.1038/71120; Moran C, 1991, BR J CLIN RES, V2, P1; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; PAPPAGALLO M, 1994, ANALGESIA, V1, pS1; Pasternak GW, 2001, NEUROSCIENTIST, V7, P220, DOI 10.1177/107385840100700307; Peloso PM, 2000, J RHEUMATOL, V27, P764; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Rahim TR, 2002, J NEUROIMMUNOL, V127, P88, DOI 10.1016/S0165-5728(02)00103-0; Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015; READY LB, 1982, PAIN, V12, P285, DOI 10.1016/0304-3959(82)90160-9; Risdahl JM, 1998, J NEUROIMMUNOL, V83, P4, DOI 10.1016/S0165-5728(97)00216-6; ROLANDI E, 1983, ACTA ENDOCRINOL-COP, V104, P257, DOI 10.1530/acta.0.1040257; Roth SH, 2000, ARCH INTERN MED, V160, P853, DOI 10.1001/archinte.160.6.853; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Roy S, 1996, NEUROCHEM RES, V21, P1375, DOI 10.1007/BF02532379; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; Savage SR, 1996, J PAIN SYMPTOM MANAG, V11, P274, DOI 10.1016/0885-3924(95)00202-2; Schofferman J, 1999, CLIN J PAIN, V15, P136, DOI 10.1097/00002508-199906000-00011; SCHOFFERMAN J, 1993, J PAIN SYMPTOM MANAG, V8, P279, DOI 10.1016/0885-3924(93)90156-P; Sheather-Reid RB, 1998, J PAIN SYMPTOM MANAG, V15, P244, DOI 10.1016/S0885-3924(98)00369-8; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; South SM., 2001, PAIN CLIN UPDATES, V9, P1; TAYLOR CB, 1980, PAIN, V8, P319, DOI 10.1016/0304-3959(80)90077-9; TENNANT FS, 1983, POSTGRAD MED, V73, P81, DOI 10.1080/00325481.1983.11698315; TISEO PJ, 1993, J PHARMACOL EXP THER, V264, P1090; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; TURK DC, 1994, PAIN, V59, P201, DOI 10.1016/0304-3959(94)90072-8; TURNER JA, 1982, PAIN, V12, P357, DOI 10.1016/0304-3959(82)90180-4; URBAN BJ, 1986, PAIN, V24, P191, DOI 10.1016/0304-3959(86)90041-2; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; Watson CPN, 1998, NEUROLOGY, V50, P1837; WILSON PR, 2002, ASA NEWSLETT, V66, P9; Ytterberg SR, 1998, ARTHRITIS RHEUM, V41, P1603, DOI 10.1002/1529-0131(199809)41:9<1603::AID-ART10>3.0.CO;2-U; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y	100	648	665	0	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1943	1953		10.1056/NEJMra025411	http://dx.doi.org/10.1056/NEJMra025411			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614170				2022-12-28	WOS:000186502400011
J	Friml, J; Vieten, A; Sauer, M; Weijers, D; Schwarz, H; Hamann, T; Offringa, R; Jurgens, G				Friml, J; Vieten, A; Sauer, M; Weijers, D; Schwarz, H; Hamann, T; Offringa, R; Jurgens, G			Efflux-dependent auxin gradients establish the apical-basal axis of Arabidopsis	NATURE			English	Article							GNOM ARF-GEF; PATTERN-FORMATION; MORPHOGEN GRADIENTS; POLAR TRANSPORT; PLANT; EMBRYO; GENE; CELLS; ROOT; EMBRYOGENESIS	Axis formation occurs in plants, as in animals, during early embryogenesis. However, the underlying mechanism is not known. Here we show that the first manifestation of the apical-basal axis in plants, the asymmetric division of the zygote, produces a basal cell that transports and an apical cell that responds to the signalling molecule auxin. This apical-basal auxin activity gradient triggers the specification of apical embryo structures and is actively maintained by a novel component of auxin efflux, PIN7, which is located apically in the basal cell. Later, the developmentally regulated reversal of PIN7 and onset of PIN1 polar localization reorganize the auxin gradient for specification of the basal root pole. An analysis of pin quadruple mutants identifies PIN-dependent transport as an essential part of the mechanism for embryo axis formation. Our results indicate how the establishment of cell polarity, polar auxin efflux and local auxin response result in apical-basal axis formation of the embryo, and thus determine the axiality of the adult plant.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; Leiden Univ, Clusius Lab, Inst Biol, NL-2333 AL Leiden, Netherlands; Max Planck Inst Dev Biol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Leiden University; Leiden University - Excl LUMC; Max Planck Society	Friml, J (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Morgenstelle 3, D-72076 Tubingen, Germany.		Sauer, Michael/G-3424-2011; Weijers, Dolf/ABI-1332-2020; Sauer, Michael/F-6519-2014; Weijers, Dolf/A-2076-2010; Friml, Jiri/D-9511-2012	Weijers, Dolf/0000-0003-4378-141X; Sauer, Michael/0000-0002-4014-9825; Weijers, Dolf/0000-0003-4378-141X; Friml, Jiri/0000-0002-8302-7596				Braselton JP, 1996, BIOTECH HISTOCHEM, V71, P84, DOI 10.3109/10520299609117139; CARUSO JL, 1995, PLANT HORMONES PHYSL, P43; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Fischer-Iglesias C, 2001, PLANT J, V26, P115, DOI 10.1046/j.1365-313x.2001.01013.x; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2002, PLANT MOL BIOL, V49, P273, DOI 10.1023/A:1015248926412; Friml J, 2003, PLANT J, V34, P115, DOI 10.1046/j.1365-313X.2003.01705.x; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hamann T, 2002, GENE DEV, V16, P1610, DOI 10.1101/gad.229402; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Haseloff J, 1999, METHOD CELL BIOL, V58, P139; Jurgens G, 2001, EMBO J, V20, P3609, DOI 10.1093/emboj/20.14.3609; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Lyczak R, 2002, DEV CELL, V3, P157, DOI 10.1016/S1534-5807(02)00226-5; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; Moctezuma E, 1999, ANN BOT-LONDON, V83, P235, DOI 10.1006/anbo.1998.0814; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; Ottenschlager I, 2003, P NATL ACAD SCI USA, V100, P2987, DOI 10.1073/pnas.0437936100; Rashotte AM, 2000, PLANT PHYSIOL, V122, P481, DOI 10.1104/pp.122.2.481; RAVEN JA, 1975, NEW PHYTOL, V74, P163, DOI 10.1111/j.1469-8137.1975.tb02602.x; Ribnicky DM, 2002, PLANTA, V214, P505, DOI 10.1007/s004250100639; RUBERY PH, 1974, PLANTA, V118, P101, DOI 10.1007/BF00388387; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; STJOHNSTON D, 1992, CELL, V68, P201; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Tabata T, 2001, NAT REV GENET, V2, P620, DOI 10.1038/35084577; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Weijers D, 2001, NATURE, V414, P709, DOI 10.1038/414709a; WEIJERS D, 2002, THESIS U LEIDEN; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	39	1339	1423	15	348	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					147	153		10.1038/nature02085	http://dx.doi.org/10.1038/nature02085			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614497				2022-12-28	WOS:000186517200034
J	Harrison, MR; Keller, RL; Hawgood, SB; Kitterman, JA; Sandberg, PL; Farmer, DL; Lee, H; Filly, RA; Farrell, JA; Albanese, CT				Harrison, MR; Keller, RL; Hawgood, SB; Kitterman, JA; Sandberg, PL; Farmer, DL; Lee, H; Filly, RA; Farrell, JA; Albanese, CT			A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FREQUENCY OSCILLATORY VENTILATION; TO-HEAD RATIO; IN-UTERO; PULMONARY HYPOPLASIA; LUNG GROWTH; CLINICAL-EXPERIENCE; LAMB MODEL; SURVIVAL; LIGATION; BALLOON	Background: Experimental and clinical data suggest that fetal endoscopic tracheal occlusion to induce lung growth may improve the outcome of severe congenital diaphragmatic hernia. We performed a randomized, controlled trial comparing fetal tracheal occlusion with standard postnatal care. Methods: Women carrying fetuses that were between 22 and 27 weeks of gestation and that had severe, left-sided congenital diaphragmatic hernia (liver herniation and a lung-to-head ratio below 1.4), with no other detectable anomalies, were randomly assigned to fetal endoscopic tracheal occlusion or standard care. The primary outcome was survival at the age of 90 days; the secondary outcomes were measures of maternal and neonatal morbidity. Results: Of 28 women who met the entry criteria, 24 agreed to randomization. Enrollment was stopped after 24 patients had been enrolled because of the unexpectedly high survival rate with standard care and the conclusion of the data safety monitoring board that further recruitment would not result in significant differences between the groups. Eight of 11 fetuses (73 percent) in the tracheal-occlusion group and 10 of 13 (77 percent) in the group that received standard care survived to 90 days of age (P=1.00). The severity of the congenital diaphragmatic hernia at randomization, as measured by the lung-to-head ratio, was inversely related to survival in both groups. Premature rupture of the membranes and preterm delivery were more common in the group receiving the intervention than in the group receiving standard care (mean [+/-SD] gestational age at delivery, 30.8+/-2.0 weeks vs. 37.0+/-1.5 weeks; P<0.001). The rates of neonatal morbidity did not differ between the groups. Conclusions: Tracheal occlusion did not improve survival or morbidity rates in this cohort of fetuses with congenital diaphragmatic hernia.	Univ Calif San Francisco, Fetal Treatment Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Harrison, MR (corresponding author), Univ Calif San Francisco, Fetal Treatment Ctr, 513 Parnassus Ave,HSW-1601, San Francisco, CA 94143 USA.	fetus@surgery.ucsf.edu	Harrison, Michael/GYD-8608-2022	Farmer, Diana/0000-0002-3530-5993	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062433] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62433] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADZICK NS, 1985, J PEDIATR SURG, V20, P673, DOI 10.1016/S0022-3468(85)80022-1; Albanese CT, 1998, PRENATAL DIAG, V18, P1138, DOI 10.1002/(SICI)1097-0223(199811)18:11<1138::AID-PD416>3.0.CO;2-A; ALBANESE CT, 1998, PEDIAT ENDOSURG INNO, V2, P47; ALCORN D, 1977, J ANAT, V123, P649; Boland RE, 1997, AM J PHYSIOL-LUNG C, V273, pL1126, DOI 10.1152/ajplung.1997.273.6.L1126; Boloker J, 2002, J PEDIATR SURG, V37, P357, DOI 10.1053/jpsu.2002.30834; Cacciari A, 2001, EUR J PEDIATR SURG, V11, P3, DOI 10.1055/s-2001-12204; Chiba T, 2000, J PEDIATR SURG, V35, P1566, DOI 10.1053/jpsu.2000.18311; Desfrere L, 2000, INTENS CARE MED, V26, P934, DOI 10.1007/s001340051284; DIFIORE JW, 1994, J PEDIATR SURG, V29, P248, DOI 10.1016/0022-3468(94)90328-X; Flageole H, 1998, J PEDIATR SURG, V33, P299, DOI 10.1016/S0022-3468(98)90451-1; Flake AW, 2000, AM J OBSTET GYNECOL, V183, P1059, DOI 10.1067/mob.2000.108871; HARRISON MR, 1990, J PEDIATR SURG, V25, P47, DOI 10.1016/S0022-3468(05)80163-0; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1981, J PEDIATR SURG, V16, P934, DOI 10.1016/S0022-3468(81)80849-4; HARRISON MR, 1980, SURGERY, V88, P174; HARRISON MR, 1980, SURGERY, V88, P260; Harrison MR, 1997, J PEDIATR SURG, V32, P1637, DOI 10.1016/S0022-3468(97)90472-3; Harrison MR, 2003, J PEDIATR SURG, V38, P1012, DOI 10.1016/S0022-3468(03)00182-9; Harrison MR, 1998, J PEDIATR SURG, V33, P1017, DOI 10.1016/S0022-3468(98)90524-3; HARRISON MR, 1993, J PEDIATR SURG, V28, P1411, DOI 10.1016/S0022-3468(05)80338-0; Harrison MR, 2001, AM J OBSTET GYNECOL, V185, P730, DOI 10.1067/mob.2001.117344; HARRISON MR, 1994, JAMA-J AM MED ASSOC, V271, P382, DOI 10.1001/jama.271.5.382; HEDRICK MH, 1994, J PEDIATR SURG, V29, P612, DOI 10.1016/0022-3468(94)90724-2; Keller RL, 2003, ULTRASOUND OBST GYN, V21, P244, DOI 10.1002/uog.44; LAWSON EE, 1978, AM REV RESPIR DIS, V118, P1023; Luks FI, 2000, SURGERY, V128, P266, DOI 10.1067/msy.2000.107373; Metkus AP, 1996, J PEDIATR SURG, V31, P148, DOI 10.1016/S0022-3468(96)90338-3; Muratore CS, 2001, J PEDIATR SURG, V36, P1171, DOI 10.1053/jpsu.2001.25746; Muratore CS, 2001, J PEDIATR SURG, V36, P133, DOI 10.1053/jpsu.2001.20031; Mychaliska GB, 1997, J PEDIATR SURG, V32, P227, DOI 10.1016/S0022-3468(97)90184-6; NARDO L, 1995, PEDIATR RES, V38, P690, DOI 10.1203/00006450-199511000-00010; Shew SB, 1999, J PEDIATR SURG, V34, P720; Stege G, 2003, PEDIATRICS, V112, P532, DOI 10.1542/peds.112.3.532; VanderWall KJ, 1997, J PEDIATR SURG, V32, P970, DOI 10.1016/S0022-3468(97)90379-1; VanderWall KJ, 1996, J PEDIATR SURG, V31, P1101, DOI 10.1016/S0022-3468(96)90096-2; WALTERS DV, 1978, PEDIATR RES, V12, P239, DOI 10.1203/00006450-197803000-00017; Wild YK, 2000, J PEDIATR SURG, V35, P775, DOI 10.1053/jpsu.2000.6067; WILSON JM, 1993, J PEDIATR SURG, V28, P1433, DOI 10.1016/0022-3468(93)90426-L	39	398	431	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1916	1924		10.1056/NEJMoa035005	http://dx.doi.org/10.1056/NEJMoa035005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614166				2022-12-28	WOS:000186502400006
J	Sander, HW; Magda, P; Chin, RL; Wu, A; Brannagan, TH; Green, PHR; Latov, N				Sander, HW; Magda, P; Chin, RL; Wu, A; Brannagan, TH; Green, PHR; Latov, N			Cerebellar ataxia and coeliac disease	LANCET			English	Editorial Material									Columbia Univ, Coll Phys & Surg, Peripheral Neuropathy Ctr, New York, NY 10022 USA; Columbia Univ, Coll Phys & Surg, Cornell Weill Med Coll, Dept Neurol, New York, NY 10022 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10022 USA; Columbia Univ, Coll Phys & Surg, Celiac Dis Ctr, New York, NY 10022 USA	Columbia University; Columbia University; Cornell University; Columbia University; Columbia University	Sander, HW (corresponding author), Columbia Univ, Coll Phys & Surg, Peripheral Neuropathy Ctr, New York, NY 10022 USA.			Sander, Howard/0000-0002-9654-7849; Brannagan, Thomas/0000-0002-1812-8331				Burk K, 2001, ANN NEUROL, V50, P827, DOI 10.1002/ana.1281; Hadjivassiliou M, 2003, BRAIN, V126, P685, DOI 10.1093/brain/awg050; Pellecchia MT, 1999, NEUROLOGY, V53, P1606, DOI 10.1212/WNL.53.7.1606-a; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Vianello M, 2003, CEREBELLUM, V2, P77, DOI 10.1080/14734220309432	5	38	39	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1548	1548		10.1016/S0140-6736(03)14743-5	http://dx.doi.org/10.1016/S0140-6736(03)14743-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615111				2022-12-28	WOS:000186464500012
J	Bitzer, M; Armeanu, S; Krober, SM; Horger, MS; Erley, CM				Bitzer, M; Armeanu, S; Krober, SM; Horger, MS; Erley, CM			A young woman with splenic infarction	LANCET			English	Article							MUTATIONS		Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 3, D-72076 Tubingen, Germany; Univ Tubingen, Dept Radiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Bitzer, M (corresponding author), Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany.							Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Beutler B, 2003, CRIT CARE, V7, P39, DOI 10.1186/cc1828; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; MUNFORD RS, 2001, HARRISONS PRINCIPLES, P927; Nores M, 1998, AM SURGEON, V64, P182	5	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1456	1456		10.1016/S0140-6736(03)14691-0	http://dx.doi.org/10.1016/S0140-6736(03)14691-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602441				2022-12-28	WOS:000186356600013
J	Lane, AA; Ley, TJ				Lane, AA; Ley, TJ			Neutrophil elastase cleaves PML-RAR alpha and is important for the development of acute promyelocytic leukemia in mice	CELL			English	Article							DIPEPTIDYL PEPTIDASE-I; RECURRING CHROMOSOMAL-ABNORMALITIES; TRANS-RETINOIC ACID; CATHEPSIN-G; PML/RAR-ALPHA; SERINE PROTEASES; FUSION PROTEIN; MOUSE MODEL; GRANZYME-B; CELL	The fusion protein PML-RARalpha, generated by the t(15;17)(q22;q11.2) translocation associated with acute promyelocytic leukemia (APL), initiates APL when expressed in the early myeloid compartment of transgenic mice. PML-RARalpha is cleaved in several positions by a neutral serine protease in a human myeloid cell line; purification revealed that the protease is neutrophil elastase (NE). Immunofluorescence localization studies suggested that the cleavage of PML-RARalpha must occur within the cell, and perhaps, within the nucleus. The functional importance of NE for APL development was assessed in NE deficient mice. Greater than 90% of bone marrow PML-RARalpha cleaving activity was lost in the absence of NE, and NE (but not Cathepsin G) deficient animals were protected from APL development. Primary mouse and human APL cells also contain NE-dependent PML-RARalpha cleaving activity. Since NE is maximally produced in promyelocytes, this protease may play a role in APL pathogenesis by facilitating the leukemogenic potential of PML-RARalpha.	Washington Univ, Sch Med, Siteman Canc Ctr, Dept Med,Div Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Siteman Canc Ctr, Dept Genet,Div Oncol, St Louis, MO 63110 USA	Siteman Cancer Center; Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Ley, TJ (corresponding author), Washington Univ, Sch Med, Siteman Canc Ctr, Dept Med,Div Oncol, St Louis, MO 63110 USA.	tley@im.wustl.edu		Lane, Andrew/0000-0001-7380-0226	NATIONAL CANCER INSTITUTE [R01CA083962] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NCI NIH HHS [CA83962] Funding Source: Medline; NHLBI NIH HHS [T32 HLO 7088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Bird CH, 2001, MOL CELL BIOL, V21, P5396, DOI 10.1128/MCB.21.16.5396-5407.2001; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GALLAGHER RE, 1995, BLOOD, V86, P1540, DOI 10.1182/blood.V86.4.1540.bloodjournal8641540; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Horwitz M, 2003, CURR OPIN HEMATOL, V10, P49, DOI 10.1097/00062752-200301000-00008; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; Jing Y, 2003, ONCOGENE, V22, P4083, DOI 10.1038/sj.onc.1206568; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Le Beau MM, 2003, BLOOD, V102, P1072, DOI 10.1182/blood-2003-01-0155; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; MacIvor DM, 1999, BLOOD, V94, P4282, DOI 10.1182/blood.V94.12.4282.424k45_4282_4293; Mcdonold SJF, 2001, BIOORG MED CHEM LETT, V11, P895, DOI 10.1016/S0960-894X(01)00078-6; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Pollock JL, 2001, CURR OPIN HEMATOL, V8, P206, DOI 10.1097/00062752-200107000-00005; Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Trapani JA, 1996, J BIOL CHEM, V271, P4127; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; Westervelt P, 2003, BLOOD, V102, P1857, DOI 10.1182/blood-2002-12-3779; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	45	103	125	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					305	318		10.1016/S0092-8674(03)00852-3	http://dx.doi.org/10.1016/S0092-8674(03)00852-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636558	Bronze			2022-12-28	WOS:000186415000010
J	Pereira, G; Schiebel, E				Pereira, G; Schiebel, E			Separase regulates INCENP-Aurora B anaphase spindle function through Cdc14	SCIENCE			English	Article							CENTROMERE PROTEIN; PHOSPHATASE CDC14; MITOTIC EXIT; CLEAVAGE; KINASE; LOCALIZATION; KINETOCHORE; MITOSIS; COHESIN; COMPLEX	The inner centromere-like protein ( INCENP) forms a complex with the evolutionarily conserved family of Aurora B kinases. The INCENP-Aurora complex helps coordinate chromosome segregation, spindle behavior, and cytokinesis during mitosis. INCENP-Aurora associates with kinetochores in metaphase and with spindle microtubules in anaphase, yet the trigger for this abrupt transfer is unknown. Here we show that the conserved phosphatase Cdc14 regulated the yeast INCENP-Aurora complex, Sli15-Ipl1. Cdc14 dephosphorylated Sli15 and thereby directed the complex to spindles. Activation of Cdc14 by separase was sufficient for Sli15 dephosphorylation and relocalization. Cdc14 not only regulates mitotic exit but also modulates spindle midzone assembly through Sli15-Ipl1.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	University of Manchester; Paterson Institute for Cancer Research	Schiebel, E (corresponding author), Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	eschiebel@picr.man.ac.uk	Pereira, Gislene/D-4024-2014					Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Buvelot S, 2003, J CELL BIOL, V160, P329, DOI 10.1083/jcb.200209018; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Jin QW, 2000, J CELL SCI, V113, P1903; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; PEREIRA G, UNPUB; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2003, NAT CELL BIOL, V5, P249, DOI 10.1038/ncb940; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415	22	210	217	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	2003	302	5653					2120	2124		10.1126/science.1091936	http://dx.doi.org/10.1126/science.1091936			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	755CB	14605209				2022-12-28	WOS:000187385200044
J	Albers, GW; Diener, HC; Grind, M; Halperin, JL; Horrow, J; Olsson, SB; Petersen, P; Vahanian, A; Frison, L; Nevinson, M; Partridge, S				Albers, GW; Diener, HC; Grind, M; Halperin, JL; Horrow, J; Olsson, SB; Petersen, P; Vahanian, A; Frison, L; Nevinson, M; Partridge, S		Executive Steering Comm SPORTIF II	Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial	LANCET			English	Article							NO INFLUENCE; PHARMACODYNAMICS; PHARMACOKINETICS; THROMBOEMBOLISM; MELAGATRAN; EQUIVALENCE; MANAGEMENT; RISK	Background Warfarin prevents ischaemic stroke in patients with non-valvular atrial fibrillation, but dose adjustment, coagulation monitoring, and bleeding risk limit its use. The oral direct thrombin inhibitor ximelagatran represents a potential alternative. We aimed to establish whether ximelagatran is non-inferior to warfarin, within a margin of 2% per year, for prevention of stroke and systemic embolism. Methods We randomised 3410 patients with atrial fibrillation and one or more stroke risk factors to open-label warfarin (adjusted-dose, international normalised ratio [INR] 2.0-3.0) or ximelagatran (fixed-dose, 36 mg twice daily); patients were recruited from 259 hospitals, doctor's offices, or health-care clinics. Primary analysis was based on masked event assessment and was by intention to treat. Primary endpoint was stroke or systemic embolism. Findings During 4941 patient-years of exposure (mean 17.4 months, SD 4.1), 96 patients had primary events (56 in the warfarin group vs 40 in the ximelagatran group). The primary event rate by intention to treat was 2.3% per year with warfarin and 1.6% per year with ximelagatran (absolute risk reduction 0.7% [95% Cl -0.1 to 1.4], p=0.10; relative risk reduction 29% [95% Cl -6.5 to 52]). Rates of disabling or fatal stroke, mortality, and major bleeding were similar between groups, but combined minor and major haemorrhages were lower with ximelagatran than with warfarin (29.8% vs 25.8% per year; relative risk reduction 14% [4 to 22]; p=0.007). Raised serum alanine aminotransferase was more common with ximelagatran. Interpretation In high-risk patients with atrial fibrillation, fixed-dose oral ximelagatran was at least as effective as well-controlled warfarin for prevention of stroke and systemic embolism.	Univ Lund Hosp, Dept Cardiol, SE-22185 Lund, Sweden; Stanford Stroke Ctr, Palo Alto, CA USA; Univ Essen Gesamthsch, Dept Neurol, Essen, Germany; Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY USA; Univ State Hosp, Dept Neurol, Copenhagen, Denmark; Hosp Tenon, Dept Cardiol, Paris, France	Lund University; Skane University Hospital; Stanford University; University of Duisburg Essen; Icahn School of Medicine at Mount Sinai; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Olsson, SB (corresponding author), Univ Lund Hosp, Dept Cardiol, SE-22185 Lund, Sweden.	bertil.olsson@kard.lu.se	Halperin, Jonathan/AAJ-4721-2020; Diener, Hans-Christoph/AAF-7275-2019	Halperin, Jonathan/0000-0002-8318-5471; Albers, Gregory/0000-0003-0263-4632; Luotola, Kari/0000-0002-6452-0254				Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Bredberg E, 2003, CLIN PHARMACOKINET, V42, P765, DOI 10.2165/00003088-200342080-00005; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; Collin C, 1988, Int Disabil Stud, V10, P61; Ebbutt AF, 1998, STAT MED, V17, P1691, DOI 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.3.CO;2-A; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson UG, 2003, EUR J CLIN PHARMACOL, V59, P35, DOI 10.1007/s00228-003-0565-7; Frykman V, 2001, EUR HEART J, V22, P1954, DOI 10.1053/euhj.2000.2300; Fuster V, 2001, EUR HEART J, V22, P1852, DOI 10.1053/euhj.2001.2983; Gomberg-Maitland M, 2003, AM HEART J, V146, P398, DOI 10.1016/S0002-8703(03)00324-7; Halperin JL, 2003, AM HEART J, V146, P431, DOI 10.1016/S0002-8703(03)00325-9; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Hirsh J, 2001, CHEST, V119, p8S, DOI 10.1378/chest.119.1_suppl.8S; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P475, DOI 10.2165/00003088-200342050-00005; Johansson LC, 2003, CLIN PHARMACOKINET, V42, P381, DOI 10.2165/00003088-200342040-00006; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Olsson SB, 2002, EUR HEART J, V23, P239; PETERSEN P, 1989, LANCET, V1, P175; Petersen P, 2003, J AM COLL CARDIOL, V41, P1445, DOI 10.1016/S0735-1097(03)00255-9; Sarich TC, 2003, CLIN PHARMACOKINET, V42, P485, DOI 10.2165/00003088-200342050-00006; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	30	674	702	2	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1691	1698						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643116				2022-12-28	WOS:000186767700006
J	Sowell, ER; Thompson, PM; Welcome, SE; Henkenius, AL; Toga, AW; Peterson, BS				Sowell, ER; Thompson, PM; Welcome, SE; Henkenius, AL; Toga, AW; Peterson, BS			Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder	LANCET			English	Article							FUNCTIONAL MAGNETIC-RESONANCE; CEREBRAL GLUCOSE-METABOLISM; DEFICIT/HYPERACTIVITY DISORDER; TOURETTE SYNDROME; BRAIN METABOLISM; BLOOD-FLOW; MRI; CORTEX; GIRLS; FMRI	Background Results of structural brain imaging studies of patients with attention-deficit hyperactivity disorder have shown subtle reductions in total brain volume and in volumes of the right frontal lobe and caudate nucleus. Although various conventional volumetric and voxel-based methods of image analysis have been used in these studies, regional brain size and grey-matter abnormalities have not yet been mapped over the entire cortical surface in patients with this disorder. We aimed to map these features in patients with attention-deficit hyperactivity disorder. Methods We used high-resolution MRI and surface-based, computational image analytic techniques to map regional brain size and grey-matter abnormalities at the cortical surface in a group of 27 children and adolescents with attention-deficit hyperactivity disorder and 46 controls, who were group-matched by age and sex. Findings Abnormal morphology was noted in the frontal cortices of patients with attention-deficit hyperactivity disorder, with reduced regional brain size localised mainly to inferior portions of dorsal prefrontal cortices bilaterally. Brain size was also reduced in anterior temporal cortices bilaterally. Prominent increases in grey matter were recorded in large portions of the posterior temporal and inferior parietal cortices bilaterally. Interpretation The frontal, temporal, and parietal regions are heteromodal association cortices that constitute a distributed neural system, which subserves attention and behavioural inhibition. We have identified region-specific anatomical abnormalities in cortical components of attentional systems, which may help better account for the symptoms of attention-deficit hyperactivity disorder.	Univ Calif Los Angeles, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90095 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA	University of California System; University of California Los Angeles; Columbia University; New York State Psychiatry Institute	Sowell, ER (corresponding author), Univ Calif Los Angeles, Dept Neurol, Lab Neuro Imaging, 710 Westwood Plaza,Room 4-238, Los Angeles, CA 90095 USA.		Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867	NCRR NIH HHS [P41 RR13642] Funding Source: Medline; NIMH NIH HHS [K01 MH01733, MH01232, MH59239] Funding Source: Medline; NINDS NIH HHS [NS3753] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR013642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001232, R01MH059239, K01MH001733] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P171, DOI 10.1016/S1388-2457(02)00362-0; Baumgardner TL, 1996, NEUROLOGY, V47, P477, DOI 10.1212/WNL.47.2.477; Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Castellanos FX, 2001, ARCH GEN PSYCHIAT, V58, P289, DOI 10.1001/archpsyc.58.3.289; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; DUPAUL GJ, 1991, J CLIN CHILD PSYCHOL, V20, P245, DOI 10.1207/s15374424jccp2003_3; Ernst M, 1997, J AM ACAD CHILD PSY, V36, P1399, DOI 10.1097/00004583-199710000-00022; ERNST M, 1994, J AM ACAD CHILD PSY, V33, P858, DOI 10.1097/00004583-199407000-00012; Evans AC, 1996, AUTOMATIC 3D REGIONA; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; FUSTER JM, 1997, PREFRONTAL CORTEX; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Goldman LS, 1998, JAMA-J AM MED ASSOC, V279, P1100, DOI 10.1001/jama.279.14.1100; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P440; Langleben DD, 2001, NUCL MED COMMUN, V22, P1333, DOI 10.1097/00006231-200112000-00009; MacDonald D, 1994, P SOC PHOTO-OPT INS, V2359, P160; MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Overmeyer S, 2001, PSYCHOL MED, V31, P1425, DOI 10.1017/S0033291701004706; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Peterson BS, 1998, ARCH GEN PSYCHIAT, V55, P326, DOI 10.1001/archpsyc.55.4.326; Petrides M, 2002, EUR J NEUROSCI, V16, P291, DOI 10.1046/j.1460-9568.2001.02090.x; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Rubia K, 1999, AM J PSYCHIAT, V156, P891, DOI 10.1176/ajp.156.6.891; Schweitzer JB, 2000, AM J PSYCHIAT, V157, P278, DOI 10.1176/appi.ajp.157.2.278; Semrud-Clikeman M, 2000, J AM ACAD CHILD PSY, V39, P477, DOI 10.1097/00004583-200004000-00017; Solanto MV, 2002, BEHAV BRAIN RES, V130, P65, DOI 10.1016/S0166-4328(01)00431-4; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Sowell ER, 2002, CEREB CORTEX, V12, P17, DOI 10.1093/cercor/12.1.17; Spalletta G, 2001, J NEURAL TRANSM, V108, P1203, DOI 10.1007/s007020170010; Thompson Paul M, 2001, Inf Process Med Imaging, V2082, P488; THOMPSON PM, 2003, P 19 C MED RECH IPSE; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; ZAMETKIN AJ, 1993, ARCH GEN PSYCHIAT, V50, P333; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	43	387	401	1	35	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1699	1707		10.1016/S0140-6736(03)14842-8	http://dx.doi.org/10.1016/S0140-6736(03)14842-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	746VE	14643117				2022-12-28	WOS:000186767700007
J	Reinhardt, D; Pesce, ER; Stieger, P; Mandel, T; Baltensperger, K; Bennett, M; Traas, J; Friml, J; Kuhlemeier, C				Reinhardt, D; Pesce, ER; Stieger, P; Mandel, T; Baltensperger, K; Bennett, M; Traas, J; Friml, J; Kuhlemeier, C			Regulation of phyllotaxis by polar auxin transport	NATURE			English	Article							ARABIDOPSIS GENE MONOPTEROS; GNOM ARF-GEF; VASCULAR DEVELOPMENT; PATTERN-FORMATION; EMBRYOGENESIS; LOCALIZATION; MERISTEM; CARRIER; EMBRYO; PIN1	The regular arrangement of leaves around a plant's stem, called phyllotaxis, has for centuries attracted the attention of philosophers, mathematicians and natural scientists; however, to date, studies of phyllotaxis have been largely theoretical. Leaves and flowers are formed from the shoot apical meristem, triggered by the plant hormone auxin. Auxin is transported through plant tissues by specific cellular influx and efflux carrier proteins. Here we show that proteins involved in auxin transport regulate phyllotaxis. Our data indicate that auxin is transported upwards into the meristem through the epidermis and the outermost meristem cell layer. Existing leaf primordia act as sinks, redistributing auxin and creating its heterogeneous distribution in the meristem. Auxin accumulation occurs only at certain minimal distances from existing primordia, defining the position of future primordia. This model for phyllotaxis accounts for its reiterative nature, as well as its regularity and stability.	Univ Bern, Inst Plant Physiol, CH-3013 Bern, Switzerland; Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; INRA, Biol Cellulaire Lab, F-78026 Versailles, France; Univ Nottingham, Sch Biosci, Nottingham NG7 2RD, England; Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland	University of Bern; Eberhard Karls University of Tubingen; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Nottingham; University of Bern	Kuhlemeier, C (corresponding author), Univ Bern, Inst Plant Physiol, Altenbergrain 21, CH-3013 Bern, Switzerland.		Traas, Jan/AAZ-7004-2020; Friml, Jiri/D-9511-2012; Reinhardt, Didier/M-8508-2014; Bennett, Malcolm/G-4004-2010	Traas, Jan/0000-0001-5107-1472; Friml, Jiri/0000-0002-8302-7596; Reinhardt, Didier/0000-0003-3495-6783; Bennett, Malcolm/0000-0003-0475-390X				Aida M, 2002, DEVELOPMENT, V129, P3965; Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Benjamins R, 2001, DEVELOPMENT, V128, P4057; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; Christensen SK, 2000, CELL, V100, P469, DOI 10.1016/S0092-8674(00)80682-0; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Fleming AJ, 1997, SCIENCE, V276, P1415, DOI 10.1126/science.276.5317.1415; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2002, PLANT MOL BIOL, V49, P273, DOI 10.1023/A:1015248926412; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; Green PB, 1996, SEMIN CELL DEV BIOL, V7, P903, DOI 10.1006/scdb.1996.0110; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Jean R., 1994, PHYLLOTAXIS SYSTEMAT; Jurgens G, 2001, EMBO J, V20, P3609, DOI 10.1093/emboj/20.14.3609; Kuhlemeier C, 2001, TRENDS PLANT SCI, V6, P187, DOI 10.1016/S1360-1385(01)01894-5; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Lomax Terri L., 1995, P509; Lynn K, 1999, DEVELOPMENT, V126, P469; Mattsson J, 2003, PLANT PHYSIOL, V131, P1327, DOI 10.1104/pp.013623; Meinhardt H., 1984, Positional controls in plant development, P1; MITCHISON GJ, 1977, SCIENCE, V196, P270, DOI 10.1126/science.196.4287.270; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; Parry G, 2001, J PLANT GROWTH REGUL, V20, P217, DOI 10.1007/s003440010030; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; Reinhardt D, 2000, PLANT CELL, V12, P507, DOI 10.1105/tpc.12.4.507; REINHARDT D, 2002, MERISTEMATIC TISSUES, P172; Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4; SACHS T, 1981, ADV BOT RES, V9, P151, DOI 10.1016/S0065-2296(08)60351-1; Schoute JC., 1913, RECL TRAV BOT EERL, V10, P153; Schwabe W. W., 1984, Positional controls in plant development, P403; SNOW M, 1962, PHILOS T ROY SOC B, V244, P483, DOI 10.1098/rstb.1962.0003; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; Steinmann T, 1999, SCIENCE, V286, P316, DOI 10.1126/science.286.5438.316; Stieger PA, 2002, PLANT J, V32, P509, DOI 10.1046/j.1365-313X.2002.01448.x; Swarup R, 2001, GENE DEV, V15, P2648, DOI 10.1101/gad.210501; Vernoux T, 2000, DEVELOPMENT, V127, P5157; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	43	1079	1145	12	247	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					255	260		10.1038/nature02081	http://dx.doi.org/10.1038/nature02081			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628043				2022-12-28	WOS:000186660800035
J	Tootle, TL; Silver, SJ; Davies, EL; Newman, V; Latek, RR; Mills, IA; Selengut, JD; Parlikar, BEW; Rebay, I				Tootle, TL; Silver, SJ; Davies, EL; Newman, V; Latek, RR; Mills, IA; Selengut, JD; Parlikar, BEW; Rebay, I			The transcription factor Eyes absent is a protein tyrosine phosphatase	NATURE			English	Article							P-TYPE ATPASE; SIGNALING PATHWAY; DROSOPHILA; PHOSPHORYLATION; SUPERFAMILY; REVEALS; COMPLEX; DOMAIN; EYA; PERVANADATE	Post-translational modifications provide sensitive and flexible mechanisms to dynamically modulate protein function in response to specific signalling inputs(1). In the case of transcription factors, changes in phosphorylation state can influence protein stability, conformation, subcellular localization, cofactor interactions, transactivation potential and transcriptional output(1). Here we show that the evolutionarily conserved transcription factor Eyes absent (Eya)(2,3) belongs to the phosphatase subgroup of the haloacid dehalogenase (HAD) superfamily(4,5), and propose a function for it as a non-thiol-based protein tyrosine phosphatase. Experiments performed in cultured Drosophila cells and in vitro indicate that Eyes absent has intrinsic protein tyrosine phosphatase activity and can autocatalytically dephosphorylate itself. Confirming the biological significance of this function, mutations that disrupt the phosphatase active site severely compromise the ability of Eyes absent to promote eye specification and development in Drosophila. Given the functional importance of phosphorylation-dependent modulation of transcription factor activity, this evidence for a nuclear transcriptional coactivator with intrinsic phosphatase activity suggests an unanticipated method of fine-tuning transcriptional regulation.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Inst Genom Res, Rockville, MD 20850 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); J. Craig Venter Institute	Rebay, I (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Tootle, Tina/AAE-1220-2019	Tootle, Tina/0000-0002-1515-9538				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Bonini NM, 1997, DEVELOPMENT, V124, P4819; Bui QT, 2000, GENETICS, V155, P709; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cohen J, 1997, BIOCHEM J, V327, P391, DOI 10.1042/bj3270391; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01252-3; Hsiao FC, 2001, DEV CELL, V1, P51, DOI 10.1016/S1534-5807(01)00011-9; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Kim SS, 2002, STRUCTURE, V10, P787, DOI 10.1016/S0969-2126(02)00769-4; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Selengut JD, 2001, BIOCHEMISTRY-US, V40, P12704, DOI 10.1021/bi011405e; Selengut JD, 2000, BIOCHEMISTRY-US, V39, P8315, DOI 10.1021/bi0005052; Silver SJ, 2003, MOL CELL BIOL, V23, P5989, DOI 10.1128/MCB.23.17.5989-5999.2003; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Tootle TL, 2003, DEVELOPMENT, V130, P845, DOI 10.1242/dev.00312; Treisman JE, 1999, BIOESSAYS, V21, P843, DOI 10.1002/(SICI)1521-1878(199910)21:10<843::AID-BIES6>3.3.CO;2-A; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917	28	202	213	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					299	302		10.1038/nature02097	http://dx.doi.org/10.1038/nature02097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628053				2022-12-28	WOS:000186660800046
J	Curran, MAJ; van Ommen, TD; Morgan, VI; Phillips, KL; Palmer, AS				Curran, MAJ; van Ommen, TD; Morgan, VI; Phillips, KL; Palmer, AS			Ice core evidence for Antarctic sea ice decline since the 1950s	SCIENCE			English	Article							METHANESULFONIC-ACID; LAW DOME; SOUTHERN-OCEAN; EXTENT; CLIMATE; VARIABILITY; TEMPERATURE; RECORD	The instrumental record of Antarctic sea ice in recent decades does not reveal a clear signature of warming despite observational evidence from coastal Antarctica. Here we report a significant correlation (P < 0.002) between methanesulphonic acid (MSA) concentrations from a Law Dome ice core and 22 years of satellite-derived sea ice extent (SIE) for the 80&DEG;E to 140&DEG;E sector. Applying this instrumental calibration to longer term MSA data (1841 to 1995 A. D.) suggests that there has been a 20% decline in SIE since about 1950. The decline is not uniform, showing large cyclical variations, with periods of about 11 years, that confuse trend detection over the relatively short satellite era.	Australian Antarctic Div, Dept Environm & Heritage, Hobart, Tas 7001, Australia; Antarctic Climate & Ecosyst Cooperat Res Ctr, Hobart, Tas 7001, Australia; Univ Tasmania, Inst Antarctic & So Ocean Studies, Hobart, Tas 7001, Australia	Australian Antarctic Division; Antarctic Climate & Ecosystems Cooperative Research Centre (ACE CRC); University of Tasmania	Curran, MAJ (corresponding author), Australian Antarctic Div, Dept Environm & Heritage, Private Bag 80, Hobart, Tas 7001, Australia.		van Ommen, Tas D/B-5020-2012	van Ommen, Tas D/0000-0002-2463-1718				ARMAND LK, 2003, SEA ICE INTRO ITS PH, P333, DOI DOI 10.1002/9780470757161.CH11; Barbraud C, 2001, NATURE, V411, P183, DOI 10.1038/35075554; Cavalieri DJ, 1997, SCIENCE, V278, P1104, DOI 10.1126/science.278.5340.1104; Curran MAJ, 1998, ANN GLACIOL, V27, P385; Curran MAJ, 2000, J GEOPHYS RES-ATMOS, V105, P20451, DOI 10.1029/2000JD900176; Curran MAJ, 2002, ANN GLACIOL-SER, V35, P333, DOI 10.3189/172756402781816528; delaMare WK, 1997, NATURE, V389, P57, DOI 10.1038/37956; Jacka TH, 1998, ANN GLACIOL, V27, P553; Jacobs SS, 2002, SCIENCE, V297, P386, DOI 10.1126/science.1069574; LEGRAND M, 1991, GEOPHYS RES LETT, V18, P187, DOI 10.1029/90GL02784; Minikin A, 1998, J GEOPHYS RES-ATMOS, V103, P10975, DOI 10.1029/98JD00249; MORGAN V, 1991, NATURE, V354, P5066; Morgan VI, 1997, J GLACIOL, V43, P3, DOI 10.3189/S0022143000002768; MURPHY EJ, 1995, DEEP-SEA RES PT I, V42, P1045, DOI 10.1016/0967-0637(95)00057-D; Nicol S, 2000, NATURE, V406, P504, DOI 10.1038/35020053; O'Dwyer J, 2000, GEOPHYS RES LETT, V27, P1159, DOI 10.1029/1999GL011106; Parkinson C. L., 1990, ANN GLACIOL, V14, P221; Pasteur EC, 1995, ANN GLACIOL, V21, P169; TURNIPSEED AA, 1993, DIMETHYLSULFIDE: OCEANS, ATMOSPHERE AND CLIMATE, P185; Vaughan Stephen, 2000, Polar Record, V36, P345; Watkins AB, 2000, J CLIMATE, V13, P4441, DOI 10.1175/1520-0442(2000)013<4441:CTIASI>2.0.CO;2; WELCH KA, 1993, GEOPHYS RES LETT, V20, P443, DOI 10.1029/93GL00499; White WB, 1996, NATURE, V380, P699, DOI 10.1038/380699a0; Wilson PR, 2001, MAR ECOL PROG SER, V213, P301, DOI 10.3354/meps213301; Wu XR, 1999, ANN GLACIOL, V29, P61, DOI 10.3189/172756499781821517; Yuan XJ, 2000, J CLIMATE, V13, P1697, DOI 10.1175/1520-0442(2000)013<1697:ASIEVA>2.0.CO;2; Yuan XJ, 2001, GEOPHYS RES LETT, V28, P3609, DOI 10.1029/2001GL012969; ZWALLY HJ, 1983, SCIENCE, V220, P1005, DOI 10.1126/science.220.4601.1005; ZWALLY HJ, 2002, J GEOPHYS RES, V107	29	235	242	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1203	1206		10.1126/science.1087888	http://dx.doi.org/10.1126/science.1087888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615537				2022-12-28	WOS:000186544300052
J	Kubatko, KAH; Helean, KB; Navrotsky, A; Burns, PC				Kubatko, KAH; Helean, KB; Navrotsky, A; Burns, PC			Stability of peroxide-containing uranyl minerals	SCIENCE			English	Article							HIGH-TEMPERATURE CALORIMETRY; NUCLEAR-FUEL; ALPHA-RADIOLYSIS; SPENT-FUEL; WATER; UO2; URANIUM; DISSOLUTION; DIRECTIONS; PLUTONIUM	Minerals containing peroxide are limited to studtite, (UO2)O-2(H2O)(4), and meta-studtite, (UO2)O-2(H2O)(2). High-temperature oxide-melt solution calorimetry and solubility measurements for studtite (standard enthalpy of formation at 298 kelvin is -2344.7 +/- 4.0 kilojoules per mole from the elements) establishes that these phases are stable in peroxide-bearing environments, even at low H2O2 concentrations. Natural radioactivity in a uranium deposit, or the radioactivity of nuclear waste, can create sufficient H2O2 by alpha radiolysis of water for studtite formation. Studtite and metastudtite may be important alteration phases of nuclear waste in a geological repository and of spent fuel under any long-term storage, possibly at the expense of the commonly expected uranyl oxide hydrates and uranyl silicates.	Univ Notre Dame, Dept Civil Engn & Geol Sci, Notre Dame, IN 46556 USA; Univ Calif Davis, Agr & Technol Org Res Unit, Thermochem Facil & Nanomat Environm, Davis, CA 95616 USA	University of Notre Dame; University of California System; University of California Davis	Burns, PC (corresponding author), Univ Notre Dame, Dept Civil Engn & Geol Sci, 156 Fitzpatrick Hall, Notre Dame, IN 46556 USA.		Burns, Peter C/J-3359-2013	Burns, Peter/0000-0002-2319-9628				Abrefah J., 1998, PNNL11806; Amme M, 2002, RADIOCHIM ACTA, V90, P399, DOI 10.1524/ract.2002.90.7_2002.399; BODANSKY D, 1996, NUCL ENERGY PRINCIPL; Burakov BE, 1997, MAT RES S C, V465, P1309, DOI 10.1557/PROC-465-1309; Burns PC, 2003, AM MINERAL, V88, P1165, DOI 10.2138/am-2003-0725; Cejka J, 1996, NEUES JB MINER MONAT, P125; Chase M. W., 1998, NIST JANAF THERMODYN; Christensen H, 1998, NUCL TECHNOL, V124, P165; CHRISTENSEN H, 1991, MATER RES SOC SYMP P, V212, P213; CORDFUNKE EHP, 1966, P S VIENN IAEA VIENN, V2, P487; DEBETS PC, 1963, J INORG NUCL CHEM, V35, P727; Finch RJ, 1999, MATER RES SOC SYMP P, V556, P431, DOI 10.1557/PROC-556-431; Finn PA, 1996, RADIOCHIM ACTA, V74, P65; Helean KB, 2002, J NUCL MATER, V303, P226, DOI 10.1016/S0022-3115(02)00795-X; McNamara B, 2003, MATER RES SOC SYMP P, V757, P401; Navrotsky A, 1997, PHYS CHEM MINER, V24, P222, DOI 10.1007/s002690050035; NAVROTSKY A, 1994, AM MINERAL, V79, P1099; NAVROTSKY A, 1977, PHYS CHEM MINER, V2, P89, DOI 10.1007/BF00307526; PEARCY EC, 1994, APPL GEOCHEM, V9, P713, DOI 10.1016/0883-2927(94)90030-2; Robie R. a., 1995, US GEOL SURV B, V2131; Robie R. A., 1978, US GEOL SURV B, V1452; Sattonnay G, 2001, J NUCL MATER, V288, P11, DOI 10.1016/S0022-3115(00)00714-5; Shoesmith DW, 2000, J NUCL MATER, V282, P1, DOI 10.1016/S0022-3115(00)00392-5; SUNDER S, 1992, J NUCL MATER, V190, P78, DOI 10.1016/0022-3115(92)90078-Y; Sunder S, 1997, J NUCL MATER, V244, P66, DOI 10.1016/S0022-3115(96)00709-X; SUNDER S, 1989, MATER RES SOC S P, V127, P317; WRONKIEWICZ DJ, 1992, J NUCL MATER, V190, P107, DOI 10.1016/0022-3115(92)90081-U	27	178	179	1	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1191	1193		10.1126/science.1090259	http://dx.doi.org/10.1126/science.1090259			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615533				2022-12-28	WOS:000186544300048
J	Neuman, KC; Abbondanzieri, EA; Landick, R; Gelles, J; Block, SM				Neuman, KC; Abbondanzieri, EA; Landick, R; Gelles, J; Block, SM			Ubiquitous transcriptional pausing is independent of RNA polymerase backtracking	CELL			English	Article							ESCHERICHIA-COLI; SINGLE-MOLECULE; CHAIN ELONGATION; STRUCTURAL BASIS; DNA-POLYMERASE; II ELONGATION; TERMINATION; MECHANISM; COMPLEX; ARREST	RNA polymerase (RNAP) transcribes DNA discontinuously, with periods of rapid nucleotide addition punctuated by frequent pauses. We investigated the mechanism of transcription by measuring the effect of both hindering and assisting forces on the translocation of single Escherichia coli transcription elongation complexes, using an optical trapping apparatus that allows for the detection of pauses as short as one second. We found that the vast majority of pauses are brief (1-6 s at 21degreesC, 1 mM NTPs), and that the probability of pausing at any particular position on a DNA template is low and fairly constant. Neither the probability nor the duration of these ubiquitous pauses was affected by hindering or assisting loads, establishing that they do not result from the backtracking of RNAP along the DNA template. We propose instead that they are caused by a structural rearrangement within the enzyme.	Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison; Brandeis University	Block, SM (corresponding author), Stanford Univ, Dept Sci Biol, Stanford, CA 94305 USA.	sblock@stanford.edu	Neuman, Keir C./F-7400-2011	Neuman, Keir C./0000-0002-0863-5671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057035] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057035-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; CHAMBERLIN MJ, 1994, HARVEY LECT, V88, P1992; Chan CL, 1997, J MOL BIOL, V268, P37, DOI 10.1006/jmbi.1997.0934; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Epshtein V, 2003, SCIENCE, V300, P801, DOI 10.1126/science.1083219; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; LANDICK R, 1985, P NATL ACAD SCI USA, V82, P4663, DOI 10.1073/pnas.82.14.4663; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854; Maier B, 2000, P NATL ACAD SCI USA, V97, P12002, DOI 10.1073/pnas.97.22.12002; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Marr MT, 2000, MOL CELL, V6, P1275, DOI 10.1016/S1097-2765(00)00126-X; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Neuman KC, 1999, BIOPHYS J, V77, P2856, DOI 10.1016/S0006-3495(99)77117-1; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; PRESS WH, 1992, NUMERICAL RECIPES; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REISBIG RR, 1981, BIOCHEMISTRY-US, V20, P1907, DOI 10.1021/bi00510a029; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; Santangelo TJ, 2003, GENE DEV, V17, P1281, DOI 10.1101/gad.1082103; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Sokal Robert R., 1969, BIOMETRY; THEISSEN G, 1990, ANAL BIOCHEM, V189, P254, DOI 10.1016/0003-2697(90)90117-R; Tinoco I, 2002, BIOPHYS CHEM, V101, P513, DOI 10.1016/S0301-4622(02)00177-1; Toulme F, 1999, EMBO J, V18, P5052, DOI 10.1093/emboj/18.18.5052; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	64	258	265	1	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2003	115	4					437	447		10.1016/S0092-8674(03)00845-6	http://dx.doi.org/10.1016/S0092-8674(03)00845-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622598	Bronze			2022-12-28	WOS:000186627100010
J	Kitano, H				Kitano, H			Cancer robustness - Tumour tactics	NATURE			English	Editorial Material							SYSTEMS		Sony Comp Sci Labs Inc, Shinagawa Ku, Tokyo 1410022, Japan	Sony Corporation	Kitano, H (corresponding author), Sony Comp Sci Labs Inc, Shinagawa Ku, 3-14-13 Higashi Gotanda, Tokyo 1410022, Japan.							Carlson JM, 2000, PHYS REV LETT, V84, P2529, DOI 10.1103/PhysRevLett.84.2529; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Morohashi M, 2002, J THEOR BIOL, V216, P19, DOI 10.1006/jtbi.2002.2537	3	107	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					125	125		10.1038/426125a	http://dx.doi.org/10.1038/426125a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614483	Bronze			2022-12-28	WOS:000186517200021
J	Waren, A; Bengtson, S; Goffredi, SK; Van Dover, CL				Waren, A; Bengtson, S; Goffredi, SK; Van Dover, CL			A hot-vent gastropod with iron sulfide dermal sclerites	SCIENCE			English	Article							OCEAN		Swedish Museum Nat Hist, SE-10405 Stockholm, Sweden; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA	Swedish Museum of Natural History; Monterey Bay Aquarium Research Institute; William & Mary	Waren, A (corresponding author), Swedish Museum Nat Hist, Box 50007, SE-10405 Stockholm, Sweden.			Bengtson, Stefan/0000-0003-0206-5791; Van Dover, Cindy/0000-0001-9845-8391				Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Ip YK, 1997, J COMP PHYSIOL B, V167, P213, DOI 10.1007/s003600050067; Lowenstam HA, 1989, BIOMINERALIZATION; Van Dover CL, 2001, SCIENCE, V294, P818, DOI 10.1126/science.1064574; Waren A, 2001, VELIGER, V44, P116; YI Q, 1989, FOSSILS STRATA, V24, P1; Zbinden M, 2003, DEEP-SEA RES PT I, V50, P269, DOI 10.1016/S0967-0637(02)00161-9	7	82	87	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1007	1007		10.1126/science.1087696	http://dx.doi.org/10.1126/science.1087696			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605361				2022-12-28	WOS:000186396300036
J	Sin, DD; McAlister, FA; Man, SFP; Anthonisen, NR				Sin, DD; McAlister, FA; Man, SFP; Anthonisen, NR			Contemporary management of chronic obstructive pulmonary disease - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; POSITIVE-PRESSURE VENTILATION; VOLUME-REDUCTION SURGERY; RESPIRATORY HEALTH WORKER; FORMOTEROL DRY POWDER; CHRONIC LUNG-DISEASE; AIR-FLOW LIMITATION; LONG-TERM TREATMENT; INHALED CORTICOSTEROIDS	Context The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course. Objective To systematically review the impact of long-acting bronchodilators, inhaled corticosteroids, nocturnal noninvasive mechanical ventilation, pulmonary rehabilitation, domiciliary oxygen therapy, and disease management programs on clinical outcomes in patients with COPD. Data Sources MEDLINE and Cochrane databases were searched to identify all randomized controlled trials and systematic reviews from 1980 to May 2002 evaluating interventions in patients with COPD. We also hand searched bibliographies of relevant articles and contacted experts in the field. Study Selection and Data Extraction We included randomized controlled trials that had follow-up of at least 3 months and contained data on at least 1 of these clinical outcomes: health-related quality of life, exacerbations associated with COPD, or death. For pulmonary rehabilitation, we included studies that had a follow-up of at least 6 weeks. Using standard meta-analytic techniques, the effects of interventions were compared with placebo or with usual care. In secondary analyses, the effects of interventions were compared against each other, where possible. Data Synthesis Long-acting beta(2)-agonists and anticholinergics (tiotropium) reduced exacerbation rates by approximately 20% to 25% (relative risk [RR] for long-acting beta(2)-agonists, 0.79; 95% CI, 0.69-0.90; RR for tiotropium, 0.74; 95% CI, 0.62-0.89) in patients with moderate to severe COPD. Inhaled corticosteroids also reduced exacerbation rates by a similar amount (RR, 0.76; 95% CI, 0.72- 0.80). The beneficial effects were most pronounced in trials enrolling patients with FEV1 between 1 L and 2 L. Combining a long-acting beta(2)-agonist with an inhaled corticosteroid resulted in an approximate 30% (RR, 0.70; 95% CI, 0.62-0.78) reduction in exacerbations. Pulmonary rehabilitation improved the health status of patients with moderate To severe disease, but no material effect was observed on long-term survival or hospitalization rates. Domiciliary oxygen therapy improved survival by approximately 40% in patients with Pao(2) lower than 60 mm Hg, but not in those without hypoxia at rest. The data on disease management programs were heterogeneous, but overall no effect was observed on survival or risk of hospitalization. Noninvasive mechanical ventilation was not associated with improved outcomes. Conclusions A significant body of evidence supports the use of long-acting bronchodilators and inhaled corticosteroids in reducing exacerbations in patients with moderate to severe COPD. Domiciliary oxygen therapy is the only intervention that has been demonstrated to prolong survival, but only in patients with resting hypoxia.	Univ Alberta, Walter C Mackenzie Ctr 2E4 29, Div Pulm Med, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Div Gen Med, Edmonton, AB T6G 2B7, Canada; Inst Hlth Econ, Edmonton, AB, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada	University of Alberta; University of Alberta; University of Manitoba	Sin, DD (corresponding author), Univ Alberta, Walter C Mackenzie Ctr 2E4 29, Div Pulm Med, Edmonton, AB T6G 2B7, Canada.	don.sin@ualberta.ca	Sin, Don/AAC-2219-2021; McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341				Aalbers R, 2002, EUR RESPIR J, V19, P936, DOI 10.1183/09031936.02.00240902; Altose MD, 2000, NEW ENGL J MED, V343, P1902; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; [Anonymous], 1980, Ann Intern Med, V93, P391; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P333, DOI 10.1164/rccm.2110093; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; Auerbach AD, 2002, JAMA-J AM MED ASSOC, V287, P1445, DOI 10.1001/jama.287.11.1445; Auerbach D, 1997, CHEST, V112, P1514; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; Barnes PJ, 2000, CHEST, V117, P63; Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342; BECKLAKE MR, 1985, CHEST, V88, P608, DOI 10.1378/chest.88.4.608; Behnke M, 2000, RESP MED, V94, P1184, DOI 10.1053/rmed.2000.0949; Bendstrup KE, 1997, EUR RESPIR J, V10, P2801, DOI 10.1183/09031936.97.10122801; BONE R, 1994, CHEST, V105, P1411; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Bourbeau J, 1998, THORAX, V53, P477, DOI 10.1136/thx.53.6.477; Brusasco V, 2003, THORAX, V58, P399, DOI 10.1136/thorax.58.5.399; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2000, AM J RESP CRIT CARE, V161, P341; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Casanova C, 2000, CHEST, V118, P1582, DOI 10.1378/chest.118.6.1582; CELLI BR, 1987, AM REV RESPIR DIS, V136, P1276, DOI 10.1164/ajrccm/136.5.1276; Chaouat A, 1999, EUR RESPIR J, V14, P1002, DOI 10.1183/09031936.99.14510029; Chapman Kenneth R, 2002, Can Respir J, V9, P178; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; COCKCROFT A, 1987, BRIT MED J, V294, P225, DOI 10.1136/bmj.294.6566.225; Confalonieri M, 1998, THORAX, V53, P583, DOI 10.1136/thx.53.7.583; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372, DOI 10.1164/ajrccm.164.3.2004029; Cox G, 1999, CHEST, V115, P1271, DOI 10.1378/chest.115.5.1271; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Dahl R, 2001, AM J RESP CRIT CARE, V164, P778, DOI 10.1164/ajrccm.164.5.2007006; Domagala-Kulawik J, 2003, CHEST, V123, P1054, DOI 10.1378/chest.123.4.1054; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Dorinsky PM, 1999, CHEST, V115, P966, DOI 10.1378/chest.115.4.966; Eaton T, 2002, EUR RESPIR J, V20, P306, DOI 10.1183/09031936.02.00301002; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; Engstrom CP, 1999, SCAND J REHABIL MED, V31, P207; Engstrom G, 2001, CIRCULATION, V103, P3086, DOI 10.1161/01.CIR.103.25.3086; Finnerty JP, 2001, CHEST, V119, P1705, DOI 10.1378/chest.119.6.1705; FIORE MC, 2000, TREATING TOBACCO USE; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1992, AM REV RESPIR DIS, V145, P1070, DOI 10.1164/ajrccm/145.5.1070; Gallefoss F, 2000, RESP MED, V94, P279, DOI 10.1053/rmed.1999.0749; Garrod R, 2000, AM J RESP CRIT CARE, V162, P1335, DOI 10.1164/ajrccm.162.4.9912029; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; Goldstein RS, 2003, THORAX, V58, P405, DOI 10.1136/thorax.58.5.405; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; Guell R, 2000, CHEST, V117, P976, DOI 10.1378/chest.117.4.976; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; Hermiz O, 2002, BRIT MED J, V325, P938, DOI 10.1136/bmj.325.7370.938; Hernandez MTE, 2000, CHEST, V118, P106, DOI 10.1378/chest.118.1.106; Hogg J C, 2000, Semin Respir Infect, V15, P32; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Hospers JJ, 2000, LANCET, V356, P1313, DOI 10.1016/S0140-6736(00)02815-4; HUGHES JR, 2003, COCHRANE DB SYST REV, V2; Hunter DJ, 1997, BRIT MED J, V315, P50, DOI 10.1136/bmj.315.7099.50; Ikeda A, 1996, THORAX, V51, P48, DOI 10.1136/thx.51.1.48; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JENKINS SC, 1987, CHEST, V91, P804, DOI 10.1378/chest.91.6.804; Johnell O, 2002, EUR RESPIR J, V19, P1058, DOI 10.1183/09031936.02.00276602; Johnson M, 2001, CHEST, V120, P258, DOI 10.1378/chest.120.1.258; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; Jones PW, 2001, THORAX, V56, P880, DOI 10.1136/thorax.56.11.880; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956, DOI 10.1164/ajrccm.150.4.7921469; Ketola E, 2000, ANN MED, V32, P239, DOI 10.3109/07853890009011767; Kips JC, 2001, AM J RESP CRIT CARE, V164, P923, DOI 10.1164/ajrccm.164.6.2010107; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LAKE FR, 1990, CHEST, V97, P1077, DOI 10.1378/chest.97.5.1077; LANCASTER T, 2002, COCHRANE DB SYST REV, V3; Larson JL, 1999, AM J RESP CRIT CARE, V160, P500, DOI 10.1164/ajrccm.160.2.9804067; LINDHOLM LH, 1995, BRIT MED J, V310, P1105, DOI 10.1136/bmj.310.6987.1105; LITTLEJOHNS P, 1991, THORAX, V46, P559, DOI 10.1136/thx.46.8.559; Mahler DA, 1999, CHEST, V115, P957, DOI 10.1378/chest.115.4.957; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; Malcolm C, 2003, ARCH INTERN MED, V163, P797, DOI 10.1001/archinte.163.7.797; MCDONALD CF, 1995, AM J RESP CRIT CARE, V152, P1616, DOI 10.1164/ajrccm.152.5.7582304; MEYER TJ, 1994, ANN INTERN MED, V120, P760, DOI 10.7326/0003-4819-120-9-199405010-00008; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray RP, 2002, PREV MED, V35, P314, DOI 10.1006/pmed.2002.1087; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; NINANE V, 1993, AM REV RESPIR DIS, V148, P1037, DOI 10.1164/ajrccm/148.4_Pt_1.1037; NINANE V, 1992, AM REV RESPIR DIS, V146, P16, DOI 10.1164/ajrccm/146.1.16; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Ram FSF., 2002, COCHRANE DB SYST REV, V2002, pCD003902, DOI DOI 10.1002/14651858.CD003902; Rennard SI, 2003, EUR RESPIR J, V21, P916, DOI 10.1183/09031936.03.00111602; Rennard SI, 2001, AM J RESP CRIT CARE, V163, P1087, DOI 10.1164/ajrccm.163.5.9903053; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; Ries AL, 2003, AM J RESP CRIT CARE, V167, P880, DOI 10.1164/rccm.200204-318OC; Ringbaek TJ, 2000, RESP MED, V94, P150, DOI 10.1053/rmed.1999.0704; Rossi A, 2002, CHEST, V121, P1058, DOI 10.1378/chest.121.4.1058; Scano G, 1999, Monaldi Arch Chest Dis, V54, P413; SILAGY C, 2002, COCHRANE DB SYST REV, V4; Silvestri M, 2001, EUR RESPIR J, V18, P139, DOI 10.1183/09031936.01.00067901; SIMPSON K, 1992, THORAX, V47, P70, DOI 10.1136/thx.47.2.70; Sin DD, 2003, CIRCULATION, V107, P1514, DOI 10.1161/01.CIR.0000056767.69054.B3; Spencer S, 2001, AM J RESP CRIT CARE, V163, P122, DOI 10.1164/ajrccm.163.1.2005009; Stulbarg Michael S, 2002, J Cardiopulm Rehabil, V22, P109, DOI 10.1097/00008483-200203000-00010; Sugiura H, 2003, THORAX, V58, P299, DOI 10.1136/thorax.58.4.299; Sullivan SD, 2000, CHEST, V117, P5; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; TASHKIN DP, 1986, AM J MED, V81, P81, DOI 10.1016/0002-9343(86)90468-7; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1; van der Valk P, 2002, AM J RESP CRIT CARE, V166, P1358, DOI 10.1164/rccm.200206-512OC; van Noord JA, 2000, THORAX, V55, P289, DOI 10.1136/thorax.55.4.289; van Noord JA, 2000, EUR RESPIR J, V15, P878, DOI 10.1034/j.1399-3003.2000.15e11.x; Verhoeven GT, 2002, THORAX, V57, P694, DOI 10.1136/thorax.57.8.694; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vilkman S, 1997, RESPIRATION, V64, P281; Vincken W, 2002, EUR RESPIR J, V19, P209, DOI 10.1183/09031936.02.00238702; Wadbo M, 2002, EUR RESPIR J, V20, P1138, DOI 10.1183/09031936.02.00301702; WATERHOUSE JC, 1999, EUR RESPIR J, V14, pS387; Watson PB, 1997, EUR RESPIR J, V10, P1267, DOI 10.1183/09031936.97.10061267; Wedzicha JA, 1998, EUR RESPIR J, V12, P363, DOI 10.1183/09031936.98.12020363; Weinberger M, 2002, JAMA-J AM MED ASSOC, V288, P1594, DOI 10.1001/jama.288.13.1594; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Weir DC, 1999, CLIN EXP ALLERGY, V29, P125, DOI 10.1046/j.1365-2222.1999.00021.x; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; Yildiz F, 2000, RESPIRATION, V67, P71, DOI 10.1159/000029466	138	262	271	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2301	2312		10.1001/jama.290.17.2301	http://dx.doi.org/10.1001/jama.290.17.2301			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600189	Bronze			2022-12-28	WOS:000186356800025
J	Muller, W; Fricke, H; Halliday, AN; McCulloch, MT; Wartho, JA				Muller, W; Fricke, H; Halliday, AN; McCulloch, MT; Wartho, JA			Origin and migration of the Alpine Iceman	SCIENCE			English	Article							ISOTOPES; CLIMATE; VALLEY	The Alpine Iceman provides a unique window into the Neolithic-Copper Age of Europe. We compared the radiogenic (strontium and lead) and stable (oxygen and carbon) isotope composition of the Iceman's teeth and bones, as well as Ar-40/Ar-39 mica ages from his intestine, to local geology and hydrology, and we inferred his habitat and range from childhood to adult life. The Iceman's origin can be restricted to a few valleys within similar to60 kilometers south(east) of the discovery site. His migration during adulthood is indicated by contrasting isotopic compositions of enamel, bones, and intestinal content. This demonstrates that the Alpine valleys of central Europe were permanently inhabited during the terminal Neolithic.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Colorado Coll, Dept Geol, Colorado Springs, CO 80903 USA; ETH, Dept Earth Sci, CH-8092 Zurich, Switzerland; Curtin Univ Technol, Dept Appl Geol, Perth, WA 6845, Australia	Australian National University; Colorado College; Swiss Federal Institutes of Technology Domain; ETH Zurich; Curtin University	Muller, W (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.	wolfgang.mueller@anu.edu.au	McCulloch, Malcolm T/C-3651-2009; Wartho, Jo-Anne/B-5169-2016	McCulloch, Malcolm T/0000-0003-1538-1558; Muller, Wolfgang/0000-0001-5368-8011				Bereuter TL, 1997, CHEM-EUR J, V3, P1032, DOI 10.1002/chem.19970030708; Budd P, 2001, ROY SOC CH, P311, DOI 10.1039/9781847551696-00311; DICKSON JH, 1996, P R SOC LONDON B, V263; FLECKINGER A, 1999, FASCINATION NEOLITHI; GABER O, 1999, GLETSCHERMUMIE KUPFE, V1, P39; HANDT O, 1994, SCIENCE, V264, P1775, DOI 10.1126/science.8209259; Hoogewerff J, 2001, J ARCHAEOL SCI, V28, P983, DOI 10.1006/jasc.2001.0659; HORN P, COMMUNICATION; Humer G., 1995, NIEDERSCHLAGSISOTOPE, V52; Kralik C, 1996, MAN IN ICE, V3, P283; LONGINELLI A, 1984, GEOCHIM COSMOCHIM AC, V48, P385, DOI 10.1016/0016-7037(84)90259-X; Longinelli A, 2003, J HYDROL, V270, P75; McDermott F, 1999, QUATERNARY SCI REV, V18, P1021, DOI 10.1016/S0277-3791(98)00107-3; Oeggl K, 2000, MAN IN ICE, V4, P163; Oeggl K, 2000, MAN IN ICE, V4, P89; PATE FD, 1994, J ARCHAEOL METHOD TH, V1, P161, DOI DOI 10.1007/BF02231415; PRINOTHFORNWAGNER R, 1994, NUCL INSTRUM METH B, V92, P282, DOI 10.1016/0168-583X(94)96020-8; ROZANSKI K, 1993, CLIMATE CHANGE CONTI; SEIDLER H, 1992, SCIENCE, V258, P455, DOI 10.1126/science.1411539; Sillen A, 1998, GEOCHIM COSMOCHIM AC, V62, P2463, DOI 10.1016/S0016-7037(98)00182-3; Spindler K., 1994, MAN ICE PRESERVED BO; Spotl C, 2002, J SEDIMENT RES, V72, P793, DOI 10.1306/041102720793; THOMAS MG, 2001, IC 2001 BOZ BOLZ IT; Thoni M, 1999, SCHWEIZ MINER PETROG, V79, P209; VANWAES HJM, 2001, KINDERZAHNMEDIZIN FA, V17; WINIGER J, 1998, BR ARCHAEOL REP INT, V701, P246	26	165	167	3	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					862	866		10.1126/science.1089837	http://dx.doi.org/10.1126/science.1089837			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593178				2022-12-28	WOS:000186258000048
J	Poskanzer, KE; Marek, KW; Sweeney, ST; Davis, GW				Poskanzer, KE; Marek, KW; Sweeney, ST; Davis, GW			Synaptotagmin I is necessary for compensatory synaptic vesicle endocytosis in vivo	NATURE			English	Article							NEUROTRANSMITTER RELEASE; C2B DOMAIN; DROSOPHILA; MUTANTS; SYNAPSES; REGULATOR; BINDING; SENSOR	Neurotransmission requires a balance of synaptic vesicle exocytosis and endocytosis(1). Synaptotagmin I (Syt I) is widely regarded as the primary calcium sensor for synaptic vesicle exocytosis(2-6). Previous biochemical data suggest that Syt I may also function during synaptic vesicle endocytosis(7-16); however, ultrastructural analyses at synapses with impaired Syt I function have provided an indirect and conflicting view of the role of Syt I during synaptic vesicle endocytosis(3,8-10,14). Until now it has not been possible experimentally to separate the exocytic and endocytic functions of Syt I in vivo. Here, we test directly the role of Syt I during endocytosis in vivo. We use quantitative live imaging of a pH-sensitive green fluorescent protein fused to a synaptic vesicle protein (synapto-pHluorin) to measure the kinetics of endocytosis in sytI-null Drosophila. We then combine live imaging of the synapto-pHluorins with photoinactivation of Syt I, through fluorescein-assisted light inactivation, after normal Syt I-mediated vesicle exocytosis. By inactivating Syt I only during endocytosis, we demonstrate that Syt I is necessary for the endocytosis of synaptic vesicles that have undergone exocytosis using a functional Syt I protein.	Univ Calif San Francisco, Dept Biochem & Biophys, Program Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Davis, GW (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Program Neurosci, 513 Parnassus Ave, San Francisco, CA 94143 USA.			Sweeney, Sean/0000-0003-2673-9578				Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Fergestad T, 2001, J NEUROSCI, V21, P1218; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; Jarousse N, 2001, J CELL BIOL, V154, P857, DOI 10.1083/jcb.200103040; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Kuromi H, 1998, NEURON, V20, P917, DOI 10.1016/S0896-6273(00)80473-0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Loewen CA, 2001, GENESIS, V31, P30, DOI 10.1002/gene.10002; Marek KW, 2002, NEURON, V36, P805, DOI 10.1016/S0896-6273(02)01068-1; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Reist NE, 1998, J NEUROSCI, V18, P7662; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Sankaranarayanan S, 2000, NAT CELL BIOL, V2, P197, DOI 10.1038/35008615; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	30	201	209	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 4	2003	426	6966					559	563		10.1038/nature02184	http://dx.doi.org/10.1038/nature02184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	749TE	14634669				2022-12-28	WOS:000186944300039
J	Aronson, JK; Ferner, RE				Aronson, JK; Ferner, RE			Joining the DoTS: new approach to classifying adverse drug reactions	BRITISH MEDICAL JOURNAL			English	Article							TOXICITY		Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	Radcliffe Infirmary; University of Oxford; University of Birmingham	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.			Ferner, Robin/0000-0003-3769-1346				Alderman CP, 1996, ANN PHARMACOTHER, V30, P55, DOI 10.1177/106002809603000110; ANDREJAK M, 2000, MEYLERS SIDE EFFECTS, P1177; ARONSON JK, 2002, DAVIDSONS PRINCIPLES, P147; ARONSON JK, 2001, NAT MED, V7, P7; BATCHELOR JR, 1980, LANCET, V1, P1107; CLERICETTI N, 1991, CLIN NEPHROL, V36, P281; DICKINSON RG, 1989, BRIT J CLIN PHARMACO, V28, P17, DOI 10.1111/j.1365-2125.1989.tb03501.x; Frenz DA, 2001, ANN ALLERG ASTHMA IM, V86, P150, DOI 10.1016/S1081-1206(10)62683-X; FRIEDMANN PS, 1983, CLIN EXP IMMUNOL, V53, P709; GEYMAN JP, 1978, J FAM PRACTICE, V7, P493; GREENBLATT DJ, 1981, CLIN PHARMACOL THER, V30, P475, DOI 10.1038/clpt.1981.191; HASSELSTROM J, 1990, BRIT J CLIN PHARMACO, V29, P289, DOI 10.1111/j.1365-2125.1990.tb03638.x; INMAN WHW, 1974, BRIT MED J, V1, P45; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; MULHALL A, 1983, BRIT MED J, V287, P1424, DOI 10.1136/bmj.287.6403.1424; PINKERTON CR, 1984, BRIT J CANCER, V49, P97, DOI 10.1038/bjc.1984.15; Rawlins M., 1977, TXB ADVERSE DRUG REA, P10; RAWLINS MD, 1981, BRIT MED J, V282, P974, DOI 10.1136/bmj.282.6268.974; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41; ROUJEAU JC, 1992, ADVERSE DRUG REACT, P44; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; Schwartz E, 2001, AM J TROP MED HYG, V65, P189, DOI 10.4269/ajtmh.2001.65.189; TROISI CL, 1985, JAMA-J AM MED ASSOC, V254, P3196, DOI 10.1001/jama.254.22.3196; Wakelkamp M, 1997, BRIT J CLIN PHARMACO, V43, P481, DOI 10.1046/j.1365-2125.1997.00592.x; WALLACE MR, 1991, J INFECT DIS, V164, P1180, DOI 10.1093/infdis/164.6.1180; YUNIS AA, 1989, AM J MED, V87, P44	26	149	159	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1222	1225		10.1136/bmj.327.7425.1222	http://dx.doi.org/10.1136/bmj.327.7425.1222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630763	Green Published			2022-12-28	WOS:000186784300026
J	Dear, J; Brookes, J; Mansell, M; Laing, C				Dear, J; Brookes, J; Mansell, M; Laing, C			Calciphylaxis	LANCET			English	Editorial Material									Univ Coll Hosp NHS Trust, Middlesex Hosp, Dept Nephrol, London W1N 8AA, England; Univ Coll Hosp NHS Trust, Middlesex Hosp, Dept Radiol, London W1N 8AA, England	University of London; University College London; University of London; University College London	Dear, J (corresponding author), Univ Coll Hosp NHS Trust, Middlesex Hosp, Dept Nephrol, Mortimer St, London W1N 8AA, England.								0	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1707	1707		10.1016/S0140-6736(03)14843-X	http://dx.doi.org/10.1016/S0140-6736(03)14843-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643118				2022-12-28	WOS:000186767700008
J	Miyamoto, T; Hasuike, S; Yogev, L; Maduro, MR; Ishikawa, M; Westphal, H; Lamb, DJ				Miyamoto, T; Hasuike, S; Yogev, L; Maduro, MR; Ishikawa, M; Westphal, H; Lamb, DJ			Azoospermia in patients heterozygous for a mutation in SYCP3	LANCET			English	Article							SYNAPTONEMAL COMPLEX; PROTEIN; GENE; SCP3	Background Many cases of male infertility are diagnosed as idiopathic, reflecting poor understanding of the molecular defects underlying the abnormality. As more gene mutations causing male infertility in mice become known, there are improving prospects that knowledge about the genetic aetiology of human male infertility can be expanded. Sycp3 encodes a component of the synaptonemal complex. A null mutation of Sycp3 in mice causes azoospermia with meiotic arrest. We tested the hypothesis that mutation of the human testis-specific SYCP3 is associated with human nonobstructive azoospermia. Methods Human SYCP3 was isolated on the basis of homology between mouse Sycp3 cDNA and human genome sequences at the aminoacid level. Tissue-specific expression of SYCP3 was analysed by PCR of human cDNA. Samples of DNA from 19 azoospermic patients with maturation arrest and 75 normal fertile control men were screened for mutations in the SYCP3 gene by sequence analysis of the gene. The functional significance of the mutations found was analysed by a protein interaction study of the wild-type and truncated SYCP3 proteins. Findings We identified in two patients a 1 bp deletion (643delA) that results in a premature stop codon and truncation of the C-terminal, coiled-coil-forming region of the SYCP3 protein. The mutant protein showed greatly reduced interaction with the wild-type protein in vitro and interfered with SYCP3 fibre formation in cultured cells. Interpretation We suggest that SYCP3 has an essential meiotic function in human spermatogenesis that is compromised by the mutant protein via dominant negative interference.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; NICHHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA; Asahikawa Med Coll, Dept Obstet & Gynecol, Asahikawa, Hokkaido 078, Japan; Lis Matern Hosp, Tel Aviv Sourasky Med Ctr, Inst Study Fertil, Tel Aviv, Israel; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Asahikawa Medical College; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Baylor College of Medicine	Lamb, DJ (corresponding author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.	dlamb@www.urol.bcm.tmc.edu		Maduro, Maria Rosa/0000-0001-8988-6722	NICHD NIH HHS [P01HD36289] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD036289] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Botelho RJ, 2001, BBA-GENE STRUCT EXPR, V1518, P294, DOI 10.1016/S0167-4781(01)00171-3; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Heyting C, 1996, CURR OPIN CELL BIOL, V8, P389, DOI 10.1016/S0955-0674(96)80015-9; Martinez-Garay I, 2002, GENOMICS, V80, P259, DOI 10.1006/geno.2002.6834; Matzuk MM, 2002, NAT MED, V8, P41, DOI 10.1038/nm-fertilityS41; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Offenberg HH, 1998, NUCLEIC ACIDS RES, V26, P2572, DOI 10.1093/nar/26.11.2572; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Sun C, 1999, NAT GENET, V23, P429, DOI 10.1038/70539; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Yuan L, 2002, SCIENCE, V296, P1115, DOI 10.1126/science.1070594; Yuan L, 1998, J CELL BIOL, V142, P331, DOI 10.1083/jcb.142.2.331; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9	16	196	224	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1714	1719		10.1016/S0140-6736(03)14845-3	http://dx.doi.org/10.1016/S0140-6736(03)14845-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643120				2022-12-28	WOS:000186767700010
J	Svenningsson, P; Tzavara, ET; Carruthers, R; Rachleff, I; Wattler, S; Nehls, M; McKinzie, DL; Fienberg, AA; Nomikos, GG; Greengard, P				Svenningsson, P; Tzavara, ET; Carruthers, R; Rachleff, I; Wattler, S; Nehls, M; McKinzie, DL; Fienberg, AA; Nomikos, GG; Greengard, P			Diverse psychotomimetics act through a common signaling pathway	SCIENCE			English	Article							CAMP-REGULATED PHOSPHOPROTEIN; SCHIZOPHRENIA; PHOSPHORYLATION; DARPP-32; MODELS; DRUG	Three distinct classes of drugs: dopaminergic agonists (such as D-amphetamine), serotonergic agonists (such as LSD), and glutamatergic antagonists (such as PCP) all induce psychotomimetic states in experimental animals that closely resemble schizophrenia symptoms in humans. Here we implicate a common signaling pathway in mediating these effects. In this pathway, dopamine- and an adenosine 3', 5'-monophosphate (cAMP)-regulated phosphoprotein of 32 kilodaltons (DARPP-32) is phosphorylated or dephosphorylated at three sites, in a pattern predicted to cause a synergistic inhibition of protein phosphatase-1 and concomitant regulation of its downstream effector proteins glycogen synthesis kinase-3 (GSK-3), cAMP response element-binding protein (CREB), and c-Fos. In mice with a genetic deletion of DARPP-32 or with point mutations in phosphorylation sites of DARPP-32, the effects of D-amphetamine, LSD, and PCP on two behavioral parameters-sensorimotor gating and repetitive movements-were strongly attenuated.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Eli Lilly & Co, Lilly Corp Ctr, Neurosci Discovery Res, Indianapolis, IN 46285 USA; Lexicon Genet Inc, The Woodlands, TX 77381 USA; Intracellular Therapies Inc, New York, NY 10032 USA	Rockefeller University; Eli Lilly; Lexicon Pharmaceuticals	Greengard, P (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.		Svenningsson, Per JL/K-5210-2014		NIDA NIH HHS [DA10044] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761; BERMAN KF, 1988, ARCH GEN PSYCHIAT, V45, P616; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Carlsson A, 2001, ANNU REV PHARMACOL, V41, P237, DOI 10.1146/annurev.pharmtox.41.1.237; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/s002130100811; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; LIPSKA BK, 1994, NEUROPSYCHOPHARMACOL, V10, P199, DOI 10.1038/npp.1994.22; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; RIDLEY RM, 1994, PROG NEUROBIOL, V44, P221, DOI 10.1016/0301-0082(94)90039-6; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; SHAW E, 1956, SCIENCE, V124, P121, DOI 10.1126/science.124.3212.121; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; SNYDER SH, 1973, AM J PSYCHIAT, V130, P61, DOI 10.1176/ajp.130.1.61; SVENNINGSSON P, UNPUB; Vollenweider FX, 1998, PHARMACOPSYCHIATRY, V31, P92, DOI 10.1055/s-2007-979353	20	256	263	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1412	1415		10.1126/science.1089681	http://dx.doi.org/10.1126/science.1089681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631045				2022-12-28	WOS:000186683500057
J	Lebwohl, M; Tyring, SK; Hamilton, TK; Toth, D; Glazer, S; Tawfik, NH; Walicke, P; Dummer, W; Wang, X; Garovoy, MR; Pariser, D; Efalizumab Study Grp				Lebwohl, M; Tyring, SK; Hamilton, TK; Toth, D; Glazer, S; Tawfik, NH; Walicke, P; Dummer, W; Wang, X; Garovoy, MR; Pariser, D; Efalizumab Study Grp			A novel targeted T-cell modulator, efalizumab, for plaque psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY; MODERATE; DISEASE; SAFETY; LFA-1; CYCLOSPORINE; METHOTREXATE; ALEFACEPT; EFFICACY; ADHESION	Background: Interactions between leukocyte-function-associated antigen type 1 (LFA-1) and intercellular adhesion molecules are important in the pathogenesis of psoriasis. Efalizumab, a humanized monoclonal antibody, binds to the (alpha) subunit (CD11a) of LFA-1 and inhibits the activation of T cells. Methods: In a phase 3, multicenter, randomized, placebo-controlled, double-blind study, we assign 597 subjects with psoriasis to receive subcutaneous efalizumab (1 or 2 mg per kilogram of body weight per week) or placebo for 12 weeks. Depending on the response after 12 weeks, subjects received an additional 12 weeks of treatment with efalizumab or placebo. Study treatments were discontinued at week 24, and subjects were followed for an additional 12 weeks. Results: At week 12, there was an improvement of 75 percent or more in the psoriasis area-and-severity index in 22 percent of the subjects who had received 1 mg of efalizumab per kilogram per week and 28 percent of those who had received 2 mg of efalizumab per kilogram per week, as compared with 5 percent of the subjects in the placebo group (P<0.001 for both comparisons). Efalizumab-treated subjects had greater improvement than those in the placebo group as early as week 4 (P<0.001). Among the efalizumab-treated subjects who had an improvement of 75 percent or more at week 12, improvement was maintained through week 24 in 77 percent of those who continued to receive efalizumab, as compared with 20 percent of those who were switched to placebo (P<0.001 for both comparisons). After the discontinuation of efalizumab at week 24, an improvement of 50 percent or more in the psoriasis area-and-severity index was maintained in approximately 30 percent of subjects during the 12 weeks of follow-up. Efalizumab was well tolerated, and adverse events were generally mild to moderate. Conclusions: Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease. Extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses.	CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Atlanta Dermatol Vein & Res Ctr, Alpharetta, GA USA; Prob Med Res, Windsor, ON, Canada; Welborn Clin, Evansville, IN USA; Genentech Inc, San Francisco, CA 94080 USA; Xoma Corp, Berkeley, CA 94710 USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA; Virginia Clin Res, Norfolk, VA USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Medical Branch Galveston; Roche Holding; Genentech; Eastern Virginia Medical School	Lebwohl, M (corresponding author), CUNY Mt Sinai Sch Med, 5 E 98th St,12th Fl,Box 1048, New York, NY 10029 USA.							Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185; BOS JD, 1983, ARCH DERMATOL RES, V275, P181, DOI 10.1007/BF00510050; Christophers E, 2001, CLIN EXP DERMATOL, V26, P314, DOI 10.1046/j.1365-2230.2001.00832.x; Crandall WV, 2003, ALIMENT PHARM THER, V17, P75, DOI 10.1046/j.1365-2036.2003.01411.x; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Gottlieb A, 2000, J AM ACAD DERMATOL, V42, P428, DOI 10.1016/S0190-9622(00)90214-7; Gottlieb AB, 2002, ARCH DERMATOL, V138, P591, DOI 10.1001/archderm.138.5.591; GOTTLIEB AB, 1998, DIS MANAGE CLIN OUTC, V1, P195; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Grossman RM, 1996, ARCH DERMATOL, V132, P623, DOI 10.1001/archderm.132.6.623; Heydendael VMR, 2003, NEW ENGL J MED, V349, P658, DOI 10.1056/NEJMoa021359; Krueger GG, 2000, J AM ACAD DERMATOL, V43, P281, DOI 10.1067/mjd.2000.106374; Krueger GG, 2002, J AM ACAD DERMATOL, V47, P821, DOI 10.1067/mjd.2002.127247; Krueger GG, 2002, EXPERT OPIN BIOL TH, V2, P431, DOI 10.1517/14712598.2.4.431; Krueger J, 2000, J INVEST DERMATOL, V115, P333, DOI 10.1046/j.1523-1747.2000.00abs-8.x; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; KUYPERS TW, 1989, RES IMMUNOL, V140, P461, DOI 10.1016/0923-2494(89)90114-4; Lebwohl M, 2000, J AM ACAD DERMATOL, V43, pS43; Papp K, 2001, J AM ACAD DERMATOL, V45, P665, DOI 10.1067/mjd.2001.117850; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Sandborn WJ, 1999, INFLAMM BOWEL DIS, V5, P119, DOI 10.1097/00054725-199905000-00008; SERN RS, 2000, J AM ACAD DERMATOL, V44, P755; Tristani-Firouzi P, 1998, Cutis, V61, P11; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEI LJ, 1989, CONTROL CLIN TRIALS, V10, pA126; Werther WA, 1996, J IMMUNOL, V157, P4986; Wollina U, 2001, CLIN RHEUMATOL, V20, P406, DOI 10.1007/s100670170004	27	447	466	0	16	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2004	2013		10.1056/NEJMoa030002	http://dx.doi.org/10.1056/NEJMoa030002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627785				2022-12-28	WOS:000186642900004
J	Li, X; Oghi, KA; Zhang, J; Krones, A; Bush, KT; Glass, CK; Nigam, SK; Aggarwal, AK; Maas, R; Rose, DW; Rosenfeld, MG				Li, X; Oghi, KA; Zhang, J; Krones, A; Bush, KT; Glass, CK; Nigam, SK; Aggarwal, AK; Maas, R; Rose, DW; Rosenfeld, MG			Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis	NATURE			English	Article							EYES-ABSENT GENE; MUSCLE PRECURSOR CELLS; KIDNEY DEVELOPMENT; DROSOPHILA DACHSHUND; NUCLEAR RECEPTORS; SKELETAL-MUSCLE; MULTIPLE STEPS; MYOGENIN GENE; MICE LACKING; EXPRESSION	The precise mechanistic relationship between gene activation and repression events is a central question in mammalian organogenesis, as exemplified by the evolutionarily conserved sine oculis ( Six), eyes absent (Eya) and dachshund ( Dach) network of genetically interacting proteins. Here, we report that Six1 is required for the development of murine kidney, muscle and inner ear, and that it exhibits synergistic genetic interactions with Eya factors. We demonstrate that the Eya family has a protein phosphatase function, and that its enzymatic activity is required for regulating genes encoding growth control and signalling molecules, modulating precursor cell proliferation. The phosphatase function of Eya switches the function of Six1-Dach from repression to activation, causing transcriptional activation through recruitment of co-activators. The gene-specific recruitment of a co-activator with intrinsic phosphatase activity provides a molecular mechanism for activation of specific gene targets, including those regulating precursor cell proliferation and survival in mammalian organogenesis.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Li, X (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, 9500 Gilman Dr,Room 345, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Bonini NM, 1997, DEVELOPMENT, V124, P4819; Brohmann H, 2000, DEVELOPMENT, V127, P437; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Daston G, 1996, DEVELOPMENT, V122, P1017; Davies JA, 1998, CURR TOP DEV BIOL, V39, P245, DOI 10.1016/S0070-2153(08)60458-5; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Davis RJ, 1999, DEV GENES EVOL, V209, P526, DOI 10.1007/s004270050285; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dietrich S, 1999, DEVELOPMENT, V126, P1621; Glass CK, 2000, GENE DEV, V14, P121; Gross MK, 2000, DEVELOPMENT, V127, P413; Hammond KL, 1998, MECH DEVELOP, V74, P121, DOI 10.1016/S0925-4773(98)00071-9; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Li X, 2002, SCIENCE, V297, P1180; MARDON G, 1994, DEVELOPMENT, V120, P3473; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Oliver G, 1995, DEVELOPMENT, V121, P4045; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Pohl M, 2000, ANNU REV PHYSIOL, V62, P595, DOI 10.1146/annurev.physiol.62.1.595; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Schafer K, 1999, NAT GENET, V23, P213, DOI 10.1038/13843; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shen WP, 1997, DEVELOPMENT, V124, P45; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Torres M, 1995, DEVELOPMENT, V121, P4057; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu PX, 1997, DEVELOPMENT, V124, P219; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Zhu CQC, 2002, DEVELOPMENT, V129, P2835	50	476	500	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					247	254		10.1038/nature02083	http://dx.doi.org/10.1038/nature02083			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628042				2022-12-28	WOS:000186660800034
J	Bridson, J; Hammond, C; Leach, A; Chester, MR				Bridson, J; Hammond, C; Leach, A; Chester, MR			Making consent patient centred	BRITISH MEDICAL JOURNAL			English	Article							SHARED DECISION-MAKING; FRAMEWORK		Univ Liverpool, Dept Primary Care, Unite Study Hlth Care Eth, Liverpool L69 3GB, Merseyside, England; Liverpool NHS Trust, Natl Reference Angina Ctr, Ctr Cardiothorac, Liverpool L14 3PE, Merseyside, England	University of Liverpool	Bridson, J (corresponding author), Univ Liverpool, Dept Primary Care, Unite Study Hlth Care Eth, Liverpool L69 3GB, Merseyside, England.							Brazier M., 1992, MED PATIENTS LAW; *BRIST ROYAL INF I, LEARN BRIST REP PUBL; *BRIT MED ASS, 2001, REP CONS WORK PART I; Chamberlain DA, 1997, LANCET, V350, P461; Charles C, 1999, BRIT MED J, V319, P780, DOI 10.1136/bmj.319.7212.780; CHESTER MR, CHRONIC REFRACTORY A; *DEP HLTH, 2000, NHS PLAN; Department of Health, 2001, REF GUID CONS EX TRE; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Towle A, 1999, BRIT MED J, V319, P766, DOI 10.1136/bmj.319.7212.766	13	30	30	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1159	1161		10.1136/bmj.327.7424.1159	http://dx.doi.org/10.1136/bmj.327.7424.1159			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615345	Green Published			2022-12-28	WOS:000186622100026
J	McLeod, H; Ham, C; Kipping, R				McLeod, H; Ham, C; Kipping, R			Booking patients for hospital admissions: evaluation of a pilot programme for day cases	BRITISH MEDICAL JOURNAL			English	Article								Problem NHS patients requiring elective surgery usually have to wait before being treated and are usually told when a date becomes available. Design 18 month pilot programme to enable day case patients to book date of hospital admission at time of decision to operate. Background and setting 24 pilot sites in England with relatively short waiting times and some experience of booking appointments. Key measures for improvement Proportion of patients with booked or "to come in" date during and after pilot programme, proportion not attending for admission, and proportion waiting greater than or equal to6 months. Comparison of pilot sites with non-pilot sites. Strategies for change National Patients' Access Team established to help pilot sites enable patients to book admission dates. Provision of pound9.9m to pilot sites to employ project managers, purchase equipment, buy extra time from clinical and other staff, and invest in information and communications technology. Effects of change Proportion of patients with booked or "to come in" date increased from 51.1% to 72.7% between end of March 1999 and end of March 2000, and then fell to 66.2% by end of March 2001. Over the same periods, the proportion of patients waiting 6 months fell from 10.9% to 10.5% and then increased to 11.9%. The proportion of patients failing to attend fell from 5.7% to 3.1% between the first quarter of 1999 and the first quarter of 2000, and then increased to 4.0% in the first quarter of 2001. Pilot sites varied widely in performance during and after the pilot phase. Pilot sites had higher proportions of patients with booked or "to come in" date than non-pilot sites at end of each period. Lessons learnt Increasing the proportion of patients who book their date of hospital admission is possible, but there are difficulties in sustaining this. Several factors facilitated or hindered the implementation of booking, and the roll out of the programme across the NHS is seeking to incorporate these factors.	Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	McLeod, H (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.			Kipping, Ruth/0000-0002-5446-8077; McLeod, Hugh/0000-0002-2266-7303				[Anonymous], IMPR EXP REF NEXT 3; Armitage P., 1987, STAT METHODS MED RES; BEECHAM L, 1991, BRIT MED J, V302, P929; COX AG, 1977, LANCET, V1, P301; Department of Health, 2002, IMPR EXP REF NEXT 3; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; Fraser G, 1993, WAITING LISTS WAITIN; HAM C, 2002, CAPACITY CULTURE LEA; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; *S W REG HLTH AUTH, 1991, PROV HIGH QUAL SERV; *SECR STAT HLTH, 2000, NHS PLAN PLAN INV PL; YATES JM, 1998, BOOKING SYSTEMS SCOR	12	5	5	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1147	+		10.1136/bmj.327.7424.1147	http://dx.doi.org/10.1136/bmj.327.7424.1147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615342	Green Published			2022-12-28	WOS:000186622100023
J	Nolte, E; McKee, M				Nolte, E; McKee, M			Measuring the health of nations: analysis of mortality amenable to health care	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; NEW-ZEALAND; DECLINE; TRENDS; RATES; SYSTEMS	Objective To assess whether and how the rankings of the world's health systems based on disability adjusted life expectancy as done in the 2000 World Health Report change when using the narrower concept of mortality amenable to health care, an outcome more closely linked to health system performance. Design Analysis of mortality amenable to health care (including and excluding ischaemic heart disease). Main outcome measure Age standardised mortality from causes amenable to health care. Setting 19 countries belonging to the Organisation for Economic Cooperation and Development. Results Rankings based on mortality amenable to health care (excluding ischaemic heart disease) differed substantially from rankings of health attainment given in the 2000 World Health Report. No country retained the same position. Rankings for southern European countries and Japan, which had performed well in the report, fell sharply, whereas those of the Nordic countries improved. Some middle ranking countries (United Kingdom, Netherlands) also fell considerably; New Zealand improved its position. Rankings changed when ischaemic heart disease was included as amenable to health care. Conclusion The 2000 World Health Report has been cited widely to support claims for the merits of otherwise different health systems. High levels of health attainment in well performing countries may be a consequence of good fortune in geography, and thus dietary habits, and success in the health effects of policies in other sectors. When assessed in terms of achievements that are more explicitly linked to health care, their performance may not be as good.	Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Nolte, E (corresponding author), Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, Keppel St, London WC1E 7HT, England.		McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683; Nolte, Ellen/0000-0002-2289-117X				Adachi Y, 2001, Gastric Cancer, V4, P166, DOI 10.1007/s10120-001-8007-7; Almeida C, 2001, LANCET, V357, P1692, DOI 10.1016/S0140-6736(00)04825-X; Beaglehole R, 2001, LANCET, V358, P661, DOI 10.1016/S0140-6736(01)05784-1; Bots M L, 1996, J Cardiovasc Risk, V3, P271, DOI 10.1097/00043798-199606000-00002; Capewell S, 1999, HEART, V81, P380, DOI 10.1136/hrt.81.4.380; Capewell S, 2000, CIRCULATION, V102, P1511, DOI 10.1161/01.CIR.102.13.1511; CHARLTON JRH, 1983, LANCET, V1, P691; HHOLLAND WW, 1988, COMMIISSION EUROPEAN; HOLLAND WW, 1988, COMMMISSION EUROPEAN, V3; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Law CK, 2003, B WORLD HEALTH ORGAN, V81, P43; Levi F, 2000, LEUKEMIA, V14, P1980, DOI 10.1038/sj.leu.2401915; Levi F, 2001, LANCET, V357, P1853, DOI 10.1016/S0140-6736(00)04973-4; Mackenbach J., 2000, IMPROVING POPULATION, P53; Marks R, 2002, RECENT RESULTS CANC, V160, P113; McKee M, 2001, BRIT MED J, V323, P295, DOI 10.1136/bmj.323.7308.295; Navarro V, 2001, INT J HEALTH SERV, V31, P23, DOI 10.2190/3LM8-A37Q-FKJ4-TE0R; NOLTE E, IN PRESS DOES HLTH C; Pedersen KM, 2002, HEALTH ECON, V11, P93, DOI 10.1002/hec.691; POIKOLAINEN K, 1986, LANCET, V1, P199; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; Tobias M, 2001, AUST NZ J PUBL HEAL, V25, P12, DOI 10.1111/j.1467-842X.2001.tb00543.x; Tunstall-Pedoe H, 2000, LANCET, V355, P688, DOI 10.1016/S0140-6736(99)11181-4; Waterhouse J, 1976, CANC INCIDENCE 5 CON; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, WHO MORT DAT	26	150	158	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1129	+		10.1136/bmj.327.7424.1129	http://dx.doi.org/10.1136/bmj.327.7424.1129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744HL	14615335	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000186622100016
J	Campbell, BA; Campbell, DB; Chandler, JF; Hine, AA; Nolan, MC; Perillat, PJ				Campbell, BA; Campbell, DB; Chandler, JF; Hine, AA; Nolan, MC; Perillat, PJ			Radar imaging of the lunar poles - Long-wavelength measurements reveal a paucity of ice in the Moon's polar craters.	NATURE			English	Editorial Material									Smithsonian Inst, Ctr Earth & Planetary Studies, Washington, DC 20013 USA; Cornell Univ, Ithaca, NY 14853 USA; Arecibo Observ, Arecibo, PR 00612 USA; Smithsonian Astrophys Observ, Cambridge, MA 02138 USA	Smithsonian Institution; Cornell University; National Aeronautics & Space Administration (NASA); Harvard University; Smithsonian Institution	Campbell, BA (corresponding author), Smithsonian Inst, Ctr Earth & Planetary Studies, Box 37012, Washington, DC 20013 USA.	campbellb@nasm.si.edu	Nolan, Michael C/H-4980-2012	Nolan, Michael C/0000-0001-8316-0680				Black GJ, 2001, ICARUS, V151, P167, DOI 10.1006/icar.2001.6616; BLACK GJ, 2002, LUNAR PLANET SCI C, V33; Bussey DB, 1999, GEOPHYS RES LETT, V26, P1187, DOI 10.1029/1999GL900213; Feldman WC, 2001, J GEOPHYS RES-PLANET, V106, P23231, DOI 10.1029/2000JE001444; HARMON JK, 1994, NATURE, V369, P213, DOI 10.1038/369213a0; Margot JL, 1999, SCIENCE, V284, P1658, DOI 10.1126/science.284.5420.1658; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; Nozette S, 2001, J GEOPHYS RES-PLANET, V106, P23253, DOI 10.1029/2000JE001417; Stacy NJS, 1997, SCIENCE, V276, P1527, DOI 10.1126/science.276.5318.1527	9	38	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					137	138		10.1038/426137a	http://dx.doi.org/10.1038/426137a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614491				2022-12-28	WOS:000186517200028
J	Monger, R; Hrywnak, V				Monger, R; Hrywnak, V			Arthritis mutilans	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cheyenne Med Specialists, Cheyenne, WY 82009 USA; Univ Wyoming, Cheyenne, WY 82001 USA	University of Wyoming	Monger, R (corresponding author), Cheyenne Med Specialists, Cheyenne, WY 82009 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1935	1935		10.1056/NEJMicm030130	http://dx.doi.org/10.1056/NEJMicm030130			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614168				2022-12-28	WOS:000186502400008
J	Kingsnorth, A; LeBlanc, K				Kingsnorth, A; LeBlanc, K			Hernias: inguinal and incisional	LANCET			English	Review							PERIOPERATIVE ANTIBIOTIC-PROPHYLAXIS; PROSPECTIVE RANDOMIZED-TRIAL; OPEN PREPERITONEAL MESH; TENSION-FREE; GROIN HERNIA; LAPAROSCOPIC HERNIOPLASTY; SIMULTANEOUS REPAIR; POLYPROPYLENE MESH; LOCAL-ANESTHESIA; VENTRAL HERNIA	In the past decade hernia surgery has been challenged by two new technologies: by laparoscopy, which has attempted to change the traditional open operative techniques, and by prosthetic mesh, which has achieved much lower recurrence rates. The demand by health care providers for increasingly efficient and cost-effective surgery has resulted in modifications to pathways of care to encourage more widespread adoption of day case, outpatient surgery, and local anaesthesia. In addition, the UK National Institute for Clinical Excellence has recommended strategies for bilateral and recurrent hernias. Here, we discuss these strategies and review some neglected aspects of hernia management such as trusses, antibiotic cover, return to work and activity, and emergency surgery. Many of the principles of management apply equally to inguinal and incisional hernias. We recommend that the more difficult and complex of the procedures be referred to specialists.	Derriford Hosp, Plymouth PL6 8DH, Devon, England; Surg Specialty Grp, Baton Rouge, LA USA	Derriford Hospital	Kingsnorth, A (corresponding author), Derriford Hosp, Level 7, Plymouth PL6 8DH, Devon, England.	andrew.kingsnorth@phnt.swest.nhs.uk						Amid PK, 1996, ANN SURG, V223, P249, DOI 10.1097/00000658-199603000-00004; AMID PK, 1993, AM J SURG, V165, P369, DOI 10.1016/S0002-9610(05)80847-5; ARLT G, 1995, INGUINAL HERNIA REPAIR, P60; BARKUN JS, 1995, SURGERY, V118, P703, DOI 10.1016/S0039-6060(05)80038-8; Bay-Nielsen M, 2001, LANCET, V358, P1124, DOI 10.1016/S0140-6736(01)06251-1; BEETS GL, 1998, SURG ENDOSC; BELLIS CJ, 1992, INT SURG, V77, P167; BENDAVID R, 1995, INGUINAL HERNIA REPAIR, P48; Bowley DMG, 2003, SURGERY, V133, P141, DOI 10.1067/msy.2003.34; Bradley M, 2003, ANN ROY COLL SURG, V85, P178, DOI 10.1308/003588403321661334; Carbajo MA, 1999, SURG ENDOSC-ULTRAS, V13, P250, DOI 10.1007/s004649900956; Champault GG, 1997, SURG LAPAROSC ENDOSC, V7, P445, DOI 10.1097/00019509-199712000-00002; CHEEK CM, 1995, BRIT J SURG, V82, P1611, DOI 10.1002/bjs.1800821207; CHEVREL JP, 1979, NOUV PRESSE MED, V8, P695; Ciampolini J, 1998, ANN ROY COLL SURG, V80, P335; Cohen RV, 1998, SURG LAPAROSC ENDOSC, V8, P264, DOI 10.1097/00019509-199808000-00004; CORCIONE F, 1997, HERNIA, V1, P37; Dakkuri RA, 2002, AM J SURG, V183, P554, DOI 10.1016/S0002-9610(02)00838-3; DAVIES N, 1994, BRIT J SURG, V81, P1478, DOI 10.1002/bjs.1800811025; DeMaria EJ, 2000, SURG ENDOSC-ULTRAS, V14, P326, DOI 10.1007/s004640020013; DEYSINE M, 1991, ARCH SURG-CHICAGO, V126, P628; Edelman DS, 2001, SURG ENDOSC-ULTRAS, V15, P976, DOI 10.1007/s004640080102; Felix EL, 2001, SURG ENDOSC, V15, P969, DOI 10.1007/s004640080091; FINGERHUT A, 1993, THEOR SURG, V8, P163; Fingerhut A, 2001, SURG ENDOSC, V15, P1061, DOI 10.1007/s004640000382; Flum DR, 2003, ANN SURG, V237, P129, DOI 10.1097/00000658-200301000-00018; Franklin ME, 1998, SURG LAPAROSC ENDOSC, V8, P294, DOI 10.1097/00019509-199808000-00012; GALLEGOS NC, 1991, BRIT J SURG, V78, P1171, DOI 10.1002/bjs.1800781007; GER R, 1982, ANN R COLL SURG ENGL, V64, P242; Gianetta E, 1997, BRIT J SURG, V84, P983, DOI 10.1002/bjs.1800840721; Gianom D, 2002, CHIRURG, V73, P1105, DOI 10.1007/s00104-002-0509-2; Gilbert A I, 1988, J Fla Med Assoc, V75, P742; GILBERT AI, 1995, INGUINAL HERNIA REPAIR, P44; GILBERT AI, 1993, SURG GYNECOL OBSTET, V177, P126; GLASSOW F, 1963, SURG GYNECOL OBSTET, V116, P701; GLASSOW F, 1984, ANN ROY COLL SURG, V66, P382; Grant A, 2000, BRIT J SURG, V87, P854, DOI 10.1046/j.1365-2168.2000.01539.x; GROTZINGER U, 1992, THER UMSCH, V49, P478; Gunnarsson U, 1999, EUR J SURG, V165, P326; Hair A, 2000, BRIT J SURG, V87, P1722, DOI 10.1046/j.1365-2168.2000.01598.x; Heikkinen TJ, 1998, SURG ENDOSC-ULTRAS, V12, P1199, DOI 10.1007/s004649900820; Heniford BT, 2000, J AM COLL SURGEONS, V190, P645, DOI 10.1016/S1072-7515(00)00280-5; Hodgson NCF, 2000, ANN SURG, V231, P436, DOI 10.1097/00000658-200003000-00018; Holzman MD, 1997, SURG ENDOSC, V11, P32, DOI 10.1007/s004649900290; Israelsson LA, 1998, EUR J SURG, V164, P353, DOI 10.1080/110241598750004382; Johansson B, 1999, ANN SURG, V230, P225, DOI 10.1097/00000658-199908000-00013; JOHANSSON B, 1997, SURG ENDOSC, V11, P170; Jones KR, 2001, SURGERY, V129, P128, DOI 10.1067/msy.2001.111696; Kapiris SA, 2001, SURG ENDOSC-ULTRAS, V15, P972, DOI 10.1007/s004640080090; KARK AE, 1995, ANN ROY COLL SURG, V77, P299; Kawji R, 1999, HERNIA, V3, P31, DOI DOI 10.1007/BF01576739; Khoury N, 1998, J LAPAROENDOSC ADV A, V8, P367, DOI 10.1089/lap.1998.8.367; Kingsnorth A N, 2002, Hernia, V6, P113; Kingsnorth AN, 2003, ANN ROY COLL SURG, V85, P18, DOI 10.1308/003588403321001363; KINGSNORTH AN, 1992, BRIT J SURG, V79, P1068, DOI 10.1002/bjs.1800791026; KINGSNORTH AN, 2003, MANAGEMENT ABDOMINAL, P164; Kingsnorth AN, 2000, HERNIA, V4, P255; Kingsnorth AN, 2000, HERNIA, V4, P1; KINGSNORTH AN, IN PRESS BMJ; KIRK RM, 1983, BMJ-BRIT MED J, V287, P4, DOI 10.1136/bmj.287.6384.4; Korenkov M, 2001, LANGENBECK ARCH SURG, V386, P65, DOI 10.1007/s004230000182; Kurzer M, 2002, BRIT J SURG, V89, P90, DOI 10.1046/j.0007-1323.2001.01956.x; KUX M, 1994, AM J SURG, V168, P15, DOI 10.1016/S0002-9610(05)80063-7; Kuzbari R, 1998, PLAST RECONSTR SURG, V101, P1235, DOI 10.1097/00006534-199804050-00010; Kyzer S, 1999, SURG ENDOSC-ULTRAS, V13, P928, DOI 10.1007/s004649901137; LAW NW, 1992, BRIT MED J, V304, P1092, DOI 10.1136/bmj.304.6834.1092; LAWRENCE K, 1995, BRIT MED J, V311, P981; LAZORTHES F, 1992, SURG GYNECOL OBSTET, V175, P569; LEAPER DJ, 1977, BRIT J SURG, V64, P603, DOI 10.1002/bjs.1800640822; LeBlanc K A, 2001, Hernia, V5, P135; LEBLANC KA, 1993, SURG LAPAROSC ENDOSC, V3, P39; LEIBL B, 1995, CHIRURG, V66, P895; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; Liem MSL, 1997, AM J EPIDEMIOL, V146, P721; Liem MSL, 1997, NEW ENGL J MED, V336, P1541, DOI 10.1056/NEJM199705293362201; LLANORA AA, 2000, EUR RADIOL, V10, P914; Lorenz D, 2000, WORLD J SURG, V24, P739, DOI 10.1007/s002689910119; Luijendijk RW, 2000, NEW ENGL J MED, V343, P392, DOI 10.1056/NEJM200008103430603; MADDERN GJ, 1994, SURG ENDOSC-ULTRAS, V8, P1404; MCENTEE GP, 1989, BRIT J SURG, V76, P725, DOI 10.1002/bjs.1800760724; Metzger J, 2001, ANN ROY COLL SURG, V83, P209; MILAMED DR, 1994, ANN SURG, V219, P94, DOI 10.1097/00000658-199401000-00015; MILLAT B, 1993, BRIT J SURG, V80, P1158, DOI 10.1002/bjs.1800800932; MILLER AR, 1991, ANN SURG, V213, P272, DOI 10.1097/00000658-199103000-00016; MORENO IG, 1947, SURGERY, V22, P945; *NAT I CLIN EXC, TECHN APPR GUID, V18; NYHUS LM, 1991, CURR PROB SURG, V28, P417; O'Dwyer P, 1999, LANCET, V354, P185; Onitsuka A, 2003, SURG TODAY, V33, P155, DOI 10.1007/s005950300036; PALOT JP, 1998, HERNIA, V2, P31; PANOS RG, 1992, SURG GYNECOL OBSTET, V175, P315; Pans A, 1997, BRIT J SURG, V84, P310; Park A, 1998, SURGERY, V124, P816, DOI 10.1067/msy.1998.92102; Paul A, 1998, EUR J SURG, V164, P361; PAYNE JH, 1994, ARCH SURG-CHICAGO, V129, P973; PELISSIER EP, 1997, HERNIA, V1, P185; PLATT R, 1990, NEW ENGL J MED, V322, P153, DOI 10.1056/NEJM199001183220303; Primatesta P, 1996, INT J EPIDEMIOL, V25, P835, DOI 10.1093/ije/25.4.835; RAMIREZ OM, 1990, PLAST RECONSTR SURG, V86, P519, DOI 10.1097/00006534-199009000-00023; Ramshaw BJ, 1999, AM SURGEON, V65, P827; Rives J, 1973, Chirurgie, V99, P547; ROBBINS AW, 1993, SURG CLIN N AM, V73, P501; Rosen M, 2001, SURG LAPARO ENDO PER, V11, P28; RUTTEN P, 1992, ACTA CHIR BELG, P168; SANCHEZMANUEL FJ, 2003, COCHRANE LIB; Sarli L, 2001, SURG LAPARO ENDO PER, V11, P262, DOI 10.1097/00129689-200108000-00007; Schmedt CG, 2002, SURG ENDOSC, V16, P240, DOI 10.1007/s00464-001-8184-9; Schrenk P, 1996, SURG ENDOSC, V10, P628, DOI 10.1007/s004649900115; Schwetling R, 1998, ZBL CHIR, V123, P193; SHULMAN AG, 1992, AM SURGEON, V58, P255; SHULMAN AG, 1994, BRIT MED J, V309, P216, DOI 10.1136/bmj.309.6949.216; SHULMAN AG, 1995, INT SURG, V80, P35; STOKER D, 1994, LANCET, V343, P1243, DOI 10.1016/S0140-6736(94)92148-2; Stoppa R, 2003, Hernia, V7, P57, DOI 10.1007/s10029-002-0107-8; Taylor EW, 1997, WORLD J SURG, V21, P811, DOI 10.1007/s002689900311; The Royal College of Surgeons of England, 1993, CLIN GUID MAN GROIN; Toms AP, 1999, BRIT J SURG, V86, P1243, DOI 10.1046/j.1365-2168.1999.01211.x; Toy FK, 1998, SURG ENDOSC, V12, P955, DOI 10.1007/s004649900755; TRABUCCO EE, 2000, OSP ITAL CHIRUG, V6, P225; Tran NV, 2003, J AM COLL SURGEONS, V196, P484, DOI 10.1016/S1072-7515(02)01896-3; TRAN VK, 2001, SURG ENDOSC, V15, P972; VALENTI G, 1999, HERNIA, V3, P5; van den Berg JC, 1999, INVEST RADIOL, V34, P739, DOI 10.1097/00004424-199912000-00002; Van Hee R, 1998, ACTA CHIR BELG, V98, P132; van't Riet M, 2002, BRIT J SURG, V89, P1350, DOI 10.1046/j.1365-2168.2002.02258.x; VOGT DM, 1995, AM J SURG, V169, P84, DOI 10.1016/S0002-9610(99)80114-7; Wellwood J, 1998, BRIT MED J, V317, P103, DOI 10.1136/bmj.317.7151.103; WILLIAMS M, 1992, HERNIA REPAIR EPIDEM; WILLIAMS M, 1992, HERNIA REPAIR EPIDEM, P9; Willis B, 2000, J SURG RES, V88, P13, DOI 10.1006/jsre.1999.5768; Wong SY, 2001, INT J SUR INVEST INT J SUR INVEST, V3, P407; Wright D, 2002, ANN SURG, V235, P333, DOI 10.1097/00000658-200203000-00004; Wysocki A, 2001, Hernia, V5, P105; Yerdel MA, 2001, ANN SURG, V233, P26, DOI 10.1097/00000658-200101000-00005	134	526	549	2	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	2003	362	9395					1561	1571		10.1016/S0140-6736(03)14746-0	http://dx.doi.org/10.1016/S0140-6736(03)14746-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615114				2022-12-28	WOS:000186464500024
J	Mukherjee, JS; Farmer, PE; Niyizonkiza, D; McCorkle, L; Vanderwarker, C; Teixeira, P; Kim, JY				Mukherjee, JS; Farmer, PE; Niyizonkiza, D; McCorkle, L; Vanderwarker, C; Teixeira, P; Kim, JY			Tackling HIV in resource poor countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION; PREVENTION; HIV/AIDS		Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; WHO, CH-1211 Geneva, Switzerland; Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02115 USA; Partners Hlth, Boston, MA 02115 USA	Harvard University; Harvard Medical School; World Health Organization; Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Mukherjee, JS (corresponding author), Harvard Univ, Sch Med, Dept Social Med, 641 Huntington Ave, Boston, MA 02115 USA.	jmukherjee@pih.org						Batson A, 1998, VACCINE, V16, pS93, DOI 10.1016/S0264-410X(98)00306-5; Bennell P.S., 2002, CTR INT ED, P1; Blower S, 2003, AIDSCIENCE, V3; Blower SM, 2003, LANCET INFECT DIS, V3, P10, DOI 10.1016/S1473-3099(03)00479-1; Bosch X, 2003, LANCET, V362, P299, DOI 10.1016/S0140-6736(03)14008-1; Brody S, 1996, NEW ENGL J MED, V335, P1998, DOI 10.1056/NEJM199612263352614; *CDC, 2003, MMWR-MORBID MORTAL W, V52, P329; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P512; Coates TJ, 2000, LANCET, V356, P103, DOI 10.1016/S0140-6736(00)02446-6; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; DZISAH M, 1999, COTE IVOIRE AIDS IS; *FAO UN, 2001, RURL WOM CARR FAM BU; FARMER P, 2001, B WORLD HEALTH ORGAN, V79, P12; GOLIBER T, 2000, EXPLORING IMPLICATIO; Grassly NC, 2001, B WORLD HEALTH ORGAN, V79, P1121; Lamptey PR, 2002, BMJ-BRIT MED J, V324, P207, DOI 10.1136/bmj.324.7331.207; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; MULLER O, 1992, AIDS, V6, P869, DOI 10.1097/00002030-199208000-00016; Okware S, 2001, B WORLD HEALTH ORGAN, V79, P1113; Piot P, 2001, B WORLD HEALTH ORGAN, V79, P1106; Roth DL, 2001, INT J STD AIDS, V12, P181, DOI 10.1258/0956462011916992; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *URB MAN PROGR REG, MAK LINK HIV AIDS UR; World Health Organization, 2002, SCAL RESP INF DIS WA; 2001, B EPIDEMIOLOGICO AID, V15	26	41	41	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2003	327	7423					1104	1106		10.1136/bmj.327.7423.1104	http://dx.doi.org/10.1136/bmj.327.7423.1104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604937	Green Published			2022-12-28	WOS:000186530400026
J	Slabinski, L; Pelley, K; Jacob, ST; Long, JM; Leaning, J				Slabinski, L; Pelley, K; Jacob, ST; Long, JM; Leaning, J			Reframing HIV and AIDS	BRITISH MEDICAL JOURNAL			English	Article									Oregon Hlth Sci Univ, Sch Med, Portland, OR 97239 USA; SUNY Buffalo, Buffalo, NY 14214 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA	Oregon Health & Science University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard T.H. Chan School of Public Health; Wake Forest University	Jacob, ST (corresponding author), Oregon Hlth Sci Univ, Sch Med, 3181 SW Sam Jackson Pk Rd,L102, Portland, OR 97239 USA.		Grepin, Karen Ann/P-1248-2018; Jacob, Shevin/CAF-0449-2022; Long, Jason/Y-3193-2019	Grepin, Karen Ann/0000-0003-4368-0045; Long, Jason/0000-0001-6268-0943; Jacob, Shevin/0000-0003-2425-9394				DEWAAL A, FLETCHER FORUM WORLD, V27, P2; DEWAAL A, DOES HIV AIDS IMPLY; Okware S, 2001, B WORLD HEALTH ORGAN, V79, P1113; *SARS EXP COMM, REP SARS HONG KONG E; *UN EC SOC COUNC U, 1985, SIR PRINC LIM DER PR; *UNICEF, 2003, HIV AIDS BIG PICT; United Nations Development Programme, 1992, OV DIS MAN; VENDRELL EG, INCIDENT COMMAND SYS; *WHO, 2002, COMM ACT EXP ACC HIV; World Health Organization, 2003, SEV AC RESP SYNDR ST	10	7	8	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1101	1103		10.1136/bmj.327.7423.1101	http://dx.doi.org/10.1136/bmj.327.7423.1101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604936	Green Published			2022-12-28	WOS:000186530400025
J	Prospero, JM; Lamb, PJ				Prospero, JM; Lamb, PJ			African droughts and dust transport to the Caribbean: Climate change implications	SCIENCE			English	Article							LONG-RANGE TRANSPORT; MINERAL DUST; UNITED-STATES; NORTH-AFRICA; TRADE WINDS; EL-NINO; AEROSOLS; RAINFALL; STORMS; SAHEL	Great quantities of African dust are carried over large areas of the Atlantic and to the Caribbean during much of the year. Measurements made from 1965 to 1998 in Barbados trade winds show large interannual changes that are highly anticorrelated with rainfall in the Soudano-Sahel, a region that has suffered varying degrees of drought since 1970. Regression estimates based on long-term rainfall data suggest that dust concentrations were sharply lower during much of the 20th century before 1970, when rainfall was more normal. Because of the great sensitivity of dust emissions to climate, future changes in climate could result in large changes in emissions from African and other arid regions that, in turn, could lead to impacts on climate over large areas.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Cooperat Inst Marine & Atmospher Studies, Miami, FL 33149 USA; Univ Oklahoma, Cooperat Inst Mesoscale Meteorol Studies, Norman, OK 73019 USA	University of Miami; University of Oklahoma System; University of Oklahoma - Norman	Prospero, JM (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Cooperat Inst Marine & Atmospher Studies, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.	jprospero@rsmas.miami.edu	Prospero, Joseph/AAT-6996-2020	Prospero, Joseph/0000-0003-3608-6160				Brooks N, 2000, ADV GLOB CHANGE RES, V6, P1; Diaz JP, 2001, J GEOPHYS RES-ATMOS, V106, P18403, DOI 10.1029/2001JD900020; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Gillette D. A., 1999, Contributions to Atmospheric Physics, V72, P67; Ginoux P, 2004, ENVIRON MODELL SOFTW, V19, P113, DOI 10.1016/S1364-8152(03)00114-2; Ginoux P, 2001, J GEOPHYS RES-ATMOS, V106, P20255, DOI 10.1029/2000JD000053; GLANTZ MH, 1994, DROUGHT FOLLOWS PLOW, P33; Goudie AS, 2001, EARTH-SCI REV, V56, P179, DOI 10.1016/S0012-8252(01)00067-8; GOUDIE AS, 1992, CLIMATIC CHANGE, V20, P197, DOI 10.1007/BF00139839; Houghton J. T., 2001, CLIMATE CHANGE 2001; Husar RB, 1997, J GEOPHYS RES-ATMOS, V102, P16889, DOI 10.1029/96JD04009; Kaufman YJ, 2002, NATURE, V419, P215, DOI 10.1038/nature01091; LAMB PJ, 1992, J CLIMATE, V5, P476, DOI 10.1175/1520-0442(1992)005<0476:FCSOTA>2.0.CO;2; LANDSEA CW, 1992, J CLIMATE, V5, P435, DOI 10.1175/1520-0442(1992)005<0435:TSABWS>2.0.CO;2; Lelieveld J, 2002, SCIENCE, V298, P794, DOI 10.1126/science.1075457; Li X, 1996, NATURE, V380, P416, DOI 10.1038/380416a0; Mbourou GN, 1997, J APPL METEOROL, V36, P868, DOI 10.1175/1520-0450(1997)036<0868:TDASCO>2.0.CO;2; Michaels AF, 1996, BIOGEOCHEMISTRY, V35, P181, DOI 10.1007/BF02179827; Moulin C, 1997, NATURE, V387, P691, DOI 10.1038/42679; Nicholson S, 2000, REV GEOPHYS, V38, P117, DOI 10.1029/1999RG900014; Nicholson SE, 1998, B AM METEOROL SOC, V79, P815, DOI 10.1175/1520-0477(1998)079<0815:DDASVA>2.0.CO;2; Nicholson SE, 2000, J CLIMATE, V13, P2628, DOI 10.1175/1520-0442(2000)013<2628:AAORRC>2.0.CO;2; Perry KD, 1997, J GEOPHYS RES-ATMOS, V102, P11225, DOI 10.1029/97JD00260; Prospero JM, 1999, J GEOPHYS RES-ATMOS, V104, P15917, DOI 10.1029/1999JD900072; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; Prospero JM, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000095; Prospero JM, 2001, WATER AIR SOIL POLL, V125, P291, DOI 10.1023/A:1005277214288; PROSPERO JM, UNPUB; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Rosenfeld D, 2001, P NATL ACAD SCI USA, V98, P5975, DOI 10.1073/pnas.101122798; Sassen K, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017371; Sokolik IN, 2001, J GEOPHYS RES-ATMOS, V106, P18015, DOI 10.1029/2000JD900498; van Aardenne JA, 2001, GLOBAL BIOGEOCHEM CY, V15, P909, DOI 10.1029/2000GB001265; Ward MN, 1998, J CLIMATE, V11, P3167, DOI 10.1175/1520-0442(1998)011<3167:DASLTP>2.0.CO;2; *WORLD RES I EARTH, 2001, TABL HD 1 DEM IND	36	715	726	1	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1024	1027		10.1126/science.1089915	http://dx.doi.org/10.1126/science.1089915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605365				2022-12-28	WOS:000186396300041
J	Choi, KW; Chau, TN; Tsang, O; Tso, E; Chiu, MC; Tong, WL; Lee, PO; Ng, TK; Ng, WF; Lee, KC; Lam, W; Yu, WC; Lai, JY; Lai, ST				Choi, KW; Chau, TN; Tsang, O; Tso, E; Chiu, MC; Tong, WL; Lee, PO; Ng, TK; Ng, WF; Lee, KC; Lam, W; Yu, WC; Lai, JY; Lai, ST		Princess Margaret Hosp Study Grp	Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong	ANNALS OF INTERNAL MEDICINE			English	Article							CORONAVIRUS; OUTBREAK; SARS; IDENTIFICATION	Background: severe acute respiratory syndrome (SARS) has become a global public health emergency. Objective: To evaluate the characteristics and outcomes of patients with SARS in Hong Kong and to identify predictors of mortality. Design: Retrospective cohort study. Setting: Quarantine hospital for patients with SARS in Hong Kong. Patients: 267 consecutive patients hospitalized from 26 February to 31 March 2003 for probable or confirmed SARS. Measurements: Clinical, laboratory, and radiographic measures; 3-month mortality rate. Results: According to our case definition, there were 227 cases of confirmed SARS and 40 cases of probable SARS. Common presenting symptoms were fever (99% of patients), chills (74%), malaise (63%), and myalgia (50%). Laboratory findings included lymphopenia (73%), thrombocytopenia (50%), hyponatremia (60%), and elevated levels of lactate dehydrogenase (47%) and C-reactive protein (75%). During hospitalization, incidence of diarrhea (53%), anemia (53%), and acute renal failure (6%) increased. Sixty-nine patients (26%) required intensive care because of respiratory failure. The 3-month mortality rate was 12% (95% Cl, 8% to 16%). Factors contributing to mortality were respiratory failure, acute renal failure, and nosocomial sepsis. On multivariate Cox regression, age older than 60 years (relative risk, 5.10 [Cl, 2.30 to 11.31]; P < 0.001) and lactate dehydrogenase level greater than 3.8 mu kat/L at presentation (relative risk, 2.20 [Cl, 1.03 to 4.71]; P = 0.04) were independent predictors of mortality. Conclusion: Because of the longer follow-up period in our cohort, the mortality rate in these patients is higher than rates reported in previous studies. Advanced age and high lactate dehydrogenase level at presentation predict mortality.	Princess Margaret Hosp, Dept Med & Geriatr, Kowloon, Hong Kong, Peoples R China		Lai, ST (corresponding author), Princess Margaret Hosp, Dept Med & Geriatr, Kowloon, Hong Kong, Peoples R China.	stpmh@netvigator.com						[Anonymous], 2003, UPD INT US CAS DEF S; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015; Chan-Yeung M, 2003, BRIT MED J, V326, P850, DOI 10.1136/bmj.326.7394.850; Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X; *DEP HLTH, 2003, AT PNEUM; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rainer TH, 2003, BRIT MED J, V326, P1354, DOI 10.1136/bmj.326.7403.1354; So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5; Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; World Health Organization, 2003, CAS DEF SURV SEV AC; ZUCKERFRANKLIN D, 1994, SEMIN HEMATOL, V31, P329	21	252	268	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					715	723		10.7326/0003-4819-139-9-200311040-00005	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738XJ	14597455				2022-12-28	WOS:000186312900001
J	Mazel, CH; Cronin, TW; Caldwell, RL; Marshall, NJ				Mazel, CH; Cronin, TW; Caldwell, RL; Marshall, NJ			Fluorescent enhancement of signaling in a mantis shrimp	SCIENCE			English	Article									Phys Sci Inc, Andover, MA 01810 USA; Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Queensland, Vis Touch & Hearing Res Ctr, Brisbane, Qld 4072, Australia	Physical Sciences Inc.; University System of Maryland; University of Maryland Baltimore County; University of California System; University of California Berkeley; University of Queensland	Mazel, CH (corresponding author), Phys Sci Inc, 20 New England Business Ctr, Andover, MA 01810 USA.			Marshall, Justin/0000-0001-9006-6713				Arnold KE, 2002, SCIENCE, V295, P92, DOI 10.1126/science.295.5552.92; Cronin TW, 2000, PHILOS T ROY SOC B, V355, P1263, DOI 10.1098/rstb.2000.0680; Lythgoe J.N., 1979, ECOLOGY VISION; Mathger LM, 2001, J EXP BIOL, V204, P2103; Mazel CH, 2003, LIMNOL OCEANOGR, V48, P390, DOI 10.4319/lo.2003.48.1_part_2.0390	5	68	69	3	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	2004	303	5654					51	51		10.1126/science.1089803	http://dx.doi.org/10.1126/science.1089803			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14615546				2022-12-28	WOS:000187710600027
J	Jochim, S; Bartenstein, M; Altmeyer, A; Hendl, G; Riedl, S; Chin, C; Denschlag, JH; Grimm, R				Jochim, S; Bartenstein, M; Altmeyer, A; Hendl, G; Riedl, S; Chin, C; Denschlag, JH; Grimm, R			Bose-Einstein condensation of molecules	SCIENCE			English	Article							COLLECTIVE EXCITATIONS; FERMI GAS; SUPERFLUIDITY	We report on the Bose-Einstein condensation of more than 10(5) Li-2 molecules in an optical trap starting from a spin mixture of fermionic lithium atoms. During forced evaporative cooling, the molecules are formed by three-body recombination near a Feshbach resonance and finally condense in a long-lived thermal equilibrium state. We measured the characteristic frequency of a collective excitation mode and demonstrated the magnetic field-dependent mean field by controlled condensate spilling.	Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Quantenopt & Quanteninformat, A-6020 Innsbruck, Austria	University of Innsbruck; Austrian Academy of Sciences	Grimm, R (corresponding author), Univ Innsbruck, Inst Expt Phys, Technikerstr 25, A-6020 Innsbruck, Austria.	rudolf.grimm@uibk.ac.at	Denschlag, Johannes P Hecker/B-6047-2008; Grimm, Rudolf/D-2864-2009; Jochim, Selim/G-1287-2011	Denschlag, Johannes P Hecker/0000-0003-1984-4994; Grimm, Rudolf/0000-0003-1085-5558; Jochim, Selim/0000-0001-6049-2658				ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Bourdel T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.020402; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; Chin C, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.033201; Cho A, 2003, SCIENCE, V301, P750; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Dieckmann K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.203201; Donley EA, 2002, NATURE, V417, P529, DOI 10.1038/417529a; Granade SR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.120405; Guery-Odelin D, 1999, PHYS REV A, V60, P4851, DOI 10.1103/PhysRevA.60.4851; Herbig J, 2003, SCIENCE, V301, P1510, DOI 10.1126/science.1088876; Holland M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.120406; Houbiers M, 1998, PHYS REV A, V57, pR1497, DOI 10.1103/PhysRevA.57.R1497; Inouye S, 1998, NATURE, V392, P151, DOI 10.1038/32354; Jin DS, 1997, PHYS REV LETT, V78, P764, DOI 10.1103/PhysRevLett.78.764; Jochim S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.273202; JOCHIM S, IN PRESS PHYS REV LE; Mosk A, 2001, OPT LETT, V26, P1837, DOI 10.1364/OL.26.001837; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; O'Hara KM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.041401; O'Hara KM, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.051403; Ohashi Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.130402; Pitaevskii L, 2002, SCIENCE, V298, P2144, DOI 10.1126/science.1080087; Regal CA, 2003, NATURE, V424, P47, DOI 10.1038/nature01738; Stamper-Kurn DM, 1998, PHYS REV LETT, V81, P500, DOI 10.1103/PhysRevLett.81.500; Stoof HTC, 1996, PHYS REV LETT, V76, P10, DOI 10.1103/PhysRevLett.76.10; Strecker KE, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.080406; Stringari S, 1996, PHYS REV LETT, V77, P2360, DOI 10.1103/PhysRevLett.77.2360; Timmermans E, 2001, PHYS LETT A, V285, P228, DOI 10.1016/S0375-9601(01)00346-2; Wynar R, 2000, SCIENCE, V287, P1016, DOI 10.1126/science.287.5455.1016	30	974	995	2	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	2003	302	5653					2101	2103		10.1126/science.1093280	http://dx.doi.org/10.1126/science.1093280			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	755CB	14615548				2022-12-28	WOS:000187385200037
J	Clarke, MP; Wright, CM; Hrisos, S; Anderson, JD; Henderson, J; Richardson, SR				Clarke, MP; Wright, CM; Hrisos, S; Anderson, JD; Henderson, J; Richardson, SR			Randomised controlled trial of treatment of unilateral visual impairment detected at preschool vision screening	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AMBLYOPIA; CHILDREN; THERAPY; AGE	Objectives To test the efficacy of treatment for unilateral visual loss detected by preschool vision screening and the extent to which effectiveness varies with initial severity. Design Randomised controlled trial of full treatment with glasses and patching, if required, compared with glasses only or no treatment. Masked assessment of best corrected acuity after one year of follow up. Setting Eight UK eye departments. Participants 177 children aged 3-5 years with mild to moderate unilateral impairment of acuity (6/9 to 6/36) detected by screening. Results Children in the full and glasses treatment groups had incrementally better visual acuity at follow up than children who received no treatment, but the mean treatment effect between full and no treatment was equivalent to only one line on a Snellen chart (0.11 log units; 95% confidence interval 0.050 to 0.171; P<0.0001). The effects of treatment depended on initial acuity: full treatment showed a substantial effect in the moderate acuity group (6/36 to 6/18 at recruitment) and no significant effect in the mild acuity group (6/9 to 6/12 at recruitment) (P=0.006 for linear regression interaction term). For 64 children with moderate acuity loss the treatment effect was 0.20 log units, equivalent to one to two lines on a Snellen chart. When all children had received treatment, six months after the end of the trial, there was no significant difference in acuity between the groups. Conclusions Treatment is worth while in children with the poorest acuity, but in children with mild (6/9 to 6/12) unilateral acuity loss there was little benefit. Delay in treatment until the age of 5 did not seem to influence effectiveness.	Newcastle Univ, Sch Neurobiol Neurol & Psychiat, Dept Ophthalmol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Glasgow, Dept Child Hlth, PEACH Unit, Glasgow G3 8SJ, Lanark, Scotland; Royal Victoria Infirm, Dept Ophthalmol, Orthopt Dept, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; University of Glasgow; Newcastle University - UK	Clarke, MP (corresponding author), Newcastle Univ, Sch Neurobiol Neurol & Psychiat, Dept Ophthalmol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	M.P.Clarke@ncl.ac.uk						Barnes GR, 2001, J PHYSIOL-LONDON, V533, P281, DOI 10.1111/j.1469-7793.2001.0281b.x; Beardsell R, 1989, BR ORTHOPT J, V46, P7; BIRNBAUM MH, 1977, AM J OPTOM PHYS OPT, V54, P269; Bray LC, 1996, EYE, V10, P714, DOI 10.1038/eye.1996.166; CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; Garey L J, 1979, Prog Brain Res, V51, P445; Glaser SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P268; HALL D, 2002, HLTH ALL CHILDREN; Hardman Lea S J, 1989, Eye (Lond), V3 ( Pt 6), P783; Hartmann EE, 2001, OPHTHALMOLOGY, V108, P479, DOI 10.1016/S0161-6420(00)00588-1; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; INGRAM RM, 1986, BRIT J OPHTHALMOL, V70, P16, DOI 10.1136/bjo.70.1.16; KUTSCHKE PJ, 1991, OPHTHALMOLOGY, V98, P258; Kvarnstrom G, 2001, ACTA OPHTHALMOL SCAN, V79, P240, DOI 10.1034/j.1600-0420.2001.790306.x; Moseley M., 2002, AMBLYOPIA MULTIDISCI, P81; Moseley MJ, 1997, BRIT J OPHTHALMOL, V81, P956, DOI 10.1136/bjo.81.11.956; Reeves BC., 2002, AMBLYOPIA MULTIDISCI, P68; Snowdon SK, 1997, HEALTH TECHNOL ASSES, V1, P1; STEWARTBROWN S, 1985, DEV MED CHILD NEUROL, V27, P504; STEWARTBROWN SL, 1988, ARCH DIS CHILD, V63, P356, DOI 10.1136/adc.63.4.356; TAYLOR D, 1987, ARCH DIS CHILD, V62, P982, DOI 10.1136/adc.62.10.982; Von Noorden GK, 2001, BINOCULAR VISION OCU, V6th, P571; Williams C, 2002, BMJ-BRIT MED J, V324, P1549, DOI 10.1136/bmj.324.7353.1549	23	106	109	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	2003	327	7426					1251	1254		10.1136/bmj.327.7426.1251	http://dx.doi.org/10.1136/bmj.327.7426.1251			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644966	Green Published, Bronze			2022-12-28	WOS:000186948800015
J	McCulloch, P; Ward, J; Tekkis, PP				McCulloch, P; Ward, J; Tekkis, PP		British Oesophago-Gastric Canc Grp	Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL VOLUME; GASTRIC-CANCER; CARE; STOMACH	Objective To evaluate the effect of comorbidity and other risk factors on postoperative mortality and morbidity in patients undergoing major oesophageal and gastric surgery. Design Multicentre cohort study with data on postoperative mortality and morbidity in hospital. Data source and methods The ASCOT prospective database, comprising 2087 patients with newly diagnosed oesophageal and gastric cancer in 24 hospitals in England and Wales between 1 January 1999 and 31 December 2002. Multivariate logistic regression analysis was used to model the risk of death and postoperative complications. Results 955 patients underwent oesophagectomy or gastrectomy. Of these, 253 (27%) were graded ASA III or IV, and 187 (20%) had a high physiological POSSUM score (greater than or equal to20). Operative mortality was 12% (111/955). Physiological POSSUM score, surgeon's assessment, type of operation, hospital case volume, and tumour stage independently predicted operative mortality. Medical complications were associated with higher physiological POSSUM scores and ASA grade, oesophagectomy or total gastrectomy, thoracotomy, and radical nodal dissection. Stage and additional organ resection predicted surgical (technical) complications. Conclusions Many patients undergoing surgery for gastro-oesophageal cancer have major comorbid disease, which strongly influences their risk of postoperative death. Technical complications do not seem to be influenced by preoperative factors but reflect the extent of surgery and perhaps surgical judgment. Detailed prospective multicentre cooperative audit, with appropriate risk adjustment, is fundamental in the evaluation of cancer care and must be properly resourced.	Univ Liverpool, Univ Hosp Aintree, Acad Surg Unit, Liverpool L9 7AL, Merseyside, England; Chorley & S Ribble Dist Gen Hosp, Chorley PR7 1PP, Lancs, England; Kings Coll Hosp London, Acad Dept Surg, London SE5 9RS, England	University of Liverpool; King's College Hospital NHS Foundation Trust; King's College Hospital	McCulloch, P (corresponding author), Univ Liverpool, Univ Hosp Aintree, Acad Surg Unit, Liverpool L9 7AL, Merseyside, England.	petermcculloch@aol.com		McCulloch, Peter/0000-0002-3210-8273				Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; Bachmann MO, 2002, BRIT J SURG, V89, P914, DOI 10.1046/j.1365-2168.2002.02135.x; Bailey SH, 2003, ANN THORAC SURG, V75, P217, DOI 10.1016/S0003-4975(02)04368-0; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; *BRIT HEART FDN, INT STAT; *CLIN OUTC GROUP N, 2001, GUID COMM CANC SERV; COPELAND GP, 1991, BRIT J SURG, V78, P356; CROSBY DL, 1994, ANN ROY COLL SURG, V76, P14; Cummins J, 2001, EUR J SURG ONCOL, V27, P709, DOI 10.1053/ejso.2001.1176; Evans W K, 1998, Cancer Prev Control, V2, P304; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Karl RC, 2000, ANN SURG, V231, P635, DOI 10.1097/00000658-200005000-00003; Meyer W, 2002, DIGEST SURG, V19, P269, DOI 10.1159/000064579; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pye JK, 2001, BRIT J SURG, V88, P278, DOI 10.1046/j.1365-2168.2001.01655.x; Robertsson O, 1999, ACTA ORTHOP SCAND, V70, P467, DOI 10.3109/17453679909000982; Sano T, 2002, BRIT J SURG, V89, P123; Siewert JR, 1998, ANN SURG, V228, P449, DOI 10.1097/00000658-199810000-00002; Spiegelhalter DJ, 2002, J R STAT SOC A STAT, V165, P191, DOI 10.1111/1467-985X.02021; Thompson AM, 2002, BRIT J SURG, V89, P89; Turner M, 1999, J ROY COLL SURG EDIN, V44, P19; VACANTI CJ, 1970, ANESTH ANAL CURR RES, V49, P564; van Lanschot JJB, 2001, CANCER-AM CANCER SOC, V91, P1574, DOI 10.1002/1097-0142(20010415)91:8<1574::AID-CNCR1168>3.0.CO;2-2; WANEBO HJ, 1993, ANN SURG, V218, P583, DOI 10.1097/00000658-199321850-00002; Warsi AA, 2002, EUR J SURG ONCOL, V28, P850, DOI 10.1053/ejso.2002.1283	25	270	281	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	2003	327	7425					1192	1196		10.1136/bmj.327.7425.1192	http://dx.doi.org/10.1136/bmj.327.7425.1192			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630753	Green Published, Bronze			2022-12-28	WOS:000186784300016
J	Tredicucci, A				Tredicucci, A			Marriage of two device concepts	SCIENCE			English	Editorial Material							PHOTONIC CRYSTALS; LASER		INFM, NEST, I-56126 Pisa, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Scuola Normale Superiore di Pisa	Tredicucci, A (corresponding author), INFM, NEST, Piazza Cavalieri 7, I-56126 Pisa, Italy.	a.tredicucci@sns.it	Tredicucci, Alessandro/M-6166-2015	Tredicucci, Alessandro/0000-0003-3619-3011				Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Beck M, 2002, SCIENCE, V295, P301, DOI 10.1126/science.1066408; Benisty H, 2001, NATO SCI SER II-MATH, V563, P117; Capasso F, 2002, PHYS TODAY, V55, P34, DOI 10.1063/1.1485582; Colombelli R, 2003, SCIENCE, V302, P1374, DOI 10.1126/science.1090561; Cubukcu E, 2003, NATURE, V423, P604, DOI 10.1038/423604b; FAIST J, 1994, SCIENCE, V264, P553, DOI 10.1126/science.264.5158.553; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; Kohler R, 2002, NATURE, V417, P156, DOI 10.1038/417156a; Russell P, 2003, SCIENCE, V299, P358, DOI 10.1126/science.1079280; Samuelson L., 2003, MATER TODAY, V6, P22, DOI DOI 10.1016/S1369-7021(03)01026-5; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	12	5	5	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1346	1347		10.1126/science.1092490	http://dx.doi.org/10.1126/science.1092490			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631027				2022-12-28	WOS:000186683500037
J	Head, IM; Jones, DM; Larter, SR				Head, IM; Jones, DM; Larter, SR			Biological activity in the deep subsurface and the origin of heavy oil	NATURE			English	Review							SULFATE-REDUCING BACTERIA; UPPER TEMPERATURE LIMIT; NORWEGIAN NORTH-SEA; CRUDE-OIL; PETROLEUM RESERVOIRS; FIELD WATERS; HYDROCARBON DEGRADATION; MICROBIAL-DEGRADATION; ANAEROBIC DEGRADATION; MANNVILLE GROUP	At temperatures up to about 80 degreesC, petroleum in subsurface reservoirs is often biologically degraded, over geological timescales, by microorganisms that destroy hydrocarbons and other components to produce altered, denser 'heavy oils'. This temperature threshold for hydrocarbon biodegradation might represent the maximum temperature boundary for life in the deep nutrient-depleted Earth. Most of the world's oil was biodegraded under anaerobic conditions, with methane, a valuable commodity, often being a major by-product, which suggests alternative approaches to recovering the world's vast heavy oil resource that otherwise will remain largely unproduced.	Newcastle Univ, Sch Civil Engn & Geosci, NRG Petr Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK	Head, IM (corresponding author), Newcastle Univ, Sch Civil Engn & Geosci, NRG Petr Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	steve_larter@hotmail.com		Larter, Stephen/0000-0001-7195-1477; Head, Ian/0000-0002-5373-162X				AITKEN CM, 2002, ISOLATION IDENTIFICA; Alexander R., 1983, APPEA J, V23, P53; Anderson RT, 2000, NATURE, V404, P722, DOI 10.1038/35008145; Annweiler E, 2002, APPL ENVIRON MICROB, V68, P852, DOI 10.1128/AEM.68.2.852-858.2002; BAILEY NJL, 1973, CHEM GEOL, V11, P203, DOI 10.1016/0009-2541(73)90017-X; BARNARD PC, 1991, GEOLOGICAL SOC SPECI, V59, P167; Barson D, 2001, B CAN PETROL GEOL, V49, P376, DOI 10.2113/49.3.376; Bastin ES, 1926, SCIENCE, V63, P21, DOI 10.1126/science.63.1618.21; Bennett PC, 2001, GEOMICROBIOL J, V18, P3, DOI 10.1080/01490450151079734; Bennett PC, 2000, HYDROGEOL J, V8, P47, DOI 10.1007/s100400050007; BJORLYKKE K, 1999, GROWTH DISSOLUTION P, P381; Blochl E, 1997, EXTREMOPHILES, V1, P14; Boreham CJ, 2001, APPEA J, V41, P523, DOI [DOI 10.1071/AJ00026, 10.1071/AJ00026]; BROOKS PW, 1988, ORG GEOCHEM, V12, P519, DOI 10.1016/0146-6380(88)90144-1; Butler R, 2001, J CAN PETROL TECHNOL, V40, P18, DOI 10.2118/01-01-DAS; Chapelle FH, 2002, NATURE, V415, P312, DOI 10.1038/415312a; Charlou JL, 2002, CHEM GEOL, V191, P345, DOI 10.1016/S0009-2541(02)00134-1; Connan J., 1986, ADV PETROLEUM GEOCHE, V1, P299, DOI DOI 10.1016/B978-0-12-032001-1.50011-0; CONNAN J, 1996, P 1995 INT GAS RES C, P21; CREANEY S, 1990, GEOL SOC SPEC PUBL, V50, P189; DEMAISON GJ, 1977, AAPG BULL, V61, P1950; DIMITRAKOPOULOS R, 1987, CHEM GEOL, V65, P283, DOI 10.1016/0168-9622(87)90008-X; Ehrenberg SN, 2001, SEDIMENTOLOGY, V48, P703, DOI 10.1046/j.1365-3091.2001.00387.x; ENGLAND WA, 1987, J GEOL SOC LONDON, V144, P327, DOI 10.1144/gsjgs.144.2.0327; EVANS CR, 1971, CHEM GEOL, V8, P147, DOI 10.1016/0009-2541(71)90002-7; FEDORAK PM, 1984, APPL ENVIRON MICROB, V47, P858, DOI 10.1128/AEM.47.4.858-862.1984; HELGESON HC, 1993, GEOCHIM COSMOCHIM AC, V57, P3295, DOI 10.1016/0016-7037(93)90541-4; HIEBERT FK, 1992, SCIENCE, V258, P278, DOI 10.1126/science.258.5080.278; Holba AG, 1996, ORG GEOCHEM, V24, P1179, DOI 10.1016/S0146-6380(96)00101-5; Horstad I, 1997, AAPG BULL, V81, P222; HORSTAD I, 1992, ORG GEOCHEM, V19, P107, DOI 10.1016/0146-6380(92)90030-2; Huang HP, 2003, ORG GEOCHEM, V34, P951, DOI 10.1016/S0146-6380(03)00033-0; Hunkeler D, 1998, J CONTAM HYDROL, V32, P41, DOI 10.1016/S0169-7722(97)00079-X; Hunt J.M., 1979, PETROLEUM GEOCHEMIST; JAMES AT, 1984, AAPG BULL, V68, P957; JAMES KH, 1990, GEOL SOC SPEC PUBL, V50, P9; Kartsev A. A., 1959, GEOCHEMICAL METHODS, P347; Kashefi K, 2003, SCIENCE, V301, P934, DOI 10.1126/science.1086823; Krejci-Graf K, 1932, AAPG BULL, V16, P1038; Larter S, 2003, ORG GEOCHEM, V34, P601, DOI 10.1016/S0146-6380(02)00240-1; LARTER S, 1999, P AAPG HEDB RES C NA; Mackenzie A. S., 1983, ADV ORG GEOCHEM, P637; Magot M, 2000, ANTON LEEUW INT J G, V77, P103, DOI 10.1023/A:1002434330514; MANNING DA, IN PRESS APPL GEOCHE; Masterson WD, 2001, ORG GEOCHEM, V32, P411, DOI 10.1016/S0146-6380(00)00187-X; Meredith W, 2000, ORG GEOCHEM, V31, P1059, DOI 10.1016/S0146-6380(00)00136-4; MOLDOWAN JM, 1995, GEOCHIM COSMOCHIM AC, V59, P1891, DOI 10.1016/0016-7037(95)00072-8; Murphy EM, 1998, GEOCHIM COSMOCHIM AC, V62, P3395, DOI 10.1016/S0016-7037(98)00254-3; Nazina TN, 1995, GEOMICROBIOL J, V13, P181, DOI 10.1080/01490459509378016; NG TK, 1989, GEOMICROBIOL J, V7, P185, DOI 10.1080/01490458909377861; Nilsen RK, 1996, APPL ENVIRON MICROB, V62, P1793, DOI 10.1128/AEM.62.5.1793-1798.1996; OBRAZTSOVA AY, 1987, MICROBIOLOGY+, V56, P523; OLDENBURG T, IN PRESS ORG GEOCHEM; Orphan VJ, 2000, APPL ENVIRON MICROB, V66, P700, DOI 10.1128/AEM.66.2.700-711.2000; Pallasser RJ, 2000, ORG GEOCHEM, V31, P1363, DOI 10.1016/S0146-6380(00)00101-7; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; PEPPER A, 2001, EARTH SYST PROC GEOL; Peters K.E., 1993, BIOMARKER GUIDE; Peters KE, 2002, ORG GEOCHEM, V33, P5, DOI 10.1016/S0146-6380(01)00125-5; PIGGOTT N, 1991, PETROLEUM MIGRATION, P207; Riediger CL, 1999, B CAN PETROL GEOL, V47, P43; Roadifer R. E., 1987, EXPLORATION HEAVY CR, P3; Rogers JR, 1998, AM MINERAL, V83, P1532, DOI 10.2138/am-1998-11-1241; Roling WFM, 2003, RES MICROBIOL, V154, P321, DOI 10.1016/S0923-2508(03)00086-X; Rowland S, 2001, ENVIRON SCI TECHNOL, V35, P2640, DOI 10.1021/es0018264; ROWLAND SJ, 1986, ORG GEOCHEM, V9, P153, DOI 10.1016/0146-6380(86)90065-3; ROZANOVA EP, 1995, MICROBIOLOGY+, V64, P85; RUBINSTEIN I, 1977, GEOCHIM COSMOCHIM AC, V41, P1341, DOI 10.1016/0016-7037(77)90077-1; RUETER P, 1994, NATURE, V372, P455, DOI 10.1038/372455a0; SCOTT AR, 1994, AAPG BULL, V78, P1186; Stetter KO, 1999, FEBS LETT, V452, P22, DOI 10.1016/S0014-5793(99)00663-8; Takahata Y, 2001, ARCH MICROBIOL, V176, P264, DOI 10.1007/s002030100318; Taylor P, 2001, ORG GEOCHEM, V32, P341, DOI 10.1016/S0146-6380(00)00176-5; Thorn KA, 1998, ORG GEOCHEM, V29, P909, DOI 10.1016/S0146-6380(98)00167-3; Tomczyk NA, 2001, ENERG FUEL, V15, P1498, DOI 10.1021/ef010106v; Volkman J.K., 1984, ORG GEOCHEM, V6, P619, DOI DOI 10.1016/0146-6380(84)90084-6; VOLKMAN JK, 1983, GEOCHIM COSMOCHIM AC, V47, P785, DOI 10.1016/0016-7037(83)90112-6; Warren E. A., 1994, N SEA FORMATION WATE; Wellsbury P, 1997, NATURE, V388, P573, DOI 10.1038/41544; Wenger L. M., 2001, 71450 SPE; Whelan JK, 2001, GEOCHIM COSMOCHIM AC, V65, P3529, DOI 10.1016/S0016-7037(01)00684-6; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Widdel F, 2001, CURR OPIN BIOTECH, V12, P259, DOI 10.1016/S0958-1669(00)00209-3; Wilhelms A, 2001, NATURE, V411, P1034, DOI 10.1038/35082535; Wilkes H, 2002, ARCH MICROBIOL, V177, P235, DOI 10.1007/s00203-001-0381-3; Winters J.C., 1969, AM CHEM SOC DIV PET, pE22; Yu AZ, 2002, WORLD OIL        APR, P1; Zengler K, 1999, NATURE, V401, P266, DOI 10.1038/45777; ZHANG C, 1999, SHIYOU YU TIANRANQI, V20, P341; [No title captured]	90	806	879	12	313	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					344	352		10.1038/nature02134	http://dx.doi.org/10.1038/nature02134			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628064				2022-12-28	WOS:000186660800056
J	Kopp, JB; Schiffmann, R				Kopp, JB; Schiffmann, R			Fabry's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Kopp, JB (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.		Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002984] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					E20	E20		10.1056/ENEJMicm000011	http://dx.doi.org/10.1056/ENEJMicm000011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627801				2022-12-28	WOS:000186642900008
J	Sijen, T; Plasterk, RHA				Sijen, T; Plasterk, RHA			Transposon silencing in the Caenorhabditis elegans germ line by natural RNAi	NATURE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; GENE; INTERFERENCE; HELICASE; HOMOLOG; RDE-1	Transposable elements are stretches of DNA that can move and multiply within the genome of an organism. The Caenorhabditis elegans genome contains multiple Tc1 transposons that jump in somatic cells, but are silenced in the germ line(1-3). Many mutants that have lost this silencing have also lost the ability to execute RNA interference (RNAi)(2,3), a process whereby genes are suppressed by exposure to homologous double-stranded RNA ( dsRNA). Here we show how RNAi causes transposon silencing in the nematode germ line. We find evidence for transposon-derived dsRNAs, in particular to the terminal inverted repeats, and show that these RNAs may derive from read-through transcription of entire transposable elements. Small interfering RNAs of Tc1 were detected. When a germline-expressed reporter gene is fused to a stretch of Tc1 sequence, this transgene is silenced in a manner dependent on functional mutator genes (mut-7, mut-16 and pk732). These results indicate that RNAi surveillance is triggered by fortuitous read-through transcription of dispersed Tc1 copies, which can form dsRNA as a result of 'snap-back' of the terminal inverted repeats. RNAi mediated by this dsRNA silences transposase gene expression.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Plasterk, RHA (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	plasterk@niob.knaw.nl						Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Aroian RV, 1997, EMBO J, V16, P1541, DOI 10.1093/emboj/16.7.1541; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fischer SEJ, 2003, GENETICS, V164, P127; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Praitis V, 2001, GENETICS, V157, P1217; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sijen T, 2001, CURR BIOL, V11, P436, DOI 10.1016/S0960-9822(01)00116-6; Sijen T, 1996, PLANT CELL, V8, P2277, DOI 10.1105/tpc.8.12.2277; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Vastenhouw NL, 2003, CURR BIOL, V13, P1311, DOI 10.1016/s0960-9822(03)00539-6; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; Wilm T, 1999, GENE, V229, P31, DOI 10.1016/S0378-1119(99)00043-8; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	30	337	364	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					310	314		10.1038/nature02107	http://dx.doi.org/10.1038/nature02107			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628056				2022-12-28	WOS:000186660800049
J	Buehler, MJ; Abraham, FF; Gao, HJ				Buehler, MJ; Abraham, FF; Gao, HJ			Hyperelasticity governs dynamic fracture at a critical length scale	NATURE			English	Article							INSTABILITY DYNAMICS; CRACK-PROPAGATION; BRITTLE-FRACTURE; COMPUTER; VELOCITY; SPEED	The elasticity of a solid can vary depending on its state of deformation. For example, metals will soften and polymers may stiffen as they are deformed to levels approaching failure. It is only when the deformation is infinitesimally small that elastic moduli can be considered constant, and hence the elasticity linear. Yet, many existing theories model fracture using linear elasticity, despite the fact that materials will experience extreme deformations at crack tips. Here we show by large-scale atomistic simulations that the elastic behaviour observed at large strains-hyperelasticity-can play a governing role in the dynamics of fracture, and that linear theory is incapable of fully capturing all fracture phenomena. We introduce the concept of a characteristic length scale for the energy flux near the crack tip, and demonstrate that the local hyperelastic wave speed governs the crack speed when the hyperelastic zone approaches this energy length scale.	Max Planck Inst Met Res, D-70569 Stuttgart, Germany; IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	Max Planck Society; International Business Machines (IBM)	Gao, HJ (corresponding author), Max Planck Inst Met Res, Heisenbergstr 3, D-70569 Stuttgart, Germany.	hjgao@mf.mpg.de	Gao, Huajian/F-9360-2010; Buehler, Markus J./C-4580-2008	Gao, Huajian/0000-0002-8656-846X; Buehler, Markus J./0000-0002-4173-9659				Abraham FF, 1997, J MECH PHYS SOLIDS, V45, P1461, DOI 10.1016/S0022-5096(97)00017-3; Abraham FF, 1997, J MECH PHYS SOLIDS, V45, P1595, DOI 10.1016/S0022-5096(96)00103-2; ABRAHAM FF, 1994, PHYS REV LETT, V73, P272, DOI 10.1103/PhysRevLett.73.272; Abraham FF, 2000, PHYS REV LETT, V84, P3113, DOI 10.1103/PhysRevLett.84.3113; Abraham FF, 2002, P NATL ACAD SCI USA, V99, P5777, DOI 10.1073/pnas.062012699; Abraham FF, 1996, PHYS REV LETT, V77, P869, DOI 10.1103/PhysRevLett.77.869; Abraham FF, 2001, J MECH PHYS SOLIDS, V49, P2095, DOI 10.1016/S0022-5096(01)00028-X; Allen M. P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; Broberg B. K., 1999, CRACKS FRACTURE; BROBERG KB, 1995, INT J SOLIDS STRUCT, V32, P883, DOI 10.1016/0020-7683(94)00166-T; Cramer T, 2000, PHYS REV LETT, V85, P788, DOI 10.1103/PhysRevLett.85.788; Falk ML, 2001, J PHYS IV, V11, P43, DOI 10.1051/jp4:2001506; FIELD JE, 1971, CONTEMP PHYS, V12, P1, DOI 10.1080/00107517108205103; FINEBERG J, 1991, PHYS REV LETT, V67, P457, DOI 10.1103/PhysRevLett.67.457; Fratini S, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.104104; Freund L.B., 1998, DYNAMIC FRACTURE MEC; Gao HJ, 1997, PHIL MAG LETT, V76, P307, DOI 10.1080/095008397178896; Gao HJ, 1996, J MECH PHYS SOLIDS, V44, P1453, DOI 10.1016/0022-5096(96)00038-5; Hauch JA, 1999, PHYS REV LETT, V82, P3823, DOI 10.1103/PhysRevLett.82.3823; Hauch JA, 1998, INT J FRACTURE, V90, P133, DOI 10.1023/A:1007491318198; Heizler SI, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.016126; HULL D, 1966, INT J FRACT MECH, V2, P468; KNAUSS WG, 1966, J APPL MECH, V33, P356, DOI 10.1115/1.3625049; Ravi-Chandar K, 1998, INT J FRACTURE, V90, P83, DOI 10.1023/A:1007432017290; Rosakis AJ, 2002, ADV PHYS, V51, P1189, DOI 10.1080/00018730210122328; Rountree CL, 2002, ANNU REV MATER RES, V32, P377, DOI 10.1146/annurev.matsci.32.111201.142017; Sharon E, 1999, NATURE, V397, P333, DOI 10.1038/16891; Slepyan L.I., 2002, FDN ENGN MECH, DOI 10.1007/978-3-540-48010-5; Swadener JG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.085503; WASHABAUGH PD, 1994, INT J FRACTURE, V65, P97; Zhou SJ, 1996, PHYS REV LETT, V76, P2318, DOI 10.1103/PhysRevLett.76.2318; ZIMMERMANN JA, 1999, THESIS STANFORD U	32	244	252	11	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					141	146		10.1038/nature02096	http://dx.doi.org/10.1038/nature02096			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614496				2022-12-28	WOS:000186517200033
J	Mang, PK; Larochelle, S; Greven, M				Mang, PK; Larochelle, S; Greven, M			Condensed-matter physics - Spurious magnetism in high-T-c superconductor	NATURE			English	Editorial Material									Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Mang, PK (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.							Kang HJ, 2003, NATURE, V423, P522, DOI 10.1038/nature01641; MOON RM, 1968, PHYS REV, V176, P722, DOI 10.1103/PhysRev.176.722; TOKURA Y, 1989, NATURE, V337, P345, DOI 10.1038/337345a0	3	19	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					139	140		10.1038/426139b	http://dx.doi.org/10.1038/426139b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614494	Green Submitted			2022-12-28	WOS:000186517200031
J	Tamber, PS; Godlee, F; Newmark, P				Tamber, PS; Godlee, F; Newmark, P			Open access to peer-reviewed research: making it happen	LANCET			English	Article							TRIALS		BioMed Cent, London W1T 4LB, England; BMJ Knowledge, London WC1H 9JR, England		Tamber, PS (corresponding author), BioMed Cent, Middlesex House, London W1T 4LB, England.							BROWN P, WHAT MUST SCI DO EXP; Clarke M, 1998, JAMA-J AM MED ASSOC, V280, P280, DOI 10.1001/jama.280.3.280; Cozzarelli NR, 2000, P NATL ACAD SCI USA, V97, P1, DOI 10.1073/pnas.97.1.1; Delamothe T, 2001, BMJ-BRIT MED J, V322, P1, DOI 10.1136/bmj.322.7277.1; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; HAYNES RB, 1993, J CLIN EPIDEMIOL, V46, P595, DOI 10.1016/0895-4356(93)90030-5; *HLTH INT, 2 PHAS HINARI UND; Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4; ODLYZKO AM, TRAGIC LOSS GOOD RID; Smith J, 2000, BRIT MED J, V320, P6, DOI 10.1136/bmj.320.7226.6; Tamber PS, 2000, BMC NEWS VIEWS, V1, P1; VELTEROP J, 2001, BMC NEWS VIEWS, V2, P2; 2003, NATURE, V421, P1	13	20	22	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1575	1577		10.1016/S0140-6736(03)14748-4	http://dx.doi.org/10.1016/S0140-6736(03)14748-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615116				2022-12-28	WOS:000186464500026
J	Zajicek, J; Fox, P; Sanders, H; Wright, D; Vickery, J; Nunn, A; Thompson, A				Zajicek, J; Fox, P; Sanders, H; Wright, D; Vickery, J; Nunn, A; Thompson, A		UK MS Res Grp	Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial	LANCET			English	Article							RECEPTOR; BRAIN; MS	Background Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much anecdotal evidence suggests that cannabinoids could help these symptoms. Our aim was to test the notion that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis. Methods We did a randomised, placebo-controlled trial, to which we enrolled 667 patients with stable multiple sclerosis and muscle spasticity. 630 participants were treated at 33 UK centres with oral cannabis extract (n=211), Delta(9)-tetrahydrocannabinol (Delta(9)-THC; n=206), or placebo (n=213). Trial duration was 15 weeks. Our primary outcome measure was change in overall spasticity scores, using the Ashworth scale. Analysis was by intention to treat. Findings 611 of 630 patients were followed up for the primary endpoint. We noted no treatment effect of cannabinoids on the primary outcome (p=0.40). The estimated difference in mean reduction in total Ashworth score for participants taking cannabis extract compared with placebo was 0.32 (95% Cl -1-04 to 1.67), and for those taking Delta(9)-THC versus placebo it was 0.94 (-0.44 to 2.31). There was evidence of a treatment effect on patient-reported spasticity and pain (p=0.003), with improvement in spasticity reported in 61% (n=121, 95% Cl 54.6-68-2), 60% (n=108, 52.5-66-8), and 46% (n=91, 39.0-52-9) of participants on cannabis extract, Delta(9)-THC, and placebo, respectively. Interpretation Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale. However, though there was a degree of unmasking among the patients in the active treatment groups, objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful.	Peninsula Med Sch, Plymouth PL6 8BX, Devon, England; Univ Plymouth, Sch Math & Stat, Plymouth PL4 8AA, Devon, England; MRC, Clin Trials Unit, London, England; Univ Coll Hosp, Natl Hosp Neurol & Neurosurg, London, England	University of Plymouth; University of Plymouth; Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Zajicek, J (corresponding author), Peninsula Med Sch, Plymouth PL6 8BX, Devon, England.	john.zajicek@phnt.swest.nhs.uk	Macedo, Ana/L-9912-2018; Thompson, Alan J/C-2654-2008	Macedo, Ana/0000-0002-6978-8989; Thompson, Alan J/0000-0002-4333-8496; Nunn, Andrew/0000-0002-9158-4595; Murray, Dianna/0000-0003-3481-825X	Multiple Sclerosis Society [601] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		[Anonymous], 1994, CLIN REHABIL, DOI DOI 10.1177/026921559400800403; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BEGG CB, 1980, BIOMETRICS, V36, P81, DOI 10.2307/2530497; Campbell FA, 2001, BMJ-BRIT MED J, V323, P13, DOI 10.1136/bmj.323.7303.13; Collen F M, 1991, Int Disabil Stud, V13, P50; Consroe P, 1997, EUR NEUROL, V38, P44, DOI 10.1159/000112901; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Evans S. J. W., 1990, MINIM MINIMISATION P; Goldberg D, 1991, USERS GUIDE GEN HLTH; GREENBERG HS, 1994, CLIN PHARMACOL THER, V55, P324, DOI 10.1038/clpt.1994.33; Hinson JL, 1996, UROL CLIN N AM, V23, P475, DOI 10.1016/S0094-0143(05)70326-8; HOBART J, 2002, DIS NERVOUS SYSTEM C; *HOUS LORDS COMM S, 1998, 9 HOUS LORDS COMM SC; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MAHONEY F I, 1965, Md State Med J, V14, P61; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PATY DW, 1998, MULTIPLE SCLEROSIS; PETRO DJ, 1981, J CLIN PHARMACOL, V21, pS413, DOI 10.1002/j.1552-4604.1981.tb02621.x; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RIAZI A, 2003, ECTRIMS, V9, pS151; ROG D, 2003, MULTIPLE SCLEROSIS E, V9, pS25; Schwartz CE, 1999, NEUROLOGY, V52, P626, DOI 10.1212/WNL.52.3.626; SHAKESPEARE DT, 2003, COCHRANE LIB; Sharrack B, 1999, MULT SCLER, V5, P223, DOI 10.1191/135245899678846131; Sliwa JA, 1996, ARCH PHYS MED REHAB, V77, P247, DOI 10.1016/S0003-9993(96)90106-9; SMITH C, 1994, NEUROLOGY, V44, P34; Thompson AJ, 2002, NEUROLOGY, V58, P1323, DOI 10.1212/WNL.58.9.1323; *UK TIZ TRIAL GROU, 1994, NEUROLOGY S9, V44, pS70; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39; VANEY C, 2003, MULTIPLE SCLEROSIS E, V9, pS14; WIFFEN P, 2003, COCHRANE LIB	37	522	556	4	80	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	2003	362	9395					1517	1526		10.1016/S0140-6736(03)14738-1	http://dx.doi.org/10.1016/S0140-6736(03)14738-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615106				2022-12-28	WOS:000186464500007
J	Prahlad, V; Pilgrim, D; Goodwin, EB				Prahlad, V; Pilgrim, D; Goodwin, EB			Roles for mating and environment in C. elegans sex determination	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; NEMATODE	In Caenorhabditis elegans the two sexes, hermaphrodites and males, are thought to be irreversibly determined at fertilization by the ratio of X chromosomes to sets of autosomes: XX embryos develop as hermaphrodites and XO embryos as males. We show instead that both sex and genotype of C. elegans can be altered postembryonically and that this. exibility requires sexual reproduction. When grown in specific bacterial metabolites, some XX larvae generated by mating males and hermaphrodites develop as males and lose one X chromosome. However, XX larvae produced by hermaphrodite self-fertilization show no such changes. We propose that sexual reproduction increases developmental. exibility of progeny, allowing for better adaptation to changing environments.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Alberta, Ctr Biol Sci, CW 405, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Alberta	Goodwin, EB (corresponding author), Univ Wisconsin, Dept Genet, 445 Henry Mall, Madison, WI 53706 USA.	goodwin@wisc.edu	; Pilgrim, David/A-2676-2014	Prahlad, Veena/0000-0002-0413-6074; Pilgrim, David/0000-0001-7820-7915	NIGMS NIH HHS [GM51836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bassler BL, 2002, CELL, V109, P421, DOI 10.1016/S0092-8674(02)00749-3; BRENNER S, 1974, GENETICS, V77, P71; Butlin R, 2002, NAT REV GENET, V3, P311, DOI 10.1038/nrg749; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; Chasnov JR, 2002, GENETICS, V160, P983; Delmotte F, 2002, MOL ECOL, V11, P711, DOI 10.1046/j.1365-294X.2002.01478.x; DONIACH T, 1986, GENETICS, V114, P53; Edgley ML, 2001, MOL GENET GENOMICS, V266, P385, DOI 10.1007/s004380100523; HODGKIN J, 1992, BIOESSAYS, V14, P253, DOI 10.1002/bies.950140409; KELLY WB, COMMUNICATION; Kelly WG, 2002, DEVELOPMENT, V129, P479; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; MAYNARD SMITH J., 1978, EVOLUTION SEX; NELSON GA, 1978, DEV BIOL, V66, P386, DOI 10.1016/0012-1606(78)90247-6; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; Pigliucci M, 1998, CURR OPIN PLANT BIOL, V1, P87, DOI 10.1016/S1369-5266(98)80133-7; PRAHLAD V, UNPUB; Stewart AD, 2002, GENETICS, V160, P975; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WARD S, 1979, DEV BIOL, V73, P304, DOI 10.1016/0012-1606(79)90069-1; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi	21	22	26	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1046	1049		10.1126/science.1087946	http://dx.doi.org/10.1126/science.1087946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605370				2022-12-28	WOS:000186396300049
J	Bliss, SJ; Moseley, RH; Del Valle, J; Saint, S				Bliss, SJ; Moseley, RH; Del Valle, J; Saint, S			A window of opportunity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HERPES-SIMPLEX-VIRUS; ACUTE LIVER-FAILURE; FULMINANT-HEPATITIS; ADULTS; PATIENT; TESTS		Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Med Serv, Ann Arbor, MI USA; Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Bliss, SJ (corresponding author), Univ Michigan Hlth Syst, Canton Hlth Ctr, 1051 N Canton Ctr Rd, Canton, MI 48187 USA.		Haigh, Richard P/H-7455-2016; Saint, Sanjay/AAF-5126-2019	Haigh, Richard P/0000-0001-7347-7043; 	AHRQ HHS [P20-HS11540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABOGUDDAH A, 1991, J RHEUMATOL, V18, P1406; CHOPRA S, 1985, AM J MED, V79, P221, DOI 10.1016/0002-9343(85)90013-0; Farr RW, 1997, CLIN INFECT DIS, V24, P1191, DOI 10.1086/513646; Green RM, 2002, GASTROENTEROLOGY, V123, P1367, DOI 10.1053/gast.2002.36061; JOHNSON JR, 1992, CLIN INFECT DIS, V14, P38, DOI 10.1093/clinids/14.1.38; Kaufman B, 1997, CLIN INFECT DIS, V24, P334, DOI 10.1093/clinids/24.3.334; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; Ostapowicz G, 2002, ANN INTERN MED, V137, P947, DOI 10.7326/0003-4819-137-12-200212170-00007; Peters DJ, 2000, DIGEST DIS SCI, V45, P2399, DOI 10.1023/A:1005699210816; Pinna AD, 2002, DIGEST DIS SCI, V47, P750, DOI 10.1023/A:1014779614525; Seksik P, 1999, INTENS CARE MED, V25, P415, DOI 10.1007/s001340050869; SHANLEY CJ, 1995, TRANSPLANTATION, V59, P145, DOI 10.1097/00007890-199501150-00028; SHLIEN RD, 1988, GUT, V29, P257, DOI 10.1136/gut.29.2.257	13	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1848	1853		10.1056/NEJMcps031315	http://dx.doi.org/10.1056/NEJMcps031315			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602884				2022-12-28	WOS:000186353800011
J	Jeffcoate, W				Jeffcoate, W			Contract for UK consultants - round 2: medical profession KO'd, OK?	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Jeffcoate, W (corresponding author), The Lancet, London NW1 7BY, England.							CARVEL J, HOSP CONSULTANTS ACC	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1432	1432		10.1016/S0140-6736(03)14728-9	http://dx.doi.org/10.1016/S0140-6736(03)14728-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602434				2022-12-28	WOS:000186356600006
J	Mwaba, P; Cassol, S; Pilon, R; Chintu, C; Janes, M; Nunn, A; Zumla, A				Mwaba, P; Cassol, S; Pilon, R; Chintu, C; Janes, M; Nunn, A; Zumla, A			Use of dried whole blood spots to measure CD4+lymphocyte counts in HIV-1-infected patients	LANCET			English	Article								As antiretroviral drugs become widely available in developing countries, practical, field-friendly, and cheap methods of measuring CD4+ lymphocyte counts need to be developed. We tested use of whole blood spots dried on filter paper to measure CD4+ lymphocyte counts. We obtained blood from 42 HIV-1-infected patients from Zambia. We dried blood spots on filter paper and measured CD4+ lymphocyte counts with an established commercial enzyme immunoassay. We compared these measurements with those obtained from matched liquid whole-blood samples analysed with standard flow cytometry. Results of the filter-paper method accorded well with flow cytometry CD4 counts greater than 200 cells/muL. (mean difference 13.6 [SD 52.4]). Dried whole blood stored on filter paper could be developed into a field-friendly alternative for CD4+ lymphocyte count measurements.	Univ Teaching Hosp, Sch Med, UNZA UCLMS Res & Training Project, Lusaka, Zambia; Ottawa Gen Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; MRC, Clin Trials Unit, London, England; UCL, Ctr Infect Dis & Int Hlth, London, England	University of Zambia; University of Ottawa; Ottawa Hospital Research Institute; Medical Research Council Clinical Trials Unit; University of London; University College London	Zumla, A (corresponding author), Univ Teaching Hosp, Sch Med, UNZA UCLMS Res & Training Project, Box 50110, Lusaka, Zambia.	a.zumla@ucl.ac.uk	Mwaba, Peter/V-6017-2019; ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Pilon, Richard/0000-0003-0100-6917; Nunn, Andrew/0000-0002-9158-4595				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Cassol S, 1996, AIDS RES HUM RETROV, V12, P1435, DOI 10.1089/aid.1996.12.1435; Comeau AM, 1996, J PEDIATR-US, V129, P111, DOI 10.1016/S0022-3476(96)70197-X; NICHOLSON JKA, 1994, J IMMUNOL METHODS, V177, P43, DOI 10.1016/0022-1759(94)90142-2; Saah AJ, 1997, ARCH PATHOL LAB MED, V121, P960	5	53	55	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1459	1460		10.1016/S0140-6736(03)14693-4	http://dx.doi.org/10.1016/S0140-6736(03)14693-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602443				2022-12-28	WOS:000186356600015
J	Chen, WG; Chang, Q; Lin, YX; Meissner, A; West, AE; Griffith, EC; Jaenisch, R; Greenberg, ME				Chen, WG; Chang, Q; Lin, YX; Meissner, A; West, AE; Griffith, EC; Jaenisch, R; Greenberg, ME			Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2	SCIENCE			English	Article							CPG-BINDING PROTEIN-2; RETT-SYNDROME; HISTONE DEACETYLASE; SIGNALING PATHWAY; MESSENGER-RNAS; EXPRESSION; MUTATIONS; NEURONS; CELLS; GENE	Mutations in MeCP2, which encodes a protein that has been proposed to function as a global transcriptional repressor, are the cause of Rett syndrome (RTT), an X-linked progressive neurological disorder. Although the selective inactivation of MeCP2 in neurons is sufficient to confer a Rett-like phenotype in mice, the specific functions of MeCP2 in postmitotic neurons are not known. We find that MeCP2 binds selectively to BDNF promoter III and functions to repress expression of the BDNF gene. Membrane depolarization triggers the calcium-dependent phosphorylation and release of MeCP2 from BDNF promoter III, thereby facilitating transcription. These studies indicate that MeCP2 plays a key role in the control of neuronal activity-dependent gene regulation and suggest that the deregulation of this process may underlie the pathology of RTT.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.			Griffith, Eric/0000-0003-0428-3215; Chen, Wen/0000-0003-0853-7526; /0000-0002-7002-1275	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18655] Funding Source: Medline; NINDS NIH HHS [NS28829] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akbarian S, 2001, NEUROBIOL DIS, V8, P784, DOI 10.1006/nbdi.2001.0420; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen W., UNPUB; Chen WG, 2003, J NEUROSCI, V23, P2572; Drewell RA, 2002, NUCLEIC ACIDS RES, V30, P1139, DOI 10.1093/nar/30.5.1139; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jung BP, 2003, J NEUROBIOL, V55, P86, DOI 10.1002/neu.10201; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shahbazian MD, 2001, CURR OPIN NEUROL, V14, P171, DOI 10.1097/00019052-200104000-00006; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Tokuyama W, 2000, NAT NEUROSCI, V3, P1134, DOI 10.1038/80655; Traynor Jeff, 2002, BMC Med Genet, V3, P12, DOI 10.1186/1471-2350-3-12; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; Van den Veyver IB, 2000, CURR OPIN GENET DEV, V10, P275, DOI 10.1016/S0959-437X(00)00083-6; Wan MM, 2001, HUM MOL GENET, V10, P1085, DOI 10.1093/hmg/10.10.1085; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	37	945	988	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					885	889		10.1126/science.1086446	http://dx.doi.org/10.1126/science.1086446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593183				2022-12-28	WOS:000186258000055
J	Wernet, MF; Labhart, T; Baumann, F; Mazzoni, EO; Pichaud, F; Desplan, C				Wernet, MF; Labhart, T; Baumann, F; Mazzoni, EO; Pichaud, F; Desplan, C			Homothorax switches function of Drosophila photoreceptors from color to polarized light sensors	CELL			English	Article							MARGINAL OMMATIDIA; OPTIC LOBE; CELL FATES; EYE; RHODOPSIN; GENES; R7; ENCODES; PROTEIN; DIFFERENTIATION	Different classes of photoreceptors (PRs) allow animals to perceive various types of visual information. In the Drosophila eye, the outer PRs of each ommatidium are involved in motion detection while the inner PRs mediate color vision. In addition, flies use a specialized class of inner PRs in the "dorsal rim area" of the eye (DRA) to detect the e-vector of polarized light, allowing them to exploit skylight polarization for orientation. We show that homothorax is both necessary and sufficient for inner PRs to adopt the polarization-sensitive DRA fate instead of the color-sensitive default state. Homothorax increases rhabdomere size and uncouples R7-R8 communication to allow both cells to express the same opsin rather than different ones as required for color vision. Homothorax expression is induced by the iroquois complex and the wingless (wg) pathway. However, crucial wg pathway components are not required, suggesting that additional signals are involved.	NYU, Dept Biol, New York, NY 10003 USA; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	New York University; University of Zurich	Desplan, C (corresponding author), NYU, Dept Biol, 100 Washington Sq E, New York, NY 10003 USA.	cd38@nyu.edu		Pichaud, Franck/0000-0002-8393-716X; Desplan, Claude/0000-0002-6914-1413; mazzoni, esteban/0000-0001-8994-681X	NATIONAL EYE INSTITUTE [R01EY013010] Funding Source: NIH RePORTER; MRC [MC_U122673973] Funding Source: UKRI; Medical Research Council [MC_U122673973] Funding Source: Medline; NEI NIH HHS [R01 EY13010] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bessa J, 2002, GENE DEV, V16, P2415, DOI 10.1101/gad.1009002; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brennan CA, 2000, CELL MOL LIFE SCI, V57, P195, DOI 10.1007/PL00000684; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; Cavodeassi F, 2001, DEVELOPMENT, V128, P2847; Chen CM, 1999, DEVELOPMENT, V126, P5441; Chou WH, 1996, NEURON, V17, P1101, DOI 10.1016/S0896-6273(00)80243-3; Chou WH, 1999, DEVELOPMENT, V126, P607; Cook T, 2003, DEV CELL, V4, P853, DOI 10.1016/S1534-5807(03)00156-4; FORTINI ME, 1991, CELL TISSUE RES, V265, P185, DOI 10.1007/BF00318153; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FRANCESCHINI N, 1981, SCIENCE, V213, P1264, DOI 10.1126/science.7268434; FRANCESCHINI N, 1971, KYBERNETIK, V8, P1, DOI 10.1007/BF00270828; Frankfort BJ, 2001, NEURON, V32, P403, DOI 10.1016/S0896-6273(01)00480-9; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Hardie R.C., 1985, Progress in Sensory Physiology, V5, P1; HARDIE RC, 1984, J COMP PHYSIOL, V154, P157, DOI 10.1007/BF00604981; Huber A, 1997, FEBS LETT, V406, P6, DOI 10.1016/S0014-5793(97)00210-X; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; KIRSCHFE.K, 1968, KYBERNETIK, V5, P47, DOI 10.1007/BF00272694; KIRSCHFELD K, 1977, BIOPHYS STRUCT MECH, V3, P191, DOI 10.1007/BF00535818; Labhart T, 1999, MICROSC RES TECHNIQ, V47, P368, DOI 10.1002/(SICI)1097-0029(19991215)47:6<368::AID-JEMT2>3.3.CO;2-H; Labhart T, 2000, NATURWISSENSCHAFTEN, V87, P133, DOI 10.1007/s001140050691; Labhart T, 2002, CURR OPIN NEUROBIOL, V12, P707, DOI 10.1016/S0959-4388(02)00384-7; LABHART T, 1988, NATURE, V331, P435, DOI 10.1038/331435a0; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; Mollereau B, 2000, MECH DEVELOP, V93, P151, DOI 10.1016/S0925-4773(00)00287-2; Mollereau B, 2001, NATURE, V412, P911, DOI 10.1038/35091076; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Papatsenko D, 1997, DEVELOPMENT, V124, P1665; Pichaud F, 2001, DEVELOPMENT, V128, P815; Pichaud F, 2000, MECH DEVELOP, V96, P15, DOI 10.1016/S0925-4773(00)00372-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROSSEL S, 1986, NATURE, V323, P128, DOI 10.1038/323128a0; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Tahayato A, 2003, DEV CELL, V5, P391, DOI 10.1016/S1534-5807(03)00239-9; TOMLINSON A, 2003, IN PRESS DEV CELL; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; VONPHILIPSBORN A, 1990, J COMP PHYSIOL A, V167, P737, DOI 10.1007/BF00189764; WADA S, 1974, Z MORPHOL TIERE, V77, P87, DOI 10.1007/BF00374212; WEHNER R, 1994, FORTS ZOOL, V39, P103; WOLF R, 1980, J COMP PHYSIOL, V139, P177, DOI 10.1007/BF00657080; WOLFF T, 2000, DROSOPHILA PROTOCOLS, P201; Wolff Tanya, 1993, P1277; WUNDERER H, 1982, INT J INSECT MORPHOL, V11, P25, DOI 10.1016/0020-7322(82)90035-6; XU T, 1993, DEVELOPMENT, V117, P1223; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	50	146	151	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					267	279		10.1016/S0092-8674(03)00848-1	http://dx.doi.org/10.1016/S0092-8674(03)00848-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636555	Bronze			2022-12-28	WOS:000186415000007
J	Liddle, R; Davies, CS; Colquhoun, M; Handley, AJ				Liddle, R; Davies, CS; Colquhoun, M; Handley, AJ			ABC of resuscitation - The automated external defibrillator	BRITISH MEDICAL JOURNAL			English	Review							ADVANCED-LIFE-SUPPORT; WORKING GROUP; EXECUTIVE-COMMITTEE; STATEMENT; COUNCIL; GUIDELINES		Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; Natl Defibrillator Programme, London, England; Univ Wales Coll Med, Wales Heart Res Inst, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Med, Prehosp Emergency Res Unit, Cardiff CF4 4XN, S Glam, Wales	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cardiff University; Cardiff University	Liddle, R (corresponding author), Wythenshawe Hosp, Manchester M23 9LT, Lancs, England.							[Anonymous], 2000, RESUSCITATION, V46, P73; BOSSAERT L, 1992, RESUSCITATION, V24, P211, DOI 10.1016/0300-9572(92)90181-B; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; Davies CS, 2002, RESUSCITATION, V52, P13; Kloeck W, 1997, RESUSCITATION, V34, P109, DOI 10.1016/S0300-9572(97)01100-3; Monsieurs KG, 2001, RESUSCITATION, V48, P207, DOI 10.1016/S0300-9572(00)00378-6; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; *RES COUNC UK, 2002, IMM LIF SUPP MAN; Robertson C, 1998, RESUSCITATION, V37, P81, DOI 10.1016/S0300-9572(98)00035-5; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701	10	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1216	1218		10.1136/bmj.327.7425.1216	http://dx.doi.org/10.1136/bmj.327.7425.1216			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630761	Green Published			2022-12-28	WOS:000186784300024
J	Owen, CG; Whincup, PH; Gilg, JA; Cook, DG				Owen, CG; Whincup, PH; Gilg, JA; Cook, DG			Effect of breast feeding in infancy on blood pressure in later life: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; DOCOSAHEXAENOIC ACID; PRETERM INFANTS; EARLY NUTRITION; BIRTH-WEIGHT; HEART-RATE; FOLLOW-UP; SODIUM; CHILDREN; CHOLESTEROL	Objective To determine whether breast feeding in infancy compared with bottle feeding formula milk is associated with lower mean blood pressure at different ages. Design Systematic review. Data sources Embase, Medline, and Web of Science databases. Study selection Studies showing the effects of feeding in infancy on blood pressure at different ages. Data extraction Pooled mean differences in blood pressure between breast fed infants and those bottle fed formula milk, based on random effects models. synthesis The pooled mean difference in systolic blood pressure was -1.10 mm Hg (95% confidence interval -1.79 to -0.42 turn Hg) but with significant heterogeneity between estimates (P < 0.001). The difference was largest in studies of <300 participants (-2.05 mm Hg, -3.30 to -0.80 min Hg), intermediate in studies of 300-1000 participants (1.13 mm Hg, -2.53 to 0.27 mm Hg), and smallest in studies of >1000 participants (-0.16 nun Hg, -0.60 to 0.28 min Hg). An Egger test but not Begg test was statistically significant for publication bias. The difference was unaltered by adjustment for current size and was independent of age at measurement of blood pressure and year of birth. Diastolic blood pressure was not significantly related to type of feeding in infancy. Conclusions Selective publication of small studies with positive findings may have exaggerated claims that breast feeding in infancy reduces systolic blood pressure in later life. The results of larger studies suggest that feeding in infancy has at most a modest effect on blood pressure, which is of limited clinical or public health importance.	St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England	St Georges University London	Owen, CG (corresponding author), St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England.	c.owen@sghms.ac.uk		Whincup, Peter/0000-0002-5589-4107; Owen, Christopher/0000-0003-1135-5977; Cook, Derek/0000-0002-9723-5759				ANTONELLA EDP, 1994, INT J OBESITY, V18, P596; BARANOWSKI T, 1992, J CLIN EPIDEMIOL, V45, P513, DOI 10.1016/0895-4356(92)90100-2; Barker DJP, 1998, MOTHERS BABIES HLTH; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERNSTEIN HM, 1990, S AFR MED J, V78, P644; Boulton J, 1981, Acta Paediatr Scand Suppl, V284, P1; BUTLER N, 1996, 1970 BRIT COHORT STU; BUTLER N, 1997, BRIT COHORT STUDY 10; COHEN M, 1992, DEV PSYCHOBIOL, V25, P291, DOI 10.1002/dev.420250406; Colhoun HM, 1998, J HUM HYPERTENS, V12, P91, DOI 10.1038/sj.jhh.1000558; Cowin I, 2000, INT J OBESITY, V24, P330, DOI 10.1038/sj.ijo.0801133; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; Cunnane SC, 2000, LIPIDS, V35, P105, DOI 10.1007/s11745-000-0501-6; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DILLON MJ, 1976, ARCH DIS CHILD, V51, P537, DOI 10.1136/adc.51.7.537; Donker GA, 1997, AM J EPIDEMIOL, V145, P387; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Engler MM, 1999, PROSTAG LEUKOTR ESS, V61, P289, DOI 10.1054/plef.1999.0102; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Fergusson DM, 1999, PAEDIATR PERINAT EP, V13, P144; Forsyth JS, 2003, BRIT MED J, V326, P953, DOI 10.1136/bmj.326.7396.953; Geleijnse JM, 1997, HYPERTENSION, V29, P913, DOI 10.1161/01.HYP.29.4.913; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Hediger ML, 2001, JAMA-J AM MED ASSOC, V285, P2453, DOI 10.1001/jama.285.19.2453; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; KARK JD, 1984, J EPIDEMIOL COMMUN H, V38, P218, DOI 10.1136/jech.38.3.218; KOLACEK S, 1993, ACTA PAEDIATR, V82, P377, DOI 10.1111/j.1651-2227.1993.tb12701.x; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; Leeson CPM, 2001, BRIT MED J, V322, P643, DOI 10.1136/bmj.322.7287.643; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Light R.J., 1984, SUMMING SCI REV RES; LUCAS A, 1991, CIBA F SYMP, V156, P38; LUCAS A, 1994, BRIT MED J, V309, P304, DOI 10.1136/bmj.309.6950.304; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; Mori TA, 1999, HYPERTENSION, V34, P253, DOI 10.1161/01.HYP.34.2.253; Oppe TE, 1980, ARTIFICIAL FEEDS YOU; OPPE TE, 1974, PRESENT DAY PRACTICE; Owen CG, 2002, PEDIATRICS, V110, P597, DOI 10.1542/peds.110.3.597; Pomeranz A, 2002, J HYPERTENS, V20, P203, DOI 10.1097/00004872-200202000-00009; Ravelli ACJ, 2000, ARCH DIS CHILD, V82, P248, DOI 10.1136/adc.82.3.248; Roberts SB, 2001, LANCET, V357, P406, DOI 10.1016/S0140-6736(00)04021-6; Rona RJ, 1996, J EPIDEMIOL COMMUN H, V50, P512, DOI 10.1136/jech.50.5.512; SCHACHTER J, 1979, AM J EPIDEMIOL, V110, P205, DOI 10.1093/oxfordjournals.aje.a112805; Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; Wadsworth M E, 1987, Paediatr Perinat Epidemiol, V1, P95, DOI 10.1111/j.1365-3016.1987.tb00093.x; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Zeman J, 1981, Cesk Pediatr, V36, P593; ZINNER SH, 1980, HYPERTENSION, V2, pI99, DOI 10.1161/01.HYP.2.4_Pt_2.I99	55	140	146	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	2003	327	7425					1189	1192		10.1136/bmj.327.7425.1189	http://dx.doi.org/10.1136/bmj.327.7425.1189			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630752	Green Published, Bronze			2022-12-28	WOS:000186784300015
J	Leonardi, CL; Powers, JL; Matheson, RT; Goffe, BS; Zitnik, R; Wang, A; Gottlieb, AB; Bagel, J; Camisa, C; Caro, I; DiGiovanna, JJ; Dunlap, FF; Elewski, BE; Gribetz, CE; Farber, HF; Feldman, SR; Frankel, EH; Gaspari, AA; Goodman, JJ; Gordon, KB; Hampel, FC; Herdener, RS; Hoffman, MD; Humeniuk, JM; Johnson, SM; Kang, S; Kimball, AB; Kirsner, RS; Korman, NJ; Krueger, GG; Kuwahara, RT; Lebwohl, M; Ling, MR; Liu, DC; Lowe, N; McCall, CO; Menter, A; Miller, BH; Moore, JK; Nayak, AS; Ratner, PH; Savin, RC; Shupack, JL; Smith, SL; Stone, SP; Swinehart, JM; Taborn, J; Tschen, EH; Weinstein, GD; Werth, VP; Yamauchi, PS; Zanolli, MD				Leonardi, CL; Powers, JL; Matheson, RT; Goffe, BS; Zitnik, R; Wang, A; Gottlieb, AB; Bagel, J; Camisa, C; Caro, I; DiGiovanna, JJ; Dunlap, FF; Elewski, BE; Gribetz, CE; Farber, HF; Feldman, SR; Frankel, EH; Gaspari, AA; Goodman, JJ; Gordon, KB; Hampel, FC; Herdener, RS; Hoffman, MD; Humeniuk, JM; Johnson, SM; Kang, S; Kimball, AB; Kirsner, RS; Korman, NJ; Krueger, GG; Kuwahara, RT; Lebwohl, M; Ling, MR; Liu, DC; Lowe, N; McCall, CO; Menter, A; Miller, BH; Moore, JK; Nayak, AS; Ratner, PH; Savin, RC; Shupack, JL; Smith, SL; Stone, SP; Swinehart, JM; Taborn, J; Tschen, EH; Weinstein, GD; Werth, VP; Yamauchi, PS; Zanolli, MD		Etanercept Psoriasis Study Grp	Etanercept as monotherapy in patients with psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; THERAPY; IMPROVEMENT; EFFICACY; MODERATE	Background: Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis. Methods: In this 24-week, double-blind study, 672 patients underwent randomization and 652 either received placebo or received etanercept subcutaneously at a low dose (25 mg once weekly), a medium dose (25 mg twice weekly), or a high dose (50 mg twice weekly). After 12 weeks, patients in the placebo group began twice-weekly treatment with 25 mg of etanercept. The primary measure of clinical response was the psoriasis area-and-severity index. Results: At week 12, there was an improvement from base line of 75 percent or more in the psoriasis area-and-severity index in 4 percent of the patients in the placebo group, as compared with 14 percent of those in the low-dose-etanercept group, 34 percent in the medium-dose-etanercept group, and 49 percent in the high-dose-etanercept group (P<0.001 for all three comparisons with the placebo group). The clinical responses continued to improve with longer treatment. At week 24, there was at least a 75 percent improvement in the psoriasis area-and-severity index in 25 percent of the patients in the low-dose group, 44 percent of those in the medium-dose group, and 59 percent in the high-dose group. The responses as measured by improvements in the psoriasis area-and-severity index were paralleled by improvements in global assessments by physicians and the patients and in quality-of-life measures. Etanercept was generally well tolerated. Conclusions: The treatment of psoriasis with etanercept led to a significant reduction in the severity of disease over a period of 24 weeks.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Clin Res Ctr, New Brunswick, NJ 08903 USA; St Louis Univ, Sch Med, St Louis, MO USA; Radiant Res, Scottsdale, AZ USA; Oregon Med Res Ctr, Portland, OR USA; Minor & James Med Ctr, Seattle, WA USA; Amgen Inc, Thousand Oaks, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Saint Louis University; Amgen	Gottlieb, AB (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Clin Res Ctr, 1 Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.	gottliab@umdnj.edu	Kimball, Alexandra B./M-6347-2019; Feldman, Steven R./AAH-6971-2021; menter md, alan/A-8250-2009	Kimball, Alexandra B./0000-0001-9405-0479; Feldman, Steven R./0000-0002-0090-6289; 				Bonifati C, 1999, INT J DERMATOL, V38, P241, DOI 10.1046/j.1365-4362.1999.00622.x; BONIFATI C, 1994, CLIN EXP DERMATOL, V19, P383, DOI 10.1111/j.1365-2230.1994.tb02687.x; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; FINLAY AY, 1995, BRIT J DERMATOL, V132, P236; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Gaspari A, 2002, J INVEST DERMATOL, V119, P236; Gottlieb AB, 2003, J AM ACAD DERMATOL, V48, P68, DOI 10.1067/mjd.2003.10; Koo J, 1996, DERMATOL CLIN, V14, P485, DOI 10.1016/S0733-8635(05)70376-4; Krueger G, 2001, ARCH DERMATOL, V137, P280; Krueger GG, 2000, J AM ACAD DERMATOL, V43, P281, DOI 10.1067/mjd.2000.106374; Krueger GG, 2002, J AM ACAD DERMATOL, V47, P821, DOI 10.1067/mjd.2002.127247; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Mease P, 2001, ARTHRITIS RHEUM, V44, pS90; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; MOPRELAND LW, 2002, ARTHRITIS RHEUM S, V46, pS532; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Mussi A, 1997, J BIOL REG HOMEOS AG, V11, P115; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401	24	934	971	2	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2014	2022		10.1056/NEJMoa030409	http://dx.doi.org/10.1056/NEJMoa030409			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627786	Bronze			2022-12-28	WOS:000186642900005
J	Pickering, S; Braude, P				Pickering, S; Braude, P			ABC of subfertility - Further advances and uses of assisted conception technology	BRITISH MEDICAL JOURNAL			English	Review							PREIMPLANTATION GENETIC DIAGNOSIS		Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England; Guys & St Thomass Assisted Concept Unit, London, England	University of London; King's College London	Pickering, S (corresponding author), Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England.							Braude P, 2002, NAT REV GENET, V3, P941, DOI 10.1038/nrg953; *CHIEF MED OFF EXP, 2000, STEM CELLS MED PROGR; *DEP HLTH, 2002, PREIMPL GEN DIAGN GU; Flinter FA, 2001, BRIT MED J, V322, P1008, DOI 10.1136/bmj.322.7293.1008; *MULT WORK GROUP B, 2003, HUM FERTIL, V6, P1; *ROYAL COLL OBST G, 2000, STOR OV PREP TEST TI	6	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1156	1158		10.1136/bmj.327.7424.1156	http://dx.doi.org/10.1136/bmj.327.7424.1156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615344	Green Published			2022-12-28	WOS:000186622100025
J	Stanek, G; Strle, F				Stanek, G; Strle, F			Lyme borreliosis	LANCET			English	Review							BURGDORFERI-SENSU-STRICTO; ACRODERMATITIS CHRONICA ATROPHICANS; TICK-BORNE ENCEPHALITIS; OUTER-SURFACE PROTEIN; ERYTHEMA MIGRANS; ANTIBIOTIC-TREATMENT; DISEASE SEROLOGY; DOUBLE-BLIND; LATO; INFECTION	Lyme borrellosis is the most common tick-transmitted disease in the northern hemisphere and is caused by spirochaetes of the Borrelia burgdorferi species complex. A complete presentation of the disease is an extremely unusual observation in which a skin lesion results from a tick bite and is followed by heart and nervous system involvement, and later on by arthritis. Late involvement of eye, nervous system, joints, and skin can also occur. The only sign that enables a reliable clinical diagnosis of Lyme borreliosis is erythema migrans. Other features of some diagnostic value are earlobe lymphocytoma, meningoradiculoneuritis (Garin-Bujadoux-Bannwarth syndrome), and acrodermatitis chronica atrophicans. The many other symptoms and signs have little diagnostic value. Microbial or serological confirmation of borrelial infection is needed for all manifestations of the disease except for typical early skin lesions. However, even erythema migrans might not be pathognomonic for Lyme borreliosis, especially in the southern part of the USA where there is no microbiological evidence for infection with the agent. Treatment with antibiotics is beneficial for all stages of Lyme borrellosis, but is most successful early in the course of the illness. Prevention relies mainly on avoiding exposure to tick bites but there is some interest in chemoprophylaxis and also in vaccine development following initial disappointments.	Univ Vienna, Dept Hyg & Med Microbiol, A-1095 Vienna, Austria; Univ Med Ctr Ljubljana, Dept Infect Dis, Ljubljana 1525, Slovenia	University of Vienna; University Medical Centre Ljubljana	Stanek, G (corresponding author), Univ Vienna, Dept Hyg & Med Microbiol, Kinderspitalgasse 15, A-1095 Vienna, Austria.	gerold.stanek@univie.ac.at						ABERER E, 1991, DERMATOLOGICA, V182, P145, DOI 10.1159/000247767; Afzelius A., 1910, ARCH DERMATOL SYPH, V101, P404, DOI DOI 10.1007/BF01832773; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASBRINK E, 1986, ZBL BAKT-INT J MED M, V263, P253; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BARBOUR AG, 1985, J INFECT DIS, V152, P478, DOI 10.1093/infdis/152.3.478; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1989, REV INFECT DIS, V11, pS1470; BERGLUND J, 1995, NEW ENGL J MED, V333, P1319, DOI 10.1056/NEJM199511163332004; Bergstrom Sven, 2002, P47, DOI 10.1079/9780851996325.0047; BRADE V, 1992, IMMUNOBIOLOGY, V185, P453, DOI 10.1016/S0171-2985(11)80087-2; Breier FH, 1999, BRIT J DERMATOL, V140, P925, DOI 10.1046/j.1365-2133.1999.02828.x; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Campbell GL, 1998, AM J EPIDEMIOL, V148, P1018, DOI 10.1093/oxfordjournals.aje.a009568; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; Cimperman J, 1998, INFECTION, V26, P160, DOI 10.1007/BF02771842; Dattwyler RJ, 1997, NEW ENGL J MED, V337, P289, DOI 10.1056/NEJM199707313370501; DINERMAN H, 1992, ANN INTERN MED, V90, P523; Gern L, 1998, WIEN KLIN WOCHENSCHR, V110, P856; Gern Lise, 2002, P149, DOI 10.1079/9780851996325.0149; GOODMAN JL, 1995, AM J MED, V99, P6, DOI 10.1016/S0002-9343(99)80097-7; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; HANSEN K, 1994, ACTA NEUROL SCAND, V89, P6; Hayes EB, 2003, NEW ENGL J MED, V348, P2424, DOI 10.1056/NEJMra021397; Herxheimer K, 1902, ARCH DERMATOL SYPH-G, V61, P57, DOI 10.1007/BF01933570; HOROWITZ HW, 1994, CLIN INFECT DIS, V18, P166, DOI 10.1093/clinids/18.2.166; Huegli D, 2002, J CLIN MICROBIOL, V40, P4735, DOI 10.1128/JCM.40.12.4735-4737.2002; Hunfeld KP, 2002, WIEN KLIN WOCHENSCHR, V114, P591; JOHNSON RC, 1984, INT J SYST BACTERIOL, V34, P1029; Jurca T, 1998, CLIN INFECT DIS, V27, P636, DOI 10.1086/514715; Kahl O, 1998, ZBL BAKT-INT J MED M, V287, P41; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Korenberg Edward I., 2002, P175, DOI 10.1079/9780851996325.0175; Korenberg EI, 2001, EMERG INFECT DIS, V7, P459, DOI 10.3201/eid0703.017319; Kraiczy P, 2003, EUR J IMMUNOL, V33, P697, DOI 10.1002/eji.200323571; Kraiczy P, 2002, WIEN KLIN WOCHENSCHR, V114, P568; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Kristoferitsch W., 1993, Aspects of Lyme borreliosis., P219; KRISTOFERITSCH W, 1983, NERVENARZT, V54, P640; KRISTOFERITSCH W, 1991, SCAND J INFECT DIS, P64; Liang FT, 1999, J CLIN MICROBIOL, V37, P3990, DOI 10.1128/JCM.37.12.3990-3996.1999; Lipshutz B, 1913, ARCH DERMATOL SYPH-G, V118, P349, DOI 10.1007/BF02076105; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; Lotric-Fulan S, 1999, WIEN KLIN WOCHENSCHR, V111, P970; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; Maraspin V, 2002, WIEN KLIN WOCHENSCHR, V114, P515; Maraspin V, 1996, CLIN INFECT DIS, V22, P788, DOI 10.1093/clinids/22.5.788; Maraspin V, 1999, WIEN KLIN WOCHENSCHR, V111, P923; Masters E, 1998, ARCH DERMATOL, V134, P955, DOI 10.1001/archderm.134.8.955; Mikkila HO, 2000, OPHTHALMOLOGY, V107, P581, DOI 10.1016/S0161-6420(99)00128-1; Miyamoto Kenji, 2002, P201, DOI 10.1079/9780851996325.0201; Nadelman RB, 1997, NEW ENGL J MED, V337, P27, DOI 10.1056/NEJM199707033370105; Nadelman RB, 1998, LANCET, V352, P557, DOI 10.1016/S0140-6736(98)01146-5; Nadelman RB, 2001, NEW ENGL J MED, V345, P79, DOI 10.1056/NEJM200107123450201; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; OLSEN B, 1995, J CLIN MICROBIOL, V33, P3270, DOI 10.1128/JCM.33.12.3270-3274.1995; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; Picken RN, 1998, J INVEST DERMATOL, V110, P211, DOI 10.1046/j.1523-1747.1998.00130.x; Picken RN, 1996, J INFECT DIS, V174, P1112, DOI 10.1093/infdis/174.5.1112; Picken RN, 1997, J INVEST DERMATOL, V108, P92, DOI 10.1111/1523-1747.ep12285646; Piesman Joseph, 2002, P223, DOI 10.1079/9780851996325.0223; PIKELJ F, 1989, ANN INTERN MED, V111, P90, DOI 10.7326/0003-4819-111-1-90_1; PREACMURSIC V, 1989, INFECTION, V17, P355, DOI 10.1007/BF01645543; PREACMURSIC V, 1993, J CLIN NEURO-OPHTHAL, V13, P155; REES DHE, 1994, ANN RHEUM DIS, V53, P553, DOI 10.1136/ard.53.9.553; Robertson J, 2000, J CLIN MICROBIOL, V38, P2097; Rosa P, 1998, WIEN KLIN WOCHENSCHR, V110, P859; Schmutzhard E, 2002, WIEN KLIN WOCHENSCHR, V114, P539; Schonherr U, 1993, ASPECTS LYME BORRELI, P131; Seinost G, 1999, INFECT IMMUN, V67, P3518, DOI 10.1128/IAI.67.7.3518-3524.1999; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1995, AM J MED S4A, V98, P25; STANEK G, 1987, LANCET, V1, P1490, DOI 10.1016/S0140-6736(87)92235-5; Stanek G, 1996, WIEN KLIN WOCHENSCHR, V108, P741; Stanek G, 1999, WIEN KLIN WOCHENSCHR, V111, P951; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; STEERE AC, 2000, PRINCIPLES PRACTICE, V2, P2504; Straubinger RK, 1997, J CLIN MICROBIOL, V35, P111, DOI 10.1128/JCM.35.1.111-116.1997; Strle F, 1996, INFECTION, V24, P80, DOI 10.1007/BF01780665; Strle F, 2002, WIEN KLIN WOCHENSCHR, V114, P493; STRLE F, 1991, INFECTION, V19, P351, DOI 10.1007/BF01645368; Strle F, 1996, CLIN INFECT DIS, V23, P61, DOI 10.1093/clinids/23.1.61; Strle F, 1999, ANN INTERN MED, V130, P32, DOI 10.7326/0003-4819-130-1-199901050-00006; Strle F, 1999, WIEN KLIN WOCHENSCHR, V111, P911; STRLE F, 1992, INFECTION, V20, P201, DOI 10.1007/BF02033059; Strle F, 1996, INFECTION, V24, P64, DOI 10.1007/BF01780661; Strle F, 1999, ZBL BAKT-INT J MED M, V289, P643; Strle F, 1994, ACTA DERM-VENEREOL, V1-2, P71; STRLE F, 1996, ACTA DERM-VENEREOL, V5, P173; VANDERLINDE MR, 1991, SCAND J INFECT DIS, P81; Wang GQ, 2002, J INFECT DIS, V186, P782, DOI 10.1086/343043; Weber K., 1993, Aspects of Lyme borreliosis., P105; Weber K., 1993, Aspects of Lyme borreliosis., P352; WILSKE B, 1993, INFECT IMMUN, V61, P2182, DOI 10.1128/IAI.61.5.2182-2191.1993; Wilske B, 2002, INT J MED MICROBIOL, V291, P114, DOI 10.1016/S1438-4221(02)80022-4; WILSKE B, 1993, J CLIN MICROBIOL, V31, P340, DOI 10.1128/JCM.31.2.340-350.1993; WILSKE B, 2000, QUALITY STANDARDS MI; Wooten RM, 2001, CURR OPIN MICROBIOL, V4, P274, DOI 10.1016/S1369-5274(00)00202-2; Wormser GP, 1997, AM J CLIN PATHOL, V107, P142, DOI 10.1093/ajcp/107.2.142; Wormser GP, 2002, WIEN KLIN WOCHENSCHR, V114, P613; Wormser GP, 1996, INFECTION, V24, P178, DOI 10.1007/BF01713335; Wormser GP, 2003, ANN INTERN MED, V138, P697, DOI 10.7326/0003-4819-138-9-200305060-00005; 1997, MMWR MORB MORTAL W S, V46, P20	110	306	317	1	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1639	1647		10.1016/S0140-6736(03)14798-8	http://dx.doi.org/10.1016/S0140-6736(03)14798-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630446				2022-12-28	WOS:000186637400023
J	Manel, N; Kim, FJ; Kinet, S; Taylor, N; Sitbon, M; Battini, JL				Manel, N; Kim, FJ; Kinet, S; Taylor, N; Sitbon, M; Battini, JL			The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV	CELL			English	Article							T-CELL LEUKEMIA; HAMSTER OVARY CELLS; VIRUS TYPE-I; SYNCYTIUM FORMATION; SURFACE EXPRESSION; HUMAN ERYTHROCYTES; BINDING-PROTEIN; LYMPHOCYTES; RETROVIRUS; ACTIVATION	The human T cell leukemia virus (HTLV) is associated with leukemia and neurological syndromes. The physiopathological effects of HTLV envelopes are unclear and the identity of the receptor, present on all vertebrate cell lines, has been elusive. We show that the receptor binding domains of both HTLV-1 and -2 envelope glycoproteins inhibit glucose transport by interacting with GLUT-1, the ubiquitous vertebrate glucose transporter. Receptor binding and HTLV envelope-driven infection are selectively inhibited when glucose transport or GLUT-1 expression are blocked by cytochalasin B or siRNAs, respectively. Furthermore, ectopic expression of GLUT-1, but not the related transporter GLUT-3, restores HTLV infection abrogated by either GLUT-1 siRNAs or interfering HTLV envelope glycoproteins. Therefore, GLUT-1 is a receptor for HTLV. Perturbations in glucose metabolism resulting from interactions of HTLV envelope glycoproteins with GLUT-1 are likely to contribute to HTLV-associated disorders.	Inst Genet Mol Montpellier, CNRS UMR 5535, IFR 122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Sitbon, M (corresponding author), Inst Genet Mol Montpellier, CNRS UMR 5535, IFR 122, F-34293 Montpellier 5, France.		Sitbon, Marc/A-6771-2010; Taylor, Naomi/H-4016-2014; Manel, Nicolas/E-2128-2011	Sitbon, Marc/0000-0003-3616-2338; Manel, Nicolas/0000-0002-1481-4430; Battini, Jean-Luc/0000-0002-5884-9934; kinet, sandrina/0000-0003-0699-108X				Akaoka H, 2001, VIRUS RES, V78, P57, DOI 10.1016/S0168-1702(01)00284-2; ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Cavrois M, 1996, ONCOGENE, V12, P2419; CHAKRABARTI R, 1994, J IMMUNOL, V152, P2660; Concha II, 1997, BLOOD, V89, P4190, DOI 10.1182/blood.V89.11.4190; Daenke S, 1999, J GEN VIROL, V80, P1429, DOI 10.1099/0022-1317-80-6-1429; Daenke S, 2000, J CELL SCI, V113, P37; DENESVRE C, 1995, J VIROL, V69, P4149, DOI 10.1128/JVI.69.7.4149-4157.1995; Denesvre C, 1996, J VIROL, V70, P4380, DOI 10.1128/JVI.70.7.4380-4386.1996; Derse D, 2003, SCIENCE, V299, P1670, DOI 10.1126/science.1083218; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; Escher SA, 1999, HEREDITAS, V130, P95, DOI 10.1111/j.1601-5223.1999.00095.x; Feuer G, 1996, J VIROL, V70, P4038, DOI 10.1128/JVI.70.6.4038-4044.1996; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GESSAIN A, 1985, LANCET, V2, P407; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; Hildreth JEK, 1997, J VIROL, V71, P1173, DOI 10.1128/JVI.71.2.1173-1180.1997; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jassal SR, 2001, J VIROL, V75, P8317, DOI 10.1128/JVI.75.17.8317-8328.2001; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kim FJ, 2000, J BIOL CHEM, V275, P23417, DOI 10.1074/jbc.C901002199; Kim FJ, 2003, J VIROL, V77, P963, DOI 10.1128/JVI.77.2.963-969.2003; KIM FJ, 2003, IN PRESS VIROLOGY; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Korgun ET, 2002, BLOOD CELL MOL DIS, V28, P152, DOI 10.1006/bcmd.2002.0504; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; MANTYCH G, 1991, BIOCHEM BIOPH RES CO, V180, P367, DOI 10.1016/S0006-291X(05)81302-6; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Nath MD, 2003, BLOOD, V101, P3085, DOI 10.1182/blood-2002-07-2277; OSAME M, 1986, LANCET, V1, P1031; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; Pinon JD, 2003, J VIROL, V77, P9922, DOI 10.1128/JVI.77.18.9922-9930.2003; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rodrigues P, 1999, J VIROL, V73, P3789, DOI 10.1128/JVI.73.5.3789-3799.1999; Rosenberg AR, 1998, J VIROL, V72, P7609, DOI 10.1128/JVI.72.9.7609-7614.1998; SIEGEL GJ, 1998, CIRCULATION ENERGY M, pCH5; Slattery JP, 1999, GENOME RES, V9, P525; Sutton RE, 1996, J VIROL, V70, P7322, DOI 10.1128/JVI.70.10.7322-7326.1996; Tailor CS, 2003, CURR TOP MICROBIOL, V281, P29; Trejo SR, 2000, VIROLOGY, V268, P41, DOI 10.1006/viro.2000.0143; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yu Q, 2003, J EXP MED, V197, P475, DOI 10.1084/jem.20021765	56	299	319	0	16	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					449	459		10.1016/S0092-8674(03)00881-X	http://dx.doi.org/10.1016/S0092-8674(03)00881-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622599	Bronze			2022-12-28	WOS:000186627100011
J	Howard, RF				Howard, RF			Current status of pain management in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECURRENT ABDOMINAL-PAIN; POSTOPERATIVE PAIN; SENSORY HYPERINNERVATION; CHRONIC MUSCULOSKELETAL; PRELIMINARY VALIDATION; INITIAL VALIDATION; TONSILLECTOMY PAIN; NEWBORN-INFANTS; ANALGESIA; SURGERY	Many changes have taken place in pediatric pain management since the undertreatment of children's pain was first reported. Notable advances include an increase in understanding pain during development and improvements in the management of acute pain. Although much more about the safe and effective management of pain in children is now known, this knowledge has not been widely or effectively translated into routine clinical practice. Lack of suitable research on which to firmly establish evidence-based care is likely to have contributed to this situation. A subject of considerable interest recently is the discovery that the experience of pain in early life may lead to long-term consequences. New research findings from laboratory and clinical studies have clearly identified possible mechanisms and provided evidence that long-term behavioral changes can extend far beyond what would be considered the normal period of postinjury recovery. Timing, degree of injury, and administered analgesia and its nature may be important determinants of the long-term outcome of infant pain. Chronic pain, including neuropathic pain, is far more common in children than was thought. The assessment and treatment of this pain and its functional consequences present a considerable unmet challenge. There is a pressing need for further research and clinical development in the management of pain in children.	Great Ormond St Hosp Sick Children, Dept Anaesthesia, London WC1N 2JH, England; Great Ormond St Hosp Sick Children, Children Nationwide Pain Res Ctr, London WC1N 2JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Howard, RF (corresponding author), Great Ormond St Hosp Sick Children, Dept Anaesthesia, Great Ormond St, London WC1N 2JH, England.	r.howard@ich.ucl.ac.uk		Howard, Richard/0000-0001-9271-0074				Alvares D, 1999, PAIN, pS71, DOI 10.1016/S0304-3959(99)00140-2; *AM PAIN SOC, PED CHRON PAIN POS S; Anand KJS, 2000, NAT MED, V6, P971, DOI 10.1038/79658; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; Andrews K, 2002, PAIN, V99, P185, DOI 10.1016/S0304-3959(02)00100-8; Andrews KA, 2002, PAIN, V100, P35, DOI 10.1016/S0304-3959(02)00288-9; [Anonymous], 1979, Pain, V6, P249; Asprey J R, 1994, J Pediatr Nurs, V9, P150; Beland B, 2001, PAIN, V90, P143, DOI 10.1016/S0304-3959(00)00397-3; BELLMAN MH, 1993, BRIT MED J, V307, P1563, DOI 10.1136/bmj.307.6918.1563; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Berde CB, 2003, PAIN INFANTS CHILDRE, P620; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Blass EM, 1999, PAIN, V83, P611, DOI 10.1016/S0304-3959(99)00166-9; Breau LM, 2000, DEV MED CHILD NEUROL, V42, P609, DOI 10.1017/S0012162200001146; Campo JV, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e1; Chambers CT, 1996, PAIN, V68, P307, DOI 10.1016/S0304-3959(96)03209-5; Chambers CT, 1998, PAIN, V78, P27, DOI 10.1016/S0304-3959(98)00112-2; Chambliss C Robert, 2002, Paediatr Drugs, V4, P737, DOI 10.2165/00148581-200204110-00005; CHAMPION DG, 1998, PROGR PAIN RES MANAG, P123; Collins JJ, 2002, HEMATOL ONCOL CLIN N, V16, P657, DOI 10.1016/S0889-8588(02)00020-5; Conroy S, 2000, BRIT J CLIN PHARMACO, V49, P93, DOI 10.1046/j.1365-2125.2000.00125.x; Cox T H, 1995, Hosp Pharm, V30, P980; COX TH, 1995, HOSP PHARM, V30, P995; CRAIG KD, 1984, SOC SCI MED, V19, P1331, DOI 10.1016/0277-9536(84)90021-2; De Lima J, 1999, BRIT J ANAESTH, V83, P662, DOI 10.1093/bja/83.4.662; DI LC, 2001, J PEDIAT, V139, P838; DOYLE E, 1993, BRIT J ANAESTH, V71, P670, DOI 10.1093/bja/71.5.670; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; Ellis JA, 2002, CLIN J PAIN, V18, P262, DOI 10.1097/00002508-200207000-00007; Fearon I, 1997, J DEV BEHAV PEDIATR, V18, P222; Finley GA, 1996, PAIN, V64, P83, DOI 10.1016/0304-3959(95)00091-7; Fitzgerald M, 2001, NEUROSCIENTIST, V7, P246, DOI 10.1177/107385840100700309; Fitzgerald M, 2003, PROG PAIN RES MANAG, V24, P185; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Flato B, 1997, CLIN EXP RHEUMATOL, V15, P569; Franck LS, 2000, PEDIATR CLIN N AM, V47, P487, DOI 10.1016/S0031-3955(05)70222-4; GEDALYDUFF V, 1994, PAIN, V57, P293, DOI 10.1016/0304-3959(94)90004-3; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; GOODMAN JE, 1991, PAIN, V46, P247, DOI 10.1016/0304-3959(91)90108-A; GRUNAU RE, 2000, PAIN NEONATES, P55; Gunter Joel B, 2002, Paediatr Drugs, V4, P649, DOI 10.2165/00128072-200204100-00003; Hadden KL, 2002, PAIN, V99, P281, DOI 10.1016/S0304-3959(02)00123-9; Herod J, 2002, PAEDIATR ANAESTH, V12, P388, DOI 10.1046/j.1460-9592.2002.00768.x; HESTER NKO, 1979, NURS RES, V28, P250; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Holden EW, 1998, J DEV BEHAV PEDIATR, V19, P109; Hotopf M, 1998, BRIT MED J, V316, P1196, DOI 10.1136/bmj.316.7139.1196; Howard RF, 2001, ANESTHESIOLOGY, V95, P421, DOI 10.1097/00000542-200108000-00026; Hunt A, 2003, INT J NURS STUD, V40, P171, DOI 10.1016/S0020-7489(02)00058-5; JAY S, 1995, PAIN, V62, P3, DOI 10.1016/0304-3959(94)00216-2; *JOINT COMM ACCR H, HOSP ACCR STAND 2000; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kokinsky E, 1999, PAEDIATR ANAESTH, V9, P243; Lee BH, 2002, J PEDIATR-US, V141, P135, DOI 10.1067/mpd.2002.124380; LEHMANN HP, 1990, J DEV BEHAV PEDIATR, V11, P128; LLOYDTHOMAS AR, 1994, PAEDIATRIC ANAESTHES, V4, P3; Malleson PN, 2001, ARCH DIS CHILD, V84, P189, DOI 10.1136/adc.84.3.189; McGrath P, 1996, PAIN, V64, P435, DOI 10.1016/0304-3959(95)00171-9; MCINTOSH N, 1994, ARCH DIS CHILD-FETAL, V70, pF177, DOI 10.1136/fn.70.3.F177; Meier PM, 2001, MUSCLE NERVE, V24, P1339, DOI 10.1002/mus.1153; Morton NS, 1999, BRIT J ANAESTH, V83, P118, DOI 10.1093/bja/83.1.118; MURAT I, 1987, BRIT J ANAESTH, V59, P1441, DOI 10.1093/bja/59.11.1441; Murray CS, 2000, ARCH DIS CHILD, V82, P231, DOI 10.1136/adc.82.3.231; MURRAY WB, 1987, S AFR MED J, V72, P839; *NAT HLTH MRC AUST, AC PAIN MAN SCI EV; Nishina K, 1999, PAEDIATR ANAESTH, V9, P187; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; Perquin CW, 2000, CLIN J PAIN, V16, P229, DOI 10.1097/00002508-200009000-00008; Perquin CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; Porter FL, 1997, PEDIATRICS, V100, P626, DOI 10.1542/peds.100.4.626; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; ROWBOTHAM DJ, 1998, GUIDELINES USE NONST; *ROYAL COLL NURS I, CLIN GUID REC ASS AC; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Schanberg LE, 2003, ARTHRITIS RHEUM-US, V48, P1390, DOI 10.1002/art.10986; SCHECHTER N, 1988, AM J NURS, V88, P719, DOI 10.2307/3425945; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Schreiner MS, 2002, ANESTH ANALG, V94, P1; Semple D, 1996, ANAESTHESIA, V51, P1170, DOI 10.1111/j.1365-2044.1996.tb15063.x; Sepponen K, 1999, PHARM WORLD SCI, V21, P168, DOI 10.1023/A:1008793223756; SHAPIRO BS, 1991, PEDIATRICS, V88, P1226; Simons J, 2001, J ADV NURS, V36, P591, DOI 10.1046/j.1365-2648.2001.02012.x; Small E, 2002, PEDIATR CLIN N AM, V49, P655, DOI 10.1016/S0031-3955(02)00008-1; Stallard P, 2001, ARCH DIS CHILD, V85, P460, DOI 10.1136/adc.85.6.460; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Voepel-Lewis T, 2002, ANESTH ANALG, V95, P1224, DOI 10.1097/00000539-200211000-00020; Weydert JA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e1; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013; Williams DG, 2001, BRIT J ANAESTH, V86, P413, DOI 10.1093/bja/86.3.413; WOLF AR, 1993, BRIT J ANAESTH, V70, P654, DOI 10.1093/bja/70.6.654; Wong D L, 1988, Pediatr Nurs, V14, P9; YASTER M, 1994, J PEDIATR-US, V124, P165, DOI 10.1016/S0022-3476(94)70300-0	98	165	174	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2464	2469		10.1001/jama.290.18.2464	http://dx.doi.org/10.1001/jama.290.18.2464			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742LH	14612483				2022-12-28	WOS:000186518300033
J	Bonnardeaux, A; Pichette, V				Bonnardeaux, A; Pichette, V			Complement dysregulation in haemolytic uraemic syndrome	LANCET			English	Editorial Material							DEFICIENCY		Univ Montreal, Hop Maison Neuve Rosemont, Serv Nephrol, Montreal, PQ H1T 2M4, Canada	Universite de Montreal	Bonnardeaux, A (corresponding author), Univ Montreal, Hop Maison Neuve Rosemont, Serv Nephrol, Montreal, PQ H1T 2M4, Canada.	bonnarda@hmr.qc.ca						CAPRIOLI J, 2003, HUM MOL GENET   1028; Donne RL, 2002, AM J KIDNEY DIS, V40, DOI 10.1053/ajkd.2002.36938; Garg AX, 2003, JAMA-J AM MED ASSOC, V290, P1360, DOI 10.1001/jama.290.10.1360; Loirat C, 2003, PEDIATR NEPHROL, V18, P1095, DOI 10.1007/s00467-003-1289-8; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100; Ruggenenti P, 2002, KIDNEY INT, V62, P1093, DOI 10.1046/j.1523-1755.2002.00543.x; Ruggenenti P, 2001, KIDNEY INT, V60, P831, DOI 10.1046/j.1523-1755.2001.060003831.x; Veyradier A, 2003, J PEDIATR-US, V142, P310, DOI 10.1067/mpd.2003.79	9	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	2003	362	9395					1514	1515		10.1016/S0140-6736(03)14777-0	http://dx.doi.org/10.1016/S0140-6736(03)14777-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615103				2022-12-28	WOS:000186464500004
J	Dadi, HK; Simon, AJ; Roifman, CM				Dadi, HK; Simon, AJ; Roifman, CM			Effect of CD3 delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-CHAIN MUTATION; SURFACE EXPRESSION; TCR/CD3 COMPLEX; CD3 DELTA; GENE; BETA; MICE; NONSENSE; SUBUNIT; PATIENT		Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Div Infect, Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Roifman, CM (corresponding author), Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca						Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805; Bank I, 1998, J ALLERGY CLIN IMMUN, V102, P621, DOI 10.1016/S0091-6749(98)70279-9; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; BUFERNE M, 1992, J IMMUNOL, V148, P657; Carrasco YR, 2002, SEMIN IMMUNOL, V14, P325, DOI 10.1016/S1044-5323(02)00065-9; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HAYNES BF, 1995, J EXP MED, V181, P1445, DOI 10.1084/jem.181.4.1445; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Roifman CM, 2000, BLOOD, V96, P2803; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SCHMALSTIEG FC, 1995, J CLIN INVEST, V95, P1169, DOI 10.1172/JCI117765; Sharfe N, 1997, J CLIN INVEST, V100, P3036, DOI 10.1172/JCI119858; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	32	135	141	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1821	1828		10.1056/NEJMoa031178	http://dx.doi.org/10.1056/NEJMoa031178			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602880	Bronze			2022-12-28	WOS:000186353800006
J	Hoffmann, JA				Hoffmann, JA			The immune response of Drosophila	NATURE			English	Review							PEPTIDOGLYCAN-RECOGNITION PROTEIN; ANTIMICROBIAL PEPTIDE GENES; GRAM-POSITIVE BACTERIA; GENOME-WIDE ANALYSIS; ANTIBACTERIAL DEFENSE; INNATE IMMUNITY; INDUCIBLE EXPRESSION; SIGNALING PATHWAYS; NEGATIVE BACTERIA; DEFICIENCY IMD	Drosophila mounts a potent host defence when challenged by various microorganisms. Analysis of this defence by molecular genetics has now provided a global picture of the mechanisms by which this insect senses infection, discriminates between various classes of microorganisms and induces the production of effector molecules, among which antimicrobial peptides are prominent. An unexpected result of these studies was the discovery that most of the genes involved in the Drosophila host defence are homologous of very similar to genes implicated in mammalian innate immune defences. Recent progress in research on Drosophila immune defence provides evidence for similarities and difference between Drosophila immune responses and mammalian innate immunity.	CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hoffmann, JA (corresponding author), CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France.	J.Hoffmann@ibmc.u-strasbg.fr						Avila A, 2002, MOL CELL BIOL, V22, P8787, DOI 10.1128/MCB.22.24.8787-8795.2002; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Braun A, 1998, P NATL ACAD SCI USA, V95, P14337, DOI 10.1073/pnas.95.24.14337; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Charatsi I, 2003, MECH DEVELOP, V120, P219, DOI 10.1016/S0925-4773(02)00410-0; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; Fernandez NQ, 2001, DEVELOPMENT, V128, P2963; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; GOBERT V, UNPUB SCIENCE; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kambris Zakaria, 2002, Gene Expression Patterns, V2, P311, DOI 10.1016/S1567-133X(02)00020-0; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Liepinsh E, 2003, J MOL BIOL, V327, P833, DOI 10.1016/S0022-2836(03)00185-2; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Liu LD, 2003, J IMMUNOL, V170, P575, DOI 10.4049/jimmunol.170.1.575; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Nicolas E, 1998, J BIOL CHEM, V273, P10463, DOI 10.1074/jbc.273.17.10463; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Parker JS, 2001, PROTEINS, V45, P71, DOI 10.1002/prot.1125; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RIZKI RM, 1984, P NATL ACAD SCI-BIOL, V81, P6154, DOI 10.1073/pnas.81.19.6154; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; STJOHNSTON D, 1992, CELL, V68, P201; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Sun HY, 2002, P NATL ACAD SCI USA, V99, P12871, DOI 10.1073/pnas.202396399; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	85	1076	1196	14	225	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					33	38		10.1038/nature02021	http://dx.doi.org/10.1038/nature02021			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603309				2022-12-28	WOS:000186370800033
J	Wenger, NS; Solomon, DH; Roth, CP; MacLean, CH; Saliba, D; Kamberg, CJ; Rubenstein, LZ; Young, RT; Sloss, EM; Louie, R; Adams, J; Chang, JT; Venus, PJ; Schnelle, JF; Shekelle, PG				Wenger, NS; Solomon, DH; Roth, CP; MacLean, CH; Saliba, D; Kamberg, CJ; Rubenstein, LZ; Young, RT; Sloss, EM; Louie, R; Adams, J; Chang, JT; Venus, PJ; Schnelle, JF; Shekelle, PG			The quality of medical care provided to vulnerable community-dwelling older patients	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; OF-CARE; ELDERS; BENEFICIARIES; IMPROVEMENT	Background: Many people 65 years of age and older are at risk for functional decline and death. However, the resource-intensive medical care provided to this group has received little evaluation. Previous studies have focused on general medical conditions aimed at prolonging life, not on geriatric issues important for quality of life. Objective: To measure the quality of medical care provided to vulnerable elders by evaluating the process of care using Assessing Care of Vulnerable Elders quality indicators (Qls). Design: Observational cohort study. Setting: Managed care organizations in the northeastern and southwestern United States. Patients: Vulnerable older patients identified by a brief interview from a random sample of community-dwelling adults 65 years of age or older who were enrolled in 2 managed care organizations and received care between July 1998 and July 1999. Measurements: Percentage of 207 Qls passed, overall and for 22 target conditions; by domain of care (prevention, diagnosis, treatment, and follow-up); and by general medical condition (for example, diabetes and heart failure) or geriatric condition (for example, falls and incontinence). Results: Patients were eligible for 10 711 Qls, of which 55% were passed. There was no overall difference between managed care organizations. Wide variation in adherence was found among conditions, ranging from 9% for end-of-life care to 82% for stroke care. More treatment Qls were completed (81%) compared with other domains (follow-up, 63%; diagnosis, 46%; and prevention, 43%). Adherence to Qls was lower for geriatric conditions than for general medical conditions (31% vs. 52%; P < 0.001). Conclusions: Care for vulnerable elders falls short of acceptable levels for a wide variety of conditions. Care for geriatric conditions is much less optimal than care for general medical conditions.	RAND Corp, Hlth, Santa Monica, CA 90407 USA; RAND Corp, Hlth, Washington, DC USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA; Los Angeles Jewish Home Aging, Los Angeles, CA USA; Borun Ctr Gerontol Res, Los Angeles, CA USA; United Healthcare Corp, Ctr Hlth Care Policy & Evaluat, Minnetonka, MN USA	RAND Corporation; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Wenger, NS (corresponding author), RAND Corp, Hlth, 1700 Main St,M-26, Santa Monica, CA 90407 USA.	nwenger@mednet.ucla.edu	Chang, John T./L-7840-2019	Rubenstein, Laurence/0000-0001-5910-0266				Allison JJ, 2000, JAMA-J AM MED ASSOC, V284, P1256, DOI 10.1001/jama.284.10.1256; [Anonymous], 2001, ANN INTERN MED, V135, P653, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00004; Ballard J E, 1997, Jt Comm J Qual Improv, V23, P434; Brook RH, 2000, INT J QUAL HEALTH C, V12, P281, DOI 10.1093/intqhc/12.4.281; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Cleary LM, 2001, AM J MED, V111, P738, DOI 10.1016/S0002-9343(01)01051-8; Field MJ, 1997, APPROACHING DEATH IM; Hodgson TA, 1999, HEALTH CARE FINANC R, V21, P119; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; JARRETT PG, 1995, ARCH INTERN MED, V155, P1060, DOI 10.1001/archinte.155.10.1060; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; Luthi J C, 2000, Eff Clin Pract, V3, P69; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Marshall C L, 1996, Am J Med Qual, V11, P87, DOI 10.1177/0885713X9601100206; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; Retchin SM, 1997, JAMA-J AM MED ASSOC, V278, P119; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; Shekelle PG, 2001, ANN INTERN MED, V135, P647, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00003; Sloss EM, 2000, J AM GERIATR SOC, V48, P363, DOI 10.1111/j.1532-5415.2000.tb04691.x; Solomon DH, 2003, J AM GERIATR SOC, V51, P902, DOI 10.1046/j.1365-2389.2003.513331.x; Solomon DH, 2000, MED CARE, V38, P383, DOI 10.1097/00005650-200004000-00005; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823	26	295	297	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					740	747		10.7326/0003-4819-139-9-200311040-00008	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	738XJ	14597458				2022-12-28	WOS:000186312900004
J	Candy, DCA				Candy, DCA			Rotavirus in the blood - another turn of the wheel	LANCET			English	Editorial Material							CHILDREN		Royal W Sussex NHS Trust, Paediat Gastroenterol & Nutr Serv, Chichester PO19 4SE, England		Candy, DCA (corresponding author), Royal W Sussex NHS Trust, Paediat Gastroenterol & Nutr Serv, Chichester PO19 4SE, England.							BISHOP RF, 1973, LANCET, V2, P1281, DOI 10.1016/s0140-6736(73)92867-5; Lynch M, 2001, CLIN INFECT DIS, V33, P932, DOI 10.1086/322650; OSBORNE MP, 1988, J PEDIATR GASTR NUTR, V7, P236, DOI 10.1097/00005176-198803000-00014; Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176-199704000-00008	4	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1429	1429		10.1016/S0140-6736(03)14725-3	http://dx.doi.org/10.1016/S0140-6736(03)14725-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602431				2022-12-28	WOS:000186356600003
J	Zhao, GQ; Zhang, YF; Hoon, MA; Chandrashekar, J; Erlenbach, I; Ryba, NJP; Zuker, CS				Zhao, GQ; Zhang, YF; Hoon, MA; Chandrashekar, J; Erlenbach, I; Ryba, NJP; Zuker, CS			The receptors for mammalian sweet and umami taste	CELL			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PHOSPHOLIPASE-C; GENE-EXPRESSION; CHORDA TYMPANI; BITTER TASTE; RESPONSES; CELLS; MICE; IDENTIFICATION; FAMILY	Sweet and umami (the taste of monosodium glutamate) are the main attractive taste modalities in humans. T1Rs are candidate mammalian taste receptors that combine to assemble two heteromeric G-protein-coupled receptor complexes: T1R1+3, an umami sensor, and T1R2+3, a sweet receptor. We now report the behavioral and physiological characterization of T1R1, T1R2, and T1R3 knockout mice. We demonstrate that sweet and umami taste are strictly dependent on T1R-receptors, and show that selective elimination of T1R-subunits differentially abolishes detection and perception of these two taste modalities. To examine the basis of sweet tastant recognition and coding, we engineered animals expressing either the human T1R2-receptor (hT1R2), or a modified opioid-receptor (RASSL) in sweet cells. Expression of hT1R2 in mice generates animals with humanized sweet taste preferences, while expression of RASSL drives strong attraction to a synthetic opiate, demonstrating that sweet cells trigger dedicated behavioral outputs, but their tastant selectivity is determined by the nature of the receptors.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ryba, NJP (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	nr13k@nih.gov; charles@flyeye.ucsd.edu		Chandrashekar, jayaram/0000-0001-6412-0114; Ryba, Nicholas/0000-0002-2060-8393	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000561] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abaffy T, 2003, AM J PHYSIOL-CELL PH, V284, pC1420, DOI 10.1152/ajpcell.00556.2002; Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Bachmanov AA, 2000, J NUTR, V130, p935S, DOI 10.1093/jn/130.4.935S; Bufe B, 2002, NAT GENET, V32, P397, DOI 10.1038/ng1014; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Chaudhari N, 1998, ANN NY ACAD SCI, V855, P398, DOI 10.1111/j.1749-6632.1998.tb10598.x; Chaudhari N, 2000, NAT NEUROSCI, V3, P113, DOI 10.1038/72053; Chaudhari N, 1996, J NEUROSCI, V16, P3817; Dahl M, 1997, BRAIN RES, V756, P22, DOI 10.1016/S0006-8993(97)00131-5; Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155; Danilova V, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-5; Danilova V, 1998, J NEUROPHYSIOL, V80, P2102, DOI 10.1152/jn.1998.80.4.2102; Glendinning JI, 2002, CHEM SENSES, V27, P461, DOI 10.1093/chemse/27.5.461; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Kinnamon SC, 2000, NEURON, V25, P507, DOI 10.1016/S0896-6273(00)81054-5; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lindemann B, 1996, PHYSIOL REV, V76, P719, DOI 10.1152/physrev.1996.76.3.719; Margolskee RF, 2002, J BIOL CHEM, V277, P1, DOI 10.1074/jbc.R100054200; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Mody SM, 2000, MOL PHARMACOL, V57, P13; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ninomiya Y, 1999, J NEUROPHYSIOL, V81, P3087, DOI 10.1152/jn.1999.81.6.3087; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Redfern CH, 1999, NAT BIOTECHNOL, V17, P165, DOI 10.1038/6165; Rossler P, 1998, EUR J CELL BIOL, V77, P253; Sainz E, 2001, J NEUROCHEM, V77, P896, DOI 10.1046/j.1471-4159.2001.00292.x; SCHIFFMAN SS, 1981, PHARMACOL BIOCHEM BE, V15, P377, DOI 10.1016/0091-3057(81)90266-5; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; YOSHII K, 1986, BRAIN RES, V367, P45, DOI 10.1016/0006-8993(86)91577-5; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; Zhang YF, 2003, CELL, V112, P293, DOI 10.1016/S0092-8674(03)00071-0	40	898	958	7	167	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					255	266		10.1016/S0092-8674(03)00844-4	http://dx.doi.org/10.1016/S0092-8674(03)00844-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636554	Bronze			2022-12-28	WOS:000186415000006
J	He, YH; Michaels, SD; Amasino, RM				He, YH; Michaels, SD; Amasino, RM			Regulation of flowering time by histone acetylation in Arabidopsis	SCIENCE			English	Article							POLYAMINE OXIDASE; LOCUS-C; GENE; THALIANA; ENCODES; PROTEIN; VERNALIZATION; REPRESSION; EXPRESSION; COMPLEXES	The Arabidopsis autonomous floral-promotion pathway promotes flowering independently of the photoperiod and vernalization pathways by repressing FLOWERING LOCUS C (FLC), a MADS-box transcription factor that blocks the transition from vegetative to reproductive development. Here, we report that FLOWERING LOCUS D (FLD), one of six genes in the autonomous pathway, encodes a plant homolog of a protein found in histone deacetylase complexes in mammals. Lesions in FLD result in hyperacetylation of histones in FLC chromatin, up-regulation of FLC expression, and extremely delayed flowering. Thus, the autonomous pathway regulates flowering in part by histone deacetylation. However, not all autonomous-pathway mutants exhibit FLC hyperacetylation, indicating that multiple means exist by which this pathway represses FLC expression.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Amasino, RM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Michaels, Scott/D-5458-2009; HE, Yuehui/Y-8792-2018; HE, Yuehui/H-9795-2012	HE, Yuehui/0000-0003-3304-4555; HE, Yuehui/0000-0003-3304-4555; Michaels, Scott/0000-0001-5248-3487				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Aravind L, 2002, GENOME BIOL, V3; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Chua YL, 2003, PLANT CELL, V15, P1468, DOI 10.1105/tpc.011825; Eimer S, 2002, EMBO J, V21, P5787, DOI 10.1093/emboj/cdf561; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Mouradov A, 2002, PLANT CELL, V14, pS111, DOI 10.1105/tpc.001362; Murray-Stewart T, 2002, BIOCHEM J, V368, P673, DOI 10.1042/BJ20021587; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Sanda SL, 1996, PLANT PHYSIOL, V111, P641, DOI 10.1104/pp.111.2.641; Schomburg FM, 2001, PLANT CELL, V13, P1427, DOI 10.1105/tpc.13.6.1427; Sheldon CC, 2002, PLANT CELL, V14, P2527, DOI 10.1105/tpc.004564; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Simpson GG, 1999, ANNU REV CELL DEV BI, V15, P519, DOI 10.1146/annurev.cellbio.15.1.519; Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2; Tian L, 2001, P NATL ACAD SCI USA, V98, P200, DOI 10.1073/pnas.011347998	24	371	417	10	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 5	2003	302	5651					1751	1754		10.1126/science.1091109	http://dx.doi.org/10.1126/science.1091109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	750AX	14593187				2022-12-28	WOS:000186970100044
J	Quist-Paulsen, P; Gallefoss, F				Quist-Paulsen, P; Gallefoss, F			Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; FOLLOW-UP; STOPPING SMOKING; AMBLYOPIA; AGE; MORTALITY; CHILDREN; THERAPY; SURGERY; ANGINA	Objective To determine whether a nurse led smoking cessation intervention affects smoking cessation rates in patients admitted for coronary heart disease. Design Randomised controlled trial. Setting Cardiac ward of a general hospital, Norway. Participants 240 smokers aged under 76 years admitted for myocardial infarction, unstable angina, or cardiac bypass surgery. 118 were randomly assigned to the intervention and 122 to usual care (control group). Intervention The intervention was based on a booklet and focused on fear arousal and prevention of relapses. The intervention was delivered by cardiac nurses without special training. The intervention was initiated in hospital, and the participants were contacted regularly for at least five months. Main outcome measure Smoking cessation rates at 12 months determined by self report and biochemical verification. Results 12 months after admission to hospital, 57% (n=57/100) of patients in the intervention group and 37% (n=44/118) in the control group had quit smoking (absolute risk reduction 20%, 95% confidence interval 6% to 33%). The number needed to treat to get one additional person who would quit was 5 (95% confidence interval, 3 to 16). Assuming all dropouts relapsed at 12 months, the smoking cessation rates were 50% in the intervention group and 37% in the control group (absolute risk reduction 13%, 0% to 26%). Conclusion A smoking cessation programme delivered by cardiac nurses without special training, significantly reduced smoking rates in patients 12 months after admission to hospital for coronary heart disease.	Soerlandet Sykehus Kristiansand, Dept Med, N-4604 Kristiansand, Norway		Quist-Paulsen, P (corresponding author), St Olavs Hosp, Dept Haematol, N-7006 Trondheim, Norway.	petterqp@online.no						Attebo K, 1998, OPHTHALMOLOGY, V105, P154, DOI 10.1016/S0161-6420(98)91862-0; Barnes GR, 2001, J PHYSIOL-LONDON, V533, P281, DOI 10.1111/j.1469-7793.2001.0281b.x; Beardsell R, 1989, BR ORTHOPT J, V46, P7; BIRNBAUM MH, 1977, AM J OPTOM PHYS OPT, V54, P269; Bray LC, 1996, EYE, V10, P714, DOI 10.1038/eye.1996.166; BURT A, 1974, LANCET, V1, P304; CAMPBELL NC, 2002, BMJ-BRIT MED J, V324, P87; CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; Carlsson R, 1997, HEART, V77, P256, DOI 10.1136/hrt.77.3.256; DALY LE, 1983, BMJ-BRIT MED J, V287, P324, DOI 10.1136/bmj.287.6388.324; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Dornelas EA, 2000, PREV MED, V30, P261, DOI 10.1006/pmed.2000.0644; GAREY I, 1979, PROG BRAIN RES, V51, P445; Glaser SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P268; Hajek P, 2002, BMJ-BRIT MED J, V324, P87, DOI 10.1136/bmj.324.7329.87; HALL D, 2002, HLTH ALL CHILDREN; Hard AL, 1995, ACTA OPHTHALMOL SCAN, V73, P483; Hardman Lea S J, 1989, Eye (Lond), V3 ( Pt 6), P783; Hartmann EE, 2001, OPHTHALMOLOGY, V108, P479, DOI 10.1016/S0161-6420(00)00588-1; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; INGRAM RM, 1986, BRIT J OPHTHALMOL, V70, P16, DOI 10.1136/bjo.70.1.16; Jakobsson P, 2002, ACTA OPHTHALMOL SCAN, V80, P44, DOI 10.1034/j.1600-0420.2002.800109.x; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Kemper AR, 1999, PEDIATRICS, V104, P1220; KUTSCHKE PJ, 1991, OPHTHALMOLOGY, V98, P258; Kvarnstrom G, 2001, ACTA OPHTHALMOL SCAN, V79, P240, DOI 10.1034/j.1600-0420.2001.790306.x; MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x; Moseley MJ, 1997, BRIT J OPHTHALMOL, V81, P956, DOI 10.1136/bjo.81.11.956; OCKENE J, 1992, HEALTH PSYCHOL, V11, P119, DOI 10.1037//0278-6133.11.5.277; Ortigosa AM, 2000, MED CLIN-BARCELONA, V114, P209; Pediat Eye Dis Investigator Grp, 2003, ARCH OPHTHALMOL-CHIC, V121, P603; PERKINS KA, 1986, INT J ADDICT, V21, P1173, DOI 10.3109/10826088609074847; RAHI J, 2000, LANCET, V360, P597; Reeves BC., 2002, AMBLYOPIA MULTIDISCI, P68; RIGOTTI NA, 1991, J GEN INTERN MED, V6, P305, DOI 10.1007/BF02597426; RIGOTTI NA, 1994, ANN INTERN MED, V120, P287, DOI 10.7326/0003-4819-120-4-199402150-00005; *ROYAL COLL OPHTH, 2002, GUID CHILDR EYE CAR; Simons K, 1999, BRIT J OPHTHALMOL, V83, P582, DOI 10.1136/bjo.83.5.582; STEWARTBROWN S, 1985, DEV MED CHILD NEUROL, V27, P504; STEWARTBROWN SL, 1988, ARCH DIS CHILD, V63, P356, DOI 10.1136/adc.63.4.356; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; TAYLOR CB, 1988, ADDICT BEHAV, V13, P331, DOI 10.1016/0306-4603(88)90039-1; Taylor DM, 2001, RADIOACTIV ENVIRONM, V1, P1; VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/j.2044-8260.1994.tb01133.x; VANNOORDEN GK, 2001, BINOCULAR VISION OCU; Williams C, 2002, BMJ-BRIT MED J, V324, P1549, DOI 10.1136/bmj.324.7353.1549; Wilson K, 2000, ARCH INTERN MED, V160, P939, DOI 10.1001/archinte.160.7.939	47	87	93	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	2003	327	7426					1254	1257		10.1136/bmj.327.7426.1254	http://dx.doi.org/10.1136/bmj.327.7426.1254			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644967	Bronze, Green Published			2022-12-28	WOS:000186948800016
J	Nicholson, KG; Wood, JM; Zambon, M				Nicholson, KG; Wood, JM; Zambon, M			Influenza	LANCET			English	Review							RESPIRATORY SYNCYTIAL VIRUS; LONG-TERM-CARE; NEURAMINIDASE INHIBITOR OSELTAMIVIR; A VIRUS; ELDERLY PERSONS; DOUBLE-BLIND; VACCINE EFFECTIVENESS; INHALED ZANAMIVIR; HONG-KONG; PREVENTING HOSPITALIZATION	Although most influenza infections are self-limited, few other diseases exert such a huge toll of suffering and economic loss. Despite the importance of influenza, there had been, until recently, little advance in its control since amantadine was licensed almost 40 years ago. During the past decade, evidence has accrued on the protection afforded by inactivated vaccines and the safety and efficacy in children of live influenza-virus vaccines. There have been many new developments in vaccine technology. Moreover, work on viral neuraminidase has led to the licensing of potent selective antiviral drugs, and economic decision modelling provides further justification for annual vaccination and a framework for the use of neuraminidase inhibitors. Progress has also been made on developing near-patient testing for influenza that may assist individual diagnosis or the recognition of widespread virus circulation, and so optimise clinical management. Despite these advances, the occurrence of avian H5N1, H9N2, and H7N7 influenza in human beings and the rapid global spread of severe acute respiratory syndrome are reminders of our vulnerability to an emerging pandemic. The contrast between recent cases of H5N1 infection, associated with high mortality, and the typically mild, self-limiting nature of human infections with avian H7N7 and H9N2 influenza shows the gaps in our understanding of molecular correlates of pathogenicity and underlines the need for continuing international research into pandemic influenza. Improvements in animal and human surveillance, new approaches to vaccination, and increasing use of vaccines and antiviral drugs to combat annual influenza outbreaks are essential to reduce the global toll of pandemic and interpandemic influenza.	Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Cent Publ Hlth Lab, London NW9 5HT, England	University of Leicester; National Institute for Biological Standards & Control; Public Health England	Nicholson, KG (corresponding author), Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England.	karlgnicholson@doctors.org.uk						Ahmed AH, 1997, EPIDEMIOL INFECT, V118, P27, DOI 10.1017/S0950268896007121; Banzhoff A, 2003, GERONTOLOGY, V49, P177, DOI 10.1159/000069172; Belshe RB, 2000, J PEDIATR-US, V136, P168, DOI 10.1016/S0022-3476(00)70097-7; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Boulianne N, 2001, Can Commun Dis Rep, V27, P85; Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655; Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9; Cass LMR, 2000, RESP MED, V94, P166, DOI 10.1053/rmed.1999.0718; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Chan KH, 2002, J CLIN MICROBIOL, V40, P1675, DOI 10.1128/JCM.40.5.1675-1680.2002; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; Chen WS, 2001, INT CONGR SER, V1219, P123, DOI 10.1016/S0531-5131(01)00333-8; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546; Choudhri Yogesh, 2002, Can Commun Dis Rep, V28, P2; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; CLOVER RD, 1991, J INFECT DIS, V163, P300, DOI 10.1093/infdis/163.2.300; Colquhoun AJ, 1997, EPIDEMIOL INFECT, V119, P335, DOI 10.1017/S095026889700825X; Cox NJ, 1996, INT CONGR SER, V1123, P591; COX NJ, 1994, EUR J EPIDEMIOL, V10, P467, DOI 10.1007/BF01719678; Crocetti E, 2001, EUR J EPIDEMIOL, V17, P163, DOI 10.1023/A:1017978420601; Davis JW, 2001, MED CARE, V39, P1273, DOI 10.1097/00005650-200112000-00003; Deguchi Y, 2000, J MED MICROBIOL, V49, P553, DOI 10.1099/0022-1317-49-6-553; Diggory P, 2001, BRIT MED J, V322, P1; DOMINGUEZ EA, 1993, J CLIN MICROBIOL, V31, P2286, DOI 10.1128/JCM.31.9.2286-2290.1993; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Effler PV, 2002, EMERG INFECT DIS, V8, P23, DOI 10.3201/eid0801.010067; Ellis JS, 2002, REV MED VIROL, V12, P375, DOI 10.1002/rmv.370; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581, DOI 10.1017/S095026880005874X; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; FOUCHIER R, 2003, 200304190959 INT SOC; FRANK AL, 1985, J INFECT DIS, V151, P73, DOI 10.1093/infdis/151.1.73; Freund B, 1999, DRUG SAFETY, V21, P267, DOI 10.2165/00002018-199921040-00003; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GRAVENSTEIN S, 2000, OPT CONTR INFL HERS, V4, P140; Gregory V, 2002, VIROLOGY, V300, P1, DOI 10.1006/viro.2002.1513; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; GRUBER WC, 1990, AM J DIS CHILD, V144, P595, DOI 10.1001/archpedi.1990.02150290089035; Guan Y, 1999, P NATL ACAD SCI USA, V96, P9363, DOI 10.1073/pnas.96.16.9363; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; GUO YJ, 1992, J GEN VIROL, V73, P383, DOI 10.1099/0022-1317-73-2-383; Hak E, 1998, J EPIDEMIOL COMMUN H, V52, P120, DOI 10.1136/jech.52.2.120; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hedrick JA, 2000, PEDIATR INFECT DIS J, V19, P410, DOI 10.1097/00006454-200005000-00005; Hehme N, 2002, MED MICROBIOL IMMUN, V191, P203, DOI 10.1007/s00430-002-0147-9; Heijnen M.L.A., 1999, Euro Surveill, V4, P81; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; Holm KJ, 1999, BIODRUGS, V11, P137, DOI 10.2165/00063030-199911020-00007; Hurwitz ES, 2000, J INFECT DIS, V182, P1218, DOI 10.1086/315820; Hurwitz ES, 2000, JAMA-J AM MED ASSOC, V284, P1677, DOI 10.1001/jama.284.13.1677; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Jefferson T.O., 2001, COCHRANE LIB; Kaiser L, 2000, CLIN INFECT DIS, V30, P587, DOI 10.1086/313696; Kaiser L, 1999, J CLIN VIROL, V14, P191, DOI 10.1016/S1386-6532(99)00058-X; Khan AS, 1996, J INFECT DIS, V173, P453, DOI 10.1093/infdis/173.2.453; Kramarz P, 2001, J PEDIATR-US, V138, P306, DOI 10.1067/mpd.2001.112168; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; Lalezari J, 2001, ARCH INTERN MED, V161, P212, DOI 10.1001/archinte.161.2.212; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; Lavallee P, 2002, STROKE, V33, P513, DOI 10.1161/hs0202.102328; Li SQ, 1999, J INFECT DIS, V179, P1132, DOI 10.1086/314713; LI XS, 1992, J GEN VIROL, V73, P1329, DOI 10.1099/0022-1317-73-6-1329; Makela MJ, 2000, J INFECTION, V40, P42, DOI 10.1053/jinf.1999.0602; Meier CR, 2000, EUR J CLIN MICROBIOL, V19, P834, DOI 10.1007/s100960000376; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; MONTO AS, 1985, AM J EPIDEMIOL, V121, P811, DOI 10.1093/oxfordjournals.aje.a114052; MONTO AS, 1995, AM J EPIDEMIOL, V141, P502, DOI 10.1093/oxfordjournals.aje.a117464; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; Morishima T, 2002, CLIN INFECT DIS, V35, P512, DOI 10.1086/341407; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Murphy KR, 2000, CLIN DRUG INVEST, V20, P337, DOI 10.2165/00044011-200020050-00005; Naghavi M, 2000, CIRCULATION, V102, P3039; *NAT I CLIN EXC, 2003, GUID US ZAN OS AM TR; *NAT I CLIN EXC, 2003, GUID US OS AM PROPH; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Neuzil KM, 2001, PEDIATR INFECT DIS J, V20, P733, DOI 10.1097/00006454-200108000-00004; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Nicholson KG, 1999, EPIDEMIOL INFECT, V123, P103, DOI 10.1017/S095026889900271X; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; Nicholson KG, 1998, LANCET, V351, P326, DOI 10.1016/S0140-6736(97)07468-0; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Nicholson KG, 1998, TXB INFLUENZA, P219; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Noyola DE, 2000, PEDIATR INFECT DIS J, V19, P303, DOI 10.1097/00006454-200004000-00008; Noyola DE, 2000, PEDIATR DEVEL PATHOL, V3, P162, DOI 10.1007/s100240050020; Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240; Oshitani H, 2000, INFECT CONT HOSP EP, V21, P728, DOI 10.1086/501725; Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5; Perdue ML, 2000, VET MICROBIOL, V74, P77, DOI 10.1016/S0378-1135(00)00168-1; Peters PH, 2001, J AM GERIATR SOC, V49, P1025, DOI 10.1046/j.1532-5415.2001.49204.x; Poehling KA, 2002, PEDIATRICS, V110, P83, DOI 10.1542/peds.110.1.83; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; PuigBarbera J, 1997, J EPIDEMIOL COMMUN H, V51, P526, DOI 10.1136/jech.51.5.526; Quach C, 2002, CLIN DIAGN LAB IMMUN, V9, P925, DOI 10.1128/CDLI.9.4.925-926.2002; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; Reina J, 2002, J CLIN MICROBIOL, V40, P3515, DOI 10.1128/JCM.40.9.3515-3517.2002; Rodriguez WJ, 2002, PEDIATR INFECT DIS J, V21, P193, DOI 10.1097/00006454-200203000-00006; RUDENKO LG, 1993, J INFECT DIS, V168, P881, DOI 10.1093/infdis/168.4.881; RYANPOIRIER KA, 1992, J CLIN MICROBIOL, V30, P1072, DOI 10.1128/JCM.30.5.1072-1075.1992; Saxen H, 1999, PEDIATR INFECT DIS J, V18, P779, DOI 10.1097/00006454-199909000-00007; Sener M, 1999, J ASTHMA, V36, P165, DOI 10.3109/02770909909056313; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Siscovick DS, 2000, AM J EPIDEMIOL, V152, P674, DOI 10.1093/aje/152.7.674; Steinhauer DA, 1999, VIROLOGY, V258, P1, DOI 10.1006/viro.1999.9716; Sugaya Norio, 2002, Semin Pediatr Infect Dis, V13, P79, DOI 10.1053/spid.2002.122993; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; TURNER D, SYSTEMATIC REV EC DE; *US FDA, REL; Uyeki TM, 2002, EMERG INFECT DIS, V8, P154, DOI 10.3201/eid0802.010148; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5; WEBSTER RG, 1981, NEW ENGL J MED, V304, P911; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; WRIGHT PF, 1980, AM J EPIDEMIOL, V112, P814, DOI 10.1093/oxfordjournals.aje.a113053; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zambon MC, 2001, REV MED VIROL, V11, P227, DOI 10.1002/rmv.319; Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X; 2002, WKLY EPIDEMIOL REC, V46, P381	137	617	705	5	154	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1733	1745		10.1016/S0140-6736(03)14854-4	http://dx.doi.org/10.1016/S0140-6736(03)14854-4			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643124	Bronze, Green Published			2022-12-28	WOS:000186767700023
J	Hall, C; Tharakan, P; Hallock, J; Cleveland, C; Jefferson, M				Hall, C; Tharakan, P; Hallock, J; Cleveland, C; Jefferson, M			Hydrocarbons and the evolution of human culture	NATURE			English	Editorial Material							LOWER 48 STATES; OIL PRODUCTION; ENERGY	Most of the progress in human culture has required the exploitation of energy resources. About 100 years ago, the major source of energy shifted from recent solar to fossil hydrocarbons, including liquid and gaseous petroleum. Technology has generally led to a greater use of hydrocarbon fuels for most human activities, making civilization vulnerable to decreases in supply. At this time our knowledge is not sufficient for us to choose between the different estimates of, for example, resources of conventional oil.	SUNY Coll Environm Sci & Forestry, Dept Environm, Syracuse, NY 13210 USA; SUNY Coll Environm Sci & Forestry, Dept Forest Biol, Syracuse, NY 13210 USA; SUNY Coll Environm Sci & Forestry, Grad Program Environm Sci, Syracuse, NY 13210 USA; Univ Montana, Flathead Lake Biol Stn, Polson, MT 59860 USA; Syracuse Univ, Maxwell Sch Citizenship & Publ Affairs, Syracuse, NY USA; Boston Univ, Ctr Energy & Environm Studies, Boston, MA 02215 USA; Boston Univ, Dept Geog, Boston, MA 02215 USA; Global Energy & Environm Consultants, Old Stables, Felmersham MK43 7HJ, Beds, England	State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; University of Montana System; University of Montana; Syracuse University; Boston University; Boston University	Hall, C (corresponding author), SUNY Coll Environm Sci & Forestry, Dept Environm, Syracuse, NY 13210 USA.	chall@esf.edu; cutler@bu.edu; jeffers@dircon.co.uk						Campbell CJ, 1998, SCI AM, V278, P77; CLEVELAND CJ, 1984, SCIENCE, V225, P890, DOI 10.1126/science.225.4665.890; Cooper C., 1998, WALL STREET J   1012; *EN INF ADM, 2003, DOEEIA0484 US DEP EN; HAKES J, LONG TERM WORLD OIL; Hall C, 2001, BIOSCIENCE, V51, P663, DOI 10.1641/0006-3568(2001)051[0663:TNTRTN]2.0.CO;2; HALLOCK J, IN PRESS ENERGY; Hubbert M., 1962, ENERGY RESOURCES REP; *INT WORK GROUP, 2000, LBNL44029; KAUFMANN RK, 1991, RESOUR ENERG, V13, P111, DOI 10.1016/0165-0572(91)90022-U; Kaufmann RK, 2001, ENERG J, V22, P27; KAUFMANN RK, IN PRESS ENERGY J; Lynch M.C., 2002, Q REV EC FINANCE, V42, P373, DOI DOI 10.1016/S1062-9769(02)00126-6; Munasinghe M., 2002, INT J SUSTAIN DEV, V5, P125, DOI DOI 10.1504/IJSD.2002.002563; Sadorsky P, 1999, ENERG ECON, V21, P449, DOI 10.1016/S0140-9883(99)00020-1; Smulders S, 2003, RESOUR ENERGY ECON, V25, P59, DOI 10.1016/S0928-7655(02)00017-9; Tainter J., 1988, COLLAPSE COMPLEX SYS; Tharakan P.J, 2001, ENVIRON SCI POLICY, V4, P319, DOI [10.1016/S1462-9011(01)00036-3, DOI 10.1016/S1462-9011(01)00036-3]; Tissot B.P., 1979, GEOL J, V116, P243, DOI [10.1017/S0016756800043685, DOI 10.1017/S0016756800043685]; United States Geological Survey (USGS), 2003, WORLD PETR ASS 2000; *USGS, 2000, US DEP LONG TERM WOR	21	155	161	1	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					318	322		10.1038/nature02130	http://dx.doi.org/10.1038/nature02130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628060				2022-12-28	WOS:000186660800052
J	Wraith, DC; Goldman, M; Lambert, PH				Wraith, DC; Goldman, M; Lambert, PH			Vaccination and autoimmune disease: what is the evidence?	LANCET			English	Review							MYELIN BASIC-PROTEIN; GUILLAIN-BARRE-SYNDROME; HEPATITIS-B VACCINATION; REACTIVE T-CELLS; THROMBOCYTOPENIC PURPURA; RUBELLA VACCINATION; MULTIPLE-SCLEROSIS; CROSS-REACTIVITY; TRANSGENIC MICE; INDUCTION	As many as one in 20 people in Europe and North America have some form of autoimmune disease. These diseases arise in genetically predisposed individuals but require an environmental trigger. Of the many potential environmental factors, infections are the most likely cause. Microbial antigens can induce cross-reactive immune responses against self-antigens, whereas infections can non-specifically enhance their presentation to the immune system. The immune system uses fail-safe mechanisms to suppress infection-associated tissue damage and thus limits autoimmune responses. The association between infection and autoimmune disease has, however, stimulated a debate as to whether such diseases might also be triggered by vaccines. Indeed there are numerous claims and counter claims relating to such a risk. Here we review the mechanisms involved in the induction of autoimmunity and assess the implications for vaccination in human beings.	Univ Bristol, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Free Univ Brussels, Hop Erasme, Dept Immunol, B-1070 Brussels, Belgium; Univ Geneva, Dept Pathol, Ctr Vaccinol, CH-1211 Geneva, Switzerland	University of Bristol; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Geneva	Wraith, DC (corresponding author), Univ Bristol, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England.	d.c.wraith@bris.ac.uk		Wraith, David/0000-0003-2147-5614				Anderton SM, 2002, NAT REV IMMUNOL, V2, P487, DOI 10.1038/nri842; Anderton SM, 2001, J EXP MED, V193, P1, DOI 10.1084/jem.193.1.1; [Anonymous], 2001, Wkly Epidemiol Rec, V76, P85; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Beeler J, 1996, PEDIATR INFECT DIS J, V15, P88, DOI 10.1097/00006454-199601000-00020; BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; BUCY RP, 1993, J IMMUNOL, V151, P1039; Burkhart C, 1999, INT IMMUNOL, V11, P1625, DOI 10.1093/intimm/11.10.1625; Carpo M, 1999, J NEUROL SCI, V168, P78, DOI 10.1016/S0022-510X(99)00173-2; *CERT PROF SEM, 2001, J EXP MED, V193, P41; Chen RT, 2001, J AUTOIMMUN, V16, P309, DOI 10.1006/jaut.2000.0491; Classen JB, 1999, BRIT MED J, V319, P1133, DOI 10.1136/bmj.319.7217.1133; Classen JB, 1999, AUTOIMMUNITY, V31, P43, DOI 10.3109/08916939908993858; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; DeStefano F, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e112; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Fournie GJ, 2001, J AUTOIMMUN, V16, P319, DOI 10.1006/jaut.2000.0482; Fugger L, 2000, CURR OPIN IMMUNOL, V12, P698, DOI 10.1016/S0952-7915(00)00165-5; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; Gout O, 1998, REV NEUROL-FRANCE, V154, P205; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; Green A, 2000, LANCET, V355, P873; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; GRUENEWALD R, 1991, ARCH NEUROL-CHICAGO, V48, P1080, DOI 10.1001/archneur.1991.00530220102027; Hemmer B, 2000, J NEUROIMMUNOL, V107, P148, DOI 10.1016/S0165-5728(00)00226-5; Horwitz MS, 2002, J CLIN INVEST, V109, P79, DOI 10.1172/JCI11198; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Itoh M, 1999, J IMMUNOL, V162, P5317; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; JonvilleBera AP, 1996, PEDIATR INFECT DIS J, V15, P44, DOI 10.1097/00006454-199601000-00010; Karvonen M, 1999, BRIT MED J, V318, P1169, DOI 10.1136/bmj.318.7192.1169; Kissler S, 2002, J AUTOIMMUN, V19, P183, DOI 10.1006/jaut.2002.0614; Kissler S, 2001, J AUTOIMMUN, V16, P303, DOI 10.1006/jaut.2000.0498; Kono DH, 1998, J IMMUNOL, V161, P234; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; MELNICK SC, 1964, J NEUROL NEUROSUR PS, V27, P395, DOI 10.1136/jnnp.27.5.395; Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227; Miller SD, 2001, J AUTOIMMUN, V16, P219, DOI 10.1006/jaut.2000.0489; Morse SS, 1999, J IMMUNOL, V162, P5309; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Olsen JK, 2001, J CLIN INVEST, V108, P311; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; OSKI FA, 1966, NEW ENGL J MED, V275, P352, DOI 10.1056/NEJM196608182750703; Panoutsakopoulou V, 2001, IMMUNITY, V15, P137, DOI 10.1016/S1074-7613(01)00172-8; Pool V, 1997, PEDIATR INFECT DIS J, V16, P423; REES JH, 1995, ANN NEUROL, V38, P809, DOI 10.1002/ana.410380516; SAKAGUCHI N, 1994, J IMMUNOL, V152, P2586; SAKAGUCHI S, 1982, J EXP MED, V156, P1577, DOI 10.1084/jem.156.6.1577; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; Segal BM, 1997, J IMMUNOL, V158, P5087; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; STUART G., 1928, ANN TROP MED & PARASITOL, V22, P327; Sundstedt A, 1997, J IMMUNOL, V158, P180; Theofilopoulos AN, 2001, J CLIN INVEST, V108, P335, DOI 10.1172/JCI12173; Todd JA, 2001, IMMUNITY, V15, P387, DOI 10.1016/S1074-7613(01)00202-3; Tourbah A, 1999, NEUROLOGY, V53, P396, DOI 10.1212/WNL.53.2.396; Trinchieri G, 2001, J EXP MED, V194, pF53, DOI 10.1084/jem.194.10.f53; Vlacha V, 1996, PEDIATRICS, V97, P738; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235; WYNN DR, 1990, NEUROLOGY, V40, P780, DOI 10.1212/WNL.40.5.780	69	226	231	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1659	1666		10.1016/S0140-6736(03)14802-7	http://dx.doi.org/10.1016/S0140-6736(03)14802-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630450				2022-12-28	WOS:000186637400027
J	Doshi, P; Cohen, I; Zhang, WW; Siegel, M; Howell, P; Basaran, OA; Nagel, SR				Doshi, P; Cohen, I; Zhang, WW; Siegel, M; Howell, P; Basaran, OA; Nagel, SR			Persistence of memory in drop breakup: The breakdown of universality	SCIENCE			English	Article							SINGULARITIES; DYNAMICS	A low-viscosity drop breaking apart inside a viscous fluid is encountered when air bubbles, entrained in thick syrup or honey, rise and break apart. Experiments, simulations, and theory show that the breakup under conditions in which the interior viscosity can be neglected produces an exceptional form of singularity. In contrast to previous studies of drop breakup, universality is violated so that the final shape at breakup retains an imprint of the initial and boundary conditions. A finite interior viscosity, no matter how small, cuts off this form of singularity and produces an unexpectedly long and slender thread. If exterior viscosity is large enough, however, the cutoff does not occur because the minimum drop radius reaches subatomic dimensions first.	Univ Chicago, James Franck Inst, Dept Phys, Chicago, IL 60637 USA; Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA; Math Inst, Oxford OX 13LB, England	University of Chicago; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; New Jersey Institute of Technology	Zhang, WW (corresponding author), Univ Chicago, James Franck Inst, Dept Phys, 5640 S Ellis Ave, Chicago, IL 60637 USA.	wzhang@uchicago.edu		Cohen, Itai/0000-0001-9218-043X				Almgren R, 1996, PHYS FLUIDS, V8, P1356, DOI 10.1063/1.868915; Bohr N, 1939, NATURE, V143, P330, DOI 10.1038/143330a0; BUCKMASTER JD, 1972, J FLUID MECH, V55, P385, DOI 10.1017/S0022112072001910; Chandrasekhar S., 1967, INTRO STUDY STELLAR; Chen AU, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174501; Cohen I, 1999, PHYS REV LETT, V83, P1147, DOI 10.1103/PhysRevLett.83.1147; Cohen I, 2001, PHYS FLUIDS, V13, P3533, DOI 10.1063/1.1409369; Cohen I, 2001, SCIENCE, V292, P265, DOI 10.1126/science.1059175; Eggers J, 1997, REV MOD PHYS, V69, P865, DOI 10.1103/RevModPhys.69.865; Eggers J, 2001, PHYS REV LETT, V86, P4290, DOI 10.1103/PhysRevLett.86.4290; Ganan-Calvo AM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.274501; GOLDSTEIN RE, 1993, PHYS REV LETT, V70, P3043, DOI 10.1103/PhysRevLett.70.3043; Lorenceau E, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.184501; Notz PK, 2001, PHYS FLUIDS, V13, P549, DOI 10.1063/1.1343906; Odian G., 1991, PRINCIPLES POLYM, V3; SHI XD, 1994, SCIENCE, V265, P219, DOI 10.1126/science.265.5169.219; SIEROU A, IN PRESS J FLUID MEC; Simpkins PG, 2000, NATURE, V403, P641, DOI 10.1038/35001043; Zhang WW, 1999, PHYS REV LETT, V83, P1151, DOI 10.1103/PhysRevLett.83.1151	19	128	129	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1185	1188		10.1126/science.1089272	http://dx.doi.org/10.1126/science.1089272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615531	Green Submitted			2022-12-28	WOS:000186544300046
J	Ira, G; Malkova, A; Liberi, G; Foiani, M; Haber, JE				Ira, G; Malkova, A; Liberi, G; Foiani, M; Haber, JE			Srs2 and Sgs1-Top3 suppress crossovers during double-strand break repair in yeast	CELL			English	Article							SYNDROME GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; TOPOISOMERASE-III; CROSSING-OVER; HOMOLOGOUS RECOMBINATION; DNA HELICASE; FUNCTIONAL OVERLAP; HOLLIDAY JUNCTIONS; SGS1	Very few gene conversions in mitotic cells are associated with crossovers, suggesting that these events are regulated. This may be important for the maintenance of genetic stability. We have analyzed the relationship between homologous recombination and crossing-over in haploid budding yeast and identified factors involved in the regulation of crossover outcomes. Gene conversions unaccompanied by a crossover appear 30 min before conversions accompanied by exchange, indicating that there are two different repair mechanisms in mitotic cells. Crossovers are rare (5%), but deleting the BLM/WRN homolog, SGS1, or the SRS2 helicase increases crossovers 2- to 3-fold. Overexpressing SRS2 nearly eliminates crossovers, whereas overexpression of RAD51 in srs2Delta cells almost completely eliminates the noncrossover recombination pathway. We suggest Sgs1 and its associated topoisomerase Top3 remove double Holliday junction intermediates from a crossover-producing repair pathway, thereby reducing crossovers. Srs2 promotes the noncrossover synthesis-dependent strand-annealing (SDSA) pathway, apparently by regulating Rad51 binding during strand exchange.	Brandeis Univ, Rosentiel Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Ist FIRC Oncol Mol, I-20141 Milan, Italy; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy	Brandeis University; Brandeis University; IFOM - FIRC Institute of Molecular Oncology; University of Milan	Haber, JE (corresponding author), Brandeis Univ, Rosentiel Ctr, Waltham, MA 02454 USA.	haber@brandeis.edu	Foiani, Marco/M-8234-2014; Ira, Grzegorz/B-7912-2010; LIBERI, GIORDANO/AAY-7273-2020	Foiani, Marco/0000-0003-4795-834X; LIBERI, GIORDANO/0000-0003-3160-2242; Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061766, R37GM020056, R01GM080600, R01GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM020056, R37 GM020056, R01 GM080600, R01 GM061766, GM20056, GM61766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; AGUILERA A, 1988, GENETICS, V119, P779; Ajima J, 2002, MUTAT RES-FUND MOL M, V504, P157, DOI 10.1016/S0027-5107(02)00089-1; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Church G M, 1985, Prog Clin Biol Res, V177, P17; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; ESPOSITO MS, 1978, P NATL ACAD SCI USA, V75, P4436, DOI 10.1073/pnas.75.9.4436; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Frei C, 2000, GENE DEV, V14, P81; Fricke WM, 2001, J BIOL CHEM, V276, P8848, DOI 10.1074/jbc.M009719200; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; Hickson ID, 2001, BIOCHEM SOC T, V29, P201, DOI 10.1042/0300-5127:0290201; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Ira G, 2002, MOL CELL BIOL, V22, P6384, DOI 10.1128/MCB.22.18.6384-6392.2002; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Kang LE, 2000, MOL CELL BIOL, V20, P9162, DOI 10.1128/MCB.20.24.9162-9172.2000; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Khazanehdari KA, 2000, CHROMOSOMA, V109, P94, DOI 10.1007/s004120050416; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Kwan KY, 2003, P NATL ACAD SCI USA, V100, P2526, DOI 10.1073/pnas.0437998100; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Malkova A, 2000, P NATL ACAD SCI USA, V97, P14500, DOI 10.1073/pnas.97.26.14500; Mankouri HW, 2002, NUCLEIC ACIDS RES, V30, P1103, DOI 10.1093/nar/30.5.1103; MCGILL C, 1989, CELL, V57, P459, DOI 10.1016/0092-8674(89)90921-5; MILNE GT, 1995, GENETICS, V139, P1189; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; Prado F, 2003, TRENDS GENET, V19, P428, DOI 10.1016/S0168-9525(03)00173-2; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Rockmill B, 2003, CURR BIOL, V13, P1954, DOI 10.1016/j.cub.2003.10.059; RONG L, 1991, GENETICS, V127, P75; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Shor E, 2002, GENETICS, V162, P647; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Sugawara N, 2000, MOL CELL BIOL, V20, P5300, DOI 10.1128/MCB.20.14.5300-5309.2000; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Virgin JB, 2001, GENETICS, V157, P63; Watt PM, 1996, GENETICS, V144, P935; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636	67	454	461	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2003	115	4					401	411		10.1016/S0092-8674(03)00886-9	http://dx.doi.org/10.1016/S0092-8674(03)00886-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622595	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000186627100007
J	Morillon, A; Karabetsou, N; O'Sullivan, J; Kent, N; Proudfoot, N; Mellor, J				Morillon, A; Karabetsou, N; O'Sullivan, J; Kent, N; Proudfoot, N; Mellor, J			Isw1 chromatin remodeling ATPase coordinates transcription elongation and termination by RNA polymerase II	CELL			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; IN-VIVO; PROCESSING FACTORS; GENE-EXPRESSION; CAPPING ENZYME; HISTONE H3; YEAST; COMPLEX; RECRUITMENT	We demonstrate that distinct forms of the yeast chromatin-remodeling enzyme lsw1p sequentially regulate each stage of the transcription cycle. The lsw1a complex (lswlp/loc3p) represses gene expression at initiation through specific positioning of a promoter proximal dinucleosome, whereas the lsw1b complex (lswlp/loc2p/loc4p) acts within coding regions to control the amount of RNA polymerase (RNAPII) released into productive elongation and to coordinate elongation with termination and pre-mRNA processing. These effects of lsw1b are controlled via phosphorylation of the heptad repeat carboxy-terminal domain (CTD) of RNAPII and methylation of the chromatin template. The transcription elongation factor Spt4p antagonizes lsw1p and overcomes the lsw1p dependent pausing of RNAPII at the onset of the elongation cycle. Overall these studies establish the central role played by lsw1p in the coordination of transcription.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Mellor, J (corresponding author), Univ Oxford, Dept Biochem, S Pk Rd, Oxford OX1 3QU, England.	jane.mellor@bioch.ox.ac.uk	Morillon, Antonin/M-4751-2017; O'Sullivan, Justin/HDO-1639-2022; Pillay, Nischalan/F-9536-2012; Kent, Nicholas/A-4503-2010	Morillon, Antonin/0000-0002-0575-5264; O'Sullivan, Justin/0000-0003-2927-450X; Kent, Nicholas/0000-0002-4114-1307; Proudfoot, Nicholas/0000-0001-8646-3222				Adams A, 1997, METHODS YEAST GENETI; Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Badenhorst P, 2002, GENE DEV, V16, P3186, DOI 10.1101/gad.1032202; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dower K, 2002, RNA, V8, P686, DOI 10.1017/S1355838202024068; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 2003, CURR OPIN GENET DEV, V13, P119, DOI 10.1016/S0959-437X(03)00024-8; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Kulish D, 2001, MOL CELL BIOL, V21, P4162, DOI 10.1128/MCB.21.13.4162-4168.2001; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; Morillon A, 2003, SCIENCE, V300, P492, DOI 10.1126/science.1081379; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Rondon AG, 2003, EMBO J, V22, P612, DOI 10.1093/emboj/cdg047; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwartz BE, 2003, MOL CELL BIOL, V23, P6876, DOI 10.1128/MCB.23.19.6876-6886.2003; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Teng YM, 1997, J MOL BIOL, V267, P324, DOI 10.1006/jmbi.1996.0908; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Vary JC, 2003, MOL CELL BIOL, V23, P80, DOI 10.1128/MCB.23.1.80-91.2003; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503	57	140	145	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2003	115	4					425	435		10.1016/S0092-8674(03)00880-8	http://dx.doi.org/10.1016/S0092-8674(03)00880-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622597	Bronze			2022-12-28	WOS:000186627100009
J	Johnston, M; Stormo, GD				Johnston, M; Stormo, GD			Heirlooms in the attic	SCIENCE			English	Editorial Material							SEQUENCES; GENOME		Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL)	Johnston, M (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.		Stormo, Gary D/C-5367-2013; Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Stormo, Gary D/0000-0001-6896-1850; Johnston, Mark/0000-0002-4932-7229; 				Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Dermitzakis ET, 2003, SCIENCE, V302, P1033, DOI 10.1126/science.1087047; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; Kirkness EF, 2003, SCIENCE, V301, P1898, DOI 10.1126/science.1086432; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	6	6	6	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					997	+		10.1126/science.1092271	http://dx.doi.org/10.1126/science.1092271			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605357				2022-12-28	WOS:000186396300032
J	Chabre, M; Cone, R; Saibil, H				Chabre, M; Cone, R; Saibil, H			Biophysics - Is rhodopsin dimeric in native rods?	NATURE			English	Editorial Material							X-RAY-DIFFRACTION; MEMBRANES; MICROSCOPY; DIFFUSION; RECEPTORS		Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol, F-06560 Valbonne, France; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Johns Hopkins University; University of London; Birkbeck University London	Chabre, M (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol, F-06560 Valbonne, France.							BLASIE JK, 1969, J MOL BIOL, V39, P407, DOI 10.1016/0022-2836(69)90135-1; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CHABRE M, 1975, BIOCHIM BIOPHYS ACTA, V382, P322, DOI 10.1016/0005-2736(75)90274-6; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; SAIBIL H, 1976, NATURE, V262, P266, DOI 10.1038/262266a0; Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200	10	89	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					30	31		10.1038/426030b	http://dx.doi.org/10.1038/426030b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603306				2022-12-28	WOS:000186370800030
J	Lu, D; Searles, MA; Klug, A				Lu, D; Searles, MA; Klug, A			Crystal structure of a zinc-finger - RNA complex reveals two modes of molecular recognition	NATURE			English	Article							TRANSCRIPTION FACTOR IIIA; 5S RNA; DNA RECOGNITION; BINDING; PROTEIN; OOCYTES; TFIIIA	Zinc-finger proteins of the classical Cys(2)His(2) type are the most frequently used class of transcription factor and account for about 3% of genes in the human genome(1,2). The zinc-finger motif was discovered(3) during biochemical studies on the transcription factor TFIIIA, which regulates the 5S ribosomal RNA genes of Xenopus laevis(4,5). Zinc-fingers mostly interact with DNA, but TFIIIA binds not only specifically to the promoter DNA, but also to 5S RNA itself(6-9). Increasing evidence indicates that zinc-fingers are more widely used to recognize RNA(10-13). There have been numerous structural studies on DNA binding(14), but none on RNA binding by zinc-finger proteins. Here we report the crystal structure of a three-finger complex with 61 bases of RNA, derived(15) from the central regions of the complete nine-finger TFIIIA - 5S RNA complex. The structure reveals two modes of zinc-finger binding, both of which differ from that in common use for DNA: first, the zinc-fingers interact with the backbone of a double helix; and second, the zinc-fingers specifically recognize individual bases positioned for access in otherwise intricately folded 'loop' regions of the RNA.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Klug, A (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	akl@mrc-lmb.cam.ac.uk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BOGENHAGEN DF, 1992, NUCLEIC ACIDS RES, V20, P2639, DOI 10.1093/nar/20.11.2639; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clamp M, 2003, NUCLEIC ACIDS RES, V31, P38, DOI 10.1093/nar/gkg083; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; Finerty PJ, 1997, J MOL BIOL, V271, P195, DOI 10.1006/jmbi.1997.1177; Friesen WJ, 1997, J BIOL CHEM, V272, P10994; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ladomery M, 2003, J CELL SCI, V116, P1539, DOI 10.1242/jcs.00324; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nagai K, 2001, BIOCHEM SOC T, V29, P15; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; Searles MA, 2000, J MOL BIOL, V301, P47, DOI 10.1006/jmbi.2000.3946; Setzer DR, 1996, RNA, V2, P1254; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; Theunissen O, 1998, EUR J BIOCHEM, V258, P758, DOI 10.1046/j.1432-1327.1998.2580758.x; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	30	149	154	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					96	100		10.1038/nature02088	http://dx.doi.org/10.1038/nature02088			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603324				2022-12-28	WOS:000186370800049
J	Qurishi, N; Kreuzberg, C; Luchters, G; Effenberger, W; Kupfer, B; Sauerbruch, T; Rockstroh, JK; Spengler, U				Qurishi, N; Kreuzberg, C; Luchters, G; Effenberger, W; Kupfer, B; Sauerbruch, T; Rockstroh, JK; Spengler, U			Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR; INFECTED PATIENTS; DRUG-USERS; NATURAL-HISTORY; DISEASE; PROGRESSION; VIREMIA; IMPACT; HCV	Background Highly active antiretroviral therapy (HAART) has improved the prognosis of HIV infection. However, replication of hepatitis C virus (HCV) is not inhibited by HAART, and treatment-related hepatotoxicity is common. To clarify the effect of HAART in HIV/HCV-coinfected patients, we studied liver-related mortality and overall mortality in 285 patients who were regularly treated during the period 1990-2002 at our department. Methods Survival was analysed retrospectively by Kaplan-Meier and Cox's regression analyses after patients (81% haemophiliacs) had been stratified into three groups according to their antiretroviral therapy (HAART n=93, available after 1995; treatment exclusively with nucleoside analogues n=55, available after 1992; or no treatment, n=137). Findings Liver-related mortality rates were 0.45, 0.69, and 1.70 per 100 person-years in the HAART, antiretroviral-treatment, and untreated groups. Kaplan-Meier analysis of liver related mortality confirmed the significant survival benefit in patients with antiretroviral therapy (p=0.018), and regression analysis identified HAART (odds ratio 0.106 [95% CI 0.020-0.564]), antiretroviral treatment (0.283 [0.103-0.780]), CD4-positive T-cell count (0.746 [0.641-0.868] per 0.05X10(9) cells/L), serum cholinesterase (0.962 [0.938-0.986] per 100 U/L), and age (1.065 [1.027-1.105] per year) as independent predictors of liver-related survival. Severe drug-related hepatotoxicity was seen in five patients treated with nucleoside analogues alone and 13 treated with HAART. No patient died from drug-related hepatotoxicity. Interpretation In addition to improved overall survival, antiretroviral therapy significantly reduced long-term liver related mortality in our patients. This survival benefit seems to outweigh by far the associated risks of severe hepatotoxicity.	Univ Bonn, Med Klin & Poliklin 1, Dept Internal Med, D-53105 Bonn, Germany; Univ Bonn, Inst Expt Hematol & Transfus Med, D-53105 Bonn, Germany; Univ Bonn, Inst Microbiol & Immunol, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Spengler, U (corresponding author), Univ Bonn, Med Klin & Poliklin 1, Dept Internal Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.	spengler@uni-bonn.de						Benhamou Y, 2001, HEPATOLOGY, V34, P283, DOI 10.1053/jhep.2001.26517; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; Cacoub P, 2001, CLIN INFECT DIS, V32, P1207, DOI 10.1086/319747; Carr A, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(05)62892-9; *CDC, 1986, MMWR-MORBID MORTAL W, V35, P334; Daar ES, 2001, J INFECT DIS, V183, P589, DOI 10.1086/318539; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; Delladetsima J, 2002, HAEMOPHILIA, V8, P668, DOI 10.1046/j.1365-2516.2002.00670.x; Di Martino V, 2001, HEPATOLOGY, V34, P1193, DOI 10.1053/jhep.2001.29201; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; Fialaire P, 1999, J INFECT DIS, V180, P574, DOI 10.1086/314910; Garcia-Samaniego J, 1998, J HEPATOL, V28, P526, DOI 10.1016/S0168-8278(98)80334-6; HAYASHI PH, 1991, J MED VIROL, V33, P177, DOI 10.1002/jmv.1890330307; Hernandez-Aguado I, 2001, EUR J EPIDEMIOL, V17, P539, DOI 10.1023/A:1014560431726; IMBERTI L, 1991, J VIROL METHODS, V34, P233, DOI 10.1016/0166-0934(91)90103-7; MARTIN P, 1989, GASTROENTEROLOGY, V97, P1559, DOI 10.1016/0016-5085(89)90405-8; Martin-Carbonero L, 2001, AIDS RES HUM RETROV, V17, P1467, DOI 10.1089/08892220152644160; Martinez-Sierra C, 2003, CLIN INFECT DIS, V36, P491, DOI 10.1086/367643; MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824; MILITO AD, 1999, J MED VIROL, V57, P140; Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perez-Olmeda M, 2000, AIDS, V14, P212, DOI 10.1097/00002030-200001280-00023; Pol S, 2002, J VIRAL HEPATITIS, V9, P1, DOI 10.1046/j.1365-2893.2002.00326.x; Puoti M, 2000, J ACQ IMMUN DEF SYND, V24, P211; Ragni MV, 1999, J INFECT DIS, V180, P2027, DOI 10.1086/315143; Ragni MV, 2001, J INFECT DIS, V183, P1112, DOI 10.1086/319273; Rizzieri DA, 1997, LANCET, V349, P775, DOI 10.1016/S0140-6736(05)60200-0; Rockstroh JK, 1996, AM J GASTROENTEROL, V91, P2563; Rockstroh JK, 1998, AIDS, V12, pS42; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808; Saves M, 1999, AIDS, V13, pF115, DOI 10.1097/00002030-199912030-00002; SHERMAN KE, 1991, J INFECT DIS, V163, P414, DOI 10.1093/infdis/163.2.414; Soriano V, 1999, EUR J EPIDEMIOL, V15, P1, DOI 10.1023/A:1007506617734; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; Sterling RK, 2003, JAIDS-J ACQ IMM DEF, V32, P30, DOI 10.1097/00126334-200301010-00005; Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V288, P199, DOI 10.1001/jama.288.2.199; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Takamatsu J, 2001, HAEMOPHILIA, V7, P575, DOI 10.1046/j.1365-2516.2001.00567.x; TELFER PT, 1994, BRIT J HAEMATOL, V88, P397, DOI 10.1111/j.1365-2141.1994.tb05038.x; Toyoda H, 1999, CLIN INFECT DIS, V29, P1332, DOI 10.1086/313480; VANGEMEN B, 1993, J VIROL METHODS, V43, P177, DOI 10.1016/0166-0934(93)90075-3; Vento S, 1998, AIDS, V12, P116; Woitas RP, 1997, J IMMUNOL, V159, P1012; Yokozaki S, 2000, BLOOD, V96, P4293; Zylberberg H, 1998, CLIN INFECT DIS, V26, P1104, DOI 10.1086/520281	48	398	407	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1708	1713		10.1016/S0140-6736(03)14844-1	http://dx.doi.org/10.1016/S0140-6736(03)14844-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643119				2022-12-28	WOS:000186767700009
J	Grunewald, K; Desai, P; Winkler, DC; Heymann, JB; Belnap, DM; Baumeister, W; Steven, AC				Grunewald, K; Desai, P; Winkler, DC; Heymann, JB; Belnap, DM; Baumeister, W; Steven, AC			Three-dimensional structure of herpes simplex virus from cryo-electron tomography	SCIENCE			English	Article							CELLS; DNA; MICROSCOPY	Herpes simplex virus, a DNA virus of high complexity, consists of a nucleocapsid surrounded by the tegument-a protein compartment-and the envelope. The latter components, essential for infectivity, are pleiomorphic. Visualized in cryo-electron tomograms of isolated virions, the tegument was seen to form an asymmetric cap: On one side, the capsid closely approached the envelope; on the other side, they were separated by similar to35 nanometers of tegument. The tegument substructure was particulate, with some short actin-like. laments. The envelope contained 600 to 750 glycoprotein spikes that varied in length, spacing, and in the angles at which they emerge from the membrane. Their distribution was nonrandom, suggesting functional clustering.	NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Johns Hopkins University; California Institute of Technology; Max Planck Society	Steven, AC (corresponding author), NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA.	Alasdair_Steven@nih.gov	Grünewald, Kay/AAW-3652-2020; Heymann, Bernard/F-6825-2011; Heymann, Bernard/H-8265-2019	Grünewald, Kay/0000-0002-4788-2691; Heymann, Bernard/0000-0002-8872-5326; Winkler, Dennis/0000-0003-1445-6554	NIAID NIH HHS [R01 AI033077, AI33077, R01 AI033077-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR027002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker T., 1997, STRUCTURAL BIOL VIRU, P38; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Frangakis AS, 2001, J STRUCT BIOL, V135, P239, DOI 10.1006/jsbi.2001.4406; Frank J, 1992, ELECT TOMOGRAPHY; Granzow H, 2001, J VIROL, V75, P3675, DOI 10.1128/JVI.75.8.3675-3684.2001; Grunewald K, 2003, BIOPHYS CHEM, V100, P577, DOI 10.1016/S0301-4622(02)00307-1; Lee GE, 2003, J VIROL, V77, P2038, DOI 10.1128/JVI.77.3.2038-2045.2003; McIntosh JR, 2001, J CELL BIOL, V153, pF25, DOI 10.1083/jcb.153.6.F25; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Mettenleiter TC, 2002, J VIROL, V76, P1537, DOI 10.1128/JVI.76.4.1537-1547.2002; Newcomb WW, 2000, J VIROL, V74, P1663, DOI 10.1128/JVI.74.4.1663-1673.2000; NEWCOMB WW, 1993, J MOL BIOL, V232, P499, DOI 10.1006/jmbi.1993.1406; Newcomb WW, 2001, J VIROL, V75, P10923, DOI 10.1128/JVI.75.22.10923-10932.2001; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Roizman B., 1974, COMPREHENSIVE VIROLO, P229, DOI DOI 10.1007/978-1-4684-2703-5_4; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; Skepper JN, 2001, J VIROL, V75, P5697, DOI 10.1128/JVI.75.12.5697-5702.2001; Smith GA, 2002, ANNU REV CELL DEV BI, V18, P135, DOI 10.1146/annurev.cellbio.18.012502.105920; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; STANNARD LM, 1987, J GEN VIROL, V68, P715, DOI 10.1099/0022-1317-68-3-715; STEVEN AC, 1997, STRUCTURAL BIOL VIRU, P312; Trus BL, 1999, J VIROL, V73, P2181, DOI 10.1128/JVI.73.3.2181-2192.1999; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Whitley RJ, FIELDS VIROLOGY FIEL, V2, P297; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999; Zhou ZH, 2000, SCIENCE, V288, P877, DOI 10.1126/science.288.5467.877	28	407	420	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1396	1398		10.1126/science.1090284	http://dx.doi.org/10.1126/science.1090284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631040				2022-12-28	WOS:000186683500052
J	White, N; Thompson, M; Barwise, T				White, N; Thompson, M; Barwise, T			Understanding the thermal evolution of deep-water continental margins	NATURE			English	Review							EXTENSIONAL SEDIMENTARY BASINS; STRAIN-RATE; HEAT-FLOW; INVERSE METHOD; MODEL; OCEAN; DEFORMATION; SUBSIDENCE; MAGMATISM; VELOCITY	Areas of exploration for new hydrocarbons are changing as the hydrocarbon industry seeks new resources for economic and political reasons. Attention has turned from easily accessible onshore regions such as the Middle East to offshore continental shelves. Over the past ten years, there has been a marked shift towards deep-water continental margins (500-2,500 m below sea level). In these more hostile regions, the risk and cost of exploration is higher, but the prize is potentially enormous. The key to these endeavours is a quantitative understanding of the structure and evolution of the thinned crust and lithosphere that underlie these margins.	Dept Earth Sci, Bullard Labs, Cambridge CB3 0EZ, England; BP Explorat Operating Co Ltd, Staines TW18 1DY, Middx, England	University of Cambridge; BP	White, N (corresponding author), Trinity Coll Dublin, Dept Geol, Dublin 2, Ireland.			White, Nicky/0000-0002-4460-299X	Natural Environment Research Council [NER/A/S/2000/00439] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Aki K., 1980, QUANTITATIVE SEISMOL; BASSI G, 1995, GEOPHYS J INT, V122, P195, DOI 10.1111/j.1365-246X.1995.tb03547.x; Bauer K, 2000, J GEOPHYS RES-SOL EA, V105, P25829, DOI 10.1029/2000JB900227; Beavan J, 2001, J GEOPHYS RES-SOL EA, V106, P741, DOI 10.1029/2000JB900302; Bellingham P, 2000, BASIN RES, V12, P219, DOI 10.1046/j.1365-2117.2000.00122.x; BOWN JW, 1995, RIFTED OCEAN CONTINE; BURNHAM AK, 1989, GEOCHIM COSMOCHIM AC, V53, P2649, DOI 10.1016/0016-7037(89)90136-1; Chian DP, 1995, J GEOPHYS RES-SOL EA, V100, P24239, DOI 10.1029/95JB02162; Davis M, 2002, GEOPHYS J INT, V149, P524, DOI 10.1046/j.1365-246X.2002.01666.x; *DOUGL WESTW INF S, 2003, 4 DOUGL WESTW INF SY; ENGLAND P, 1982, GEOPHYS J ROY ASTR S, V70, P295, DOI 10.1111/j.1365-246X.1982.tb04969.x; FOUCHER JP, 1992, TECTONOPHYSICS, V203, P77, DOI 10.1016/0040-1951(92)90216-S; Gallagher K, 1997, MAR PETROL GEOL, V14, P201, DOI 10.1016/S0264-8172(96)00068-2; Gassmann F., 1951, VIERTEL NAT GES ZURI, V96, P1; HAINES AJ, 1993, J GEOPHYS RES-SOL EA, V98, P12057, DOI 10.1029/93JB00892; HOLBROOK WS, 1993, NATURE, V364, P433, DOI 10.1038/364433a0; Holbrook WS, 2001, EARTH PLANET SC LETT, V190, P251, DOI 10.1016/S0012-821X(01)00392-2; Holt WE, 2000, J GEOPHYS RES-SOL EA, V105, P19185, DOI 10.1029/2000JB900045; Kreemer C, 2000, EARTH PLANETS SPACE, V52, P765, DOI 10.1186/BF03352279; KUENEN PH, 1950, J GEOL, V58, P91, DOI 10.1086/625710; KUYKENDALL C, 2003, MK HUBBERT HIS HEIRS; LEPICHON X, 1981, J GEOPHYS RES, V86, P3708, DOI 10.1029/JB086iB05p03708; Louden KE, 1999, PHILOS T R SOC A, V357, P767, DOI 10.1098/rsta.1999.0352; LOUDEN KE, 1991, J GEOPHYS RES-SOL EA, V96, P16131, DOI 10.1029/91JB01453; Louden KE, 1997, EARTH PLANET SC LETT, V151, P233, DOI 10.1016/S0012-821X(97)81851-1; LUCAZEAU F, 1985, EARTH PLANET SC LETT, V74, P92, DOI 10.1016/0012-821X(85)90169-4; Malvern L.E, 1969, INTRO MECH CONTINUOU, P306; MARTON LG, 2000, GEOPHYS MONOGR, V115; MCKENZIE D, 1978, EARTH PLANET SC LETT, V40, P25, DOI 10.1016/0012-821X(78)90071-7; MILLIMAN JD, 1992, J GEOL, V100, P525, DOI 10.1086/629606; Minshull TA, 2002, PHILOS T R SOC A, V360, P2839, DOI 10.1098/rsta.2002.1059; Newman R, 1999, PHILOS T R SOC A, V357, P805, DOI 10.1098/rsta.1999.0353; NOTTVEDT A, 2000, DYNAMICS NORWEGIAN C; Parrish J.T., 1987, MARINE PETROLEUM SOU, V26, P199; PEGRUM RM, 2001, AM ASS PETR GEOL REG; RUTHERFORD SR, 1989, GEOPHYSICS, V54, P680, DOI 10.1190/1.1442696; SHUEY RT, 1985, GEOPHYSICS, V50, P609, DOI 10.1190/1.1441936; STECKLER MS, 1978, EARTH PLANET SC LETT, V41, P1, DOI 10.1016/0012-821X(78)90036-5; Watts AB, 1998, EARTH PLANET SC LETT, V156, P239, DOI 10.1016/S0012-821X(98)00018-1; Wessel P., 1995, EOS T AM GEOPHYS UN, V79, P329, DOI [10.1029/95EO00198, DOI 10.1029/95EO00198]; WHITE N, 1994, EARTH PLANET SC LETT, V122, P351, DOI 10.1016/0012-821X(94)90008-6; White N., 2002, J GEOPHYS RES, V107; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; Whitmarsh RB, 2001, NATURE, V413, P150, DOI 10.1038/35093085; ZOEPPRITZ K, 1919, GOTTINGER NACHR, V1, P66, DOI DOI 10.1190/1.9781560801931.CH3N	45	52	57	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					334	343		10.1038/nature02133	http://dx.doi.org/10.1038/nature02133			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628063				2022-12-28	WOS:000186660800055
J	Gerdesmeyer, L; Wagenpfeil, S; Haake, M; Maier, M; Loew, M; Wortler, K; Lampe, R; Seil, R; Handle, G; Gassel, S; Rompe, JD				Gerdesmeyer, L; Wagenpfeil, S; Haake, M; Maier, M; Loew, M; Wortler, K; Lampe, R; Seil, R; Handle, G; Gassel, S; Rompe, JD			Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTHROSCOPIC TREATMENT; CALCAREOUS TENDINITIS; FOLLOW-UP; SHOULDER; LITHOTRIPSY; CAVITATION; DEPOSITS; BLIND; ESWL	Context Extracorporeal shock wave therapy (ESWT) has been used to treat calcific tendonitis of the shoulder, but trials of ESWT for this purpose have had methodological deficiencies and thus there is limited evidence for its effectiveness. Objective To determine whether fluoroscopy-guided ESWT improves function, reduces pain, and diminishes the size of calcific deposits in patients with chronic calcific tendonitis of the shoulder. Design, Setting, and Participants Double-blind, randomized, placebo-controlled trial conducted between February 1997 and March 2001 among 144 patients (of 164 screened) recruited from referring primary care physicians, orthopedic surgeons, and sports physicians in 7 orthopedic departments in Germany and Austria. Interventions Either high-energy ESWT, low-energy ESWT, or placebo (sham treatment). The 2 ESWT groups received the same cumulative energy dose. Patients in all 3 groups received 2 treatment sessions approximately 2 weeks apart, followed by physical-therapy. Main Outcome Measures The primary end point was the change in the mean Constant and Murley Scale (CMS) score from baseline to 6 months after the intervention. Secondary end points were changes in the mean CMS scores at 3 and 12 months, as well as changes in self-rated pain and radiographic change in size of calcific deposits at 3, 6, and 12 months. Results Of 144 patients enrolled, all completed treatment as randomized and 134 completed the 6-month follow-up. Both high-energy and low-energy ESWT resulted in significant improvement in the 6-month mean (95% confidence interval [CI]) CMS score compared with sham treatment (high-energy ESWT: 31.0 [26.7-35.3] points; low-energy ESWT: 15.0 [10.2-19.8] points; sham treatment: 6.6 [1.4-11.8] points; P<.001 for both comparisons). Patients who received high-energy ESWT also had significant 6-month CMS improvements compared with those who received low-energy ESWT (P<.001). We found similar results for both the 3-month and 12-month CMS comparisons, as well as for self-rated pain and radiographic changes at 3, 6, and 12 months. Conclusions Both high-energy and low-energy ESWT appeared to provide a beneficial effect on shoulder function, as well as on self-rated pain and diminished size of calcifications, compared with placebo. Furthermore, high-energy ESWT appeared to be superior to low-energy ESWT.	Tech Univ Munich, Dept Orthoped Surg & Sportstraumatol, D-81675 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-81675 Munich, Germany; Tech Univ Munich, Dept Radiol, D-81675 Munich, Germany; Univ Regensburg, Dept Orthoped Surg, Bad Abbach, Germany; Univ Munich, Dept Orthoped Surg, Munich, Germany; Heidelberg Univ, Dept Orthoped Surg, Heidelberg, Germany; Univ Homburg, Dept Orthoped Surg, D-6650 Homburg, Germany; Univ Innsbruck, Dept Orthoped Surg, A-6020 Innsbruck, Austria; Univ Bonn, Dept Orthoped Surg, D-5300 Bonn, Germany; Johannes Gutenberg Univ Mainz, Sch Med, Dept Orthoped Surg, D-6500 Mainz, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; University of Regensburg; University of Munich; Ruprecht Karls University Heidelberg; University of Innsbruck; University of Bonn; Johannes Gutenberg University of Mainz	Gerdesmeyer, L (corresponding author), Tech Univ Munich, Dept Orthoped Surg & Sportstraumatol, Ismaninger Str 22, D-81675 Munich, Germany.	Gerdesmeyer@aol.com	Gerdesmeyer, Ludger/S-7961-2019; Seil, Romain/AAX-7873-2020; Zmistowski, Ben/AAI-7901-2020	Lampe, Renee/0000-0002-1016-0249				ARK JW, 1992, ARTHROSCOPY, V8, P183, DOI 10.1016/0749-8063(92)90034-9; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Bosworth BM, 1941, J AMER MED ASSOC, V116, P2477, DOI 10.1001/jama.1941.02820220019004; Chiou HJ, 2002, J ULTRAS MED, V21, P289, DOI 10.7863/jum.2002.21.3.289; Conboy VB, 1996, J BONE JOINT SURG BR, V78B, P229, DOI 10.1302/0301-620X.78B2.0780229; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Cosentino R, 2003, ANN RHEUM DIS, V62, P248, DOI 10.1136/ard.62.3.248; Daecke W, 2002, J SHOULDER ELB SURG, V11, P476, DOI 10.1067/mse.2002.126614; Daecke W, 2002, ORTHOPADE, V31, P645, DOI 10.1007/s00132-002-0324-y; DELACRETAZ G, 1995, ULTRASOUND MED BIOL, V21, P97, DOI 10.1016/0301-5629(94)00091-3; Durst HB, 2002, J BONE JOINT SURG BR, V84B, P744, DOI 10.1302/0301-620X.84B5.12282; Ebenbichler GR, 1999, NEW ENGL J MED, V340, P1533, DOI 10.1056/NEJM199905203402002; *EUR AG EV MED PRO, 1996, ICH TOP E 6 GUID GOO; *EUR AG EV MED PRO, 1998, ICH TOP E 9 STAT PRI; GARTNER J, 1993, Z ORTHOP GRENZGEB, V131, P461, DOI 10.1055/s-2008-1040055; GAZIELLY DF, 1997, CUFF, P181; GRANZ B, 1992, J STONE DIS, V4, P123; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; Haake M, 2002, CLIN ORTHOP RELAT R, P323; Haake M, 2001, INT J TECHNOL ASSESS, V17, P612, DOI 10.1017/S0266462301107166; HARMON PH, 1958, AM J SURG, V95, P527, DOI 10.1016/0002-9610(58)90436-7; *IEC, 1998, PUBL IEC; JIM YF, 1993, SKELETAL RADIOL, V22, P183, DOI 10.1007/BF00206150; KILCOYNE RF, 1989, AM J ROENTGENOL, V153, P795, DOI 10.2214/ajr.153.4.795; Loew M, 1999, J BONE JOINT SURG BR, V81B, P863, DOI 10.1302/0301-620X.81B5.9374; LOEW M, 1993, Z ORTHOP GRENZGEB, V131, P470, DOI 10.1055/s-2008-1040056; Loew M, 1996, Z ORTHOP GRENZGEB, V134, P354, DOI 10.1055/s-2008-1039774; LOEW M, 1995, UROLOGE A, V34, P49; Loske AM, 2002, PHYS MED BIOL, V47, P3945, DOI 10.1088/0031-9155/47/22/303; Maier M, 2002, Z ORTHOP GRENZGEB, V140, P656, DOI 10.1055/s-2002-36033; Maier M, 2002, ARCH ORTHOP TRAUM SU, V122, P436, DOI 10.1007/s00402-002-0420-9; Maier M, 2001, ARCH ORTHOP TRAUM SU, V121, P371, DOI 10.1007/s004020000255; Maier M, 1997, Z ORTHOP GRENZGEB, V135, pOA20; MOLE D, 1993, REV CHIR ORTHOP, V79, P532; Perlick L, 1999, Z ORTHOP GRENZGEB, V137, P10, DOI 10.1055/s-2008-1037029; Rochwerger A, 1999, CLIN RHEUMATOL, V18, P313, DOI 10.1007/s100670050108; Rompe JD, 1998, J BONE JOINT SURG BR, V80B, P546, DOI 10.1302/0301-620X.80B3.8434; Rompe JD, 1998, J SHOULDER ELB SURG, V7, P505, DOI 10.1016/S1058-2746(98)90203-8; Rompe JD, 2002, Z ORTHOP GRENZGEB, V140, P267, DOI 10.1055/s-2002-32477; Rompe JD, 2001, CLIN ORTHOP RELAT R, P72; Rompe JD, 2000, Z ORTHOP GRENZGEB, V138, P335, DOI 10.1055/s-2000-10158; ROMPE JD, 1995, CLIN ORTHOP RELAT R, V321, P196; Rubenthaler F, 1997, Z ORTHOP GRENZGEB, V135, P354, DOI 10.1055/s-2008-1039401; Rupp S, 2000, ORTHOPADE, V29, P852, DOI 10.1007/s001320050536; Sapozhnikov OA, 2002, J ACOUST SOC AM, V112, P1183, DOI 10.1121/1.1500754; Schmitt J, 2001, J BONE JOINT SURG BR, V83B, P873, DOI 10.1302/0301-620X.83B6.11591; Seil R, 1999, Z ORTHOP GRENZGEB, V137, P310, DOI 10.1055/s-2008-1039717; Speed CA, 2002, J BONE JOINT SURG BR, V84B, P509, DOI 10.1302/0301-620X.84B4.12318; UHTHOFF HK, 1998, SHOULDER, P989; Vaterlein N, 2000, ARCH ORTHOP TRAUM SU, V120, P403, DOI 10.1007/PL00013770; Wang CJ, 2003, AM J SPORT MED, V31, P425, DOI 10.1177/03635465030310031701; Welfling J, 1965, Rev Rhum Mal Osteoartic, V32, P325	52	241	252	3	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2573	2580		10.1001/jama.290.19.2573	http://dx.doi.org/10.1001/jama.290.19.2573			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744DQ	14625334	Bronze			2022-12-28	WOS:000186613000027
J	Waisbren, SE; Albers, S; Amat, S; Ampola, M; Brewster, TG; Demmer, L; Eaton, RB; Greenstein, R; Korson, M; Larson, C; Marsden, D; Msall, M; Naylor, EW; Pueschel, S; Seashore, M; Shih, VE; Levy, HL				Waisbren, SE; Albers, S; Amat, S; Ampola, M; Brewster, TG; Demmer, L; Eaton, RB; Greenstein, R; Korson, M; Larson, C; Marsden, D; Msall, M; Naylor, EW; Pueschel, S; Seashore, M; Shih, VE; Levy, HL			Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TANDEM MASS-SPECTROMETRY; INBORN-ERRORS; DEFICIENCY; METABOLISM; INFANTS; PROGRAM; HEALTH; TESTS	Context Tandem mass spectrometry now allows newborn screening for more than 20 biochemical genetic disorders. Questions about the effectiveness and risks of expanded newborn screening for biochemical genetic disorders need to be answered prior to its widespread acceptance as a state-mandated program. Objectives To compare newborn identification by expanded screening with clinical identification of biochemical genetic disorders and to assess the impact on families of a false-positive screening result compared with a normal result in the expanded newborn screening program. Design Prospective study involving an inception cohort of newly diagnosed children. Setting Massachusetts, Maine, and a private laboratory in Pennsylvania with expanded newborn screening; other New England states with limited screening. Participants Families of 50 affected children identified through expanded newborn screening (82% of eligible cases); 33 affected children identified clinically (97% of eligible cases); 94 screened children with false-positive results (75% of eligible cases); and 81 screened children with normal results (63% of eligible cases). Main Outcome Measures Child's health and development and the Parental Stress Index. Results Within the first 6 months of life, 28% of children identified by newborn screening compared with 55% of clinically identified children required hospitalization (P=.02). One child identified by newborn screening compared with 8 (42%) identified clinically performed in the range of mental retardation (P<.001). Mothers in the screened group reported lower overall stress on the Parental Stress Index than mothers in the clinically identified group (z=3.38, P<.001). Children with false-positive results compared with children with normal results were twice as likely to experience hospitalization (21% [n=20] vs 10% [n=8], respectively; P=.06). Mothers of children in the false-positive group compared with mothers of children with normal screening results attained higher scores on the Parental Stress Index (z=4.25, P<.001) and the Parent-Child Dysfunction subscale (z=5.30, P<.001). Conclusions Expanded newborn screening may lead to improved health outcomes for affected children and lower stress for their parents. However, false-positive screening results may place families at risk for increased stress and parent-child dysfunction.	Childrens Hosp Boston, Boston, MA 02115 USA; Univ Munster, D-4400 Munster, Germany; Eastern Maine Med Ctr, Bangor, ME USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Maine Med Ctr, Portland, ME 04102 USA; Univ Massachusetts, Sch Med, New England Newborn Screening Program, Jamaica Plain, MA USA; Rhode Isl Hosp, Providence, RI USA; Univ Connecticut, Ctr Hlth, Farmington, CT USA; Pediat Screening Inc, Bridgeville, PA USA; Yale Univ, Sch Med, New Haven, CT USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; University of Munster; Eastern Maine Medical Center; Tufts Medical Center; Maine Medical Center; University of Massachusetts System; Lifespan Health Rhode Island; Rhode Island Hospital; University of Connecticut; Yale University; Harvard University; Massachusetts General Hospital	Waisbren, SE (corresponding author), Childrens Hosp Boston, IC Smith 108,300 Longwood Ave, Boston, MA 02115 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002085] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG02085] Funding Source: Medline; PHS HHS [5H46 MC 00158] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abidin RR., 1995, PSYCHOL ASSESSMENT R; Albers S, 2001, J INHERIT METAB DIS, V24, P303, DOI 10.1023/A:1010391623104; Andresen BS, 2001, AM J HUM GENET, V68, P1408, DOI 10.1086/320602; Atkinson K, 2001, PUBLIC HEALTH REP, V116, P122, DOI 10.1016/S0033-3549(04)50004-3; Bayley N, 1993, BAYLEY SCALES INFANT; Bear M, 1998, PUBLIC HEALTH NURS, V15, P50, DOI 10.1111/j.1525-1446.1998.tb00321.x; Chace DH, 2001, CHEM REV, V101, P445, DOI 10.1021/cr990077+; Cunningham G, 2002, NEW ENGL J MED, V346, P1084, DOI 10.1056/NEJM200204043461411; Filiano JJ, 2002, PEDIATR NEUROL, V26, P201, DOI 10.1016/S0887-8994(01)00384-8; GUTHRIE R, 1968, Birth Defects Original Article Series, V4, P92; GUTHRIE R, 1963, PEDIATRICS, V32, P338; Hermeren G, 1999, ACTA PAEDIATR, V88, P99, DOI 10.1080/080352599750029501; Hollingshead A. B., 1991, HDB RES DESIGN SOCIA, P351; Holtzman NA, 1999, CLIN CHEM, V45, P732; Insinga RP, 2002, J PEDIATR-US, V141, P524, DOI 10.1067/mpd.2002.128116; Leslie L K, 1996, Pediatr Rev, V17, P323, DOI 10.1542/pir.17-9-323; Levy HL, 1998, CLIN CHEM, V44, P2401; Levy HL, 2000, ANNU REV GENOM HUM G, V1, P139, DOI 10.1146/annurev.genom.1.1.139; MCNEIL TF, 1985, ACTA PSYCHIAT SCAND, V72, P491, DOI 10.1111/j.1600-0447.1985.tb02645.x; *NAT RES COUNC COM, 1975, GEN SCREEN PROGR PRI; *NEWB SCREEN TASK, 2000, PEDIATRICS, V106, P383; Paul D, 1999, PERSPECT BIOL MED, V42, P207; PIERCE GR, 1991, J PERS SOC PSYCHOL, V61, P1028, DOI 10.1037/0022-3514.61.6.1028; Pollitt RI, 1997, HEALTH TECHNOL ASSES, V1, pi; Pollitt RJ, 1999, ACTA PAEDIATR, V88, P40, DOI 10.1080/080352599750029358; Read CY, 2002, CLIN GENET, V61, P268, DOI 10.1034/j.1399-0004.2002.610405.x; Schoen EJ, 2002, PEDIATRICS, V110, P781, DOI 10.1542/peds.110.4.781; SORENSON JR, 1984, PEDIATRICS, V73, P183; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; *STATACORP, 1999, STAT STAT SOFTW REL; THERRELL BL, US NATL SCREENING ST; Thomason MJ, 1998, J PUBLIC HEALTH MED, V20, P331, DOI 10.1093/oxfordjournals.pubmed.a024777; THORNDIKE RL, 1986, STANFORDBINET INTELL; TYMSTRA T, 1986, FAM PRACT, V3, P92, DOI 10.1093/fampra/3.2.92; Waisbren SE, 2002, J INHERIT METAB DIS, V25, P599, DOI 10.1023/A:1022003726224; Wang SS, 1999, GENET MED, V1, P332; Weglage J, 2001, PEDIATR RES, V49, P532, DOI 10.1203/00006450-200104000-00015; Wilcken B, 2003, NEW ENGL J MED, V348, P2304, DOI 10.1056/NEJMoa025225; Zytkovicz TH, 2001, CLIN CHEM, V47, P1945	39	245	249	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2564	2572		10.1001/jama.290.19.2564	http://dx.doi.org/10.1001/jama.290.19.2564			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744DQ	14625333				2022-12-28	WOS:000186613000026
J	Mandelblatt, J; Saha, S; Teutsch, S; Hoerger, T; Siu, AL; Atkins, D; Klein, J; Helfand, M				Mandelblatt, J; Saha, S; Teutsch, S; Hoerger, T; Siu, AL; Atkins, D; Klein, J; Helfand, M		Cost Work Grp US Preventive Serv	The cost-effectiveness of screening mammography beyond age 65 years: A systematic review for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							BREAST-CANCER PATIENTS; OLDER WOMEN; LIFE-EXPECTANCY; ELDERLY-WOMEN; PATTERNS; SURVIVAL; MODEL; INTERVENTIONS; COMORBIDITY; DIAGNOSIS	Purpose: There are few data on the effects of disease biology and competing mortality on the effectiveness of screening women for breast cancer after age 65 years. The authors performed a review to determine the costs and benefits of mammography screening after age 65 years. Data Sources: Cost-effectiveness articles published between January 1989 and March 2002. Study Selection: Studies were identified by using MEDLINE and the National Health Service Economic Evaluation Database. The authors included research on screening after age 65 years conducted from a societal or government perspective; reviews and analyses of other technologies were excluded. Data Synthesis: 115 studies were identified and 10 met inclusion criteria. One study modeled age-dependent assumptions of disease biology. No study fully captured the potential harms of screening, including anxiety associated with false-positive results, overdiagnosis, and previous knowledge of cancer or living longer with the consequences of treatment. Studies differed in the specific strategies compared and in analytic approaches. On average, extending biennial screening to age 75 or 80 years was estimated to cost $34 000 to $88 000 (2002 U.S. dollars) per life-year gained, compared with stopping screening at age 65 years. Two studies suggested that it was more cost-effective to target healthy women than those with several competing risks for death. Conclusions: Current estimates suggest that biennial breast cancer screening after age 65 years reduces mortality at reasonable costs for women without clinically significant comorbid conditions. More data are needed on disease biology and preferences for benefits and harms in older women.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA; Merck & Co Inc, West Point, PA USA; Univ N Carolina, Res Triangle Inst, Res Triangle Pk, NC USA; Mt Sinai Sch Med, New York, NY USA; Agcy Healthcare Res & Qual, Rockville, MD USA; Univ Rochester, Rochester, NY USA	Georgetown University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; VA Portland Health Care System; Merck & Company; Research Triangle Institute; University of North Carolina; Icahn School of Medicine at Mount Sinai; Agency for Healthcare Research & Quality; University of Rochester	Mandelblatt, J (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 2233 Wisconsin Ave,Suite 317, Washington, DC 20007 USA.	mandelbj@georgetown.edu		Saha, Shampa/0000-0002-8305-3495; Hoerger, Thomas/0000-0003-4154-7806	NATIONAL CANCER INSTITUTE [K05CA096940, U01CA088283] Funding Source: NIH RePORTER; NCI NIH HHS [KO5 CA96940, U01CA88283] Funding Source: Medline; PHS HHS [290-97-0011, 290-97-0018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1996, COST EFFECTIVENESS H; Boer R, 1998, BRIT MED J, V317, P376; Boer R, 1999, CANCER, V86, P1506, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1506::AID-CNCR17>3.0.CO;2-2; Breen Nancy, 1999, Ethnicity and Disease, V9, P111; BROWN ML, 1992, J GERONTOL, V47, P51; CAPLAN LS, 1992, J GERONTOL, V47, P101; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DESCH CE, 1993, J CLIN ONCOL, V11, P777, DOI 10.1200/JCO.1993.11.4.777; DUFFY SW, 1995, STAT MED, V14, P1531, DOI 10.1002/sim.4780141404; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; ELLEDGE RM, 1994, J NATL CANCER I, V86, P705, DOI 10.1093/jnci/86.9.705; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Ershler W B, 1994, In Vivo, V8, P737; Ershler WB, 1997, JNCI-J NATL CANCER I, V89, P1489, DOI 10.1093/jnci/89.20.1489; Extermann M, 2000, J CLIN ONCOL, V18, P1709, DOI 10.1200/JCO.2000.18.8.1709; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; Gapstur SM, 1996, CANCER, V77, P1465, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1465::AID-CNCR7>3.0.CO;2-B; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HUTCHISON GB, 1968, JNCI-J NATL CANCER I, V41, P665; Kerlikowske K, 1999, JAMA-J AM MED ASSOC, V282, P2156, DOI 10.1001/jama.282.22.2156; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kerner JF, 2001, BREAST CANCER RES TR, V69, P81, DOI 10.1023/A:1012457703106; Lash TL, 1998, J NATL CANCER I, V90, P399, DOI 10.1093/jnci/90.5.399; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; Lyman, 1996, Cancer Control, V3, P421; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; Mandelblatt JS, 2000, CANCER, V89, P561, DOI 10.1002/1097-0142(20000801)89:3<561::AID-CNCR11>3.0.CO;2-A; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; McCarthy EP, 2000, J AM GERIATR SOC, V48, P1226, DOI 10.1111/j.1532-5415.2000.tb02595.x; McPherson CP, 2002, J AM GERIATR SOC, V50, P1061, DOI 10.1046/j.1532-5415.2002.50261.x; Messecar D C, 2000, J Gerontol Nurs, V26, P14; *NAT CANC I, 2002, SURV EP END RES SEER; Randolph WM, 2002, ANN INTERN MED, V137, P783, DOI 10.7326/0003-4819-137-10-200211190-00006; Rosenquist CJ, 1998, CANCER, V82, P2235, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V; Saha S, 2001, AM J PREV MED, V20, P36, DOI 10.1016/S0749-3797(01)00260-4; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; Smith-Bindman R, 2000, AM J MED, V108, P112, DOI 10.1016/S0002-9343(99)00406-4; SOLDO BJ, 1988, AM ELDERLY; Teutsch SM, 1999, AM J MANAG CARE, V5, P301; *US CENS BUR, 2002, CURR POP SURV JUL 20; *US PREV SERV TASK, 2002, BREAST CANC SCREEN S; Van Der Maas PJ, 1989, INT J CANCER, V43, P1055, DOI 10.1002/ijc.2910430617	44	86	86	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					835	842		10.7326/0003-4819-139-10-200311180-00011	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744ZV	14623621				2022-12-28	WOS:000186663500007
J	Heller, RF; Buchan, L; Edwards, R; Lyratzopoulos, G; McElduff, P; St Leger, S				Heller, RF; Buchan, L; Edwards, R; Lyratzopoulos, G; McElduff, P; St Leger, S			Communicating risks at the population level: application of population impact numbers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; MORTALITY; CHOLESTEROL; MEANINGFUL; SMOKING; TREAT; MEN	Communicating population risk to policy makers and the public is important, but traditional epidemiological measures of risk are difficult to understand. PIN-ER-t, a measure of the population impact of risk factors, is simpler to understand and hence may be useful.	Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Evidence Populat Hlth Unit, Manchester M13 9PT, Lancs, England	University of Manchester	Heller, RF (corresponding author), Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Evidence Populat Hlth Unit, Manchester M13 9PT, Lancs, England.	dick.heller@man.ac.uk	Buchan, Iain E/H-5767-2013; Lyratzopoulos, Georgios/B-6301-2012; Lyratzopoulos, Georgios/O-8260-2019; Edwards, Richard/O-4771-2017	Buchan, Iain E/0000-0003-3392-1650; Lyratzopoulos, Georgios/0000-0002-2873-7421; Edwards, Richard/0000-0003-2264-9823; Heller, Richard/0000-0003-3161-5967				Armitage P., 2002, STAT METHODS MED RES; Attia J, 2002, J EPIDEMIOL COMMUN H, V56, P600, DOI 10.1136/jech.56.8.600; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; *DEP HLTH, 1999, HLTH SURV ENGL 1998; *DEP HLTH, 2002, COMP CLIN HLTH IND 2; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Ezzati M, 2003, TOB CONTROL, V12, P79, DOI 10.1136/tc.12.1.79; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; Gail MH., 2000, ENCY EPIDEMIOLOGIC M; Heller RF, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-7; Heller RF, 2002, BMJ-BRIT MED J, V325, P134, DOI 10.1136/bmj.325.7356.134; Heller RF, 2002, J EPIDEMIOL COMMUN H, V56, P606, DOI 10.1136/jech.56.8.606; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; Kristiansen IS, 2002, J CLIN EPIDEMIOL, V55, P888, DOI 10.1016/S0895-4356(02)00432-8; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Marang-van de Mheen PJ, 1999, SOC SCI MED, V48, P1851, DOI 10.1016/S0277-9536(99)00071-4; MCPHERSONN K, 2002, CORONARY HEART DIS E; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MILWARD L, 2001, PUBLIC HLTHH INTERVE; Morgenstern H, 1982, J Community Health, V7, P292, DOI 10.1007/BF01318961; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; Nexoe J, 2002, FAM PRACT, V19, P3, DOI 10.1093/fampra/19.1.3; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; SCHOENVBACH VJ, 2002, RELATING RISK FACTOR; WALKER A, 2002, LIVING BRIT 2001 HLT; Walter SD, 2000, J CLIN EPIDEMIOL, V53, P931, DOI 10.1016/S0895-4356(00)00210-9; WALTER SD, 1980, AM J EPIDEMIOL, V112, P409, DOI 10.1093/oxfordjournals.aje.a113007	30	38	39	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	2003	327	7424					1162	1165		10.1136/bmj.327.7424.1162	http://dx.doi.org/10.1136/bmj.327.7424.1162			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615346	Green Published, Green Submitted			2022-12-28	WOS:000186622100027
J	Fedoroff, NV				Fedoroff, NV			Prehistoric GM corn	SCIENCE			English	Editorial Material							MAIZE; DOMESTICATION; ORIGIN; GENES		Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Fedoroff, NV (corresponding author), Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.							BEADLE GW, 1980, SCI AM, V242, P112, DOI 10.1038/scientificamerican0180-112; Bennetzen J, 2001, LAT AM ANTIQ, V12, P84, DOI 10.2307/971759; Benz BF, 2001, P NATL ACAD SCI USA, V98, P2104, DOI 10.1073/pnas.98.4.2104; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; DOEBLEY J, 1992, TRENDS GENET, V8, P302, DOI 10.1016/0168-9525(92)90261-2; Eyre-Walker A, 1998, P NATL ACAD SCI USA, V95, P4441, DOI 10.1073/pnas.95.8.4441; Huckell BB, 1996, J WORLD PREHIST, V10, P305, DOI 10.1007/BF02286419; Jaenicke-Despres V, 2003, SCIENCE, V302, P1206, DOI 10.1126/science.1089056; Mangelsdorf PC, 1938, P NATL ACAD SCI USA, V24, P303, DOI 10.1073/pnas.24.8.303; Matsuoka Y, 2002, P NATL ACAD SCI USA, V99, P6080, DOI 10.1073/pnas.052125199; Piperno DR, 2001, P NATL ACAD SCI USA, V98, P2101, DOI 10.1073/pnas.98.4.2101; White S, 1998, TRENDS GENET, V14, P327, DOI 10.1016/S0168-9525(98)01524-8	12	19	21	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1158	1159		10.1126/science.1092042	http://dx.doi.org/10.1126/science.1092042			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615520				2022-12-28	WOS:000186544300034
J	Jenkins, M				Jenkins, M			Prospects for biodiversity	SCIENCE			English	Article							WILD NATURE; ENDEMISM	Assuming no radical transformation in human behavior, we can expect important changes in biodiversity and ecosystem services by 2050. A considerable number of species extinctions will have taken place. Existing large blocks of tropical forest will be much reduced and fragmented, but temperate forests and some tropical forests will be stable or increasing in area, although the latter will be biotically impoverished. Marine ecosystems will be very different from today's, with few large marine predators, and freshwater biodiversity will be severely reduced almost everywhere. These changes will not, in themselves, threaten the survival of humans as a species.	UN, Environm Programme, World Conservat Monitoring Ctr, Cambridge CB3 ODL, England	United Nations Environment Programme	Jenkins, M (corresponding author), UN, Environm Programme, World Conservat Monitoring Ctr, 219C Huntingdon Rd, Cambridge CB3 ODL, England.							Alley RB, 2003, SCIENCE, V299, P2005, DOI 10.1126/science.1081056; BALMFORD A, 1994, NATURE, V372, P623, DOI 10.1038/372623a0; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; Birdlife International, 2000, THREAT BIRDS WORLD; Bruinsma J, 2003, WORLD AGR 2015 2030; Caldecott JO, 1996, BIODIVERS CONSERV, V5, P699, DOI 10.1007/BF00051782; Cohen JE, 2003, SCIENCE, V302, P1172, DOI 10.1126/science.1088665; *ESA P WP, 180 ESAPWP; *FAO UN, 2000, 140 FAO; Groombridge B, 2002, WORLD ATLAS BIODIVER; Intergovernmental Panel on Climate Change, 2001, 3 ASS REP; Jenkins M, 2003, CONSERV BIOL, V17, P20, DOI 10.1046/j.1523-1739.2003.01719.x; Jepson P, 2001, SCIENCE, V292, P859, DOI 10.1126/science.1061727; LEADERWILLIAMS N, 2002, 27 IUCN SPEC SURV CO; LOH J, 2002, LIVING PLANET REPORT; Martin PS, 1984, QUATERNARY EXTINCTIO; PAULY D, IN PRESS SCIENCE; Roberts RG, 2001, SCIENCE, V292, P1888, DOI 10.1126/science.1060264; Schule W., 1992, P45; Steadman DW, 2002, SCIENCE, V298, P2136, DOI 10.1126/science.1078915; *UNESCO BERGH BOOK, 2003, UN WORLD WAT DEV REP; *WORLD CONS MON CT, 1998, FRESHW BIOD PREL GLO	22	328	340	4	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1175	1177		10.1126/science.1088666	http://dx.doi.org/10.1126/science.1088666			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615529				2022-12-28	WOS:000186544300043
J	Glatzel, M; Abela, E; Maissen, M; Aguzzi, A				Glatzel, M; Abela, E; Maissen, M; Aguzzi, A			Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INCLUSION-BODY MYOSITIS; TONSIL BIOPSY; VARIANT CJD; CLASSIFICATION; VCJD; BSE	BACKGROUND: In patients with sporadic Creutzfeldt-Jakob disease, pathologic disease-associated prion protein (PrP(sup Sc)) has been identified only in the central nervous system and olfactory-nerve tissue. Understanding the distribution of PrP(sup Sc) in Creutzfeldt-Jakob disease is important for classification and diagnosis and perhaps even for prevention. METHODS: We used a highly sensitive method of detection -- involving the concentration of PrP(sup Sc) by differential precipitation with sodium phosphotungstic acid, which increased the sensitivity of Western blot analysis by up to three orders of magnitude -- to search for PrP(sup Sc) in extraneural organs of 36 patients with sporadic Creutzfeldt-Jakob disease who died between 1996 and 2002. RESULTS: PrP(sup Sc) was present in the brain tissue of all patients. In addition, we found PrP(sup Sc) in 10 of 28 spleen specimens and in 8 of 32 skeletal-muscle samples. Three patients had PrP(sup Sc) in both spleen and muscle specimens. Patients with extraneural PrP(sup Sc) had a significantly longer duration of disease and were more likely to have uncommon molecular variants of sporadic Creutzfeldt-Jakob disease than were patients without extraneural PrP(sup Sc). CONCLUSIONS: Using sensitive techniques, we identified extraneural deposition of PrP(sup Sc) in spleen and muscle samples from approximately one third of patients who died with sporadic Creutzfeldt-Jakob disease. Extraneural PrP(sup Sc) appears to correlate with a long duration of disease.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Natl Reference Ctr Prion Dis, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Glatzel, Markus/V-8844-2019; Aguzzi, Adriano/A-3351-2008; Glatzel, Markus/G-3356-2011	Glatzel, Markus/0000-0002-7720-8817; Glatzel, Markus/0000-0002-7720-8817; Aguzzi, Adriano/0000-0002-0344-6708; Abela, Eugenio/0000-0002-9356-1450				Aguzzi A, 2003, NATURE, V423, P127, DOI 10.1038/423127a; Aguzzi A, 2000, HAEMATOLOGICA, V85, P3; Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; ASKANAS V, 1993, NEUROREPORT, V5, P25, DOI 10.1097/00001756-199310000-00006; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; Bosque PJ, 2002, P NATL ACAD SCI USA, V99, P3812, DOI 10.1073/pnas.052707499; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collinge J, 1997, NATURE, V389, P526, DOI 10.1038/39116; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Glatzel M, 2002, LANCET, V360, P139, DOI 10.1016/S0140-6736(02)09384-4; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Joiner S, 2002, J NEUROL NEUROSUR PS, V73, P597, DOI 10.1136/jnnp.73.5.597; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Nakamura Y, 2000, EPIDEMIOL INFECT, V125, P201, DOI 10.1017/S0950268899004240; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rossetti AO, 2003, J NEUROL, V250, P491, DOI 10.1007/s00415-003-1006-3; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1999, HUM GENET, V105, P244, DOI 10.1007/s004390051096; Zanusso G, 2001, BRAIN PATHOL, V11, P182	31	266	274	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1812	1820		10.1056/NEJMoa030351	http://dx.doi.org/10.1056/NEJMoa030351			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602879				2022-12-28	WOS:000186353800005
J	Marshall, CH; Pielke, RA; Steyaert, LT				Marshall, CH; Pielke, RA; Steyaert, LT			Wetlands: Crop freezes and land-use change in Florida	NATURE			English	Editorial Material									Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; US Geol Survey, EROS Data Ctr, Greenbelt, MD 20771 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Colorado State University; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Marshall, CH (corresponding author), Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA.		Pielke, Roger A/A-5015-2009					Kalnay E, 2003, NATURE, V423, P528, DOI 10.1038/nature01675; Miller K.A., 1991, CLIM RES, V1, P133, DOI DOI 10.3354/CR001133; Walko RL, 2000, J APPL METEOROL, V39, P931, DOI 10.1175/1520-0450(2000)039<0931:CABHMF>2.0.CO;2; [No title captured]; [No title captured]; [No title captured]	6	36	37	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					29	30		10.1038/426029a	http://dx.doi.org/10.1038/426029a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603304				2022-12-28	WOS:000186370800028
J	Kim, SJ; Kim, YS; Yuan, JP; Petralia, RS; Worley, PF; Linden, DJ				Kim, SJ; Kim, YS; Yuan, JP; Petralia, RS; Worley, PF; Linden, DJ			Activation of the TRPC1 cation channel by metabotropic glutamate receptor mGluR1	NATURE			English	Article							LONG-TERM DEPRESSION; SYNAPTIC ACTIVATION; CEREBELLAR; CONDUCTANCE; RELEASE; DEFICIT; HOMER	Group I metabotropic glutamate receptors (consisting of mGluR1 and mGluR5) are G-protein-coupled neurotransmitter receptors(1) that are found in the perisynaptic region of the postsynaptic membrane(2). These receptors are not activated by single synaptic volleys but rather require bursts of activity(3-5). They are implicated in many forms of neural plasticity including hippocampal long-term potentiation and depression(6-8), cerebellar long-term depression(8-11), associative learning(7,11), and cocaine addiction(12). When activated, group I mGluRs engage two G-protein-dependent signalling mechanisms: stimulation of phospholipase C and activation of an unidentified, mixed-cation excitatory postsynaptic conductance (EPSC), displaying slow activation, in the plasma membrane(4,5,13-15). Here we report that the mGluR1-evoked slow EPSC is mediated by the TRPC1 cation channel. TRPC1 is expressed in perisynaptic regions of the cerebellar parallel fibre-Purkinje cell synapse and is physically associated with mGluR1. Manipulations that interfere with TRPC1 block the mGluR1-evoked slow EPSC in Purkinje cells; however, fast transmission mediated by AMPA-type glutamate receptors remains unaffected. Furthermore, co-expression of mGluR1 and TRPC1 in a heterologous system reconstituted a mGluR1-evoked conductance that closely resembles the slow EPSC in Purkinje cells.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Kangwon Natl Univ, Sch Med, Dept Physiol, Chunchon 20071, South Korea; NIDCD, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Kangwon National University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	pworley@jhmi.edu; dlinden@jhmi.edu	Kim, Sang Jeong/J-2740-2012	Kim, Sang Jeong/0000-0001-8931-3713				AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BATCHELOR AM, 1994, NEUROSCIENCE, V63, P911, DOI 10.1016/0306-4522(94)90558-4; Bortolotto ZA, 1999, CURR OPIN NEUROBIOL, V9, P299, DOI 10.1016/S0959-4388(99)80044-0; Canepari M, 2001, J PHYSIOL-LONDON, V533, P765, DOI 10.1111/j.1469-7793.2001.00765.x; Chiamulera C, 2001, NAT NEUROSCI, V4, P873, DOI 10.1038/nn0901-873; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; Gee CE, 2003, J PHYSIOL-LONDON, V546, P655, DOI 10.1113/jphysiol.2002.032961; HARTMANN J, 2002, SOC NEUR ABSTR; Hirono M, 1998, BIOCHEM BIOPH RES CO, V251, P753, DOI 10.1006/bbrc.1998.9465; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; Knopfel T, 2000, EUR J NEUROSCI, V12, P2199, DOI 10.1046/j.1460-9568.2000.00122.x; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; Maejima T, 2001, NEURON, V31, P463, DOI 10.1016/S0896-6273(01)00375-0; Miyata M, 2001, EUR J NEUROSCI, V13, P1945, DOI 10.1046/j.0953-816x.2001.01570.x; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Narasimhan K, 1998, J NEUROPHYSIOL, V80, P2963, DOI 10.1152/jn.1998.80.6.2963; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; Petralia RS, 2001, EUR J NEUROSCI, V13, P1722, DOI 10.1046/j.0953-816x.2001.01553.x; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tabata T, 2002, MOL CELL NEUROSCI, V20, P56, DOI 10.1006/mcne.2002.1118; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; Tempia F, 2001, J NEUROPHYSIOL, V86, P1389, DOI 10.1152/jn.2001.86.3.1389; Tempia F, 1998, J NEUROPHYSIOL, V80, P520, DOI 10.1152/jn.1998.80.2.520; Tozzi A, 2003, EUR J NEUROSCI, V18, P2133, DOI 10.1046/j.1460-9568.2003.02936.x; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	30	283	291	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					285	291		10.1038/nature02162	http://dx.doi.org/10.1038/nature02162			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14614461	Bronze			2022-12-28	WOS:000186660800043
J	Rabani, E; Reichman, DR; Geissler, PL; Brus, LE				Rabani, E; Reichman, DR; Geissler, PL; Brus, LE			Drying-mediated self-assembly of nanoparticles	NATURE			English	Article							DIFFUSION; NANOCRYSTALS	Systems far from equilibrium can exhibit complex transitory structures, even when equilibrium fluctuations are mundane(1,2). A dramatic example of this phenomenon has recently been demonstrated for thin-film solutions of passivated nanocrystals during the irreversible evaporation of the solvent(3-14). The relatively weak attractions between nanocrystals, which are efficiently screened in solution, become manifest as the solvent evaporates, initiating assembly of intricate, slowly evolving structures(4). Although certain aspects of this aggregation process can be explained using thermodynamic arguments alone(6), it is in principle a non-equilibrium process(7). A representation of this process as arising from the phase separation between a dense nanocrystal 'liquid' and dilute nanocrystal 'vapour' captures some of the behaviour observed in experiments(3), but neglects entirely the role of solvent fluctuations, which can be considerable on the nanometre length scale(15). Here we present a coarse-grained model of nanoparticle self-assembly that explicitly includes the dynamics of the evaporating solvent. Simulations using this model not only account for all observed spatial and temporal patterns, but also predict network structures that have yet to be explored. Two distinct mechanisms of ordering emerge, corresponding to the homogeneous and heterogeneous limits of evaporation dynamics. Our calculations show how different choices of solvent, nanoparticle size (and identity) and thermodynamic state give rise to the various morphologies of the final structures. The resulting guide for designing statistically patterned arrays of nanoparticles suggests the possibility of fabricating spontaneously organized nanoscale devices.	Tel Aviv Univ, Sch Chem, IL-69978 Tel Aviv, Israel; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Tel Aviv University; Harvard University; Massachusetts Institute of Technology (MIT); Columbia University	Rabani, E (corresponding author), Tel Aviv Univ, Sch Chem, IL-69978 Tel Aviv, Israel.	rabani@tau.ac.il; reichman@chemistry.harvard.edu	Rabani, Eran/M-1263-2013	Rabani, Eran/0000-0003-2031-3525				Andres RP, 1996, SCIENCE, V273, P1690, DOI 10.1126/science.273.5282.1690; BRAY AJ, 1994, ADV PHYS, V43, P357, DOI 10.1080/00018739400101505; ELBAUM M, 1994, PHYS REV LETT, V72, P3562, DOI 10.1103/PhysRevLett.72.3562; FREEMAN RG, 1995, SCIENCE, V267, P1629, DOI 10.1126/science.267.5204.1629; Fried T, 2001, ADV MATER, V13, P1158, DOI 10.1002/1521-4095(200108)13:15<1158::AID-ADMA1158>3.0.CO;2-6; Ge GL, 2000, J PHYS CHEM B, V104, P9573, DOI 10.1021/jp002280a; Ge GL, 2001, NANO LETT, V1, P219, DOI 10.1021/nl015520m; Gelbart WM, 1999, FARADAY DISCUSS, V112, P299, DOI 10.1039/a809582e; Harfenist SA, 1996, J PHYS CHEM-US, V100, P13904, DOI 10.1021/jp961764x; Lo A, 2000, J CHEM PHYS, V112, P1966, DOI 10.1063/1.480756; Maillard M, 2000, J PHYS CHEM B, V104, P11871, DOI 10.1021/jp002605n; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Puntes VF, 2001, SCIENCE, V291, P2115, DOI 10.1126/science.1057553; Redl FX, 2003, NATURE, V423, P968, DOI 10.1038/nature01702; Sear RP, 1999, PHYS REV E, V59, pR6255, DOI 10.1103/PhysRevE.59.R6255; Stowell C, 2001, NANO LETT, V1, P595, DOI 10.1021/nl015601i; Tanaka H, 2000, J PHYS-CONDENS MAT, V12, pR207, DOI 10.1088/0953-8984/12/15/201; Tang J, 2002, J PHYS CHEM B, V106, P5653, DOI 10.1021/jp014559c; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; WITTEN TA, 1981, PHYS REV LETT, V47, P1400, DOI 10.1103/PhysRevLett.47.1400	20	797	816	12	515	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					271	274		10.1038/nature02087	http://dx.doi.org/10.1038/nature02087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628047				2022-12-28	WOS:000186660800039
J	Hilgenkamp, H; Moshchalkov, VV; Kes, P				Hilgenkamp, H; Moshchalkov, VV; Kes, P			Flux quanta on the move	SCIENCE			English	Editorial Material							SUPERCONDUCTORS		Univ Twente, Fac Sci & Technol, Low Temp Div, NL-7500 AE Enschede, Netherlands; Univ Twente, MESA Res Inst, NL-7500 AE Enschede, Netherlands; Katholieke Univ Leuven, Vaste Stof Fys & Magnetisme Lab, B-3001 Leuven, Belgium; Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands	University of Twente; University of Twente; KU Leuven; Leiden University; Leiden University - Excl LUMC	Hilgenkamp, H (corresponding author), Univ Twente, Fac Sci & Technol, Low Temp Div, POB 217, NL-7500 AE Enschede, Netherlands.		Moshchalkov, Victor V/I-7232-2013	Hilgenkamp, Hans/0000-0001-6109-8804				Kwok WK, 2002, PHYSICA C, V382, P137, DOI 10.1016/S0921-4534(02)01213-3; Lee CS, 1999, NATURE, V400, P337, DOI 10.1038/22578; Likharev KK, 1991, IEEE T APPL SUPERCON, V1, P3, DOI 10.1109/77.80745; Mannhart J, 1996, SUPERCOND SCI TECH, V9, P49, DOI 10.1088/0953-2048/9/2/001; Reimann P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3; Rosseel E, 1996, PHYS REV B, V53, pR2983, DOI 10.1103/PhysRevB.53.R2983; Villegas JE, 2003, SCIENCE, V302, P1188, DOI 10.1126/science.1090390; Zhu BY, 2003, PHYSICA E, V18, P318, DOI 10.1016/S1386-9477(02)01062-7; Zhu BY, 2003, PHYSICA E, V18, P322, DOI 10.1016/S1386-9477(02)01066-4	9	2	2	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1159	1160		10.1126/science.1092038	http://dx.doi.org/10.1126/science.1092038			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615521				2022-12-28	WOS:000186544300035
J	Greiner, J; Klose, S; Reinsch, K; Schmid, HM; Sari, R; Hartmann, DH; Kouveliotou, C; Rau, A; Palazzi, E; Straubmeier, C; Stecklum, B; Zharikov, S; Tovmassian, G; Barnbantner, O; Ries, C; Jehin, E; Henden, A; Kaas, AA; Grav, T; Hjorth, J; Pedersen, H; Wijers, RAMJ; Kaufer, A; Park, HS; Williams, G; Reimer, O				Greiner, J; Klose, S; Reinsch, K; Schmid, HM; Sari, R; Hartmann, DH; Kouveliotou, C; Rau, A; Palazzi, E; Straubmeier, C; Stecklum, B; Zharikov, S; Tovmassian, G; Barnbantner, O; Ries, C; Jehin, E; Henden, A; Kaas, AA; Grav, T; Hjorth, J; Pedersen, H; Wijers, RAMJ; Kaufer, A; Park, HS; Williams, G; Reimer, O			Evolution of the polarization of the optical afterglow of the gamma-ray burst GRB030329	NATURE			English	Article							29 MARCH 2003; GRB 990510; SPECTROPOLARIMETRY; GRB-020405; GRB-030329; EMISSION	The association of a supernova with GRB030329(1,2) strongly supports the 'collapsar' model(3) of gamma-ray bursts, where a relativistic jet(4) forms after the progenitor star collapses. Such jets cannot be spatially resolved because gamma-ray bursts lie at cosmological distances; their existence is instead inferred from 'breaks' in the light curves of the afterglows, and from the theoretical desire to reduce the estimated total energy of the burst by proposing that most of it comes out in narrow beams. Temporal evolution of the polarization of the afterglows(5-7) may provide independent evidence for the jet structure of the relativistic outflow. Small-level polarization (similar to1-3 per cent)(8-17) has been reported for a few bursts, but its temporal evolution has yet to be established. Here we report polarimetric observations of the afterglow of GRB030329. We establish the polarization light curve, detect sustained polarization at the per cent level, and find significant variability. The data imply that the afterglow magnetic field has a small coherence length and is mostly random, probably generated by turbulence, in contrast with the picture arising from the high polarization detected in the prompt gamma-rays from GRB021206 (ref. 18).	Max Planck Inst Extraterr Phys, D-85741 Garching, Germany; Thuringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany; Univ Sternwarte Gottingen, D-37083 Gottingen, Germany; ETH, Inst Astron, CH-8092 Zurich, Switzerland; CALTECH, Pasadena, CA 91125 USA; Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA; NSSTC, Huntsville, AL 35805 USA; CNR, Ist Astrofis Spaziale & Fis Cosm, Sez Bologna, I-40129 Bologna, Italy; Univ Cologne, Inst Phys, D-50937 Cologne, Germany; Univ Nacl Autonoma Mexico, Inst Astron, Ensenada 22860, Baja California, Mexico; Univ Sternwarte, Wendelstein Observ, D-81679 Munich, Germany; European So Observ, Santiago 19, Chile; USN Observ, Univ Space Res Assoc, Flagstaff, AZ 86002 USA; Nord Opt Telescope, Santa Cruz De La Palma 38700, Spain; Univ Oslo, Inst Theoret Astrophys, N-0315 Oslo, Norway; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Copenhagen, NBIfAFG, Astron Observ, DK-2100 Copenhagen O, Denmark; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; Univ Arizona, Multiple Mirror Telescope Observ, Tucson, AZ 85721 USA; Ruhr Univ Bochum, D-44780 Bochum, Germany	Max Planck Society; University of Gottingen; Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Clemson University; Consiglio Nazionale delle Ricerche (CNR); University of Cologne; Universidad Nacional Autonoma de Mexico; University of Munich; European Southern Observatory; United States Department of Defense; United States Navy; Universities Space Research Association (USRA); University of Oslo; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Copenhagen; University of Amsterdam; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Arizona; Ruhr University Bochum	Greiner, J (corresponding author), Max Planck Inst Extraterr Phys, D-85741 Garching, Germany.	jcg@mpe.mpg.de	Tovmassian, Gagik/ABD-7754-2021; ZHARIKOV, SERGEY/AAR-2577-2020; Reimer, Olaf/A-3117-2013; Hjorth, Jens/M-5787-2014; Palazzi, Eliana/N-4746-2015	Tovmassian, Gagik/0000-0002-2953-7528; ZHARIKOV, SERGEY/0000-0003-2526-2683; Reimer, Olaf/0000-0001-6953-1385; Hjorth, Jens/0000-0002-4571-2306; Palazzi, Eliana/0000-0002-8691-7666; Greiner, Jochen/0000-0002-9875-426X; Wijers, Ralph/0000-0002-3101-1808				Barth AJ, 2003, ASTROPHYS J, V584, pL47, DOI 10.1086/373889; Bersier D, 2003, ASTROPHYS J, V583, pL63, DOI 10.1086/368158; Bjornsson G, 2002, ASTROPHYS J, V579, pL59, DOI 10.1086/345292; BURENIN R, 2003, ASTRON LETT+, V29, P1; Coburn W, 2003, NATURE, V423, P415, DOI 10.1038/nature01612; Covino S, 2003, ASTRON ASTROPHYS, V400, pL9, DOI 10.1051/0004-6361:20030133; Covino S, 1999, ASTRON ASTROPHYS, V348, pL1; Ghisellini G, 1999, MON NOT R ASTRON SOC, V309, pL7, DOI 10.1046/j.1365-8711.1999.03025.x; GREINER J, 2003, 2020 GCN; Gruzinov A, 1999, ASTROPHYS J, V525, pL29, DOI 10.1086/312323; Hjorth J, 1999, SCIENCE, V283, P2073, DOI 10.1126/science.283.5410.2073; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; Leonard DC, 2002, PUBL ASTRON SOC PAC, V114, P1333, DOI 10.1086/345092; MARSHALL FE, 2003, 2052 GCN; Masetti N, 2003, ASTRON ASTROPHYS, V404, P465, DOI 10.1051/0004-6361:20030491; Meszaros P, 2002, ANNU REV ASTRON ASTR, V40, P137, DOI 10.1146/annurev.astro.40.060401.093821; Price PA, 2003, NATURE, V423, P844, DOI 10.1038/nature01734; Rol E, 2003, ASTRON ASTROPHYS, V405, pL23, DOI 10.1051/0004-6361:20030731; Rol E, 2000, ASTROPHYS J, V544, P707, DOI 10.1086/317256; Sari R, 1999, ASTROPHYS J, V524, pL43, DOI 10.1086/312294; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; Tiengo A, 2003, ASTRON ASTROPHYS, V409, P983, DOI 10.1051/0004-6361:20031127; Uemura M, 2003, NATURE, V423, P843, DOI 10.1038/nature01735; VANDERSPEK R, 2003, LONG EXTREMELY BRIGH; Wang LF, 2001, ASTROPHYS J, V550, P1030, DOI 10.1086/319822; Wijers RAMJ, 1999, ASTROPHYS J, V523, pL33, DOI 10.1086/312262; Woosley SE, 1999, ASTROPHYS J, V516, P788, DOI 10.1086/307131	28	111	112	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					157	159		10.1038/nature02077	http://dx.doi.org/10.1038/nature02077			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614499	Green Submitted, Green Accepted			2022-12-28	WOS:000186517200036
J	Lin, EHB; Katon, W; Von Korff, M; Tang, LQ; Williams, JW; Kroenke, K; Hunkeler, E; Harpole, L; Hegel, M; Arean, P; Hoffing, M; Della Penna, R; Langston, C; Unutzer, J				Lin, EHB; Katon, W; Von Korff, M; Tang, LQ; Williams, JW; Kroenke, K; Hunkeler, E; Harpole, L; Hegel, M; Arean, P; Hoffing, M; Della Penna, R; Langston, C; Unutzer, J		IMPACT Investigators	Effect of improving depression care on pain and functional outcomes among older adults with arthritis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOID-ARTHRITIS; HEALTH-CARE; KNEE OSTEOARTHRITIS; LATE-LIFE; DISABILITY; SYMPTOMS; LIMITATIONS; IMPAIRMENT; MANAGEMENT; SERVICES	Context Depression and arthritis are disabling and common health problems in late life. Depression is also a risk factor for poor health outcomes among arthritis patients. Objective To determine whether enhancing care for depression improves pain and functional outcomes in older adults with depression and arthritis. Design, Setting, and Participants Preplanned subgroup analyses of Improving Mood-Promoting Access to Collaborative Treatment (IMPACT), a randomized controlled trial of 1801 depressed older adults (greater than or equal to60 years), which was performed at 18 primary care clinics from 8 health care organizations in 5 states across the United States from July 1999 to August 2001. A total of 1001 (56%) reported coexisting arthritis at baseline. Intervention Antidepressant medications and/or 6 to 8 sessions of psychotherapy (Problem-Solving Treatment in Primary Care). Main Outcome Measures Depression, pain intensity (scale of 0 to 10), interference with daily activities due to arthritis (scale of 0 to 10), general health status, and overall quality-of-life outcomes assessed at baseline, 3, 6, and 12 months. Results In addition to reduction in depressive symptoms, the intervention group compared with the usual care group at 12 months had lower mean (SE) scores for pain intensity (5.62 [0.16] vs 6.15 [0.16]; between-group difference, -0.53; 95% confidence interval [CI], -0.92 to -0.14; P=.009), interference with daily activities due to arthritis (4.40 [0.18] vs 4.99 [0.17]; between-group difference, -0.59; 95% CI, -1.00 to -0.19; P=.004), and interference with daily activities due to pain (2.92 [0.07] Vs 3.17 [0.07]; between-group difference, -0.26; 95% CI, -0.41 to -0.10; P=.002). Overall health and quality of life were also enhanced among intervention patients relative to control patients at 12 months. Conclusions In a large and diverse population of older adults with arthritis (mostly osteoarthritis) and comorbid depression, benefits of improved depression care extended beyond reduced depressive symptoms and included decreased pain as well as improved functional status and quality of life.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Psychiat, Seattle, WA 98195 USA; UCLA Neuropsychiat Inst, Ctr Hlth Serv Res, Los Angeles, CA USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA; Indiana Univ, Sch Med, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Kaiser Permanente No Calif, Oakland, CA USA; Dartmouth Hitchcock Med Ctr, Dept Behav Med, Hanover, NH USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Desert Med Grp, Palm Springs, CA USA; Kaiser Permanente So Calif, San Diego, CA USA; John A Hartford Fdn, New York, NY USA	Group Health Cooperative; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Kaiser Permanente; Dartmouth College; University of California System; University of California San Francisco; Kaiser Permanente	Lin, EHB (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	lin.e@ghc.org	Arean, Patricia/GLR-1550-2022; Williams, John W/A-3696-2008; Unutzer, Jurgen/N-4048-2018; Williams, John/AAM-4572-2020	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558; Kroenke, Kurt/0000-0002-0114-4669				Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; ALTMAN RD, 1991, J RHEUMATOL, V18, P10; Ash G, 1999, RHEUMATOLOGY, V38, P959, DOI 10.1093/rheumatology/38.10.959; Astin JA, 2002, ARTHRIT RHEUM-ARTHR, V47, P291, DOI 10.1002/art.10416; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Bird H, 2000, J RHEUMATOL, V27, P2791; Callahan CM, 2002, MED CARE, V40, P771, DOI 10.1097/00005650-200209000-00007; Creamer P, 2000, RHEUMATOLOGY, V39, P490, DOI 10.1093/rheumatology/39.5.490; Creamer P, 1998, CLIN GERIATR MED, V14, P435; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; DEVELLIS BM, 1993, BAILLIERE CLIN RHEUM, V7, P241, DOI 10.1016/S0950-3579(05)80088-3; DEXTER P, 1994, J RHEUMATOL, V21, P279; Dionne CE, 1997, J CLIN EPIDEMIOL, V50, P31, DOI 10.1016/S0895-4356(96)00313-7; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015; Fields HL, 2000, PROG BRAIN RES, V122, P245; First M.B., 2014, STRUCTURED CLIN INTE; Fishbain D, 2000, ANN MED, V32, P305, DOI 10.3109/07853890008995932; Fishman SM, 2003, CLEV CLIN J MED, V70, P119, DOI 10.3949/ccjm.70.2.119; FRANK RG, 1988, J RHEUMATOL, V15, P1632; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; Hirakawa N, 2000, NEUROSCIENCE, V100, P861, DOI 10.1016/S0306-4522(00)00329-8; Katon W, 2001, ANN INTERN MED, V134, P917, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00017; Keefe FJ, 1997, MED CLIN N AM, V81, P277, DOI 10.1016/S0025-7125(05)70515-0; Kroenke K, 2000, PSYCHOTHER PSYCHOSOM, V69, P205, DOI 10.1159/000012395; Lamb SE, 2000, ANN RHEUM DIS, V59, P331, DOI 10.1136/ard.59.5.331; LAVORI PW, 1995, STAT MED, V14, P1913, DOI 10.1002/sim.4780141707; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Leon AC, 1997, INT J PSYCHIAT MED, V27, P93, DOI 10.2190/T8EM-C8YH-373N-1UWD; Lin EHB, 2000, ARCH FAM MED, V9, P1052, DOI 10.1001/archfami.9.10.1052; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; LITTLE RJA, 1988, J BUS ECON STAT, V6, P287, DOI 10.2307/1391878; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Lynch ME, 2001, J PSYCHIATR NEUROSCI, V26, P30; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Memel DS, 2000, BRIT J GEN PRACT, V50, P645; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; O'Malley PG, 1999, J FAM PRACTICE, V48, P980; OXMAN TE, 1990, PSYCHOSOMATICS, V31, P174, DOI 10.1016/S0033-3182(90)72191-3; Penninx BWJH, 2001, ARCH INTERN MED, V161, P2309, DOI 10.1001/archinte.161.19.2309; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; PUTTINI PS, 1988, J INT MED RES, V16, P331, DOI 10.1177/030006058801600502; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SIMON GE, 1995, ARCH GEN PSYCHIAT, V52, P850; TANG L, 2002, P AM STAT ASS HLTH P, P3430; Thomas KS, 2002, BMJ-BRIT MED J, V325, P752, DOI 10.1136/bmj.325.7367.752; TURNER JA, 1993, J FAM PRACTICE, V37, P545; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Unutzer J, 2000, INT PSYCHOGERIATR, V12, P15, DOI 10.1017/S1041610200006177; Vali FM, 1998, MED CARE, V36, P1073, DOI 10.1097/00005650-199807000-00013; van Baar ME, 1998, J RHEUMATOL, V25, P125; Von Korff M, 2000, SPINE, V25, P3140, DOI 10.1097/00007632-200012150-00009; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WELLS KB, 1988, AM J PSYCHIAT, V145, P712; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; YELIN E, 1995, ARTHRITIS RHEUM, V38, P1351, DOI 10.1002/art.1780381002; Yelin EH, 1995, ARTHRIT CARE RES, V8, P311, DOI 10.1002/art.1790080417	63	413	426	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2428	2434		10.1001/jama.290.18.2428	http://dx.doi.org/10.1001/jama.290.18.2428			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742LH	14612479	Bronze			2022-12-28	WOS:000186518300029
J	Hill, S; Edwards, RS; Aliaga-Alcalde, N; Christou, G				Hill, S; Edwards, RS; Aliaga-Alcalde, N; Christou, G			Quantum coherence in an exchange-coupled dimer of single-molecule magnets	SCIENCE			English	Article								A multi -high-frequency electron paramagnetic resonance method is used to probe the magnetic excitations of a dimer of single-molecule magnets. The measured spectra display well-resolved quantum transitions involving coherent superposition states of both molecules. The behavior may be understood in terms of an isotropic superexchange coupling between pairs of single-molecule magnets, in analogy with several recently proposed quantum devices based on artificially fabricated quantum dots or clusters. These findings highlight the potential utility of supramolecular chemistry in the design of future quantum devices based on molecular nanomagnets.	Univ Florida, Dept Phys, Gainesville, FL 32611 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hill, S (corresponding author), Univ Florida, Dept Phys, Gainesville, FL 32611 USA.	hill@phys.ufl.edu	Aliaga-Alcalde, Núria/ABI-6678-2020; Christou, George/A-3072-2014; Aliaga-Alcalde, Núria/H-5886-2011; Hill, Stephen/J-5383-2014	Aliaga-Alcalde, Núria/0000-0003-1080-3862; Aliaga-Alcalde, Núria/0000-0003-1080-3862; Hill, Stephen/0000-0001-6742-3620; Edwards, Rachel S./0000-0003-2550-3627				Benjamin SC, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.247901; Burkard G, 2000, FORTSCHR PHYS, V48, P965, DOI 10.1002/1521-3978(200009)48:9/11<965::AID-PROP965>3.0.CO;2-V; Christou G, 2000, MRS BULL, V25, P66, DOI 10.1557/mrs2000.226; DiVincenzo DP, 2000, NATURE, V408, P339, DOI 10.1038/35042541; DiVincenzo DP, 1999, J MAGN MAGN MATER, V200, P202, DOI 10.1016/S0304-8853(99)00315-7; Dube M, 2001, CHEM PHYS, V268, P257, DOI 10.1016/S0301-0104(01)00303-2; Edwards RS, 2003, POLYHEDRON, V22, P1911, DOI 10.1016/S0277-5387(03)00239-0; Gatteschi D, 2003, ANGEW CHEM INT EDIT, V42, P268, DOI 10.1002/anie.200390099; HENDRICKSON DN, 1992, J AM CHEM SOC, V114, P2455, DOI 10.1021/ja00033a022; Kovalev AE, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.134513; Leuenberger MN, 2001, NATURE, V410, P789, DOI 10.1038/35071024; MAIER F, 2003, PHYS REV B, V68; Mola M, 2000, REV SCI INSTRUM, V71, P186, DOI 10.1063/1.1150182; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Park K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.014426; Schweiger A., 2001, PRINCIPLES PULSED EL; Warren WS, 1997, SCIENCE, V277, P1688, DOI 10.1126/science.277.5332.1688; Wernsdorfer W, 2002, NATURE, V416, P406, DOI 10.1038/416406a; WERNSDORFER W, COMMUNICATION	19	494	496	6	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1015	1018		10.1126/science.1090082	http://dx.doi.org/10.1126/science.1090082			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605362	Green Submitted			2022-12-28	WOS:000186396300038
J	Pebay-Peyroula, E; Dahout-Gonzalez, C; Kahn, R; Trezeguet, V; Lauquin, GJM; Brandolin, R				Pebay-Peyroula, E; Dahout-Gonzalez, C; Kahn, R; Trezeguet, V; Lauquin, GJM; Brandolin, R			Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside	NATURE			English	Article							ADENINE-NUCLEOTIDE CARRIER; BEEF-HEART MITOCHONDRIA; ELECTRON-DENSITY MAPS; ADP ATP CARRIER; OXIDATIVE-PHOSPHORYLATION; LIVER MITOCHONDRIA; TRITON X-100; PROTEIN; YEAST; ATRACTYLOSIDE	ATP, the principal energy currency of the cell, fuels most biosynthetic reactions in the cytoplasm by its hydrolysis into ADP and inorganic phosphate. Because resynthesis of ATP occurs in the mitochondrial matrix, ATP is exported into the cytoplasm while ADP is imported into the matrix. The exchange is accomplished by a single protein, the ADP/ATP carrier. Here we have solved the bovine carrier structure at a resolution of 2.2 Angstrom by X-ray crystallography in complex with an inhibitor, carboxyatractyloside. Six alpha-helices form a compact transmembrane domain, which, at the surface towards the space between inner and outer mitochondrial membranes, reveals a deep depression. At its bottom, a hexapeptide carrying the signature of nucleotide carriers ( RRRMMM) is located. Our structure, together with earlier biochemical results, suggests that transport substrates bind to the bottom of the cavity and that translocation results from a transient transition from a 'pit' to a 'channel' conformation.	Univ Grenoble 1, CNRS, CEA, Inst Biol Struct,UMR 5075, F-38027 Grenoble 1, France; Univ Grenoble 1, CNRS,CEA,UMR 5092, Dept Reponse & Dynam Cellulaires, Lab Biochim & Biophys Syst Integres, F-38054 Grenoble, France; CNRS, Inst Biochim & Genet Cellulaires, Lab Physiol Mol & Cellulaire, UMR 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Pebay-Peyroula, E (corresponding author), Univ Grenoble 1, CNRS, CEA, Inst Biol Struct,UMR 5075, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.			Trezeguet, Veronique/0000-0003-2487-7571				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; BECK JC, 1968, P NATL ACAD SCI USA, V60, P186, DOI 10.1073/pnas.60.1.186; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BLOCK MR, 1984, BIOCHIM BIOPHYS ACTA, V767, P369, DOI 10.1016/0005-2728(84)90207-X; BLOCK MR, 1982, BIOCHEM BIOPH RES CO, V109, P471, DOI 10.1016/0006-291X(82)91745-4; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; BRANDOLIN G, 1985, BIOCHEMISTRY-US, V24, P1991, DOI 10.1021/bi00329a029; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNI A, 1964, NATURE, V201, P1219, DOI 10.1038/2011219a0; CANDY HA, 1977, PHYTOCHEMISTRY, V16, P1308, DOI 10.1016/S0031-9422(00)94388-7; CRAIG JC, 1976, PHYTOCHEMISTRY, V15, P1178, DOI 10.1016/0031-9422(76)85126-6; Denessiouk KA, 2000, PROTEINS, V38, P310, DOI 10.1002/(SICI)1097-0134(20000215)38:3<310::AID-PROT7>3.0.CO;2-T; Dianoux AC, 2000, BIOCHEMISTRY-US, V39, P11477, DOI 10.1021/bi000618l; DUEE ED, 1965, BIOCHIM BIOPHYS ACTA, V107, P184, DOI 10.1016/0304-4165(65)90419-8; DUYCKAERTS C, 1980, EUR J BIOCHEM, V106, P1; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fiore C, 2001, CLIN CHIM ACTA, V311, P125, DOI 10.1016/S0009-8981(01)00581-2; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Gropp T, 1999, BIOPHYS J, V77, P714, DOI 10.1016/S0006-3495(99)76926-2; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Harrenga A, 1999, J BIOL CHEM, V274, P33296, DOI 10.1074/jbc.274.47.33296; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOVAC L, 1967, SCIENCE, V158, P1564, DOI 10.1126/science.158.3808.1564; Kunji ERS, 2003, J BIOL CHEM, V278, P36985, DOI 10.1074/jbc.C300304200; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; Moodie SL, 1996, J MOL BIOL, V263, P486, DOI 10.1006/jmbi.1996.0591; Muller V, 1997, BIOCHEMISTRY-US, V36, P16008, DOI 10.1021/bi971867l; Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panneels V, 2003, BIOCHEM BIOPH RES CO, V300, P65, DOI 10.1016/S0006-291X(02)02795-X; PFAFF E, 1965, BIOCHIM BIOPHYS ACTA, V104, P312, DOI 10.1016/0304-4165(65)90258-8; TORRONI A, 1990, J BIOL CHEM, V265, P20589; Trezeguet V, 2000, BBA-BIOENERGETICS, V1457, P81, DOI 10.1016/S0005-2728(99)00115-2; VIGNAIS PV, 1976, BIOCHIM BIOPHYS ACTA, V456, P1, DOI 10.1016/0304-4173(76)90007-0; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Zeman I, 2003, J BIOENERG BIOMEMBR, V35, P243, DOI 10.1023/A:1024611731860	50	748	764	2	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					39	44		10.1038/nature02056	http://dx.doi.org/10.1038/nature02056			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603310				2022-12-28	WOS:000186370800034
J	Shearman, AM; Cupples, LA; Demissie, S; Peter, I; Schmid, CH; Karas, RH; Mendelsohn, ME; Housman, DE; Levy, D				Shearman, AM; Cupples, LA; Demissie, S; Peter, I; Schmid, CH; Karas, RH; Mendelsohn, ME; Housman, DE; Levy, D			Association between estrogen receptor alpha gene variation and cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY-DISEASE; BONE-MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; VITAMIN-D-RECEPTOR; POSTMENOPAUSAL WOMEN; PLUS PROGESTIN; BREAST-CANCER; HEART-DISEASE; MYOCARDIAL-INFARCTION; DISRUPTIVE MUTATION	Context Estrogen and related hormone therapies activate estrogen receptors, which in turn regulate genes for several cardiovascular disease (CVD) risk factors. Relatively little is known, however, about the impact of genetic variation in estrogen receptor a (ESR1) on CVD risk. Objective To investigate whether the ESR1 c.454-397T>C polymorphism is associated with CVD risk. Design, Setting, and Participants Prospective study of 1739 unrelated men and women from the population-based offspring cohort of the Framingham Heart Study, who were followed up from 1971 to 1998. Main Outcome Measures Total atherosclerotic CVD events, defined as recognized or unrecognized myocardial infarction (MI), angina pectoris, coronary insufficiency, intermittent claudication, coronary heart disease death, or atherothrombotic stroke (n=178); major atherosclerotic CVD, defined as recognized acute MI, coronary insufficiency, coronary heart disease death, or atherothrombotic stroke (n=83); and recognized acute MI (n=59). Results Twenty percent of participants (n=352) were homozygous for the ESR1 c.454-397C allele. After adjustment for covariates (age, sex, body mass index, hypertension, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, and cigarette smoking), the CC genotype was significantly associated with major atherosclerotic CVD, with an odds ratio of 2.0 (95% confidence interval [CI], 1.3-3.2; P=.004) compared with individuals with the CT or TT genotypes. Participants with the CC genotype had 3.0-fold greater odds of MI (95% Cl, 1.7-5,2; P<.001) compared with those with the CT or TT genotype. The results remained significant when analyses were restricted to men; too few women had events to study them separately. Conclusions Individuals with the common ESR1 c.454-397CC genotype have a substantial increase in risk of MI. Whether ESR1 c.454-397T>C is causally related to MI risk or in linkage disequilibrium with 1 or more causal variants remains to be determined. These findings support the importance of estrogen receptors in CVD susceptibility, especially in men. Estrogen receptor variation also has potential to explain recent conflicting data regarding the effects of hormone therapy on CVD susceptibility in women.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Tufts Univ New England Med Ctr, Dept Med, Div Clin Care Res, Biostat Res Ctr, Boston, MA USA; Tufts Univ New England Med Ctr, Dept Med, Mol Cardiol Res Inst, Boston, MA USA; Tufts Univ New England Med Ctr, Specialized Ctr Res Ischem Heart Dis, Boston, MA USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Massachusetts Institute of Technology (MIT); Boston University; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Shearman, AM (corresponding author), MIT, Ctr Canc Res, E17-536, Cambridge, MA 02139 USA.	shearman@mit.edu	Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Schmid, Christopher H./J-2398-2014	Levy, Daniel/0000-0003-1843-8724; Schmid, Christopher H./0000-0002-0855-5313; Demissie, Serkalem/0000-0002-8009-0987; Cupples, L. Adrienne/0000-0003-0273-7965	NHLBI NIH HHS [N01-HC-25195, P50-HL63494, P50 HL63494, N01-HC-38038, R01-HL65230] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195, N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063494, R01HL065230] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1999, NAT GENET, V22, P1; Becherini L, 2000, HUM MOL GENET, V9, P2043, DOI 10.1093/hmg/9.13.2043; Braunstein JB, 2002, CHEST, V121, P906, DOI 10.1378/chest.121.3.906; Brouchet L, 2001, CIRCULATION, V103, P423; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; CASTAGNOLI A, 1987, NUCLEIC ACIDS RES, V15, P866, DOI 10.1093/nar/15.2.866; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Deng HW, 1999, OSTEOPOROSIS INT, V9, P499, DOI 10.1007/s001980050268; Evangelopoulos D, 2003, CLIN CHIM ACTA, V331, P37, DOI 10.1016/S0009-8981(03)00080-9; Ferrara A, 2003, CIRCULATION, V107, P43, DOI 10.1161/01.CIR.0000042701.17528.95; Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88; Herrington DM, 2002, NEW ENGL J MED, V346, P967, DOI 10.1056/NEJMoa012952; Holmberg-Marttila D, 2000, CALCIFIED TISSUE INT, V66, P184, DOI 10.1007/PL00005836; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Kang HJ, 2002, CANCER LETT, V178, P175, DOI 10.1016/S0304-3835(01)00861-8; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Kim JG, 2001, MENOPAUSE, V8, P222, DOI 10.1097/00042192-200105000-00013; Kunnas TA, 2000, BRIT MED J, V321, P273, DOI 10.1136/bmj.321.7256.273; Langdahl BL, 2000, J BONE MINER RES, V15, P2222, DOI 10.1359/jbmr.2000.15.11.2222; Lau EMC, 2001, BONE, V29, P96, DOI 10.1016/S8756-3282(01)00481-1; Lehtimaki T, 2002, J MOL MED-JMM, V80, P176, DOI 10.1007/s00109-001-0311-5; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Lu H, 2002, ARTERIOSCL THROM VAS, V22, P817, DOI 10.1161/01.ATV.0000014424.18209.21; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; Matsubara Y, 1997, ARTERIOSCL THROM VAS, V17, P3006, DOI 10.1161/01.ATV.17.11.3006; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mizunuma H, 1997, BONE, V21, P379, DOI 10.1016/S8756-3282(97)00178-6; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Petrovic D, 2003, CARDIOLOGY, V99, P163, DOI 10.1159/000070673; Prandoni P, 2003, NEW ENGL J MED, V348, P1435, DOI 10.1056/NEJMoa022157; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sudhir K, 1997, CIRCULATION, V96, P3774; Sudhir K, 1997, LANCET, V349, P1146, DOI 10.1016/S0140-6736(05)63022-X; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Willing M, 1998, J BONE MINER RES, V13, P695, DOI 10.1359/jbmr.1998.13.4.695; YAICH L, 1992, CANCER RES, V52, P77; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	43	230	234	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2263	2270		10.1001/jama.290.17.2263	http://dx.doi.org/10.1001/jama.290.17.2263			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600184	Bronze			2022-12-28	WOS:000186356800020
J	Giot, L; Bader, JS; Brouwer, C; Chaudhuri, A; Kuang, B; Li, Y; Hao, YL; Ooi, CE; Godwin, B; Vitols, E; Vijayadamodar, G; Pochart, P; Machineni, H; Welsh, M; Kong, Y; Zerhusen, B; Malcolm, R; Varrone, Z; Collis, A; Minto, M; Burgess, S; McDaniel, L; Stimpson, E; Spriggs, F; Williams, J; Neurath, K; Ioime, N; Agee, M; Voss, E; Furtak, K; Renzulli, R; Aanensen, N; Carrolla, S; Bickelhaupt, E; Lazovatsky, Y; DaSilva, A; Zhong, J; Stanyon, CA; Finley, RL; White, KP; Braverman, M; Jarvie, T; Gold, S; Leach, M; Knight, J; Shimkets, RA; McKenna, MP; Chant, J; Rothberg, JM				Giot, L; Bader, JS; Brouwer, C; Chaudhuri, A; Kuang, B; Li, Y; Hao, YL; Ooi, CE; Godwin, B; Vitols, E; Vijayadamodar, G; Pochart, P; Machineni, H; Welsh, M; Kong, Y; Zerhusen, B; Malcolm, R; Varrone, Z; Collis, A; Minto, M; Burgess, S; McDaniel, L; Stimpson, E; Spriggs, F; Williams, J; Neurath, K; Ioime, N; Agee, M; Voss, E; Furtak, K; Renzulli, R; Aanensen, N; Carrolla, S; Bickelhaupt, E; Lazovatsky, Y; DaSilva, A; Zhong, J; Stanyon, CA; Finley, RL; White, KP; Braverman, M; Jarvie, T; Gold, S; Leach, M; Knight, J; Shimkets, RA; McKenna, MP; Chant, J; Rothberg, JM			A protein interaction map of Drosophila melanogaster	SCIENCE			English	Article							BINDING-PROTEIN; SYSTEMATIC ANALYSIS; UBIQUITIN-LIGASE; ADAPTER PROTEIN; IDENTIFICATION; REPRESSION; REAPER; DOMAIN; GRIM; RNA	Drosophila melanogaster is a proven model system for many aspects of human biology. Here we present a two-hybrid-based protein-interaction map of the fly proteome. A total of 10,623 predicted transcripts were isolated and screened against standard and normalized complementary DNA libraries to produce a draft map of 7048 proteins and 20,405 interactions. A computational method of rating two-hybrid interaction confidence was developed to re. ne this draft map to a higher confidence map of 4679 proteins and 4780 interactions. Statistical modeling of the network showed two levels of organization: a short-range organization, presumably corresponding to multiprotein complexes, and a more global organization, presumably corresponding to intercomplex connections. The network recapitulated known pathways, extended pathways, and uncovered previously unknown pathway components. This map serves as a starting point for a systems biology modeling of multicellular organisms, including humans.	GuraGen Corp, New Haven, CT 06511 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Wayne State University; Yale University	Chant, J (corresponding author), GuraGen Corp, 555 Long Wharf Dr, New Haven, CT 06511 USA.	jchant@curagen.com	Stanyon, Clem/AAM-5040-2020; Bader, Joel/A-1818-2009; guntain, sodsri/C-5090-2009; Kong, Yong/B-5105-2014	Bader, Joel/0000-0002-6020-4625; Kong, Yong/0000-0002-2881-5274; Finley, Russ/0000-0003-1144-6887; Stanyon, Clement/0000-0001-5030-6823	NHGRI NIH HHS [HG01536] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R29HG001536, R01HG001536] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BADER JS, IN PRESS NATURE BIOT; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Courey AJ, 2001, GENE DEV, V15, P2786; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dong XZ, 1997, GENE DEV, V11, P94, DOI 10.1101/gad.11.1.94; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Feller SM, 2002, MECH DEVELOP, V116, P129, DOI 10.1016/S0925-4773(02)00147-8; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Graham P, 2003, BIOESSAYS, V25, P1, DOI 10.1002/bies.10207; Graveley BR, 2002, CELL, V109, P409, DOI 10.1016/S0092-8674(02)00750-X; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; Guglielmi B, 2002, J BIOL CHEM, V277, P35712, DOI 10.1074/jbc.M205526200; Heinrichs V, 1997, P NATL ACAD SCI USA, V94, P115, DOI 10.1073/pnas.94.1.115; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jagla K, 2001, BIOESSAYS, V23, P125, DOI 10.1002/1521-1878(200102)23:2<125::AID-BIES1019>3.3.CO;2-3; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jimenez G, 1999, MOL CELL BIOL, V19, P2080; Jimenez G, 2000, GENE DEV, V14, P224; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Khush RS, 2002, CURR BIOL, V12, P1728, DOI 10.1016/S0960-9822(02)01214-9; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; Li SH, 2002, MOL CELL BIOL, V22, P6854, DOI 10.1128/MCB.22.19.6854-6865.2002; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pazman C, 2000, DEVELOPMENT, V127, P1715; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Raj L, 2000, CURR BIOL, V10, P1265, DOI 10.1016/S0960-9822(00)00745-4; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Reiter LT, 2001, GENOME RES, V11, P1114, DOI 10.1101/gr.169101; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sotkis A, 2001, CELL COMMUN ADHES, V8, P277, DOI 10.3109/15419060109080737; Sprinzak E, 2001, J MOL BIOL, V311, P681, DOI 10.1006/jmbi.2001.4920; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200	57	1762	1834	2	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	2003	302	5651					1727	1736		10.1126/science.1090289	http://dx.doi.org/10.1126/science.1090289			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	750AX	14605208				2022-12-28	WOS:000186970100038
J	Gould, MK; Kuschner, WG; Rydzak, CE; Maclean, CC; Demas, AN; Shigemitsu, H; Chan, JK; Owens, DK				Gould, MK; Kuschner, WG; Rydzak, CE; Maclean, CC; Demas, AN; Shigemitsu, H; Chan, JK; Owens, DK			Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer - A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							LYMPH-NODE METASTASES; FDG-PET SCAN; SOLITARY PULMONARY NODULES; HEAD GAMMA-CAMERA; F-18 FLUORODEOXYGLUCOSE; BRONCHOGENIC-CARCINOMA; COMPARATIVE EFFICACY; SYSTEMATIC REVIEWS; COST-EFFECTIVENESS; CLINICAL IMPACT	Purpose: To compare the diagnostic accuracy of computed tomography (CT) and positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) for mediastinal staging in patients with non-small-cell lung cancer and to determine whether test results are conditionally dependent (the sensitivity and specificity of FDG-PET depend on the presence or absence of enlarged mediastinal lymph nodes on CT). Data Sources: Computerized search of MEDLINE, EMBASE, BIOSIS, and CancerLit through March 2003 and reference lists of retrieved studies and review articles. Study Selection: Studies in any language that examined FDG-PET for mediastinal staging in patients with known or suspected non-small-cell lung cancer, enrolled at least 10 participants (including at least 5 participants with mediastinal metastasis), and provided enough data to permit calculation of sensitivity and specificity for identifying lymph node involvement. Data Extraction: One reviewer (of non-English-language studies) or 2 reviewers (of English-language studies) independently evaluated studies for inclusion, rated methodologic quality, and abstracted relevant data. Data Synthesis: Thirty-nine studies met inclusion criteria. Methodologic quality varied, but few aspects of study quality affected diagnostic accuracy. The authors constructed summary receiver-operating characteristic curves for CT and FDG-PET. Positron emission tomography with 18-fluorodeoxyglucose was more accurate than CT for identifying lymph node involvement (P < 0.001). For CT, median sensitivity and specificity were 61% (interquartile range, 50% to 71%) and 79% (interquartile range, 66% to 89%), respectively. For FDG-PET, median sensitivity and specificity were 85% (interquartile range, 67% to 91%) and 90% (interquartile range, 82% to 96%), respectively. Fourteen studies provided information about the conditional test performance of CT and FDG-PET. Positron emission tomography with 18-fluorodeoxyglucose was more sensitive but less specific when CT showed enlarged lymph nodes (median sensitivity, 100% [interquartile range, 90% to 100%]; median specificity, 78% [interquartile range, 68% to 100%]) than when CT showed no lymph node enlargement (median sensitivity, 82% [interquartile range, 65% to 100%]; median specificity, 93% [interquartile range, 92% to 100%]; P = 0.002). Conclusions: Positron emission tomography with 18-fluorodeoxyglucose is more accurate than CT for mediastinal staging. Positron emission tomography with 18-fluorodeoxyglucose is more sensitive but less specific when CT shows enlarged mediastinal lymph nodes.	Vet Affairs Palo Alto Hlth Care Syst, Pulm Sect, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Gould, MK (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Pulm Sect, 111P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	gould@stanford.edu		Kuschner, Ware/0000-0002-9732-1366				Adams S, 2000, NUKLEARMED-NUCL MED, V39, pN83; Albes JM, 1999, THORAC CARDIOV SURG, V47, P42, DOI 10.1055/s-2007-1013107; Albes JM, 2002, EUR J SURG ONCOL, V28, P55, DOI 10.1053/ejso.2001.1144; Begg C., 1994, HDB RES SYNTHESIS, P399; Berlangieri SU, 1999, EUR J CARDIO-THORAC, V16, pS25, DOI 10.1016/S1010-7940(99)00179-7; Bury T, 1996, REV MAL RESPIR, V13, P281; Bury T, 1996, EUR J NUCL MED, V23, P204, DOI 10.1007/BF01731846; Bury T, 1996, EUR RESPIR J, V9, P2560, DOI 10.1183/09031936.96.09122560; Bury T, 1997, EUR RESPIR J, V10, P2529, DOI 10.1183/09031936.97.10112529; Changlai SP, 2001, ONCOL REP, V8, P337; CHIN R, 1995, AM J RESP CRIT CARE, V152, P2090, DOI 10.1164/ajrccm.152.6.8520780; Cook GJR, 1996, CLIN RADIOL, V51, P603, DOI 10.1016/S0009-9260(96)80052-3; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; Demura Y, 2000, Nihon Kokyuki Gakkai Zasshi, V38, P676; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dietlein M, 2000, EUR J NUCL MED, V27, P1598, DOI 10.1007/s002590000376; Dillon WilliamR., 1984, MULTIVARIATE ANAL ME; Dunagan DP, 2001, CHEST, V119, P333, DOI 10.1378/chest.119.2.333; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.1093/biomet/68.3.589; Eschmann SM, 2002, EUR J NUCL MED MOL I, V29, P804, DOI 10.1007/s00259-002-0801-x; Farrell MA, 2000, RADIOLOGY, V215, P886, DOI 10.1148/radiology.215.3.r00jn29886; Ferlin G, 1997, TUMORI, V83, P679, DOI 10.1177/030089169708300311; Fisher LD., 1997, BIOMETRICS, V53, P1182; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Fritscher-Ravens A, 2003, CHEST, V123, P442, DOI 10.1378/chest.123.2.442; GARCIA AJT, 1997, ARCH BRONCONEUMOL, V33, P553; Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914; GOULD MK, 1998, AM J RESP CRIT CARE, V157, pA256; Graeber GM, 1999, J THORAC CARDIOV SUR, V117, P719, DOI 10.1016/S0022-5223(99)70292-8; Graeter TP, 2003, ANN THORAC SURG, V75, P231, DOI 10.1016/S0003-4975(02)04350-3; GRAHEK D, 2000, MED NUCL IMAGERIE FO, V24, P99; Guan Y, 2001, Zhonghua Yi Xue Za Zhi, V81, P1180; Guhlmann A, 1997, THORAX, V52, P438, DOI 10.1136/thx.52.5.438; Gupta N C, 2000, Clin Lung Cancer, V2, P146, DOI 10.3816/CLC.2000.n.028; Gupta NC, 2000, CHEST, V117, P773, DOI 10.1378/chest.117.3.773; Gupta NC, 1996, J NUCL MED, V37, P943; Gupta NC, 1999, ANN SURG, V229, P286, DOI 10.1097/00000658-199902000-00018; GUPTA NC, 1992, RADIOLOGY, V184, P441, DOI 10.1148/radiology.184.2.1620844; Gupta NC, 2001, CHEST, V120, P521, DOI 10.1378/chest.120.2.521; Hagberg RC, 1997, EUR J CARDIO-THORAC, V12, P92, DOI 10.1016/S1010-7940(97)00159-0; Hara T, 2000, J NUCL MED, V41, P1507; Higashi K, 1998, J NUCL MED, V39, P9; HIGASHI K, 1999, JAPANESE J CLIN RADI, V44, P191; Imdahl A, 2001, EUR J CARDIO-THORAC, V20, P324, DOI 10.1016/S1010-7940(01)00800-4; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Kalff V, 2001, J CLIN ONCOL, V19, P111, DOI 10.1200/JCO.2001.19.1.111; Kelsey J.L., 1996, METHODS OBSERVATIONA; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; Kernstine KH, 1999, ANN THORAC SURG, V68, P1022, DOI 10.1016/S0003-4975(99)00788-2; Kernstine KH, 2002, ANN THORAC SURG, V73, P394, DOI 10.1016/S0003-4975(01)03432-4; Kiernan PD, 2002, SOUTHERN MED J, V95, P1168; KITASE M, 2000, JAPANESE J CLIN RADI, V45, P209; KUBOTA K, 2000, JPN J CLIN RADIOL, V45, P199; Kutlu CA, 1998, LUNG CANCER-J IASLC, V21, P177, DOI 10.1016/S0169-5002(98)00026-9; Lardinois D, 2003, NEW ENGL J MED, V348, P2500, DOI 10.1056/NEJMoa022136; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LEWIS P, 1994, LANCET, V344, P1265, DOI 10.1016/S0140-6736(94)90753-6; Liewald F, 2000, THORAC CARDIOV SURG, V48, P93, DOI 10.1055/s-2000-9870; Lonneux M, 1998, NUCL MED COMMUN, V19, P1047, DOI 10.1097/00006231-199811000-00004; Lowe VJ, 1998, THORAX, V53, P703, DOI 10.1136/thx.53.8.703; Magnani P, 1999, J CARDIOVASC SURG, V40, P741; Marom EM, 1999, RADIOLOGY, V212, P803, DOI 10.1148/radiology.212.3.r99se21803; MATSUMOTO K, 1987, SHITSURYO BUNSEKI, V35, P15; MCLOUD TC, 1992, RADIOLOGY, V182, P319, DOI 10.1148/radiology.182.2.1732943; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Nettelbladt OS, 1998, J NUCL MED, V39, P640; Owens DK, 1996, ANN INTERN MED, V124, P803, DOI 10.7326/0003-4819-124-9-199605010-00004; Owens DK, 1996, JAMA-J AM MED ASSOC, V276, P1302; OWENS DK, 2000, MED INFORMATICS COMP; PATZ EF, 1995, CHEST, V108, P1617, DOI 10.1378/chest.108.6.1617; PATZ EF, 1994, RADIOL CLIN N AM, V32, P811; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Pieterman RM, 2002, J NUCL MED, V43, P167; Poncelet AJ, 2001, EUR J CARDIO-THORAC, V20, P468, DOI 10.1016/S1010-7940(01)00827-2; PRIMACK SL, 1994, RADIOLOGY, V193, P795, DOI 10.1148/radiology.193.3.7972827; Richter JA, 1999, MED CLIN-BARCELONA, V113, P567; Roberts PF, 2000, ANN THORAC SURG, V70, P1154, DOI 10.1016/S0003-4975(00)01769-0; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; Roman MR, 2001, CLIN NUCL MED, V26, P383, DOI 10.1097/00003072-200105000-00001; Rubinstein R, 2001, Harefuah, V140, P100; Ryu JS, 2002, LUNG CANCER, V35, P179, DOI 10.1016/S0169-5002(01)00332-4; Sasaki M, 1996, EUR J NUCL MED, V23, P741, DOI 10.1007/BF00843701; Saunders CAB, 1999, ANN THORAC SURG, V67, P790, DOI 10.1016/S0003-4975(98)01257-0; Sazon DAD, 1996, AM J RESP CRIT CARE, V153, P417, DOI 10.1164/ajrccm.153.1.8542152; Schelbert HR, 1998, J NUCL MED, V39, P1302; Scott WJ, 1998, ANN THORAC SURG, V66, P1876, DOI 10.1016/S0003-4975(98)01055-8; Scott WJ, 1996, J THORAC CARDIOV SUR, V111, P642, DOI 10.1016/S0022-5223(96)70317-3; SCOTT WJ, 1994, ANN THORAC SURG, V58, P698, DOI 10.1016/0003-4975(94)90730-7; SCOTT WJ, 1995, CHEST, V107, P1174, DOI 10.1378/chest.107.4.1174; Shreve PD, 1998, RADIOLOGY, V207, P431, DOI 10.1148/radiology.207.2.9577492; Steinert HC, 1997, RADIOLOGY, V202, P441, DOI 10.1148/radiology.202.2.9015071; Stokkel MPM, 1999, NUCL MED COMMUN, V20, P1001, DOI 10.1097/00006231-199911000-00004; Sugio K, 1999, Nihon Geka Gakkai Zasshi, V100, P718; Tatsumi M, 1999, J NUCL MED, V40, P566; Tatsumi M, 2000, J COMPUT ASSIST TOMO, V24, P574, DOI 10.1097/00004728-200007000-00011; TRAMPERT L, 1995, NUKLEARMED, V34, P79; Valk PE, 1995, ANN THORAC SURG, V60, P1573, DOI 10.1016/0003-4975(95)00752-0; Vansteenkiste JF, 1998, J CLIN ONCOL, V16, P2142, DOI 10.1200/JCO.1998.16.6.2142; Vansteenkiste JF, 1998, EUR J NUCL MED, V25, P1495, DOI 10.1007/s002590050327; Vansteenkiste JF, 1997, CHEST, V112, P1480, DOI 10.1378/chest.112.6.1480; Vesselle H, 2002, J THORAC CARDIOV SUR, V124, P511, DOI 10.1067/mtc.2002.123130; von Haag DW, 2002, J SURG RES, V103, P160, DOI 10.1006/jsre.2002.6354; WAHL RL, 1994, RADIOLOGY, V191, P371, DOI 10.1148/radiology.191.2.8153308; Wang H, 1997, CLIN NUCL MED, V22, P243, DOI 10.1097/00003072-199704000-00008; WEBB WR, 1991, RADIOLOGY, V178, P705, DOI 10.1148/radiology.178.3.1847239; Weber WA, 1999, EUR J NUCL MED, V26, P388, DOI 10.1007/s002590050402; Weng E, 2000, AM J CLIN ONCOL-CANC, V23, P47, DOI 10.1097/00000421-200002000-00014	109	501	546	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					879	892		10.7326/0003-4819-139-11-200311180-00013	http://dx.doi.org/10.7326/0003-4819-139-11-200311180-00013			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644890				2022-12-28	WOS:000186884800001
J	Garattini, S; Bertele, V; Bassi, LL				Garattini, S; Bertele, V; Bassi, LL			European Council waters down European Parliament's drug-regulatory legislation	LANCET			English	Editorial Material									Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, S (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.		Bertele, Vittorio/AAA-6461-2020; Garattini, Silvio/AAA-6390-2020	Bertele, Vittorio/0000-0002-0032-7033; Garattini, Silvio/0000-0003-0647-9297				Garattini S, 2003, LANCET, V361, P635, DOI 10.1016/S0140-6736(03)12615-3; Garattini S, 2001, LANCET, V358, P64, DOI 10.1016/S0140-6736(00)05258-2	2	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1688	1689		10.1016/S0140-6736(03)14882-9	http://dx.doi.org/10.1016/S0140-6736(03)14882-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643114				2022-12-28	WOS:000186767700004
J	Tattersall, M				Tattersall, M			Learning from experience?	LANCET			English	Editorial Material									Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia	University of Sydney	Tattersall, M (corresponding author), Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1745	1745		10.1016/S0140-6736(03)14855-6	http://dx.doi.org/10.1016/S0140-6736(03)14855-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643125				2022-12-28	WOS:000186767700024
J	Wolf, G; Stahl, RAK				Wolf, G; Stahl, RAK			CD2-associated protein and glomerular disease	LANCET			English	Review							CONGENITAL NEPHROTIC SYNDROME; SLIT DIAPHRAGM; RENAL-DISEASES; NEPHRIN; CD2AP; GLOMERULOSCLEROSIS; MUTATIONS; PODOCYTE	Context Proteinuria is a major cause of progression in renal disease. The glomerular ultrafiltration barrier, containing highly differentiated podocytes, normally restricts protein access to the urine. Patients with urinary protein in the nephrotic range (>3.5 g daily) often have effaced podocyte foot-processes. Slit diaphragms span the gaps between foot processes as a barrier to macromolecules. Nephrin and podocin are slit-diaphragm proteins identified in families with congenital nephrotic syndromes. CD2-associated protein (CD2AP) is an adapter protein originally identified as a novel ligand interacting with the T-cell-adhesion protein CD2. CD2AP knockout mice develop a congenital nephrotic syndrome with podocyte foot-process effacements and die at 6 weeks. of age from renal failure. CD2AP localises to the slit diaphragm and links nephrin and podocin to phosphoinositide 3-OH kinase; this complex has cell-signalling properties. Starting point The CD2AP +/- heterozygous mice developed by Jeong Kim and colleagues (Science 2003; 300: 1298-300) are haploinsufficient and develop glomerular changes at 9 months of age with a histological pattern similar to that in human focal segmental glomerulosclerosis. These researchers found that 2 of 30 African-American patients with idiopathic-focal segmental glomerulosclerosis had a CD2AP mutation that ablated expression of one allele. Where next? Further studies should address the normal distribution of the CD2AP heterozygous mutation in different ethnic populations, because the association with human idiopathic focal segmental glomerulosclerosis could be accidental. Decreased expression of CD2AP in podocytes of individuals with the CD2AP heterozygous mutation would help to understand how the haploinsufficiency translates into increased susceptibility to renal disease. Transfection of podocytes with-mutated CD2AP or study of cultured podocytes from CD2AP +/- mice would provide further insight into whether the nephrin-podocin-CD2AP signal-transduction pathway is altered and leads to increased apoptosis of pododytes.,, Assuming that a decrease in CD2AP attenuates clearance of glomerular immune complexes, patients with other types of idiopathic glomerulonephritis should also have a CD2AP mutation. However, first studies looking at, the most common form of glomerulonephritis, IgA nephropathy, have failed to show decreased renal CD2AP expression.	Univ Hamburg, Dept Med, Div Nephrol Rheumatol & Osteol, D-20246 Hamburg, Germany	University of Hamburg	Wolf, G (corresponding author), Univ Hamburg, Dept Med, Div Nephrol Rheumatol & Osteol, Martinistr 52, D-20246 Hamburg, Germany.							Ahola H, 2003, J AM SOC NEPHROL, V14, P1731, DOI 10.1097/01.ASN.0000075553.33781.9F; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gagliardini E, 2003, AM J NEPHROL, V23, P277, DOI 10.1159/000072281; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kerjaschki D, 2001, J CLIN INVEST, V108, P1583, DOI 10.1172/JCI200114629; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KIRN JM, 2003, SCIENCE, V300, P1298; Kriz W, 1999, CURR OPIN NEPHROL HY, V8, P489, DOI 10.1097/00041552-199907000-00014; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Patrakka J, 2000, KIDNEY INT, V58, P972, DOI 10.1046/j.1523-1755.2000.00254.x; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruggenenti P, 2001, LANCET, V357, P1601, DOI 10.1016/S0140-6736(00)04728-0; Salant DJ, 2003, SPRINGER SEMIN IMMUN, V24, P423, DOI 10.1007/s00281-002-0102-2; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312	20	59	69	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1746	1748		10.1016/S0140-6736(03)14856-8	http://dx.doi.org/10.1016/S0140-6736(03)14856-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643126				2022-12-28	WOS:000186767700025
J	Thompson, M; Haeusler, RA; Good, PD; Engelke, DR				Thompson, M; Haeusler, RA; Good, PD; Engelke, DR			Nucleolar clustering of dispersed tRNA genes	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; RIBONUCLEASE-P; YEAST; LOCALIZATION; 5S; HYBRIDIZATION; TRANSCRIPTION; COMPLEXES; SUBUNIT; REGION	Early transfer RNA (tRNA) processing events in Saccharomyces cerevisiae are co-ordinated in the nucleolus, the site normally associated with ribosome biosynthesis. To test whether spatial organization of the tRNA pathway begins with nucleolar clustering of the genes, we have probed the subnuclear location of five different tRNA gene families. The results show that tRNA genes, though dispersed in the linear genome, colocalize with 5S ribosomal DNA and U14 small nucleolar RNA at the nucleolus. Nucleolar localization requires tRNA gene transcription-complex formation, because inactivation of the promoter at a single locus removes its nucleolar association. This organization of tRNA genes must profoundly affect the spatial packaging of the genome and raises the question of whether gene types might be coordinated in three dimensions to regulate transcription.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Engelke, DR (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Haeusler, Rebecca/0000-0002-6973-9845	NIGMS NIH HHS [GM63142, T32 GM007544, R01 GM063142] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063142, T32GM007544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; Bolton EC, 2003, GENOME RES, V13, P254, DOI 10.1101/gr.612203; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Hediger F, 2002, CURR BIOL, V12, P2076, DOI 10.1016/S0960-9822(02)01338-6; HIGHETT MI, 1993, J CELL SCI, V105, P1151; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; HULL M, 1994, MOL CELL BIOL, V14, P3244; Jacobson MR, 1997, J CELL SCI, V110, P829; Jarrous N, 1999, J CELL BIOL, V146, P559, DOI 10.1083/jcb.146.3.559; KAPLAN FS, 1993, GENOMICS, V15, P123, DOI 10.1006/geno.1993.1020; Kendall A, 2000, P NATL ACAD SCI USA, V97, P13108, DOI 10.1073/pnas.240454997; KINSEY PT, 1991, NUCLEIC ACIDS RES, V19, P1317, DOI 10.1093/nar/19.6.1317; Lee B, 1996, P NATL ACAD SCI USA, V93, P11471, DOI 10.1073/pnas.93.21.11471; LEE Y, 1995, NUCLEIC ACIDS RES, V23, P634, DOI 10.1093/nar/23.4.634; LILJELUND P, 1992, P NATL ACAD SCI USA, V89, P9302, DOI 10.1073/pnas.89.19.9302; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; Montijn MB, 1999, CHROMOSOME RES, V7, P387, DOI 10.1023/A:1009272115295; NARAYANSWAMI S, 1990, CYTOMETRY, V11, P144, DOI 10.1002/cyto.990110117; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241	26	245	267	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1399	1401		10.1126/science.1089814	http://dx.doi.org/10.1126/science.1089814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631041	Green Published, Green Accepted			2022-12-28	WOS:000186683500053
J	Zhong, ZH; Wang, DL; Cui, Y; Bockrath, MW; Lieber, CM				Zhong, ZH; Wang, DL; Cui, Y; Bockrath, MW; Lieber, CM			Nanowire crossbar arrays as address decoders for integrated nanosystems	SCIENCE			English	Article							CARBON-NANOTUBE; LOGIC GATES; BUILDING-BLOCKS; ELECTRONICS; CIRCUITS; TRANSISTORS; DEVICES	The development of strategies for addressing arrays of nanoscale devices is central to the implementation of integrated nanosystems such as biological sensor arrays and nanocomputers. We report a general approach for addressing based on molecular-level modification of crossed semiconductor nanowire field-effect transistor (cNW-FET) arrays, where selective chemical modi. cation of cross points in the arrays enables NW inputs to turn specific FET array elements on and off. The chemically modified cNW-FET arrays function as decoder circuits, exhibit gain, and allow multiplexing and demultiplexing of information. These results provide a step toward the realization of addressable integrated nanosystems in which signals are restored at the nanoscale.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA	Harvard University; Harvard University; California Institute of Technology	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.		Cui, Yi/L-5804-2013	Cui, Yi/0000-0002-6103-6352				Chen Y, 2003, NANOTECHNOLOGY, V14, P462, DOI 10.1088/0957-4484/14/4/311; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Cui Y, 2003, NANO LETT, V3, P149, DOI 10.1021/nl025875l; DeHon A, 2003, IEEE T NANOTECHNOL, V2, P23, DOI 10.1109/TNANO.2003.808508; Derycke V, 2001, NANO LETT, V1, P453, DOI 10.1021/nl015606f; Duan XF, 2003, NATURE, V421, P241, DOI 10.1038/nature01353; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Javey A, 2002, NAT MATER, V1, P241, DOI 10.1038/nmat769; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Lauhon LJ, 2002, NATURE, V420, P57, DOI 10.1038/nature01141; Luo Y, 2002, CHEMPHYSCHEM, V3, P519, DOI 10.1002/1439-7641(20020617)3:6<519::AID-CPHC519>3.0.CO;2-2; Melosh NA, 2003, SCIENCE, V300, P112, DOI 10.1126/science.1081940; Paul D., 2001, TECHNOLOGY ROADMAP N; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Rueckes T, 2000, SCIENCE, V289, P94, DOI 10.1126/science.289.5476.94; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Whang D, 2003, NANO LETT, V3, P1255, DOI 10.1021/nl0345062	23	519	566	6	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1377	1379		10.1126/science.1090899	http://dx.doi.org/10.1126/science.1090899			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631034				2022-12-28	WOS:000186683500046
J	Berner, RA				Berner, RA			The long-term carbon cycle, fossil fuels and atmospheric composition	NATURE			English	Article							ORGANIC-CARBON; SEAWATER COMPOSITION; CENOZOIC EVOLUTION; OXYGEN-CONTENT; CO2; SULFUR; MODEL; PRESERVATION; SEDIMENTS; BURIAL	The long-term carbon cycle operates over millions of years and involves the exchange of carbon between rocks and the Earth's surface. There are many complex feedback pathways between carbon burial, nutrient cycling, atmospheric carbon dioxide and oxygen, and climate. New calculations of carbon fluxes during the Phanerozoic eon (the past 550 million years) illustrate how the long-term carbon cycle has affected the burial of organic matter and fossil-fuel formation, as well as the evolution of atmospheric composition.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University	Berner, RA (corresponding author), Yale Univ, Dept Geol & Geophys, POB 6666, New Haven, CT 06520 USA.	robert.berner@yale.edu						BERGMAN N, 2003, EUR GEOPH SOC GEOPH, V5, P11208; BERNER RA, 1983, GEOCHIM COSMOCHIM AC, V47, P855, DOI 10.1016/0016-7037(83)90151-5; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; Berner RA, 2003, ANNU REV EARTH PL SC, V31, P105, DOI 10.1146/annurev.earth.31.100901.141329; Berner RA, 2001, GEOCHIM COSMOCHIM AC, V65, P685, DOI 10.1016/S0016-7037(00)00572-X; BERNER RA, 1989, AM J SCI, V289, P333, DOI 10.2475/ajs.289.4.333; BERRY WBN, 1978, AM J SCI, V278, P257, DOI 10.2475/ajs.278.3.257; BESTOUGEFF MA, 1980, 26TH INT GEOL CONG P, V35, P353; BETTS JN, 1991, GLOBAL PLANET CHANGE, V97, P5, DOI 10.1016/0031-0182(91)90178-T; CANFIELD DE, 1994, CHEM GEOL, V114, P315, DOI 10.1016/0009-2541(94)90061-2; Colman A. S., 2000, MARINE AUTHIGENESIS, P53, DOI DOI 10.2110/PEC.00.66; Crowley T. J., 1991, PALEOCLIMATOLOGY; Crowley TJ, 2001, SCIENCE, V292, P870, DOI 10.1126/science.1061664; DEMAISON GJ, 1980, AAPG BULL, V64, P1179; Ebelmen J.J., 1845, ANN REV MINES, V12, P627; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; GARRELS RM, 1976, AM SCI, V64, P306; GARRELS RM, 1984, AM J SCI, V284, P989, DOI 10.2475/ajs.284.9.989; Hansen KW, 2003, AM J SCI, V303, P94, DOI 10.2475/ajs.303.2.94; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; Hedges JI, 1999, AM J SCI, V299, P529, DOI 10.2475/ajs.299.7-9.529; Holland H. D., 1978, CHEM ATMOSPHERE OCEA; KLEMME HD, 1991, AAPG BULL, V75, P1809; KORTE C, 2003, EUR GEOPH SOC GEOPH, V5, P13061; Lenton TM, 2000, GLOBAL BIOGEOCHEM CY, V14, P249, DOI 10.1029/1999GB900076; PEDERSEN TF, 1990, AAPG BULL, V74, P454; Royer DL, 2001, EARTH-SCI REV, V54, P349, DOI 10.1016/S0012-8252(00)00042-8; Strauss H, 1999, CHEM GEOL, V161, P89, DOI 10.1016/S0009-2541(99)00082-0; Tajika E, 1998, EARTH PLANET SC LETT, V160, P695, DOI 10.1016/S0012-821X(98)00121-6; Urey H.C., 1952, PLANETS THEIR ORIGIN, DOI [10.1063/1.3067687, DOI 10.1063/1.3067687]; VanCappellen P, 1996, SCIENCE, V271, P493, DOI 10.1126/science.271.5248.493; Veizer J, 1999, CHEM GEOL, V161, P59, DOI 10.1016/S0009-2541(99)00081-9; WALKER JCG, 1986, MAR GEOL, V70, P159, DOI 10.1016/0025-3227(86)90093-9; Wallmann K, 2001, GEOCHIM COSMOCHIM AC, V65, P3005, DOI 10.1016/S0016-7037(01)00638-X; Watson R.T., 2001, CLIMATE CHANGE 2001, P388; WEISSERT H, 1989, SURV GEOPHYS, V10, P1, DOI 10.1007/BF01901664	37	317	348	26	286	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					323	326		10.1038/nature02131	http://dx.doi.org/10.1038/nature02131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628061				2022-12-28	WOS:000186660800053
J	Herman, JG; Baylin, SB				Herman, JG; Baylin, SB			Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-SUPPRESSOR GENE; CPG-ISLAND METHYLATION; CELL LUNG-CANCER; HISTONE DEACETYLASE INHIBITION; DNA METHYLTRANSFERASE GENE; ABERRANT P16 METHYLATION; LEUKEMIA GROUP-B; MOLECULAR-DETECTION; COLORECTAL-CANCER; BREAST-CANCER		Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Herman, JG (corresponding author), Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.	hermanji@jhmi.edu; sbaylin@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA058184, U01CA084986, R01CA043318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011858] Funding Source: NIH RePORTER; NCI NIH HHS [UO1CA84986, P50CA58184, R01CA43318] Funding Source: Medline; NIEHS NIH HHS [ES11858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahuja N, 1998, CANCER RES, V58, P5489; Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bestor TH, 1998, CIBA F SYMP, V214, P187; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1998, NOVART FDN SYMP, V214, P228; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cairns P, 2001, CLIN CANCER RES, V7, P2727; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Cohen O, 1999, J CELL BIOL, V146, P141; Corn PG, 1999, CANCER RES, V59, P3352; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Eads CA, 2002, CANCER RES, V62, P1296; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Esteller M, 2000, NEW ENGL J MED, V343, P1740; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, J NATL CANCER I, V94, P26; Esteller M, 1999, CANCER RES, V59, P3853; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fahrner JA, 2002, CANCER RES, V62, P7213; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1987, SEMIN SURG ONCOL, V3, P149, DOI 10.1002/ssu.2980030304; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Goessl C, 2001, ANN NY ACAD SCI, V945, P51; Grady WM, 2001, CANCER RES, V61, P900; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hibi K, 2001, CLIN CANCER RES, V7, P3135; Holliday R, 1993, EXS, V64, P452; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kornblith AB, 2002, J CLIN ONCOL, V20, P2441, DOI 10.1200/JCO.2002.04.044; Kuzmichev A, 2001, CURR TOP MICROBIOL, V254, P35; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee TL, 2002, CLIN CANCER RES, V8, P1761; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P287, DOI 10.1016/0163-7258(85)90053-1; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Nguyen CT, 2002, CANCER RES, V62, P6456; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Palmisano WA, 2000, CANCER RES, V60, P5954; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Richon VM, 2002, CLIN CANCER RES, V8, P662; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Riggs A. D., 1996, EPIGENETIC MECH GENE, P29; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson John A., 2001, American Journal of Bioethics, V1, P2, DOI 10.1162/152651601300048143; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sanchez-Cespedes M, 1999, CLIN CANCER RES, V5, P2450; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Shao ZM, 2002, ANTI-CANCER DRUG, V13, P353, DOI 10.1097/00001813-200204000-00003; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; TAYLOR SM, 1982, J CELL PHYSIOL, V111, P187, DOI 10.1002/jcp.1041110210; Usadel H, 2002, CANCER RES, V62, P371; VESELY J, 1985, PHARMACOL THERAPEUT, V28, P227, DOI 10.1016/0163-7258(85)90012-9; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wessels LFA, 2002, CANCER RES, V62, P7110; Wong IHN, 1999, CANCER RES, V59, P71; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007; Zou HZ, 2002, CLIN CANCER RES, V8, P188	130	2540	2723	9	292	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2042	2054		10.1056/NEJMra023075	http://dx.doi.org/10.1056/NEJMra023075			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627790				2022-12-28	WOS:000186642900010
J	Skinner, G; Gorenstein, P				Skinner, G; Gorenstein, P			Astronomy - Black holes, fleas and microlithography	NATURE			English	Editorial Material							HIGH-ENERGY ASTRONOMY; OPTICS		Ctr Etud Spatiale Rayonnements, F-31208 Toulouse, France; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Skinner, G (corresponding author), Ctr Etud Spatiale Rayonnements, F-31208 Toulouse, France.							Cash W, 2003, P SOC PHOTO-OPT INS, V4852, P196, DOI 10.1117/12.460915; GIL D, IN PRESS J VAC SCI B; Gorenstein P, 2003, P SOC PHOTO-OPT INS, V4851, P599, DOI 10.1117/12.461605; Jerius D, 2000, P SOC PHOTO-OPT INS, V4012, P17, DOI 10.1117/12.391555; *NASA STRUCT EV UN, 2003, EINST BIG BANG BLACK; Skinner GK, 2002, ASTRON ASTROPHYS, V383, P352, DOI 10.1051/0004-6361:20011700; Skinner GK, 2001, ASTRON ASTROPHYS, V375, P691, DOI 10.1051/0004-6361:20010745; White N, 2000, NATURE, V407, P146, DOI 10.1038/35025179	8	3	3	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					245	246		10.1038/426245b	http://dx.doi.org/10.1038/426245b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628040				2022-12-28	WOS:000186660800032
J	Sloan, ED				Sloan, ED			Fundamental principles and applications of natural gas hydrates	NATURE			English	Review							METHANE HYDRATE; CLATHRATE; DISSOCIATION	Natural gas hydrates are solid, non-stoichiometric compounds of small gas molecules and water. They form when the constituents come into contact at low temperature and high pressure. The physical properties of these compounds, most notably that they are non-flowing crystalline solids that are denser than typical fluid hydrocarbons and that the gas molecules they contain are effectively compressed, give rise to numerous applications in the broad areas of energy and climate effects. In particular, they have an important bearing on flow assurance and safety issues in oil and gas pipelines, they offer a largely unexploited means of energy recovery and transportation, and they could play a significant role in past and future climate change.	Colorado Sch Mines, Ctr Hydrate Res, Golden, CO 80401 USA	Colorado School of Mines	Sloan, ED (corresponding author), Colorado Sch Mines, Ctr Hydrate Res, Golden, CO 80401 USA.	esloan@.mines.edu						Ballard A., 2002, P 4 INT C GAS HYDR; Bishnoi PR, 1996, FLUID PHASE EQUILIBR, V117, P168, DOI 10.1016/0378-3812(95)02950-8; DALLIMORE SR, 1999, GEOLOGICAL SURVEY CA, V544, P1; Davidson D.W., 1973, WATER COMPREHENSIVE, Vvol. 2; DAVIDSON DW, 1984, NATURE, V311, P142, DOI 10.1038/311142a0; Dickens GR, 2003, SCIENCE, V299, P1017, DOI 10.1126/science.1080789; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Dickens GR, 2000, B SOC GEOL FR, V171, P37; Dillon WP, 1998, GEOL SOC SPEC PUBL, V137, P293, DOI 10.1144/GSL.SP.1998.137.01.23; ENGLEZOS P, 1993, IND ENG CHEM RES, V32, P1251, DOI 10.1021/ie00019a001; Gudmundsson J, 1996, NGH '96 - 2ND INTERNATIONAL CONFERENCE ON NATURAL GAS HYDRATES, PROCEEDINGS, P415; GUDMUNDSSON J, ANN NY ACAD SCI, V912, P403; Hendriks EM, 1996, FLUID PHASE EQUILIBR, V117, P193, DOI 10.1016/0378-3812(95)02953-2; HESTER K, IN PRESS FLUID PHASE; HOLDER GD, 1982, CHEM ENG SCI, V37, P9, DOI 10.1016/0009-2509(82)80062-6; Huo ZX, 2003, AICHE J, V49, P1300, DOI 10.1002/aic.690490521; Kaiho K, 1996, PALEOCEANOGRAPHY, V11, P447, DOI 10.1029/96PA01021; Kennett JP, 2003, METHANE HYDRATES QUA; KOBAYASHI R, 1949, J PETROL TECHNOL, V2579, P66; Koen Billy Vaughn, 2003, DISCUSSION METHOD CO; KVENVOLDEN KA, 1998, METHANE HYDRATES RES; Makogon Y. F., 1997, HYDRATES HYDROCARBON; Mao WL, 2002, SCIENCE, V297, P2247, DOI 10.1126/science.1075394; MASLIN M, 2003, GEOPH RES ABSTR, V5, P12015; Mehta AP, 2003, SPE PROD FACIL, V18, P73, DOI 10.2118/81927-PA; MILKOV AV, 2002, P 4 INT C GAS HYDRAT, P111; MORIDIS G, 2002, P 4 INT C GAS HYDR, P239; Nakajima Y., 2002, P 4 INT C GAS HYDR, P987; Paull C.K., 2000, P OC DRILL PROGR SCI, V164, P3, DOI DOI 10.2973/ODP.PROC.SR.164.204.2000; Paull C.K., 2001, NATURAL GAS HYDRATES; Ripmeester JA, 2000, ANN NY ACAD SCI, V912, P1; RIPMEESTER JA, 1987, NATURE, V325, P135, DOI 10.1038/325135a0; SHIROTA H, 2002, P 4 INT C GAS HYDR; Sloan E. D., 1998, CLATHRATE HYDRATES N; Sloan E.D., 2000, HYDRATE ENG; Sloan ED, 1998, GEOL SOC SPEC PUBL, V137, P31, DOI 10.1144/GSL.SP.1998.137.01.03; Sloan ED, 2003, J CHEM THERMODYN, V35, P41; SOLOVIEV V, 1987, CRYOGEOTHERMY NATURA; STAYKOVA DK, 2002, P 4 INT C GAS HYDRAT; Subramanian S, 2000, CHEM ENG SCI, V55, P1981, DOI 10.1016/S0009-2509(99)00389-9; VANDERWAALS JH, 1959, ADV CHEM PHYS, V2, P1; von Stackelberg M, 1949, NATURWISSENSCHAFTEN, V11-12, P1	43	1943	2046	60	1265	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					353	359		10.1038/nature02135	http://dx.doi.org/10.1038/nature02135			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628065				2022-12-28	WOS:000186660800057
J	McLaughlin, T; Abbasi, F; Cheal, K; Chu, J; Lamendola, C; Reaven, G				McLaughlin, T; Abbasi, F; Cheal, K; Chu, J; Lamendola, C; Reaven, G			Use of metabolic markers to identify overweight individuals who are insulin resistant	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; MEDIATED GLUCOSE DISPOSAL; HIGH-DENSITY-LIPOPROTEIN; DEPENDENT DIABETES-MELLITUS; WEIGHT-LOSS; HDL-CHOLESTEROL; OBESITY; RISK; HYPERINSULINEMIA; PREDICTOR	Background: Insulin resistance is more common in overweight individuals and is associated with increased risk for type 2 diabetes mellitus and cardiovascular disease. Given the current epidemic of obesity and the fact that lifestyle interventions, such as weight loss and exercise, decrease insulin resistance, a relatively simple means to identify overweight individuals who are insulin resistant would be clinically useful. Objective: To evaluate the ability of metabolic markers associated with insulin resistance and increased risk for cardiovascular disease to identify the subset of overweight individuals who are insulin resistant. Design: Cross-sectional study. Setting: General clinical research center. Patients: 258 nondiabetic, normotensive overweight volunteers. Measurements: Body mass index; fasting glucose, insulin, lipid and lipoprotein concentrations; and insulin-mediated glucose disposal as quantified by the steady-state plasma glucose concentration during the insulin suppression test. Overweight was defined as body mass index of 25 kg/m(2) or greater, and insulin resistance was defined as being in the top tertile of steady-state plasma glucose concentrations. Receiver-operating characteristic curve analysis was used to identify the best markers of insulin resistance; optimal cut-points were identified and analyzed for predictive power. Results: Plasma triglyceride concentration, ratio,of triglyceride to high-density lipoprotein cholesterol concentrations, and insulin concentration were the most useful metabolic markers in identifying insulin-resistant individuals. The optimal cut-points were 1.47 mmol/L (130 mg/dL) for triglycericle, 1.8 in SI units (3.0 in traditional units) for the triglyceride-high-density lipoprotein cholesterol ratio, and 109 pmol/L for insulin. Respective sensitivity and specifity for these cut-points were 67%, 64%, and 57% and 71%, 68%, and 85%. Their ability to identify insulin-resistant individuals was similar to the ability of the criteria proposed by the Adult Treatment Panel III to diagnose the metabolic syndrome (sensitivity, 52%, and specificity, 85%). Conclusions: Three relatively simple metabolic markers can help identify overweight individuals who are sufficiently insulin resistant to be at increased risk for various adverse outcomes. In the absence of a standardized insulin assay, we suggest that the most practical approach to identify overweight individuals who are insulin resistant is to use the cut-points for either triglycericle concentration or the triglyceride-high-density lipoprotein cholesterol concentration ratio.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Div Cardiovasc Med, Stanford, CA 94305 USA	Stanford University	Reaven, G (corresponding author), Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Div Cardiovasc Med, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016071] Funding Source: NIH RePORTER; NCRR NIH HHS [RR000070-40, RR16071-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abbasi F, 2002, J AM COLL CARDIOL, V40, P937, DOI 10.1016/S0735-1097(02)02051-X; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; Facchini FS, 2001, J CLIN ENDOCR METAB, V86, P3574, DOI 10.1210/jc.86.8.3574; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; GREENFIELD MS, 1981, DIABETES, V30, P387, DOI 10.2337/diabetes.30.5.387; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Jeppesen J, 1998, J INTERN MED, V243, P293; Jeppesen J, 2001, ARCH INTERN MED, V161, P361, DOI 10.1001/archinte.161.3.361; Jones CNO, 2000, AM J PHYSIOL-ENDOC M, V278, pE501, DOI 10.1152/ajpendo.2000.278.3.E501; KADISH AH, 1968, CLIN CHEM, V14, P116; Khan LK, 2001, ANN INTERN MED, V134, P282, DOI 10.7326/0003-4819-134-4-200102200-00011; KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LAWS A, 1992, J INTERN MED, V231, P25, DOI 10.1111/j.1365-2796.1992.tb00494.x; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; McLaughlin T, 2002, CIRCULATION, V106, P2908, DOI 10.1161/01.CIR.0000041046.32962.86; McLaughlin T, 2001, METABOLISM, V50, P795, DOI 10.1053/meta.2001.24210; McLaughlin T, 1999, J CLIN ENDOCR METAB, V84, P578, DOI 10.1210/jc.84.2.578; MILLER GJ, 1975, LANCET, V1, P16; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; PEI D, 1994, DIABETOLOGIA, V37, P843, DOI 10.1007/BF00404344; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; Reaven G, 2001, AM J CARDIOL, V87, P827, DOI 10.1016/S0002-9149(00)01521-6; REAVEN GM, 1993, DIABETES, V42, P1324, DOI 10.2337/diabetes.42.9.1324; REAVEN GM, 2001, HDB PHYSL 7, V2, P1169; SHEN SW, 1970, J CLIN INVEST, V49, P2151, DOI 10.1172/JCI106433; Tuan CY, 2003, AM J CARDIOL, V92, P606, DOI 10.1016/S0002-9149(03)00735-5; WAHLEFELD A., 1974, METHOD ENZYMAT AN, P1831; WHO Expert Comm, 1998, WHO TECH REP SER, V881, P1; Woodward M., 2014, EPIDEMIOLOGY STUDY D; Yeni-Komshian H, 2000, DIABETES CARE, V23, P171, DOI 10.2337/diacare.23.2.171; Yip J, 1998, J CLIN ENDOCR METAB, V83, P2773, DOI 10.1210/jc.83.8.2773; ZAVARONI I, 1994, J INTERN MED, V235, P51, DOI 10.1111/j.1365-2796.1994.tb01031.x; Zavaroni I, 1999, METABOLISM, V48, P989, DOI 10.1016/S0026-0495(99)90195-6	43	687	714	3	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					802	809		10.7326/0003-4819-139-10-200311180-00007	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744ZV	14623617				2022-12-28	WOS:000186663500002
J	Degos, B; Echaniz-Laguna, A; Tranchant, C				Degos, B; Echaniz-Laguna, A; Tranchant, C			Clinical picture - A carpenter with dementia	LANCET			English	Editorial Material									Hospices Civils Strasbourg, Neurol Clin, Serv Malad Syst Nerveux & Muscle, F-67091 Strasbourg, France	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Degos, B (corresponding author), Hospices Civils Strasbourg, Neurol Clin, Serv Malad Syst Nerveux & Muscle, 1 Pl Hop,BP426, F-67091 Strasbourg, France.			tranchant, christine/0000-0002-2895-1292					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1647	1647		10.1016/S0140-6736(03)14799-X	http://dx.doi.org/10.1016/S0140-6736(03)14799-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630447				2022-12-28	WOS:000186637400024
J	Royston, D; Cox, F				Royston, D; Cox, F			Anaesthesia: the patient's point of view	LANCET			English	Review							AUDITORY-EVOKED-RESPONSE; POSTOPERATIVE COGNITIVE DYSFUNCTION; ARTERY BYPASS-SURGERY; THORACIC EPIDURAL-ANESTHESIA; RANDOMIZED CONTROLLED TRIAL; GENERAL-ANESTHESIA; CARDIAC-SURGERY; PULSE OXIMETRY; COHERENT FREQUENCY; BISPECTRAL INDEX	Patients scheduled for surgical procedures continue to express concerns about their safety, outcome, and comfort. All medical interventions carry risks, but the patient often considers anaesthesia as the intervention with the greatest risk. Many still worry that they will not wake up after their surgery, or that they will be awake during the operation. Such events have received attention from the media, but are very rare. Challenges to Improve the comfort of patients continue, especially with regard to the almost universal problems of nausea, vomiting, and pain after surgery. A newer concern is that patients will develop some degree of mental impairment that may delay return to a full work and social lifestyle for days and weeks. Developments in technology, education, and training have had a major effect on anaesthetic practice, so that anaesthesia is increasingly regarded as safe for the patient. This article explores patients' concerns, and considers whether science and technology help to provide solutions to these complex difficulties.	Harefield Hosp, Royal Brompton & Harefield NHS Trust, Harefield UB9 6JH, Middx, England	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital	Royston, D (corresponding author), Harefield Hosp, Royal Brompton & Harefield NHS Trust, Hill End Rd, Harefield UB9 6JH, Middx, England.	Dave@tharg.demon.co.uk						Ancelin ML, 2000, REV EPIDEMIOL SANTE, V48, P459; Andrade J, 1996, ANESTH ANALG, V83, P1279, DOI 10.1097/00000539-199612000-00026; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Audit Commission, 1997, AN EX EFF EFF AN PAI; Baguley WA, 1997, ANESTH ANALG, V84, P1380, DOI 10.1097/00000539-199706000-00038; Borowicz L, 2002, PSYCHOSOMATICS, V43, P464, DOI 10.1176/appi.psy.43.6.464; Bosek V, 2000, ANESTHESIOLOGY, V92, P885, DOI 10.1097/00000542-200003000-00040; BRESSLER SL, 1990, TRENDS NEUROSCI, V13, P161, DOI 10.1016/0166-2236(90)90039-D; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Chen PP, 2001, ANESTH ANALG, V92, P224; Chew S. T. H., 1998, SMJ, V39, P399; Christensen H, 2001, AUST NZ J PSYCHIAT, V35, P768, DOI 10.1046/j.1440-1614.2001.00966.x; Coloma M, 2002, ANESTHESIOLOGY, V96, P1346, DOI 10.1097/00000542-200206000-00013; Coloma M, 2002, ANESTHESIOLOGY, V97, P1387, DOI 10.1097/00000542-200212000-00009; COOPER JB, 1978, ANESTHESIOLOGY, V49, P399, DOI 10.1097/00000542-197812000-00004; Cooper JB, 2002, ANESTHESIOLOGY, V97, P1335, DOI 10.1097/00000542-200212000-00003; CRICK F, 1990, COLD SH Q B, V55, P953; Di Carlo G, 2003, EXPERT OPIN INV DRUG, V12, P39, DOI 10.1517/eoid.12.1.39.21246; Dijkstra JB, 1999, BRIT J ANAESTH, V82, P867, DOI 10.1093/bja/82.6.867; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; EICHHORN JH, 1993, ANESTHESIOLOGY, V78, P423; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; Eriksson H, 1997, CURR OPIN ANAESTH, V10, P438; Gaba DM, 2000, BRIT MED J, V320, P785, DOI 10.1136/bmj.320.7237.785; Gal J, 2000, J CARDIOTHOR VASC AN, V14, P22; GALAMBOS R, 1981, P NATL ACAD SCI-BIOL, V78, P2643, DOI 10.1073/pnas.78.4.2643; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; GHONEIM MM, 1992, ANESTHESIOLOGY, V76, P279; Ghoneim MM, 2000, ACTA ANAESTH SCAND, V44, P133, DOI 10.1034/j.1399-6576.2000.440202.x; Ghoneim MM, 1997, ANESTHESIOLOGY, V87, P387, DOI 10.1097/00000542-199708000-00027; Gillies MAM, 2001, EUR J ANAESTH, V18, P620, DOI 10.1046/j.1365-2346.2001.00891.x; Golembiewski Julie A, 2002, J Perianesth Nurs, V17, P364, DOI 10.1053/jpan.2002.36596; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Grichnik KP, 1999, ANN THORAC SURG, V68, P1786, DOI 10.1016/S0003-4975(99)00992-3; Harter R L, 2000, Curr Opin Anaesthesiol, V13, P469, DOI 10.1097/00001503-200008000-00012; HENEGHAN CPH, 1987, BRIT J ANAESTH, V59, P277, DOI 10.1093/bja/59.3.277; Henzi I, 1999, BRIT J ANAESTH, V83, P761, DOI 10.1093/bja/83.5.761; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; HUME MA, 1994, ANAESTHESIA, V49, P715, DOI 10.1111/j.1365-2044.1994.tb04408.x; John ER, 2002, BRAIN RES REV, V39, P1, DOI 10.1016/S0165-0173(02)00142-X; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; KEATS AS, 1961, ANESTHESIOLOGY   MAR, P213; Keenan R L, 1991, J Clin Anesth, V3, P354; KEEP PJ, 1978, ANAESTHESIA, V33, P43, DOI 10.1111/j.1365-2044.1978.tb08277.x; KEHLET H, IN PRESS LANCET; Knoerl D V, 1999, Medsurg Nurs, V8, P25; Kochs E, 1999, ANESTH ANALG, V88, P1412, DOI 10.1097/00000539-199906000-00039; Kochs E, 2001, ANESTHESIOLOGY, V95, P1141, DOI 10.1097/00000542-200111000-00018; Kranke P, 2002, ANESTH ANALG, V95, P133, DOI 10.1097/00000539-200207000-00024; Kranke P, 2001, ACTA ANAESTH SCAND, V45, P160, DOI 10.1034/j.1399-6576.2001.450205.x; Lagasse RS, 2002, ANESTHESIOLOGY, V97, P1609, DOI 10.1097/00000542-200212000-00038; LASSEN HCA, 1953, LANCET, V264, P37; LIU WHD, 1991, ANAESTHESIA, V46, P435, DOI 10.1111/j.1365-2044.1991.tb11677.x; Loewen PS, 2002, EXPERT OPIN INV DRUG, V11, P801, DOI 10.1517/13543784.11.6.801; LUNN JN, 1987, LANCET, V2, P1384; Lyketsos CG, 1999, AM J PSYCHIAT, V156, P58, DOI 10.1176/ajp.156.1.58; Matthey P, 2001, CAN J ANAESTH, V48, P333, DOI 10.1007/BF03014959; McGaw CD, 1998, W INDIAN MED J, V47, P64; Meehan D A, 1995, Am J Crit Care, V4, P435; Miaskowski C, 1999, PAIN, V80, P23, DOI 10.1016/S0304-3959(98)00192-4; Millar K, 2001, BRIT J ANAESTH, V86, P63, DOI 10.1093/bja/86.1.63; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P436, DOI 10.1097/00000542-199303000-00006; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MUNGLANI R, 1993, BRIT J ANAESTH, V71, P633, DOI 10.1093/bja/71.5.633; Myles PS, 2002, MED J AUSTRALIA, V177, P536, DOI 10.5694/j.1326-5377.2002.tb04947.x; Nay PG, 1996, ANAESTHESIA, V51, P741, DOI 10.1111/j.1365-2044.1996.tb06198.x; NEWMAN S, 1989, J PSYCHOSOM RES, V33, P227, DOI 10.1016/0022-3999(89)90050-0; NEWTON DEF, 1990, BRIT J ANAESTH, V65, P609, DOI 10.1093/bja/65.5.609; NIELSON WR, 1990, ANESTHESIOLOGY, V73, P1103, DOI 10.1097/00000542-199012000-00006; Nordstrom O, 1997, ACTA ANAESTH SCAND, V41, P978, DOI 10.1111/j.1399-6576.1997.tb04823.x; Nyssen AS, 2002, ANESTH ANALG, V94, P1560, DOI 10.1097/00000539-200206000-00035; Oddby-Muhrbeck E, 2002, ANESTHESIOLOGY, V96, P1109, DOI 10.1097/00000542-200205000-00013; Priestley MC, 2002, ANESTH ANALG, V94, P275, DOI 10.1097/00000539-200202000-00009; Pusch F, 2002, ANESTH ANALG, V94, P1652; RAMSAY MAE, 1972, ANAESTHESIA, V27, P396, DOI 10.1111/j.1365-2044.1972.tb08244.x; Reilly JG, 2000, LANCET, V355, P1048, DOI 10.1016/S0140-6736(00)02035-3; Rodig G, 1999, ANAESTHESIA, V54, P826; Rowbotham DJ, 2001, BRIT J ANAESTH, V87, P1, DOI 10.1093/bja/87.1.1; Sala Blanch X, 2000, REV ESP ANESTESIOL R, V47, P10; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; SCHACTER DL, 1994, INT REV NEUROBIOL, V37, P271; SCHWENDER D, 1994, ANESTHESIOLOGY, V80, P493, DOI 10.1097/00000542-199403000-00004; Schwid HA, 2002, ANESTHESIOLOGY, V97, P1434, DOI 10.1097/00000542-200212000-00015; Schwid HA, 2001, TEACH LEARN MED, V13, P92, DOI 10.1207/S15328015TLM1302_4; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; SHEVDE K, 1991, ANESTH ANALG, V73, P190; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SMITH PLC, 1986, LANCET, V1, P823; Struys MMRF, 2002, ANESTHESIOLOGY, V96, P803, DOI 10.1097/00000542-200204000-00006; Sung YF, 1996, DRUG SAFETY, V14, P181, DOI 10.2165/00002018-199614030-00005; Svensson I, 2001, EUR J PAIN, V5, P125, DOI 10.1053/eujp.2001.0227; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TAYLOR G, 1976, JAMA-J AM MED ASSOC, V236, P2758, DOI 10.1001/jama.236.24.2758; Thomas R, 2002, ANAESTHESIA, V57, P1119, DOI 10.1046/j.1365-2044.2002.02782_4.x; Thornton C, 1998, BRIT J ANAESTH, V81, P771, DOI 10.1093/bja/81.5.771; THORNTON C, 1989, BRIT J ANAESTH, V63, P113, DOI 10.1093/bja/63.1.113; THORNTON C, 1983, BRIT J ANAESTH, V55, P479, DOI 10.1093/bja/55.6.479; THORNTON C, 1986, BRIT J ANAESTH, V58, P422, DOI 10.1093/bja/58.4.422; THORNTON C, 1984, BRIT J ANAESTH, V56, P315, DOI 10.1093/bja/56.4.315; Timmons M E, 1993, Orthop Nurs, V12, P23, DOI 10.1097/00006416-199301000-00007; Tramer M, 1997, BRIT J ANAESTH, V78, P247, DOI 10.1093/bja/78.3.247; Tramer M, 1996, BRIT J ANAESTH, V76, P186, DOI 10.1093/bja/76.2.186; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P14, DOI 10.1034/j.1399-6576.2001.450103.x; Tzourio C, 1999, NEUROLOGY, V53, P1948, DOI 10.1212/WNL.53.9.1948; UTTING JE, 1979, CAN ANAESTH SOC J, V26, P472, DOI 10.1007/BF03006159; VANWIJK MGF, 1990, ANAESTHESIA, V45, P679; Venn RM, 2001, BRIT J ANAESTH, V87, P684, DOI 10.1093/bja/87.5.684; Wang DX, 2002, ANESTH ANALG, V95, P1134, DOI 10.1097/00000539-200211000-00002; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Werner MU, 2002, ANESTH ANALG, V95, P1361, DOI 10.1097/00000539-200211000-00049; White PF, 1999, ANESTH ANALG, V89, P1337, DOI 10.1097/00000539-199912000-00001; White PF, 2002, ANESTHESIOLOGY, V97, P1075, DOI 10.1097/00000542-200211000-00008; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44	119	31	31	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1648	1658		10.1016/S0140-6736(03)14800-3	http://dx.doi.org/10.1016/S0140-6736(03)14800-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630448				2022-12-28	WOS:000186637400025
J	Stevens, AM; Hermes, HM; Rutledge, JC; Buyon, JP; Nelson, JL				Stevens, AM; Hermes, HM; Rutledge, JC; Buyon, JP; Nelson, JL			Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block	LANCET			English	Article							UMBILICAL-CORD BLOOD; IN-SITU HYBRIDIZATION; BONE-MARROW; AUTOIMMUNE-DISEASE; CELLS; ANTIBODIES; CHIMERISM; ERYTHEMATOSUS; IDENTIFICATION; AUTOANTIBODIES	Background During pregnancy, maternal cells pass into the fetus, where they can persist for many years after birth. We investigated the presence of maternal cells in neonatal lupus syndrome (NLS), an autoimmune disease that develops in utero. The most serious complication of NLS is inflammation of the atrioventricular node leading to congenital heart block (CHB). Methods In a blinded case-control study, maternal (female) cells were detected and quantified in male NLS and control heart-tissue samples. We used fluorescence in-situ hybridisation to label X and Y chromosomes. Studies in transplantation suggest that donor cells can differentiate into somatic tissue cells. Therefore, we asked whether maternal cells transferred in utero have cellular plasticity. To simultaneously identify and characterise maternal cells, we developed a technique by which multiple phenotypic markers could be detected concurrently with fluorescence in-situ hybridisation in the same cells of a tissue section. Findings Maternal cells were found in 15 of 15 sections of NLS heart tissue, ranging from 0.025% to 2.2% of total cells. By contrast, maternal cells were found in two of eight control sections (0-0.1%). Very few maternal cells expressed the haemopoietic cell marker CD45. Most expressed sarcomeric alpha actin, a specific marker for cardiac myocytes. Interpretation Our findings suggest that differentiated tissue-specific maternal microchimerism can occur in neonates. Thus, semiallogeneic maternal cells could be the target of an immune response. Alternatively, maternal cells could contribute to a secondary process of tissue repair.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Childrens Hosp & Reg Med Ctr, Seattle, WA USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Hosp Joint Dis & Med Ctr, New York, NY USA; Univ Washington, Dept Med, Seattle, WA USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; University of Washington; University of Washington Seattle	Stevens, AM (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D2-100,POB 19024, Seattle, WA 98109 USA.	astevens@fhcrc.org		Buyon, Jill/0000-0002-3852-7129	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041721] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI041721] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNAIZVILLENA A, 1989, ARTHRITIS RHEUM-US, V32, P1421, DOI 10.1002/anr.1780321111; Artlett CM, 2000, LANCET, V356, P2155, DOI 10.1016/S0140-6736(00)03499-1; BENIISCHKE K, 1990, PATHOLOGY HUMAN PLAC, P684; Boutjdir M, 1997, CIRC RES, V80, P354, DOI 10.1161/01.RES.80.3.354; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brucato A, 2001, ARTHRITIS RHEUM-US, V44, P1832, DOI 10.1002/1529-0131(200108)44:8<1832::AID-ART320>3.0.CO;2-C; BUYON JP, 1995, LUPUS, V4, P116, DOI 10.1177/096120339500400207; CANNAT A, 1973, BIOMEDICINE, V19, P108; DESAI RG, 1963, BLOOD, V21, P665, DOI 10.1182/blood.V21.6.665.665; HALL JM, 1995, BLOOD, V86, P2829; HORSFALL AC, 1991, J AUTOIMMUN, V4, P165, DOI 10.1016/0896-8411(91)90015-5; Johnson KL, 2000, BIOTECHNIQUES, V29, P1220, DOI 10.2144/00296st01; Kita H, 2002, J EXP MED, V195, P113, DOI 10.1084/jem.20010956; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lagaaij EL, 2001, LANCET, V357, P33, DOI 10.1016/S0140-6736(00)03569-8; Lee TH, 1999, BLOOD, V93, P3127; Lo YMD, 2000, CLIN CHEM, V46, P1301; Lo YMD, 1996, BLOOD, V88, P4390; Lo YMD, 1998, BRIT J HAEMATOL, V100, P605; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Miranda-Carus ME, 1998, J IMMUNOL, V161, P5886; Miyagawa S, 1997, ARTHRITIS RHEUM, V40, P982, DOI 10.1002/art.1780400532; Nelson JL, 2002, TRENDS MOL MED, V8, P109, DOI 10.1016/S1471-4914(01)02269-9; OREILLY RJ, 1973, TRANSPLANTATION, V15, P505; Petit T, 1997, BRIT J HAEMATOL, V98, P767, DOI 10.1046/j.1365-2141.1997.2603076.x; Petit T, 1995, EXP HEMATOL, V23, P1601; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reed AM, 2000, LANCET, V356, P2156, DOI 10.1016/S0140-6736(00)03500-5; REICHLIN M, 1994, ARTHRITIS RHEUM, V37, P1698, DOI 10.1002/art.1780371120; Rinkevich B, 2001, HUM IMMUNOL, V62, P651, DOI 10.1016/S0198-8859(01)00249-X; Saleeb S, 1999, ARTHRITIS RHEUM, V42, P2335, DOI 10.1002/1529-0131(199911)42:11<2335::AID-ANR12>3.0.CO;2-3; Setiady YY, 2003, J IMMUNOL, V170, P4656, DOI 10.4049/jimmunol.170.9.4656; SOCIE G, 1994, BLOOD, V83, P340; Stevens Anne, 2002, NEOREVIEWS, V3, pe11, DOI DOI 10.1542/NEO.3-1-E11; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Tran HB, 2002, ARTHRITIS RHEUM-US, V46, P1572, DOI 10.1002/art.10316; Tseng CE, 1997, RHEUM DIS CLIN N AM, V23, P31, DOI 10.1016/S0889-857X(05)70313-6; VANDERVEEN FM, 1982, ADV EXP MED BIOL, V149, P669; WATSON RM, 1984, MEDICINE, V63, P362, DOI 10.1097/00005792-198411000-00003; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	42	103	113	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	2003	362	9396					1617	1623		10.1016/S0140-6736(03)14795-2	http://dx.doi.org/10.1016/S0140-6736(03)14795-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630442				2022-12-28	WOS:000186637400010
J	Kaido, T; Imamura, M				Kaido, T; Imamura, M			Giant hepatic hemangioma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Kyoto Univ, Sch Med, Kyoto 6068507, Japan	Kyoto University	Kaido, T (corresponding author), Kyoto Univ, Sch Med, Kyoto 6068507, Japan.		Yalcin, Ahmet/A-4428-2018; DURUR-KARAKAYA, Afak/AAH-8367-2020; Kantarci, Mecit/AAL-5940-2021; Yalcin, Ahmet/AAU-1944-2020	Yalcin, Ahmet/0000-0002-9708-0988; DURUR-KARAKAYA, Afak/0000-0003-3604-6791; Kantarci, Mecit/0000-0002-1043-6719; Yalcin, Ahmet/0000-0002-9708-0988					0	3	4	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					E19	E19		10.1056/ENEJMicm010097	http://dx.doi.org/10.1056/ENEJMicm010097			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614181				2022-12-28	WOS:000186502400009
J	Parish, MM; Littlewood, PB				Parish, MM; Littlewood, PB			Non-saturating magnetoresistance in heavily disordered semiconductors	NATURE			English	Article							INHOMOGENEITIES; GAP	The resistance of a homogeneous semiconductor increases quadratically with magnetic field at low fields and, except in very special cases, saturates at fields much larger than the inverse of the carrier mobility, a number typically of the order of 1 T (refs 1, 2). A surprising exception to this behaviour has recently been observed in doped silver chalcogenides(3-5), which exhibit an anomalously large, quasi-linear magnetoresistive response that extends down to low fields and survives, even at extreme fields of 55 T and beyond. Here we present a simple model of a macroscopically disordered and strongly inhomogeneous semiconductor that exhibits a similar non-saturating magnetoresistance. In addition to providing a possible explanation for the behaviour of doped silver chalcogenides, our model suggests potential routes for the construction of magnetic field sensors with a large, controllable and linear response.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Los Alamos Natl Lab, Pulsed Field Facil, Natl High Magnet Field Lab, Los Alamos, NM 87545 USA	University of Cambridge; United States Department of Energy (DOE); Los Alamos National Laboratory	Parish, MM (corresponding author), Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England.		Littlewood, Peter B/B-7746-2008; Parish, Meera/E-5102-2013; Littlewood, Peter/M-4960-2019					Abrikosov AA, 1998, PHYS REV B, V58, P2788, DOI 10.1103/PhysRevB.58.2788; Balagurov B. Ya., 1986, Soviet Physics - Solid State, V28, P1694; BEER AC, 1963, SOLID STATE PHYSIC S, V4; Bergman DJ, 2000, PHYS REV B, V62, P6603, DOI 10.1103/PhysRevB.62.6603; BRULS GJCL, 1981, PHYS REV LETT, V46, P553, DOI 10.1103/PhysRevLett.46.553; BUTTIKER M, 1990, PHYS REV B, V42, P3197, DOI 10.1103/PhysRevB.42.3197; DALVEN R, 1967, PHYS REV, V159, P645, DOI 10.1103/PhysRev.159.645; Dreizin Yu.A., 1973, SOV PHYS JETP, V36, P127; HERRING C, 1960, J APPL PHYS, V31, P1939, DOI 10.1063/1.1735477; Husmann A, 2002, NATURE, V417, P421, DOI 10.1038/417421a; Kapitza P, 1929, P R SOC LOND A-CONTA, V123, P292, DOI 10.1098/rspa.1929.0072; Kittel Ch., 1963, QUANTUM THEORY SOLID; Lee M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.066602; Ogorelec Z, 1999, EUROPHYS LETT, V46, P56, DOI 10.1209/epl/i1999-00562-1; REYNOLDS JA, 1957, P PHYS SOC LOND B, V70, P769, DOI 10.1088/0370-1301/70/8/306; Smith Robert Allan, 1978, SEMICONDUCTORS+, V2nd; Solin SA, 2000, SCIENCE, V289, P1530, DOI 10.1126/science.289.5484.1530; Solin SA, 2000, PHYSICA B, V279, P37, DOI 10.1016/S0921-4526(99)00661-4; STROUD D, 1976, PHYS REV B, V13, P1434, DOI 10.1103/PhysRevB.13.1434; Tokura Y., 2000, COLOSSAL MAGNETORESI; Xu R, 1997, NATURE, V390, P57, DOI 10.1038/36306	21	454	461	3	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					162	165		10.1038/nature02073	http://dx.doi.org/10.1038/nature02073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614501	Green Submitted			2022-12-28	WOS:000186517200038
J	Bagshawe, A; Taylor, A				Bagshawe, A; Taylor, A			ABC of subfertility - Intractable infertility	BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomass Assisted Concept Unit, London, England; Guys Kings & St Thomass Sch Med, Dept Womens Hlth, London, England	University of London; King's College London	Bagshawe, A (corresponding author), Guys & St Thomass Assisted Concept Unit, London, England.							BLYTHE E, 1998, TRUTH CHILD 10 YEARS; HUMPHREY M, 1998, FAMILIES DIFFERENCE; Mason, 1993, MALE INFERTILITY MEN; SNOWDEN R, 1993, GIFT CHILD; STANTON AL, 1991, INFERTILITY PERSPECT	5	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1098	1100		10.1136/bmj.327.7423.1098	http://dx.doi.org/10.1136/bmj.327.7423.1098			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604935	Green Published			2022-12-28	WOS:000186530400024
J	Schlagenhauf, P; Tschopp, A; Johnson, R; Nothdurft, HD; Beck, B; Schwartz, E; Herold, M; Krebs, B; Veit, O; Allwinn, R; Steffen, R				Schlagenhauf, P; Tschopp, A; Johnson, R; Nothdurft, HD; Beck, B; Schwartz, E; Herold, M; Krebs, B; Veit, O; Allwinn, R; Steffen, R			Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ATOVAQUONE-PROGUANIL; FALCIPARUM-MALARIA; PROPHYLAXIS; MEFLOQUINE; DOXYCYCLINE; CHLOROQUINE; AZITHROMYCIN; TRIAL	Objective To compare the tolerability of malaria chemoprophylaxis regimens in non-immune travellers. Design Randomised, double blind, study with placebo run-in phase. Setting Travel clinics in Switzerland, Germany, and Israel. Main outcome measure Proportion of participants in each treatment arm with subjectively moderate or severe adverse events. Participants 623 non-immune travellers to sub-Saharan Africa: 153 each received either doxycycline, mefloquine, or the fixed combination chloroquine and proguanil, and 164 received the fixed combination atovaquone and proguanil. Results A high proportion of patients reported adverse events, even in the initial placebo group. No events were serious. The chloroquine and proguanil arm had the highest proportion of mild to moderate adverse events (69/153; 45%, 95% confidence interval 37% to 53%) followed by mefloquine (64/153; 42%, 34% to 50%), doxycycline (51/153; 33%, 26% to 41%), and atovaquone and proguanil (53/164; 32%, 25% to 40%) (P=0.048 for all). The mefloquine and combined chloroquine and proguanil arms had the highest proportion of more severe events (n=19; 12%, 7% to 18%) and (n=16; 11%, 61% to 15%, respectively), Whereas the combined atovaquone and proguanil and doxycycline arms had the lowest (n=11; 7%, 2% to 11% and n=9; 6%, 2% to 10%, respectively: P=0.137 for all). The mefloquine arm had the highest proportion of moderate to severe neuropsychological adverse events, particularly in Women (n=56; 37%, 29% to 44% versus chloroquine and proguanil, n=46; 30%, 23% to 37%; doxycycline, n=36; 24%,17% to 30%; and atovaquone and proguanil, n=32; 20%, 13% to 26%: P=0.003 for all). The highest proportion of moderate or severe skin problems were reported in the chloroquine and proguanil arm (n=12; 8%, 4% to 13% versus doxycycline, n=5; 3%, 1% to 6%; atovaquone and proguanil, n=4; 2%, 0% to 5%; mefloquine, n=2; 1%, 0% to 3%: P=0.013). Conclusions Combined atovaquone and proguanil and doxycyline are well tolerated antimalarial drugs. Broader experience with both agents is needed to accumulate reports of rare adverse events.	Univ Zurich, Inst Social & Prevent Med, Div Epidemiol & Communicable Dis, CH-8006 Zurich, Switzerland; Univ Zurich, Inst Social & Prevent Med, Dept Biostat, CH-8006 Zurich, Switzerland; USA, Environm Med Res Inst, Mil Performance Div, Natick, MA 01760 USA; Univ Munich, Dept Trop Med & Infect Dis, D-80539 Munich, Germany; Swiss Trop Inst, CH-4002 Basel, Switzerland; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Goethe Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany	University of Zurich; University of Zurich; University of Munich; University of Basel; Swiss Tropical & Public Health Institute; Tel Aviv University; Chaim Sheba Medical Center; Goethe University Frankfurt	Schlagenhauf, P (corresponding author), Univ Zurich, Inst Social & Prevent Med, Div Epidemiol & Communicable Dis, CH-8006 Zurich, Switzerland.	pat@ifspm.unizh.ch		Schlagenhauf, Patricia/0000-0002-1075-7010				Andersen SL, 1998, CLIN INFECT DIS, V26, P146, DOI 10.1086/516281; ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BOUDREAU E, 1993, TROP MED PARASITOL, V44, P257; Bradley D J, 2001, Commun Dis Public Health, V4, P84; *CDC, 2001, HLTH INF INT TRAV; *COMM ADV TROP MED, 2001, CAN REC PREV TREATM; CROFT AM, 2001, COCHRANE DATABASE SY, P138; CROFT AM, 2001, COCHRANE DB SYST REV, V1, P138; Hogh B, 2000, LANCET, V356, P1888, DOI 10.1016/S0140-6736(00)03260-8; Jelinek T, 1998, AM J TROP MED HYG, V59, P35, DOI 10.4269/ajtmh.1998.59.35; McNair DM., 1992, EDITS MANUAL PROFILE; Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560; NASVELD PE, 2000, AM J TROP MED HYG S; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; PANG L, 1988, J INFECT DIS, V158, P1124, DOI 10.1093/infdis/158.5.1124; PANG LW, 1987, LANCET, V1, P1161; Petersen E, 2000, J TRAVEL MED, V7, P79; Phillips, 1996, J Travel Med, V3, P40, DOI 10.1111/j.1708-8305.1996.tb00695.x; Schlagenhauf P, 1996, TROP MED INT HEALTH, V1, P485, DOI 10.1046/j.1365-3156.1996.d01-85.x; Schlagenhauf P, 1999, J TRAVEL MED, V6, P122, DOI 10.1111/j.1708-8305.1999.tb00843.x; SHANKS GD, 2001, TRAVELERS MALARIA, P227; Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; WEISS WR, 1995, J INFECT DIS, V171, P1569, DOI 10.1093/infdis/171.6.1569; *WHO, 2002, INT TRAV HLTH 2002	27	145	147	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2003	327	7423					1078	+		10.1136/bmj.327.7423.1078	http://dx.doi.org/10.1136/bmj.327.7423.1078			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604928	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000186530400017
J	Kimura, T; Goto, T; Shintani, H; Ishizaka, K; Arima, T; Tokura, Y				Kimura, T; Goto, T; Shintani, H; Ishizaka, K; Arima, T; Tokura, Y			Magnetic control of ferroelectric polarization	NATURE			English	Article							DIFFRACTION; PEROVSKITE	The magnetoelectric effect - the induction of magnetization by means of an electric field and induction of polarization by means of a magnetic field - was first presumed to exist by Pierre Curie(1), and subsequently attracted a great deal of interest in the 1960s and 1970s ( refs 2 - 4). More recently, related studies on magnetic ferroelectrics(5-14) have signalled a revival of interest in this phenomenon. From a technological point of view, the mutual control of electric and magnetic properties is an attractive possibility(15), but the number of candidate materials is limited and the effects are typically too small to be useful in applications. Here we report the discovery of ferroelectricity in a perovskite manganite, TbMnO3, where the effect of spin frustration causes sinusoidal antiferromagnetic ordering. The modulated magnetic structure is accompanied by a magnetoelastically induced lattice modulation, and with the emergence of a spontaneous polarization. In the magnetic ferroelectric TbMnO3, we found gigantic magnetoelectric and magnetocapacitance effects, which can be attributed to switching of the electric polarization induced by magnetic fields. Frustrated spin systems therefore provide a new area to search for magnetoelectric media.	Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan; Univ Tsukuba, Inst Mat Sci, Tsukuba, Ibaraki 3058573, Japan	University of Tokyo; University of Tsukuba	Kimura, T (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	tkimura@lanl.gov	Kimura, Tsuyoshi/F-8090-2018; Tokura, Yoshinori/C-7352-2009; Arima, Tala-hisa/G-9217-2012; Ishizaka, Kyoko/M-7643-2016	Tokura, Yoshinori/0000-0002-2732-4983; Arima, Tala-hisa/0000-0002-6959-0454; Ishizaka, Kyoko/0000-0002-1710-7176				AIKI K, 1969, J PHYS SOC JPN, V26, P1064, DOI 10.1143/JPSJ.26.1064; BIDAUX R, 1975, J PHYS-PARIS, V36, P803, DOI 10.1051/jphys:01975003609080300; Blinc R., 1986, INCOMMENSURATE PHASE, V1; BOHR J, 1990, PHYS REV B, V42, P4322, DOI 10.1103/PhysRevB.42.4322; BOHR J, 1989, PHYSICA B, V159, P93, DOI 10.1016/0921-4526(89)90026-4; BOUREE JE, 1975, J PHYS-PARIS, V36, P391, DOI 10.1051/jphys:01975003605039100; Curie P., 1894, J PHYS-PARIS, V3, P393, DOI DOI 10.1051/JPHYSTAP:018940030039300; dos Santos AM, 2002, SOLID STATE COMMUN, V122, P49, DOI 10.1016/S0038-1098(02)00087-X; Fiebig M, 2002, NATURE, V419, P818, DOI 10.1038/nature01077; Freeman A. J., 1975, MAGNETOELECTRIC INTE; GOLDSMITH GJ, 1959, J CHEM PHYS, V31, P1175, DOI 10.1063/1.1730568; GREENWALD S, 1950, NATURE, V166, P523, DOI 10.1038/166523a0; Hanamura E, 2003, J PHYS-CONDENS MAT, V15, pL103, DOI 10.1088/0953-8984/15/3/102; Huang ZJ, 1997, PHYS REV B, V56, P2623, DOI 10.1103/PhysRevB.56.2623; Iwata N, 1998, J PHYS SOC JPN, V67, P3318, DOI 10.1143/JPSJ.67.3318; Katsufuji T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.104419; Kimura T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.180401; Kimura T, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.060403; Levanyuk A.P, 1974, SOV PHYS USP, V17, P199, DOI DOI 10.1070/PU1974V017N02ABEH004336; O'Dell T.H., 1970, ELECTRODYNAMICS MAGN; QUEZEL S, 1977, PHYSICA B & C, V86, P916, DOI 10.1016/0378-4363(77)90740-9; SAWADA S, 1977, J PHYS SOC JPN, V43, P2099, DOI 10.1143/JPSJ.43.2099; Seshadri R, 2001, CHEM MATER, V13, P2892, DOI 10.1021/cm010090m; SMART JS, 1951, PHYS REV, V82, P113, DOI 10.1103/PhysRev.82.113; Smolenskii G. A., 1982, Soviet Physics - Uspekhi, V25, P475, DOI 10.1070/PU1982v025n07ABEH004570; Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615; Wood V. E., 1974, International Journal of Magnetism, V5, P303; Zhong CG, 2002, J PHYS-CONDENS MAT, V14, P8605, DOI 10.1088/0953-8984/14/36/316	28	3824	3889	50	1442	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					55	58		10.1038/nature02018	http://dx.doi.org/10.1038/nature02018			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603314				2022-12-28	WOS:000186370800038
J	Cao, K; Nakajima, R; Meyer, HH; Zheng, YX				Cao, K; Nakajima, R; Meyer, HH; Zheng, YX			The AAA-ATPase Cdc48/p97 regulates spindle disassembly at the end of mitosis	CELL			English	Article							MICROTUBULE DYNAMIC INSTABILITY; XENOPUS EGG EXTRACTS; CELL-CYCLE; MITOTIC-SPINDLE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; PROTEIN DISLOCATION; IMPORTIN-ALPHA; RAN	Spindle disassembly at the end of mitosis is a complex and poorly understood process. Here, we report that the AAA-ATPase Cdc48/p97 and its adapters Ufd1-Np14, which have a well-established role in membrane functions, also regulate spindle disassembly by modulating microtubule dynamics and bundling at the end of mitosis. In the absence of p97-Ufd1-Np14 function, microtubules in Xenopus egg extracts remain as monopolar spindles attached to condensed chromosomes after Cdc2 kinase activity has returned to the interphase level. Consequently, interphase microtubule arrays and nuclei are not established. Genetic analyses of Cdc48, the yeast homolog of p97, reveal that Cdc48 is also required for disassembly of mitotic spindles after execution of the mitotic exit pathway. Furthermore, Cdc48/p97-Ufd1-Np14 directly binds to spindle assembly factors and regulates their interaction with microtubules at the end of mitosis. Therefore, Cdc48/p97-Ufd1-Np14 is an essential chaperone that regulates transformation of the microtubule structure as cells reenter interphase.	Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21210 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21210 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland	Carnegie Institution for Science; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zheng, YX (corresponding author), Carnegie Inst Sci, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	zheng@ciwemb.edu	Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796				Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Carazo-Salas RE, 2001, NAT CELL BIOL, V3, P228, DOI 10.1038/35060009; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Hoyt MA, 2000, CELL, V102, P267, DOI 10.1016/S0092-8674(00)00031-3; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jarosch E, 2002, TRAFFIC, V3, P530, DOI 10.1034/j.1600-0854.2002.30803.x; Jensen S, 2002, CURR BIOL, V12, pR221, DOI 10.1016/S0960-9822(02)00756-X; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; MOIR D, 1982, GENETICS, V100, P547; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Shirasu-Hiza M, 2003, J CELL BIOL, V161, P349, DOI 10.1083/jcb.200211095; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; van Breugel M, 2003, J CELL BIOL, V161, P359, DOI 10.1083/jcb.200211097; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	58	166	174	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					355	367		10.1016/S0092-8674(03)00815-8	http://dx.doi.org/10.1016/S0092-8674(03)00815-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636562	Bronze			2022-12-28	WOS:000186415000014
J	Ridgwell, AJ; Kennedy, MJ; Caldeira, K				Ridgwell, AJ; Kennedy, MJ; Caldeira, K			Carbonate deposition, climate stability, and neoproterozoic ice ages	SCIENCE			English	Article							SNOWBALL EARTH; ATMOSPHERIC CO2; DEGLACIATION; DIOXIDE; CYCLE; PRECIPITATION; ACCUMULATION; EXCURSIONS; HYPOTHESIS; RECORD	The evolutionary success of planktic calcifiers during the Phanerozoic stabilized the climate system by introducing a new mechanism that acts to buffer ocean carbonate-ion concentration: the saturation-dependent preservation of carbonate in sea-floor sediments. Before this, buffering was primarily accomplished by adjustment of shallow-water carbonate deposition to balance oceanic inputs from weathering on land. Neoproterozoic ice ages of near-global extent and multimillion-year duration and the formation of distinctive sedimentary (cap) carbonates can thus be understood in terms of the greater sensitivity of the Precambrian carbon cycle to the loss of shallow-water environments and CO2-climate feedback on ice-sheet growth.	Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; Lawrence Livermore Natl Lab, Climate & Carbon Cycle Modeling Grp, Livermore, CA 94550 USA	University of California System; University of California Riverside; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Ridgwell, AJ (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.		Caldeira, Ken/E-7914-2011; Ridgwell, Andy/AAD-9487-2021	Caldeira, Ken/0000-0002-4591-643X; Ridgwell, Andy/0000-0003-2333-0128; Kennedy, Martin/0000-0002-1330-6864				Baum SK, 2001, GEOPHYS RES LETT, V28, P583, DOI 10.1029/2000GL011557; BERGER WH, 1982, NATURWISSENSCHAFTEN, V69, P87, DOI 10.1007/BF00441228; BERNER RA, 1990, SCIENCE, V249, P1382, DOI 10.1126/science.249.4975.1382; BOSS SK, 1991, J GEOL, V99, P497, DOI 10.1086/629513; BROECKER WS, 1986, RADIOCARBON, V28, P309, DOI 10.1017/S0033822200007414; CALDEIRA K, 1993, PALEOCEANOGRAPHY, V8, P515, DOI 10.1029/93PA01163; CALDEIRA K, 1991, GEOLOGY, V19, P204, DOI 10.1130/0091-7613(1991)019<0204:CPCPAT>2.3.CO;2; Crowell J.C., 1999, PREMESOZOIC ICE AGES, V192; Crowley TJ, 2001, GEOPHYS RES LETT, V28, P283, DOI 10.1029/2000GL011836; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Jones IW, 2002, GLOBAL PLANET CHANGE, V33, P139, DOI 10.1016/S0921-8181(02)00067-X; Kennedy MJ, 1996, J SEDIMENT RES, V66, P1050, DOI 10.2110/jsr.66.1050; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; Leclercq N, 2000, GLOB CHANGE BIOL, V6, P329, DOI 10.1046/j.1365-2486.2000.00315.x; MILLIMAN JD, 1993, GLOBAL BIOGEOCHEM CY, V7, P927, DOI 10.1029/93GB02524; Munhoven G, 1996, J GEOPHYS RES-ATMOS, V101, P21423, DOI 10.1029/96JD01842; Ramaswamy V., 2001, CLIMATE CHANGE 2001, P349; Ridgwell AJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001877; RIDGWELL AJ, IN PRESS PALEOCEANOG; Riding R, 2000, SEDIMENTOLOGY, V47, P179, DOI 10.1046/j.1365-3091.2000.00003.x; Runnegar B, 2000, NATURE, V405, P403, DOI 10.1038/35013168; Schrag DP, 2001, NATURE, V409, P306, DOI 10.1038/35053170; Sohl LE, 1999, GEOL SOC AM BULL, V111, P1120, DOI 10.1130/0016-7606(1999)111<1120:PPRIMC>2.3.CO;2; WALKER JCG, 1995, PALEOCEANOGRAPHY, V10, P415, DOI 10.1029/94PA02963; Wood RA, 2002, SCIENCE, V296, P2383, DOI 10.1126/science.1071599; ZHONG SJ, 1993, GEOCHIM COSMOCHIM AC, V57, P1409	29	117	124	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					859	862		10.1126/science.1088342	http://dx.doi.org/10.1126/science.1088342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593177				2022-12-28	WOS:000186258000047
J	Zhang, ZL; Sigle, W; Phillipp, F; Ruhle, M				Zhang, ZL; Sigle, W; Phillipp, F; Ruhle, M			Direct atom-resolved imaging of oxides and their grain boundaries	SCIENCE			English	Article							STRONTIUM-TITANATE; RESOLUTION; SRTIO3; CERAMICS; OXYGEN	Using high-resolution transmission electron microscopy, we obtained structure images of strontium titanate (SrTiO3) with a clearly resolved oxygen sublattice along different crystallographic directions in the bulk lattice and for a Sigma3 tilt grain boundary. Comparison with image simulations showed that the grain boundary contains oxygen vacancies. Measurements of atom displacements near the grain boundary revealed close correspondence with theoretical calculations.	Max Planck Inst Met Res, D-70569 Stuttgart, Germany	Max Planck Society	Ruhle, M (corresponding author), Max Planck Inst Met Res, Heisenbergstr 3, D-70569 Stuttgart, Germany.		Zhang, Zaoli/I-3299-2013	Zhang, Zaoli/0000-0002-7717-2500				Brunner D, 2001, J AM CERAM SOC, V84, P1161, DOI 10.1111/j.1151-2916.2001.tb00805.x; Denk I, 1997, J ELECTROCHEM SOC, V144, P3526, DOI 10.1149/1.1838044; Hutt S, 2001, J PHYS-CONDENS MAT, V13, P3949, DOI 10.1088/0953-8984/13/18/305; Jia CL, 2003, SCIENCE, V299, P870, DOI 10.1126/science.1079121; Kienzle O, 1998, PHYS STATUS SOLIDI A, V166, P57, DOI 10.1002/(SICI)1521-396X(199803)166:1<57::AID-PSSA57>3.0.CO;2-S; Kisielowski C, 2001, ULTRAMICROSCOPY, V89, P243, DOI 10.1016/S0304-3991(01)00090-0; Kurtz W, 2002, Z METALLKD, V93, P432, DOI 10.3139/146.020432; Mobus G, 1997, J ELECTRON MICROSC, V46, P381, DOI 10.1093/oxfordjournals.jmicro.a023534; STADELMANN PA, 1987, ULTRAMICROSCOPY, V21, P131, DOI 10.1016/0304-3991(87)90080-5; Waser R, 2000, ACTA MATER, V48, P797, DOI 10.1016/S1359-6454(99)00367-5; Zhang Z., UNPUB; Zhang ZL, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.094108	12	75	76	5	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					846	849		10.1126/science.1089785	http://dx.doi.org/10.1126/science.1089785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593173				2022-12-28	WOS:000186258000043
J	Miao, L; Vanderlinde, O; Stewart, M; Roberts, TM				Miao, L; Vanderlinde, O; Stewart, M; Roberts, TM			Retraction in amoeboid cell motility powered by cytoskeletal dynamics	SCIENCE			English	Article							PROTEIN MSP CYTOSKELETON; ACTIN-BASED MOTILITY; HEAVY-CHAIN GENE; NEMATODE SPERM; ASCARIS SPERM; BODY; DEPOLYMERIZATION; TRANSLOCATION; NUCLEATION; MECHANISM	Cells crawl by coupling protrusion of their leading edge with retraction of their cell body. Protrusion is generated by the polymerization and bundling of. laments, but the mechanism of retraction is less clear. We have reconstituted retraction in vitro by adding Yersinia tyrosine phosphatase to the major sperm protein-based motility apparatus assembled from Ascaris sperm extracts. Retraction in vitro parallels that observed in vivo and is generated primarily by disassembly and rearrangement of the cytoskeleton. Therefore, cytoskeletal dynamics alone, unassisted by conventional motors, are able to generate both of these central components of amoeboid locomotion.	Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	State University System of Florida; Florida State University; MRC Laboratory Molecular Biology	Roberts, TM (corresponding author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.	roberts@bio.fsu.edu		Miao, Long/0000-0002-0562-6681	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029994] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM29994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KI, 1996, J CELL BIOL, V134, P1209, DOI 10.1083/jcb.134.5.1209; Berg, 2018, RANDOM WALKS BIOL; Bottino D, 2002, J CELL SCI, V115, P367; Bray D, 2001, CELL MOVEMENTS MOL M; Bullock TL, 1998, NAT STRUCT BIOL, V5, P184, DOI 10.1038/nsb0398-184; Cameron LA, 2001, CURR BIOL, V11, P130, DOI 10.1016/S0960-9822(01)00022-7; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Feringa BL, 2000, NATURE, V408, P151, DOI 10.1038/35041665; HUXLEY HE, 1973, NATURE, V244, P445, DOI 10.1038/243445a0; Italiano JE, 1996, CELL, V84, P105, DOI 10.1016/S0092-8674(00)80997-6; Italiano JE, 1999, J CELL BIOL, V146, P1087, DOI 10.1083/jcb.146.5.1087; KING KL, 1994, CELL MOTIL CYTOSKEL, V27, P193, DOI 10.1002/cm.970270302; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LeClaire LL, 2003, J CELL SCI, V116, P2655, DOI 10.1242/jcs.00469; LI Y, 1992, ANNU REV MATER SCI, V22, P243; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; Pollard TD, 2003, CELL, V113, P549, DOI 10.1016/S0092-8674(03)00357-X; Roberts TM, 2000, J CELL BIOL, V149, P7, DOI 10.1083/jcb.149.1.7; Roberts TM, 1998, J CELL BIOL, V140, P367, DOI 10.1083/jcb.140.2.367; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Theriot JA, 1996, CELL, V84, P1, DOI 10.1016/S0092-8674(00)80068-9; Uchida KSK, 2003, J CELL SCI, V116, P51, DOI 10.1242/jcs.00195; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161	26	49	53	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1405	1407		10.1126/science.1089129	http://dx.doi.org/10.1126/science.1089129			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631043				2022-12-28	WOS:000186683500055
J	Roberts, DL; Solow, AR				Roberts, DL; Solow, AR			Flightless birds - When did the dodo become extinct?	NATURE			English	Editorial Material									Royal Bot Gardens, Richmond TW9 3AE, Surrey, England; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Royal Botanic Gardens, Kew; Woods Hole Oceanographic Institution	Roberts, DL (corresponding author), Royal Bot Gardens, Richmond TW9 3AE, Surrey, England.			Roberts, David/0000-0001-6788-2691				Cheke A.S., 1987, P5, DOI 10.1017/CBO9780511735769.003; COOKE P, 1980, BIOMETRIKA, V67, P257; Fuller E., 2002, DODO BRIEF HIST	3	117	125	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					245	245		10.1038/426245a	http://dx.doi.org/10.1038/426245a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628039				2022-12-28	WOS:000186660800031
J	Granot, J; Nakar, E; Piran, T				Granot, J; Nakar, E; Piran, T			Astrophysics - Refreshed shocks from a gamma-ray burst	NATURE			English	Editorial Material							AFTERGLOW		Inst Adv Study, Princeton, NJ 08540 USA; Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel	Institute for Advanced Study - USA; Hebrew University of Jerusalem	Granot, J (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.	udini@phys.huji.ac.il		Granot, Jonathan/0000-0001-8530-8941				Granot J, 2001, ESO ASTROPHY SYMP, P312, DOI 10.1007/10853853_82; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; Kumar P, 2000, ASTROPHYS J, V532, P286, DOI 10.1086/308537; Price PA, 2003, NATURE, V423, P844, DOI 10.1038/nature01734; Rees MJ, 1998, ASTROPHYS J, V496, pL1, DOI 10.1086/311244; Sari R, 2000, ASTROPHYS J, V535, pL33, DOI 10.1086/312689; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976	7	101	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					138	139		10.1038/426138a	http://dx.doi.org/10.1038/426138a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614492	Green Submitted			2022-12-28	WOS:000186517200029
J	Kremer, JM; Westhovens, R; Leon, M; Di Giorgio, E; Alten, R; Steinfeld, S; Russell, A; Dougados, M; Emery, P; Nuamah, IF; Williams, GR; Becker, JC; Hagerty, DT; Moreland, LW				Kremer, JM; Westhovens, R; Leon, M; Di Giorgio, E; Alten, R; Steinfeld, S; Russell, A; Dougados, M; Emery, P; Nuamah, IF; Williams, GR; Becker, JC; Hagerty, DT; Moreland, LW			Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA MONOCLONAL-ANTIBODY; TRYPTOPHAN CATABOLISM; DENDRITIC CELLS; SYNOVIAL TISSUE; CD28; CD86; METHOTREXATE; EXPRESSION; MOLECULES; ANTIGEN	Background: Effective new therapies are needed for rheumatoid arthritis. Current therapies target the products of activated macrophages; however, T cells also have an important role in rheumatoid arthritis. A fusion protein- cytotoxic T-lymphocyte-associated antigen 4-IgG1 (CTLA4Ig)-is the first in a new class of drugs known as costimulation blockers being evaluated for the treatment of rheumatoid arthritis. CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and preventing T-cell activation. A preliminary study showed that CTLA4Ig may be effective for the treatment of rheumatoid arthritis. Methods: We randomly assigned patients with active rheumatoid arthritis despite methotrexate therapy to receive 2 mg of CTLA4Ig per kilogram of body weight (105 patients), 10 mg of CTLA4Ig per kilogram (115 patients), or placebo (119 patients) for six months. All patients also received methotrexate therapy during the study. The clinical response was assessed at six months with use of the criteria of the American College of Rheumatology (ACR), which define the response according to its extent: 20 percent (ACR 20), 50 percent (ACR 50), or 70 percent (ACR 70). Additional end points included measures of the health-related quality of life. Results: Patients treated with 10 mg of CTLA4Ig per kilogram were more likely to have an ACR 20 than were patients who received placebo (60 percent vs. 35 percent, P<0.001). Significantly higher rates of ACR 50 and ACR 70 responses were seen in both CTLA4Ig groups than in the placebo group. The group given 10 mg of CTLA4Ig per kilogram had clinically meaningful and statistically significant improvements in all eight subscales of the Medical Outcomes 36-Item Short-Form General Health Survey. CTLA4Ig was well tolerated, with an overall safety profile similar to that of placebo. Conclusions: In patients with active rheumatoid arthritis who were receiving methotrexate, treatment with CTLA4Ig significantly improved the signs and symptoms of rheumatoid arthritis and the health-related quality of life. CTLA4Ig is a promising new therapy for rheumatoid arthritis.	Ctr Rheumatol, Albany, NY 12206 USA; Univ Ziekenhuizen Leuven, Dept Rheumatol, Louvain, Belgium; Free Univ Brussels, Ctr Hosp Univ Ambroise Pare, Mons, Belgium; Ctr Enfermedades Reumat, Quilmes, Argentina; Schlosspk Klin, Dept Rheumatol, Berlin, Germany; Erasme Univ Hosp, Dept Rheumatol, B-1070 Brussels, Belgium; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Univ Paris 05, Hop Cochin, Assistance Publ Hop Paris, Paris, France; Leeds Gen Infirm, Dept Rheumatol, Leeds, W Yorkshire, England; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA; Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA	KU Leuven; University Hospital Leuven; Universite Libre de Bruxelles; University of Alberta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Leeds General Infirmary; University of Leeds; Bristol-Myers Squibb; University of Alabama System; University of Alabama Birmingham	Kremer, JM (corresponding author), Ctr Rheumatol, 1367 Washington Ave,Suite 1, Albany, NY 12206 USA.		Alten, Rieke/M-1045-2019	Moreland, Larry/0000-0003-4483-0359				Balsa A, 1996, BRIT J RHEUMATOL, V35, P33; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bathon JM, 2001, NEW ENGL J MED, V344, P240; BATHON JM, 2001, NEW ENGL J MED, V344, P76; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; CUSH JJ, 1988, ARTHRITIS RHEUM-US, V31, P1230, DOI 10.1002/art.1780311003; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FINCK B, 1994, SCIENCE, V256, P1225; Grassi W, 1998, EUR J RADIOL, V27, pS18, DOI 10.1016/S0720-048X(98)00038-2; Greene JAL, 1996, J BIOL CHEM, V271, P26762, DOI 10.1074/jbc.271.43.26762; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1995, IMMUNITY, V2, pA203; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Liu MF, 1996, ARTHRITIS RHEUM, V39, P110, DOI 10.1002/art.1780390115; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Moreland LW, 2002, ARTHRITIS RHEUM, V46, P1470, DOI 10.1002/art.10294; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MORELAND LW, 1993, AM J MED SCI, V305, P40, DOI 10.1097/00000441-199301000-00008; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; RANHEIM EA, 1994, ARTHRITIS RHEUM-US, V37, P1637, DOI 10.1002/art.1780371113; Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003; Sfikakis PP, 1997, CLIN IMMUNOL IMMUNOP, V83, P195, DOI 10.1006/clin.1997.4368; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; STRAND V, 2002, ANN RHEUM DIS S1, V61, P175; Thomas R, 1996, J IMMUNOL, V156, P3074; Tian CR, 2002, J IMMUNOL, V169, P3771, DOI 10.4049/jimmunol.169.7.3771; VANBOXEL JA, 1975, NEW ENGL J MED, V293, P517, DOI 10.1056/NEJM197509112931101; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 2001, SF 36 PHYSICAL MENTA; WARE JE, 1994, SF 36 PHYSICAL MENT; Webb LMC, 1996, EUR J IMMUNOL, V26, P2320, DOI 10.1002/eji.1830261008; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840; YOUNG JW, 1993, J CLIN INVEST, V91, P1853	45	806	886	0	32	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1907	1915		10.1056/NEJMoa035075	http://dx.doi.org/10.1056/NEJMoa035075			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614165				2022-12-28	WOS:000186502400005
J	Mollenauer, LF				Mollenauer, LF			Nonlinear optics in fibers	SCIENCE			English	Editorial Material							PHOTONIC CRYSTAL FIBERS; SELF-FREQUENCY SHIFT; SOLITONS		Bell Labs, Lucent Technol, Holmdel, NJ 07733 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Mollenauer, LF (corresponding author), Bell Labs, Lucent Technol, 101 Crawford Corner Rd, Holmdel, NJ 07733 USA.							DYNAOV EM, 1985, JETP LETT, V41, P221; Knight JC, 1998, SCIENCE, V282, P1476, DOI 10.1126/science.282.5393.1476; MITSCHKE FM, 1986, OPT LETT, V11, P659, DOI 10.1364/OL.11.000659; Mollenauer L.F., 1997, OPTICAL FIBER TELE A, VIII A; Mollenauer LF, 2003, OPT LETT, V28, P2043, DOI 10.1364/OL.28.002043; Ouzounov DG, 2003, SCIENCE, V301, P1702, DOI 10.1126/science.1088387; Russell P, 2003, SCIENCE, V299, P358, DOI 10.1126/science.1079280; Skryabin DV, 2003, SCIENCE, V301, P1705, DOI 10.1126/science.1088516; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	9	25	25	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					996	997		10.1126/science.1091168	http://dx.doi.org/10.1126/science.1091168			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605356				2022-12-28	WOS:000186396300031
J	Smith, RJ; Muir, RDJ; Walpole, MJ; Balmford, A; Leader-Williams, N				Smith, RJ; Muir, RDJ; Walpole, MJ; Balmford, A; Leader-Williams, N			Governance and the loss of biodiversity	NATURE			English	Article							CONSERVATION; COSTS	Most of the world's biodiversity occurs within developing countries that require donor support to build their conservation capacity(1). Unfortunately, some of these countries experience high levels of political corruption(2), which may limit the success of conservation projects by reducing effective funding levels and distorting priorities(3). We investigated whether changes in three well surveyed and widespread components of biodiversity were associated with national governance scores and other socioeconomic measures. Here we show that governance scores were correlated with changes in total forest cover, but not with changes in natural forest cover. We found strong associations between governance scores and changes in the numbers of African elephants and black rhinoceroses, and these socio-economic factors explained observed patterns better than any others. Finally, we show that countries rich in species and identified as containing priority areas for conservation have lower governance scores than other nations. These results stress the need for conservationists to develop and implement policies that reduce the effects of political corruption and, in this regard, we question the universal applicability of an influential approach to conservation that seeks to ban international trade in endangered species.	Univ Kent, Durrell Inst Conservat & Ecol, Canterbury CT2 7NS, Kent, England; Univ Cambridge, Dept Zool, Conservat Biol Grp, Cambridge CB2 3EJ, England	University of Kent; University of Cambridge	Smith, RJ (corresponding author), Univ Kent, Durrell Inst Conservat & Ecol, Canterbury CT2 7NS, Kent, England.	R.J.Smith@kent.ac.uk	Smith, Robert J/D-9660-2011	Smith, Robert J/0000-0003-1599-9171; Balmford, Andrew/0000-0002-0144-3589				Archabald K, 2001, ENVIRON CONSERV, V28, P135, DOI 10.1017/S0376892901000145; Azfar O, 2001, ANN AM ACAD POLIT SS, V573, P42, DOI 10.1177/0002716201573001003; Balmford A, 2003, ORYX, V37, P238, DOI 10.1017/S0030605303000413; Balmford A, 2003, P NATL ACAD SCI USA, V100, P1046, DOI 10.1073/pnas.0236945100; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; Barnes R., 1999, AFRICAN ELEPHANT DAT; BARNES RFW, 1995, BIOL CONSERV, V71, P125, DOI 10.1016/0006-3207(94)00014-H; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Didia DO, 1997, GLOBAL ENVIRON CHANG, V7, P63, DOI 10.1016/S0959-3780(96)00024-6; Emslie R., 1999, AFRICAN RHINO STATUS; Geist HJ, 2002, BIOSCIENCE, V52, P143, DOI 10.1641/0006-3568(2002)052[0143:PCAUDF]2.0.CO;2; Hughey KFD, 2003, CONSERV BIOL, V17, P93, DOI 10.1046/j.1523-1739.2003.01317.x; *INT I ENV DEV, 1994, WHOS ED OV COMM APPR; James A, 2001, BIOSCIENCE, V51, P43, DOI 10.1641/0006-3568(2001)051[0043:CWATCB]2.0.CO;2; James A. N., 1999, GLOBAL REV PROTECTED; Jepson P, 2001, SCIENCE, V292, P859, DOI 10.1126/science.1061727; Kaufmann D, 1997, FOREIGN POLICY, P114, DOI 10.2307/1149337; LEADERWILLIAMS N, 1988, NATURE, V336, P533, DOI 10.1038/336533a0; Leakey R., 2001, WILDLIFE WARS MY BAT; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; MYERS N, 1992, PRIMARY SOURCE TROPI; Oldfield S., 2002, TRADE WILDLIFE REGUL; Robertson JMY, 2001, ORYX, V35, P26, DOI 10.1046/j.1365-3008.2001.00149.x; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Salafsky N, 2002, CONSERV BIOL, V16, P1469, DOI 10.1046/j.1523-1739.2002.01232.x; Stattersfield A.J., 1998, ENDEMIC BIRD AREAS W, V115, P1089, DOI 10.2307/4089533; Transparency International, 2002, CORR PERC IND 2002; Walpole MJ, 2001, NATURE, V413, P771, DOI 10.1038/35101762; Whitten T, 2001, CONSERV BIOL, V15, P1, DOI 10.1046/j.1523-1739.2001.01_01.x; *WORLD WID FUND NA, 1999, LIV PLAN CAMP CALL A	30	268	278	1	162	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					67	70		10.1038/nature02025	http://dx.doi.org/10.1038/nature02025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603318				2022-12-28	WOS:000186370800042
J	Khairy, P; O'Donnell, CP; Landzberg, MJ				Khairy, P; O'Donnell, CP; Landzberg, MJ			Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli - A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							ATRIAL SEPTAL ANEURYSM; CEREBRAL ISCHEMIC EVENTS; INTERMEDIATE-TERM RISK; CRYPTOGENIC STROKE; SURGICAL CLOSURE; CEREBROVASCULAR EVENTS; SECONDARY PREVENTION; PERCUTANEOUS CLOSURE; COST-EFFECTIVENESS; TRANSESOPHAGEAL	Background: The optimal strategy to. prevent recurrent presumed paradoxical emboli in patients, with patent foramen ovale is unknown. Purpose: To synthesize the current knowledge about and qualitatively assess the relative benefits of transcatheter closure versus medical therapy for patent foramen ovale. Data Sources: English-language and foreign-language journals listed in the MEDLINE database from January 1985 to July 2003 were systematically searched. Secondary sources were also used. Study Selection: Secondary prevention studies of transcatheter closure or medical therapy for patent foramen ovale were required to include at least 10 patients followed for more than 1 year and to report recurrent neurologic events. Data Extraction: Data from published studies were manually extracted and summarized. Data Synthesis: Ten studies of transcatheter closure (1355 patients) and 6 studies of medical therapy (895 patients) for patent foramen ovale were included. Overall, the 1-year rate of recurrent neurologic thromboembolism with transcatheter intervention was 0% to 4.9%, and the incidence of major and minor complications was 1.5% and 7.9%, respectively. Medical management was associated with a 1-year recurrence rate of 3.8% to 12.0%. However, limitations resulting from uncontrolled data, nonstandardized definitions, vigilance of follow-up, and baseline imbalances preclude definitive conclusions about the superiority of a particular approach. General differences in study samples included older age, greater proportion of men, and higher prevalence of diabetes and smoking among medically treated patients. Patients undergoing treatment with a transcatheter device were more likely to have had multiple thromboembolic events at baseline. Conclusion: Transcatheter closure of patent foramen ovale may prevent a substantial proportion of cryptogenic strokes. Randomized clinical trials are needed.	Harvard Univ, Sch Med, Childrens Hosp Boston,Dept Cardiol, Boston Adult Congenital Heart Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston Adult Congenital Heart Serv, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Landzberg, MJ (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston,Dept Cardiol, Boston Adult Congenital Heart Serv, 300 Longwood Ave, Boston, MA 02115 USA.	michael.landzberg@cardio.chboston.org						Agmon Y, 2001, AM J CARDIOL, V88, P330, DOI 10.1016/S0002-9149(01)01656-3; Albers CW, 2001, CHEST, V119, p300S, DOI 10.1378/chest.119.1_suppl.300S; BALLI E, 1995, BRIT HEART J, V74, P470; Beitzke A, 2001, J Interv Cardiol, V14, P223, DOI 10.1111/j.1540-8183.2001.tb00740.x; Bogousslavsky J, 1996, NEUROLOGY, V46, P1301, DOI 10.1212/WNL.46.5.1301; Braun MU, 2002, J AM COLL CARDIOL, V39, P2019, DOI 10.1016/S0735-1097(02)01904-6; BRIDGES ND, 1992, CIRCULATION, V86, P1902, DOI 10.1161/01.CIR.86.6.1902; Butera G, 2001, Ital Heart J, V2, P115; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; Cujec B, 1999, CAN J CARDIOL, V15, P57; De Castro S, 2000, STROKE, V31, P2407, DOI 10.1161/01.STR.31.10.2407; Devuyst G, 1996, NEUROLOGY, V47, P1162, DOI 10.1212/WNL.47.5.1162; Du ZD, 2002, CATHETER CARDIO INTE, V55, P189, DOI 10.1002/ccd.10067; Ebrahim S, 1999, STROKE, V30, P2759, DOI 10.1161/01.STR.30.12.2759; Ende DJ, 1996, AM J CARDIOL, V78, P233, DOI 10.1016/S0002-9149(96)90405-1; FISHER DC, 1995, CHEST, V107, P1504, DOI 10.1378/chest.107.6.1504; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Halperin JL, 2002, CIRCULATION, V105, P2580, DOI 10.1161/01.CIR.0000020353.63751.2F; Hankey GJ, 1999, J CARDIOVASC RISK, V6, P207; HART RG, 1983, STROKE, V14, P110, DOI 10.1161/01.STR.14.1.110; Homma S, 2002, CIRCULATION, V105, P2625, DOI 10.1161/01.CIR.0000017498.88393.44; Homma S, 1997, STROKE, V28, P2376, DOI 10.1161/01.STR.28.12.2376; Hung J, 2000, J AM COLL CARDIOL, V35, P1311, DOI 10.1016/S0735-1097(00)00514-3; JOB FP, 1994, AM J CARDIOL, V74, P381, DOI 10.1016/0002-9149(94)90407-3; Kothari V, 2002, STROKE, V33, P1776, DOI 10.1161/01.STR.0000020091.07144.C7; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; Martin F, 2002, CIRCULATION, V106, P1121, DOI 10.1161/01.CIR.0000027819.19722.EE; Mas JL, 2001, NEW ENGL J MED, V345, P1740, DOI 10.1056/NEJMoa011503; MAS JL, 1994, EUR HEART J, V15, P446, DOI 10.1093/oxfordjournals.eurheartj.a060524; MUGGE A, 1995, CIRCULATION, V91, P2785, DOI 10.1161/01.CIR.91.11.2785; NAGELHOUT DA, 1991, AM HEART J, V121, P1552, DOI 10.1016/0002-8703(91)90170-M; Nakayama T, 2000, NEUROEPIDEMIOLOGY, V19, P217, DOI 10.1159/000026259; Nedeltchev K, 2002, J NEUROL NEUROSUR PS, V72, P347, DOI 10.1136/jnnp.72.3.347; Nendaz M, 1997, EUR NEUROL, V37, P199, DOI 10.1159/000117442; Nendaz MR, 1998, AM HEART J, V135, P532, DOI 10.1016/S0002-8703(98)70332-1; Ockene IS, 1997, CIRCULATION, V96, P3243, DOI 10.1161/01.CIR.96.9.3243; Onorato Eustaquio, 2003, J Interv Cardiol, V16, P43; Orgera MA, 2001, SOUTHERN MED J, V94, P699; Overell JR, 2000, NEUROLOGY, V55, P1172, DOI 10.1212/WNL.55.8.1172; Ruchat P, 1997, EUR J CARDIO-THORAC, V11, P824, DOI 10.1016/S1010-7940(97)01175-5; Sacco RL, 1997, EUR NEUROL, V37, P205, DOI 10.1159/000117443; Sarasin FP, 2000, ARCH INTERN MED, V160, P2773, DOI 10.1001/archinte.160.18.2773; Sievert H, 2001, J Interv Cardiol, V14, P261, DOI 10.1111/j.1540-8183.2001.tb00745.x; Srivastava TN, 1997, NEW ENGL J MED, V337, P681, DOI 10.1056/NEJM199709043371005; STEGMAYR B, 1995, DIABETOLOGIA, V38, P1061, DOI 10.1007/BF00402176; Steiner MM, 1998, STROKE, V29, P944, DOI 10.1161/01.STR.29.5.944; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tuomilehto J, 1999, J CARDIOVASC RISK, V6, P241; Wahl A, 2001, NEUROLOGY, V57, P1330, DOI 10.1212/WNL.57.7.1330; WEBSTER MWI, 1988, LANCET, V2, P11; Windecker S, 2000, CIRCULATION, V101, P893, DOI 10.1161/01.CIR.101.8.893	51	302	316	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					753	760		10.7326/0003-4819-139-9-200311040-00010	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738XJ	14597460				2022-12-28	WOS:000186312900005
J	Oparil, S; Zaman, A; Calhoun, DA				Oparil, S; Zaman, A; Calhoun, DA			Pathogenesis of hypertension	ANNALS OF INTERNAL MEDICINE			English	Review							SERUM URIC-ACID; ISOLATED SYSTOLIC HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; END-POINT REDUCTION; ENDOTHELIN-RECEPTOR ANTAGONIST; INFLUENCING BLOOD-PRESSURE; CARDIOVASCULAR MORBIDITY; LOSARTAN INTERVENTION; HEART-RATE; SYMPATHETIC OVERACTIVITY		Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Oparil, S (corresponding author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Zeigler Bldg 1034,703 19th St S, Birmingham, AL 35294 USA.							ABBOUD FM, 1966, CIRC RES, V18, P263, DOI 10.1161/01.RES.18.3.263; ABBOUD FM, 1974, FED PROC, V33, P143; Alderman MH, 1999, HYPERTENSION, V34, P144, DOI 10.1161/01.HYP.34.1.144; BIANCHETTI MG, 1986, KIDNEY INT, V29, P882, DOI 10.1038/ki.1986.81; BIRON P, 1976, CAN MED ASSOC J, V115, P773; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brook RD, 2000, AM J HYPERTENS, V13, p112S, DOI 10.1016/S0895-7061(00)00228-4; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; CALHOUN DA, 1993, HYPERTENSION, V22, P801, DOI 10.1161/01.HYP.22.6.801; Calhoun DA, 2002, HYPERTENSION, V40, P892, DOI 10.1161/01.HYP.0000040261.30455.B6; Calhoun DA, 2002, CURR HYPERTENS REP, V4, P221, DOI 10.1007/s11906-002-0011-8; CALHOUN DA, 2000, CARDIOLOGY; Carey RM, 2003, ENDOCR REV, V24, P261, DOI 10.1210/er.2003-0001; Carretero OA, 2000, CIRCULATION, V101, P329, DOI 10.1161/01.CIR.101.3.329; Carter AR, 2001, AM J PHYSIOL-CELL PH, V281, pC1413, DOI 10.1152/ajpcell.2001.281.5.C1413; Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X; CHAPLEAU MW, 1992, AM J PHYSIOL, V263, pR103, DOI 10.1152/ajpregu.1992.263.1.R103; CHAPLEAU MW, 1988, AM J MED SCI, V295, P327, DOI 10.1097/00000441-198804000-00019; Chen XL, 1998, CIRC RES, V83, P952; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; Corvol P, 1999, HYPERTENSION, V33, P1324, DOI 10.1161/01.HYP.33.6.1324; COWLEY AW, 1995, HYPERTENSION, V25, P663, DOI 10.1161/01.HYP.25.4.663; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dibona Gerald F., 1995, P1349; Ergul S, 1996, HYPERTENSION, V28, P652, DOI 10.1161/01.HYP.28.4.652; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; Esler M, 2000, AM J HYPERTENS, V13, p99S, DOI 10.1016/S0895-7061(00)00225-9; Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; Fornage M, 1998, CIRCULATION, V97, P1773, DOI 10.1161/01.CIR.97.18.1773; Franse LV, 2000, J HYPERTENS, V18, P1149, DOI 10.1097/00004872-200018080-00021; FROHLICH ED, 2000, HYPERTENSION COMPANI, P637; Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45; GOLDBLATT H, 1947, PHYSIOL REV, V27, P120, DOI 10.1152/physrev.1947.27.1.120; GRASSI G, 1995, HYPERTENSION, V26, P348, DOI 10.1161/01.HYP.26.2.348; GUO GB, 1984, AM J PHYSIOL, V246, pH720, DOI 10.1152/ajpheart.1984.246.5.H720; GUO GB, 1983, CIRC RES, V53, P223, DOI 10.1161/01.RES.53.2.223; GUO GB, 1984, AM J PHYSIOL, V246, pH80, DOI 10.1152/ajpheart.1984.246.1.H80; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HARRAP SB, 2000, HYPERTENSION COMPANI, P29; HEISTAD DD, 1968, J APPL PHYSIOL, V25, P542, DOI 10.1152/jappl.1968.25.5.542; HENKE F, 1925, HDB SPEZIELLEN PATHO, V6, P368; HOLLENBERG NK, 1975, MEDICINE, V54, P29, DOI 10.1097/00005792-197501000-00002; Hsueh WC, 2000, CIRCULATION, V101, P2810, DOI 10.1161/01.CIR.101.24.2810; Hunt SC, 2002, HYPERTENSION, V40, P1, DOI 10.1161/01.HYP.0000022660.28915.B1; Hyman David J., 2000, J Clin Hypertens (Greenwich), V2, P324; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078; Julius S, 1996, CLIN EXP HYPERTENS, V18, P305, DOI 10.3109/10641969609088965; Kim JR, 1999, HYPERTENSION, V33, P640, DOI 10.1161/01.HYP.33.2.640; Kjeldsen SE, 2002, JAMA-J AM MED ASSOC, V288, P1491, DOI 10.1001/jama.288.12.1491; Kristjansson K, 2002, HYPERTENSION, V39, P1044, DOI 10.1161/01.HYP.0000018580.24644.18; Krum H, 1998, NEW ENGL J MED, V338, P784, DOI 10.1056/NEJM199803193381202; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; Levy D, 2000, HYPERTENSION, V36, P477, DOI 10.1161/01.HYP.36.4.477; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Li Z, 1996, CIRC RES, V79, P802, DOI 10.1161/01.RES.79.4.802; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Light KC, 2000, HYPERTENSION, P59; Lijnen P, 2000, J MOL CELL CARDIOL, V32, P865, DOI 10.1006/jmcc.2000.1129; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; LONGINI IM, 1984, AM J EPIDEMIOL, V120, P131, DOI 10.1093/oxfordjournals.aje.a113862; Luft FC, 2000, CURR OPIN NEPHROL HY, V9, P259, DOI 10.1097/00041552-200005000-00009; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MARCUS R, 1994, CIRCULATION, V90, P928, DOI 10.1161/01.CIR.90.2.928; Mark AL, 1996, J HYPERTENS, V14, pS159; Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839; Mazzali M, 2002, AM J PHYSIOL-RENAL, V282, pF991, DOI 10.1152/ajprenal.00283.2001; McConnaughey MM, 1999, J CLIN PHARMACOL, V39, P547, DOI 10.1177/00912709922008155; Melander O, 1998, HYPERTENSION, V31, P1118, DOI 10.1161/01.HYP.31.5.1118; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; Mulvany MJ, 1996, HYPERTENSION, V28, P505; Mulvany MJ, 2002, CURR HYPERTENS REP, V4, P49, DOI 10.1007/s11906-002-0053-y; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; Niu TH, 1999, HYPERTENSION, V33, P698, DOI 10.1161/01.HYP.33.2.698; O'Donnell CJ, 1998, CIRCULATION, V97, P1766, DOI 10.1161/01.CIR.97.18.1766; OROURKE MF, 1997, AM J HYPERTENS, V10, pA3; OROURKE MF, 2000, HYPERTENSION COMPANI, P134; Panza JA, 2001, NEW ENGL J MED, V345, P1337, DOI 10.1056/NEJM200111013451810; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RAO GN, 1991, J BIOL CHEM, V266, P8604; Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607; Rich MW, 2000, AM J CARDIOL, V85, P1018, DOI 10.1016/S0002-9149(99)00922-4; Safar ME, 1999, J HUM HYPERTENS, V13, P813, DOI 10.1038/sj.jhh.1000930; SAITO I, 1978, J AM GERIATR SOC, V26, P241, DOI 10.1111/j.1532-5415.1978.tb02396.x; Sanai T, 1996, J LAB CLIN MED, V128, P89, DOI 10.1016/S0022-2143(96)90117-1; Schiffrin EL, 2001, CURR OPIN NEPHROL HY, V10, P617, DOI 10.1097/00041552-200109000-00011; SEALEY JE, 1988, J HYPERTENS, V6, P763, DOI 10.1097/00004872-198811000-00001; SELBY JV, 1991, JAMA-J AM MED ASSOC, V265, P2079, DOI 10.1001/jama.265.16.2079; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SOMERS VK, 1988, HYPERTENSION, V11, P608, DOI 10.1161/01.HYP.11.6.608; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Staessen JA, 2000, LANCET, V355, P865, DOI 10.1016/S0140-6736(99)07330-4; Staessen JA, 1999, J HYPERTENS, V17, P9, DOI 10.1097/00004872-199917010-00003; Tea BS, 2000, HYPERTENSION, V35, P1069, DOI 10.1161/01.HYP.35.5.1069; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; THOREN P, 1979, CLIN SCI, V57, pS197, DOI 10.1042/cs057197s; THYBO NK, 1995, HYPERTENSION, V25, P474, DOI 10.1161/01.HYP.25.4.474; Tummala PE, 1999, CIRCULATION, V100, P1223, DOI 10.1161/01.CIR.100.11.1223; Vaziri ND, 2000, HYPERTENSION, V36, P142, DOI 10.1161/01.HYP.36.1.142; Welch WJ, 2000, AM J PHYSIOL-RENAL, V278, pF769, DOI 10.1152/ajprenal.2000.278.5.F769; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; XIE PL, 1990, J CLIN INVEST, V86, P625, DOI 10.1172/JCI114754; XIE PL, 1991, HYPERTENSION, V17, P72, DOI 10.1161/01.HYP.17.1.72; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zafari AM, 1999, ANTIOXID REDOX SIGN, V1, P167, DOI 10.1089/ars.1999.1.2-167; ZIEGLER MG, 1991, AM J HYPERTENS, V4, P586, DOI 10.1093/ajh/4.7.586	118	409	438	2	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					761	776		10.7326/0003-4819-139-9-200311040-00011	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00011			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738XJ	14597461				2022-12-28	WOS:000186312900006
J	Gilg, O; Hanski, I; Sittler, B				Gilg, O; Hanski, I; Sittler, B			Cyclic dynamics in a simple vertebrate predator-prey community	SCIENCE			English	Article							DICROSTONYX-GROENLANDICUS; POPULATION-CYCLES; RODENT DYNAMICS; LEMMINGS; MODEL	The collared lemming in the high-Arctic tundra in Greenland is preyed upon by four species of predators that show marked differences in the numbers of lemmings each consumes and in the dependence of their dynamics on lemming density. A predator-prey model based on the field-estimated predator responses robustly predicts 4-year periodicity in lemming dynamics, in agreement with long-term empirical data. There is no indication in the field that food or space limits lemming population growth, nor is there need in the model to consider those factors. The cyclic dynamics are driven by a 1-year delay in the numerical response of the stoat and stabilized by strongly density-dependent predation by the arctic fox, the snowy owl, and the long-tailed skua.	Univ Helsinki, Dept Systemat & Ecol, Div Populat Biol, FIN-00014 Helsinki, Finland; INRA, IRD, Equipe Biol & Gest Pullulat, CBGP, F-34988 Montferrier Sur Lez, Lez, France; Univ Freiburg, Inst Landespflege, D-79085 Freiburg, Germany	University of Helsinki; INRAE; Institut de Recherche pour le Developpement (IRD); University of Freiburg	Gilg, O (corresponding author), Univ Helsinki, Dept Systemat & Ecol, Div Populat Biol, POB 65, FIN-00014 Helsinki, Finland.	olivier.gilg@libertysurf.fr	GILG, Olivier/C-2588-2008	GILG, Olivier/0000-0002-9083-4492				ANDERSSON M, 1976, J ANIM ECOL, V45, P537, DOI 10.2307/3890; Batzli G.O., 1980, ARCTIC ECOSYSTEM COA, P335, DOI DOI 10.1575/1912/222; Berg T.B., 2003, THESIS U COPENHAGEN; CHERNYAVSKII FB, 1975, MATERIALY EKOLOGII M, P13; CHERNYAVSKY FB, 1981, ECOLOGY BIRDS MAMMAL; CHESSON P, 1994, THEOR POPUL BIOL, V45, P227, DOI 10.1006/tpbi.1994.1013; Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343; DUNAEVA T N, 1978, Byulleten' Moskovskogo Obshchestva Ispytatelei Prirody Otdel Biologicheskii, V83, P18; DUNAEVA TN, 1948, P I GEOGRAPHY ACAD S, V51, P78; FITZGERALD BM, 1977, J ANIM ECOL, V46, P367, DOI 10.2307/3818; Gilg O, 2002, OIKOS, V99, P499, DOI 10.1034/j.1600-0706.2002.11989.x; GILG O, 2002, THESIS U FRANCHE COM; HANSKI I, 1995, ECOLOGY, V76, P840, DOI 10.2307/1939349; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; Hanski I, 2001, ECOLOGY, V82, P1505, DOI 10.1890/0012-9658(2001)082[1505:SRDAP]2.0.CO;2; HENRY GHR, 1990, CAN J BOT, V68, P2660, DOI 10.1139/b90-336; Klemola T, 2003, ADV ECOL RES, V33, P75, DOI 10.1016/S0065-2504(03)33010-7; Lambin X, 2002, POPULATION CYCLES: THE CASE FOR TROPHIC INTERACTIONS, P155; MIKKELSEN PS, 1994, NORDOST GRONLAND 190; Millar JS, 2001, ECOSCIENCE, V8, P145, DOI 10.1080/11956860.2001.11682639; Oli MK, 2003, TRENDS ECOL EVOL, V18, P105, DOI 10.1016/S0169-5347(03)00005-3; SITTLER B, 1995, ANN ZOOL FENN, V32, P79; Sittler B, 2000, ARCTIC, V53, P53; Turchin P, 1997, AM NAT, V149, P842, DOI 10.1086/286027; Turchin P, 2001, ECOL LETT, V4, P267, DOI 10.1046/j.1461-0248.2001.00204.x; Turchin P, 2000, NATURE, V405, P562, DOI 10.1038/35014595; Turchin Peter, 2003, Monographs in Population Biology, V35, pi	27	234	245	7	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					866	868		10.1126/science.1087509	http://dx.doi.org/10.1126/science.1087509			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593179				2022-12-28	WOS:000186258000049
J	Kubori, T; Galan, JE				Kubori, T; Galan, JE			Temporal regulation of Salmonella virulence effector function by proteasome-dependent protein degradation	CELL			English	Article							III SECRETION SYSTEM; YERSINIA-ENTEROCOLITICA; BACTERIAL TOXIN; HOST-CELLS; TYPHIMURIUM; CHAPERONE; IDENTIFICATION; YOPE; TRANSLOCATION; GENES	Salmonella enterica invasion of host cells requires the reversible activation of the Rho-family GTPases Cdc42 and Rac1 by the bacterially encoded GEF SopE and the GAP SptP, which exert their function at different times during infection and are delivered into host cells by a type III secretion system. We found that SopE and SptP are delivered in equivalent amounts early during infection. However, SopE is rapidly degraded through a proteosome-mediated pathway, while SptP exhibits much slower degradation kinetics. The half-lives of these effector proteins are determined by their secretion and translocation domains. Chimeric protein analysis indicated that delivery of SptP into host cells by the SopE secretion and translocation domain drastically shortened its half-life. Conversely, delivery of SopE by the SptP secretion and translocation signals significantly increased its half-life, resulting in persistent actin cytoskeleton rearrangements. This regulatory mechanism constitutes a remarkable example of a pathogen's adaptation to modulate cellular functions.	Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.	jorge.galan@yale.edu	Kubori, Tomoko/AAH-3609-2019	Kubori, Tomoko/0000-0003-1098-6021	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030492, R37AI030492, R01AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30492] Funding Source: Medline; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birtalan SC, 2002, MOL CELL, V9, P971, DOI 10.1016/S1097-2765(02)00529-4; Boyd AP, 2000, J BACTERIOL, V182, P4811, DOI 10.1128/JB.182.17.4811-4821.2000; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; Francis MS, 2001, MOL MICROBIOL, V42, P1075, DOI 10.1046/j.1365-2958.2001.02702.x; Fu YX, 1998, J BACTERIOL, V180, P3393, DOI 10.1128/JB.180.13.3393-3399.1998; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lucas RL, 2000, MOL MICROBIOL, V36, P1024, DOI 10.1046/j.1365-2958.2000.01961.x; Marcus SL, 2002, CELL MICROBIOL, V4, P435, DOI 10.1046/j.1462-5822.2002.00202.x; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Schesser K, 1996, J BACTERIOL, V178, P7227, DOI 10.1128/jb.178.24.7227-7233.1996; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; Stebbins CE, 2000, MOL CELL, V6, P1449, DOI 10.1016/S1097-2765(00)00141-6; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; WATTIAU P, 1993, MOL MICROBIOL, V8, P123, DOI 10.1111/j.1365-2958.1993.tb01209.x; WATTIAU P, 1994, P NATL ACAD SCI USA, V91, P10493, DOI 10.1073/pnas.91.22.10493; Wulff-Strobel CR, 2002, MOL MICROBIOL, V43, P411, DOI 10.1046/j.1365-2958.2002.02752.x; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x	40	217	224	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	2003	115	3					333	342		10.1016/S0092-8674(03)00849-3	http://dx.doi.org/10.1016/S0092-8674(03)00849-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636560	Bronze			2022-12-28	WOS:000186415000012
J	Takahashi, T; Sutherland, SC; Feely, RA; Cosca, CE				Takahashi, T; Sutherland, SC; Feely, RA; Cosca, CE			Decadal variation of the surface water PCO2 in the western and central equatorial Pacific	SCIENCE			English	Article							INTERANNUAL VARIABILITY; CO2 DISTRIBUTIONS; EL-NINO; SEA; OCEAN; CARBON; PCO(2)	The equatorial Pacific Ocean is one of the most important yet highly variable oceanic source areas for atmospheric carbon dioxide (CO2). Here, we used the partial pressure of CO2 (PCO2), measured in surface waters from 1979 through early 2001, to examine the effect on the equatorial Pacific CO2 chemistry of the Pacific Decadal Oscillation phase shift, which occurred around 1988 to 1992. During the decade before the shift, the surface water PCO2 (corrected for temperature changes and atmospheric CO2 uptake) in the central and western equatorial Pacific decreased at a mean rate of about -20 muatm per decade, whereas after the shift, it increased at about +15 muatm per decade. These changes altered the CO2 sink and source flux of the equatorial Pacific significantly.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA	Columbia University; National Oceanic Atmospheric Admin (NOAA) - USA	Takahashi, T (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	taka@ldeo.columbia.edu	Feely, Richard A./ABI-5740-2020					Archer DE, 1996, DEEP-SEA RES PT II, V43, P779, DOI 10.1016/0967-0645(96)00017-3; Bates NR, 1998, J GEOPHYS RES-OCEANS, V103, P15567, DOI 10.1029/98JC00247; BORGNE RL, 2002, DEEP SEA RES 2, V49, P2425; Chavez FP, 2003, SCIENCE, V299, P217, DOI 10.1126/science.1075880; CHIPMAN DW, 1993, DEEP-SEA RES PT II, V40, P151, DOI 10.1016/0967-0645(93)90011-B; Dore JE, 2003, NATURE, V424, P754, DOI 10.1038/nature01885; Feely RA, 1997, DEEP-SEA RES PT II, V44, P1851, DOI 10.1016/S0967-0645(97)00061-1; Feely RA, 1999, NATURE, V398, P597, DOI 10.1038/19273; FEELY RA, 1995, DEEP-SEA RES PT II, V42, P365, DOI 10.1016/0967-0645(95)00027-N; Feely RA, 2002, DEEP-SEA RES PT II, V49, P2443, DOI 10.1016/S0967-0645(02)00044-9; Gu DF, 1997, SCIENCE, V275, P805, DOI 10.1126/science.275.5301.805; Guilderson TP, 1998, SCIENCE, V281, P240, DOI 10.1126/science.281.5374.240; Hare SR, 2000, PROG OCEANOGR, V47, P103, DOI 10.1016/S0079-6611(00)00033-1; Marzban C, 2001, MON WEATHER REV, V129, P884, DOI 10.1175/1520-0493(2001)129<0884:TCBUST>2.0.CO;2; McPhaden MJ, 2002, NATURE, V415, P603, DOI 10.1038/415603a; *NOAA CLIM MON DIA, 2001, GLOBALVIEW CO2 COOP; PRESS WH, 1986, NUMERICAL RECIPES, P491; REYNOLDS RW, 2003, NOAA OPTIMUM INTERPO; Schneider N, 1999, J PHYS OCEANOGR, V29, P1056, DOI 10.1175/1520-0485(1999)029<1056:SODNPT>2.0.CO;2; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; TAKAHASHI T, 1993, GLOBAL BIOGEOCHEM CY, V7, P843, DOI 10.1029/93GB02263; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; WANNINKHOF R, 1993, MAR CHEM, V44, P189, DOI 10.1016/0304-4203(93)90202-Y	24	59	60	4	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					852	856		10.1126/science.1088570	http://dx.doi.org/10.1126/science.1088570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593175				2022-12-28	WOS:000186258000045
J	Zoghbi, HY				Zoghbi, HY			Postnatal neurodevelopmental disorders: Meeting at the synapse?	SCIENCE			English	Article							LINKED MENTAL-RETARDATION; CPG-BINDING PROTEIN-2; RETT-SYNDROME BRAIN; AUTISTIC DISORDER; MECP2 MUTATIONS; DNA METHYLATION; PROXIMAL 15Q; ANGELMAN-SYNDROME; INFANTILE-AUTISM; SYNDROME GENE	We often think of neurodevelopmental disorders as beginning before birth, and many certainly do. A handful, however, strike many months after birth, following a period of apparently normal growth and development. Autism and Rett syndrome are two such disorders, and here I consider some of their similarities at the phenotypic and pathogenic levels. I propose that both disorders result from disruption of postnatal or experience-dependent synaptic plasticity.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.	hzoghbi@bcm.tmc.edu		Zoghbi, Huda/0000-0002-0700-3349	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD040301] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 40301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akbarian S, 2001, NEUROBIOL DIS, V8, P784, DOI 10.1006/nbdi.2001.0420; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Amir RE, 2000, ANN NEUROL, V47, P670, DOI 10.1002/1531-8249(200005)47:5<670::AID-ANA20>3.3.CO;2-6; ARMSTRONG D, 1995, J NEUROPATH EXP NEUR, V54, P195, DOI 10.1097/00005072-199503000-00006; Armstrong DD, 1999, PEDIATR NEUROL, V20, P125, DOI 10.1016/S0887-8994(98)00124-6; Armstrong J, 2001, ANN NEUROL, V50, P692, DOI 10.1002/ana.1272; Aylward EH, 1999, NEUROLOGY, V53, P2145, DOI 10.1212/WNL.53.9.2145; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; BAILEY A, 1993, LANCET, V341, P1225, DOI 10.1016/0140-6736(93)91065-T; BAKER P, 1994, J AUTISM DEV DISORD, V24, P529, DOI 10.1007/BF02172133; Balmer D, 2003, J MOL MED-JMM, V81, P61, DOI 10.1007/s00109-002-0396-5; BAUMAN ML, 1995, NEUROPEDIATRICS, V26, P105, DOI 10.1055/s-2007-979737; Beaudet Arthur L., 2002, Genetics in Medicine, V4, P399, DOI 10.1097/00125817-200209000-00013; BELICHENKO PV, 1994, NEUROREPORT, V5, P1509, DOI 10.1097/00001756-199407000-00025; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bolton PF, 2001, AM J MED GENET, V105, P675, DOI 10.1002/ajmg.1551; Boyar FZ, 2001, CLIN GENET, V60, P421, DOI 10.1034/j.1399-0004.2001.600604.x; Carney RM, 2003, PEDIATR NEUROL, V28, P205, DOI 10.1016/S0887-8994(02)00624-0; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; CHENG SD, 1994, AM J HUM GENET, V55, P753; Cohen D, 2002, AM J PSYCHIAT, V159, P148, DOI 10.1176/appi.ajp.159.1.148-a; Cohen DRS, 2003, MOL CELL NEUROSCI, V22, P417, DOI 10.1016/S1044-7431(03)00026-5; Colantuoni C, 2001, NEUROBIOL DIS, V8, P847, DOI 10.1006/nbdi.2001.0428; Cook EH, 1997, AM J HUM GENET, V60, P928; Courchesne E, 2003, JAMA-J AM MED ASSOC, V290, P337, DOI 10.1001/jama.290.3.337; Couvert P, 2001, HUM MOL GENET, V10, P941, DOI 10.1093/hmg/10.9.941; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; FOLSTEIN S, 1977, J CHILD PSYCHOL PSYC, V18, P297, DOI 10.1111/j.1469-7610.1977.tb00443.x; Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559; Frith U, 2001, NEURON, V32, P969, DOI 10.1016/S0896-6273(01)00552-9; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; GLAZE DG, 1987, ARCH NEUROL-CHICAGO, V44, P1053, DOI 10.1001/archneur.1987.00520220051016; Gurrieri F, 1999, NEUROLOGY, V52, P1694, DOI 10.1212/WNL.52.8.1694; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Hardan AY, 2001, J CHILD NEUROL, V16, P421, DOI 10.2310/7010.2001.7113; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Herbert MR, 2003, BRAIN, V126, P1182, DOI 10.1093/brain/awg110; Hoffbuhr K, 2001, NEUROLOGY, V56, P1486, DOI 10.1212/WNL.56.11.1486; HOTOPF M, 1995, J AUTISM DEV DISORD, V25, P41, DOI 10.1007/BF02178166; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; JELLINGER K, 1986, AM J MED GENET, V24, P259; Jung BP, 2003, J NEUROBIOL, V55, P86, DOI 10.1002/neu.10201; Kanner L, 1943, NERV CHILD, V2, P217; Kashiwagi A, 2003, J HUM GENET, V48, P194, DOI 10.1007/s10038-003-0009-3; Kemper TL, 1998, J NEUROPATH EXP NEUR, V57, P645, DOI 10.1097/00005072-199807000-00001; Klauck SM, 2002, AM J HUM GENET, V70, P1034, DOI 10.1086/339553; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Konstantareas MM, 1999, J AUTISM DEV DISORD, V29, P275, DOI 10.1023/A:1022155201662; Laan LAEM, 2002, EPILEPSIA, V43, P1590, DOI 10.1046/j.1528-1157.2002.30802.x; LaSalle JM, 2001, HUM MOL GENET, V10, P1729, DOI 10.1093/hmg/10.17.1729; Luna B, 2002, NEUROLOGY, V59, P834, DOI 10.1212/WNL.59.6.834; Meloni I, 2000, AM J HUM GENET, V67, P982, DOI 10.1086/303078; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; NIELSEN JB, 1990, ARCH NEUROL-CHICAGO, V47, P982, DOI 10.1001/archneur.1990.00530090054013; Orrico A, 2000, FEBS LETT, V481, P285, DOI 10.1016/S0014-5793(00)01994-3; PICKLES A, 1995, AM J HUM GENET, V57, P717; Raymond GV, 1996, ACTA NEUROPATHOL, V91, P117; REISS AL, 1993, ANN NEUROL, V34, P227, DOI 10.1002/ana.410340220; Rett A, 1966, Wien Med Wochenschr, V116, P723; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Schroer RJ, 1998, AM J MED GENET, V76, P327, DOI 10.1002/(SICI)1096-8628(19980401)76:4<327::AID-AJMG8>3.0.CO;2-M; Shahbazian MD, 2002, AM J HUM GENET, V71, P1259, DOI 10.1086/345360; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shahbazian MD, 2002, HUM MOL GENET, V11, P115, DOI 10.1093/hmg/11.2.115; Silva AE, 2002, ARQ NEURO-PSIQUIAT, V60, P290, DOI 10.1590/S0004-282X2002000200021; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Steffenburg S, 1996, PEDIATR NEUROL, V14, P131, DOI 10.1016/0887-8994(96)00011-2; STEFFENBURG S, 1989, J CHILD PSYCHOL PSYC, V30, P405, DOI 10.1111/j.1469-7610.1989.tb00254.x; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Thomas JA, 2003, AM J MED GENET A, V119A, P111, DOI 10.1002/ajmg.a.10176; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; VERMA NP, 1986, ELECTROEN CLIN NEURO, V64, P394, DOI 10.1016/0013-4694(86)90072-6; Villard L, 2000, NEUROLOGY, V55, P1188, DOI 10.1212/WNL.55.8.1188; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Watson P, 2001, J MED GENET, V38, P224, DOI 10.1136/jmg.38.4.224; Wilson S, 2003, DEV MED CHILD NEUROL, V45, P508, DOI 10.1111/j.1469-8749.2003.tb00950.x; Winnepenninckx B, 2002, HUM MUTAT, V20, P249, DOI 10.1002/humu.10130; Wolpert CM, 2000, AM J MED GENET, V96, P365, DOI 10.1002/1096-8628(20000612)96:3<365::AID-AJMG25>3.0.CO;2-X; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	81	506	528	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					826	830		10.1126/science.1089071	http://dx.doi.org/10.1126/science.1089071			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593168				2022-12-28	WOS:000186258000038
J	Kuhlman, B; Dantas, G; Ireton, GC; Varani, G; Stoddard, BL; Baker, D				Kuhlman, B; Dantas, G; Ireton, GC; Varani, G; Stoddard, BL; Baker, D			Design of a novel globular protein fold with atomic-level accuracy	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; DE-NOVO DESIGN; ELECTRON-DENSITY; SPECIFICITY; PREDICTION; SELECTION; DATABASE; VARIANT; SURFACE; DOMAIN	A major challenge of computational protein design is the creation of novel proteins with arbitrarily chosen three-dimensional structures. Here, we used a general computational strategy that iterates between sequence design and structure prediction to design a 93-residue alpha/beta protein called Top7 with a novel sequence and topology. Top7 was found experimentally to be folded and extremely stable, and the x-ray crystal structure of Top7 is similar (root mean square deviation equals 1.2 angstroms) to the design model. The ability to design a new protein fold makes possible the exploration of the large regions of the protein universe not yet observed in nature.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Baker, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Dantas, Gautam/0000-0003-0455-8370; Kuhlman, Brian/0000-0003-4907-9699				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bonneau R, 2001, PROTEINS, P119; Bowers PM, 2000, J BIOMOL NMR, V18, P311, DOI 10.1023/A:1026744431105; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Jaramillo A, 2002, P NATL ACAD SCI USA, V99, P13554, DOI 10.1073/pnas.212068599; Jin WZ, 2003, STRUCTURE, V11, P581, DOI 10.1016/S0969-2126(03)00075-3; Johnson EC, 1999, STRUCTURE, V7, P967, DOI 10.1016/S0969-2126(99)80123-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keating AE, 2001, P NATL ACAD SCI USA, V98, P14825, DOI 10.1073/pnas.261563398; KISSINGER CR, EPMR PROGRAM CRYSTAL; Koehl P, 1999, J MOL BIOL, V293, P1161, DOI 10.1006/jmbi.1999.3211; Kortemme T, 2003, J MOL BIOL, V326, P1239, DOI 10.1016/S0022-2836(03)00021-4; Kuhlman B, 2000, P NATL ACAD SCI USA, V97, P10383, DOI 10.1073/pnas.97.19.10383; Kuhlman B, 2002, J MOL BIOL, V315, P471, DOI 10.1006/jmbi.2001.5229; Larson SM, 2002, PROTEIN SCI, V11, P2804, DOI 10.1110/ps.0203902; LAZARIDIS T, 1999, PROTEINS, V35, P132; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mirny L, 2001, J MOL BIOL, V308, P123, DOI 10.1006/jmbi.2001.4602; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MURZIN AV, COMMUNICATION; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Raha K, 2000, PROTEIN SCI, V9, P1106, DOI 10.1110/ps.9.6.1106; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; ROHL C, IN PRESS METHODS ENZ; Su A, 1997, PROTEIN SCI, V6, P1701, DOI 10.1002/pro.5560060810	36	1147	1195	8	264	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1364	1368		10.1126/science.1089427	http://dx.doi.org/10.1126/science.1089427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631033				2022-12-28	WOS:000186683500043
J	Van Dyk, SD				Van Dyk, SD			Elusive supernova progenitors	SCIENCE			English	Editorial Material							IA SUPERNOVAE; MODELS; SEARCH; STAR		CALTECH, Ctr Infrared Proc & Anal, Pasadena, CA 91125 USA	California Institute of Technology	Van Dyk, SD (corresponding author), CALTECH, Ctr Infrared Proc & Anal, Pasadena, CA 91125 USA.							BRANCH D, 1995, PUBL ASTRON SOC PAC, V107, P1019, DOI 10.1086/133657; BRANCH D, 1992, ANNU REV ASTRON ASTR, V30, P359; Cumming RJ, 1996, MON NOT R ASTRON SOC, V283, P1355, DOI 10.1093/mnras/283.4.1355; Filippenko AV, 1997, ANNU REV ASTRON ASTR, V35, P309, DOI 10.1146/annurev.astro.35.1.309; Hamuy M, 2003, NATURE, V424, P651, DOI 10.1038/nature01854; Livio M, 2003, ASTROPHYS J, V594, pL93, DOI 10.1086/378765; Livio M, 2001, SPACE TEL S, V13, P334; NOMOTO K, 1984, ASTROPHYS J, V286, P644, DOI 10.1086/162639; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Van Dyk SD, 2003, PUBL ASTRON SOC PAC, V115, P1, DOI 10.1086/345748; VanDyk SD, 1996, ASTRON J, V111, P2017, DOI 10.1086/117937; WOOSLEY SE, 1986, ANNU REV ASTRON ASTR, V24, P205, DOI 10.1146/annurev.aa.24.090186.001225	13	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1161	1162		10.1126/science.1091612	http://dx.doi.org/10.1126/science.1091612			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615523				2022-12-28	WOS:000186544300037
J	Pfeffer, MA; McMurray, JJV; Velazquez, EJ; Rouleau, JL; Kober, L; Maggioni, AP; Solomon, SD; Swedberg, K; Van de Werf, F; White, H; Leimberger, JD; Henis, M; Edwards, S; Zelenkofske, S; Sellers, MA; Califf, RM; Aylward, P; Armstrong, P; Barvik, S; Belenkov, Y; Dalby, A; Diaz, R; Drexler, H; Ertl, G; Francis, G; Hampton, J; Harsanyi, A; Kvasnicka, J; Mareev, V; Marin-Neto, J; Murin, J; Myers, M; Nordlander, R; Opolski, G; Soler-Soler, J; Spac, J; Stefenelli, T; Sugrue, D; Van Gilst, W; Varshavsky, S; Weaver, D; Zannad, F; Aguilar, D; Alvarez, A; Al-Taweel, M; Anavekar, N; Finn, P; Lopez-Jimenez, F; Mercier, R; Lewis, E; Massoom, S; Manes, C; Mirza, A; Sampson, U; Skali, H; Skali, N; Szummer, K; Tokmakova, M; Zornoff, L; Mahaffey, K; Bozeman, T; Doletski, R; Lail, R; Smith, M; Taylor, L; Thomas, B; Schulman, K; Radeva, J; Reed, S; Weinfurt, W; Leizorovicz, A; Boutitie, F; Cody, R; Dargie, H; Hennekens, C; Pocock, S; Guerrero, RAA; Albisu, JP; Amuchastegui, M; Avila, EM; Arrieta, CAB; Bastianelli, R; Becker, C; Bono, J; Bortman, G; Labarta, GB; Caccavo, A; Caime, GD; Castellanos, CR; Castro, H; Covelli, G; Cuneo, CA; Del Rio, A; Fernandez, A; Cid, GF; Queirel, EF; Fuselli, JJ; Garcia, MA; Duran, RG; Garrido, M; Gentile, A; Gorini, NU; Grancelli, H; Hasbani, E; Hominal, MA; Hrabar, AD; Leiva, JE; Lopez, R; Luciardi, HL; Macin, SM; Mariano, L; Marinesco, A; Martingano, R; Martino, GD; Marzetti, EM; Mezzina, V; Moreno, HL; Muntaner, J; Nordaby, R; Nul, D; Orlandini, AD; Pavich, MAP; Pomposiello, JC; Quijano, RA; Rusculleda, M; Ryba, D; Sampo, E; Sanchez, JA; Serra, CM; Sokn, F; Sosa, CH; Liprandi, AS; Trivi, M; Vallejos, F; Vico, M; Vita, NA; Vogel, D; Volmaro, JA; Arnolda, L; Aroney, G; Aylward, P; Bett, N; Carroll, P; Carroll, P; Cross, D; Fitzpatrick, D; Garrahy, P; Hill, A; Horowitz, J; Hunt, D; Ireland, M; Lane, G; Lefkovits, J; Leitch, JW; Nelson, G; Rajappa, K; Rankin, J; Rees, D; Russell, A; Singh, B; Taylor, R; Thomson, A; Waites, J; Walsh, W; Eber, B; Krempler, FW; Kuhn, P; Pichler, M; Roggla, G; Siostrzonek, P; Stefenelli, T; Tragl, KH; Bergez, B; El Allaf, D; Smolders, W; Van Dorpe, A; Vandenbossche, JP; Vanneste, L; Albuquerque, D; Ayoub, J; Bassan, R; Carvalho, AC; Castro, LR; Coelho, O; Costa, FA; Esteves, J; Feitosa, G; Filho, J; Gun, C; Saraiva, JK; Leaes, P; Maia, L; Marin-Neto, JA; Marino, R; Mesquita, E; Piegas, LS; Rabelo, A; Rassi, S; Rassi, A; Scherr, C; Spadaro, J; Vaz, R; Arnold, M; Bedard, J; Bernstein, V; Bhesania, T; Bonafede, N; Brossoit, R; Burke, B; Castan, R; Charles, J; Cheung, MT; Chua, G; Costi, P; Davies, R; Descoings, B; Desrochers, D; Dhingra, S; Dion, D; Duchesne, L; Dupuis, J; Dupuis, R; Ervin, F; Fowlis, R; Gendreau, R; Germain, C; Giannoccaro, P; Goode, E; Gossard, D; Gosselin, G; Goulet, G; Heath, J; Heath, VA; Hess, A; Honos, G; Howlett, J; Huynh, T; Javier, J; Kincade, D; Klinke, WP; Kouz, S; Kwok, K; Lee, R; Lenis, J; Lepage, S; Lubelsky, B; McKelvie, R; Minkovitz, J; Moe, G; Montigny, M; Nadeau, R; Nitkin, C; O'Kelly, B; Palaic, M; Parker, J; Parker, T; Pesant, Y; Phaneuf, D; Pistawaka, K; Proulx, G; Roux, R; Rupka, D; Saulnier, D; Senaratne, M; Sestier, F; Sharma, N; St Hilaire, R; Stone, J; Strauss, H; Sussex, B; Talbot, P; Tremblay, B; Vizel, S; Warnica, JW; Weigel, M; Wisenberg, G; Drazka, J; Filipovsky, J; Horky, K; Jansky, P; Kral, R; Kvasnicka, J; Martinek, A; Spinar, J; Svitil, P; Agner, E; Andersen, HK; Angelo-Nielsen, K; Asklund, M; Berning, J; Brons, M; Buhl, J; Eliasen, P; Flogstad, T; Jensen, T; Klarlund, K; Kober, L; Kristensen, KS; Kroell, L; Larsen, J; Rasmussen, SL; Madsen, H; Markenvard, J; Mortensen, B; Nielsen, H; Nielsen, I; Nielsen, T; Davidson, AN; Nyvad, O; Ottesen, M; Pedersen, OL; Rickers, H; Rokkedal, J; Scheibel, M; Sejersen, H; Sorensen, EV; Sorensen, PJ; Stenteberg, SE; Bareiss, P; Barraine, R; Battistella, PD; Beaufils, P; Bonneau, A; Boulenc, JM; Bouvier, JM; Cheggour, S; Citron, B; Coisne, D; Delahaye, F; Ferriere, M; Fournier, C; Kahn, JC; Koenig, A; Laperche, T; Loiselet, P; Luccioni, R; Martelet, M; Matina, D; Ouakli, A; Parisot, M; Pavin, D; Quiret, JC; Rifai, A; Tran-Thanh, X; Angermann, CE; Bauriedel, G; Bethge, H; Borst, M; Braun, M; Drexler, H; Echternach, C; Engberding, R; Epping, J; Ertl, G; Figulla, HR; Gaudron, P; Hambrecht, R; Hanrath, P; Hey, D; Jany, B; Karmann, W; Keller, HJ; Kohler, B; Kreider-Stempfle, HU; Maisch, B; Matthes, T; Munzel, T; Nast, HP; Nienaber, C; Nitsch, J; Pfeiffer, D; Pieske, B; Rommele, U; Rupp, W; Schatz, R; Schultheiss, HP; Senges, J; Simon, R; Solzbach, U; Strasser, RH; Tebbe, U; Topp, H; Unger, T; Urbaszek, W; von Knorre, GH; von Olshausen, K; Wagner, J; Wirth, M; Wolf, MW; Csanady, M; Edes, I; Erdei, A; Hanis, B; Harsanyi, A; Janosi, A; Kalo, E; Karpati, P; Komives, S; Kutor, G; Moser, G; Rumi, G; Simon, G; Szaboki, F; Tarjan, J; Timar, S; Toth, K; Barton, JJ; Crean, P; Daly, K; Fitzgerald, D; Kearney, P; Sugrue, D; Alboni, P; Aloisi, B; Antenucci, C; Bellet, C; Bernardi, D; Bini, A; Bortolini, F; Branzi, A; Bugatti, U; Bugiardini, R; Capuano, V; Carrone, M; Celli, P; Chiesa, F; Ciconte, V; Corsini, G; De Angelis, G; Di Pasquale, G; Fanelli, R; Filorizzo, G; Fioretti, P; Grieco, A; Ignone, G; Mafrici, A; Maglia, G; Mangia, R; Maras, P; Masini, F; Mauric, A; Paci, A; Pettinati, G; Pirani, R; Rauhe, W; Sala, L; Sibilio, G; Slavich, G; Soravia, G; Tartarini, G; Tavazzi, L; Terrosu, P; Trevi, G; Trimarco, B; Turri, M; Turrini, P; Valagussa, F; Vassanelli, C; Volpe, M; Arnold, AER; Bijl, M; De Milliano, PAR; Dunselman, PHJM; Fels, PW; Kupper, AF; Herweijer, AH; Jaarsma, W; Kamp, O; Koornstra, HJJ; Kragten, JA; Kuijer, PJP; Leenders, CM; Liem, AH; Linssen, GCM; Lionarons, RJ; Lok, DJA; Louridtz, WJS; Michels, HR; van de Moer, WMM; Nierop, PR; Posma, JL; Van der Burgh, PH; van Kalmthout, PM; van Kempen, LHJ; van Veldhuisen, DJ; Wesdorp, JCL; Withagen, AJAM; Abdul-Ghaffar, N; French, J; Friedlander, D; Gerber, I; Hamer, A; Hammet, C; Hedley, J; Ikram, H; Mann, S; Matsis, P; Rankin, R; Scott, D; White, H; Wilkins, G; Williams, M; Wong, CK; Barvik, S; Dickstein, K; Hoeg, V; Banasiak, W; Demczuk, M; Dyduszynski, A; Goch, JH; Gorny, J; Janion, M; Kawecka-Jaszcz, K; Kopaczewski, J; Loboz-Grudzien, K; Ogorek, M; Opolski, G; Piotrowski, W; Ruszkowski, P; Rynkiewicz, A; Sciborski, R; Stopinski, M; Trusz-Gluza, M; Waszyrowski, T; Wojciechowski, D; Wrabec, K; Zambrzycki, J; Ananchenko, V; Arutyunov, G; Baluda, M; Barbarash, O; Belenkiy, D; Belousov, S; Belousov, YB; Boiarkin, M; Bokarev, I; Charchoglian, RA; Chepky, DA; Chumakova, G; Doschicyn, V; Dovgalevsky, P; Ermoshkina, L; Filonenko, GS; Fomin, I; Fomina, I; Foytanov, S; Freydlina, M; Glezer, M; Golikov, A; Goloshchekin, B; Gospodarenko, A; Gratsiansky, N; Ivanov, G; Katelnitskaya, L; Khrakovskaya, M; Khrustalev, O; Klenina, I; Kostenko, V; Kozlova, M; Lapin, O; Leontieva, N; Lopatin, YM; Lusov, V; Markov, V; Martioushov, S; Martynov, A; Mezentseva, N; Michailov, A; Mkrtchyan, VR; Moiseev, V; Nedogoda, S; Nefedov, AV; Nefedov, M; Nikitin, Y; Olbinskaya, L; Perepech, N; Rebrov, A; Rogalev, K; Ruda, M; Shlyahto, E; Shmyrova, V; Shpector, A; Shustov, S; Shwartz, Y; Sidorenko, B; Simonenko, V; Sobolev, K; Sorokin, L; Stefanenko, M; Stepura, O; Striouk, R; Sulimov, V; Sumin, A; Syrkin, A; Tankhilevitch, B; Tarasov, N; Tchutchalin, A; Troshina, E; Tuev, AV; Vaniev, S; Vertkin, A; Vishnevsky, A; Yacushin, S; Yarokhno, N; Zadiontchenko, V; Zborovsky, A; Zemtsovsky, E; Zverev, D; Brunclik, P; Duris, T; Hasilla, J; Kohn, R; Kovar, F; Murin, J; Renker, B; Rybar, R; Slanina, M; Uhliar, R; Bennet, JM; Dalby, AJ; Duncan, DI; Essop, MR; Kok, A; Manga, P; Posen, BMM; Roos, JS; Snyders, FA; Steingo, L; Ruiz, AB; Fernandez, JB; Fernandez, JMC; Basilio, EG; Diaz, MD; Minguell, ER; Cusi, LS; Tudela, VV; Rami, JAV; Ahremark, U; Astrom, L; Boman, K; Brunmark, P; Dahlstrom, U; Fredholm, O; Frisell, JE; Hardhammar, P; Hartford, M; Hurtig, U; Jonasson, L; Klintberg, L; Larsson, LE; Nicol, P; Nilsson, O; Nilsson, SB; Ohlin, H; Ohlsson, A; Perk, J; Perrson, H; Peterson, M; Rasmanis, G; Ringquist, C; Stenberg, A; Swedberg, K; Ticic, D; Timberg, I; Bugge, KW; Wodlin, P; Adgey, J; Al-Khoffash, M; Andrews, R; Avery, P; Ball, S; Baxter, R; Been, M; Birkhead, J; Bridges, A; Broadhurst, P; Anson, RC; Cleland, J; Clifford, P; Connelly, D; Crake, T; Davies, J; Davies, M; Dhawan, J; Dunn, F; Findlay, I; Hampton, J; Hanley, S; Higham, P; Jacob, A; Jones, C; Kaski, J; Lip, G; MacFadyen, R; Mattu, R; McAlpine, H; McMurray, J; Metcalfe, M; Moriarty, A; Morley, C; Murdoch, D; Mushahwar, S; Penny, W; Pitcher, D; Puri, S; Purvis, J; Ramsey, M; Reid, C; Richardson, G; Rowlands, D; Saltissi, S; Senior, R; Shahi, J; Smith, L; Spyrou, N; Squire, I; Stephens, J; Swan, J; Travill, C; Uren, N; Vincent, R; Wheeldon, N; Acheatel, R; Ackell, P; Adler, D; Akosah, K; Amidi, M; Amsterdam, P; Anand, I; Anderson, J; Aranda, J; Ashar, R; Ayala, K; Badger, R; Balk, M; Bannon, P; Basnight, M; Battles, V; Bayron, C; Becker, J; Belkin, R; Bellamy, B; Bellinger, R; Bengtson, J; Bennett, S; Bhalodkar, N; Bhat, G; Birkhead, R; Bittl, J; Boland, M; Book, W; Brachfeld, C; Broderick, G; Brodsky, M; Brown, C; Bruns, D; Butler, J; Calnon, D; Calvin, J; Camacho, A; Cambier, P; Camp, A; Campbell, P; Cannon, JD; Cansino, S; Carlson, R; Carr, K; Casale, P; Chadow, H; Chalasani, P; Chandna, H; Chapman, D; Charlton, G; Cheirif, J; Childs, D; Chin, J; Chu, A; Churchill, D; Clark, L; Cobb, F; Colfer, H; Corder, C; Croitoru, M; Cullinane, D; Cunningham, M; Dauber, I; Davis, T; Dawley, D; Deedwania, P; Delemos, J; DeLeon, A; Dennish, G; Denny, DM; Desai, S; D'Haem, C; Dhruva, N; Dionisopoulos, P; Dixon, E; Dodin, E; Dohad, S; Dowdy, D; Drury, J; Duvernoy, C; Edin, A; Edwards, T; Eelani, F; El Shahawy, M; Ellestad, M; Ensley, RD; Fahey, F; Farahi, J; Farnham, J; Fattal, P; Fernandez, J; Fialkow, J; Figueredo, V; Fintel, D; Fishbein, G; Fishberg, R; Fisher, B; Fitzpatrick, P; Flaker, G; Foster, M; French, W; Frey, M; Friedman, B; Furiasse, J; George, J; Ghali, J; Gilbert, J; Giles, P; Glassman, J; Gleva, M; Glynn, R; Goldman, S; Goldner, D; Goodfield, P; Gordon, D; Gottdeiner, J; Goulah, R; Grady, T; Graf, R; Graham, B; Graziano, J; Gredler, F; Greenberg, D; Greenspan, M; Gros, B; Hall, J; Hanley, H; Harris, B; Harris, K; Hartman, C; Hashimi, MW; Hassett, A; Haught, WH; Hill, D; Hillert, M; Hochman, J; Hodsden, J; Hoffmann, R; Honan, M; Hsi, D; Hudson, M; Ingersoll, H; Israel, N; Jackman, D; Jackson, B; Jafri, S; Jain, A; Jamal, N; Jenkins, L; Jennison, S; Jones, M; Joseph, J; Josephson, R; Kannam, J; Karamali, A; Karns, R; Katz, W; Kereiakes, D; Kerut, EK; Kesselbrenner, M; Kieval, J; King, J; Kipperman, R; Kizilbash, A; Klancke, K; Klein, M; Kmonicek, J; Kosolcharoen, P; Kowalski, B; Kraemer, M; Kreisman, K; Kwan, M; Lafoe, W; Lai, P; Lakow, M; Lamas, G; Lancaster, L; Langager, J; Larsen, G; Lash, J; Lauer, M; Laufer, N; Laughrun, D; Lee, C; Leesar, M; Lefkovic, L; Leimbach, W; Leimgruber, P; Lenz, F; Lessmeier, T; Lester, M; Levitte, M; Lieberman, C; Lillestol, M; Little, T; Lopez, F; Lopez, M; Losordo, D; Lucke, J; MacDonald, G; Madyoon, H; Magorien, R; Maher, P; Maislos, F; Manda, R; Mansuri, M; McClure, R; McCord, D; McGreevy, MJ; McGrew, F; McKoy, RC; McLaughlin, P; Mehta, S; Menapace, F; Meyer, T; Millar, R; Miller, G; Miller, L; Minisi, A; Mitchell, J; Mody, FV; Mohan, KK; Mohiuddin, S; Moore, C; Moore, R; Morris, K; Motta, M; Muhlestein, JB; Murali, S; Musser, WE; Navas, J; Niederman, A; Nukta, ED; Nygaard, T; O'Bryan, J; O'Connor, C; O'Dea, D; Oliveros, R; Oparil, S; Orchard, R; Ostrzega, E; Owens, J; Pak, P; Palac, R; Papasifakis, E; Paraboschi, C; Pearce, D; Peizner, D; Ponce, G; Popper, P; Porter, C; Prisant, LM; Pritza, D; Ptacin, M; Raab, C; Radtke, W; Rahko, P; Ramirez, J; Rana, M; Reeves, B; Reimers, C; Retter, K; Revtyak, G; Rezkalla, S; Rink, L; Rivera, E; Roark, S; Rohrbeck, S; Rosenthal, J; Rossi, P; Sacco, J; Saeian, K; Saltiel, F; Samaha, F; Schechter, C; Schneider, R; Schrank, J; Schulman, S; Schuyler, G; Sequeira, R; Shalev, Y; Sheikh, K; Sheikh, S; Siddique, M; Siegel, R; Silver, T; Simek, C; Sklar, J; Small, D; Smith, T; Soucier, R; Spaedy, T; Spatz, A; Srivastava, N; Stahl, A; Stark, K; Stein, P; Stern, M; Stevens, T; Stine, R; Sundram, S; Sutliff, G; Taikowski, R; Taylor, A; Thadani, U; Thompson, C; Thompson, M; Timmis, G; Tischler, M; Torelli, J; Traub, S; Treasure, C; Tsai, C; Tschida, V; Tung, C; Unks, DM; Urban, P; Uretsky, B; Vaganos, N; Vasudemurthy, K; Vaughan, M; Vazquez-Bauza, J; Vijay, N; Von Der Lohe, E; Vorchheimer, D; Voyce, S; Wall, T; Walsh, M; Watkins, J; Weiss, R; Wenger, N; Werner, J; Whayne, T; Whitsitt, T; Wilensky, M; Wilmer, C; Wilson, V; Wolbrette, D; Wolinsky, D; Wright, R; Yaacoub, A; Yakubov, S; Zakhary, B; Zaroff, J; Zelenkofske, S; Zolnick, M; Zwicke, D; Boyd, C; Adam, M; Whittom, L; Marquis, J; Pascual, A; Medina, A; Astley, C; Schofield, M; Kelkar, M; Bucan, O; Scott, M; Lindbratt, S; Sherlitz, C; Cornwell, K; Carlsen, J; Mercier, R; Spencker, T; Pohlner, K; Black, A; Steven, T; Leblanc, C; Sellers, MA; Rittenhouse, L; Sunas, L; Leimberger, J; Walden, A; Moreira, M; Houbracken, K; Vandenberghe, K; Ageev, F; Skvortsov, A; Narusov, O; Mareeva, G; Gurskaya, J; Shargorodskaya, A; Zelenkofske, S; Henis, M; Edwards, S; Gong, J; Han, X; Shinomoto, J; Barbiero, P; Jezek, T; Kaczor, J; Keating, NB; Koempf, R; McGarry, R; Rossy, G; Salemi, C; Trapani, A				Pfeffer, MA; McMurray, JJV; Velazquez, EJ; Rouleau, JL; Kober, L; Maggioni, AP; Solomon, SD; Swedberg, K; Van de Werf, F; White, H; Leimberger, JD; Henis, M; Edwards, S; Zelenkofske, S; Sellers, MA; Califf, RM; Aylward, P; Armstrong, P; Barvik, S; Belenkov, Y; Dalby, A; Diaz, R; Drexler, H; Ertl, G; Francis, G; Hampton, J; Harsanyi, A; Kvasnicka, J; Mareev, V; Marin-Neto, J; Murin, J; Myers, M; Nordlander, R; Opolski, G; Soler-Soler, J; Spac, J; Stefenelli, T; Sugrue, D; Van Gilst, W; Varshavsky, S; Weaver, D; Zannad, F; Aguilar, D; Alvarez, A; Al-Taweel, M; Anavekar, N; Finn, P; Lopez-Jimenez, F; Mercier, R; Lewis, E; Massoom, S; Manes, C; Mirza, A; Sampson, U; Skali, H; Skali, N; Szummer, K; Tokmakova, M; Zornoff, L; Mahaffey, K; Bozeman, T; Doletski, R; Lail, R; Smith, M; Taylor, L; Thomas, B; Schulman, K; Radeva, J; Reed, S; Weinfurt, W; Leizorovicz, A; Boutitie, F; Cody, R; Dargie, H; Hennekens, C; Pocock, S; Guerrero, RAA; Albisu, JP; Amuchastegui, M; Avila, EM; Arrieta, CAB; Bastianelli, R; Becker, C; Bono, J; Bortman, G; Labarta, GB; Caccavo, A; Caime, GD; Castellanos, CR; Castro, H; Covelli, G; Cuneo, CA; Del Rio, A; Fernandez, A; Cid, GF; Queirel, EF; Fuselli, JJ; Garcia, MA; Duran, RG; Garrido, M; Gentile, A; Gorini, NU; Grancelli, H; Hasbani, E; Hominal, MA; Hrabar, AD; Leiva, JE; Lopez, R; Luciardi, HL; Macin, SM; Mariano, L; Marinesco, A; Martingano, R; Martino, GD; Marzetti, EM; Mezzina, V; Moreno, HL; Muntaner, J; Nordaby, R; Nul, D; Orlandini, AD; Pavich, MAP; Pomposiello, JC; Quijano, RA; Rusculleda, M; Ryba, D; Sampo, E; Sanchez, JA; Serra, CM; Sokn, F; Sosa, CH; Liprandi, AS; Trivi, M; Vallejos, F; Vico, M; Vita, NA; Vogel, D; Volmaro, JA; Arnolda, L; Aroney, G; Aylward, P; Bett, N; Carroll, P; Carroll, P; Cross, D; Fitzpatrick, D; Garrahy, P; Hill, A; Horowitz, J; Hunt, D; Ireland, M; Lane, G; Lefkovits, J; Leitch, JW; Nelson, G; Rajappa, K; Rankin, J; Rees, D; Russell, A; Singh, B; Taylor, R; Thomson, A; Waites, J; Walsh, W; Eber, B; Krempler, FW; Kuhn, P; Pichler, M; Roggla, G; Siostrzonek, P; Stefenelli, T; Tragl, KH; Bergez, B; El Allaf, D; Smolders, W; Van Dorpe, A; Vandenbossche, JP; Vanneste, L; Albuquerque, D; Ayoub, J; Bassan, R; Carvalho, AC; Castro, LR; Coelho, O; Costa, FA; Esteves, J; Feitosa, G; Filho, J; Gun, C; Saraiva, JK; Leaes, P; Maia, L; Marin-Neto, JA; Marino, R; Mesquita, E; Piegas, LS; Rabelo, A; Rassi, S; Rassi, A; Scherr, C; Spadaro, J; Vaz, R; Arnold, M; Bedard, J; Bernstein, V; Bhesania, T; Bonafede, N; Brossoit, R; Burke, B; Castan, R; Charles, J; Cheung, MT; Chua, G; Costi, P; Davies, R; Descoings, B; Desrochers, D; Dhingra, S; Dion, D; Duchesne, L; Dupuis, J; Dupuis, R; Ervin, F; Fowlis, R; Gendreau, R; Germain, C; Giannoccaro, P; Goode, E; Gossard, D; Gosselin, G; Goulet, G; Heath, J; Heath, VA; Hess, A; Honos, G; Howlett, J; Huynh, T; Javier, J; Kincade, D; Klinke, WP; Kouz, S; Kwok, K; Lee, R; Lenis, J; Lepage, S; Lubelsky, B; McKelvie, R; Minkovitz, J; Moe, G; Montigny, M; Nadeau, R; Nitkin, C; O'Kelly, B; Palaic, M; Parker, J; Parker, T; Pesant, Y; Phaneuf, D; Pistawaka, K; Proulx, G; Roux, R; Rupka, D; Saulnier, D; Senaratne, M; Sestier, F; Sharma, N; St Hilaire, R; Stone, J; Strauss, H; Sussex, B; Talbot, P; Tremblay, B; Vizel, S; Warnica, JW; Weigel, M; Wisenberg, G; Drazka, J; Filipovsky, J; Horky, K; Jansky, P; Kral, R; Kvasnicka, J; Martinek, A; Spinar, J; Svitil, P; Agner, E; Andersen, HK; Angelo-Nielsen, K; Asklund, M; Berning, J; Brons, M; Buhl, J; Eliasen, P; Flogstad, T; Jensen, T; Klarlund, K; Kober, L; Kristensen, KS; Kroell, L; Larsen, J; Rasmussen, SL; Madsen, H; Markenvard, J; Mortensen, B; Nielsen, H; Nielsen, I; Nielsen, T; Davidson, AN; Nyvad, O; Ottesen, M; Pedersen, OL; Rickers, H; Rokkedal, J; Scheibel, M; Sejersen, H; Sorensen, EV; Sorensen, PJ; Stenteberg, SE; Bareiss, P; Barraine, R; Battistella, PD; Beaufils, P; Bonneau, A; Boulenc, JM; Bouvier, JM; Cheggour, S; Citron, B; Coisne, D; Delahaye, F; Ferriere, M; Fournier, C; Kahn, JC; Koenig, A; Laperche, T; Loiselet, P; Luccioni, R; Martelet, M; Matina, D; Ouakli, A; Parisot, M; Pavin, D; Quiret, JC; Rifai, A; Tran-Thanh, X; Angermann, CE; Bauriedel, G; Bethge, H; Borst, M; Braun, M; Drexler, H; Echternach, C; Engberding, R; Epping, J; Ertl, G; Figulla, HR; Gaudron, P; Hambrecht, R; Hanrath, P; Hey, D; Jany, B; Karmann, W; Keller, HJ; Kohler, B; Kreider-Stempfle, HU; Maisch, B; Matthes, T; Munzel, T; Nast, HP; Nienaber, C; Nitsch, J; Pfeiffer, D; Pieske, B; Rommele, U; Rupp, W; Schatz, R; Schultheiss, HP; Senges, J; Simon, R; Solzbach, U; Strasser, RH; Tebbe, U; Topp, H; Unger, T; Urbaszek, W; von Knorre, GH; von Olshausen, K; Wagner, J; Wirth, M; Wolf, MW; Csanady, M; Edes, I; Erdei, A; Hanis, B; Harsanyi, A; Janosi, A; Kalo, E; Karpati, P; Komives, S; Kutor, G; Moser, G; Rumi, G; Simon, G; Szaboki, F; Tarjan, J; Timar, S; Toth, K; Barton, JJ; Crean, P; Daly, K; Fitzgerald, D; Kearney, P; Sugrue, D; Alboni, P; Aloisi, B; Antenucci, C; Bellet, C; Bernardi, D; Bini, A; Bortolini, F; Branzi, A; Bugatti, U; Bugiardini, R; Capuano, V; Carrone, M; Celli, P; Chiesa, F; Ciconte, V; Corsini, G; De Angelis, G; Di Pasquale, G; Fanelli, R; Filorizzo, G; Fioretti, P; Grieco, A; Ignone, G; Mafrici, A; Maglia, G; Mangia, R; Maras, P; Masini, F; Mauric, A; Paci, A; Pettinati, G; Pirani, R; Rauhe, W; Sala, L; Sibilio, G; Slavich, G; Soravia, G; Tartarini, G; Tavazzi, L; Terrosu, P; Trevi, G; Trimarco, B; Turri, M; Turrini, P; Valagussa, F; Vassanelli, C; Volpe, M; Arnold, AER; Bijl, M; De Milliano, PAR; Dunselman, PHJM; Fels, PW; Kupper, AF; Herweijer, AH; Jaarsma, W; Kamp, O; Koornstra, HJJ; Kragten, JA; Kuijer, PJP; Leenders, CM; Liem, AH; Linssen, GCM; Lionarons, RJ; Lok, DJA; Louridtz, WJS; Michels, HR; van de Moer, WMM; Nierop, PR; Posma, JL; Van der Burgh, PH; van Kalmthout, PM; van Kempen, LHJ; van Veldhuisen, DJ; Wesdorp, JCL; Withagen, AJAM; Abdul-Ghaffar, N; French, J; Friedlander, D; Gerber, I; Hamer, A; Hammet, C; Hedley, J; Ikram, H; Mann, S; Matsis, P; Rankin, R; Scott, D; White, H; Wilkins, G; Williams, M; Wong, CK; Barvik, S; Dickstein, K; Hoeg, V; Banasiak, W; Demczuk, M; Dyduszynski, A; Goch, JH; Gorny, J; Janion, M; Kawecka-Jaszcz, K; Kopaczewski, J; Loboz-Grudzien, K; Ogorek, M; Opolski, G; Piotrowski, W; Ruszkowski, P; Rynkiewicz, A; Sciborski, R; Stopinski, M; Trusz-Gluza, M; Waszyrowski, T; Wojciechowski, D; Wrabec, K; Zambrzycki, J; Ananchenko, V; Arutyunov, G; Baluda, M; Barbarash, O; Belenkiy, D; Belousov, S; Belousov, YB; Boiarkin, M; Bokarev, I; Charchoglian, RA; Chepky, DA; Chumakova, G; Doschicyn, V; Dovgalevsky, P; Ermoshkina, L; Filonenko, GS; Fomin, I; Fomina, I; Foytanov, S; Freydlina, M; Glezer, M; Golikov, A; Goloshchekin, B; Gospodarenko, A; Gratsiansky, N; Ivanov, G; Katelnitskaya, L; Khrakovskaya, M; Khrustalev, O; Klenina, I; Kostenko, V; Kozlova, M; Lapin, O; Leontieva, N; Lopatin, YM; Lusov, V; Markov, V; Martioushov, S; Martynov, A; Mezentseva, N; Michailov, A; Mkrtchyan, VR; Moiseev, V; Nedogoda, S; Nefedov, AV; Nefedov, M; Nikitin, Y; Olbinskaya, L; Perepech, N; Rebrov, A; Rogalev, K; Ruda, M; Shlyahto, E; Shmyrova, V; Shpector, A; Shustov, S; Shwartz, Y; Sidorenko, B; Simonenko, V; Sobolev, K; Sorokin, L; Stefanenko, M; Stepura, O; Striouk, R; Sulimov, V; Sumin, A; Syrkin, A; Tankhilevitch, B; Tarasov, N; Tchutchalin, A; Troshina, E; Tuev, AV; Vaniev, S; Vertkin, A; Vishnevsky, A; Yacushin, S; Yarokhno, N; Zadiontchenko, V; Zborovsky, A; Zemtsovsky, E; Zverev, D; Brunclik, P; Duris, T; Hasilla, J; Kohn, R; Kovar, F; Murin, J; Renker, B; Rybar, R; Slanina, M; Uhliar, R; Bennet, JM; Dalby, AJ; Duncan, DI; Essop, MR; Kok, A; Manga, P; Posen, BMM; Roos, JS; Snyders, FA; Steingo, L; Ruiz, AB; Fernandez, JB; Fernandez, JMC; Basilio, EG; Diaz, MD; Minguell, ER; Cusi, LS; Tudela, VV; Rami, JAV; Ahremark, U; Astrom, L; Boman, K; Brunmark, P; Dahlstrom, U; Fredholm, O; Frisell, JE; Hardhammar, P; Hartford, M; Hurtig, U; Jonasson, L; Klintberg, L; Larsson, LE; Nicol, P; Nilsson, O; Nilsson, SB; Ohlin, H; Ohlsson, A; Perk, J; Perrson, H; Peterson, M; Rasmanis, G; Ringquist, C; Stenberg, A; Swedberg, K; Ticic, D; Timberg, I; Bugge, KW; Wodlin, P; Adgey, J; Al-Khoffash, M; Andrews, R; Avery, P; Ball, S; Baxter, R; Been, M; Birkhead, J; Bridges, A; Broadhurst, P; Anson, RC; Cleland, J; Clifford, P; Connelly, D; Crake, T; Davies, J; Davies, M; Dhawan, J; Dunn, F; Findlay, I; Hampton, J; Hanley, S; Higham, P; Jacob, A; Jones, C; Kaski, J; Lip, G; MacFadyen, R; Mattu, R; McAlpine, H; McMurray, J; Metcalfe, M; Moriarty, A; Morley, C; Murdoch, D; Mushahwar, S; Penny, W; Pitcher, D; Puri, S; Purvis, J; Ramsey, M; Reid, C; Richardson, G; Rowlands, D; Saltissi, S; Senior, R; Shahi, J; Smith, L; Spyrou, N; Squire, I; Stephens, J; Swan, J; Travill, C; Uren, N; Vincent, R; Wheeldon, N; Acheatel, R; Ackell, P; Adler, D; Akosah, K; Amidi, M; Amsterdam, P; Anand, I; Anderson, J; Aranda, J; Ashar, R; Ayala, K; Badger, R; Balk, M; Bannon, P; Basnight, M; Battles, V; Bayron, C; Becker, J; Belkin, R; Bellamy, B; Bellinger, R; Bengtson, J; Bennett, S; Bhalodkar, N; Bhat, G; Birkhead, R; Bittl, J; Boland, M; Book, W; Brachfeld, C; Broderick, G; Brodsky, M; Brown, C; Bruns, D; Butler, J; Calnon, D; Calvin, J; Camacho, A; Cambier, P; Camp, A; Campbell, P; Cannon, JD; Cansino, S; Carlson, R; Carr, K; Casale, P; Chadow, H; Chalasani, P; Chandna, H; Chapman, D; Charlton, G; Cheirif, J; Childs, D; Chin, J; Chu, A; Churchill, D; Clark, L; Cobb, F; Colfer, H; Corder, C; Croitoru, M; Cullinane, D; Cunningham, M; Dauber, I; Davis, T; Dawley, D; Deedwania, P; Delemos, J; DeLeon, A; Dennish, G; Denny, DM; Desai, S; D'Haem, C; Dhruva, N; Dionisopoulos, P; Dixon, E; Dodin, E; Dohad, S; Dowdy, D; Drury, J; Duvernoy, C; Edin, A; Edwards, T; Eelani, F; El Shahawy, M; Ellestad, M; Ensley, RD; Fahey, F; Farahi, J; Farnham, J; Fattal, P; Fernandez, J; Fialkow, J; Figueredo, V; Fintel, D; Fishbein, G; Fishberg, R; Fisher, B; Fitzpatrick, P; Flaker, G; Foster, M; French, W; Frey, M; Friedman, B; Furiasse, J; George, J; Ghali, J; Gilbert, J; Giles, P; Glassman, J; Gleva, M; Glynn, R; Goldman, S; Goldner, D; Goodfield, P; Gordon, D; Gottdeiner, J; Goulah, R; Grady, T; Graf, R; Graham, B; Graziano, J; Gredler, F; Greenberg, D; Greenspan, M; Gros, B; Hall, J; Hanley, H; Harris, B; Harris, K; Hartman, C; Hashimi, MW; Hassett, A; Haught, WH; Hill, D; Hillert, M; Hochman, J; Hodsden, J; Hoffmann, R; Honan, M; Hsi, D; Hudson, M; Ingersoll, H; Israel, N; Jackman, D; Jackson, B; Jafri, S; Jain, A; Jamal, N; Jenkins, L; Jennison, S; Jones, M; Joseph, J; Josephson, R; Kannam, J; Karamali, A; Karns, R; Katz, W; Kereiakes, D; Kerut, EK; Kesselbrenner, M; Kieval, J; King, J; Kipperman, R; Kizilbash, A; Klancke, K; Klein, M; Kmonicek, J; Kosolcharoen, P; Kowalski, B; Kraemer, M; Kreisman, K; Kwan, M; Lafoe, W; Lai, P; Lakow, M; Lamas, G; Lancaster, L; Langager, J; Larsen, G; Lash, J; Lauer, M; Laufer, N; Laughrun, D; Lee, C; Leesar, M; Lefkovic, L; Leimbach, W; Leimgruber, P; Lenz, F; Lessmeier, T; Lester, M; Levitte, M; Lieberman, C; Lillestol, M; Little, T; Lopez, F; Lopez, M; Losordo, D; Lucke, J; MacDonald, G; Madyoon, H; Magorien, R; Maher, P; Maislos, F; Manda, R; Mansuri, M; McClure, R; McCord, D; McGreevy, MJ; McGrew, F; McKoy, RC; McLaughlin, P; Mehta, S; Menapace, F; Meyer, T; Millar, R; Miller, G; Miller, L; Minisi, A; Mitchell, J; Mody, FV; Mohan, KK; Mohiuddin, S; Moore, C; Moore, R; Morris, K; Motta, M; Muhlestein, JB; Murali, S; Musser, WE; Navas, J; Niederman, A; Nukta, ED; Nygaard, T; O'Bryan, J; O'Connor, C; O'Dea, D; Oliveros, R; Oparil, S; Orchard, R; Ostrzega, E; Owens, J; Pak, P; Palac, R; Papasifakis, E; Paraboschi, C; Pearce, D; Peizner, D; Ponce, G; Popper, P; Porter, C; Prisant, LM; Pritza, D; Ptacin, M; Raab, C; Radtke, W; Rahko, P; Ramirez, J; Rana, M; Reeves, B; Reimers, C; Retter, K; Revtyak, G; Rezkalla, S; Rink, L; Rivera, E; Roark, S; Rohrbeck, S; Rosenthal, J; Rossi, P; Sacco, J; Saeian, K; Saltiel, F; Samaha, F; Schechter, C; Schneider, R; Schrank, J; Schulman, S; Schuyler, G; Sequeira, R; Shalev, Y; Sheikh, K; Sheikh, S; Siddique, M; Siegel, R; Silver, T; Simek, C; Sklar, J; Small, D; Smith, T; Soucier, R; Spaedy, T; Spatz, A; Srivastava, N; Stahl, A; Stark, K; Stein, P; Stern, M; Stevens, T; Stine, R; Sundram, S; Sutliff, G; Taikowski, R; Taylor, A; Thadani, U; Thompson, C; Thompson, M; Timmis, G; Tischler, M; Torelli, J; Traub, S; Treasure, C; Tsai, C; Tschida, V; Tung, C; Unks, DM; Urban, P; Uretsky, B; Vaganos, N; Vasudemurthy, K; Vaughan, M; Vazquez-Bauza, J; Vijay, N; Von Der Lohe, E; Vorchheimer, D; Voyce, S; Wall, T; Walsh, M; Watkins, J; Weiss, R; Wenger, N; Werner, J; Whayne, T; Whitsitt, T; Wilensky, M; Wilmer, C; Wilson, V; Wolbrette, D; Wolinsky, D; Wright, R; Yaacoub, A; Yakubov, S; Zakhary, B; Zaroff, J; Zelenkofske, S; Zolnick, M; Zwicke, D; Boyd, C; Adam, M; Whittom, L; Marquis, J; Pascual, A; Medina, A; Astley, C; Schofield, M; Kelkar, M; Bucan, O; Scott, M; Lindbratt, S; Sherlitz, C; Cornwell, K; Carlsen, J; Mercier, R; Spencker, T; Pohlner, K; Black, A; Steven, T; Leblanc, C; Sellers, MA; Rittenhouse, L; Sunas, L; Leimberger, J; Walden, A; Moreira, M; Houbracken, K; Vandenberghe, K; Ageev, F; Skvortsov, A; Narusov, O; Mareeva, G; Gurskaya, J; Shargorodskaya, A; Zelenkofske, S; Henis, M; Edwards, S; Gong, J; Han, X; Shinomoto, J; Barbiero, P; Jezek, T; Kaczor, J; Keating, NB; Koempf, R; McGarry, R; Rossy, G; Salemi, C; Trapani, A		VALIANT Trial Investigators	Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORTALITY; TRIAL; MORBIDITY; ACE; CANDESARTAN; SURVIVAL; THERAPY; PLACEBO; VALIANT	Background: Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients. Methods: Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause. Results: During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients in the captopril group (hazard ratio in the valsartan group as compared with the captopril group, 1.00; 97.5 percent confidence interval, 0.90 to 1.11; P=0.98; hazard ratio in the valsartan-and-captopril group as compared with the captopril group, 0.98; 97.5 percent confidence interval, 0.89 to 1.09; P=0.73). The upper limit of the one-sided 97.5 percent confidence interval for the comparison of the valsartan group with the captopril group was within the prespecified margin for noninferiority with regard to mortality (P=0.004) and with regard to the composite end point of fatal and nonfatal cardiovascular events (P<0.001). The valsartan-and-captopril group had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group, and cough, rash, and taste disturbance were more common in the captopril group. Conclusions: Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Duke Univ, Med Ctr, Durham, NC USA; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; Assoc Nazl Med Cardiol Osped Res Ctr, Florence, Italy; Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden; Leuven Coordinating Ctr, Louvain, Belgium; Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand; Med Pharmaceut Consultants, Randolph, NJ USA; Novartis Pharmaceut, E Hanover, NJ USA	Harvard University; Brigham & Women's Hospital; University of Glasgow; Duke University; Universite de Montreal; Rigshospitalet; University of Copenhagen; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Sahlgrenska University Hospital; KU Leuven; Novartis	Pfeffer, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	mpfeffer@rics.bwh.harvard.edu	Volpe, Massimo/K-5240-2016; van Gilst, Wiek/R-1806-2019; Maisch, Bernhard/AAH-9198-2020; Arnold, Malcolm/G-2869-2011; Cleland, John G./AAZ-4185-2020; Figueredo, Vincent/AAV-7610-2021; Solomon, Scott/I-5789-2013; Jafri, Wasim/AAE-5085-2020; Belenkov, Yury N/B-4159-2018; Marin-Neto, Jose Antonio/F-6099-2012; Bugiardini, Raffaele/L-6446-2015; de Lemos, James/ABD-6669-2021; Nedogoda, Sergey V/O-4656-2014; Zannad, Faiez/K-4649-2019; mcmurray, John/B-2467-2013; Dupuis, Jocelyn/C-6613-2013; Rassi, Anis/AAJ-3368-2020; Trimarco, Bruno BT/K-7851-2016; Maia, Lilia Nigro/AAV-6938-2021; Maggioni, Aldo Pietro/AAL-5334-2020; Chumakova, Galina A/L-5677-2015; Markov, Valentin A/O-4459-2016; Arutyunov, Gregory/M-7368-2019; van Veldhuisen, Dirk Jan/E-8967-2014; Howlett, Jonathan/T-2589-2019; Lopatin, Yury/J-7353-2019; Markov, Valentin A/F-6359-2014; Tavazzi, Luigi/ABD-5119-2020; Sumin, Alexey N/P-8897-2016; Arnolda, Leonard/Z-1174-2019; Yarokhno, Natalya/R-4854-2017; Casale, Paolo/AAB-8032-2020; Swedberg, Karl/B-2475-2008; Slavich, George/ABD-5450-2021; Martínek, Arnošt/R-6518-2019; Mareev, Viacheslav Yurivich/Q-1375-2017; Munzel, Thomas/A-2912-2014; Aguilar, David/GZM-1928-2022	Volpe, Massimo/0000-0002-9642-8380; van Gilst, Wiek/0000-0003-2968-8585; Cleland, John G./0000-0002-1471-7016; Bugiardini, Raffaele/0000-0002-6819-6818; Nedogoda, Sergey V/0000-0001-5981-1754; mcmurray, John/0000-0002-6317-3975; Dupuis, Jocelyn/0000-0002-3193-1014; Trimarco, Bruno BT/0000-0002-0701-6449; Maggioni, Aldo Pietro/0000-0003-2764-6779; Chumakova, Galina A/0000-0002-2810-6531; Markov, Valentin A/0000-0002-5959-2771; Arutyunov, Gregory/0000-0002-6645-2515; Lopatin, Yury/0000-0001-8744-7144; Markov, Valentin A/0000-0002-5959-2771; Tavazzi, Luigi/0000-0003-0336-8356; Arnolda, Leonard/0000-0001-8173-3318; Yarokhno, Natalya/0000-0003-2055-648X; Casale, Paolo/0000-0002-7899-5736; Martínek, Arnošt/0000-0001-7597-3235; Mareev, Viacheslav Yurivich/0000-0002-7285-2048; Munzel, Thomas/0000-0001-5503-4150; Aguilar, David/0000-0002-0916-2722; Van de Werf, Frans/0000-0001-9479-7767; Patt, Mitchell/0000-0001-9696-4477; kamp, otto/0000-0003-2707-2090; Kober, Lars/0000-0002-6635-1466; Losordo, Douglas/0000-0002-6857-7506; Maglia, Giampiero/0000-0001-9518-5877				AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; BALL SG, 1993, LANCET, V342, P821; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COLLINS R, 1995, LANCET, V345, P669; CPMP, 2001, BRIT J CLIN PHARMACO, V52, P223; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; DEVITA C, 1994, LANCET, V343, P1115; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Dickstein K, 2003, AM HEART J, V145, P754, DOI 10.1016/S0002-8703(03)00168-6; Fisher LD, 1998, J AM COLL CARDIOL, V31, p49A, DOI 10.1016/S0735-1097(97)83927-7; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; Hasselblad V, 2001, DRUG INF J, V35, P435, DOI 10.1177/009286150103500212; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; LIU LS, 1995, LANCET, V345, P686; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Petrie MC, 2001, J AM COLL CARDIOL, V37, P1056, DOI 10.1016/S0735-1097(01)01111-1; Pfeffer MA, 2000, AM HEART J, V140, P727, DOI 10.1067/mhj.2000.108832; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; PFEFFER MA, 1995, NEW ENGL J MED, V332, P118, DOI 10.1056/NEJM199501123320210; Remme WJ, 2001, EUR HEART J, V22, P2217; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Skali H, 2001, J RENIN-ANGIO-ALDO S, V2, P215, DOI 10.3317/jraas.2001.034; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; Velazquez EJ, 2003, EUR J HEART FAIL, V5, P537, DOI 10.1016/S1388-9842(03)00112-0; Yusuf S, 2002, AM J CARDIOL, V89, p18A	29	1698	1793	3	118	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1893	1906		10.1056/NEJMoa032292	http://dx.doi.org/10.1056/NEJMoa032292			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14610160	Bronze			2022-12-28	WOS:000186502400004
J	Moore, H; Summerbell, CD; Greenwood, DC; Tovey, P; Griffiths, J				Moore, H; Summerbell, CD; Greenwood, DC; Tovey, P; Griffiths, J			Improving management of obesity in primary care: cluster randomised trial	BRITISH MEDICAL JOURNAL			English	Article								Objective To evaluate a training programme intended to improve the management of obesity, delivered to general practice teams. Design Cluster randomised trial. Setting Northern and Yorkshire region of England Participants 44 general practices invited consecutively attending obese adults to participate; 843 patients attended for collection of baseline data and were subsequently randomised. Intervention 4.5 hour training programme promoting an obesity management model. Main outcome measures Difference in weight between patients in intervention and control groups at 12 months (main outcome measure) and at 3 months and 18 months; change in practitioners' knowledge and behaviour in obesity management consultations. Results Twelve months after training the patients in the intervention group were 1 (95% confidence interval -1.9 to 3.9) kg heavier than controls (P=0.5). Some evidence indicated that practitioners' knowledge had improved. Some aspects of the management model, including recording weight, target weight, and dietary targets, occurred more frequently in intervention practices after the training, but in absolute terms levels of implementation were low Conclusion A training package promoting a brief, prescriptive approach to the treatment of obesity through lifestyle modification, intended to be incorporated into routine clinical practice, did not ultimately affect the weight of this motivated and at risk cohort of patients.	Univ Leeds, Ctr Res Primary Care, Leeds LS2 9PL, W Yorkshire, England; Univ Teesside, Sch Hlth, Middlesbrough TS1 3BA, Cleveland, England; Univ Leeds, Biostat Unit, Leeds LS2 9LN, W Yorkshire, England; Univ Leeds, Sch Healthcare Studies, Leeds LS2 9JT, W Yorkshire, England; St Marys Hosp, Dept Nutr & Dietet, Leeds LS12 3QE, W Yorkshire, England; Univ Hosp N Durham, Dept Nutr & Dietet, Durham DH1 5TW, England; Royal Victoria Infirm, Newcastle Hosp NHS Trust, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Scarborough Gen Hosp, Whitby & Ryedale Primary Care Trust, Dept Nutr & Dietet, Scarborough, ON YO12 6QL, Canada; Univ Newcastle Upon Tyne, Human Nutr Res Ctr, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Leeds; University of Teesside; University of Leeds; University of Leeds; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Scarborough Hospital; Newcastle University - UK	Moore, H (corresponding author), Univ Leeds, Ctr Res Primary Care, Leeds LS2 9PL, W Yorkshire, England.		Greenwood, Darren C/C-3220-2008; Summerbell, Carolyn/AAC-3159-2019	Greenwood, Darren C/0000-0001-7035-3096; Summerbell, Carolyn/0000-0003-1910-9383; Adamson, Ashley/0000-0003-3735-2846				ANDERSSON I, 1992, INT J OBESITY, V16, P1013; Centre for Reviews and Dissemination, 1997, EFF HLTH CARE, V3; *DEP HLTH, 2002, HLTH IMPR PREV NAT S; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Harvey EL, 1999, INT J OBESITY, V23, P1213, DOI 10.1038/sj.ijo.0800932; Moore H, 2003, BRIT J GEN PRACT, V53, P271; Moore H, 2001, STAT MED, V20, P331, DOI 10.1002/1097-0258(20010215)20:3&lt;331::AID-SIM795&gt;3.0.CO;2-K; National Audit Office, 2001, TACKL OB ENGL REP CO; Raab GM, 2001, STAT MED, V20, P351, DOI 10.1002/1097-0258(20010215)20:3<351::AID-SIM797>3.0.CO;2-C; *SCOTT INT GUID NE, 1996, 8 SIGN; Yanovski SZ, 1999, AM J CLIN NUTR, V69, P366	12	77	78	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2003	327	7423					1085	1088		10.1136/bmj.327.7423.1085	http://dx.doi.org/10.1136/bmj.327.7423.1085			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604931	Green Accepted, Green Published			2022-12-28	WOS:000186530400020
J	Dufour, SC; Felbeck, H				Dufour, SC; Felbeck, H			Sulphide mining by the superextensile foot of symbiotic thyasirid bivalves	NATURE			English	Article							MOLLUSKS; ADAPTATIONS; TRANSPORT; HABITAT	In a symbiotic association between an invertebrate host and chemoautotrophic bacteria, each partner has different metabolic requirements, and the host typically supplies the bacteria with necessary reduced chemicals ( sulphide or methane). Some combination of anatomical, physiological and behavioural adaptations in the host often facilitates uptake and transport of reduced chemicals to the symbionts(1-4). We have studied five species of bivalve molluscs of the family Thyasiridae ( that is, thyasirids) three of which harbour chemoautotrophic bacteria. Here we show that the symbiotic bivalves extend their feet to form elongated and ramifying burrows in the sediment, most probably to gain access to reduced sulphur. Closely related bivalves ( including some thyasirid species) without bacterial symbionts show no comparable foot extension behaviour. The length and number of burrows formed by chemosymbiotic thyasirids are related to the concentration of hydrogen sulphide in the sediment. The burrows are formed by the foot of each bivalve, which can extend up to 30 times the length of the shell, and may be the most extreme case of animal structure elongation documented to date.	Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Dufour, SC (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.							ALLEN JA, 1958, PHILOS T R SOC B, V241, P421, DOI 10.1098/rstb.1958.0010; ALLEN JA, 1953, NATURE, V171, P1117, DOI 10.1038/1711117b0; ARP AJ, 1984, PHYSIOL ZOOL, V57, P648, DOI 10.1086/physzool.57.6.30155991; CHILDRESS JJ, 1993, J EXP BIOL, V179, P131; CHILDRESS JJ, 1986, SCI AM, V256, P114; DANDO PR, 1986, J MAR BIOL ASSOC UK, V66, P915, DOI 10.1017/S0025315400048529; DANDO PR, 1986, PROC R SOC SER B-BIO, V227, P227, DOI 10.1098/rspb.1986.0021; GIERE O, 1991, MAR ECOL PROG SER, V68, P287; GILBOAGARBER N, 1971, ANAL BIOCHEM, V43, P129, DOI 10.1016/0003-2697(71)90116-3; Julian D, 1999, J EXP BIOL, V202, P2245; LEPENNEC M, 1995, COMP BIOCHEM PHYS A, V111, P183, DOI 10.1016/0300-9629(94)00211-B; McALESTER A. LEE, 1966, MALACOLOGIA, V3, P433; PAYNE CM, 1991, PHILOS T ROY SOC B, V334, P481, DOI 10.1098/rstb.1991.0128; REID RGB, 1986, VELIGER, V29, P3; Seilacher A., 1990, Historical Biology, V3, P289; SOUTHWARD EC, 1986, J MAR BIOL ASSOC UK, V66, P889, DOI 10.1017/S0025315400048517; Stanley S.M., 1970, GEOLOGICAL SOC AM, V125, P1, DOI 10.1130/MEM125-p1; TRUEMAN ER, 1986, J MOLLUS STUD, V52, P265, DOI 10.1093/mollus/52.3.265; Zuschin Martin, 2001, Historical Biology, V15, P123	19	59	64	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					65	67		10.1038/nature02095	http://dx.doi.org/10.1038/nature02095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603317				2022-12-28	WOS:000186370800041
J	Karl, DM; Laws, EA; Morris, P; Williams, PJL; Emerson, S				Karl, DM; Laws, EA; Morris, P; Williams, PJL; Emerson, S			Global carbon cycle - Metabolic balance of the open sea	NATURE			English	Editorial Material							PRODUCTIVITY; RESPIRATION; FLUX		Univ Hawaii, Dept Oceanog, Honolulu, HI 96822 USA; Univ Coll N Wales, Sch Ocean Sci, Menai Bridge LL59 5PP, Gwynedd, Wales; Univ Washington, Sch Oceanog, Seattle, WA 98195 USA	University of Hawaii System; Bangor University; University of Washington; University of Washington Seattle	Karl, DM (corresponding author), Univ Hawaii, Dept Oceanog, Honolulu, HI 96822 USA.	dkarl@hawaii.edu	Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				delGiorgio PA, 1997, NATURE, V385, P148, DOI 10.1038/385148a0; Duarte CM, 1998, SCIENCE, V281, P234, DOI 10.1126/science.281.5374.234; Duarte CM, 1999, SCIENCE, V284, P1735, DOI DOI 10.1126/SCIENCE.284.5421.1735B; Emerson S, 1997, NATURE, V389, P951, DOI 10.1038/40111; EMERSON S, 1995, J GEOPHYS RES-OCEANS, V100, P15873, DOI 10.1029/95JC01333; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Gregg MC, 2003, NATURE, V422, P513, DOI 10.1038/nature01507; McGillicuddy DJ, 1998, NATURE, V394, P263, DOI 10.1038/28367; Najjar RG, 2000, GLOBAL BIOGEOCHEM CY, V14, P573, DOI 10.1029/1999GB900086; Uz BM, 2001, NATURE, V409, P597, DOI 10.1038/35054527; Williams P. J. le B, 2002, PHYTOPLANKTON PRODUC, P222, DOI [10.1002/9780470995204.ch9, DOI 10.1002/9780470995204.CH9]; Young RW, 1991, GLOBAL BIOGEOCHEM CY, V5, P119, DOI 10.1029/91GB00927	12	143	146	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					32	32		10.1038/426032a	http://dx.doi.org/10.1038/426032a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603308	Bronze			2022-12-28	WOS:000186370800032
J	Liu, TB; Diemann, E; Li, HL; Dress, AWM; Muller, A				Liu, TB; Diemann, E; Li, HL; Dress, AWM; Muller, A			Self-assembly in aqueous solution of wheel-shaped Mo-154 oxide clusters into vesicles	NATURE			English	Article							COLLOIDAL ORGANIZATION; KEPLERATE; SYMMETRY; IONS	Surfactants and membrane lipids readily assemble into complex structures(1) such as micelles, liposomes or hollow vesicles owing to their amphiphilic character - the fact that part of their structure is attracted to polar environments while another part is attracted to non-polar environments. The self-assembly of complex structures also occurs in polyoxometallate chemistry, as exemplified by the molybdenum blue solutions known for centuries. But while the presence of nanometre-sized metal oxide aggregates in these solutions has long been recognized, unravelling the composition and formation process of these aggregates proved difficult. Recent work has indicated that discrete, wheel-shaped mixed-valence polyoxomolybdate clusters of the type {Mo-154} (refs 2 - 4) assemble into well-defined nanometre-sized aggregates, including spherical structures(5). Here we report light-scattering data and transmission electron microscopy images of hollow spherical structures with an average, almost monodisperse radius of about 45 nm and composed of approximately 1,165 {Mo-154} wheel-shaped clusters. The clusters appear to lie flat and homogeneously distributed on the vesicle surface. Unlike conventional lipid vesicles, the structures we observe are not stabilized by hydrophobic interactions. Instead, we believe the polyoxomolybdate- based vesicles form owing to a subtle interplay between short-range van der Waals attraction and long-range electrostatic repulsion, with important further stabilization arising from hydrogen bonding involving water molecules encapsulated between the wheel-shaped clusters and in the vesicles' interior.	Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Bielefeld, Fac Chem, D-33501 Bielefeld, Germany; Univ Bielefeld, Fac Math, D-33501 Bielefeld, Germany	United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Bielefeld; University of Bielefeld	Liu, TB (corresponding author), Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA.	liu@bnl.gov; a.mueller@uni-bielefeld.de	Liu, Tianbo/D-8915-2017	Liu, Tianbo/0000-0002-8181-1790; Li, Huilin/0000-0001-8085-8928; Muller, Achim/0000-0003-0117-4021				Berzelius J., 1826, POGG ANN, V6, P369; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Cronin L., 2003, INORGANIC EXPT, P340; Evans D.F, 1999, COLLOIDAL DOMAIN PHY, V2nd; HIEMENZ PC, 1997, PRINCIPLES COLLOID S, pCH5; Kurth DG, 2000, CHEM MATER, V12, P2829, DOI 10.1021/cm001032o; Liu TB, 2003, J AM CHEM SOC, V125, P312, DOI 10.1021/ja028933d; Liu TB, 2002, J AM CHEM SOC, V124, P10942, DOI 10.1021/ja027045f; Muller A, 2003, CHEM COMMUN, P2000, DOI 10.1039/b305447k; Muller A, 2003, SCIENCE, V300, P749, DOI 10.1126/science.1084991; Muller A, 1999, NATURE, V397, P48, DOI 10.1038/16215; Muller A, 2001, CHEM COMMUN, P1928, DOI 10.1039/b103639b; Muller A, 2001, CHEM COMMUN, P657, DOI 10.1039/b009518b; Muller A, 2000, ACCOUNTS CHEM RES, V33, P2, DOI 10.1021/ar9601510; Muller A, 1999, Z ANORG ALLG CHEM, V625, P1187, DOI 10.1002/(SICI)1521-3749(199907)625:7<1187::AID-ZAAC1187>3.0.CO;2-#; Muller A, 1999, CHEM COMMUN, P1347, DOI 10.1039/a901436e; Polarz S, 2001, CHEMPHYSCHEM, V2, P457, DOI 10.1002/1439-7641(20010716)2:7<457::AID-CPHC457>3.0.CO;2-#; Polarz S, 2000, ADV MATER, V12, P1503, DOI 10.1002/1521-4095(200010)12:20<1503::AID-ADMA1503>3.0.CO;2-X; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; ROSLER HJ, 1991, LEHRBUCH MINERALOGIE, P418; SCHEELE CW, 1971, SAMTLICHE PHYSISCHE, V1, P185; Zhou SQ, 2001, SCIENCE, V291, P1944, DOI 10.1126/science.291.5510.1944	22	425	433	5	223	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					59	62		10.1038/nature02036	http://dx.doi.org/10.1038/nature02036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603315				2022-12-28	WOS:000186370800039
J	Messerli, FH				Messerli, FH			ALLHAT, or the soft science of the secondary end point	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DIURETIC THERAPY; METAANALYSIS; HYPERTENSION; OUTCOMES; RISK	The recent Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that the primary end point, coronary heart disease, was identical in the chlorthalidone, lisinopril, and amlodipine groups. Yet the major conclusion of this trial was that thiazide diuretics are superior in preventing 1 or more major forms of cardiovascular disease and should be preferred for first-line antihypertensive therapy. This conclusion was based solely on an analysis of secondary end points and cost As evidenced by the dictum to "use thiazides for most patients with uncomplicated hypertension" in the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, this interpretation of, ALLHAT broadly adumbrated these guidelines. Although diuretics will rightfully remain a cornerstone in anti hypertensive therapy, we should remember (as we were told by the ALLHAT investigators) that secondary end points are "soft data" that should not form a basis for main conclusions or lead to a labeling of a drug class as preferred.	Ochsner Clin Fdn, New Orleans, LA 70121 USA	Ochsner Health System	Messerli, FH (corresponding author), Ochsner Clin Fdn, 1514 Jefferson Highway, New Orleans, LA 70121 USA.	fmesserli@aol.com	Messerli, Franz/AAR-4783-2021					ALTMAN LK, 2000, NY TIMES        0829, pA17; [Anonymous], 1990, Circulation, V82, P1616; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COLUCCI WS, 1986, NEW ENGL J MED, V314, P290, DOI 10.1056/NEJM198601303140506; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lindholm LH, 2003, J HYPERTENS, V21, P1563, DOI 10.1097/00004872-200308000-00022; McAlister FA, 2003, ANN INTERN MED, V138, P938, DOI 10.7326/0003-4819-138-11-200306030-00016; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; Messerli FH, 2003, JAMA-J AM MED ASSOC, V289, P2067, DOI 10.1001/jama.289.16.2067; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Messerli FH, 1999, EUR HEART J, V20, P1441, DOI 10.1053/euhj.1999.1534; MESSERLI FH, 2003, JAMA-J AM MED ASSOC, V289, P2069; MESSERLI FH, IN PRESS AM J HYPERT; Pahor M, 2000, LANCET, V356, P1949, DOI 10.1016/S0140-6736(00)03306-7; Schrier RW, 2000, HYPERTENSION, V35, P1031, DOI 10.1161/01.HYP.35.5.1031; Tenenbaum A, 2001, AM J MED, V110, P143, DOI 10.1016/S0002-9343(00)00674-4; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Younis N, 2003, LANCET, V361, P195, DOI 10.1016/S0140-6736(03)12267-2; Yusuf S, 2000, NEW ENGL J MED, V342, P145	21	34	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 4	2003	139	9					777	780		10.7326/0003-4819-139-9-200311040-00012	http://dx.doi.org/10.7326/0003-4819-139-9-200311040-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738XJ	14597462				2022-12-28	WOS:000186312900007
J	Liu, HB; Gao, JM; Lynch, SR; Saito, YD; Maynard, L; Kool, ET				Liu, HB; Gao, JM; Lynch, SR; Saito, YD; Maynard, L; Kool, ET			A four-base paired genetic helix with expanded size	SCIENCE			English	Article							NUCLEIC-ACIDS; BASE-PAIR; LIN-BENZOADENOSINE; HYDROPHOBIC BASE; DNA; OLIGONUCLEOTIDES; RECOGNITION; ISOGUANINE; ALPHABET; THYMINE	We describe a new molecular class of genetic-pairing system that has a native DNA backbone but has all four base pairs replaced by new, larger pairs. The base pairs include size-expanded analogs of thymine and of adenine, both extended by the width of a benzene ring (2.4 Angstrom). The expanded-diameter double helices are more thermodynamically stable than the Watson-Crick helix, likely because of enhanced base stacking. Structural data confirm a right-handed, double-stranded, and base-paired helical form. Because of the larger base size, all the pairs of this helical system are fluorescent, which suggests practical applications in detection of natural DNA and RNA. Our findings establish that there is no apparent structural or thermodynamic prohibition against genetic systems having sizes different from the natural one.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Kool, ET (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.			Gao, Jianmin/0000-0001-9341-1287; Kool, Eric/0000-0002-7310-2935	NIGMS NIH HHS [GM52956, GM63587] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063587, R01GM052956] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benner SA, 1998, PURE APPL CHEM, V70, P263, DOI 10.1351/pac199870020263; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Eschenmoser A, 1999, SCIENCE, V284, P2118, DOI 10.1126/science.284.5423.2118; Groebke K, 1998, HELV CHIM ACTA, V81, P375, DOI 10.1002/hlca.19980810302; HOFFER M, 1960, CHEM BER-RECL, V93, P2777, DOI 10.1002/cber.19600931204; Hoffmann MFH, 2000, HELV CHIM ACTA, V83, P2580, DOI 10.1002/1522-2675(20000906)83:9<2580::AID-HLCA2580>3.0.CO;2-6; KAUFFMAN RF, 1978, BIOCHEMISTRY-US, V17, P3686, DOI 10.1021/bi00611a002; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; LEONARD NJ, 1976, J AM CHEM SOC, V98, P3987, DOI 10.1021/ja00429a040; LESSOR RA, 1984, BIOCHEMISTRY-US, V23, P3868, DOI 10.1021/bi00312a012; Liu H., UNPUB; Matray TJ, 1998, J AM CHEM SOC, V120, P6191, DOI 10.1021/ja9803310; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; McMinn DL, 1999, J AM CHEM SOC, V121, P11585, DOI 10.1021/ja9925150; Michel J, 1996, NUCLEIC ACIDS RES, V24, P1127, DOI 10.1093/nar/24.6.1127; Mitsui T, 2003, J AM CHEM SOC, V125, P5298, DOI 10.1021/ja028806h; MURAKAMI A, 1985, BIOCHEMISTRY-US, V24, P4041, DOI 10.1021/bi00336a036; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; PRAKASH G, 1992, J AM CHEM SOC, V114, P3523, DOI 10.1021/ja00035a056; RAPPAPORT HP, 1988, NUCLEIC ACIDS RES, V16, P7253, DOI 10.1093/nar/16.15.7253; Seela F, 1998, NUCLEOS NUCLEOT, V17, P2045, DOI 10.1080/07328319808004745; SEELA F, 1997, BIOORG MED CHEM LETT, V17, P2173; Tanaka K, 2003, SCIENCE, V299, P1212, DOI 10.1126/science.1080587	23	206	216	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					868	871		10.1126/science.1088334	http://dx.doi.org/10.1126/science.1088334			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593180				2022-12-28	WOS:000186258000050
J	Monsonego, A; Weiner, HL				Monsonego, A; Weiner, HL			Immunotherapeutic approaches to Alzheimer's disease	SCIENCE			English	Review							CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA-PEPTIDE; REGULATORY T-CELLS; NITRIC-OXIDE; MOUSE MODEL; IN-VITRO; NEGATIVE SELECTION; PRECURSOR PROTEIN; CLONAL SELECTION; GAMMA-SECRETASE	Although neurodegenerative diseases such as Alzheimer's disease are not classically considered mediated by inflammation or the immune system, in some instances the immune system may play an important role in the degenerative process. Furthermore, it has become clear that the immune system itself may have beneficial effects in nervous system diseases considered neurodegenerative. Immunotherapeutic approaches designed to induce a humoral immune response have recently been developed for the treatment of Alzheimer's disease. These studies have led to human trials that resulted in both beneficial and adverse effects. In animal models, it has also been shown that immunotherapy designed to induce a cellular immune response may be of benefit in central nervous system injury, although T cells may have either a beneficial or detrimental effect depending on the type of T cell response induced. These areas provide a new avenue for exploring immune system based therapy of neurodegenerative diseases and will be discussed here with a primary focus on Alzheimer's disease. We will also discuss how these approaches affect microglia activation, which plays a key role in therapy of such diseases.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Monsonego, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	amonsonego@rics.bwh.harvard.edu; hweiner@rics.bwh.harvard.edu						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bauer J, 1998, AM J PATHOL, V153, P715, DOI 10.1016/S0002-9440(10)65615-5; Becher B, 2000, GLIA, V29, P293; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; Cohen IR, 2001, J AUTOIMMUN, V16, P337, DOI 10.1006/jaut.2000.0481; Cooper NR, 2000, NEUROBIOL AGING, V21, P451, DOI 10.1016/S0197-4580(00)00148-2; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; ElKhoury J, 1996, NATURE, V382, P716; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Ford AL, 1996, J EXP MED, V184, P1737, DOI 10.1084/jem.184.5.1737; Frenkel D, 2000, P NATL ACAD SCI USA, V97, P11455, DOI 10.1073/pnas.97.21.11455; FRENKEL D, 2002, CLIN IMMUNOL S, V1, P411; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; Haas J, 2002, NEUROSCI LETT, V322, P121, DOI 10.1016/S0304-3940(02)00095-2; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Heneka MT, 2002, J NEUROSCI, V22, P2434, DOI 10.1523/JNEUROSCI.22-07-02434.2002; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Husemann J, 2001, J NEUROIMMUNOL, V114, P142, DOI 10.1016/S0165-5728(01)00239-9; Janeway CA, 1999, CURR BIOL, V9, pR342, DOI 10.1016/S0960-9822(99)80209-7; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawahata K, 2002, J IMMUNOL, V168, P4399, DOI 10.4049/jimmunol.168.9.4399; Kim HJ, 2002, CLIN IMMUNOL, V104, P105, DOI 10.1006/clim.2002.5258; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Kitani A, 2000, J IMMUNOL, V165, P691, DOI 10.4049/jimmunol.165.2.691; Lemere CA, 2000, ANN NY ACAD SCI, V920, P328; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Monsonego A, 2003, J IMMUNOL, V171, P2216, DOI 10.4049/jimmunol.171.5.2216; Monsonego A, 2003, J CLIN INVEST, V112, P415, DOI 10.1172/JCI200318104; Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298; MONSONEGO A, UNPUB; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Peterson DA, 1999, IMMUNITY, V11, P453, DOI 10.1016/S1074-7613(00)80120-X; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Phillips LM, 1999, J NEUROIMMUNOL, V96, P218, DOI 10.1016/S0165-5728(99)00034-X; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Seguin R, 2003, GLIA, V42, P36, DOI 10.1002/glia.10201; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Spooner ET, 2002, VACCINE, V21, P290, DOI 10.1016/S0264-410X(02)00464-4; Tarkowski E, 2001, ACTA NEUROL SCAND, V103, P166, DOI 10.1034/j.1600-0404.2001.103003166.x; van der Veen RC, 2001, INT IMMUNOPHARMACOL, V1, P1491, DOI 10.1016/S1567-5769(01)00093-5; van Exel E, 2002, STROKE, V33, P1135, DOI 10.1161/01.STR.0000014206.05597.9E; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N; WEKERLE H, 1993, INTERVIROLOGY, V35, P95, DOI 10.1159/000150299; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Williams K, 2001, GLIA, V36, P156, DOI 10.1002/glia.1105; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	73	181	221	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					834	838		10.1126/science.1088469	http://dx.doi.org/10.1126/science.1088469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593170				2022-12-28	WOS:000186258000040
J	Car, J; Sheikh, A				Car, J; Sheikh, A			10-minute consultation - Recurrent urinary tract infection in women	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London SW7 2AZ, England; Univ Edinburgh, Div Community Hlth Serv, GP Sect, Edinburgh EH10 5PF, Midlothian, Scotland	Imperial College London; University of Edinburgh	Car, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London SW7 2AZ, England.		Car, Josip/H-6755-2015	Car, Josip/0000-0001-8969-371X; Sheikh, Aziz/0000-0001-7022-3056					0	17	21	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1204	1204		10.1136/bmj.327.7425.1204	http://dx.doi.org/10.1136/bmj.327.7425.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630757	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000186784300020
J	McLeod, P; Reed, N; Dienes, Z				McLeod, P; Reed, N; Dienes, Z			Psychophysics - How fielders arrive in time to catch the ball	NATURE			English	Editorial Material									Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Univ Sussex, Dept Expt Psychol, Brighton BN1 9QG, E Sussex, England	University of Oxford; University of Sussex	McLeod, P (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.			Reed, Nick/0000-0002-7794-6123; Dienes, Zoltan/0000-0001-7454-3161				Land MF, 2000, NAT NEUROSCI, V3, P1340, DOI 10.1038/81887; LAND MF, 1974, J COMP PHYSIOL, V89, P331, DOI 10.1007/BF00695351; McLeod P, 2001, J EXP PSYCHOL HUMAN, V27, P1347, DOI 10.1037/0096-1523.27.6.1347; MCLEOD P, UNPUB J EXP PSYCHOL; TRESILIAN JR, 1995, Q J EXP PSYCHOL-A, V48, P688, DOI 10.1080/14640749508401411	5	40	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					244	245		10.1038/426244a	http://dx.doi.org/10.1038/426244a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628038				2022-12-28	WOS:000186660800030
J	Seymour, RS; White, CR; Gibernan, M				Seymour, RS; White, CR; Gibernan, M			Environmental biology: Heat reward for insect pollinators	NATURE			English	Editorial Material							PHILODENDRON; INFLORESCENCES; RESPIRATION		Univ Adelaide, Adelaide, SA 5005, Australia; Univ Toulouse 3, Lab Evolut & Divers Biol, F-31062 Toulouse, France	University of Adelaide; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Seymour, RS (corresponding author), Univ Adelaide, Adelaide, SA 5005, Australia.	roger.seymour@adelaide.edu.au	Gibernau, Marc/A-7388-2010; White, Craig R/F-9062-2010; Seymour, Roger/C-3469-2009	White, Craig R/0000-0002-0200-2187; Seymour, Roger/0000-0002-3395-0059				Barabe D, 2002, BOT J LINN SOC, V139, P79, DOI 10.1046/j.1095-8339.2002.00040.x; BARTHOLOMEW GA, 1977, SCIENCE, V195, P882, DOI 10.1126/science.841312; Bernhardt P, 2000, PLANT SYST EVOL, V222, P293, DOI 10.1007/BF00984108; Endress P. K., 1994, DIVERSITY EVOLUTIONA; Gibernau M, 2000, CAN J BOT, V78, P685, DOI 10.1139/cjb-78-5-685; GOTTSBERGER G, 1991, BIOTROPICA, V23, P23, DOI 10.2307/2388684; GOTTSBERGER G, 1988, TAXON, V37, P630, DOI 10.2307/1221105; Heinrich B., 1993, HOT BLOODED INSECTS; Schatz GE, 1990, REPROD ECOLOGY TROPI, P69; Seymour RS, 1999, J EXP BOT, V50, P845, DOI 10.1093/jexbot/50.335.845; Seymour RS, 1997, ENDEAVOUR, V21, P125, DOI 10.1016/S0160-9327(97)80222-0; Seymour RS, 1999, P ROY SOC B-BIOL SCI, V266, P1975, DOI 10.1098/rspb.1999.0875; Thien LB, 2000, INT J PLANT SCI, V161, pS225, DOI 10.1086/317575	13	156	164	4	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					243	244		10.1038/426243a	http://dx.doi.org/10.1038/426243a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628037				2022-12-28	WOS:000186660800029
J	Stankiewicz, BA				Stankiewicz, BA			Integration of geoscience and engineering in the oil industry - just a dream?	NATURE			English	Editorial Material								The past two decades of the twentieth century have been very 'rocky' for the oil industry, as shown by the overall negative perception of the oil companies by the general public. Fluctuating oil prices, many rounds of staff redundancies, environmental disasters and budget cuts supported the overall image of the oil industry as being 'the technology impaired and environmentally insensible giant'. But advances and positive changes have been quietly happening in most of the oil companies. In the twenty-first century, we will witness the metamorphosis of the oil and gas companies into energy businesses - the era of cleaner and safer oil and gas production, and alternative energy resources such as wind, solar and hydrogen is already underway.	Shell Int Explorat & Prod BV, NL-2280 AB Rijswijk, Netherlands	Royal Dutch Shell	Stankiewicz, BA (corresponding author), Shell Int Explorat & Prod BV, Volmerlaan 8, NL-2280 AB Rijswijk, Netherlands.	astankiewicz@wanadoo.nl						Hammami A, 2000, ENERG FUEL, V14, P14, DOI 10.1021/ef990104z; Hammami A, 1999, SPE J, V4, P9, DOI 10.2118/54021-PA; Jamaluddin AKM, 2002, J CAN PETROL TECHNOL, V41, P25; Karan K, 2003, PETROL SCI TECHNOL, V21, P629, DOI 10.1081/LFT-120018543; KOOL H, 2002, PETROMI, V28, P26; MACLEOD G, 2004, INTEGRATION ORGANIC; MEHTA A, 2000, ANN NY ACAD SCI, V912, P361; Ratulowski J, 2003, SPE RESERV EVAL ENG, V6, P168, DOI 10.2118/84777-PA; STANKIEWICZ BA, 2001, 20 INT M ORG GEOCH, V1, P121; Yergin D., 1991, PRIZE; [No title captured]	11	5	5	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					360	363		10.1038/nature02136	http://dx.doi.org/10.1038/nature02136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628066				2022-12-28	WOS:000186660800058
J	Guskiewicz, KM; McCrea, M; Marshall, SW; Cantu, RC; Randolph, C; Barr, W; Onate, JA; Kelly, JP				Guskiewicz, KM; McCrea, M; Marshall, SW; Cantu, RC; Randolph, C; Barr, W; Onate, JA; Kelly, JP			Cumulative effects associated with recurrent concussion in collegiate football players - The NCAA Concussion Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIMENTAL HEAD-INJURY; LONGITUDINAL DATA-ANALYSIS; POISSON REGRESSION-MODELS; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; CEREBRAL CONCUSSION; SAFE RETURN; PERFORMANCE; METABOLISM	Context Approximately 300000 sport-related concussions occur annually in the United States, and the likelihood of serious sequelae may increase with repeated head injury. Objective To estimate the incidence of concussion and time to recovery after concussion in collegiate football players. Design, Setting, and Participants Prospective cohort study of 2905 football players from 25 US colleges were tested at preseason baseline in 1999, 2000, and 2001 on a variety of measures and followed up prospectively to ascertain concussion occurrence. Players injured with a concussion were monitored until their concussion symptoms resolved and were followed up for repeat concussions until completion of their collegiate football career or until the end of the 2001 football season. Main Outcome Measures Incidence of concussion and repeat concusion; type and duration of symptoms and course of recovery among players who were injured with a concussion during the seasons. Results During follow-up of 4251 player-seasons, 184 players (6.3%) had a concussion, and 12 (6.5%) of these players had a repeat concussion within the same season. There was an association between reported number of previous concussions and likelihood of incident concussion. Players reporting a history of 3 or more previous concussions were 3.0 (95% confidence interval, 1.6-5.6) times more likely to have an incident concussion than players with no concussion history. Headache was the most commonly reported symptom at the time of injury (85.2%), and mean overall symptom duration was 82 hours. Slowed recovery was associated with a history of multiple previous concussions (30.0% of those with greater than or equal to3 previous concussions had symptoms lasting >1 week compared with 14.6% of those with 1 previous concussion). Of the 12 incident within-season repeat concussions, 11 (91.7%) occurred within 10 days of the first injury, and 9 (75.0%) occurred within 7 days of the first injury. Conclusions Our study suggests that players with a history of previous concussions are more likely to have future concussive injuries than those with no history; 1 in 15 players With a concussion may have additional concussions in the same playing season; and previous concussions may be associated with slower recovery of neurological function.	Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Emerson Hosp, Neurosurg Serv, Concord, MA USA; Northwestern Univ, Feinberg Sch Med, Chicago Neurol Inst, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; Loyola Univ, Sch Med, Dept Neurol, Maywood, IL 60153 USA; NYU, Sch Med, Dept Neurol, New York, NY USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Rehabil Sci, Athlet Training Program, Boston, MA 02215 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Medical College of Wisconsin; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Loyola University Chicago; New York University; Boston University	Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, CB 8700,211 Fetzer, Chapel Hill, NC 27599 USA.		Onate, James/E-3790-2011	Marshall, Stephen/0000-0002-2664-9233; Guskiewicz, Kevin/0000-0002-8682-2130; Barr, William/0000-0001-7711-7758				ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Barth J.T., 1989, MILD HEAD INJURY, P257; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bruce D A, 1982, Clin Sports Med, V1, P495; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu, 1991, Adolesc Med, V2, P141; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Dick R, 2002, 2001 2002 NCAA INJUR; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2001, J ATHL TRAINING, V36, P280; FROME EL, 1985, AM J EPIDEMIOL, V121, P309, DOI 10.1093/oxfordjournals.aje.a114001; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza C. C., 2000, NEUROLOGIC ATHLETIC, P80; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greenland S, 1998, MODERN EPIDEMIOLOGY; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JORDAN B, 1994, P MILD BRAIN INJ SPO, P43; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; MCCREA M, IN PRESS CLIN J SPOR; MCCULLOCH CE, 2001, GEN LINEAR MIXED MOD, P223; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; *NAT COLL ATHL ASS, 2002, 1981 1982 2001 2002; Nelson S, 1966, HEAD INJURY, P444; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; Ommaya A, 1994, P MILD BRAIN INJ SPO, P72; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; PRINCE DA, 1973, BRAIN RES, V50, P489, DOI 10.1016/0006-8993(73)90758-0; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	54	1118	1132	5	250	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2549	2555		10.1001/jama.290.19.2549	http://dx.doi.org/10.1001/jama.290.19.2549			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744DQ	14625331	Bronze			2022-12-28	WOS:000186613000024
J	Barkun, A; Bardou, M; Marshall, JK				Barkun, A; Bardou, M; Marshall, JK		Nonvariceal Upper GI Bleeding Con	Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Conference of the Canadian-Association-of-Gastroenterology	JUN 08-09, 2002	BANFF, CANADA	Canadian Assoc Gastroenter			PEPTIC-ULCER HEMORRHAGE; ENDOSCOPIC INJECTION THERAPY; NONBLEEDING VISIBLE VESSEL; HEATER PROBE THERMOCOAGULATION; HELICOBACTER-PYLORI INFECTION; PROTON PUMP INHIBITORS; HYPERTONIC SALINE-EPINEPHRINE; RISK SCORING SYSTEM; UPPER GI HEMORRHAGE; RANDOMIZED-TRIAL	Background: The management of patients with acute non-variceal upper gastrointestinal bleeding has evolved substantially over the past 10 years amid a paucity of published consensus guidelines. Purpose: To provide evidence-based management recommendations that address clinically relevant issues. Review and Consensus Processes: A multidisciplinary consensus group of 25 voting participants representing 11 national societies used a 7-step approach to develop recommendation statements according to accepted standards. Sources of data included. narrative and systematic reviews as well as published and new meta-analyses. The quality of the evidence, the strength of the recommendation, and the level of consensus were graded according to recognized classifications. Main Findings: Recommendations emphasize appropriate initial resuscitation of the patient and a multidisciplinary approach to clinical risk stratification that determines the need for early endoscopy. Early endoscopy allows safe and prompt discharge of selected patients classified as low risk. Endoscopic hemostasis is reserved for patients with high-risk endoscopic lesions. Although monotherapy with injection or thermal coagulation is effective, the combination is superior to either treatment alone. The placement of endoscopic clips for endoscopic hemostasis appears promising. High-dose intravenous proton-pump inhibition is recommended in patients who have undergone successful endoscopic therapy. Routine second-look endoscopy is not recommended. Patients with upper gastrointestinal bleeding should be tested for Helicobacter pylori infection and receive eradication therapy if infection is present. Future Directions: The efficacy of newer endoscopic therapeutic technologies, the optimal regimen of proton-pump inhibition, and the roles of other pharmacologic agents require further research.	McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada; Fac Med Dijon, Dijon, France; McMaster Univ, Hamilton, ON, Canada	McGill University; Universite de Bourgogne; McMaster University	Barkun, A (corresponding author), McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal Gen Hosp Site,1650 Cedar Ave,Room D7-148, Montreal, PQ H3G 1A4, Canada.							ACALOVSCHI I, 1990, INTENS CARE MED, V16, P180, DOI 10.1007/BF01724799; Ahmed S Z, 1975, J Assoc Physicians India, V23, P321; Almela P, 2000, Med Clin (Barc), V114 Suppl 2, P68; Almela P, 2001, AM J GASTROENTEROL, V96, P2341; Archimandritis A, 2000, J GASTROEN HEPATOL, V15, P369, DOI 10.1046/j.1440-1746.2000.02171.x; BAIR D, 2001, CAN J GASTROENTEROL, V15, pA21; BALANZO J, 1990, ENDOSCOPY, V22, P157, DOI 10.1055/s-2007-1012828; Bardou M, 2003, GASTROENTEROLOGY, V124, pA239, DOI 10.1016/S0016-5085(03)81201-5; Bardou M, 2003, GASTROENTEROLOGY, V124, pA625, DOI 10.1016/S0016-5085(03)83169-4; BARKUN A, 2002, GASTROENTEROLOGY, V122, pA67; BERG PL, 1994, ENDOSCOPY, V26, P528, DOI 10.1055/s-2007-1009028; Blatchford O, 1997, BMJ-BRIT MED J, V315, P510, DOI 10.1136/bmj.315.7107.510; Blatchford O, 2000, LANCET, V356, P1318, DOI 10.1016/S0140-6736(00)02816-6; Bleau BL, 2002, GASTROINTEST ENDOSC, V56, P1, DOI 10.1067/mge.2002.125365; BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BOUR B, 1993, GASTROEN CLIN BIOL, V17, P329; BRANICKI FJ, 1990, WORLD J SURG, V14, P262, DOI 10.1007/BF01664889; Brullet E, 1996, GASTROINTEST ENDOSC, V43, P111, DOI 10.1016/S0016-5107(06)80110-0; Brullet E, 1996, GUT, V39, P155, DOI 10.1136/gut.39.2.155; Buffoli F, 2001, AM J GASTROENTEROL, V96, P89; Cameron EA, 2002, EUR J GASTROEN HEPAT, V14, P497, DOI 10.1097/00042737-200205000-00006; Cardi M, 1997, ANN CHIR, V51, P136; CARTER R, 1994, BRIT J SURG, V81, P869, DOI 10.1002/bjs.1800810625; Cebollero-Santamaria F, 1999, AM J GASTROENTEROL, V94, P1242, DOI 10.1016/S0002-9270(99)00129-X; Chak A, 2001, GASTROINTEST ENDOSC, V53, P6, DOI 10.1067/mge.2001.108965; Chau CH, 2003, GASTROINTEST ENDOSC, V57, P455, DOI 10.1016/S0016-5107(03)80008-1; CHOUDARI CP, 1994, GUT, V35, P608, DOI 10.1136/gut.35.5.608; CHOUDARI CP, 1992, GUT, V33, P1159, DOI 10.1136/gut.33.9.1159; Chua R T, 1996, Zhonghua Yi Xue Za Zhi (Taipei), V57, P139; Chung IK, 1999, GASTROINTEST ENDOSC, V49, P13, DOI 10.1016/S0016-5107(99)70439-6; Chung IK, 2001, ENDOSCOPY, V33, P969, DOI 10.1055/s-2001-17951; CHUNG SCS, 1991, GASTROENTEROLOGY, V100, P33, DOI 10.1016/0016-5085(91)90579-A; CHUNG SCS, 1993, GASTROINTEST ENDOSC, V39, P611; Chung SCS, 1996, GASTROINTEST ENDOSC, V43, P591, DOI 10.1016/S0016-5107(96)70197-9; Chung SSC, 1997, BMJ-BRIT MED J, V314, P1307, DOI 10.1136/bmj.314.7090.1307; Cipolletta L, 1998, GASTROINTEST ENDOSC, V48, P191, DOI 10.1016/S0016-5107(98)70163-4; Cipolletta L, 2002, GASTROINTEST ENDOSC, V55, P1, DOI 10.1067/mge.2002.119219; Cipolletta L, 2001, GASTROINTEST ENDOSC, V53, P147, DOI 10.1067/mge.2001.111386; Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21; Colin R, 2000, GASTROEN CLIN BIOL, V24, P31; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Cooper GS, 1999, GASTROINTEST ENDOSC, V49, P145, DOI 10.1016/S0016-5107(99)70478-5; Cooper GS, 1998, GASTROINTEST ENDOSC, V48, P348, DOI 10.1016/S0016-5107(98)70002-1; Cooper GS, 1998, MED CARE, V36, P462, DOI 10.1097/00005650-199804000-00003; Cooper GS, 1996, GASTROENTEROLOGY, V111, P385, DOI 10.1053/gast.1996.v111.pm8690203; Coraggio F, 1998, EUR J GASTROEN HEPAT, V10, P673; Corley DA, 1998, AM J GASTROENTEROL, V93, P336, DOI 10.1111/j.1572-0241.1998.00336.x; CUELLAR RE, 1990, ARCH INTERN MED, V150, P1381, DOI 10.1001/archinte.150.7.1381; DALKEY N, 1969, FUTURES, V1, P408, DOI 10.1016/S0016-3287(69)80025-X; DANESHMEND TK, 1992, BRIT MED J, V304, P143, DOI 10.1136/bmj.304.6820.143; Dent J, 1999, GUT, V44, pS1, DOI 10.1136/gut.44.2008.S1; Dulai GS, 2002, GASTROINTEST ENDOSC, V55, P321, DOI 10.1067/mge.2002.121880; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; Eisen GA, 2002, GASTROINTEST ENDOSC, V55, P780, DOI 10.1016/S0016-5107(02)70403-3; Enns RA, 2003, ALIMENT PHARM THER, V17, P225, DOI 10.1046/j.1365-2036.2003.01412.x; Farrell RJ, 2000, LANCET, V356, P1289, DOI 10.1016/S0140-6736(00)02808-7; Field MJ, 1990, CLIN PRACTICE GUIDEL; Gevers AM, 2002, GASTROINTEST ENDOSC, V55, P466, DOI 10.1067/mge.2002.112613; Giacomini MK, 2000, INT J TECHNOL ASSESS, V16, P987, DOI 10.1017/S026646230010306X; Ginsberg GG, 2002, GASTROINTEST ENDOSC, V55, P807, DOI 10.1016/S0016-5107(02)70408-2; Gisbert JP, 2001, ALIMENT PHARM THER, V15, P917, DOI 10.1046/j.1365-2036.2001.01012.x; GOLDBLOOM R, 1986, CAN MED ASSOC J, V134, P721; Goldstein JA, 2001, BRIT J CLIN PHARMACO, V52, P349, DOI 10.1046/j.0306-5251.2001.01499.x; GOLETTI O, 1994, ITAL J GASTROENTEROL, V26, P72; GRAHAM DY, 1993, SCAND J GASTROENTERO, V28, P939, DOI 10.3109/00365529309098288; Gralnek IM, 1998, AM J GASTROENTEROL, V93, P2047; Grino P, 2001, SCAND J GASTROENTERO, V36, P1254, DOI 10.1080/003655201317097083; GROSSO C, 1995, SCAND J GASTROENTERO, V30, P872, DOI 10.3109/00365529509101593; Guglielmi A, 2002, ENDOSCOPY, V34, P778, DOI 10.1055/s-2002-34261; Hasselgren G, 1997, SCAND J GASTROENTERO, V32, P328, DOI 10.3109/00365529709007680; Hay JA, 1997, JAMA-J AM MED ASSOC, V278, P2151, DOI 10.1001/jama.278.24.2151; Hayward R S, 1993, Ann Intern Med, V118, P731; Heldwein W, 1996, ENDOSCOPY, V28, P756, DOI 10.1055/s-2007-1005600; Houghton J, 2002, GASTROINTEST ENDOSC, V55, P11, DOI 10.1067/mge.2002.120391; HSU PI, 1994, GUT, V35, P746, DOI 10.1136/gut.35.6.746; HUI WM, 1991, GASTROINTEST ENDOSC, V37, P299, DOI 10.1016/S0016-5107(91)70719-0; Hussain H, 2000, GASTROENTEROL CLIN N, V29, P445, DOI 10.1016/S0889-8553(05)70122-9; Imperiale TF, 1997, ANN INTERN MED, V127, P1062, DOI 10.7326/0003-4819-127-12-199712150-00002; JARAMILLO JL, 1994, AM J GASTROENTEROL, V89, P2135; JARAMILLO JL, 1993, GUT, V34, P1502, DOI 10.1136/gut.34.11.1502; JASPERSEN D, 1995, GASTROINTEST ENDOSC, V41, P5, DOI 10.1016/S0016-5107(95)70267-9; Javid G, 2001, AM J MED, V111, P280, DOI 10.1016/S0002-9343(01)00812-9; Jensen DM, 2002, GASTROENTEROLOGY, V123, P407, DOI 10.1053/gast.2002.34782; Jiranek GC, 1996, SURG CLIN N AM, V76, P83, DOI 10.1016/S0039-6109(05)70424-2; Jung HK, 2002, AM J GASTROENTEROL, V97, P1736; KATSCHINSKI B, 1994, DIGEST DIS SCI, V39, P706, DOI 10.1007/BF02087411; Kaviani MJ, 2003, ALIMENT PHARM THER, V17, P211, DOI 10.1046/j.1365-2036.2003.01416.x; Khuroo M S, 1974, J Indian Med Assoc, V63, P185; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; Kollef MH, 1997, CRIT CARE MED, V25, P1125, DOI 10.1097/00003246-199707000-00011; KOYAMA T, 1995, GASTROINTEST ENDOSC, V42, P128, DOI 10.1016/S0016-5107(95)70068-4; Kubba AK, 1996, GASTROENTEROLOGY, V111, P623, DOI 10.1053/gast.1996.v111.pm8780566; Kubba AK, 1997, BRIT J SURG, V84, P265; Lai KC, 1997, GASTROINTEST ENDOSC, V45, P26, DOI 10.1016/S0016-5107(97)70299-2; Lai KC, 2000, AM J GASTROENTEROL, V95, P2225; LAI KH, 1994, ENDOSCOPY, V26, P338, DOI 10.1055/s-2007-1008987; LAINE L, 1990, GASTROENTEROLOGY, V99, P1303, DOI 10.1016/0016-5085(90)91154-X; LAINE L, 1992, GASTROENTEROLOGY, V102, P314, DOI 10.1016/0016-5085(92)91816-M; Laine L, 1996, GASTROINTEST ENDOSC, V43, P107, DOI 10.1016/S0016-5107(06)80109-4; Laine L, 2002, GASTROINTEST ENDOSC, V55, P6, DOI 10.1067/mge.2002.120390; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LANAS A, 1995, J CLIN GASTROENTEROL, V21, P103, DOI 10.1097/00004836-199509000-00008; Lau JYW, 2000, NEW ENGL J MED, V343, P310, DOI 10.1056/NEJM200008033430501; Lau JYW, 1999, NEW ENGL J MED, V340, P751, DOI 10.1056/NEJM199903113401002; Lau JYW, 1998, ENDOSCOPY, V30, P513, DOI 10.1055/s-2007-1001336; Lau JYW, 1997, GASTROINTEST ENDOSC, V46, P33, DOI 10.1016/S0016-5107(97)70206-2; Lee JG, 1999, GASTROINTEST ENDOSC, V50, P755, DOI 10.1016/S0016-5107(99)70154-9; Lee JM, 2000, AM J GASTROENTEROL, V95, P1166, DOI 10.1111/j.1572-0241.2000.02004.x; Lee KJ, 2000, ENDOSCOPY, V32, P505, DOI 10.1055/s-2000-3816; LENNARDJONES JE, 1992, J ROY COLL PHYS LOND, V26, P281; Levine JE, 2002, ALIMENT PHARM THERAP, V16, P1137, DOI 10.1046/j.1365-2036.2002.01274.x; Li YY, 2000, J GASTROEN HEPATOL, V15, P148, DOI 10.1046/j.1440-1746.2000.02055.x; Lin HJ, 1999, GUT, V44, P715, DOI 10.1136/gut.44.5.715; Lin HJ, 1998, ARCH INTERN MED, V158, P54, DOI 10.1001/archinte.158.1.54; Lin HJ, 1996, GASTROINTEST ENDOSC, V43, P470; LIN HJ, 1990, GUT, V31, P753, DOI 10.1136/gut.31.7.753; LIN HJ, 1993, GUT, V34, P1182, DOI 10.1136/gut.34.9.1182; LIN HJ, 1994, GUT, V35, P1389, DOI 10.1136/gut.35.10.1389; LIN HJ, 1993, GASTROINTEST ENDOSC, V39, P15, DOI 10.1016/S0016-5107(93)70003-6; LIN HJ, 1995, J CLIN GASTROENTEROL, V21, P95, DOI 10.1097/00004836-199509000-00006; Lin HJ, 1995, HEPATO-GASTROENTEROL, V42, P856; LIN HJ, 1990, GASTROINTEST ENDOSC, V36, P241, DOI 10.1016/S0016-5107(90)71015-2; Lin HJ, 1996, J CLIN GASTROENTEROL, V22, P267, DOI 10.1097/00004836-199606000-00005; LIN HJ, 1995, J CLIN GASTROENTEROL, V21, P99, DOI 10.1097/00004836-199509000-00007; Llach J, 1996, GASTROINTEST ENDOSC, V43, P117, DOI 10.1016/S0016-5107(06)80111-2; LOIZOU LA, 1991, GUT, V32, P1100, DOI 10.1136/gut.32.10.1100; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; Longstreth GF, 1998, GASTROINTEST ENDOSC, V47, P219, DOI 10.1016/S0016-5107(98)70316-5; LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; LONGSTRETH GF, 1995, AM J GASTROENTEROL, V90, P206; MacSween HM, 1997, CAN J GASTROENTEROL, V11, P429, DOI 10.1155/1997/761054; Mahadeva S, 2002, POSTGRAD MED J, V78, P347, DOI 10.1136/pmj.78.920.347; Marshall JK, 1999, AM J GASTROENTEROL, V94, P1841; MATTHEWSON K, 1990, GASTROENTEROLOGY, V98, P1239, DOI 10.1016/0016-5085(90)90339-3; Menon K, 2001, AM J GASTROENTEROL, V96, P2646; Messmann H, 1998, ENDOSCOPY, V30, P583, DOI 10.1055/s-2007-1001360; MICHEL P, 1994, GASTROEN CLIN BIOL, V18, P1102; Mondardini A, 1998, ENDOSCOPY, V30, P508, DOI 10.1055/s-2007-1001335; MORETO M, 1992, GUT, V33, P456, DOI 10.1136/gut.33.4.456; MYSZOR MF, 1989, Q J MED, V70, P73; Okan A, 2000, HEPATO-GASTROENTEROL, V47, P1325; Okazaki K, 2002, GUT, V51, P1, DOI 10.1136/gut.51.1.1; OXNER RBG, 1992, LANCET, V339, P966, DOI 10.1016/0140-6736(92)91537-I; PANES J, 1991, GASTROINTEST ENDOSC, V37, P611, DOI 10.1016/S0016-5107(91)70865-1; PARK KGM, 1994, BRIT J SURG, V81, P1465, DOI 10.1002/bjs.1800811021; PERNG CL, 1994, AM J GASTROENTEROL, V89, P1811; Pescatore P, 2002, GASTROINTEST ENDOSC, V55, P348, DOI 10.1067/mge.2002.121875; PETERSON WL, 1990, GASTROINTEST ENDOSC, V36, pS14; Peura DA, 1997, AM J GASTROENTEROL, V92, P924; PULANIC R, 1995, ENDOSCOPY, V27, P291, DOI 10.1055/s-2007-1005695; Quirk DM, 1997, GASTROENTEROLOGY, V113, P1443, DOI 10.1053/gast.1997.v113.pm9352845; RAJGOPAL C, 1991, GUT, V32, P727, DOI 10.1136/gut.32.7.727; Riemann JF, 1997, GASTROINTEST ENDOSC, V46, P299, DOI 10.1016/S0016-5107(97)70114-7; Rockall TA, 1996, LANCET, V347, P1138, DOI 10.1016/S0140-6736(96)90607-8; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROKKAS T, 1995, GASTROINTEST ENDOSC, V41, P1, DOI 10.1016/S0016-5107(95)70266-0; RUTGEERTS P, 1993, GUT, V34, P348, DOI 10.1136/gut.34.3.348; Rutgeerts P, 1997, LANCET, V350, P692, DOI 10.1016/S0140-6736(97)03233-9; SACKS HS, 1990, JAMA-J AM MED ASSOC, V264, P494, DOI 10.1001/jama.264.4.494; SAEED ZA, 1993, AM J GASTROENTEROL, V88, P1842; Saeed ZA, 1996, ENDOSCOPY, V28, P288, DOI 10.1055/s-2007-1005455; Sanders DS, 2002, AM J GASTROENTEROL, V97, P630; SCHILLER KF, 1970, BRIT MED J, V2, P7, DOI 10.1136/bmj.2.5700.7; Selby NM, 2000, ALIMENT PHARM THERAP, V14, P1119; Sharma VK, 2001, ALIMENT PHARM THER, V15, P1939, DOI 10.1046/j.1365-2036.2001.01134.x; SILVERSTEIN FE, 1981, GASTROINTEST ENDOSC, V27, P80, DOI 10.1016/S0016-5107(81)73156-0; Sofia C, 2000, HEPATO-GASTROENTEROL, V47, P1332; Spiegel BMR, 2001, ARCH INTERN MED, V161, P1393, DOI 10.1001/archinte.161.11.1393; Sung JJY, 2003, ANN INTERN MED, V139, P237, DOI 10.7326/0003-4819-139-4-200308190-00005; Sung JJY, 1997, DIGEST DIS SCI, V42, P2524, DOI 10.1023/A:1018816729449; TEKANT Y, 1995, BRIT J SURG, V82, P223, DOI 10.1002/bjs.1800820231; Terdiman JP, 1997, AM J GASTROENTEROL, V92, P1805; TULASSAY Z, 1992, DIGESTION, V51, P211, DOI 10.1159/000200900; Udd M, 2001, SCAND J GASTROENTERO, V36, P1332; VILLANUEVA C, 1993, J CLIN GASTROENTEROL, V17, P195, DOI 10.1097/00004836-199310000-00005; VILLANUEVA C, 1994, GASTROINTEST ENDOSC, V40, P34, DOI 10.1016/S0016-5107(94)70006-0; VILLANUEVA C, 1993, DIGEST DIS SCI, V38, P2062, DOI 10.1007/BF01297086; VILLANUEVA C, 1995, ENDOSCOPY, V27, P308, DOI 10.1055/s-2007-1005698; Vreeburg EM, 1997, AM J GASTROENTEROL, V92, P236; Vreeburg EM, 1999, GUT, V44, P331, DOI 10.1136/gut.44.3.331; WALT RP, 1992, LANCET, V340, P1058, DOI 10.1016/0140-6736(92)93078-2; WARING JP, 1991, GASTROINTEST ENDOSC, V37, P295; YAVORSKI RT, 1995, AM J GASTROENTEROL, V90, P568; Zed PJ, 2001, ANN PHARMACOTHER, V35, P1528; ZIMMERMAN J, 1995, SCAND J GASTROENTERO, V30, P327, DOI 10.3109/00365529509093285; ZIMMERMAN J, 1995, J INTERN MED, V237, P331, DOI 10.1111/j.1365-2796.1995.tb01183.x; 1999, AM SURG, V65, P295; [No title captured]; 1989, NATL I HLTH CONSENS, V7, P1; 1981, CONN MED, V45, P445	192	384	427	1	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					843	857		10.7326/0003-4819-139-10-200311180-00012	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00012			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	744ZV	14623622				2022-12-28	WOS:000186663500008
J	Jaenicke-Despres, V; Buckler, ES; Smith, BD; Gilbert, MTP; Cooper, A; Doebley, J; Paabo, S				Jaenicke-Despres, V; Buckler, ES; Smith, BD; Gilbert, MTP; Cooper, A; Doebley, J; Paabo, S			Early allelic selection in maize as revealed by ancient DNA	SCIENCE			English	Article							BRANCH CHAIN-LENGTH; PROLAMIN BOX; DOMESTICATION; STARCH; EVOLUTION; DETERMINANT; DOMINANCE; DIVERSITY; GENES	Maize was domesticated from teosinte, a wild grass, by similar to6300 years ago in Mexico. After initial domestication, early farmers continued to select for advantageous morphological and biochemical traits in this important crop. However, the timing and sequence of character selection are, thus far, known only for morphological features discernible in corn cobs. We have analyzed three genes involved in the control of plant architecture, storage protein synthesis, and starch production from archaeological maize samples from Mexico and the southwestern United States. The results reveal that the alleles typical of contemporary maize were present in Mexican maize by 4400 years ago. However, as recently as 2000 years ago, allelic selection at one of the genes may not yet have been complete.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; ARS, USDA, Raleigh, NC 27695 USA; N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; Smithsonian Inst, Natl Museum Nat Hist, Dept Anthropol, Washington, DC 20560 USA; Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	Max Planck Society; United States Department of Agriculture (USDA); University of North Carolina; North Carolina State University; Smithsonian Institution; Smithsonian National Museum of Natural History; University of Oxford; University of Wisconsin System; University of Wisconsin Madison	Paabo, S (corresponding author), Max Planck Inst Evolutionary Anthropol, Deutsch Pl 6, D-04103 Leipzig, Germany.		Buckler, Edward/GPS-4932-2022; Buckler, Edward/L-7651-2019; Cooper, Alan/E-8171-2012; Gilbert, Marcus TP/A-8936-2013	Buckler, Edward/0000-0002-3100-371X; Cooper, Alan/0000-0002-7738-7851; Gilbert, Marcus TP/0000-0002-5805-7195				Benz BF, 2001, P NATL ACAD SCI USA, V98, P2104, DOI 10.1073/pnas.98.4.2104; Benz BF, 2000, CURR ANTHROPOL, V41, P459; Buckler ES, 2001, GENET RES, V77, P213, DOI 10.1017/S0016672301005158; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; DOEBLEY J, 1995, GENETICS, V141, P333; DOEBLEY J, 1992, TRENDS GENET, V8, P302, DOI 10.1016/0168-9525(92)90261-2; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; Handt O, 1996, AM J HUM GENET, V59, P368; Huckell BB, 1996, J WORLD PREHIST, V10, P305, DOI 10.1007/BF02286419; JAMES MG, 1995, PLANT CELL, V7, P417, DOI 10.1105/tpc.7.4.417; Jane J, 1999, CEREAL CHEM, V76, P629, DOI 10.1094/CCHEM.1999.76.5.629; JANE JL, 1992, CEREAL CHEM, V69, P60; Matsuoka Y, 2002, P NATL ACAD SCI USA, V99, P6080, DOI 10.1073/pnas.052125199; Piperno DR, 2001, P NATL ACAD SCI USA, V98, P2101, DOI 10.1073/pnas.98.4.2101; Rahman A, 1998, PLANT PHYSIOL, V117, P425, DOI 10.1104/pp.117.2.425; Smith B. D., 1998, EMERGENCE AGR; Smith BD, 1997, LAT AM ANTIQ, V8, P342, DOI 10.2307/972107; SMITH BD, 1989, SCIENCE, V246, P1566, DOI 10.1126/science.246.4937.1566; UEDA T, 1994, MOL CELL BIOL, V14, P4350, DOI 10.1128/MCB.14.7.4350; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; Vigouroux Y, 2002, P NATL ACAD SCI USA, V99, P9650, DOI 10.1073/pnas.112324299; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; Wang ZD, 1998, GENE, V223, P321, DOI 10.1016/S0378-1119(98)00244-3; Whitt SR, 2002, P NATL ACAD SCI USA, V99, P12959, DOI 10.1073/pnas.202476999	24	182	192	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1206	1208		10.1126/science.1089056	http://dx.doi.org/10.1126/science.1089056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615538				2022-12-28	WOS:000186544300053
J	Libina, N; Berman, JR; Kenyon, C				Libina, N; Berman, JR; Kenyon, C			Tissue-specific activities of C-elegans DAF-16 in the regulation of lifespan	CELL			English	Article							CAENORHABDITIS-ELEGANS; INSULIN-RECEPTOR; STRESS RESISTANCE; INTERACTING GENES; OXIDATIVE STRESS; DAUER FORMATION; FAMILY-MEMBER; LONGEVITY; NEMATODE; IDENTIFICATION	In C. elegans, the transcription factor DAF-16 promotes longevity in response to reduced insulin/IGF-1 signaling or germline ablation. In this study, we have asked how different tissues interact to specify the life-span of the animal. We find that several tissues act as signaling centers. In particular, DAF-16 activity in the intestine, which is also the animal's adipose tissue, completely restores the longevity of daf-16(-) germline-deficient animals, and increases the lifespans of daf-16(-) insulin/IGF-1-pathway mutants substantially. Our findings indicate that DAF-16 may control two types of downstream signals: DAF-16 activity in signaling cells upregulates DAF-16 in specific responding tissues, possibly via regulation of insulin-like peptides, and also evokes DAF-16-independent responses. We suggest that this network of tissue interactions and feedback regulation allows the tissues to equilibrate and fine-tune their expression of downstream genes, which, in turn, coordinates their rates of aging within the animal.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Miss Bay Genentech Hall,600 16th St,Room S312D, San Francisco, CA 94143 USA.	ckenyon@biochem.ucsf.edu		Kenyon, Cynthia/0000-0003-3446-2636	NIA NIH HHS [AG11816] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011816, R37AG011816] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; APFELD J, 1999, THESIS U CALIFORNIA; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; den Boer BGW, 1998, DEVELOPMENT, V125, P3213; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 1998, GENETICS, V150, P129; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; GOTTLIEB S, 1994, GENETICS, V137, P107; HEDGECOCK EM, 1995, GENETICS, V141, P989; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; HERMAN RK, 1984, GENETICS, V108, P165; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kawano T, 2000, BIOCHEM BIOPH RES CO, V273, P431, DOI 10.1006/bbrc.2000.2971; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LABOUESSE M, 1994, DEVELOPMENT, V120, P2359; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; LAWLESS JF, 1982, MODELS METHODS LIFET; Lee RYN, 2001, CURR BIOL, V11, P1950, DOI 10.1016/S0960-9822(01)00595-4; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Lundquist EA, 1998, NEURON, V21, P385, DOI 10.1016/S0896-6273(00)80547-4; MADURO M, 1995, GENETICS, V141, P977; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Mello C, 1995, METHOD CELL BIOL, V48, P451; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 2001, CURR BIOL, V11, P1517, DOI 10.1016/S0960-9822(01)00453-5; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ookuma S, 2003, CURR BIOL, V13, P427, DOI 10.1016/S0960-9822(03)00108-8; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; RIDDLE DL, 1997, ELEGANS, V2, P739; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VOWELS JJ, 1992, GENETICS, V130, P105; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210	58	564	592	4	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2003	115	4					489	502		10.1016/S0092-8674(03)00889-4	http://dx.doi.org/10.1016/S0092-8674(03)00889-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622602	Bronze			2022-12-28	WOS:000186627100014
J	Berger, E; Kulkarni, SR; Pooley, G; Frail, DA; McIntyre, V; Wark, RM; Sari, R; Soderberg, AM; Fox, DW; Yost, S; Price, PA				Berger, E; Kulkarni, SR; Pooley, G; Frail, DA; McIntyre, V; Wark, RM; Sari, R; Soderberg, AM; Fox, DW; Yost, S; Price, PA			A common origin for cosmic explosions inferred from calorimetry of GRB030329	NATURE			English	Article							GAMMA-RAY BURST; 29 MARCH 2003; ENERGY RESERVOIR; AFTERGLOWS; SUPERNOVA; JETS; EMISSION	Past studies(1-3) have suggested that long-duration gamma-ray bursts have a 'standard' energy of E(gamma)approximate to10(51) erg in the ultra-relativistic ejecta, after correcting for asymmetries in the explosion ('jets'). But a group of sub-energetic bursts, including the peculiar GRB980425 associated(4) with the supernova SN1998bw (E(gamma)approximate to10(48) erg), has recently been identified(2,3). Here we report radio observations of GRB030329 that allow us to undertake calorimetry of the explosion. Our data require a two-component explosion: a narrow (5degrees opening angle) ultra-relativistic component responsible for the gamma-rays and early afterglow, and a wide, mildly relativistic component that produces the radio and optical afterglow more than 1.5 days after the explosion. The total energy release, which is dominated by the wide component, is similar(1-3,5) to that of other gamma-ray bursts, but the contribution of the gamma-rays is energetically minor. Given the firm link(6,7) of GRB030329 with SN2003dh, our result indicates a common origin for cosmic explosions in which, for reasons not yet understood, the energy in the highest-velocity ejecta is extremely variable.	CALTECH, Caltech Opt Observ 105 24, Pasadena, CA 91125 USA; CALTECH, Space Radiat Lab 220 47, Pasadena, CA 91125 USA; Univ Cambridge, Cavendish Lab, Mullard Radio Astron Observ, Cambridge CB3 0HE, England; Natl Radio Astron Observ, Socorro, NM 87801 USA; CSIRO, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; CSRIO, Australia Telescope Natl Facil, Narrabri, NSW 2390, Australia; Australian Natl Univ, RSAA, Mt Stromlo Observ, Weston, ACT 2611, Australia	California Institute of Technology; California Institute of Technology; University of Cambridge; National Radio Astronomy Observatory (NRAO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Australian National University	Berger, E (corresponding author), CALTECH, Caltech Opt Observ 105 24, Pasadena, CA 91125 USA.			Fox, Derek/0000-0002-3714-672X				Berger E, 2003, ASTROPHYS J, V590, P379, DOI 10.1086/374892; Berger E, 2000, ASTROPHYS J, V545, P56, DOI 10.1086/317814; Bloom JS, 2003, ASTROPHYS J, V594, P674, DOI 10.1086/377125; Chevalier RA, 2000, ASTROPHYS J, V536, P195, DOI 10.1086/308914; Frail DA, 2003, ASTRON J, V125, P2299, DOI 10.1086/374364; Frail DA, 2001, ASTROPHYS J, V562, pL55, DOI 10.1086/338119; Freedman DL, 2001, ASTROPHYS J, V547, P922, DOI 10.1086/318386; Galama TJ, 2003, ASTROPHYS J, V585, P899, DOI 10.1086/346083; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; GRANOT J, 2003, VARIABLE LIGHT CURVE; HENDEN A, 2003, 2123 GRB; Hjorth J, 2003, NATURE, V423, P847, DOI 10.1038/nature01750; IBRAHIMOV MA, 2003, 2191 GRB; Kumar P, 2000, ASTROPHYS J, V538, pL125, DOI 10.1086/312821; Li ZY, 1999, ASTROPHYS J, V526, P716, DOI 10.1086/308031; MacFadyen AI, 2001, ASTROPHYS J, V550, P410, DOI 10.1086/319698; Panaitescu A, 2002, ASTROPHYS J, V571, P779, DOI 10.1086/340094; Price PA, 2003, NATURE, V423, P844, DOI 10.1038/nature01734; Rossi E, 2002, MON NOT R ASTRON SOC, V332, P945, DOI 10.1046/j.1365-8711.2002.05363.x; Sari R, 1999, ASTROPHYS J, V519, pL17, DOI 10.1086/312109; Sari R, 2001, ASTROPHYS J, V548, P787, DOI 10.1086/319003; Sari R, 2000, ASTROPHYS J, V535, pL33, DOI 10.1086/312689; SHETH K, UNPUB ASTROPHYS J; Stanek KZ, 2003, ASTROPHYS J, V591, pL17, DOI 10.1086/376976; TESTA V, 2003, 2141 GRB; TIENGO A, 2003, XRAY AFTERGLOW GRB03	26	288	289	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					154	157		10.1038/nature01998	http://dx.doi.org/10.1038/nature01998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614498	Green Submitted			2022-12-28	WOS:000186517200035
J	Guthrie, RD				Guthrie, RD			Rapid body size decline in Alaskan Pleistocene horses before extinction	NATURE			English	Article							POLLEN RECORDS; BERINGIA; TRANSITION; EUROPE; STEPPE; END	About 70% of North American large mammal species were lost at the end of the Pleistocene epoch(1). The causes of this extinction the role of humans versus that of climate-have been the focus of much controversy(1-6). Horses have figured centrally in that debate, because equid species dominated North American late Pleistocene faunas in terms of abundance, geographical distribution, and species variety, yet none survived into the Holocene epoch. The timing of these equid regional extinctions and accompanying evolutionary changes are poorly known. In an attempt to document better the decline and demise of two Alaskan Pleistocene equids, I selected a large number of fossils from the latest Pleistocene for radiocarbon dating. Here I show that horses underwent a rapid decline in body size before extinction, and I propose that the size decline and subsequent regional extinction at 12,500 radiocarbon years before present are best attributed to a coincident climatic/vegetational shift. The present data do not support human overkill(1) and several other proposed extinction causes(2,3), and also show that large mammal species responded somewhat individualistically to climate changes(4-6) at the end of the Pleistocene.	Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA	University of Alaska System; University of Alaska Fairbanks	Guthrie, RD (corresponding author), Univ Alaska, Inst Arctic Biol, Fairbanks, AK 99775 USA.							Alroy J, 2001, SCIENCE, V292, P1893, DOI 10.1126/science.1059342; AMTHEUS P, 2003, 3 INT MAMM C 3 5 YUK; ANDERSON PM, 1988, QUATERNARY RES, V29, P263, DOI 10.1016/0033-5894(88)90035-X; BROWN TA, 1988, RADIOCARBON, V30, P171, DOI 10.1017/S0033822200044118; EISENMANN V, 1982, Bulletin du Museum National d'Histoire Naturelle Section C Sciences de la Terre Paleontologie Geologie Mineralogie, V4, P75; FORSTEN A, 1991, MAMMALIA, V55, P407, DOI 10.1515/mamm.1991.55.3.407; FORSTREN A, 1982, J MAMMAL, V67, P422; Goetcheus VG, 2001, QUATERNARY SCI REV, V20, P135, DOI 10.1016/S0277-3791(00)00127-X; Graham RW, 1984, QUATERNARY EXTINCTIO; Guthrie R.D., 1984, P259; Guthrie R.D., 1990, FROZEN FAUNA MAMMOTH; Guthrie R. Dale, 2001, BAR International Series, V944, P32; Guthrie RD, 2001, QUATERNARY SCI REV, V20, P549; GUTHRIE RD, 1965, EVOLUTION, V19, P214, DOI 10.1111/j.1558-5646.1965.tb01708.x; GUTHRIE RD, 1984, MAMMOTH HOT SPRINGS, V1, P42; GUTHRIE RD, 1964, CONTRIBUTIONS VERTEB, P482; Harington C.R., 2003, ANNOTATED BIBLIO QUA; Holmes CE, 2001, ARCTIC ANTHROPOL, V38, P154; Kachigan S.K., 1991, MULTIVARIATE STAT AN; Lamb H.F., 1988, VEGETATION HIST, P519, DOI DOI 10.1007/978-94-009-3081-0_14; LOWE JJ, 1994, J QUATERNARY SCI, V9, P185, DOI 10.1002/jqs.3390090215; LOZHKIN AV, 1993, QUATERNARY RES, V39, P314, DOI 10.1006/qres.1993.1038; MacPhee Ross D.E., 1997, P169; Martin P. S., 1984, QUATERNARY EXTINCTIO, P345; MCDONALD J, 1984, QUATERNARY EXTINCTIO, P409; Sher AV, 1997, NATO ASI SER SER I, V47, P319; Stuart AJ, 2002, QUATERNARY SCI REV, V21, P1559, DOI 10.1016/S0277-3791(02)00026-4; Vila C, 2001, SCIENCE, V291, P474, DOI 10.1126/science.291.5503.474; Wilson MC, 1996, QUATERN INT, V32, P97, DOI 10.1016/S1040-6182(96)90017-8; ZIMOV SA, 1995, AM NAT, V146, P765, DOI 10.1086/285824	31	157	170	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					169	171		10.1038/nature02098	http://dx.doi.org/10.1038/nature02098			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614503				2022-12-28	WOS:000186517200040
J	Simons, SHP; van Dijk, M; van Lingen, R; Roofthooft, D; Duivenvoorden, HJ; Jongeneel, N; Bunkers, C; Smink, E; Anand, KJS; van den Anker, JN; Tibboel, D				Simons, SHP; van Dijk, M; van Lingen, R; Roofthooft, D; Duivenvoorden, HJ; Jongeneel, N; Bunkers, C; Smink, E; Anand, KJS; van den Anker, JN; Tibboel, D			Routine morphine infusion in preterm newborns who received ventilatory support - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; BIOBEHAVIORAL PAIN RESPONSES; WEEKS POSTCONCEPTIONAL AGE; INTRAVENTRICULAR HEMORRHAGE; BETA-ENDORPHIN; PREMATURE-INFANTS; BRAIN ULTRASOUND; RECOMMENDED USE; CHILDREN; ANALGESIA	Context Newborns admitted to neonatal intensive care units (NICUs) undergo a variety of painful procedures and stressful events. Because the effect of continuous morphine infusion in preterm neonates has not been investigated systematically, there is confusion regarding whether morphine should be used routinely in this setting. Objective To evaluate the effects of continuous intravenous morphine infusion on pain responses, incidence of intraventricular hemorrhage (IVH), and poor neurologic outcome (severe IVH, periventricular leukomalacia, or death). Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial conducted between December 2000 and October 2002 in 2 level III NICUs in the Netherlands of 150 newborns who had received ventilatory support (inclusion criteria: postnatal age younger than 3 days and ventilation for less than 8 hours; exclusion criteria: severe asphyxia, severe IVH; major congenital malformations, and administration of neuromuscular blockers). Interventions Intravenous morphine (100 mug/kg and 10 mug/kg per hour) or placebo infusion was given for 7 days (or less because of clinical necessity in several cases). Main Outcome Measures The analgesic effect of morphine, as assessed using validated scales; the effect of morphine on the incidence of IVH; and poor neurologic outcome. Results The analgesic effect did not differ between the morphine and placebo groups, judging from the following median (interquartile range) pain scores: Premature Infant Pain Profile, 10.1,(8.2-11.6) vs 10.0 (8.2-12.0) (P=.94); Neonatal Infant Pain Scale, 4.8 (3.7-6.0) vs 4.8 (3.2-6.0) (P=.58); and visual analog scale, 2.8 (2.0-3.9) vs 2.6 (1.8-4.3) (P=.14), respectively. Routine morphine infusion decreased the incidence of IVH (23% vs 40%, P=.04) but did not influence poor neurologic outcome (10% vs 16%, P=.66). In addition, analyses were adjusted for the use of additional open-label morphine (27% of morphine group vs 40% of placebo group, P=.10). Conclusions Lack of a measurable analgesic effect and absence of a beneficial effect on poor neurologic outcome do not support the routine-use of morphine infusions as a standard of care in preterm newborns who have received ventilatory support. Follow-up is needed to evaluate the long-term effects of morphine infusions on the neurobehavioral outcomes of prematurity.	Erasmus MC Sophia, Dept Pediat Surg, NL-3015 GJ Rotterdam, Netherlands; Erasmus MC Sophia, Dept Pediat, NL-3015 GJ Rotterdam, Netherlands; Erasmus MC Sophia, Div Neonatol, NL-3015 GJ Rotterdam, Netherlands; Erasmus MC, Dept Med Psychol, Rotterdam, Netherlands; Isala Clin, Dept Pediat, Div Neonatol, Zwolle, Netherlands; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; George Washington Univ, Dept Pediat, Div Pediat Clin Pharmacol, Washington, DC 20052 USA; George Washington Univ, Dept Pharmacol, Div Pediat Clin Pharmacol, Washington, DC 20052 USA	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Isala Clinics; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; George Washington University; George Washington University	Tibboel, D (corresponding author), Erasmus MC Sophia, Dept Pediat Surg Pediat, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.		van Dijk, Monique/B-6327-2009; simons, sinno/AAC-7442-2019; Anand, Kanwaljeet/B-3287-2014	van Dijk, Monique/0000-0002-9856-0318; Simons, Sinno/0000-0001-5219-5696; Anand, Kanwaljeet/0000-0001-6498-1483				Ambalavanan N, 1999, J PEDIATR-US, V135, P403, DOI 10.1016/S0022-3476(99)70156-3; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; ANAND KJS, 2000, PAIN NEONATES, V10, P180; ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; BACIGALUPO G, 1987, J PERINAT MED, V15, P45, DOI 10.1515/jpme.1987.15.1.45; Ballantyne M, 1999, CLIN J PAIN, V15, P297, DOI 10.1097/00002508-199912000-00006; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; Blauer T, 1998, CLIN J PAIN, V14, P39, DOI 10.1097/00002508-199803000-00006; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; DUBOWITZ LMS, 1984, J PEDIATR-US, V105, P452, DOI 10.1016/S0022-3476(84)80028-1; Evans J C, 1997, Neonatal Netw, V16, P33; Feingold E, 2002, J ADOLESCENT HEALTH, V31, P234, DOI 10.1016/S1054-139X(01)00407-4; FITZGERALD M, 1988, LANCET, V1, P292; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Franck LS, 1998, J PAIN SYMPTOM MANAG, V15, P41, DOI 10.1016/S0885-3924(97)00272-8; GhaziBirry HS, 1997, AM J NEURORADIOL, V18, P219; GREISEN G, 1985, ACTA PAEDIATR SCAND, V74, P525, DOI 10.1111/j.1651-2227.1985.tb11022.x; Grunau RE, 2000, CLIN J PAIN, V16, P37, DOI 10.1097/00002508-200003000-00007; Grunau RE, 2001, PEDIATRICS, V107, P105, DOI 10.1542/peds.107.1.105; HANDELMANN GE, 1985, PEPTIDES, V6, P29, DOI 10.1016/0196-9781(85)90131-7; HARTLEY R, 1993, ARCH DIS CHILD-FETAL, V69, P55, DOI 10.1136/adc.69.1_Spec_No.55; Johnston C C, 1999, J Obstet Gynecol Neonatal Nurs, V28, P587, DOI 10.1111/j.1552-6909.1999.tb02167.x; JOHNSTON CC, 1995, PAIN, V61, P471, DOI 10.1016/0304-3959(94)00213-X; Kahn DJ, 1998, ARCH PEDIAT ADOL MED, V152, P844; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; Kennedy KA, 1999, J PEDIATR-US, V134, P127, DOI 10.1016/S0022-3476(99)70399-9; KOREN G, 1985, VET HUM TOXICOL, V27, P519; Lawrence J, 1993, Neonatal Netw, V12, P59; Lemons JA, 2000, PEDIATRICS, V105, P454; LYNN AM, 1993, ANESTH ANALG, V77, P695; MacGregor R, 1998, ARCH DIS CHILD-FETAL, V79, pF40, DOI 10.1136/fn.79.1.F40; MCCULLOCH KM, 1995, EARLY HUM DEV, V41, P147, DOI 10.1016/0378-3782(95)01617-C; Oberlander TF, 2002, PEDIATRICS, V110, P570, DOI 10.1542/peds.110.3.570; Oh W, 1996, PEDIATRICS, V98, P141; PAPILE LA, 1983, J PEDIATR-US, V103, P273, DOI 10.1016/S0022-3476(83)80366-7; PERLMAN JM, 1983, NEW ENGL J MED, V309, P204, DOI 10.1056/NEJM198307283090402; Peters JWB, 2003, PEDIATRICS, V111, P129, DOI 10.1542/peds.111.1.129; POHJAVUORI M, 1986, BIOL RES PREG PERIN, V7, P1; POKELA ML, 1994, PEDIATRICS, V93, P379; POKELA ML, 1994, ACTA PAEDIATR, V83, P151, DOI 10.1111/j.1651-2227.1994.tb13040.x; Porter FL, 1999, J DEV BEHAV PEDIATR, V20, P253, DOI 10.1097/00004703-199908000-00008; Quinn MW, 1998, ARCH DIS CHILD-FETAL, V78, pF195, DOI 10.1136/fn.78.3.F195; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; RAISANEN I, 1986, OBSTET GYNECOL, V67, P384; Rutter N, 2000, ARCH DIS CHILD-FETAL, V83, pF101, DOI 10.1136/fn.83.2.F101; Saarenmaa E, 1996, ARCH DIS CHILD-FETAL, V75, pF103, DOI 10.1136/fn.75.2.F103; Saarenmaa E, 2000, CLIN PHARMACOL THER, V68, P160, DOI 10.1067/mcp.2000.108947; Sabatino G, 1997, EARLY HUM DEV, V47, P263, DOI 10.1016/S0378-3782(96)01781-1; Scott CS, 1999, J PEDIATR-US, V135, P423, DOI 10.1016/S0022-3476(99)70163-0; SHANKARAN S, 1982, J PEDIATR-US, V100, P469, DOI 10.1016/S0022-3476(82)80462-9; SKOV L, 1992, ACTA PAEDIATR, V81, P389, DOI 10.1111/j.1651-2227.1992.tb12255.x; SMITH WL, 1983, RADIOLOGY, V147, P445, DOI 10.1148/radiology.147.2.6836123; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; STEWART AL, 1983, ARCH DIS CHILD, V58, P598, DOI 10.1136/adc.58.8.598; TEMPEL A, 1991, DEV BRAIN RES, V64, P19, DOI 10.1016/0165-3806(91)90204-V; THORBURN RJ, 1981, LANCET, V1, P1119; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; van Dijk M, 2002, CLIN PERINATOL, V29, P469, DOI 10.1016/S0095-5108(02)00015-5; van Dijk M, 2002, CLIN J PAIN, V18, P310, DOI 10.1097/00002508-200209000-00006; VOHR B, 1992, J PEDIATR-US, V121, P280, DOI 10.1016/S0022-3476(05)81204-1; Volpe J. J., 2000, NEUROLOGY NEWBORN, P428; WAY WL, 1965, CLIN PHARMACOL THER, V6, P454; Wood CM, 1998, ARCH DIS CHILD-FETAL, V79, pF34, DOI 10.1136/fn.79.1.F34	67	200	204	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2003	290	18					2419	2427		10.1001/jama.290.18.2419	http://dx.doi.org/10.1001/jama.290.18.2419			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742LH	14612478	Bronze			2022-12-28	WOS:000186518300028
J	Edwards, RJ; Moss, T; Sandeman, DR				Edwards, RJ; Moss, T; Sandeman, DR			A syndrome lost in specialisation	LANCET			English	Editorial Material									Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England; Frenchay Hosp, Dept Neuropathol, Bristol BS16 1LE, Avon, England		Edwards, RJ (corresponding author), Frenchay Hosp, Dept Neurosurg, Bristol BS16 1LE, Avon, England.		Edwards, Richard/AAD-9508-2022	Edwards, Richard/0000-0001-8415-2180					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1541	1541		10.1016/S0140-6736(03)14741-1	http://dx.doi.org/10.1016/S0140-6736(03)14741-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615109	Bronze			2022-12-28	WOS:000186464500010
J	Hutin, YJF; Hauri, AM; Armstrong, GL				Hutin, YJF; Hauri, AM; Armstrong, GL			Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEPATITIS-B-VIRUS; UNSAFE INJECTIONS; RURAL TANZANIA; HIV-INFECTION; RISK-FACTORS; TRANSMISSION; CONTAMINATION; COMMUNITY; SAFETY; TRIAL	Objective To describe injection practices worldwide in terms of frequency and safety. Design Literature review The global burden of disease project of the World Health Organization defined 14 regions on the basis of geography and mortality patterns. Data sources included published studies and unpublished WHO reports. Studies were reviewed by using a standardised decision making algorithm to generate region specific estimates. Setting Healthcare facilities, both formal and informal. Data sources: General population and users of healthcare facilities. Main outcome measure Annual number of injections per person and proportion of injections administered with syringes and needles that are reused in the absence of sterilisation. Results The analysis excluded four regions (predominantly affluent, developed nations) where reuse of injection equipment in the absence of sterilisation was assumed to be negligible. In the 10 other regions, the annual ratio of injections per person ranged from 1.7 to 11.3. Of these, the proportion administered with equipment reused in the absence of sterilisation ranged from 1.2% to 75.0%. Reuse was highest in the South East Asia region "D" (seven countries, mostly located in South Asia), the eastern Mediterranean region "D" (nine countries, mostly located in the Middle East crescent), and the western Pacific region "B" (22 countries). No information regarding injection safety was available for Latin America. Conclusions Overuse of injections and unsafe practices are still common in developing and transitional countries. An urgent need exists to use injections safely and appropriately, to prevent healthcare associated infections with HIV and other bloodborne pathogens.	WHO, Dept Blood Safety & Clin Technol, Ave Appia 20, CH-1211 Geneva, Switzerland; Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	World Health Organization; Centers for Disease Control & Prevention - USA	Hutin, YJF (corresponding author), WHO, Dept Blood Safety & Clin Technol, Ave Appia 20, CH-1211 Geneva, Switzerland.	hutiny@who.int						Abulrahi HA, 1997, LANCET, V349, P23, DOI 10.1016/S0140-6736(96)03508-8; ALTAF A, 2002, 14 INT AIDS C 2002 B; ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; Archibald LK, 1998, J PEDIATR-US, V133, P640, DOI 10.1016/S0022-3476(98)70104-0; AYLWARD B, 1995, INT J EPIDEMIOL, V24, P446, DOI 10.1093/ije/24.2.446; BASS A, 2000, B WORLD HEALTH ORGAN, V18, P277; Birungi H, 1998, SOC SCI MED, V47, P1455, DOI 10.1016/S0277-9536(98)00194-4; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Centers for Disease Control, 2001, Morbidity and Mortality Weekly Report, V50, P59; Centers for Disease Control, 1999, Morbidity and Mortality Weekly Report, V48, P271; Chang Shun-Jen, 1996, Kaohsiung Journal of Medical Sciences, V12, P241; Deivanayagam N, 1993, Indian Pediatr, V30, P335; *DEM HLTH SURV, 2000, MEAS DHS PLUS; Dicko M, 2000, B WORLD HEALTH ORGAN, V78, P163; Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7; ELSAKKA H, 1997, EP INT SERV C ATL GA; Ferry B, 1995, SEXUAL BEHAV AIDS DE; FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857; Flaskerud JH, 1996, AIDS CARE, V8, P95, DOI 10.1080/09540129650126028; GROSSKURTH H, 1995, AIDS, V9, P927, DOI 10.1097/00002030-199508000-00015; GUYER B, 1980, B WORLD HEALTH ORGAN, V58, P285; Hadiyono JEP, 1996, SOC SCI MED, V42, P1177, DOI 10.1016/0277-9536(95)00391-6; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HOFMANN CA, 2001, ANN M 30 31 AUG; Hutin YJF, 1999, INT J EPIDEMIOL, V28, P782, DOI 10.1093/ije/28.4.782; Hutin YJF, 1999, B WORLD HEALTH ORGAN, V77, P787; Jain P, 2001, NATL MED J INDIA, V14, P143; JANSZEN E, 1993, IMPACT INJECTIONS DA, P43; Kane A, 1999, B WORLD HEALTH ORGAN, V77, P801; Khan AJ, 2000, B WORLD HEALTH ORGAN, V78, P956; KO Y-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P313; KO Y-C, 1991, Kaohsiung Journal of Medical Sciences, V7, P358; KO YC, 1991, AM J EPIDEMIOL, V133, P1015, DOI 10.1093/oxfordjournals.aje.a115810; KOSEN S, 1999, ASSESSMENT SAFETY EP; Lakshman M, 2000, SOC SCI MED, V51, P11, DOI 10.1016/S0277-9536(99)00426-8; Logez S., 2001, ACCESSIBILITY INJECT; Luby SP, 1997, EPIDEMIOL INFECT, V119, P349, DOI 10.1017/S0950268897007899; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1999, EPIDEMIOLOGY, V10, P594, DOI 10.1097/00001648-199909000-00029; Organization WH, 2002, WHO TRAD MED STRAT 2, P74; OTU AA, 1987, CANCER, V60, P2581, DOI 10.1002/1097-0142(19871115)60:10<2581::AID-CNCR2820601039>3.0.CO;2-G; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PRIOTTO G, 2001, INJECTION USE POPULA; Quick JD, 1997, MANAGING DRUG SUPPLY, P430; Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015; REELER AV, 1990, SOC SCI MED, V31, P1119, DOI 10.1016/0277-9536(90)90233-I; REELER AV, WHODAP948, P94; SCHNURR A, 1999, TECH NET M 1999 HAR; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; SOETERS R, 1989, TROP DOCT, V19, P124, DOI 10.1177/004947558901900310; STOICA A, 1999, ANN M SOC HEALTHC EP; Talaat M, 2003, TROP MED INT HEALTH, V8, P234, DOI 10.1046/j.1365-3156.2003.01015.x; UGALDE A, 1988, CONTEXT MED DEV COUN, P57; van Staa A, 1996, WHODAP964; Villanueva A, 1997, CLIN INFECT DIS, V24, P1147, DOI 10.1086/513656; VONG S, 2002, 51 EP INT SERV C CDC; *WHO, 2001, WHOBCT0211; *WHO, 1994, WHODAP9412; *WHO, 2001, WHOVB0130; *WHO, 1999, WKLY EPIDEMIOL REC, V11, P84; *WHO, 2000, WHO FACT SHEET, P204; World Health Organization, 2000, AID MEM NAT STRAT SA; WYAU HV, 1984, SOC SCI MED, V19, P911; 1945, LANCET          0728, P116	64	176	185	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2003	327	7423					1075	+		10.1136/bmj.327.7423.1075	http://dx.doi.org/10.1136/bmj.327.7423.1075			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742QW	14604927	Bronze, Green Published			2022-12-28	WOS:000186530400016
J	Dawson, TM; Dawson, VL				Dawson, TM; Dawson, VL			Molecular pathways of neurodegeneration in Parkinson's disease	SCIENCE			English	Review							ALPHA-SYNUCLEIN AGGREGATION; UBIQUITIN-PROTEIN LIGASE; EARLY-ONSET PARKINSONISM; OXIDATIVE STRESS; DROSOPHILA MODEL; INCLUSION-BODIES; TRANSGENIC MICE; BODY FORMATION; ANIMAL-MODELS; FATTY-ACIDS	Parkinson's disease (PD) is a complex disorder with many different causes, yet they may intersect in common pathways, raising the possibility that neuroprotective agents may have broad applicability in the treatment of PD. Current evidence suggests that mitochondrial complex I inhibition may be the central cause of sporadic PD and that derangements in complex I cause alpha-synuclein aggregation, which contributes to the demise of dopamine neurons. Accumulation and aggregation of alpha-synuclein may further contribute to the death of dopamine neurons through impairments in protein handling and detoxification. Dysfunction of parkin (a ubiquitin E3 ligase) and DJ-1 could contribute to these deficits. Strategies aimed at restoring complex I activity, reducing oxidative stress and alpha-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD.	Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Dawson, TM (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA.	tdawson@jhmi.edu	Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NINDS NIH HHS [NS38377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auluck PK, 2002, NAT MED, V8, P1185, DOI 10.1038/nm1102-1185; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Chung KKK, 2001, TRENDS NEUROSCI, V24, pS7, DOI 10.1016/S0166-2236(00)01998-6; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; FORNO LS, 1988, BRAIN RES, V448, P150, DOI 10.1016/0006-8993(88)91111-0; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; George JM, 2002, GENOME BIOL, V3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Giasson BI, 2003, SCIENCE, V300, P636, DOI 10.1126/science.1082324; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hampshire DJ, 2001, J MED GENET, V38, P680, DOI 10.1136/jmg.38.10.680; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; Hunot S, 2003, ANN NEUROL, V53, pS49, DOI 10.1002/ana.10481; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 2002, CURR OPIN GENET DEV, V12, P299, DOI 10.1016/S0959-437X(02)00302-7; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Martin ER, 2001, JAMA-J AM MED ASSOC, V286, P2245, DOI 10.1001/jama.286.18.2245; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Schapira AHV, 1998, ANN NEUROL, V44, pS89, DOI 10.1002/ana.410440714; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; Sherer TB, 2002, J NEUROSCI, V22, P7006; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Siderowf A, 2003, ANN INTERN MED, V138, P651, DOI 10.7326/0003-4819-138-8-200304150-00013; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Swerdlow RH, 2001, EXP NEUROL, V169, P479, DOI 10.1006/exnr.2001.7674; Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhang Y, 2001, CLIN NEUROSCI RES, V1, P467, DOI 10.1016/S1566-2772(01)00025-1; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	81	1328	1401	5	435	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					819	822		10.1126/science.1087753	http://dx.doi.org/10.1126/science.1087753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593166				2022-12-28	WOS:000186258000036
J	Yamada, K; Lim, J; Dale, JM; Chen, HM; Shinn, P; Palm, CJ; Southwick, AM; Wu, HC; Kim, C; Nguyen, M; Pham, P; Cheuk, R; Karlin-Newmann, G; Liu, SX; Lam, B; Sakano, H; Wu, T; Yu, GX; Miranda, M; Quach, HL; Tripp, M; Chang, CH; Lee, JM; Toriumi, M; Chan, MMH; Tang, CC; Onodera, CS; Deng, JM; Akiyama, K; Ansari, Y; Arakawa, T; Banh, J; Banno, F; Bowser, L; Brooks, S; Carninci, P; Chao, QM; Choy, N; Enju, A; Goldsmith, AD; Gurjal, M; Hansen, NF; Hayashizaki, Y; Johnson-Hopson, C; Hsuan, VW; Iida, K; Karnes, M; Khan, S; Koesema, E; Ishida, J; Jiang, PX; Jones, T; Kawai, J; Kamiya, A; Meyers, C; Nakajima, M; Narusaka, M; Seki, M; Sakurai, T; Satou, M; Tamse, R; Vaysberg, M; Wallender, EK; Wong, C; Yamamura, Y; Yuan, SL; Shinozaki, K; Davis, RW; Theologis, A; Ecker, JR				Yamada, K; Lim, J; Dale, JM; Chen, HM; Shinn, P; Palm, CJ; Southwick, AM; Wu, HC; Kim, C; Nguyen, M; Pham, P; Cheuk, R; Karlin-Newmann, G; Liu, SX; Lam, B; Sakano, H; Wu, T; Yu, GX; Miranda, M; Quach, HL; Tripp, M; Chang, CH; Lee, JM; Toriumi, M; Chan, MMH; Tang, CC; Onodera, CS; Deng, JM; Akiyama, K; Ansari, Y; Arakawa, T; Banh, J; Banno, F; Bowser, L; Brooks, S; Carninci, P; Chao, QM; Choy, N; Enju, A; Goldsmith, AD; Gurjal, M; Hansen, NF; Hayashizaki, Y; Johnson-Hopson, C; Hsuan, VW; Iida, K; Karnes, M; Khan, S; Koesema, E; Ishida, J; Jiang, PX; Jones, T; Kawai, J; Kamiya, A; Meyers, C; Nakajima, M; Narusaka, M; Seki, M; Sakurai, T; Satou, M; Tamse, R; Vaysberg, M; Wallender, EK; Wong, C; Yamamura, Y; Yuan, SL; Shinozaki, K; Davis, RW; Theologis, A; Ecker, JR			Empirical analysis of transcriptional activity in the Arabidopsis genome	SCIENCE			English	Article							FULL-LENGTH; FUNCTIONAL ANNOTATION; SEQUENCE; GENES; PREDICTION; CLONING; CDNAS; DNA; L.	Functional analysis of a genome requires accurate gene structure information and a complete gene inventory. A dual experimental strategy was used to verify and correct the initial genome sequence annotation of the reference plant Arabidopsis. Sequencing full-length cDNAs and hybridizations using RNA populations from various tissues to a set of high-density oligonucleotide arrays spanning the entire genome allowed the accurate annotation of thousands of gene structures. We identified 5817 novel transcription units, including a substantial amount of antisense gene transcription, and 40 genes within the genetically defined centromeres. This approach resulted in completion of similar to30% of the Arabidopsis ORFeome as a resource for global functional experimentation of the plant proteome.	Salk Inst Biol Studies, Genom Anal Lab, La Jolla, CA 92037 USA; Ctr Plant Gene Express, Albany, CA 94710 USA; Univ Penn, Dept Biol, Arabidopsis Thaliana Genome Ctr, Philadelphia, PA 19104 USA; Stanford Univ, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; RIKEN, Yokohama Inst, Genom Sci Ctr,Plant Mutat Explorat Team, Plant Funct Genom Res Grp, Tsukuba, Ibaraki 3050074, Japan; RIKEN, Discovery & Res Inst, Genome Sci Lab, Wako, Saitama 3510198, Japan; RIKEN GSC, Yokohama Inst, Lab Genome Explorat Res Grp, Kanagawa 2300045, Japan; RIKEN, Tsukuba Inst, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050074, Japan; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Salk Institute; University of Pennsylvania; Stanford University; RIKEN; RIKEN; RIKEN; RIKEN; Stanford University	Ecker, JR (corresponding author), Salk Inst Biol Studies, Genom Anal Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	theo@nature.berkeley.edu; ecker@salk.edu	Ecker, Joseph R/B-9144-2008; Carninci, Piero/K-1568-2014; Hayashizaki, Yoshihide/N-6590-2015; Kawai, Jun/A-6451-2016; Seki, Motoaki/I-2854-2012; Shinozaki, Kazuo/G-4202-2013; Sakurai, Tetsuya/B-2690-2010	Ecker, Joseph R/0000-0001-5799-5895; Carninci, Piero/0000-0001-7202-7243; Seki, Motoaki/0000-0001-8288-0467; Shinozaki, Kazuo/0000-0002-6317-9867; Sakurai, Tetsuya/0000-0003-2046-8973; IIDA, Kei/0000-0001-7130-8705; Koesema, Eric/0000-0002-7743-0127; Chen, Huaming/0000-0001-5289-7882; Yuan, Shiaulou/0000-0002-5061-6132; Sakano, Hitomi/0000-0002-7471-8352				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Borevitz JO, 2003, GENOME RES, V13, P513, DOI 10.1101/gr.541303; Brizuela L, 2002, ARCH MED RES, V33, P318, DOI 10.1016/S0188-4409(02)00372-7; Carninci P, 2001, GENOMICS, V77, P79, DOI 10.1006/geno.2001.6601; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Haas BJ, 2002, GENOME BIOL, V3, DOI DOI 10.1186/GB-2002-3-6-RESEARCH0029; Hirotsune S, 2003, NATURE, V423, P91, DOI 10.1038/nature01535; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kirst M, 2003, P NATL ACAD SCI USA, V100, P7383, DOI 10.1073/pnas.1132171100; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; *MAMM GEN COLL PRO, 2003, P NATL ACAD SCI USA, V99, P16899; Mathe C, 2002, NUCLEIC ACIDS RES, V30, P4103, DOI 10.1093/nar/gkf543; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MEYEROWITZ EM, 1994, ARABIDOPSIS; Morillon A, 2003, SCIENCE, V300, P492, DOI 10.1126/science.1081379; *NAT AC SCI REP, 2002, NAT PLANT GEN IN OBJ; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Osato N, 2002, GENOME RES, V12, P1127, DOI 10.1101/gr.75202; Reboul J, 2001, NAT GENET, V27, P332, DOI 10.1038/85913; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Salanoubat M, 2000, NATURE, V408, P820, DOI 10.1038/35048706; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Steinmetz LM, 2000, BIOTECHNOL GENET ENG, V17, P109, DOI 10.1080/02648725.2000.10647990; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; Tabata S, 2000, NATURE, V408, P823, DOI 10.1038/35048507; Theologis A, 2000, NATURE, V408, P816, DOI 10.1038/35048500; Tjaden B, 2002, NUCLEIC ACIDS RES, V30, P3732, DOI 10.1093/nar/gkf505; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Xiao YL, 2002, PLANT PHYSIOL, V130, P2118, DOI 10.1104/pp.010207; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Zhang MQ, 2002, NAT REV GENET, V3, P698, DOI 10.1038/nrg890	40	705	9092	10	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	2003	302	5646					842	846		10.1126/science.1088305	http://dx.doi.org/10.1126/science.1088305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593172				2022-12-28	WOS:000186258000042
J	Marshall, T				Marshall, T			Coronary heart disease prevention: insights from modelling incremental cost effectiveness	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK; METAANALYSIS; ASPIRIN; STATINS	Objective To determine which treatments for preventing coronary heart disease should be offered to which patients by assessing their incremental cost effectiveness. Design Modelling study Data sources Cost estimates (for NHS) and estimates of effectiveness obtained for aspirin, antihypertensive drugs, statins and clopidogrel. Data synthesis Treatment effects were assumed to be independent, and cost per coronary event prevented was calculated for treatments individually and in combination across patients at a range of coronary risks. Results ne most cost effective preventive treatments are aspirin, initial antihypertensive treatment (bendrofluazide and atenolol), and intensive andhypertensive treatment (bendrofluazide, atenolol and enalapril), whereas simvastatin and clopidogrel are the least cost effective (cost per coronary event prevented in a patient at 10% coronary risk over five years is pound3500 for aspirin, pound12500 for initial antihypertensives, pound18300 for intensive antihypertensives, pound60000 for clopidogrel, and pound61400 for simvastatin). Aspirin in a patient at 5% five year coronary risk costs less than a fifth as much per event prevented (pound7900) as simvastatin in a patient at 30% five year risk (pound40800). Discussion A cost effective prevention strategy would offer aspirin and initial antihypertensive treatment to all patients at greater than 7.5% five year coronary risk before offering statins or clopidogrel to patients at greater than 15% five year coronary risk. Incremental cost effectiveness analysis of treatments produces robust, practical cost effectiveness rankings that can be used to inform treatment guidelines.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Marshall, T (corresponding author), Partners Healthcare, 1620 Tremont St, Boston, MA 02120 USA.	T.P.Marshall@bham.ac.uk		Marshall, Tom/0000-0001-9277-5214				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; *BRIT MED ASS ROYA, 2002, 44 BMA RPS; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; CASPOZ JM, 2002, NEW ENGL J MED, V346, P1800; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Department of Health, 2000, NAT SERV FRAM COR HE, P1; Ebrahim S, 1999, Health Technol Assess, V3, pi; EBRAHIM S, 1999, HEALTH TECHNOL ASSES, V3, P1; Gaspoz J, 2002, NEW ENGL J MED, V346, P1800, DOI 10.1056/NEJM200206063462309; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; HANKEY GJ, 2000, COCHRANE DB SYST REV, V2; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Marshall T, 2002, BMJ-BRIT MED J, V325, P197, DOI 10.1136/bmj.325.7357.197; *NAT I CLIN EXC, 2001, NICE TECHN GUID MAN; Neal B, 2000, LANCET, V356, P1955; Netten A., 2001, UNIT COSTS HLTH SOCI; *PRESCR PRIC AUTH, 2002, DRUG TAR; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; *STAT OFF, 2000, HLTH SURV ENGL 1998; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Wood D, 1998, HEART, V80, pS1; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3	27	40	43	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 29	2003	327	7426					1264	1267		10.1136/bmj.327.7426.1264	http://dx.doi.org/10.1136/bmj.327.7426.1264			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644970	Green Published, Bronze			2022-12-28	WOS:000186948800019
J	Haggerty, JL; Reid, RJ; Freeman, GK; Starfield, BH; Adair, CE; McKendry, R				Haggerty, JL; Reid, RJ; Freeman, GK; Starfield, BH; Adair, CE; McKendry, R			Continuity of care: a multidisciplinary review	BRITISH MEDICAL JOURNAL			English	Article							MENTALLY-ILL; SERVICES		Univ Montreal, Hop Notre Dame Z8910, Dept Med Familiale, Montreal, PQ H2L 4M1, Canada; Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1W6, Canada; Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, London W6 8RP, England; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Univ Alberta, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada; Univ Alberta, Dept Psychiat, Calgary, AB T2N 4N1, Canada	Universite de Montreal; Imperial College London; Johns Hopkins University; University of Alberta; University of Alberta	Haggerty, JL (corresponding author), Univ Montreal, Hop Notre Dame Z8910, Dept Med Familiale, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.		Haggerty, Jeannie/GSD-7271-2022		PHS HHS [6U30CS00189-05 S1R1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MA, 1993, HOSP HEALTH SERV ADM, V38, P537; Bachrach L, 1993, CASE MANAGEMENT MENT, P183; BACHRACH LL, 1993, HOSP COMMUNITY PSYCH, V44, P465; BASS RD, 1972, AM J PSYCHIAT, V129, P196, DOI 10.1176/ajp.129.2.196; Benjamin A E, 1989, Med Care Rev, V46, P411, DOI 10.1177/107755878904600404; Campbell H, 1998, BMJ-BRIT MED J, V316, P133; *CAN HLTH SERV RES, 2001 OP GRANTS COMP; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; Freeman G., 2000, CONTINUITY CARE REPO; FULOP N, 1909, NATL LISTENING EXERC; Hennen B K, 1975, J Fam Pract, V2, P371; Hjortdahl P, 1990, Fam Med, V22, P361; Johnson S, 1997, SOC PSYCH PSYCH EPID, V32, P137; Keenan G, 1998, Outcomes Manag Nurs Pract, V2, P81; McWhinney I R, 1975, J Fam Pract, V2, P373; ROGERS J, 1980, AM J PUBLIC HEALTH, V70, P122, DOI 10.2105/AJPH.70.2.122; Rusch S C, 1986, Nurs Manage, V17, P38; SHORTELL SM, 1976, MED CARE, V14, P377, DOI 10.1097/00005650-197605000-00001; Sparbel KJH, 2000, J NURS SCHOLARSHIP, V32, P17, DOI 10.1111/j.1547-5069.2000.00017.x; Starfield B, 1998, PRIMARY CARE BALANCI, P143; TESSLER RC, 1986, PSYCHOSOC REHABIL, V10, P27, DOI DOI 10.1037/h0099621; Waldenstrom U, 1998, BRIT J OBSTET GYNAEC, V105, P1160, DOI 10.1111/j.1471-0528.1998.tb09969.x; WALL EM, 1981, J FAM PRACTICE, V13, P655; World Health Organization, 1996, LJUBLJ CHART REF HLT	24	1169	1212	5	146	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 22	2003	327	7425					1219	1221		10.1136/bmj.327.7425.1219	http://dx.doi.org/10.1136/bmj.327.7425.1219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	747BB	14630762	Green Published			2022-12-28	WOS:000186784300025
J	Yamaguchi, S; Isejima, H; Matsuo, T; Okura, R; Yagita, K; Kobayashi, M; Okamura, H				Yamaguchi, S; Isejima, H; Matsuo, T; Okura, R; Yagita, K; Kobayashi, M; Okamura, H			Synchronization of cellular clocks in the suprachiasmatic nucleus	SCIENCE			English	Article							CIRCADIAN-RHYTHMS; MPER1 GENE; MOUSE; TETRODOTOXIN	Individual cellular clocks in the suprachiasmatic nucleus (SCN), the circadian center, are integrated into a stable and robust pacemaker with a period length of about 24 hours. We used real-time analysis of gene expression to show synchronized rhythms of clock gene transcription across hundreds of neurons within the mammalian SCN in organotypic slice culture. Differentially phased neuronal clocks are topographically arranged across the SCN. A protein synthesis inhibitor set all cell clocks to the same initial phase and, after withdrawal, intrinsic interactions among cell clocks reestablished the stable program of gene expression across the assemblage. Na+-dependent action potentials contributed to establishing cellular synchrony and maintaining spontaneous oscillation across the SCN.	Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci, Kobe, Hyogo 6500017, Japan; Yamaguchi Univ, Dept Phys Informat & Biol, Yamaguchi 7538512, Japan; Tohoku Inst Technol, Dept Elect, Sendai, Miyagi 9828577, Japan	Kobe University; Yamaguchi University; Tohoku Institute Technology	Okamura, H (corresponding author), Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci, Kobe, Hyogo 6500017, Japan.	okamurah@kobe-u.ac.jp	MATSUO, Takuya/I-7493-2014	Ookura, Ryusuke/0000-0002-6045-9193; Okamura, Hitoshi/0000-0002-3013-4881				Abrahamson EE, 2001, BRAIN RES, V916, P172, DOI 10.1016/S0006-8993(01)02890-6; Asai M, 2001, CURR BIOL, V11, P1524, DOI 10.1016/S0960-9822(01)00445-6; BOUSKILA Y, 1993, P NATL ACAD SCI USA, V90, P3207, DOI 10.1073/pnas.90.8.3207; Colwell CS, 2000, J NEUROBIOL, V43, P379, DOI 10.1002/1097-4695(20000615)43:4<379::AID-NEU6>3.0.CO;2-0; Cutler DJ, 2003, EUR J NEUROSCI, V17, P197, DOI 10.1046/j.1460-9568.2003.02425.x; Honma S, 2000, NEUROSCI LETT, V294, P113, DOI 10.1016/S0304-3940(00)01558-5; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Nitabach MN, 2002, CELL, V109, P485, DOI 10.1016/S0092-8674(02)00737-7; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; Peng Y, 2003, PLOS BIOL, V1, P32, DOI 10.1371/journal.pbio.0000013; Quintero JE, 2003, J NEUROSCI, V23, P8070; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; SCHWARTZ WJ, 1987, P NATL ACAD SCI USA, V84, P1694, DOI 10.1073/pnas.84.6.1694; SCHWARTZ WJ, 1985, J NEUROSCI, V5, P2771; SHIBATA S, 1993, BRAIN RES, V606, P259, DOI 10.1016/0006-8993(93)90993-W; TOMINAGA K, 1994, NEUROSCIENCE, V59, P1025, DOI 10.1016/0306-4522(94)90303-4; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Yamaguchi S, 2000, CURR BIOL, V10, P873, DOI 10.1016/S0960-9822(00)00602-3; Yamaguchi S, 2001, NATURE, V409, P684, DOI 10.1038/35055628	21	695	704	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	2003	302	5649					1408	1412		10.1126/science.1089287	http://dx.doi.org/10.1126/science.1089287			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631044				2022-12-28	WOS:000186683500056
J	Glass, LC				Glass, LC			Pituitary apoplexy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Miami, Sch Med, Miami, FL 33136 USA	University of Miami	Glass, LC (corresponding author), Univ Miami, Sch Med, Miami, FL 33136 USA.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2034	2034		10.1056/NEJMicm010320	http://dx.doi.org/10.1056/NEJMicm010320			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627788				2022-12-28	WOS:000186642900007
J	Kupper, TS				Kupper, TS			Immunologic targets in psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Kupper, TS (corresponding author), Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA.		Kupper, Thomas/O-4962-2019					Dustin ML, 2002, SCIENCE, V298, P785, DOI 10.1126/science.1076386; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407	4	59	71	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					1987	1990		10.1056/NEJMp038164	http://dx.doi.org/10.1056/NEJMp038164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627782				2022-12-28	WOS:000186642900001
J	Ackermann, RT; Carroll, AE				Ackermann, RT; Carroll, AE			Support for national health insurance among US physicians: A national survey	ANNALS OF INTERNAL MEDICINE			English	Article							CARE REFORM; ATTITUDES; VIEWS	Background: Nearly 40 million persons in the United States were without health insurance for all of 2000. National health insurance would remedy this situation, and many believe the success of reform efforts in this direction may depend on physician support. Objective: To determine the general attitudes of U.S. physicians toward the financing of national health care. Design: Cross-sectional study. Setting: National mailed survey. Participants: 3188 randomly sampled physicians from the American Medical Association Physician Masterfile. Measurements: Physicians were asked whether they support or oppose 1) governmental legislation to establish national health insurance and 2) a national health insurance plan in which all health care is paid for by the federal government. Weighted multivariate logistic regression analyses were performed to identify factors that independently predicted support for each of these strategies. Results: Sixty percent of eligible participants returned a survey. Forty-nine percent of physicians supported governmental legislation to establish national health insurance, and 40% opposed it. Only 26% of all physicians supported a national health insurance plan in which all health care is paid for by the federal government. In analyses adjusting for differences in personal and practice characteristics, physicians in a primary care specialty, physicians reporting that at least 20% of their patients had Medicaid, and physicians practicing in a nonprivate setting or in an inner-city location were statistically significantly more likely to support governmental legislation to establish national health insurance. Conclusions: A plurality of U.S. physicians supports governmental legislation to establish national health insurance. This support may be relevant to the success of future efforts to reform national health care.	Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Univ Washington, Seattle, WA 98195 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Carroll, AE (corresponding author), Indiana Univ, Sch Med, 699 W Dr,Riley Res,Room 330, Indianapolis, IN 46202 USA.	aaecarro@iupui.edu						BLENDON RJ, 1994, JAMA-J AM MED ASSOC, V272, P1546, DOI 10.1001/jama.272.19.1546; BODENHEIMER TS, 1998, CLIN APPROACH; Dillman D.A., 2007, MAIL INTERNET SURVEY, V2nd; FALK IS, 1977, MILBANK FUND Q, V55, P161, DOI 10.2307/3349642; MALTER AD, 1994, WESTERN J MED, V161, P29; MILLARD PS, 1993, J FAM PRACTICE, V37, P439; MILLS RJ, 2001, HLTH INSURANCE COVER, P1; ROTHMAN DJ, 1993, J HEALTH POLIT POLIC, V18, P271, DOI 10.1215/03616878-18-2-271; Scanlan A, 1996, MED CARE, V34, P837, DOI 10.1097/00005650-199608000-00010; Starr P, 1982, SOCIAL TRANSFORMATIO; TAYLOR H, 2002, ATTITUDES US HLTH CA, V2, P1; 1993, INTERNIST, V34, P32; 1992, BUS HLTH, V10, P52; 1992, BUS HLTH, V10, P48; 1992, BUS HLTH, V10, P46	15	13	13	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					795	801		10.7326/0003-4819-139-10-200311180-00006	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	744ZV	14623616				2022-12-28	WOS:000186663500001
J	Meyer, O				Meyer, O			Neonatal cutaneous lupus and congenital heart block: it's not all antibodies	LANCET			English	Editorial Material							PATHOGENESIS; AUTOANTIGEN; AUTOANTIBODIES; PREGNANCIES; EXPRESSION; INDUCTION; CHILDREN; MOTHERS		Denis Diderot Univ, Bichat Teaching Hosp, Dept Rheumatol, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Meyer, O (corresponding author), Denis Diderot Univ, Bichat Teaching Hosp, Dept Rheumatol, F-75018 Paris, France.							BUYON JP, 1994, J RHEUMATOL, V21, P1943; Buyon JP, 1997, ARTHRITIS RHEUM-US, V40, P655, DOI 10.1002/art.1780400410; Clancy RM, 2003, J IMMUNOL, V171, P3253, DOI 10.4049/jimmunol.171.6.3253; Franceschini F, 1999, CLIN EXP RHEUMATOL, V17, P634; Furukawa F, 1999, CLIN EXP IMMUNOL, V118, P164, DOI 10.1046/j.1365-2249.1999.01026.x; Horsfall AC, 1998, ARTHRITIS RHEUM, V41, P2079; Miranda-Carus ME, 1998, J IMMUNOL, V161, P5886; Salomonsson S, 2002, ARTHRITIS RHEUM-US, V46, P1233, DOI 10.1002/art.10232; Solomon DG, 2003, LUPUS, V12, P646, DOI 10.1191/0961203303lu425xx; Tran HB, 2002, ARTHRITIS RHEUM, V46, P202, DOI 10.1002/1529-0131(200201)46:1<202::AID-ART10062>3.0.CO;2-Y; Viana VST, 1998, LUPUS, V7, P141, DOI 10.1191/096120398678919895; Wahren-Herlenius M, 1999, IMMUNOL TODAY, V20, P234, DOI 10.1016/S0167-5699(99)01458-9	12	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1596	1597		10.1016/S0140-6736(03)14838-6	http://dx.doi.org/10.1016/S0140-6736(03)14838-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630436				2022-12-28	WOS:000186637400004
J	Krack, P; Batir, A; Van Blercom, N; Chabardes, S; Fraix, V; Ardouin, C; Koudsie, A; Limousin, PD; Benazzouz, A; LeBas, JF; Benabid, AL; Pollak, P				Krack, P; Batir, A; Van Blercom, N; Chabardes, S; Fraix, V; Ardouin, C; Koudsie, A; Limousin, PD; Benazzouz, A; LeBas, JF; Benabid, AL; Pollak, P			Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-BRAIN-STIMULATION; RATING-SCALE; POSTEROVENTRAL PALLIDOTOMY; UNILATERAL PALLIDOTOMY; GLOBUS-PALLIDUS; MOTOR FUNCTION; LEVODOPA; FLUCTUATIONS; DEPRESSION; SPECTRUM	Background: Although the short-term benefits of bilateral stimulation of the subthalamic nucleus in patients with advanced Parkinson's disease have been well documented, the long-term outcomes of the procedure are unknown. Methods: We conducted a five-year prospective study of the first 49 consecutive patients whom we treated with bilateral stimulation of the subthalamic nucleus. Patients were assessed at one, three, and five years with levodopa (on medication) and without levodopa (off medication), with use of the Unified Parkinson's Disease Rating Scale. Seven patients did not complete the study: three died, and four were lost to follow-up. Results: As compared with base line, the patients' scores at five years for motor function while off medication improved by 54 percent (P<0.001) and those for activities of daily living improved by 49 percent (P<0.001). Speech was the only motor function for which off-medication scores did not improve. The scores for motor function on medication did not improve one year after surgery, except for the dyskinesia scores. On-medication akinesia, speech, postural stability, and freezing of gait worsened between year 1 and year 5 (P<0.001 for all comparisons). At five years, the dose of dopaminergic treatment and the duration and severity of levodopa-induced dyskinesia were reduced, as compared with base line (P<0.001 for each comparison). The average scores for cognitive performance remained unchanged, but dementia developed in three patients after three years. Mean depression scores remained unchanged. Severe adverse events included a large intracerebral hemorrhage in one patient. One patient committed suicide. Conclusions: Patients with advanced Parkinson's disease who were treated with bilateral stimulation of the subthalamic nucleus had marked improvements over five years in motor function while off medication and in dyskinesia while on medication. There was no control group, but worsening of akinesia, speech, postural stability, freezing of gait, and cognitive function between the first and the fifth year is consistent with the natural history of Parkinson's disease.	Univ Grenoble 1, Dept Clin & Biol Neurosci, Grenoble, France; Univ Grenoble 1, Dept Magnet Resonance Imaging, Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Krack, P (corresponding author), CHU Grenoble, Dept Neurol, Dept Clin & Biol Neurosci, BP 217, F-38043 Grenoble 9, France.	paul.krack@ujf-grenoble.fr	Benabid, Alim L/Q-3506-2017; Benazzouz, Abdelhamid/E-5050-2016; FRAIX, VALERIE/AAC-3616-2019	Krack, Paul/0000-0002-3508-7295				Albanese A, 2001, MOVEMENT DISORD, V16, P197, DOI 10.1002/mds.1069; Alkhani A, 2001, J NEUROSURG, V94, P43, DOI 10.3171/jns.2001.94.1.0043; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Berney A, 2002, NEUROLOGY, V59, P1427, DOI 10.1212/01.WNL.0000032756.14298.18; BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; De Bie RMA, 2002, MOVEMENT DISORD, V17, P533, DOI 10.1002/mds.10090; Doshi PK, 2002, MOVEMENT DISORD, V17, P1084, DOI 10.1002/mds.10198; Durif F, 2002, MOVEMENT DISORD, V17, P803, DOI 10.1002/mds.10128; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fine J, 2000, NEW ENGL J MED, V342, P1708, DOI 10.1056/NEJM200006083422304; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Funkiewiez A, 2003, MOVEMENT DISORD, V18, P524, DOI 10.1002/mds.10441; Ghika J, 1998, J NEUROSURG, V89, P713, DOI 10.3171/jns.1998.89.5.0713; Ghika J, 1999, J NEUROSURG, V91, P313, DOI 10.3171/jns.1999.91.2.0313; Goetz CG, 2002, MOVEMENT DISORD, V17, P283, DOI 10.1002/mds.10024; Goetz CG, 2000, NEUROLOGY, V54, P710, DOI 10.1212/WNL.54.3.710; GREENE P, 1993, ADV NEUROL, V60, P703; Hariz GM, 2003, MOVEMENT DISORD, V18, P373, DOI 10.1002/mds.10386; Hariz MI, 2001, J NEUROSURG, V94, P552, DOI 10.3171/jns.2001.94.4.0552; Hoehn MM, 1969, 3 S PARK DIS, P274; Houeto JL, 2002, J NEUROL NEUROSUR PS, V72, P701, DOI 10.1136/jnnp.72.6.701; Jahanshahi M, 2000, BRAIN, V123, P1142, DOI 10.1093/brain/123.6.1142; KLAWANS HL, 1986, MOVEMENT DISORD, V3, P187; Krack P, 2002, MOVEMENT DISORD, V17, pS188, DOI 10.1002/mds.10163; Krack P, 1997, LANCET, V350, P1676, DOI 10.1016/S0140-6736(05)64273-0; Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARKHAM CH, 1986, ANN NEUROL, V19, P365, DOI 10.1002/ana.410190410; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Oh MY, 2002, NEUROSURGERY, V50, P1268; Pahwa R, 2003, J NEUROSURG, V99, P71, DOI 10.3171/jns.2003.99.1.0071; Pillon B, 2000, NEUROLOGY, V55, P411, DOI 10.1212/WNL.55.3.411; Rehncrona S, 2003, MOVEMENT DISORD, V18, P163, DOI 10.1002/mds.10309; RICHARDS M, 1994, MOVEMENT DISORD, V9, P89, DOI 10.1002/mds.870090114; RILEY DE, 1993, NEUROLOGY, V43, P1459, DOI 10.1212/WNL.43.8.1459; Romito LM, 2002, MOVEMENT DISORD, V17, P1371, DOI 10.1002/mds.10265; SCHMIDT R, 1994, NEUROLOGY, V44, P964, DOI 10.1212/WNL.44.5.964; Schwab R.S., 1969, 3 S PARK DIS, P152; Speelman JD, 1998, MOVEMENT DISORD, V13, P103; Valldeoriola F, 2002, J NEUROL, V249, P1671, DOI 10.1007/s00415-002-0897-8; Zhang H, 2003, NEUROSURGERY, V52, P89, DOI 10.1227/01.NEU.0000038933.95427.AE	46	1551	1583	1	188	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2003	349	20					1925	1934		10.1056/NEJMoa035275	http://dx.doi.org/10.1056/NEJMoa035275			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742EA	14614167	Bronze, Green Published			2022-12-28	WOS:000186502400007
J	Lei, M; Podell, ER; Baumann, P; Cech, TR				Lei, M; Podell, ER; Baumann, P; Cech, TR			DNA self-recognition in the structure of Pot1 bound to telomeric single-stranded DNA	NATURE			English	Article							END-BINDING-PROTEIN; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; DOMAIN; PROTECTION; SEQUENCE	Telomeres, specialized protein-DNA complexes that cap the ends of linear chromosomes, are essential for protecting chromosomes from degradation and end-to-end fusions(1,2). The Pot1 (protection of telomeres 1) protein is a widely distributed eukaryotic end-capping protein, having been identified in fission yeast, microsporidia, plants and animals(3,4). Schizosaccharomyces pombe Pot1p is essential for telomere maintenance(3), and human POT1 has been implicated in telomerase regulation(5,6). Pot1 binds telomeric single-stranded DNA (ssDNA) with exceptionally high sequence specificity(7), the molecular basis of which has been unknown. Here we describe the 1.9-Angstrom-resolution crystal structure of the amino-terminal DNA-binding domain of S. pombe Pot1p complexed with ssDNA. The protein adopts an oligonucleotide/oligosaccharide-binding (OB) fold(8) with two loops that protrude to form a clamp for ssDNA binding. The structure explains the sequence specificity of binding: in the context of the Pot1 protein, DNA self-recognition involving base-stacking and unusual G-T base pairs compacts the DNA. Any sequence change disrupts the ability of the DNA to form this structure, preventing it from contacting the array of protein hydrogen-bonding groups. The structure also explains how Pot1p avoids binding the vast excess of RNA in the nucleus.	Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Stowers Institute for Medical Research	Cech, TR (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Campus Box 215, Boulder, CO 80309 USA.	thomas.cech@colorado.edu		Baumann, Peter/0000-0003-4892-1485				Arcus V, 2002, CURR OPIN STRUC BIOL, V12, P794, DOI 10.1016/S0959-440X(02)00392-5; Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Cervantes RB, 2002, CURR OPIN CELL BIOL, V14, P351, DOI 10.1016/S0955-0674(02)00325-3; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Classen S, 2003, BIOCHEMISTRY-US, V42, P9269, DOI 10.1021/bi0273718; Classen S, 2001, J MOL BIOL, V314, P1113, DOI 10.1006/jmbi.2000.5191; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NICHOLLS A, 1991, J COMPUT CHEM, V270, P26184; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Peersen OB, 2002, NAT STRUCT BIOL, V9, P182, DOI 10.1038/nsb761; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506	30	171	181	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					198	203		10.1038/nature02092	http://dx.doi.org/10.1038/nature02092			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614509				2022-12-28	WOS:000186517200048
J	Pearce, EL; Mullen, AC; Martins, GA; Krawczyk, CM; Hutchins, AS; Zediak, VP; Banica, M; DiCioccio, CB; Gross, DA; Mao, C; Shen, H; Cereb, N; Yang, SY; Lindsten, T; Rossant, J; Hunter, CA; Reiner, SL				Pearce, EL; Mullen, AC; Martins, GA; Krawczyk, CM; Hutchins, AS; Zediak, VP; Banica, M; DiCioccio, CB; Gross, DA; Mao, C; Shen, H; Cereb, N; Yang, SY; Lindsten, T; Rossant, J; Hunter, CA; Reiner, SL			Control of effector CD8(+) T cell function by the transcription factor Eomesodermin	SCIENCE			English	Article							LINEAGE COMMITMENT; BET; GENE; MEMORY; DIFFERENTIATION; INDUCTION; FOXP3; CD4	Activated CD8(+) T cells play a critical role in host defense against viruses, intracellular microbes, and tumors. It is not clear if a key regulatory transcription factor unites the effector functions of CD8(+) T cells. We now show that Eomesodermin (Eomes), a paralogue of T-bet, is induced in effector CD8(+) T cells in vitro and in vivo. Ectopic expression of Eomes was sufficient to invoke attributes of effector CD8(+) T cells, including interferon-gamma (IFN-gamma), perforin, and granzyme B. Loss-of-function analysis suggests Eomes may also be necessary for full effector differentiation of CD8(+) T cells. We suggest that Eomesodermin is likely to complement the actions of T-bet and act as a key regulatory gene in the development of cell-mediated immunity.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Ctr Genet Polymorphism, Ossining, NY 10562 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Reiner, SL (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.		Hunter, Christopher/H-1970-2011	Mullen, Alan/0000-0002-4096-3106; Mao, Chai-An/0000-0002-9700-6964	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042370] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-042370] Funding Source: Medline; NIGMS NIH HHS [GM-07229] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CEREB N, UNPUB; Conlon FL, 2001, DEVELOPMENT, V128, P3749; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Horton AC, 2002, J EXP ZOOL, V294, P112, DOI 10.1002/jez.10151; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; MAO C, UNPUB; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Peng SL, 2002, P NATL ACAD SCI USA, V99, P5545, DOI 10.1073/pnas.082114899; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; REINER SL, UNPUB; Russ AP, 2000, NATURE, V404, P95, DOI 10.1038/35003601; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Yi CH, 1999, GENOMICS, V55, P10, DOI 10.1006/geno.1998.5632; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	21	742	761	3	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1041	1043		10.1126/science.1090148	http://dx.doi.org/10.1126/science.1090148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605368				2022-12-28	WOS:000186396300047
J	Billas, IML; Iwema, T; Garnier, JM; Mitschler, A; Rochel, N; Moras, D				Billas, IML; Iwema, T; Garnier, JM; Mitschler, A; Rochel, N; Moras, D			Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor	NATURE			English	Article							CRYSTAL-STRUCTURE; NUCLEAR RECEPTOR; HETERODIMERIC COMPLEX; DOMAIN; ALPHA; ACTIVATION; REVEALS; INSECT; BETA; ECR	The ecdysteroid hormones coordinate the major stages of insect development, notably moulting and metamorphosis, by binding to the ecdysone receptor (EcR); a ligand-inducible nuclear transcription factor(1,2). To bind either ligand or DNA, EcR must form a heterodimer with ultraspiracle (USP), the homologue of retinoid-X receptor(3-5). Here we report the crystal structures of the ligand-binding domains of the moth Heliothis virescens EcR - USP heterodimer in complex with the ecdysteroid ponasterone A and with a non-steroidal, lepidopteran-specific agonist BYI06830 used in agrochemical pest control. The two structures of EcR - USP emphasize the universality of heterodimerization as a general mechanism common to both vertebrates and invertebrates. Comparison of the EcR structures in complex with steroidal and non-steroidal ligands reveals radically different and only partially overlapping ligand-binding pockets that could not be predicted by molecular modelling and docking studies(6,7). These findings offer new perspectives for the design of insect-specific, environmentally safe insecticides. The concept of a ligand-dependent binding pocket in EcR provides an insight into the moulding of nuclear receptors to their ligand, and has potential applications for human nuclear receptors.	Univ Strasbourg 1, IGBMC, Dept Biol & Genom Struct, CNRS,INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Univ Strasbourg 1, IGBMC, Dept Biol & Genom Struct, CNRS,INSERM, Parc Innovat BP10142, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Rochel, Natacha/A-5718-2016; Billas, Isabelle M.L./I-2790-2016	Rochel, Natacha/0000-0002-3573-5889; Billas, Isabelle M.L./0000-0003-2323-4208				Arbeitman MN, 2000, CELL, V101, P67, DOI 10.1016/S0092-8674(00)80624-8; Baker KD, 2000, INSECT BIOCHEM MOLEC, V30, P1037, DOI 10.1016/S0965-1748(00)00075-8; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Farnegardh M, 2003, J BIOL CHEM, V278, P38821, DOI 10.1074/jbc.M304842200; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gilbert LI, 2002, ANNU REV ENTOMOL, V47, P883, DOI 10.1146/annurev.ento.47.091201.145302; Greiner EF, 1996, P NATL ACAD SCI USA, V93, P10105, DOI 10.1073/pnas.93.19.10105; HENRICH VC, 1995, INSECT BIOCHEM MOLEC, V25, P881, DOI 10.1016/0965-1748(95)00030-Y; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2003, MOL ENDOCRINOL, V17, P716, DOI 10.1210/me.2002-0287; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kasuya A, 2003, J MOL MODEL, V9, P58, DOI 10.1007/s00894-002-0113-x; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Kumar MB, 2002, P NATL ACAD SCI USA, V99, P14710, DOI 10.1073/pnas.222278999; MOHAMMEDALI AK, 1995, CAN J CHEM, V73, P550, DOI 10.1139/v95-071; Potier N, 2003, PROTEIN SCI, V12, P725, DOI 10.1110/ps.0232503; Riddiford LM, 2001, VITAM HORM, V60, P1; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Toya T, 2002, BIOCHEM BIOPH RES CO, V292, P1087, DOI 10.1006/bbrc.2002.6771; Wurtz JM, 2000, PROTEIN SCI, V9, P1073, DOI 10.1110/ps.9.6.1073; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	30	191	200	5	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					91	96		10.1038/nature02112	http://dx.doi.org/10.1038/nature02112			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14595375				2022-12-28	WOS:000186370800048
J	Rose, CR; Blum, R; Pichler, B; Lepier, A; Kafitz, KW; Konnerth, A				Rose, CR; Blum, R; Pichler, B; Lepier, A; Kafitz, KW; Konnerth, A			Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells	NATURE			English	Article							NERVOUS-SYSTEM; TYROSINE KINASE; FULL-LENGTH; RECEPTOR; TRANSDUCTION; PROTEIN; BDNF; ACTIVATION; ASTROCYTES; INHIBITOR	The neurotrophin receptor TrkB is essential for normal function of the mammalian brain(1-3). It is expressed in three splice variants. Full-length receptors (TrkB(FL)) possess an intracellular tyrosine kinase domain and are considered as those TrkB receptors that mediate the crucial effects of brain-derived neurotrophic factor (BDNF) or neurotrophin 4/5 (NT- 4/5). By contrast, truncated receptors (TrkB-T1 and TrkB-T2) lack tyrosine kinase activity and have not been reported to elicit rapid intracellular signalling(4). Here we show that astrocytes predominately express TrkB-T1 and respond to brief application of BDNF by releasing calcium from intracellular stores. The calcium transients are insensitive to the tyrosine kinase blocker K-252a and persist in mutant mice lacking TrkB(FL). By contrast, neurons produce rapid BDNF-evoked signals through TrkB(FL) and the Na(v)1.9 channel(5,6). Expression of antisense TrkB messenger RNA strongly reduces BDNF-evoked calcium signals in glia. Thus, our results show that, unexpectedly, TrkB-T1 has a direct signalling role in mediating inositol-1,4,5-trisphosphate-dependent calcium release; in addition, they identify a previously unknown mechanism of neurotrophin action in the brain.	Univ Munich, Inst Physiol, D-80336 Munich, Germany	University of Munich	Rose, CR (corresponding author), Univ Munich, Inst Physiol, D-80336 Munich, Germany.		Blum, Robert/E-8899-2013	Blum, Robert/0000-0002-5270-3854				BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Baxter GT, 1997, J NEUROSCI, V17, P2683; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Blum R, 2002, NATURE, V419, P687, DOI 10.1038/nature01085; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; Climent E, 2000, NEUROSCI LETT, V288, P53, DOI 10.1016/S0304-3940(00)01207-6; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; Idestrup CP, 1998, NEUROSCIENCE, V86, P913, DOI 10.1016/S0306-4522(98)00128-6; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Kovalchuk Y, 2002, SCIENCE, V295, P1729, DOI 10.1126/science.1067766; Kryl D, 2000, BIOCHEM BIOPH RES CO, V279, P925, DOI 10.1006/bbrc.2000.4058; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Newman E A, 2001, Prog Brain Res, V132, P241; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Rasmussen R, 2001, RAPID CYCLE REAL TIM, P21, DOI [10.1007/978-3-642-59524-0_3, DOI 10.1007/978-3-642-59524-0_3]; ROBACK JD, 1995, EUR J NEUROSCI, V7, P849, DOI 10.1111/j.1460-9568.1995.tb01072.x; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Thoenen H, 2000, PROG BRAIN RES, V128, P183; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99	30	284	291	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					74	78		10.1038/nature01983	http://dx.doi.org/10.1038/nature01983			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603320				2022-12-28	WOS:000186370800044
J	Behr, E; Wood, DA; Wright, M; Syrris, P; Sheppard, MN; Casey, A; Davies, MJ; McKenna, W				Behr, E; Wood, DA; Wright, M; Syrris, P; Sheppard, MN; Casey, A; Davies, MJ; McKenna, W		SADS Steering Grp	Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome	LANCET			English	Article							LONG-QT SYNDROME	4.1% of sudden cardiac deaths in the 16-64 age-group are unexplained. In this group, cardiac pathological findings are normal and toxicological tests are negative; termed sudden arrythmic death syndrome (SADS). We searched for evidence of inherited cardiac disease in cases of SADS. Of 147 first-degree relatives of 32 people who died of SADS, 109 (74%) underwent cardiological assessment. Seven (22%) of the 32 families were diagnosed with inherited cardiac disease: four with long QT syndrome; one with non-structural cardiac electrophysiological disease; one with myotonic dystrophy; and one with hypertrophic cardiomyopathy. Families of people who die of SADS should be offered assessment in centres with experience of inherited cardiac disease.	Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; Univ London Imperial Coll Sci Technol & Med, Imperial Coll Sch Med, Natl Heart & Lung Inst, London, England	St Georges University London; Imperial College London	McKenna, W (corresponding author), Natl Heart Hosp, 16-18 Westmoreland St, London W1G 8PH, England.		SYRRIS, PETROS/C-1703-2008; Sheppard, Mary N/AAB-3364-2019; McKenna, William J/C-3243-2008	SYRRIS, PETROS/0000-0002-2363-8758; Sheppard, Mary N/0000-0003-2724-3881; McKenna, William J/0000-0001-7994-2460; Behr, Elijah/0000-0002-8731-2853				Bowker TJ, 2003, QJM-INT J MED, V96, P269, DOI 10.1093/qjmed/hcg038; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8	5	216	222	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1457	1459		10.1016/S0140-6736(03)14692-2	http://dx.doi.org/10.1016/S0140-6736(03)14692-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602442				2022-12-28	WOS:000186356600014
J	Gilliland, DG				Gilliland, DG			Proteolytic processing in development and leukemogenesis	CELL			English	Editorial Material							MLL; GENE; PROGENITORS; LEUKEMIAS	There are now numerous examples in the hematopoietic system of genes that are critical for normal hematopoietic development, but when mutated, rearranged, or overexpressed, contribute to leukemogenesis. Two papers in this issue of Cell provide a fascinating twist on this paradigm, and suggest that proteolytic processing of certain of these genes plays an important role both in development and in leukemogenesis. These findings also suggest the possibility that proteases may be therapeutic targets in leukemia.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Inst Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Inst Med, 4 Blackfan Circle,Room 418, Boston, MA 02115 USA.							Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632	9	1	5	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 31	2003	115	3					248	250		10.1016/S0092-8674(03)00854-7	http://dx.doi.org/10.1016/S0092-8674(03)00854-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636551	Bronze			2022-12-28	WOS:000186415000003
J	Anderson, RM; Latorre-Esteves, M; Neves, AR; Lavu, S; Medvedik, O; Taylor, C; Howitz, KT; Santos, H; Sinclair, DA				Anderson, RM; Latorre-Esteves, M; Neves, AR; Lavu, S; Medvedik, O; Taylor, C; Howitz, KT; Santos, H; Sinclair, DA			Yeast life-span extension by calorie restriction is independent of NAD fluctuation	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN SIR2; NICOTINAMIDE; REGULATOR; LONGEVITY; STRESS	Calorie restriction (CR) slows aging in numerous species. In the yeast Saccharomyces cerevisiae, this effect requires Sir2, a conserved NAD(+)-dependent deacetylase. We report that CR reduces nuclear NAD(+) levels in vivo. Moreover, the activity of Sir2 and its human homologue SIRT1 are not affected by physiological alterations in the NAD(+): NADH ratio. These data implicate alternate mechanisms of Sir2 regulation by CR.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Biomol Res Labs Inc, Plymouth Meeting, PA 19462 USA	Harvard University; Harvard Medical School; Universidade Nova de Lisboa	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	David_Sinclair@hms.harvard.edu	Latorre-Esteves, Magda/GMW-6353-2022; Santos, Helena/B-9141-2011; Neves, Ana/B-9476-2008	Santos, Helena/0000-0002-8050-9485; Neves, Ana/0000-0003-4896-9585; Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [R37 AG028730, R01 AG019972, R01 AG028730, R01 AG019719, P01 AG027916] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028730, R37AG028730, R01AG019719, R01AG019972, P01AG027916] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; ANDERSON RW, UNPUB; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2003, CURR OPIN CELL BIOL, V15, P241, DOI 10.1016/S0955-0674(03)00006-1; Neves AR, 2002, J BIOL CHEM, V277, P28088, DOI 10.1074/jbc.M202573200; Pahlman AK, 2001, J BIOL CHEM, V276, P3555, DOI 10.1074/jbc.M007164200; PAINE PL, 1975, J CELL BIOL, V66, P652, DOI 10.1083/jcb.66.3.652; Penfound T, 1999, J BACTERIOL, V181, P648, DOI 10.1128/JB.181.2.648-655.1999; Sandmeier JJ, 2002, GENETICS, V160, P877; Shama S, 1998, EXP CELL RES, V245, P379, DOI 10.1006/excr.1998.4279; Sies H, 1982, METABOLIC COMPARTMEN; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Swiecilo A, 2000, ACTA BIOCHIM POL, V47, P355; UNKEFER CJ, 1984, J BIOL CHEM, V259, P2311; Wei YM, 2001, BIOCHEMISTRY-US, V40, P11279, DOI 10.1021/bi011085z; Zhang QH, 2002, SCIENCE, V295, P1895	23	125	133	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	2003	302	5653					2124	2126		10.1126/science.1088697	http://dx.doi.org/10.1126/science.1088697			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	755CB	14605207	Green Accepted			2022-12-28	WOS:000187385200045
J	Mogilner, A; Oster, G				Mogilner, A; Oster, G			Shrinking gels pull cells	SCIENCE			English	Editorial Material							NEMATODE SPERM; MOTILITY; RECONSTITUTION; LOCOMOTION; PROTEINS; BODY		Univ Calif Davis, Dept Math, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Mogilner, A (corresponding author), Univ Calif Davis, Dept Math, Davis, CA 95616 USA.		Mogilner, Alex/A-3135-2008					Bottino D, 2002, J CELL SCI, V115, P367; Bray D, 2001, CELL MOVEMENTS MOL M; Italiano JE, 1996, CELL, V84, P105, DOI 10.1016/S0092-8674(00)80997-6; Italiano JE, 1999, J CELL BIOL, V146, P1087, DOI 10.1083/jcb.146.5.1087; Knoblauch M, 2003, NAT MATER, V2, P600, DOI 10.1038/nmat960; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Miao L, 2003, SCIENCE, V302, P1405, DOI 10.1126/science.1089129; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mogilner A, 2003, CURR BIOL, V13, pR721, DOI 10.1016/j.cub.2003.08.050; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Theriot JA, 1996, CELL, V84, P1, DOI 10.1016/S0092-8674(00)80068-9; WOLGEMUTH C, IN PRESS EUR BIOPHYS	13	30	31	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1340	1341		10.1126/science.1092041	http://dx.doi.org/10.1126/science.1092041			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631023				2022-12-28	WOS:000186683500033
J	Imaizumi, T; Tran, HG; Swartz, TE; Briggs, WR; Kay, SA				Imaizumi, T; Tran, HG; Swartz, TE; Briggs, WR; Kay, SA			FKF1 is essential for photoperiodic-specific light signalling in Arabidopsis	NATURE			English	Article							CIRCADIAN CLOCK; PHOTORECEPTOR PHOTOTROPIN; PROTEIN; PLANTS; NPH1; PURIFICATION; TRANSDUCTION; RECEPTORS; MEDIATE; DOMAINS	Adaptation to seasonal change is a crucial component of an organism's survival strategy. To monitor seasonal variation, organisms have developed the capacity to measure day length ( photoperiodism). Day-length assessment involves the photoperiodic control of flowering in Arabidopsis thaliana, whereby the coincidence of light and high expression of CONSTANS ( CO) induces the expression of FLOWERING LOCUS T (FT), leading to flowering in long-day conditions(1). Although controlling CO expression is clearly a key step in day-length discrimination, the mechanism that generates day-length-dependent CO expression remains unknown. Here we show that the clock-controlled FLAVIN-BINDING, KELCH REPEAT, F-BOX (FKF1)(2) protein has an essential role in generating the diurnal CO peak and that this function is dependent on light. We show that a recombinant FKF1 LIGHT, OXYGEN OR VOLTAGE ( LOV)(3) domain binds the chromophore flavin mononucleotide and undergoes light-induced photochemistry, indicating that FKF1 may function as a photoperiodic blue-light receptor. It is likely that the circadian control of FKF1 expression and the light regulation of FKF1 function coincide to control the daytime CO waveform precisely, which in turn is crucial for day-length discrimination by Arabidopsis.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	Scripps Research Institute; Carnegie Institution for Science	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878				Alabadi D, 2002, CURR BIOL, V12, P757, DOI 10.1016/S0960-9822(02)00815-1; Alabadi D, 2001, SCIENCE, V293, P880, DOI 10.1126/science.1061320; Blazquez MA, 1999, PLANT PHYSIOL, V120, P1025, DOI 10.1104/pp.120.4.1025; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Kinoshita T, 2001, NATURE, V414, P656, DOI 10.1038/414656a; Lin CT, 2002, PLANT CELL, V14, pS207, DOI 10.1105/tpc.000646; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Mizoguchi T, 2002, DEV CELL, V2, P629, DOI 10.1016/S1534-5807(02)00170-3; Nelson DC, 2000, CELL, V101, P331, DOI 10.1016/S0092-8674(00)80842-9; Onouchi H, 2000, PLANT CELL, V12, P885, DOI 10.1105/tpc.12.6.885; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Schultz TF, 2001, PLANT CELL, V13, P2659, DOI 10.1105/tpc.13.12.2659; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; Somers DE, 2000, CELL, V101, P319, DOI 10.1016/S0092-8674(00)80841-7; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996; Yanovsky MJ, 2001, J BIOL RHYTHM, V16, P523, DOI 10.1177/074873001129002213	28	414	461	4	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					302	306		10.1038/nature02090	http://dx.doi.org/10.1038/nature02090			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628054				2022-12-28	WOS:000186660800047
J	Hurst, RT; Lee, RW				Hurst, RT; Lee, RW			Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: Mechanisms and management	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR INHIBITOR; GLYCOPROTEIN IIB/IIIA BLOCKADE; LOW-DENSITY-LIPOPROTEIN; ARTERY-BYPASS-SURGERY; CARDIOVASCULAR-DISEASE; HEART-DISEASE; ENDOTHELIAL FUNCTION; POSTPRANDIAL LIPEMIA; SECONDARY PREVENTION	Type 2 diabetes mellitus is a metabolic disease of carbohydrate metabolism. However, it should also be considered a vascular disease because diabetic patients have a strong predilection for atherosclerosis. With the increasing prevalence and earlier age at onset of diabetes, the projected effect of diabetes on cardiovascular health and resource utilization is sobering. The mechanisms of the high rate of atherosclerosis are multifactorial and give clinicians and researchers insights into potential preventive therapies. Effective pharmacologic and lifestyle interventions are available for primary and secondary prevention of cardiovascular complications. However, data show that these interventions continue to be underutilized. Treatment of patients with type 2 diabetes and coronary artery disease is similar to that of patients with coronary artery disease alone. However, patients with diabetes benefit more from treatments that reduce coronary artery disease risk.	Mayo Clin, Div Cardiovasc Dis, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Lee, RW (corresponding author), Mayo Clin, Div Cardiovasc Dis, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Ahmed JM, 2000, J AM COLL CARDIOL, V36, P1186, DOI 10.1016/S0735-1097(00)00861-5; Alderman EL, 1996, NEW ENGL J MED, V335, P217; Anderson TJ, 1996, CIRCULATION, V93, P1647, DOI 10.1161/01.CIR.93.9.1647; [Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 2000, LANCET, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Aronson D, 1996, J AM COLL CARDIOL, V27, P528, DOI 10.1016/0735-1097(95)00496-3; Athyros VG, 2002, DIABETES CARE, V25, P1198, DOI 10.2337/diacare.25.7.1198; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Ballantyne CM, 2001, CIRCULATION, V104, P3046, DOI 10.1161/hc5001.100624; BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107; BERNARDI L, 1992, CIRCULATION, V86, P1443, DOI 10.1161/01.CIR.86.5.1443; Bhatt DL, 2000, J AM COLL CARDIOL, V35, P922, DOI 10.1016/S0735-1097(99)00650-6; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; Carson JL, 2002, J AM COLL CARDIOL, V40, P418, DOI 10.1016/S0735-1097(02)01969-1; Cheetham C, 2000, J AM COLL CARDIOL, V36, P1461, DOI 10.1016/S0735-1097(00)00933-5; Chen J, 1999, J AM COLL CARDIOL, V34, P1388, DOI 10.1016/S0735-1097(99)00383-6; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Chu NV, 2002, DIABETES CARE, V25, P542, DOI 10.2337/diacare.25.3.542; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2003, LANCET, V361, P2005; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Detre KM, 1999, CIRCULATION, V99, P633, DOI 10.1161/01.CIR.99.5.633; Detre KM, 2000, NEW ENGL J MED, V342, P989, DOI 10.1056/NEJM200004063421401; Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7; Ellis SG, 1997, CIRCULATION, V96, P1707, DOI 10.1161/01.CIR.96.6.1707; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Freeman DJ, 2001, CIRCULATION, V103, P357; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GRANGER CB, 1993, J AM COLL CARDIOL, V21, P920, DOI 10.1016/0735-1097(93)90348-5; Grover SA, 2001, DIABETES CARE, V24, P45, DOI 10.2337/diacare.24.1.45; Gruberg L, 2002, J AM COLL CARDIOL, V39, P1930, DOI 10.1016/S0735-1097(02)01891-0; Grundy SM, 2002, CIRCULATION, V105, P2696, DOI 10.1161/01.CIR.0000020650.86137.84; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Guzik TJ, 2002, CIRCULATION, V105, P1656, DOI 10.1161/01.CIR.0000012748.58444.08; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hasdai D, 2000, J AM COLL CARDIOL, V35, P1502, DOI 10.1016/S0735-1097(00)00591-X; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Heupler FA, 1998, CATHETER CARDIO DIAG, V43, P121, DOI 10.1002/(SICI)1097-0304(199802)43:2<121::AID-CCD1>3.0.CO;2-C; HILLEBRAND I, 1979, RES EXP MED, V175, P81, DOI 10.1007/BF01851236; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; JEPPESEN J, 1994, DIABETES CARE, V17, P1093, DOI 10.2337/diacare.17.10.1093; JEPPESEN J, 1994, DIABETOLOGIA, V37, P781, DOI 10.1007/s001250050179; Jeppesen J, 1997, ARTERIOSCL THROM VAS, V17, P1114, DOI 10.1161/01.ATV.17.6.1114; Jonas M, 1996, AM J CARDIOL, V77, P1273, DOI 10.1016/S0002-9149(96)00191-9; Jones RH, 1996, J THORAC CARDIOV SUR, V111, P1013, DOI 10.1016/S0022-5223(96)70378-1; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; King SB, 2000, J AM COLL CARDIOL, V35, P1116, DOI 10.1016/S0735-1097(00)00546-5; Kip KE, 1996, CIRCULATION, V94, P1818, DOI 10.1161/01.CIR.94.8.1818; Kleiman NS, 1998, CIRCULATION, V97, P1912, DOI 10.1161/01.CIR.97.19.1912; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kornowski R, 1997, CIRCULATION, V95, P1366; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Leibowitz G, 1996, DIABETOLOGIA, V39, P503, DOI 10.1007/BF00403296; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; LEON MB, 2002, AM J CARDIOL S6A, V90; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Mahaffey KW, 1997, J AM COLL CARDIOL, V30, P1606, DOI 10.1016/S0735-1097(97)00394-X; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 2000, CIRCULATION, V102, P1014, DOI 10.1161/01.CIR.102.9.1014; Marso SP, 1999, CIRCULATION, V100, P2477, DOI 10.1161/01.CIR.100.25.2477; Marso SP, 1999, J AM COLL CARDIOL, V33, P1269, DOI 10.1016/S0735-1097(99)00035-2; Mehilli J, 2002, AM J MED, V112, P13, DOI 10.1016/S0002-9343(01)01010-5; Merz CNB, 2002, J AM COLL CARDIOL, V40, P1877, DOI 10.1016/S0735-1097(02)02529-9; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Niles NW, 2001, J AM COLL CARDIOL, V37, P1008, DOI 10.1016/S0735-1097(00)01205-5; O'Driscoll G, 1999, J AM COLL CARDIOL, V33, P1506, DOI 10.1016/S0735-1097(99)00065-0; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Osende JI, 2001, J AM COLL CARDIOL, V38, P1307, DOI 10.1016/S0735-1097(01)01555-8; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Ray NF, 1998, DIABETES CARE, V21, P296; Roffi M, 2001, CIRCULATION, V104, P2767, DOI 10.1161/hc4801.100029; Rosenbloom Arlan L, 2002, Paediatr Drugs, V4, P209, DOI 10.2165/00128072-200204040-00001; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Schneider DJ, 2001, CONTEMP CARDIOL, P149; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; SELBY JV, 1993, CIRCULATION, V88, P381, DOI 10.1161/01.CIR.88.2.381; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Shechter M, 2000, J AM COLL CARDIOL, V35, P300, DOI 10.1016/S0735-1097(99)00545-8; Sobel BE, 1998, CIRCULATION, V97, P2213, DOI 10.1161/01.CIR.97.22.2213; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; Steinberg HO, 2000, CIRCULATION, V101, P2040, DOI 10.1161/01.CIR.101.17.2040; Stevens MJ, 1998, CIRCULATION, V98, P961, DOI 10.1161/01.CIR.98.10.961; Teirstein PS, 2001, CIRCULATION, V104, P2620, DOI 10.1161/hc4601.099465; Thogersen AM, 1998, CIRCULATION, V98, P2241, DOI 10.1161/01.CIR.98.21.2241; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; TURNER RC, 1993, J HYPERTENS, V11, P309; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; VanBelle E, 1997, CIRCULATION, V96, P1454, DOI 10.1161/01.CIR.96.5.1454; Verin V, 2001, NEW ENGL J MED, V344, P243, DOI 10.1056/NEJM200101253440401; Vink H, 2000, CIRCULATION, V101, P1500, DOI 10.1161/01.CIR.101.13.1500; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695; Wilson JD, 1998, WILLIAMS TXB ENDOCRI; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882; 1995, BYPASS ANGIOPLASTY P; 1997, ARCH INTERN MED, V157, P2413	115	92	104	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					824	834		10.7326/0003-4819-139-10-200311180-00010	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744ZV	14623620				2022-12-28	WOS:000186663500006
J	Nabarro, D; Loretti, A; Colombo, A				Nabarro, D; Loretti, A; Colombo, A			Increased equity in postconflict reconstruction	LANCET			English	Editorial Material									WHO, Director Gen Hlth Act Crises, CH-1211 Geneva 27, Switzerland; WHO, Dept Hlth Act Crises, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization	Nabarro, D (corresponding author), WHO, Director Gen Hlth Act Crises, CH-1211 Geneva 27, Switzerland.							COLOMBO A, 2003, HLTH EMERGENCIES, V17, P1; *UN, 2000, DEV IN GLOB HUM ASS; United Nations World Bank, 2003, JOINT IR NEEDS ASS; 2003, INT M GOOD HUM DON P	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1673	1673		10.1016/S0140-6736(03)14805-2	http://dx.doi.org/10.1016/S0140-6736(03)14805-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14631975				2022-12-28	WOS:000186637400030
J	Thuluvath, PJ				Thuluvath, PJ			The village woman who winked, and taught me the basics of medicine	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Thuluvath, PJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1658	1658		10.1016/S0140-6736(03)14801-5	http://dx.doi.org/10.1016/S0140-6736(03)14801-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630449				2022-12-28	WOS:000186637400026
J	Dunbar, R				Dunbar, R			Evolution of the social brain	SCIENCE			English	Editorial Material									Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	Dunbar, R (corresponding author), Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England.							BARRETT L, IN PRESS TRENDS COGN; Bergman TJ, 2003, SCIENCE, V302, P1234, DOI 10.1126/science.1087513; DUNBAR IM, 1983, REPROD DECISION EC A; Dunbar RIM, 1998, EVOL ANTHROPOL, V6, P178, DOI 10.1002/(SICI)1520-6505(1998)6:5<178::AID-EVAN5>3.0.CO;2-8; DUNBAR RIM, 1984, REPROD DECISIONS; KEVERNE EB, 1989, PSYCHONEUROENDOCRINO, V14, P155, DOI 10.1016/0306-4530(89)90065-6; Kudo H, 2001, ANIM BEHAV, V62, P711, DOI 10.1006/anbe.2001.1808; MAESTRIPIERI D, 1993, AM NAT, V141, P744, DOI 10.1086/285503; Silk JB, 2003, SCIENCE, V302, P1231, DOI 10.1126/science.1088580; SPELKE ES, 1985, MEASUREMENT AUDITION, P65; Tomasello M, 1997, PRIMATE COGNITION	11	57	59	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1160	1161		10.1126/science.1092116	http://dx.doi.org/10.1126/science.1092116			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615522				2022-12-28	WOS:000186544300036
J	Silk, JB; Alberts, SC; Altmann, J				Silk, JB; Alberts, SC; Altmann, J			Social bonds of female baboons enhance infant survival	SCIENCE			English	Article							NONHUMAN-PRIMATES; ENVIRONMENT; EVOLUTION; MONKEYS; STRESS	Among nonhuman primates, females often form strong bonds with kin and other group members. These relationships are thought to have adaptive value for females, but direct effects of sociality on fitness have never been demonstrated. We present 16 years of behavioral data from a well-studied population of wild baboons, which demonstrate that sociality of adult females is positively associated with infant survival, an important component of variation in female lifetime fitness. The effects of sociality on infant survival are independent of the effects of dominance rank, group membership, and environmental conditions. Our results are consistent with the evidence that social support has beneficial effects on human health and well-being across the life span. For humans and other primates, sociality has adaptive value.	Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA; Duke Univ, Dept Biol, Durham, NC 27708 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Natl Museums Kenya, Inst Primate Res, Nairobi, Kenya; Brookfield Zoo, Dept Conservat Biol, Brookfield, IL 60513 USA	University of California System; University of California Los Angeles; Duke University; Princeton University	Silk, JB (corresponding author), Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA.							ALBERTS SC, IN PRESS PRIMATE SEA; Altmann J, 2003, OFFSPRING, P140; AURELLI F, 2000, NATURAL CONFLICT RES, P193; Berntson, 2000, HDB PSYCHOPHYSIOLOGY, P643; Bronikowski AM, 1996, BEHAV ECOL SOCIOBIOL, V39, P11, DOI 10.1007/s002650050262; Buchan JC, 2003, NATURE, V425, P179, DOI 10.1038/nature01866; Cacioppo JT, 2000, INT J PSYCHOPHYSIOL, V35, P143, DOI 10.1016/S0167-8760(99)00049-5; CHENEY D, 1986, SCIENCE, V234, P1361, DOI 10.1126/science.3538419; Clutton-Brock T.H., 1988, REPROD SUCCESS STUDI; COHEN S, 1992, PSYCHOL SCI, V3, P301, DOI 10.1111/j.1467-9280.1992.tb00677.x; COLLINS NL, 1993, J PERS SOC PSYCHOL, V65, P1243, DOI 10.1037/0022-3514.65.6.1243; Cords M., 1997, MACHIAVELLIAN INTELL, P24; DUNBAR RIM, 1991, FOLIA PRIMATOL, V57, P121, DOI 10.1159/000156574; Henzi SP, 1999, PRIMATES, V40, P47, DOI 10.1007/BF02557701; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; LEFEVRE JA, 1992, PHYSIOL BEHAV, V52, P603, DOI 10.1016/0031-9384(92)90354-5; Melnick D.J., 1987, P121; Palombit RA, 1999, EVOL ANTHROPOL, V7, P117, DOI 10.1002/(SICI)1520-6505(1999)7:4<117::AID-EVAN2>3.0.CO;2-O; SALTZMAN W, 1991, PHYSIOL BEHAV, V50, P271, DOI 10.1016/0031-9384(91)90066-W; Sapolsky RM, 1997, ARCH GEN PSYCHIAT, V54, P1137; Seeman TE, 2002, PSYCHOSOM MED, V64, P395, DOI 10.1097/00006842-200205000-00004; Seeman TE, 1996, PSYCHOSOM MED, V58, P459, DOI 10.1097/00006842-199609000-00008; SHIVELY CA, 1989, ATHEROSCLEROSIS, V77, P69, DOI 10.1016/0021-9150(89)90011-7; Silk JB, 1999, BEHAVIOUR, V136, P679, DOI 10.1163/156853999501522; SILK JB, IN PRESS ANIM BEHAV; Smuts B.B., 1985, SEX FRIENDSHIP BABOO; *STATA, 2003, STATA 8 0; Sterck EHM, 1997, BEHAV ECOL SOCIOBIOL, V41, P291, DOI 10.1007/s002650050390; Taylor SE, 2000, PSYCHOL REV, V107, P411, DOI 10.1037/0033-295X.107.3.411; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934	30	692	703	3	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1231	1234		10.1126/science.1088580	http://dx.doi.org/10.1126/science.1088580			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	742XW	14615543				2022-12-28	WOS:000186544300060
J	Chintu, C; Mwaba, P				Chintu, C; Mwaba, P			Is there a role for chest radiography in identification of asymptornatic tuberculosis in HIV-infected people?	LANCET			English	Editorial Material									Univ Zambia, Sch Med, UNZA UCMLS Project, Lusaka, Zambia	University of Zambia	Chintu, C (corresponding author), Univ Zambia, Sch Med, UNZA UCMLS Project, Lusaka, Zambia.		Mwaba, Peter/V-6017-2019					DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; Mangura BT, 1999, LANCET, V353, P319, DOI 10.1016/S0140-6736(98)10144-7; Mwaba P, 2003, SAMJ S AFR MED J, V93, P149; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625	6	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1516	1516		10.1016/S0140-6736(03)14779-4	http://dx.doi.org/10.1016/S0140-6736(03)14779-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615105				2022-12-28	WOS:000186464500006
J	Guyatt, H; Ochola, S				Guyatt, H; Ochola, S			Use of bednets given free to pregnant women in Kenya	LANCET			English	Article								In 2001, UNICEF procured 70 000 bednets and insecticide treatments to be distributed free to pregnant women attending antenatal clinics in 35 (of 69) districts in Kenya. I year later, we interviewed 294 pregnant women who had received a free net. 267 (91%) nets had remained in the target homesteads, and only one of the nets had been sold. In a district with high malarial transmission, 93 (84%) of M women who had not previously been sleeping under a bednet had used the net while pregnant, and 97 (91%) of the 107 surviving babies were also protected; in another district, which had low transmission, 73 (58%) of 126 women used the nets during pregnancy and 91 (80%) of 114 infants were protected by the nets. These data suggest that bednets given free to pregnant women are used by recipients and their newborn children, and should be regarded as an important delivery system in increasing access to and use of insecticide-treated bednets in vulnerable groups.	Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England; Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Nairobi, Kenya; Minist Hlth, Div Malaria Control, Nairobi, Kenya	University of Oxford; Kenya Medical Research Institute	Guyatt, H (corresponding author), Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England.							Guyatt HL, 2002, TROP MED INT HEALTH, V7, P409, DOI 10.1046/j.1365-3156.2002.00879.x; *WHO, 2002, SCAL UP INS TREAT NE	2	23	23	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 8	2003	362	9395					1549	1550		10.1016/S0140-6736(03)14744-7	http://dx.doi.org/10.1016/S0140-6736(03)14744-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	741NQ	14615112				2022-12-28	WOS:000186464500013
J	Leung, GM; Johnston, JM; Tin, KYK; Wong, IOL; Ho, LM; Lam, WWT; Lam, TH				Leung, GM; Johnston, JM; Tin, KYK; Wong, IOL; Ho, LM; Lam, WWT; Lam, TH			Randomised controlled trial of clinical decision support tools to improve learning of evidence based medicine in medical students	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the educational effectiveness on learning evidence based medicine of a handheld computer clinical decision support tool compared with a pocket card containing guidelines and a control. Design Randomised controlled trial. Setting University of Hong Kong, 2001. Participants 169 fourth year medical students. Main outcome measures Factor and individual item scores from a validated questionnaire on five key self reported measures: personal application and current use of evidence based medicine; future use of evidence based medicine; use of evidence during and after clerking patients; frequency of discussing the role of evidence during teaching rounds; and self perceived confidence in clinical decision making. Results The handheld computer improved participants' educational experience with evidence based medicine the most with significant improvements in all outcome scores. More modest improvements were found with the pocket card, whereas the control group showed no appreciable changes in any of the key outcomes. No significant deterioration was observed in the improvements even after withdrawal of the handheld computer during an eight week washout period, suggesting at least short term sustainability of effects. Conclusions Rapid and convenient access to valid and relevant evidence on a portable computing device can improve learning in evidence based medicine, increase current and future use of evidence, and boost students' confidence in clinical decision making.	Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Johnston, JM (corresponding author), Univ Hong Kong, Dept Community Med, Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	jjohnsto@hku.hk	Greiver, Michelle/N-8764-2015; Lam, Wendy/C-4319-2009; Leung, Gabriel Matthew/C-4336-2009; Tin, Yiu Kei/C-4417-2009; Johnston, Janice Mary/C-4288-2009; Lam, Tai Hing/C-4317-2009	Greiver, Michelle/0000-0001-8957-0285; Lam, Wendy/0000-0003-2383-0149; Johnston, Janice Mary/0000-0002-6624-867X; Lam, Tai Hing/0000-0002-2033-9971; Leung, Gabriel/0000-0002-2503-6283; ho, lm/0000-0002-2709-927X				BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Ebell M, 2000, J FAM PRACTICE, V49, P243; Ghali WA, 2000, MED EDUC, V34, P18, DOI 10.1046/j.1365-2923.2000.00402.x; Green ML, 2000, J EVAL CLIN PRACT, V6, P121, DOI 10.1046/j.1365-2753.2000.00239.x; Hatala R, 2002, JAMA-J AM MED ASSOC, V288, P1110, DOI 10.1001/jama.288.9.1110; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; Hutchinson L, 1999, BRIT MED J, V318, P1267; *INF MAST WORK GRO, 2001, COURS MAT INF MAST W; JOHNSTON JM, IN PRESS MED ED; Lai TYY, 2003, BRIT J OPHTHALMOL, V87, P385, DOI 10.1136/bjo.87.4.385; LANGDORF MI, 1995, ACAD EMERG MED, V2, P157, DOI 10.1111/j.1553-2712.1995.tb03185.x; Langebartels C, 2001, TREE PHYSIOL SER, V2, P157; Leung G M, 2001, Asia Pac J Public Health, V13, P116, DOI 10.1177/101053950101300210; MARSHALL JG, 1992, B MED LIBR ASSOC, V80, P169; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123	18	92	94	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2003	327	7423					1090	1093		10.1136/bmj.327.7423.1090	http://dx.doi.org/10.1136/bmj.327.7423.1090			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742QW	14604933	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000186530400022
J	Horber, JKH; Miles, MJ				Horber, JKH; Miles, MJ			Scanning probe evolution in biology	SCIENCE			English	Review							ATOMIC-FORCE MICROSCOPY; CANTILEVERS; MEMBRANE	Twenty years ago the first scanning probe instrument, the scanning tunneling microscope, opened up new realms for our perception of the world. Atoms that had been abstract entities were now real objects, clearly seen as distinguishable individuals at particular positions in space. A whole family of scanning probe instruments has been developed, extending our sense of touching to the scale of atoms and molecules. Such instruments are especially useful for imaging of biomolecular structures because they can produce topographic images with submolecular resolution in aqueous environments. Instruments with increased imaging rates, lower probe-specimen force interactions, and probe configurations not constrained to planar surfaces are being developed, with the goal of imaging processes at the single-molecule level-not only at surfaces but also within three-dimensional volumes-in real time.	Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	University of Bristol; Wayne State University	Miles, MJ (corresponding author), Univ Bristol, HH Wills Phys Lab, Tyndall Ave, Bristol BS8 1TL, Avon, England.	m.j.miles@bristol.ac.uk						Ando T, 2001, P NATL ACAD SCI USA, V98, P12468, DOI 10.1073/pnas.211400898; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Baker AA, 2000, BIOPHYS J, V79, P1139, DOI 10.1016/S0006-3495(00)76367-3; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; GIESSIBL FJ, 1995, SCIENCE, V267, P68, DOI 10.1126/science.267.5194.68; HABERLE W, 1992, ULTRAMICROSCOPY, V42, P1161, DOI 10.1016/0304-3991(92)90418-J; Hobbs JK, 2001, MACROMOLECULES, V34, P5508, DOI 10.1021/ma0104478; Humphris ADL, 2003, APPL PHYS LETT, V83, P6, DOI 10.1063/1.1590737; Jeney S, 2001, METH MOL B, V164, P91; Jeremic A, 2003, BIOPHYS J, V85, P2035, DOI 10.1016/S0006-3495(03)74631-1; Lugstein A, 2002, APPL PHYS LETT, V81, P349, DOI 10.1063/1.1492304; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Scheuring S, 2002, EUR BIOPHYS J BIOPHY, V31, P172, DOI 10.1007/s00249-001-0197-8; Sulchek T, 2000, APPL PHYS LETT, V76, P1473, DOI 10.1063/1.126071; Tamayo J, 2000, APPL PHYS LETT, V77, P582, DOI 10.1063/1.127051; Tamayo J, 2001, BIOPHYS J, V81, P526, DOI 10.1016/S0006-3495(01)75719-0; Tischer C, 2001, APPL PHYS LETT, V79, P3878, DOI 10.1063/1.1423404; Walters DA, 1996, REV SCI INSTRUM, V67, P3583, DOI 10.1063/1.1147177	18	287	307	1	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1002	1005		10.1126/science.1067410	http://dx.doi.org/10.1126/science.1067410			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605360				2022-12-28	WOS:000186396300035
J	Navarro-Gonzalez, R; Rainey, FA; Molina, P; Bagaley, DR; Hollen, BJ; de la Rosa, J'; Small, AM; Quinn, RC; Grunthaner, FJ; Caceres, L; Gomez-Silva, B; McKay, CP				Navarro-Gonzalez, R; Rainey, FA; Molina, P; Bagaley, DR; Hollen, BJ; de la Rosa, J'; Small, AM; Quinn, RC; Grunthaner, FJ; Caceres, L; Gomez-Silva, B; McKay, CP			Mars-like soils in the Atacama Desert, Chile, and the dry limit of microbial life	SCIENCE			English	Article								The Viking missions showed the martian soil to be lifeless and depleted in organic material and indicated the presence of one or more reactive oxidants. Here we report the presence of Mars-like soils in the extreme arid region of the Atacama Desert. Samples from this region had organic species only at trace levels and extremely low levels of culturable bacteria. Two samples from the extreme arid region were tested for DNA and none was recovered. Incubation experiments, patterned after the Viking labeled-release experiment but with separate biological and nonbiological isomers, show active decomposition of organic species in these soils by nonbiological processes.	Univ Nacl Autonoma Mexico, Inst Ciencias Nucl, Lab Quim Plasmas & Estudios Planetarios, Mexico City 04510, DF, Mexico; Univ Paris 12, Lab Interuniv Syst Atmospher, CNRS, UMR 7583, F-94010 Creteil, France; Univ Paris 07, Lab Interuniv Syst Atmospher, CNRS, UMR 7583, F-94010 Creteil, France; Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; NASA, Div Space Sci, Ames Res Ctr, Moffett Field, CA 94035 USA; NASA, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Antofagasta, Fac Ingn, Inst Desierto, Antofagasta, Chile; Univ Antofagasta, Fac Ingn, Dept Ingn Quim, Antofagasta, Chile; Univ Antofagasta, Fac Ciencias Salud, Inst Desierto, Antofagasta, Chile; Univ Antofagasta, Fac Ciencias Salud, Dept Biomed, Unidad Bioquim, Antofagasta, Chile	Universidad Nacional Autonoma de Mexico; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Louisiana State University System; Louisiana State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Universidad de Antofagasta; Universidad de Antofagasta; Universidad de Antofagasta; Universidad de Antofagasta	Navarro-Gonzalez, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Ciencias Nucl, Lab Quim Plasmas & Estudios Planetarios, Circuito Exterior,Ciudad Univ,Apartado Postal 70-, Mexico City 04510, DF, Mexico.		Navarro-González, Rafael/D-1748-2009; GOMEZ-SILVA, BENITO/J-8324-2017; Rainey, Fred A/C-8767-2013; De la Rosa, José/A-3573-2010; Rainey, Fred/AAG-7996-2019; Gómez-Silva, Benito/AAT-8215-2020	Navarro-González, Rafael/0000-0002-6078-7621; Rainey, Fred A/0000-0001-9129-6844; Gómez-Silva, Benito/0000-0002-7611-9943; Grunthaner, Frank/0000-0003-2397-6658; Caceres, Luis/0000-0001-7359-2148				ARROYO MTK, 1988, ANN MO BOT GARD, V75, P55, DOI 10.2307/2399466; Benner SA, 2000, P NATL ACAD SCI USA, V97, P2425, DOI 10.1073/pnas.040539497; Biemann K., 1977, Journal of Geophysical Research, V82, P4641, DOI 10.1029/JS082i028p04641; Levin G. V., 1977, Journal of Geophysical Research, V82, P4663, DOI 10.1029/JS082i028p04663; McKay CP, 1998, PLANET SPACE SCI, V46, P769, DOI 10.1016/S0032-0633(98)00011-7; MCKAY CP, 2003, ASTROBIOLOGY, V3, P293; Miller A, 1976, WORLD SURVEY CLIMATO, V12, P113; Oyama V. I., 1977, Journal of Geophysical Research, V82, P4669, DOI 10.1029/JS082i028p04669; PLUMB RC, 1989, NATURE, V338, P633, DOI 10.1038/338633a0	9	396	407	8	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1018	1021		10.1126/science.1089143	http://dx.doi.org/10.1126/science.1089143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605363				2022-12-28	WOS:000186396300039
J	Busino, L; Donzelli, M; Chiesa, M; Guardavaccaro, D; Ganoth, D; Dorrello, NV; Hershko, A; Pagano, M; Draetta, GF				Busino, L; Donzelli, M; Chiesa, M; Guardavaccaro, D; Ganoth, D; Dorrello, NV; Hershko, A; Pagano, M; Draetta, GF			Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage	NATURE			English	Article							KAPPA-B-ALPHA; UBIQUITIN LIGASE; PHOSPHORYLATION; DESTRUCTION; CHECKPOINT; PROTEOLYSIS; COMPLEX; IDENTIFICATION; PROGRESSION; CATENIN	The Cdc25A phosphatase is essential for cell-cycle progression because of its function in dephosphorylating cyclin-dependent kinases. In response to DNA damage or stalled replication, the ATM and ATR protein kinases activate the checkpoint kinases Chk1 and Chk2, which leads to hyperphosphorylation of Cdc25A(1-3). These events stimulate the ubiquitin-mediated proteolysis of Cdc25A(1,4,5) and contribute to delaying cell-cycle progression, thereby preventing genomic instability(1-7). Here we report that beta-TrCP is the F-box protein that targets phosphorylated Cdc25A for degradation by the Skp1/Cul1/F-box protein complex. Downregulation of beta-TrCP1 and beta-TrCP2 expression by short interfering RNAs causes an accumulation of Cdc25A in cells progressing through S phase and prevents the degradation of Cdc25A induced by ionizing radiation, indicating that beta-TrCP may function in the intra-S-phase checkpoint. Consistent with this hypothesis, suppression of beta-TrCP expression results in radioresistant DNA synthesis in response to DNA damage - a phenotype indicative of a defect in the intra-S-phase checkpoint that is associated with an inability to regulate Cdc25A properly. Our results show that beta-TrCP has a crucial role in mediating the response to DNA damage through Cdc25A degradation.	European Inst Oncol, I-20141 Milan, Italy; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Inst Canc, New York, NY 10016 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel	IRCCS European Institute of Oncology (IEO); New York University; New York University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Donzelli, M (corresponding author), European Inst Oncol, 435 Via Ripamonti, I-20141 Milan, Italy.	mdonzell@ieo.it	Donzelli, Maddalena/ABD-3774-2020	pagano, michele/0000-0003-3210-2442; Guardavaccaro, Daniele/0000-0002-4517-1765; DONZELLI, MADDALENA/0000-0002-4045-0802	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Clucas C, 2002, EMBO J, V21, P665, DOI 10.1093/emboj/21.4.665; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	28	351	370	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					87	91		10.1038/nature02082	http://dx.doi.org/10.1038/nature02082			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603323				2022-12-28	WOS:000186370800047
J	DiMarco, JP				DiMarco, JP			Implantable cardioverter-defibrillators	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR DYSFUNCTION; SUDDEN CARDIAC DEATH; QUALITY-OF-LIFE; COST-EFFECTIVENESS; HIGH-RISK; PRIMARY PREVENTION; ANTIARRHYTHMIC-DRUG; ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; PROPHYLACTIC USE		Univ Virginia Hlth Syst, Dept Med, Div Cardiovasc, Electrophysiol Lab, Charlottesville, VA 22908 USA	University of Virginia	DiMarco, JP (corresponding author), Univ Virginia Hlth Syst, Dept Med, Div Cardiovasc, Electrophysiol Lab, POB 800158, Charlottesville, VA 22908 USA.	jdimarco@virginia.edu						Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Akiyama T, 2001, NEW ENGL J MED, V345, P391, DOI 10.1056/NEJM200108093450601; Bansch D, 2002, CIRCULATION, V105, P1453, DOI 10.1161/01.CIR.0000012350.99718.AD; Bigger JT, 1999, CIRCULATION, V99, P1416, DOI 10.1161/01.CIR.99.11.1416; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; BRISTOW MR, 2003, COMP MED RESYNCHRONI; Brode SE, 1997, J CARDIOVASC ELECTR, V8, P830, DOI 10.1111/j.1540-8167.1997.tb00842.x; Brodsky MA, 2002, AM HEART J, V144, P478, DOI 10.1067/mhj.2002.125502; Buxton AE, 2000, NEW ENGL J MED, V343, P1813; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Buxton AE, 2000, NEW ENGL J MED, V342, P1937, DOI 10.1056/NEJM200006293422602; Camm AJ, 2000, EUR HEART J, V21, P1998, DOI 10.1053/euhj.2000.2473; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P123; Chatrath R, 2002, MAYO CLIN PROC, V77, P226, DOI 10.4065/77.3.226; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; *CTR DEV RAD HLTH, 2002, INS ICD MOD 7272 DUA; Curtis AB, 2001, J CARDIOVASC ELECTR, V12, P280, DOI 10.1046/j.1540-8167.2001.00280.x; Domanski MJ, 1999, J AM COLL CARDIOL, V34, P1090, DOI 10.1016/S0735-1097(99)00327-7; Epstein AE, 1996, CIRCULATION, V94, P1147, DOI 10.1161/01.CIR.94.5.1147; Exner DV, 2001, CIRCULATION, V103, P2066; Exner DV, 2001, CIRCULATION, V104, P1564, DOI 10.1161/hc3801.096395; Glikson M, 2001, LANCET, V357, P1107, DOI 10.1016/S0140-6736(00)04263-X; Gradaus R, 2001, J CARDIOVASC ELECTR, V12, P356, DOI 10.1046/j.1540-8167.2001.00356.x; Greene HL, 2000, CLIN CARDIOL, V23, P315; Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09; Groh WJ, 1996, AM J CARDIOL, V78, P703, DOI 10.1016/S0002-9149(96)00403-3; HAMMILL SC, 1995, PACE, V18, P3, DOI 10.1111/j.1540-8159.1995.tb02469.x; Hauer RNW, 2001, EUR HEART J, V22, P1074, DOI 10.1053/euhj.2001.2584; Heller SS, 1998, PACE, V21, P1207, DOI 10.1111/j.1540-8159.1998.tb00179.x; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Irvine J, 2002, AM HEART J, V144, P282, DOI 10.1067/mhj.2002.124049; Jeffrey K, 2001, MACHINES OUR HEARTS; Kadish A, 2000, PACE, V23, P338, DOI 10.1111/j.1540-8159.2000.tb06759.x; Kennergren C, 1996, AM J CARDIOL, V78, P15, DOI 10.1016/S0002-9149(96)00497-3; Klein H, 1999, AM J CARDIOL, V83, p91D; Kron J, 2001, AM HEART J, V141, P92, DOI 10.1067/mhj.2001.111261; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Kuhlkamp V, 1999, J CARDIOVASC ELECTR, V10, P905, DOI 10.1111/j.1540-8167.1999.tb01261.x; Kuhlkamp V, 2002, J AM COLL CARDIOL, V39, P790, DOI 10.1016/S0735-1097(01)01819-8; Lozano I, 2000, PACE, V23, P1711; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Miller JM, 1996, J CARDIOVASC ELECTR, V7, P278, DOI 10.1111/j.1540-8167.1996.tb00528.x; MIROWSKI M, 1983, ANN INTERN MED, V98, P585, DOI 10.7326/0003-4819-98-5-585; MIROWSKI M, 1978, CIRCULATION, V58, P90, DOI 10.1161/01.CIR.58.1.90; Mirowski M, 1973, Heart Lung, V2, P867; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; Morgan JM, 2002, J CARDIOVASC ELECTR, V13, pS114, DOI 10.1111/j.1540-8167.2002.tb01964.x; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Naccarelli GV, 1998, J CARDIOVASC ELECTR, V9, P864, DOI 10.1111/j.1540-8167.1998.tb00127.x; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Owens DK, 2002, AM HEART J, V144, P440, DOI 10.1067/mhj.2002.125501; Pacifico A, 1999, NEW ENGL J MED, V340, P1855, DOI 10.1056/NEJM199906173402402; Pavia S, 2001, CURR OPIN CARDIOL, V16, P66, DOI 10.1097/00001573-200101000-00010; PAZ HL, 1994, CHEST, V106, P1603, DOI 10.1378/chest.106.5.1603; Petch MC, 1998, EUR HEART J, V19, P1165; Priori SG, 2002, CIRCULATION, V105, P1342, DOI 10.1161/hc1102.105288; Raj SR, 2001, PROG CARDIOVASC DIS, V44, P169, DOI 10.1053/pcad.2001.29146; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; Schron EB, 2002, CIRCULATION, V105, P589, DOI 10.1161/hc0502.103330; Seidl K, 2002, J CARDIOVASC ELECTR, V13, pS100, DOI 10.1111/j.1540-8167.2002.tb01961.x; Shannon KM, 2002, CURR OPIN CARDIOL, V17, P280, DOI 10.1097/00001573-200205000-00012; Sheldon R, 2000, CIRCULATION, V101, P1660; Sheldon R, 2001, CIRCULATION, V104, P1622, DOI 10.1161/hc3901.096720; Smith WM, 1999, ANNU REV BIOMED ENG, V1, P331, DOI 10.1146/annurev.bioeng.1.1.331; SWERDLOW CD, 1994, J AM COLL CARDIOL, V24, P416, DOI 10.1016/0735-1097(94)90298-4; SWERDLOW CD, 1994, J AM COLL CARDIOL, V23, P1342, DOI 10.1016/0735-1097(94)90376-X; Tavernier R, 2001, HEART, V85, P53, DOI 10.1136/heart.85.1.53; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; Tse HF, 1999, J CARDIOVASC ELECTR, V10, P1200, DOI 10.1111/j.1540-8167.1999.tb00296.x; Wellens HJJ, 1998, CIRCULATION, V98, P1651, DOI 10.1161/01.CIR.98.16.1651; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; Winters SL, 2001, PACE, V24, P262, DOI 10.1046/j.1460-9592.2001.00262.x; WYSE DG, 1993, AM J CARDIOL, V71, P197, DOI 10.1016/0002-9149(93)90738-X; Wyse DG, 2001, J AM COLL CARDIOL, V38, P1718, DOI 10.1016/S0735-1097(01)01597-2; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334; Zipes DP, 2001, CIRCULATION, V103, P1372, DOI 10.1161/01.CIR.103.10.1372	80	122	127	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2003	349	19					1836	1847		10.1056/NEJMra035432	http://dx.doi.org/10.1056/NEJMra035432			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739NR	14602883				2022-12-28	WOS:000186353800009
J	Hergott, LJ				Hergott, LJ			Galileo's grapes - Recognizing those who helped make us who we are	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Cahill Thomas, 1995, IRISH SAVED CIVILIZA; GRACIAN B, 1992, ART WORLDLY WISDOM; HERGOTT IJ, 1999, DENVER POST     1107, pO1; Hergott LJ, 2002, JAMA-J AM MED ASSOC, V288, P2516, DOI 10.1001/jama.288.20.2516; Hergott LJ, 2001, JAMA-J AM MED ASSOC, V285, P1938, DOI 10.1001/jama.285.15.1938; McEwan Ian, 2001, ATONEMENT	6	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2235	2236		10.1001/jama.290.17.2235	http://dx.doi.org/10.1001/jama.290.17.2235			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600167				2022-12-28	WOS:000186356800001
J	Nissen, SE; Tsunoda, T; Tuzcu, EM; Schoenhagen, P; Cooper, CJ; Yasin, M; Eaton, GM; Lauer, MA; Sheldon, WS; Grines, CL; Halpern, S; Crowe, T; Blankenship, JC; Kerensky, R				Nissen, SE; Tsunoda, T; Tuzcu, EM; Schoenhagen, P; Cooper, CJ; Yasin, M; Eaton, GM; Lauer, MA; Sheldon, WS; Grines, CL; Halpern, S; Crowe, T; Blankenship, JC; Kerensky, R			Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVASCULAR ULTRASOUND; PROGRESSION; CHOLESTEROL; ANGIOGRAPHY; PRAVASTATIN; PREVENTION; REDUCTION; CARRIERS	Context Although low levels of high-density lipoprotein cholesterol (HDL-C) increase risk for coronary disease, no data exist regarding potential benefits of administration of HDL-C or an HDL mimetic. ApoA-I Milano is a variant of apolipoprotein A-I identified in individuals in rural Italy who exhibit very low levels of HDL. Infusion of recombinant ApoA-I Milano-phospholipid complexes produces rapid regression of atherosclerosis in animal models. Objective We assessed the effect of intravenous recombinant ApoA-I Milano/ phospholipid complexes (ETC-216) on atheroma burden in patients with acute coronary syndromes (ACS). Design The study was a double-blind, randomized, placebo-controlled multicenter pilot trial comparing the effect of ETC-216 or placebo on coronary atheroma burden measured by intravascular ultrasound (IVUS). Setting Ten community and tertiary care hospitals in the United States. Patients Between November 2001 and March 2003, 123 patients aged 38 to 82 years. consented, 57 were randomly assigned, and 47 completed the protocol. Interventions In a ratio of 1:2:2, patients received 5 weekly infusions of placebo or ETC-216 at 15 mg/kg or 45 mg/kg. Intravascular ultrasound was performed within 2 weeks following ACS and repeated after 5 weekly treatments. Main Outcome Measures The primary efficacy parameter was the change in percent atheroma volume (follow-up minus baseline) in the combined ETC-216 cohort. Prespecified secondary efficacy measures included the change in total atheroma volume and average maximal atheroma thickness. Results The mean (SD) percent atheroma volume decreased by -1.06% (3.17%) in the combined ETC-216 group (median, -0.81 %; 95% confidence interval [CI], -1.53 to -0.34%; P=.02 compared with baseline). In the placebo group, mean (SD) percent atheroma volume increased by 0.14% (3.09%; median, 0.03%; 95% CI, -1.11 to 1.43%; P=.97 compared with baseline). The absolute reduction in atheroma volume in the combined treatment groups was -14.1 mm(3) or a 4.2 % decrease from baseline (P<.001). Conclusions A recombinant ApoA-I Milano/phospholipid complex (ETC-216) administered intravenously for 5 doses at weekly intervals produced significant regression of coronary atherosclerosis as measured by IVUS. Although promising, these results require confirmation in larger clinical trials with morbidity and mortality end points.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Diagnost Radiol, Cleveland, OH 44195 USA; Toho Univ, Sch Med, Tokyo, Japan; Med Coll Ohio, Dept Med, Div Cardiol, Toledo, OH 43699 USA; Integris SW Med Ctr, Dept Internal Med & Cardiac Dis, Oklahoma City, OK USA; Mid Ohio Heart Clin, Cardiac Catheterizat Program Medcent Hlth Syst, Mansfield, OH USA; Mid Ohio Heart Clin, Dept Cardiol, Mansfield, OH USA; Borgess Heart Inst, Angiog Core Lab, Kalamazoo, MI USA; Borgess Heart Inst, Dept Cardiol, Kalamazoo, MI USA; N Ohio Heart Ctr, Dept Cardiol, Elyria, OH USA; William Beaumont Hosp, Div Cardiac Dis, Cardiac Catheterizat Lab, Royal Oak, MI 48072 USA; Warrack Hosp & Radiant Res, Dept Cardiol, Coronary Unit, Santa Rosa, CA USA; Geisinger Med Ctr, Dept Cardiol, Cardiac Catheterizat Labs, Danville, PA 17822 USA; Geisinger Med Ctr, Dept Cardiol, Cardiovasc Outpatient Monitoring Unit, Danville, PA 17822 USA; Univ Florida, Dept Med, Div Cardiol, Gainesville, FL USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Toho University; Beaumont Health; Geisinger Medical Center; Geisinger Medical Center; State University System of Florida; University of Florida	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org	Schoenhagen, Paul/A-2808-2012; Blankenship, James/AAX-4084-2020	Schoenhagen, Paul/0000-0002-7751-5243; Blankenship, James/0000-0003-4966-533X				Ballantyne CM, 1998, AM J CARDIOL, V82, p3Q; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Conover WJ, 1999, PRACTICAL NONPARAMET, P360; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; Eisen HJ, 2003, NEW ENGL J MED, V349, P847, DOI 10.1056/NEJMoa022171; Fang JC, 2002, LANCET, V359, P1108, DOI 10.1016/S0140-6736(02)08154-0; Franceschini G, 1999, ARTERIOSCL THROM VAS, V19, P1257, DOI 10.1161/01.ATV.19.5.1257; GUALANDRI V, 1985, AM J HUM GENET, V37, P1083; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Nissen S, 2001, AM J CARDIOL, V87, p15A; Nissen SE, 2001, CIRCULATION, V103, P604, DOI 10.1161/01.CIR.103.4.604; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Schartl M, 2001, CIRCULATION, V104, P387, DOI 10.1161/hc2901.093188; Schoenhagen P, 2003, J AM SOC ECHOCARDIOG, V16, P277, DOI 10.1067/mje.2003.45; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shah PK, 2001, CIRCULATION, V103, P3047, DOI 10.1161/hc2501.092494; Sirtori CR, 2001, CIRCULATION, V103, P1949; Takagi T, 1997, AM J CARDIOL, V79, P1673, DOI 10.1016/S0002-9149(97)00221-X; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333	21	1377	1483	1	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2292	2300		10.1001/jama.290.17.2292	http://dx.doi.org/10.1001/jama.290.17.2292			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600188	Bronze			2022-12-28	WOS:000186356800024
J	Kennedy, JL; Farrer, LA; Andreasen, NC; Mayeux, R; St George-Hyslop, P				Kennedy, JL; Farrer, LA; Andreasen, NC; Mayeux, R; St George-Hyslop, P			The genetics of adult-onset neuropsychiatric disease: Complexities and conundra?	SCIENCE			English	Review							FAMILIAL ALZHEIMERS-DISEASE; GENOME SCAN METAANALYSIS; AMYLOID BETA-PROTEIN; BIPOLAR-DISORDER; SUSCEPTIBILITY LOCUS; MISSENSE MUTATIONS; PEDIGREE SERIES; SCHIZOPHRENIA; ASSOCIATION; LINKAGE	Genetic factors play a major role in the etiology of adult-onset neurodegenerative and neuropsychiatric disorders. Several highly penetrant genes have been cloned for rare, autosomal-dominant, early-onset forms of neurodegenerative diseases. These genes have provided important insights into the mechanisms of these diseases (often altering neuronal protein processing). However, the genes associated with inherited susceptibility to late-onset neurodegenerative diseases, schizophrenia, and bipolar disorder appear to have smaller effects and are likely to interact with each other (and with nongenetic factors) to modulate susceptibility and/or disease phenotype. Several strategies have recently been applied to address this complexity, leading to the identification of a number of candidate susceptibility loci/genes.	Univ Toronto, Ctr Res Neurodegenerat Dis, Ctr Addict & Mental Hlth, Dept Psychiat, Toronto, ON, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Ctr Addict & Mental Hlth, Dept Med, Toronto, ON, Canada; Univ Hlth Network, Dept Med, Div Neurol, Toronto, ON M5S 3H9, Canada; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ New Mexico, Dept Psychiat, MIND Inst, Albuquerque, NM 87106 USA; Univ New Mexico, Dept Neurol, MIND Inst, Albuquerque, NM 87106 USA; Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Boston University; Boston University; Boston University; Boston University; Boston University; University of Iowa; Lovelace Respiratory Research Institute; University of New Mexico; Lovelace Respiratory Research Institute; University of New Mexico; Columbia University	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Ctr Addict & Mental Hlth, Dept Psychiat, Toronto, ON, Canada.		Mayeux, Richard/E-9788-2013; Kennedy, James Lowery/AAZ-6947-2020; Farrer, Lindsay/AAS-1035-2020	Mayeux, Richard/0000-0001-6519-9696; Kennedy, James Lowery/0000-0002-8733-3806; Farrer, Lindsay/0000-0001-5533-4225; Andreasen, Nancy/0000-0001-5730-9744	NIA NIH HHS [AG07232, AG15473, U01-AG17173, R01-AG09029, P30-AG95004] Funding Source: Medline; NIMH NIH HHS [MH31593, MH43271, MH40856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040856, R01MH031593, P50MH043271, R37MH031593, P30MH043271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009029, RF1AG015473, P01AG007232, U01AG017173, R37AG015473, R01AG015473] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Bray NJ, 2003, AM J HUM GENET, V73, P152, DOI 10.1086/376578; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Chumakov I, 2002, P NATL ACAD SCI USA, V99, P13675, DOI 10.1073/pnas.182412499; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Clark CM, 2003, ANN INTERN MED, V138, P400, DOI 10.7326/0003-4819-138-5-200303040-00010; Cox NJ, 1999, NAT GENET, V21, P213, DOI 10.1038/6002; Crone SA, 2002, ANN NY ACAD SCI, V971, P547, DOI 10.1111/j.1749-6632.2002.tb04525.x; Detera-Wadleigh SD, 1999, P NATL ACAD SCI USA, V96, P5604, DOI 10.1073/pnas.96.10.5604; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; FARRER L, 1999, CEREBRAL CORTEX NEUR, V14, P433; Finckh U, 2003, J NEURAL TRANSM, V110, P253, DOI 10.1007/s00702-002-0775-7; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hattori E, 2003, AM J HUM GENET, V72, P1131, DOI 10.1086/374822; KAROUM F, 1994, J NEUROCHEM, V63, P972, DOI 10.1046/j.1471-4159.1994.63030972.x; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; Levinson DF, 2003, AM J HUM GENET, V73, P17, DOI 10.1086/376548; Lewis CM, 2003, AM J HUM GENET, V73, P34, DOI 10.1086/376549; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mayeux R, 2002, AM J HUM GENET, V70, P237, DOI 10.1086/324773; MCGUFFIN P, 2002, PSYCHIAT GENETICS GE; McMahon FJ, 1997, AM J HUM GENET, V61, P1397, DOI 10.1086/301630; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288; O'Donovan MC, 2003, HUM MOL GENET, V12, pR125, DOI 10.1093/hmg/ddg302; Pericak-Vance MA, 2000, EXP GERONTOL, V35, P1343, DOI 10.1016/S0531-5565(00)00196-0; PERICAKVANCE MA, 1997, JAMA-J AM MED ASSOC, V278, P1282; Petronis A, 2000, NEUROPSYCHOPHARMACOL, V23, P1, DOI 10.1016/S0893-133X(00)00127-5; Petronis A, 2003, SCHIZOPHRENIA BULL, V29, P169, DOI 10.1093/oxfordjournals.schbul.a006988; Petronis A, 2001, TRENDS GENET, V17, P142, DOI 10.1016/S0168-9525(00)02213-7; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Segurado R, 2003, AM J HUM GENET, V73, P49, DOI 10.1086/376547; Shao YJ, 2003, AM J HUM GENET, V72, P539, DOI 10.1086/367846; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shifman S, 2002, AM J HUM GENET, V71, P1296, DOI 10.1086/344514; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; STGEORGEHYSLOP PH, 1994, SCIENCE, V263, P536; STINE OC, 1995, AM J HUM GENET, V57, P1384; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; Tsuang M. T. E., 2002, TXB PSYCHIAT EPIDEMI	55	128	128	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					822	826		10.1126/science.1092132	http://dx.doi.org/10.1126/science.1092132			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593167				2022-12-28	WOS:000186258000037
J	Finch, TL; May, CR; Mair, FS; Mort, M; Gask, L				Finch, TL; May, CR; Mair, FS; Mort, M; Gask, L			Integrating service development with evaluation in telehealthcare: an ethnographic study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TELEMEDICINE	Objectives To identify issues that facilitate the successful integration of evaluation and development of telehealthcare services. Design Ethnographic study using various qualitative research techniques to obtain data from several sources, including in-depth semistructured interviews, project steering group meetings, and public telehealthcare meetings. Setting Seven telehealthcare evaluation projects (four randomised controlled trials and three pragmatic service evaluations) in the United Kingdom, studied over two years. Projects spanned a range of specialties-dermatology, psychiatry, respiratory medicine, cardiology, and oncology. Participants Clinicians, managers, technical experts, and researchers involved in the projects. Results and discussion Key problems in successfully integrating evaluation and service development in telehealthcare are, firstly, defining existing clinical practices (and anticipating changes) in ways that permit measurement; secondly, managing additional workload and conflicting responsibilities brought about by combining clinical and research responsibilities (including managing risk); and, thirdly, understanding various perspectives on effectiveness and the limitations of evaluation results beyond the context of the research study. Conclusions Combined implementation and evaluation of telehealthcare systems is complex, and is often underestimated. The distinction between quantitative outcomes and the workability of the system is important for producing evaluative knowledge that is of practical value. More pragmatic approaches to evaluation, that permit both quantitative and qualitative methods, are required to improve the quality of such research and its relevance for service provision in the NHS.	Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 3DN, Tyne & Wear, England; Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Lancaster, Inst Hlth Res, Lancaster LA1 4YJ, England; Univ Manchester, Sch Primary Care, Manchester M14 5NP, Lancs, England	Newcastle University - UK; University of Liverpool; Lancaster University; University of Manchester	Finch, TL (corresponding author), Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 3DN, Tyne & Wear, England.	Tracy.Finch@newcastle.ac.uk	May, Carl/A-8502-2011	Finch, Tracy/0000-0001-8647-735X; May, Carl/0000-0002-0451-2690; Mort, Margaret Mary Elizabeth/0000-0003-0188-324X; Mair, Frances/0000-0001-9780-1135				Bashshur R L, 1997, Telemed J, V3, P113, DOI 10.1089/tmj.1.1997.3.113; Glaser B.G., 1965, AWARENESS DYING; Hammersley M., 1995, ETHNOGRAPHY PRINCIPL; Heathfield H, 1998, BRIT MED J, V316, P1959, DOI 10.1136/bmj.316.7149.1959; Kaplan B, 2001, INT J MED INFORM, V64, P39, DOI 10.1016/S1386-5056(01)00184-8; Lehoux P, 2002, SOC SCI MED, V54, P889, DOI 10.1016/S0277-9536(01)00063-6; LENAGHAN J, 1998, RETHINKING IT HLTH; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; May C, 2001, SOC SCI MED, V52, P1889, DOI 10.1016/S0277-9536(00)00305-1; May C., 2001, HLTH INFORMATICS J, V7, P131, DOI DOI 10.1177/146045820100700304; Miller EA, 2001, J TELEMED TELECARE, V7, P1, DOI 10.1258/1357633011936075; Miller J. F., 2000, Genetic Programming and Evolvable Machines, V1, P7, DOI 10.1023/A:1010016313373; Mort M, 2003, SCI TECHNOL HUM VAL, V28, P274, DOI 10.1177/0162243902250907; NHS Executive, 1998, INF HLTH INF STRAT M; Prescott RJ, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI DOI 10.3310/hta3200; Sanders J H, 1995, Telemed J, V1, P115, DOI 10.1089/tmj.1.1995.1.115; Stanberry B, 2001, COMPUT METH PROG BIO, V64, P225, DOI 10.1016/S0169-2607(00)00142-5; URQUHART C, 1999, CURRENT PERSPECTIVES, P186; WHITTEN P, IN PRESS J TECHNOL H; Whitten PS, 2002, BRIT MED J, V324, P1434, DOI 10.1136/bmj.324.7351.1434	20	68	68	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	2003	327	7425					1205	1208A		10.1136/bmj.327.7425.1205	http://dx.doi.org/10.1136/bmj.327.7425.1205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	747BB	14630758	Green Published, Bronze			2022-12-28	WOS:000186784300021
J	Garcia-Miguel, FJ; Serrano-Aguilar, PG; Lopez-Bastida, J				Garcia-Miguel, FJ; Serrano-Aguilar, PG; Lopez-Bastida, J			Preoperative assessment	LANCET			English	Review							POSTOPERATIVE PULMONARY COMPLICATIONS; CHEST-X-RAY; PERIOPERATIVE CARDIOVASCULAR EVALUATION; CARDIAC RISK; GENERAL-ANESTHESIA; LABORATORY ASSESSMENT; EPIDURAL-ANESTHESIA; SPINAL-ANESTHESIA; ELECTIVE SURGERY; BLOOD-TESTS	Although anaesthetic and surgical procedures should be individualised for every patient, in practice many preoperative protocols and routines are used generally. In this article, we aim to emphasise: why preoperative assessment is important; how it should be done, and by whom; what can be expected; and the importance of test selection based on patients' needs and on scientific evidence of effectiveness. We outline the roles of preoperative medical assessment in otherwise healthy patients. Clinical history, preoperative questionnaires, physical examination, routine tests, individual risk-assessment, and fasting policies are investigated by review of published work. Cost of routine preoperative assessment, the anaesthetist's legal responsibility, and patients' views in the preoperative process are also considered. A thorough clinical preoperative assessment of the patient is more important than routine preoperative tests, which should be requested only when justified by clinical indications. Moreover, this practice eliminates unnecessary cost without compromising the safety and quality of care. Education and training of medical doctors should be more scientifically guided, emphasising the relevance of effectiveness, and cost-effectiveness in clinical decision-making and complemented by audit.	Hosp Gen Segovia, Dept Anaesthesiol & Reanimat, Segovia 40002, Spain; Serv Canario Salud, Dept Planning & Evaluat, Canary Isl, Spain		Garcia-Miguel, FJ (corresponding author), Hosp Gen Segovia, Dept Anaesthesiol & Reanimat, Crta Avila S-N, Segovia 40002, Spain.	fgarcia@hgse.sacyl.es						ACAPEM J, 1992, ANN FR ANESTH, V11, P88; ADAMS JG, 1992, ARCH SURG-CHICAGO, V127, P801; AGHAJANIAN A, 1991, OBSTET GYNECOL, V78, P837; AGUILAR PS, 2001, REV ESP ANESTESIOL R, V48, P307; Alcalde J, 2001, CIR ESPAN, V69, P584; Alsumait BM, 2002, MED PRIN PRACT, V11, P42, DOI 10.1159/000048660; *AM SOC AN, 1994, ASA DIR MEMB 1994; *ANDEM, 1992, IND PREOP TESTS; Ansermino JM, 1999, ANN ROY COLL SURG, V81, P175; Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015; ARVIDSSON S, 1994, ACTA ANAESTH SCAND, V38, P679, DOI 10.1111/j.1399-6576.1994.tb03977.x; *ASS AN GREAT BRIT, PREOP ASS ROL AN; Asua J, 2000, INT J TECHNOL ASSESS, V16, P673, DOI 10.1017/S0266462300101230; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; BRADY M, 2001, COCHRANE LIB; BrooksBrunn JA, 1997, CHEST, V111, P564, DOI 10.1378/chest.111.3.564; CELLI BR, 1984, AM REV RESPIR DIS, V130, P12; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; COHEN MM, 1988, JAMA-J AM MED ASSOC, V260, P2859, DOI 10.1001/jama.260.19.2859; Corbett AR, 1997, EUR J ANAESTH, V14, P555; DAVIS FM, 1987, BRIT J ANAESTH, V59, P1080, DOI 10.1093/bja/59.9.1080; Deber RB, 1996, ARCH INTERN MED, V156, P1414, DOI 10.1001/archinte.156.13.1414; Dowling J L Jr, 1995, R I Med, V78, P339; DUNCAN PG, 1987, CAN J ANAESTH, V34, P2, DOI 10.1007/BF03007673; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; Eriksson LI, 1996, ACTA ANAESTH SCAND, V40, P971; Escolano F, 1996, Rev Esp Anestesiol Reanim, V43, P305; FORREST JB, 1992, ANESTHESIOLOGY, V76, P3, DOI 10.1097/00000542-199201000-00002; GAGNER M, 1990, CAN J SURG, V33, P271; Garcia-Miguel F J, 2002, Rev Esp Anestesiol Reanim, V49, P80; Garcia-Miguel F J, 2002, Rev Esp Anestesiol Reanim, V49, P5; GARCIAMIGUEL FJ, 2000, THESIS U AUTONOMA MA, P269; Gilbert K, 2000, ANN INTERN MED, V133, P356, DOI 10.7326/0003-4819-133-5-200009050-00011; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; *GPAC MED SERV COM, 2000, GUID ROUT PREOP TEST; GRACEY DR, 1979, CHEST, V76, P123, DOI 10.1378/chest.76.2.123; HALL JC, 1991, CHEST, V99, P923, DOI 10.1378/chest.99.4.923; *HLTH COUNC NETH, 1997, PREOP EV; *I CLIN SYST IMPR, 2002, HLTH CAR GUID PREOP; Jadad AR, 2003, BRIT MED J, V326, P1293, DOI 10.1136/bmj.326.7402.1293; JOFFE II, 2002, UP TO DATE, V10; JOHNSON H, 1988, SURGERY, V104, P639; Johnson RK, 2002, ANAESTHESIA, V57, P914, DOI 10.1046/j.1365-2044.2002.02750.x; JONES MW, 1989, ANN ROY COLL SURG, V71, P1; KABOLI PJ, 2002, UP TO DATE, V10; KALLAR SK, 1993, ANESTH ANALG, V77, P171; KAPLAN EB, 1985, JAMA-J AM MED ASSOC, V253, P3576, DOI 10.1001/jama.253.24.3576; Karnath BM, 2002, AM FAM PHYSICIAN, V66, P1889; KERR IH, 1974, BRIT J ANAESTH, V46, P558, DOI 10.1093/bja/46.8.558; KOZAK EA, 1994, CHEST, V106, P703, DOI 10.1378/chest.106.3.703; KROENKE K, 1993, CHEST, V104, P1445, DOI 10.1378/chest.104.5.1445; KROENKE K, 1992, ARCH INTERN MED, V152, P967, DOI 10.1001/archinte.152.5.967; Ladfors MB, 2002, ACTA OBSTET GYN SCAN, V81, P437; Lavernia CJ, 1999, J ARTHROPLASTY, V14, P669, DOI 10.1016/S0883-5403(99)90220-6; Lawrence VA, 1996, CHEST, V110, P744, DOI 10.1378/chest.110.3.744; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Liu LL, 2002, J AM GERIATR SOC, V50, P1186, DOI 10.1046/j.1532-5415.2002.t01-1-50303.x; LODER RE, 1978, ANAESTHESIA, V33, P972; López-Bastida J., 2003, Gac Sanit, V17, P131, DOI 10.1157/13046570; Lundberg D, 1996, ACTA ANAESTH SCAND, V40, P961; MACARIO A, 1992, SURG GYNECOL OBSTET, V175, P539; MACDONALD J B, 1992, Health Bulletin (Edinburgh), V50, P54; MANNING SC, 1987, INT J PEDIATR OTORHI, V13, P237, DOI 10.1016/0165-5876(87)90104-2; Means LJ, 1996, PEDIATRICS, V98, P502; MENDELSON DS, 1987, RADIOLOGY, V165, P341, DOI 10.1148/radiology.165.2.3659353; Millat B, 1996, EUR J SURG, V162, P597; MITCHELL D, 1991, CLIN ORTHOP RELAT R, V269, P109; MODIG J, 1983, ANESTH ANALG, V62, P174; MOHR DN, 1988, J GEN INTERN MED, V3, P277, DOI 10.1007/BF02596344; Moller AM, 2001, ACTA ANAESTH SCAND, V45, P345, DOI 10.1034/j.1399-6576.2001.045003345.x; Moumjid Nora, 2003, Health Expect, V6, P187, DOI 10.1046/j.1369-6513.2003.00243.x; MUNRO J, 1997, ROUTINE PREOPERATIVE; Murdoch CJ, 1999, ANAESTHESIA, V54, P907; MYERS LM, 1998, PREOPERATIVE EVALUAT; Narr BJ, 1997, MAYO CLIN PROC, V72, P505, DOI 10.4065/72.6.505; NARR BJ, 1991, MAYO CLIN PROC, V66, P155, DOI 10.1016/S0025-6196(12)60487-X; *NAT I CLIN EXC, 2003, GUID US PREOP TESTS; NIELSEN PT, 1990, ACTA ORTHOP SCAND, V61, P29, DOI 10.3109/17453679008993060; ODONOHUE WJ, 1992, POSTGRAD MED, V91, P167; Oliva G, 2001, Rev Esp Anestesiol Reanim, V48, P11; *OSTEBA, 1994, HLTH AS PAT PREOP EV; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; Pandit U A, 1997, J Perianesth Nurs, V12, P181, DOI 10.1016/S1089-9472(97)80036-6; Pasternak LR, 2002, ANESTHESIOLOGY, V96, P485; PASULKA PS, 1986, ANN INTERN MED, V104, P540, DOI 10.7326/0003-4819-104-4-540; PETRING OU, 1993, ANAESTH INTENS CARE, V21, P774, DOI 10.1177/0310057X9302100605; PRINS MH, 1990, THROMB HAEMOSTASIS, V64, P497; RAMSEY G, 1983, J THORAC CARDIOV SUR, V85, P564; REES AM, 1976, BRIT MED J, V1, P1333, DOI 10.1136/bmj.1.6021.1333; Ricciardi G, 1998, INT J TECHNOL ASSESS, V14, P526, DOI 10.1017/S0266462300011508; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Roizen M., 2000, ANESTHESIA, P824; Roizen MF, 2000, NEW ENGL J MED, V342, P204, DOI 10.1056/NEJM200001203420311; Roizen MF, 1999, J ORAL MAXIL SURG, V57, P21; *ROYAL COLL AN ASS, 1998, GOOD PRACT GUID DEP; RUCKER L, 1983, JAMA-J AM MED ASSOC, V250, P3209, DOI 10.1001/jama.250.23.3209; SAGEL SS, 1974, NEW ENGL J MED, V291, P1001, DOI 10.1056/NEJM197411072911904; SANE SM, 1977, PEDIATRICS, V60, P669; Schein OD, 2000, NEW ENGL J MED, V342, P168, DOI 10.1056/NEJM200001203420304; SEYMOUR DG, 1982, POSTGRAD MED J, V58, P741, DOI 10.1136/pgmj.58.686.741; SHAMMASH JB, 2002, UP TO DATE, V10; Silvestri L, 1999, EUR J ANAESTH, V16, P749, DOI 10.1046/j.1365-2346.1999.00577.x; Simini B, 2003, BRIT MED J, V327, P79, DOI 10.1136/bmj.327.7406.79; Simini B, 2001, ANAESTHESIA, V56, P591; Smetana GW, 1999, NEW ENGL J MED, V340, P937, DOI 10.1056/NEJM199903253401207; SMETANA GW, 2002, UP TO DATE, V10; SORENSON RM, 1992, ANESTHESIOLOGY, V77, P1095, DOI 10.1097/00000542-199212000-00009; Splinter WM, 1999, ANESTH ANALG, V89, P80, DOI 10.1097/00000539-199907000-00015; *SWED COUNC TECHN, 1989, PREOP ROUT; TAPE TG, 1988, J GEN INTERN MED, V3, P15, DOI 10.1007/BF02595750; THOMAS DR, 1995, J AM GERIATR SOC, V43, P811, DOI 10.1111/j.1532-5415.1995.tb07058.x; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; TURNBULL JM, 1987, ARCH INTERN MED, V147, P1101, DOI 10.1001/archinte.147.6.1101; UMBACH GE, 1988, ARCH GYNECOL OBSTET, V243, P179, DOI 10.1007/BF00932085; Vanzetto G, 1996, AM J CARDIOL, V77, P143, DOI 10.1016/S0002-9149(96)90585-8; VELANOVICH V, 1991, SURGERY, V109, P236; Vilarasau Farre J, 2001, Rev Esp Anestesiol Reanim, V48, P4; Warner DO, 1996, ANESTHESIOLOGY, V85, P460, DOI 10.1097/00000542-199609000-00003; WARNER MA, 1989, MAYO CLIN PROC, V64, P609, DOI 10.1016/S0025-6196(12)65337-3; Warner MA, 1999, ANESTHESIOLOGY, V90, P896; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YOUNIS LT, 1995, CLIN CARDIOL, V18, P447, DOI 10.1002/clc.4960180805	126	122	136	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2003	362	9397					1749	1757		10.1016/S0140-6736(03)14857-X	http://dx.doi.org/10.1016/S0140-6736(03)14857-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643127				2022-12-28	WOS:000186767700026
J	Nejentsev, S; Guja, C; McCormack, R; Cooper, J; Howson, JMM; Nutland, S; Rance, H; Walker, N; Undlien, D; Ronningen, KS; Tuomilehto-Wolf, E; Tuomilehto, J; Ionescu-Tirgoviste, C; Gale, EAM; Bingley, PJ; Gillespie, KM; Savage, DA; Carson, DJ; Patterson, CC; Maxwell, AP; Todd, JA				Nejentsev, S; Guja, C; McCormack, R; Cooper, J; Howson, JMM; Nutland, S; Rance, H; Walker, N; Undlien, D; Ronningen, KS; Tuomilehto-Wolf, E; Tuomilehto, J; Ionescu-Tirgoviste, C; Gale, EAM; Bingley, PJ; Gillespie, KM; Savage, DA; Carson, DJ; Patterson, CC; Maxwell, AP; Todd, JA			Association of intercellular adhesion molecule-1 gene with type 1 diabetes	LANCET			English	Article								Intercellular adhesion molecule-1 (ICAM-1) functions via its ligands, the leucocyte integrins, in adhesion of immune cells to endothelial cells and in T cell activation. The third immunoglobulin-like extracellular domain binds integrin Mac-1 and contains a common non-conservative aminoacid polymorphism, G241R. Phenotypically, ICAM-1 has been associated with type I diabetes, a T-cell-mediated autoimmune disease. We assessed two independent datasets, and noted that R241 was associated with lower risk of type I diabetes than is G241 (3695 families, relative risk 0.91, p=0-03; 446 families, 0.60, p=0.006). Our data indicate an aetiological role for ICAM-1 in type I diabetes, which needs to be confirmed In future genetic and functional experiments.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Juvenile Diabet Res Fdn,Wellcome Trust Diabet & I, Cambridge CB2 2XY, England; Inst Diabet Nutr & Metab Dis N Paulescu, Diabet Clin, Bucharest, Romania; Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland; Univ Oslo, Ulleval Univ Hosp, Inst Med Genet, Oslo, Norway; Norwegian Inst Publ Hlth, Div Epidemiol, Lab Mol Epidemiol, Oslo, Norway; Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Univ Bristol, Div Med, Diabet & Metab Unit, Bristol, Avon, England; Queens Univ Belfast, Dept Child Hlth, Belfast BT7 1NN, Antrim, North Ireland; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland; Belfast City Hosp, Reg Nephrol Unit, Belfast BT9 7AD, Antrim, North Ireland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Queens University Belfast; University of Oslo; Norwegian Institute of Public Health (NIPH); Finland National Institute for Health & Welfare; University of Helsinki; University of Bristol; Queens University Belfast; Queens University Belfast; Belfast City Hospital	Nejentsev, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Juvenile Diabet Res Fdn,Wellcome Trust Diabet & I, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.		Todd, John A/A-3542-2010; Guja, Cristian/K-2334-2019	Todd, John A/0000-0003-2740-8148; Howson, Joanna/0000-0001-7618-0050; Walker, Neil/0000-0001-9796-7688; Maxwell, Alexander P./0000-0002-6110-7253				Camacho SA, 2001, NAT IMMUNOL, V2, P523, DOI 10.1038/88720; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; Cox NJ, 2001, AM J HUM GENET, V69, P820, DOI 10.1086/323501; Douek IF, 2002, DIABETOLOGIA, V45, P495, DOI 10.1007/s00125-002-0790-0; Kristiansen OP, 2000, IMMUNOGENETICS, V52, P107, DOI 10.1007/s002510000258; Weinberg CR, 2000, AM J EPIDEMIOL, V152, P197, DOI 10.1093/aje/152.3.197	6	31	32	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1723	1724		10.1016/S0140-6736(03)14847-7	http://dx.doi.org/10.1016/S0140-6736(03)14847-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643123				2022-12-28	WOS:000186767700013
J	Siwick, BJ; Dwyer, JR; Jordan, RE; Miller, RJD				Siwick, BJ; Dwyer, JR; Jordan, RE; Miller, RJD			An atomic-level view of melting using femtosecond electron diffraction	SCIENCE			English	Article							TRANSIENT MOLECULAR-STRUCTURES; ULTRAFAST ELECTRON; ALUMINUM; SEMICONDUCTORS; TRANSITIONS; RESOLUTION; DYNAMICS	We used 600-femtosecond electron pulses to study the structural evolution of aluminum as it underwent an ultrafast laser-induced solid-liquid phase transition. Real-time observations showed the loss of long-range order that was present in the crystalline phase and the emergence of the liquid structure where only short-range atomic correlations were present; this transition occurred in 3.5 picoseconds for thin-film aluminum with an excitation fluence of 70 millijoules per square centimeter. The sensitivity and time resolution were sufficient to capture the time-dependent pair correlation function as the system evolved from the solid to the liquid state. These observations provide an atomic-level description of the melting process, in which the dynamics are best understood as a thermal phase transition under strongly driven conditions.	Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada; Univ Toronto, Dept Phys, Toronto, ON M5S 3H6, Canada	University of Toronto; University of Toronto	Siwick, BJ (corresponding author), Univ Toronto, Dept Chem, 80 St George St, Toronto, ON M5S 3H6, Canada.			Dwyer, Jason/0000-0002-2938-2888				Callan JP, 2000, CHEM PHYS, V251, P167, DOI 10.1016/S0301-0104(99)00301-8; Cao J, 2003, APPL PHYS LETT, V83, P1044, DOI 10.1063/1.1593831; COCKAYNE DJH, 1988, ACTA CRYSTALLOGR A, V44, P870, DOI 10.1107/S0108767388004957; DOYLE PA, 1968, ACTA CRYSTALL A-CRYS, VA 24, P390, DOI 10.1107/S0567739468000756; Dudek RC, 2001, J PHYS CHEM A, V105, P4167, DOI 10.1021/jp010122t; FESSLER RR, 1966, PHYS REV, V150, P34, DOI 10.1103/PhysRev.150.34; Guinier A., 1994, XRAY DIFFRACTION CRY; Guo C, 2000, PHYS REV LETT, V84, P4493, DOI 10.1103/PhysRevLett.84.4493; Ihee H, 2001, SCIENCE, V291, P458, DOI 10.1126/science.291.5503.458; JAMES RW, 1962, OPTICAL PRINCIPLES D, pCH5; Jin ZH, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.055703; Lobastov VA, 2001, J PHYS CHEM A, V105, P11159, DOI 10.1021/jp013705b; Luo SN, 2003, APPL PHYS LETT, V82, P1836, DOI 10.1063/1.1563046; RETHFELD R, 2002, PHYS REV B, V65, DOI UNSP 092103; RETHFELD R, 2002, PHYS REV B, V65, P4303; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; SCHMUTTENMAER CA, 1994, PHYS REV B, V50, P8957, DOI 10.1103/PhysRevB.50.8957; SHANK CV, 1983, PHYS REV LETT, V50, P454, DOI 10.1103/PhysRevLett.50.454; Siwick BJ, 2002, J APPL PHYS, V92, P1643, DOI 10.1063/1.1487437; Sokolowski-Tinten K, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.225701; Williamson JC, 1997, NATURE, V386, P159, DOI 10.1038/386159a0; WILLIAMSON JC, 1993, CHEM PHYS LETT, V209, P10, DOI 10.1016/0009-2614(93)87193-7; WILLIAMSON S, 1984, PHYS REV LETT, V52, P2364, DOI 10.1103/PhysRevLett.52.2364	23	685	699	7	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1382	1385		10.1126/science.1090052	http://dx.doi.org/10.1126/science.1090052			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631036				2022-12-28	WOS:000186683500048
J	von der Linde, D				von der Linde, D			A picosecond view of melting	SCIENCE			English	Editorial Material									Univ Duisburg Essen, Inst Laser & Plasma Phys, D-45117 Essen, Germany	University of Duisburg Essen	von der Linde, D (corresponding author), Univ Duisburg Essen, Inst Laser & Plasma Phys, D-45117 Essen, Germany.							Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; Service RF, 2002, SCIENCE, V298, P1356, DOI 10.1126/science.298.5597.1356; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Sokolowski-Tinten K, 2003, NATURE, V422, P287, DOI 10.1038/nature01490; Sokolowski-Tinten K, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.225701; Srinivasan R, 2003, HELV CHIM ACTA, V86, P1763; WILLIAMSON S, 1984, PHYS REV LETT, V52, P2364, DOI 10.1103/PhysRevLett.52.2364	7	11	12	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1345	1346		10.1126/science.1092489	http://dx.doi.org/10.1126/science.1092489			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631026				2022-12-28	WOS:000186683500036
J	Sahai, R; Morris, M; Knapp, GR; Young, K; Barnbaum, C				Sahai, R; Morris, M; Knapp, GR; Young, K; Barnbaum, C			A collimated, high-speed outflow from the dying star V Hydrae	NATURE			English	Article							CARBON STAR; PLANETARY-NEBULAE; BIPOLAR OUTFLOW; BOW SHOCK; JET; BUBBLES; WIND	Stars with masses in the range 1-8 solar masses (M.) live ordinary lives for similar to10(9)-10(10) years, but die extraordinary deaths. First, during their death throes as asymptotic giant branch (AGB) stars they eject, over 10(4)-10(5) years, half or more of their mass in slowly expanding, spherical winds, and then, in a short (a few 100-1,000 years) and poorly understood phase, they are transformed into aspherical planetary nebula. Recent studies support the idea that high-speed, jet-like flows play a crucial role in this transformation(1). Evidence for such outflows is indirect, however; this phase is so short that few nearby stars are likely to be caught in the act. Here we report the discovery of a newly launched, high-speed jet-like outflow in the nearby AGB star, V Hydrae. We have detected both proper motions and ongoing evolution in the jet. These results support a model in which the jet is driven by an accretion disk around an unseen, compact companion. We also find a central, dense equatorial disk-like structure which may enable and/or enhance the formation of the accretion disk.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Div Astron, Dept Phys & Astrophys, Los Angeles, CA 90095 USA; Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Valdosta State Univ, Dept Phys Astron & Geosci, Valdosta, GA 31698 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles; Princeton University; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University System of Georgia; Valdosta State University	Sahai, R (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	raghvendra.sahai@jpl.nasa.gov	Sahai, Raghvendra/G-7264-2018	Sahai, Raghvendra/0000-0002-6858-5063; Morris, Mark/0000-0002-6753-2066; Knapp, Gillian/0000-0002-9259-1164				Alcolea J, 2001, ASTRON ASTROPHYS, V373, P932, DOI 10.1051/0004-6361:20010535; Bally J, 1997, ASTR SOC P, V121, P3; BARNBAUM C, 1995, ASTROPHYS J, V450, P862, DOI 10.1086/176190; EVANS TL, 1991, MON NOT R ASTRON SOC, V248, P479, DOI 10.1093/mnras/248.3.479; EVANS TL, 2000, IAU S, V177, P367; HARTIGAN P, 1987, ASTROPHYS J, V316, P323, DOI 10.1086/165204; Imai H, 2002, NATURE, V417, P829, DOI 10.1038/nature00788; Kahane C, 1996, ASTRON ASTROPHYS, V314, P871; KAHANE C, 1988, ASTROPHYS J, V328, pL25, DOI 10.1086/185153; Kastner JH, 2003, ASTROPHYS J, V591, pL37, DOI 10.1086/376979; KASTNER JH, 2003, ASTROPHYS J, V563, pL151; Kellogg E, 2001, ASTROPHYS J, V563, pL151, DOI 10.1086/338594; Knapp GR, 1997, ASTRON ASTROPHYS, V326, P318; Knapp GR, 1999, ASTRON ASTROPHYS, V351, P97; Lee CF, 2003, ASTROPHYS J, V586, P319, DOI 10.1086/346265; Livio M, 1997, ASTR SOC P, V121, P845, DOI 10.1017/S0252921100044298; MORRIS M, 1987, PUBL ASTRON SOC PAC, V99, P1115, DOI 10.1086/132089; Reipurth B, 2002, ASTRON J, V123, P362, DOI 10.1086/324738; Sahai R, 1998, ASTRON J, V116, P1357, DOI 10.1086/300504; SAHAI R, 1988, ASTRON ASTROPHYS, V201, pL9; Soker N, 2000, ASTROPHYS J, V538, P241, DOI 10.1086/309112; Soker N, 2003, PUBL ASTRON SOC PAC, V115, P1296, DOI 10.1086/379089; SOKER N, 1992, ASTROPHYS J, V389, P628, DOI 10.1086/171235; SUGERMAN B, 1996, IAU S, V170, P108	24	48	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					261	264		10.1038/nature02086	http://dx.doi.org/10.1038/nature02086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628044				2022-12-28	WOS:000186660800036
J	Tzallas, P; Charalambidis, D; Papadogiannis, NA; Witte, K; Tsakiris, GD				Tzallas, P; Charalambidis, D; Papadogiannis, NA; Witte, K; Tsakiris, GD			Direct observation of attosecond light bunching	NATURE			English	Article							HIGH-HARMONIC GENERATION; PULSE GENERATION; AUTOCORRELATOR	Temporal probing of a number of fundamental dynamical processes requires intense pulses at femtosecond or even attosecond (1 as = 10(-18) s) timescales. A frequency 'comb' of extreme-ultra-violet odd harmonics can easily be generated in the interaction of subpicosecond laser pulses with rare gases: if the spectral components within this comb possess an appropriate phase relationship to one another, their Fourier synthesis results in an attosecond pulse train(1,2). Laser pulses spanning many optical cycles have been used for the production of such light bunching(3,4), but in the limit of few-cycle pulses the same process produces isolated attosecond bursts(5,6). If these bursts are intense enough to induce a nonlinear process in a target system(7-9), they can be used for subfemtosecond pump-probe studies of ultrafast processes. To date, all methods for the quantitative investigation of attosecond light localization(4,6,10) and ultrafast dynamics(11) rely on modelling of the cross-correlation process between the extreme-ultraviolet pulses and the fundamental laser field used in their generation. Here we report the direct determination of the temporal characteristics of pulses in the subfemtosecond regime, by measuring the second-order autocorrelation trace of a train of attosecond pulses. The method exhibits distinct capabilities for the characterization and utilization of attosecond pulses for a host of applications in attoscience.	Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Inst Elect Struct & Laser, Fdn Res & Technol Hellas, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Phys, GR-71003 Voutes Heraklion, Crete, Greece	Max Planck Society; Foundation for Research & Technology - Hellas (FORTH); University of Crete	Tsakiris, GD (corresponding author), Max Planck Inst Quantum Opt, D-85748 Garching, Germany.	george.tsakiris@mpq.mpg.de	Tzallas, Paraskevas/M-6905-2014; Charalambidis, Dimitrios/G-5075-2011; Papadogiannis, Nektarios/ABH-1760-2020	Papadogiannis, Nektarios/0000-0003-0691-2468; Tzallas, Paraskevas/0000-0002-8063-5596				Bartels R, 2000, NATURE, V406, P164, DOI 10.1038/35018029; Chang Z, 1998, PHYS REV A, V58, pR30, DOI 10.1103/PhysRevA.58.R30; Christov IP, 2001, PHYS REV LETT, V86, P5458, DOI 10.1103/PhysRevLett86.5458; Christov IP, 1997, PHYS REV LETT, V78, P1251, DOI 10.1103/PhysRevLett.78.1251; Constant E, 2001, J PHYS IV, V11, P537, DOI 10.1051/jp4:20012105; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; Drescher M, 2002, NATURE, V419, P803, DOI 10.1038/nature01143; FARKAS G, 1992, PHYS LETT A, V168, P447, DOI 10.1016/0375-9601(92)90534-S; Gaarde MB, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.213901; Gaarde MB, 1999, PHYS REV A, V59, P1367, DOI 10.1103/PhysRevA.59.1367; HANSCH TW, 1990, OPT COMMUN, V80, P71, DOI 10.1016/0030-4018(90)90509-R; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Kobayashi Y, 1998, OPT LETT, V23, P64, DOI 10.1364/OL.23.000064; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; Mashiko H, 2003, APPL PHYS B-LASERS O, V76, P525, DOI 10.1007/s00340-003-1148-0; Muller HG, 2002, APPL PHYS B-LASERS O, V74, pS17, DOI 10.1007/s00340-002-0894-8; Norin J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.193901; Papadogiannis NA, 2003, APPL PHYS B-LASERS O, V76, P721, DOI 10.1007/s00340-003-1179-6; Papadogiannis NA, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133902; Papadogiannis NA, 2002, OPT LETT, V27, P1561, DOI 10.1364/OL.27.001561; Papadogiannis NA, 1999, PHYS REV LETT, V83, P4289, DOI 10.1103/PhysRevLett.83.4289; Paul PM, 2001, SCIENCE, V292, P1689, DOI 10.1126/science.1059413; PEATROSS J, 1994, OPT LETT, V19, P942, DOI 10.1364/OL.19.000942; Quere F, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.073902; Salieres P, 2001, SCIENCE, V292, P902, DOI 10.1126/science.108836; Sekikawa T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.193902; Shin HJ, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.053407; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507; Wabnitz H, 2002, NATURE, V420, P482, DOI 10.1038/nature01197	30	312	314	2	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					267	271		10.1038/nature02091	http://dx.doi.org/10.1038/nature02091			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628046				2022-12-28	WOS:000186660800038
J	Chastre, J; Wolff, M; Fagon, JY; Chevret, S; Thomas, F; Wermert, D; Clementi, E; Gonzalez, J; Jusserand, D; Asfar, P; Perrin, D; Fieux, F; Aubas, S				Chastre, J; Wolff, M; Fagon, JY; Chevret, S; Thomas, F; Wermert, D; Clementi, E; Gonzalez, J; Jusserand, D; Asfar, P; Perrin, D; Fieux, F; Aubas, S		PneumA Trial Grp	Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNITS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL RESISTANCE; ACINETOBACTER-BAUMANNII; NOSOCOMIAL PNEUMONIA; CONSENSUS CONFERENCE; ORGAN FAILURE; HOSPITALS; INFECTION; EPIDEMIOLOGY	Context The optimal duration of antimicrobial treatment for ventilator-associated pneumonia (VAP) is unknown. Shortening the length of treatment may help to contain the emergence of multiresistant bacteria in the intensive care unit (ICU). Objective To determine whether 8 days is as effective as 15 days of antibiotic treatment of patients with microbiologically proven VAP. Design, Setting, and Participants Prospective, randomized, double-blind (until day 8) clinical trial conducted in 51 French ICUs. A total of 401 patients diagnosed as having developed VAP by quantitative culture results of bronchoscopic specimens and who had received initial appropriate empirical antimicrobial therapy were enrolled between May 1999 and June 2002. Intervention A total of 197 patients were randomly assigned to receive 8 days and 204 to receive 15 days of therapy with an antibiotic regimen selected by the treating physician. Main Outcome Measures Primary outcome measures-death from any cause, microbiologically documented pulmonary infection recurrence, and antibiotic-free days-were assessed 28 days after VAP onset and analyzed on an intent-to-treat basis. Results Compared with patients treated for 15 days, those treated for 8 days had neither excess mortality (18.8% vs 17.2%; difference, 1.6%; 90% confidence interval [CI], -3.7% to 6.9%) nor more recurrent infections (28.9% vs 26.0%; difference, 2.9%; 90% CI, -3.2% to 9.1%), but they had more mean (SD) antibiotic-free days (13.1 [7.4] vs 8.7 [5.2] days, P<.001). The number of mechanical ventilation-free days, the number of organ failure-free days, the length of ICU stay, and mortality rates on day 60 for the 2 groups did not differ. Although patients with VAP caused by non-fermenting gram-negative bacilli, including Pseudomonas aeruginosa, did not have more unfavorable outcomes when antimicrobial therapy lasted only 8 days, they did have a higher pulmonary infection-recurrence rate compared with those receiving 15 days of treatment (40.6% vs; 25.4%; difference, 15.2%,90% CI, 3.9%-26.6%). Among patients who developed recurrent infections, multiresistant pathogens emerged less frequently in those who had received 8 days of antibiotics (42.1% vs 62.0% of pulmonary recurrences, P=.04). Conclusions Among patients who had received appropriate initial empirical therapy, with the possible exception of those developing nonfermenting gram-negative bacillus infections, comparable clinical effectiveness against VAP was obtained with the 8- and 15-day treatment regimens. The 8-day group had less antibiotic use.	Hop La Pitie Salpetriere, Serv Reanimat Med, Paris, France; Hop Bichat Claude Bernard, APHP, Serv Reanimat Med, F-75877 Paris 18, France; Hop Europeen Georges Pompidou, APHP, Serv Reanimat Med, Paris, France; Hop St Louis, APHP, Dept Biostat & Informat Med, Paris, France; Hop Diaconesses, Serv Reanimat, Paris, France; Hop Kremlin Bicetre, APHP, Serv Reanimat Med, Le Kremlin Bicetre, France; Hop Led Audaries, Serv Reanimat, La Roche Sur Yon, France; Hop Ray Poincare, APHP, Serv Reanimat Med, Garches, France; CHU Rouen, Dept Anesthesie & Reanimat, Rouen, France; CHU Angers, Serv Reanimat Med, Angers, France; Hop Courcouronne, Serv Reanimat, Evry, France; Hop St Louis, APHP, Serv Reanimat Med, Paris, France; CHU Montpellier, Dept Anesthesie & Reanimat, Montpellier, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Raymond-Poincare - APHP; CHU de Rouen; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier	Chastre, J (corresponding author), Grp Hosp Pitie Salpetriere, Inst Cardiol, Serv Reanimat Med, 47 Blvd Hop, F-75651 Paris 13, France.			chevret, sylvie/0000-0001-6449-4730				BASELSKI VS, 1994, CLIN MICROBIOL REV, V7, P533, DOI 10.1128/CMR.7.4.533-558.1994; Bergmans DCJJ, 1997, J ANTIMICROB CHEMOTH, V39, P527, DOI 10.1093/jac/39.4.527; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CHEST, V101, P1481, DOI 10.1378/chest.101.6.1481; Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; Combes A, 2003, CRIT CARE MED, V31, P1102, DOI 10.1097/01.CCM.0000059313.31477.2C; Dennesen PJW, 2001, AM J RESP CRIT CARE, V163, P1371, DOI 10.1164/ajrccm.163.6.2007020; DURRLEMAN S, 1990, BIOMETRICS, V46, P329, DOI 10.2307/2531438; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Fagon JY, 2000, ANN INTERN MED, V132, P621, DOI 10.7326/0003-4819-132-8-200004180-00004; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FINK MP, 1994, ANTIMICROB AGENTS CH, V38, P547, DOI 10.1128/AAC.38.3.547; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Fridkin SK, 1999, CLIN INFECT DIS, V29, P245, DOI 10.1086/520193; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Gerberding J, 1999, AM J INFECT CONTROL, V27, P520; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; Ibrahim EH, 2001, CRIT CARE MED, V29, P1109, DOI 10.1097/00003246-200106000-00003; JENNISON C, 1984, CONTROL CLIN TRIALS, V5, P33, DOI 10.1016/0197-2456(84)90148-X; Kollef MH, 2001, ANN INTERN MED, V134, P298, DOI 10.7326/0003-4819-134-4-200102200-00014; Landman D, 2002, ARCH INTERN MED, V162, P1515, DOI 10.1001/archinte.162.13.1515; Lawton RM, 2000, INFECT CONT HOSP EP, V21, P256, DOI 10.1086/501754; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lepper PM, 2002, ANTIMICROB AGENTS CH, V46, P2920, DOI 10.1128/AAC.46.9.2920-2925.2002; Lipsitch M, 2000, P NATL ACAD SCI USA, V97, P1938, DOI 10.1073/pnas.97.4.1938; Mahgoub S, 2002, INFECT CONT HOSP EP, V23, P477, DOI 10.1086/502091; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; Rello J, 1998, AM J RESP CRIT CARE, V157, P912, DOI 10.1164/ajrccm.157.3.9703014; Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766; Singh N, 2000, AM J RESP CRIT CARE, V162, P505, DOI 10.1164/ajrccm.162.2.9909095; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; WUNDERINK RG, 1992, CHEST, V102, pS580, DOI 10.1378/chest.102.5_Supplement_1.580S; 2002, MMWR MORB MORTAL WEE, V51, P565	41	853	911	0	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2003	290	19					2588	2598		10.1001/jama.290.19.2588	http://dx.doi.org/10.1001/jama.290.19.2588			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744DQ	14625336				2022-12-28	WOS:000186613000029
J	Bergman, TJ; Beehner, JC; Cheney, DL; Seyfarth, RM				Bergman, TJ; Beehner, JC; Cheney, DL; Seyfarth, RM			Hierarchical classification by rank and kinship in baboons	SCIENCE			English	Article							FEMALE BABOONS; SOCIAL RELATIONSHIPS; DOMINANCE RELATIONS; PAPIO-CYNOCEPHALUS; JAPANESE MACAQUES; BONNET MACAQUES; KIN; RECOGNITION; INDIVIDUALS; MONKEYS	Humans routinely classify others according to both their individual attributes, such as social status or wealth, and membership in higher order groups, such as families or castes. They also recognize that people's individual attributes may be influenced and regulated by their group affiliations. It is not known whether such rule-governed, hierarchical classifications are specific to humans or might also occur in nonlinguistic species. Here we show that baboons recognize that a dominance hierarchy can be subdivided into family groups. In playback experiments, baboons respond more strongly to call sequences mimicking dominance rank reversals between families than within families, indicating that they classify others simultaneously according to both individual rank and kinship. The selective pressures imposed by complex societies may therefore have favored cognitive skills that constitute an evolutionary precursor to some components of human cognition.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Bergman, TJ (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.		Seyfarth, Robert/AAX-9474-2020; Beehner, Jacinta/E-8467-2012; Bergman, Thore J/B-8196-2008	Beehner, Jacinta/0000-0001-6566-6872; Bergman, Thore J/0000-0002-9615-5001	NIMH NIH HHS [MH62249] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062249] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AURELI F, 1992, ANIM BEHAV, V44, P283, DOI 10.1016/0003-3472(92)90034-7; BERGMAN TL, UNPUB; Bernstein I.S., 1991, P6; Chapais B, 2001, INT J PRIMATOL, V22, P203, DOI 10.1023/A:1005619430744; CHAPAIS B, 1988, BEHAVIOUR, V104, P41, DOI 10.1163/156853988X00593; Cheney D. L., 1990, MONKEYS SEE WORLD IN; Cheney DL, 1999, ANIM BEHAV, V58, P67, DOI 10.1006/anbe.1999.1131; CHENEY DL, 1995, J COMP PSYCHOL, V109, P134, DOI 10.1037/0735-7036.109.2.134; DASSER V, 1988, ANIM BEHAV, V36, P225, DOI 10.1016/S0003-3472(88)80265-3; EHARDT CL, 1986, INT J PRIMATOL, V7, P157, DOI 10.1007/BF02692316; Gouzoules S., 1987, P299; Hauser MD, 2002, SCIENCE, V298, P1569, DOI 10.1126/science.298.5598.1569; HAUSFATER G, 1982, SCIENCE, V217, P752, DOI 10.1126/science.217.4561.752; Jackendoff R. S., 2002, FDN LANGUAGE BRAIN M; MACUDA T, 1995, J EXP PSYCHOL ANIM B, V21, P20, DOI 10.1037/0097-7403.21.1.20; Pinker S, 1995, LANGUAGE INSTINCT; Rendall D, 1996, ANIM BEHAV, V51, P1007, DOI 10.1006/anbe.1996.0103; SAMUELS A, 1987, ANIM BEHAV, V35, P785, DOI 10.1016/S0003-3472(87)80115-X; Schusterman RJ, 1998, ANIM BEHAV, V55, P1087, DOI 10.1006/anbe.1997.0654; Seyfarth RM, 2003, ANNU REV PSYCHOL, V54, P145, DOI 10.1146/annurev.psych.54.101601.145121; Silk JB, 1999, ANIM BEHAV, V58, P45, DOI 10.1006/anbe.1999.1129; Silk JB, 1999, BEHAVIOUR, V136, P679, DOI 10.1163/156853999501522; SILK JB, IN PRESS ANIM BEHAV; SILK JB, 2002, INT J PRIMATOL, V17, P445; Sinha A, 1998, PHILOS T ROY SOC B, V353, P619, DOI 10.1098/rstb.1998.0230; Walters J.R., 1987, P306	26	267	271	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1234	1236		10.1126/science.1087513	http://dx.doi.org/10.1126/science.1087513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615544				2022-12-28	WOS:000186544300061
J	Cohen, JE				Cohen, JE			Human population: The next half century	SCIENCE			English	Article								By 2050, the human population will probably be larger by 2 to 4 billion people, more slowly growing (declining in the more developed regions), more urban, especially in less developed regions, and older than in the 20th century. Two major demographic uncertainties in the next 50 years concern international migration and the structure of families. Economies, nonhuman environments, and cultures (including values, religions, and politics) strongly influence demographic changes. Hence, human choices, individual and collective, will have demographic effects, intentional or otherwise.	Rockefeller Univ, New York, NY 10021 USA; Columbia Univ, New York, NY 10021 USA	Rockefeller University; Columbia University	Cohen, JE (corresponding author), Rockefeller Univ, 1230 York Ave,Box 20, New York, NY 10021 USA.	cohen@rockefeller.edu	Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026				[Anonymous], 2000, NATL VITAL STAT REPO; BACHU A, 1999, CURRENT POPULATION R, pP23; BONGAARTS J, 2002, 6 BILLION FORECASTIN; Cohen J. E., 2002, WHAT FUTURE HOLDS IN, P29; Cohen J. E., 1995, MANY PEOPLE CAN EART; COHEN JE, 2001, FEDERAL RESERVE BANK, V46, P83; Demeny P, 2003, POPUL DEV REV, V29, P1, DOI 10.1111/j.1728-4457.2003.00001.x; Goldscheider FK, 2000, FUTURES, V32, P525, DOI 10.1016/S0016-3287(00)00005-7; Shriver D, 2003, POPUL DEV REV, V29, P153; UHLENBERG P, 1994, P UN INT C AG POP CO, P121; *UN POP DIV, 2002, ESAPWP173 UN POP DIV; *UN POP DIV, 2003, ESAPWP177 UN POP DIV; *UN POP DIV, 1999, ESAPWP156 UN POP DIV; *UN POP DIV, 2003, ESAPWP180 UN POP DIV; *US BUR CENS, 2003, HIST EST WORLD POP	15	509	553	3	215	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1172	1175		10.1126/science.1088665	http://dx.doi.org/10.1126/science.1088665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615528	Green Submitted			2022-12-28	WOS:000186544300042
J	McPherson, MS; Schapiro, MO				McPherson, MS; Schapiro, MO			Education - Funding roller coaster for public higher education	SCIENCE			English	Editorial Material									Spencer Fdn, Chicago, IL 60611 USA; Williams Coll, Williamstown, MA 01267 USA	Williams College	McPherson, MS (corresponding author), Spencer Fdn, Chicago, IL 60611 USA.							[Anonymous], 1995, RES LABOR EC; BURD S, 2003, CHRON HIGHER EDUC, V49, pA22; MCPHERSON MS, 1991, AM ECON REV, V81, P309; *NAT CTR ED STAT, 2003, DIG ED STAT 2002; ORSZAG P, 2003, MILKEN I REV, P17	5	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1157	1157		10.1126/science.1091568	http://dx.doi.org/10.1126/science.1091568			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615519				2022-12-28	WOS:000186544300033
J	Munro, S				Munro, S			Lipid rafts: Elusive or illusive?	CELL			English	Review							GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE DOMAINS; TOXIN B-SUBUNIT; MODEL MEMBRANES; CELL-SURFACE; LATERAL DIFFUSION; LIVING CELLS; CHOLESTEROL DEPLETION; SIGNALING ASSEMBLIES; WATER PERMEABILITY	There has been considerable recent interest in the possibility that the plasma membrane contains lipid "rafts," microdomains enriched in cholesterol and sphingolipids. It has been suggested that such rafts could play an important role in many cellular processes including signal transduction, membrane trafficking, cytoskeletal organization, and pathogen entry. However, rafts have proven difficult to visualize in living cells. Most of the evidence for their existence and function relies on indirect methods such as detergent extraction, and a number of recent studies have revealed possible problems with these methods. Direct studies of the distribution of raft components in living cells have not yet reached a consensus on the size or even the presence of these microdomains, and hence it seems that a definitive proof of raft existence has yet to be obtained.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	sean@mrc-imb.cam.ac.uk		Munro, Sean/0000-0001-6160-5773				Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; BRETSCHER MS, 1973, SCIENCE, V181, P622, DOI 10.1126/science.181.4100.622; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown RE, 1998, J CELL SCI, V111, P1; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; CHEN HW, 1978, J BIOL CHEM, V253, P3180; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Coetzee T, 1998, TRENDS NEUROSCI, V21, P126, DOI 10.1016/S0166-2236(97)01178-8; DEMEL RA, 1968, BIOCHIM BIOPHYS ACTA, V150, P655, DOI 10.1016/0005-2736(68)90055-2; Dietrich C, 2002, BIOPHYS J, V82, P274, DOI 10.1016/S0006-3495(02)75393-9; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; EDIDIN M, 1993, J CELL SCI, P165; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FINKELSTEIN A, 1976, J GEN PHYSIOL, V68, P127, DOI 10.1085/jgp.68.2.127; FINKELSTEIN A, 1967, NATURE, V216, P717, DOI 10.1038/216717a0; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; Gheber LA, 1999, BIOPHYS J, V77, P3163, DOI 10.1016/S0006-3495(99)77147-X; GRUNZE M, 1974, BIOCHIM BIOPHYS ACTA, V356, P125, DOI 10.1016/0005-2736(74)90300-9; Haines TH, 2001, PROG LIPID RES, V40, P299, DOI 10.1016/S0163-7827(01)00009-1; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Hartgroves LC, 2003, J BIOL CHEM, V278, P20389, DOI 10.1074/jbc.M301212200; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; IPSEN JH, 1987, BIOCHIM BIOPHYS ACTA, V905, P162; JACOBSON K, 1981, BIOCHEMISTRY-US, V20, P5268, DOI 10.1021/bi00521a027; Jain M K, 1977, Adv Lipid Res, V15, P1; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kahya N, 2003, J BIOL CHEM, V278, P28109, DOI 10.1074/jbc.M302969200; KARNOVSKY MJ, 1982, J CELL BIOL, V94, P1, DOI 10.1083/jcb.94.1.1; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kenworthy A, 2002, TRENDS BIOCHEM SCI, V27, P435, DOI 10.1016/S0968-0004(02)02178-3; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kovbasnjuk O, 2001, J CELL SCI, V114, P4025; Krylov AV, 2001, J GEN PHYSIOL, V118, P333, DOI 10.1085/jgp.118.4.333; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Launikonis BS, 2001, J PHYSIOL-LONDON, V534, P71, DOI 10.1111/j.1469-7793.2001.00071.x; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; LEGRIMELLEC C, 1992, KIDNEY INT, V42, P825, DOI 10.1038/ki.1992.357; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Li XM, 2001, BIOCHEMISTRY-US, V40, P5954, DOI 10.1021/bi002791n; Luzzatto L, 1997, CELL, V88, P1, DOI 10.1016/S0092-8674(00)81850-4; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; McConnell HM, 2003, ANNU REV BIOPH BIOM, V32, P469, DOI 10.1146/annurev.biophys.32.110601.141704; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MILLER RG, 1984, CELL BIOL INT REP, V8, P519, DOI 10.1016/0309-1651(84)90050-X; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Muller P, 2002, BIOPHYS J, V82, P1418, DOI 10.1016/S0006-3495(02)75496-9; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; OWICKI JC, 1980, BIOPHYS J, V30, P383, DOI 10.1016/S0006-3495(80)85103-4; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pizzo P, 2003, CURR OPIN IMMUNOL, V15, P255, DOI 10.1016/S0952-7915(03)00038-4; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; Schmidt K, 2001, J BIOL CHEM, V276, P14315, DOI 10.1074/jbc.M006221200; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMITH LM, 1980, BIOCHEMISTRY-US, V19, P5907, DOI 10.1021/bi00566a037; Sotomayor CP, 2000, BIOCHEMISTRY-US, V39, P10928, DOI 10.1021/bi000717z; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Steck TL, 2002, BIOPHYS J, V83, P2118, DOI 10.1016/S0006-3495(02)73972-6; Stoffel W, 1997, CURR OPIN NEUROBIOL, V7, P654, DOI 10.1016/S0959-4388(97)80085-2; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; Suomalainen M, 2002, TRAFFIC, V3, P705, DOI 10.1034/j.1600-0854.2002.31002.x; THEWALT JL, 1992, BIOPHYS J, V63, P1176, DOI 10.1016/S0006-3495(92)81681-8; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; TSUJI A, 1988, BIOCHEMISTRY-US, V27, P7447, DOI 10.1021/bi00419a041; UESAKA Y, 1994, MICROB PATHOGENESIS, V16, P71, DOI 10.1006/mpat.1994.1007; Valdez-Taubas J, 2003, CURR BIOL, V13, P1636, DOI 10.1016/j.cub.2003.09.001; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Wang TY, 2001, BIOPHYS J, V81, P2762, DOI 10.1016/S0006-3495(01)75919-X; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Xiang TX, 1998, BBA-BIOMEMBRANES, V1370, P64, DOI 10.1016/S0005-2736(97)00244-7; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	118	1260	1288	3	211	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	2003	115	4					377	388		10.1016/S0092-8674(03)00882-1	http://dx.doi.org/10.1016/S0092-8674(03)00882-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622593	Bronze			2022-12-28	WOS:000186627100005
J	Kulmala, M				Kulmala, M			How particles nucleate and grow	SCIENCE			English	Editorial Material							AEROSOL FORMATION; CLUSTERS; WATER		Univ Helsinki, Dept Phys Sci, Div Atmospher Sci, FIN-00014 Helsinki, Finland	University of Helsinki	Kulmala, M (corresponding author), Univ Helsinki, Dept Phys Sci, Div Atmospher Sci, FIN-00014 Helsinki, Finland.		Kulmala, Markku T/I-7671-2016	Kulmala, Markku T/0000-0003-3464-7825				Arstila H, 1998, J CHEM PHYS, V108, P1031, DOI 10.1063/1.475496; Ball SM, 1999, J GEOPHYS RES-ATMOS, V104, P23709, DOI 10.1029/1999JD900411; Horrak U, 1998, J GEOPHYS RES-ATMOS, V103, P13909, DOI 10.1029/97JD01570; Kulmala M, 2000, NATURE, V404, P66, DOI 10.1038/35003550; KULMALA M, IN PRESS J AEROSOL S; Lee SH, 2003, SCIENCE, V301, P1886, DOI 10.1126/science.1087236; Marti JJ, 1997, J GEOPHYS RES-ATMOS, V102, P6331, DOI 10.1029/96JD02545; Napari I, 2000, PHYS REV LETT, V84, P2184, DOI 10.1103/PhysRevLett.84.2184; Nilsson ED, 2001, TELLUS B, V53, P441, DOI 10.1034/j.1600-0889.2001.d01-31.x; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Vehkamaki H, 2000, J CHEM PHYS, V112, P4193, DOI 10.1063/1.480964; Wagner PE, 2001, J PHYS CHEM B, V105, P11656, DOI 10.1021/jp011460x; WEBER RJ, 1995, J ATMOS SCI, V52, P2242, DOI 10.1175/1520-0469(1995)052<2242:MOENPS>2.0.CO;2; Yu FQ, 2001, J GEOPHYS RES-ATMOS, V106, P4797, DOI 10.1029/2000JD900539; Zhang KM, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002180	15	386	405	10	260	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1000	1001		10.1126/science.1090848	http://dx.doi.org/10.1126/science.1090848			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605359				2022-12-28	WOS:000186396300034
J	McDonald, FB; Stone, EC; Cummings, AC; Heikkila, B; Lal, N; Webber, WR				McDonald, FB; Stone, EC; Cummings, AC; Heikkila, B; Lal, N; Webber, WR			Enhancements of energetic particles near the heliospheric termination shock	NATURE			English	Article							COSMIC-RAYS; SOLAR-WIND; OUTER HELIOSPHERE; ACCELERATION; IONS	The spacecraft Voyager 1 is at a distance greater than 85 AU from the Sun, in the vicinity of the termination shock that marks the abrupt slowing of the supersonic solar wind and the beginning of the extended and unexplored distant heliosphere(1,2). This shock is expected to accelerate 'anomalous cosmic rays' (3), as well as to reaccelerate Galactic cosmic rays(5) and low-energy particles from the inner Solar System(4). Here we report a significant increase in the numbers of energetic ions and electrons that persisted for seven months beginning in mid-2002. This increase differs from any previously observed in that there was a simultaneous increase in Galactic cosmic ray ions and electrons, anomalous cosmic rays and low-energy ions. The low-intensity level and spectral energy distribution of the anomalous cosmic rays, however, indicates that Voyager 1 still has not reached the termination shock. Rather, the observed increase is an expected precursor event. We argue that the radial anisotropy of the cosmic rays is expected to be small in the foreshock region, as is observed.	Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CALTECH, Pasadena, CA 91125 USA; New Mexico State Univ, Dept Phys & Astron, Las Cruces, NM 88003 USA	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California Institute of Technology; New Mexico State University	McDonald, FB (corresponding author), Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA.							BURLAGA LF, IN PRESS GEOPHYS RES; Chalov SV, 2000, ASTRON ASTROPHYS, V360, P381; CHRISTON SP, 1985, GEOPHYS RES LETT, V12, P109, DOI 10.1029/GL012i002p00109; Cummings AC, 2002, ASTROPHYS J, V578, P194, DOI 10.1086/342427; CUMMINGS AC, 2003, P 28 INT COSM RAY C, V7, P3777; GLOECKLER G, 1994, J GEOPHYS RES-SPACE, V99, P17637, DOI 10.1029/94JA01509; GURNETT DA, 1993, SCIENCE, V262, P199, DOI 10.1126/science.262.5131.199; HOLZER TE, 1989, ANNU REV ASTRON ASTR, V27, P199; JOKIPII JR, 1993, ASTROPHYS J, V405, P782, DOI 10.1086/172407; JOKIPII JR, 2003, P 28 INT COSM RAY C, V7, P3753; JOKIPII JR, UNPUB GEOPHYS RES LE; Krimigis SM, 2003, NATURE, V426, P45, DOI 10.1038/nature02068; Lukasiak A., 1999, P 26 ICRC SALT LAK C, V3, P65; MEWALDT R, 1995, P 24 ICRC ROM, V3, P804; PARKER EN, 1963, INTERPLANETARY DYNAM, P115; PESSES ME, 1981, ASTROPHYS J, V246, pL85, DOI 10.1086/183559; SCHWADRON NA, 2003, GEOPHYS RES LETT, V30; STONE EC, 1977, SPACE SCI REV, V21, P355, DOI 10.1007/BF00211546; VANALLEN JA, 1992, GEOPHYS RES LETT, V19, P1423, DOI 10.1029/92GL01445; WEBBER WR, 1993, J GEOPHYS RES-SPACE, V98, P7821, DOI 10.1029/92JA02643	20	139	141	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 6	2003	426	6962					48	51		10.1038/nature02066	http://dx.doi.org/10.1038/nature02066			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603312				2022-12-28	WOS:000186370800036
J	Stone, GW; McCullough, PA; Tumlin, JA; Lepor, NE; Madyoon, H; Murray, P; Wang, A; Chu, AA; Schaer, GL; Stevens, M; Wilensky, RL; O'Neill, WW				Stone, GW; McCullough, PA; Tumlin, JA; Lepor, NE; Madyoon, H; Murray, P; Wang, A; Chu, AA; Schaer, GL; Stevens, M; Wilensky, RL; O'Neill, WW		CONTRAST Investigators	Fenoldopam mesylate for the prevention of contrast-induced nephropathy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE; PERCUTANEOUS CORONARY INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; RADIOGRAPHIC-CONTRAST; BLOOD-FLOW; HYPERTENSIVE PATIENTS; N-ACETYLCYSTEINE; DOPAMINE; INSUFFICIENCY; NEPHROTOXICITY	Context The development of contrast-induced nephropathy in patients undergoing invasive cardiac procedures is associated with a marked increase in cardiovascular morbidity and mortality. Fenoldopam mesylate, a specific agonist of the dopamine-1 receptor, preserves renal blood flow after iodinated contrast administration and has shown promise in ameliorating contrast nephropathy in previous observational and small randomized trials. Objective To examine the efficacy of fenoldopam mesylate in preventing contrast nephropathy after invasive cardiovascular procedures. Design Prospective, placebo-controlled, double-blind, multicenter randomized trial with serial serum creatinine levels measured at a central biochemistry laboratory (at baseline and 1, 24, 48, and 72 to 96 hours after study drug administration) and 30-day clinical follow-up. Patients and Setting Between March 2001 and July 2002, 315 patients with creatinine clearance less than 60 mL/min (1.00 mL/s) at 28 centers in the United States were randomized to receive fenoldopam mesylate (n=157) or placebo (n=158). Interventions Patients were hydrated and randomized to receive intravenous fenoldopam (0.05 mug/kg/min titrated to 0.10 mug/kg/min) vs matching placebo, starting 1 hour prior to angiography and continuing for 12 hours. Main Outcome Measure Contrast-induced nephropathy, defined as an increase of 25% or more in serum creatinine level within 96 hours postprocedure. Results Mean (SD) patient age was 70 (11) years, and 49% had diabetes mellitus. Mean (SD) baseline creatinine clearance was 29.0 (10.0) mL/min (0.48 [0.16] mL/s) (range, 7.5-56.8 mL/min [0.12-0.94 mL/s]), and 157 (108) mL of contrast was administered during the procedures. The primary end point of contrast-induced nephropathy occurred in 33.6% of patients assigned to receive fenoldopam vs 30.1 % assigned to receive placebo (relative risk, 1.11; 95% confidence interval, 0.79-1.57; P=.61). There were no significant differences in the-30-day rates of death (2.0% vs 3.8%, P=.50), dialysis (2.6% vs 1.9%, P=.72), or rehospitalization (17.6% vs 19.9%, P=.66) in fenoldopam vs placebo randomized patients, respectively. Conclusion The selective dopamine-1 agonist fenoldopam mesylate does not prevent further renal function deterioration after contrast administration in patients with chronic renal insufficiency.	Cardiovasc Res Fdn, Dept Cardiol, New York, NY 10022 USA; Lenox Hill Heart & Vasc Inst, New York, NY USA; William Beaumont Hosp, Dept Cardiol, Royal Oak, MI 48072 USA; Emory Univ, Sch Med, Dept Nephrol, Atlanta, GA USA; Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA; St Josephs Med Ctr, Dept Cardiol, Stockton, CA USA; Univ Chicago, Dept Cardiol, Chicago, IL 60637 USA; Duke Univ, Med Ctr, Dept Cardiol, Durham, NC USA; St Francis Med Ctr, Dept Cardiol, Peoria, IL USA; Rush Presbyterian St Lukes Med Ctr, Dept Cardiol, Chicago, IL 60612 USA; Hosp Univ Penn, Dept Cardiol, Philadelphia, PA 19104 USA	Cardiovascular Research Foundation (CRF); Lenox Hill Heart & Vascular Institute of New York; Beaumont Health; Emory University; Cedars Sinai Medical Center; University of Chicago; Duke University; Rush University; University of Pennsylvania; Pennsylvania Medicine	Stone, GW (corresponding author), Cardiovasc Res Fdn, Dept Cardiol, 55 E 59th St,6th Floor, New York, NY 10022 USA.		Wang, Angela Y/B-9944-2008; Lepor, Norman/AAP-2488-2021	Wang, Andrew/0000-0001-8729-0933				Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; Allaqaband S, 2002, CATHETER CARDIO INTE, V57, P279, DOI 10.1002/ccd.10323; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; Bakris GL, 1999, KIDNEY INT, V56, P206, DOI 10.1046/j.1523-1755.1999.00528.x; BERNS AS, 1989, KIDNEY INT, V36, P730, DOI 10.1038/ki.1989.254; Boccalandro F, 2003, CATHETER CARDIO INTE, V58, P336, DOI 10.1002/ccd.10389; Brodsky S, 2000, J CARDIOVASC PHARM, V36, pS311; Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DERAY G, 1991, CLIN NEPHROL, V36, P93; Durham JD, 2002, KIDNEY INT, V62, P2202, DOI 10.1046/j.1523-1755.2002.00673.x; Gruberg L, 2000, J AM COLL CARDIOL, V36, P1542, DOI 10.1016/S0735-1097(00)00917-7; Guitterez Noel V, 2002, J Interv Cardiol, V15, P349; HALL KA, 1992, J SURG RES, V53, P317, DOI 10.1016/0022-4804(92)90054-4; Hizoh I, 2002, INVEST RADIOL, V37, P428, DOI 10.1097/00004424-200208000-00003; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; Katholi RE, 1998, AM J KIDNEY DIS, V32, P64, DOI 10.1053/ajkd.1998.v32.pm9669426; Kay J, 2003, JAMA-J AM MED ASSOC, V289, P553, DOI 10.1001/jama.289.5.553; KIEN ND, 1992, ANESTH ANALG, V74, P72; Kini AS, 2002, AM J CARDIOL, V89, P999, DOI 10.1016/S0002-9149(02)02259-2; Kurnik BRC, 1998, AM J KIDNEY DIS, V31, P674, DOI 10.1053/ajkd.1998.v31.pm9531185; Lasser EC, 1997, RADIOLOGY, V204, P876; Lasser EC, 1997, RADIOLOGY, V203, P605, DOI 10.1148/radiology.203.3.9169676; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Liss P, 1996, KIDNEY INT, V49, P1268, DOI 10.1038/ki.1996.181; Madyoon H, 2001, Rev Cardiovasc Med, V2 Suppl 1, pS26; Mathur VS, 1999, CRIT CARE MED, V27, P1832, DOI 10.1097/00003246-199909000-00021; McCullough P A, 2001, J Interv Cardiol, V14, P547, DOI 10.1111/j.1540-8183.2001.tb00371.x; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; MURPHY MB, 1987, CIRCULATION, V76, P1312, DOI 10.1161/01.CIR.76.6.1312; NEIBERGER RE, 1979, KIDNEY INT, V15, P219, DOI 10.1038/ki.1979.29; OConnell DP, 1997, HYPERTENSION, V29, P115, DOI 10.1161/01.HYP.29.1.115; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; SHUSTERMAN NH, 1993, AM J MED, V95, P161, DOI 10.1016/0002-9343(93)90256-O; Singer I, 1998, AM J KIDNEY DIS, V31, P743, DOI 10.1016/S0272-6386(98)70043-5; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Trivedi HS, 2003, NEPHRON CLIN PRACT, V93, pC29, DOI 10.1159/000066641; Tumlin JA, 2002, AM HEART J, V143, P894, DOI 10.1067/mhj.2002.122118; Wang A, 2000, KIDNEY INT, V57, P1675, DOI 10.1046/j.1523-1755.2000.00012.x	41	286	364	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	2003	290	17					2284	2291		10.1001/jama.290.17.2284	http://dx.doi.org/10.1001/jama.290.17.2284			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PZ	14600187				2022-12-28	WOS:000186356800023
J	Oommen, A; Lambert, PC; Grigg, J				Oommen, A; Lambert, PC; Grigg, J			Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial	LANCET			English	Article							EOSINOPHIL CATIONIC PROTEIN; PRESCHOOL-CHILDREN; AIRWAYS INFLAMMATION; CHILDHOOD ASTHMA; STEROIDS; PHENOTYPES; PREDICT; ATTACKS; YOUNG; ATOPY	Background Episodic wheeze triggered by viral colds is common in children aged between 1 and 5 years (preschool viral wheeze). Most affected children are asymptomatic by age 6 years. Persistence of wheeze is associated with above-average systemic eosinophil priming. Use of parental-initiated oral prednisolone is recommended at the first sign of preschool viral wheeze. However, evidence for this treatment strategy is conflicting. We therefore aimed to assess the efficacy of a short course of oral prednisolone for preschool viral wheeze, with stratification for systemic eosinophil priming. Methods Children aged 1-5 years admitted to hospital with viral wheeze were allocated to either a high-primed or low-primed stratum according to amounts of serum eosinophil cationic protein and eosinophil protein X, and randomised to parent-initiated prednisolone (20 mg one daily for 5 days) or placebo for the next episode. The primary outcomes were the 7-day mean daytime and night-time respiratory symptom scores, which were analysed by mean differences between treatment groups. Findings 108 children were randomised to placebo and 109 to prednisolone. Outcome data were available for 120 (78%) of 153 children who had a further episode of viral wheeze, of whom 51 received prednisolone and 69 placebo. Mean daytime (difference in means -0.01 [-0.22 to 0.20]) and night-time (0.10 [-0.12 to 0.32]) respiratory symptom scores and need for hospital admission did not differ between treatment groups. Within the high-primed (n=59) and low-primed (n=61) strata there was no difference in primary outcome between treatment groups. Interpretation There is no clear benefit of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years even in those with above-average eosinophil priming.	Univ Leicester, Inst Lung Hlth, Leicester Childrens Asthma Ctr, Leicester LE2 7LX, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester	Grigg, J (corresponding author), Univ Leicester, Inst Lung Hlth, Leicester Childrens Asthma Ctr, Leicester LE2 7LX, Leics, England.			Lambert, Paul/0000-0002-5337-663X; Grigg, Jonathan/0000-0003-3109-6028				BRUNETTE MG, 1988, PEDIATRICS, V81, P624; Fox GF, 1996, EUR J PEDIATR, V155, P512, DOI 10.1007/BF01955192; GRANT CC, 1995, PEDIATRICS, V96, P224; Kayani S, 2002, CHEST, V122, P624, DOI 10.1378/chest.122.2.624; Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; La Grutta S, 2003, AM J RESP CRIT CARE, V167, P1490, DOI 10.1164/rccm.200206-549OC; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; O'Donnell RA, 2002, THORAX, V57, P566, DOI 10.1136/thorax.57.7.566; Remes S, 1998, PEDIATR PULM, V25, P167, DOI 10.1002/(SICI)1099-0496(199803)25:3<167::AID-PPUL6>3.3.CO;2-0; Rowe BH, 2003, COCHRANE LIB; SHAPIRO GG, 1995, PEDIATRICS, V96, P347; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Shields MD, 1999, CLIN EXP ALLERGY, V29, P1382; Silverman M, 2003, THORAX, V58, P431, DOI 10.1136/thorax.58.5.431; SMITH M, 2003, COCHRANE LIB; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Venge P, 1999, CLIN EXP ALLERGY, V29, P1172; Villa JR, 1998, ARCH DIS CHILD, V78, P448, DOI 10.1136/adc.78.5.448; WEBB MSC, 1986, ARCH DIS CHILD, V61, P15, DOI 10.1136/adc.61.1.15; WEINBERGER M, 2003, J PEDIATR, V142, P45; WEINBERGER M, 2003, J PEDIATR, V142, P34; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; 2003, THORAX S1, V58, P1	28	145	150	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 1	2003	362	9394					1433	1438		10.1016/S0140-6736(03)14685-5	http://dx.doi.org/10.1016/S0140-6736(03)14685-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602435				2022-12-28	WOS:000186356600007
J	Rosenberg, RN				Rosenberg, RN			Evolutionary time and human memory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; LIFE-SPAN; DISEASE; DECLINE; AGE	Context: Cerebrospinal fluid tau protein and beta-amyloid 42 (Abeta42) protein are altered even in very mild Alzheimer disease (AD). So far, few data exist for subjects with mild cognitive impairment (MCI). Objective: To investigate the potential of cerebrospinal fluid tau and Abeta42 for predicting progression from MCI to AD in a longitudinal study of 28 patients with MCI who received follow-up for 18 months. Design: An 18-month prospective study. Setting: Clinical follow-up study of community-residing subjects with MCI. Main Outcome Measures: Cerebrospinal fluid tau and Abeta42 concentrations were measured using enzyme-linked immunosorbent assay at baseline. The potential of both biomarkers was evaluated to predict the progression to dementia, the end point of this study, using multiple logistic regression analysis. Results: Of 28 subjects with MCI, 12 progressed to dementia (2 to frontotemporal dementia; 10 to AD). Six subjects had progressive MCI, and 10 subjects showed stable MCI. Cerebrospinal fluid tau levels were significantly elevated in patients who progressed to probable AD (P=.002) and subjects with progressive MCI (P=.003) compared with subjects who had stable MCI. Cerebrospinal fluid Abeta42 levels were significantly lower in patients who progressed to probable AD (P=.007) and those with progressive MCI (P=.04) than in subjects with stable MCI. Logistic regression analysis identified elevated tau protein level as a predictor of cognitive deterioration (P=.02), whereas a delayed verbal recall score at baseline was significantly associated with the development of probable AD (P=.03). Conclusion: Our results indicate that altered tau and Abeta42 concentrations may be detectable in subjects who are clinically diagnosed as having MCI but demonstrate the pathological changes of AD.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosenberg, RN (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	roger.rosenberg@utsouthwestern.edu						Albert MS, 2002, ANN NEUROL, V51, P282, DOI 10.1002/ana.10156; DeKosky ST, 2002, ANN NEUROL, V51, P145, DOI 10.1002/ana.10069; Finch CE, 1997, SCIENCE, V278, P407, DOI 10.1126/science.278.5337.407; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Morris JC, 2002, ANN NEUROL, V51, P143, DOI 10.1002/ana.10135; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Riemenschneider M, 2002, ARCH NEUROL-CHICAGO, V59, P1729, DOI 10.1001/archneur.59.11.1729; Rosenberg RN, 2000, NEUROLOGY, V54, P2045, DOI 10.1212/WNL.54.11.2045; Small SA, 2002, ANN NEUROL, V51, P290, DOI 10.1002/ana.10105; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wolkow CA, 2002, TRENDS NEUROSCI, V25, P212, DOI 10.1016/S0166-2236(02)02133-1	14	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	2002	288	23					3045	3047						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	626CG	14619910				2022-12-28	WOS:000179854200042
J	McTigue, KM; Harris, R; Hemphill, B; Lux, L; Sutton, S; Bunton, AJ; Lohr, KN				McTigue, KM; Harris, R; Hemphill, B; Lux, L; Sutton, S; Bunton, AJ; Lohr, KN			Screening and interventions for obesity in adults: Summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							BODY-MASS INDEX; VERTICAL BANDED GASTROPLASTY; CORONARY-HEART-DISEASE; VISCERAL ADIPOSE-TISSUE; Y GASTRIC BYPASS; TERM WEIGHT-LOSS; PROSPECTIVE RANDOMIZED-TRIAL; TYPE-2 DIABETES-MELLITUS; PLACEBO-CONTROLLED TRIAL; DEPENDENT HEALTH-RISKS	Background: Obesity poses a considerable and growing health burden. This review examines evidence for screening and treating obesity in adults. Data Sources: MEDLINE and Cochrane Library (January 1994 through February 2003). Study Selection: Systematic reviews; randomized, controlled trials; and observational studies of obesity's health outcomes or efficacy of obesity treatment. Data Extraction: Two reviewers independently abstracted data on study design, sample, sample size, treatment, outcomes, and quality. Data Synthesis: No trials evaluated mass screening for obesity, so the authors evaluated indirect evidence for efficacy. Pharmacotherapy or counseling interventions produced modest (generally 3 to 5 kg) weight loss over at least 6 or 12 months, respectively. Counseling was most effective when intensive and combined with behavioral therapy. Maintenance strategies helped retain weight loss. Selected surgical patients lost substantial weight (10 to 159 kg over 1 to 5 years). Weight reduction improved blood pressure, lipid levels, and glucose metabolism and decreased diabetes incidence. The internal validity of the treatment trials was fair to good, and external validity was limited by the minimal ethnic or gender diversity of volunteer participants. No data evaluated counseling harms. Primary adverse drug effects included hypertension with sibutramine (mean increase, 0 mm Hg to 3.5 mm Hg) and gastrointestinal distress with orlistat (1% to 37% of patients). Fewer than 1% (pooled samples) of surgical patients died; up to 25% needed surgery again over 5 years. Conclusions: Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes. Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established. In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Univ Pittsburgh, Pittsburgh, PA 15260 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA; RTI Int, Res Triangle Pk, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Research Triangle Institute	McTigue, KM (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.		Lux, Linda/GPX-3639-2022	Lohr, Kathleen/0000-0002-3825-0713	PHS HHS [290-97-0011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abu-Abeid S, 1999, OBES SURG, V9, P188, DOI 10.1381/096089299765553476; Abu-Abeid S, 2001, OBES SURG, V11, P87, DOI 10.1381/096089201321454169; Albu JB, 1997, DIABETES, V46, P456, DOI 10.2337/diabetes.46.3.456; Allison D. B., 2001, International textbook of obesity, P31, DOI 10.1002/0470846739.ch3; Alper D, 2000, OBES SURG, V10, P250, DOI 10.1381/096089200321643548; ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; [Anonymous], 1995, BMJ, V310, P1099; Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; Arterburn D, 2001, BRIT MED J, V322, P1406, DOI 10.1136/bmj.322.7299.1406; Arterburn D, 2001, CLIN EVID, P412; Ashley JM, 2001, ARCH INTERN MED, V161, P1599, DOI 10.1001/archinte.161.13.1599; ATKINSON RL, 1994, JAMA-J AM MED ASSOC, V272, P1196, DOI 10.1001/jama.272.15.1196; Bacha F, 2003, J CLIN ENDOCR METAB, V88, P2534, DOI 10.1210/jc.2002-021267; Baik I, 2000, AM J EPIDEMIOL, V152, P264, DOI 10.1093/aje/152.3.264; Balsiger BM, 2000, J GASTROINTEST SURG, V4, P598, DOI 10.1016/S1091-255X(00)80108-0; Baltasar A, 1998, OBES SURG, V8, P29, DOI 10.1381/096089298765555015; Bemelmans WJE, 2000, PUBLIC HEALTH NUTR, V3, P273, DOI 10.1017/S1368980000000318; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; Bloomston M, 1997, OBES SURG, V7, P414, DOI 10.1381/096089297765555395; BOUCHARD C, 1991, NEW ENGL J MED, V324, P1887, DOI 10.1056/NEJM199106273242609; Bray GA, 1999, BEST PRACT RES CL EN, V13, P131, DOI 10.1053/beem.1999.0011; Brolin RE, 2000, J GASTROINTEST SURG, V4, P464, DOI 10.1016/S1091-255X(00)80087-6; Broom I, 2002, INT J CLIN PRACT, V56, P494; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Casas YG, 2001, AM J CLIN NUTR, V73, P13; Choban PS, 1999, J AM COLL SURGEONS, V188, P491, DOI 10.1016/S1072-7515(99)00030-7; Choi Y, 1999, OBES SURG, V9, P33, DOI 10.1381/096089299765553719; Chyou PH, 1997, ANN EPIDEMIOL, V7, P311, DOI 10.1016/S1047-2797(97)00019-7; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; CONWAY JM, 1995, AM J CLIN NUTR, V61, P765, DOI 10.1093/ajcn/61.4.765; Crampton NA, 1997, OBES SURG, V7, P489, DOI 10.1381/096089297765555232; Dargent J, 1999, OBES SURG, V9, P446, DOI 10.1381/096089299765552729; Davila-Cervantes A, 2000, OBES SURG, V10, P409, DOI 10.1381/096089200321594264; De Luca M, 2000, OBES SURG, V10, P266, DOI 10.1381/096089200321643584; de Wit LT, 1999, ANN SURG, V230, P800, DOI 10.1097/00000658-199912000-00009; Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741; DEURENBERG P, 1991, BRIT J NUTR, V65, P105, DOI 10.1079/BJN19910073; DEURENBERG P, 1989, EUR J CLIN NUTR, V43, P231; DICKSON R, 1997, EFFECTIVE HLTH CARE, V3, P1; Dietz WH, 2001, J PEDIATR-US, V138, P453, DOI 10.1067/mpd.2001.113635; Doherty C, 1998, J Gastrointest Surg, V2, P102, DOI 10.1016/S1091-255X(98)80110-8; Doldi SB, 2000, OBES SURG, V10, P171, DOI 10.1381/096089200321668730; Douketis JD, 1999, CAN MED ASSOC J, V160, P513; DOWLING HJ, 1993, DIABETES, V42, P537, DOI 10.2337/diabetes.42.4.537; Dujovne CA, 2001, AM HEART J, V142, P489, DOI 10.1067/mhj.2001.117510; Durazo-Arvizu RA, 1998, AM J EPIDEMIOL, V147, P739, DOI 10.1093/oxfordjournals.aje.a009518; Eden KB, 2002, ANN INTERN MED, V137, P208, DOI 10.7326/0003-4819-137-3-200208060-00015; Field AE, 2001, INT J OBESITY, V25, P1113, DOI 10.1038/sj.ijo.0801643; Finer N, 2000, INT J OBESITY, V24, P306, DOI 10.1038/sj.ijo.0801128; Fogelholm M, 1999, INT J OBESITY, V23, P203, DOI 10.1038/sj.ijo.0800825; Fogelholm M, 2000, ARCH INTERN MED, V160, P2177, DOI 10.1001/archinte.160.14.2177; Folsom AR, 2000, ARCH INTERN MED, V160, P2117, DOI 10.1001/archinte.160.14.2117; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Forestieri P, 1998, OBES SURG, V8, P49, DOI 10.1381/096089298765555051; Forsell P, 1997, OBES SURG, V7, P345, DOI 10.1381/096089297765555601; Forsell P, 1999, OBES SURG, V9, P11, DOI 10.1381/096089299765553647; Freeman JB, 1997, OBES SURG, V7, P337, DOI 10.1381/096089297765555593; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; Fujioka K, 2000, DIABETES OBES METAB, V2, P175, DOI 10.1046/j.1463-1326.2000.00081.x; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; GIUGLIANO D, 1993, EUR J CLIN PHARMACOL, V44, P107, DOI 10.1007/BF00315466; Gokcel A, 2002, DIABETES OBES METAB, V4, P49, DOI 10.1046/j.1463-1326.2002.00181.x; Gokcel A, 2001, DIABETES CARE, V24, P1957, DOI 10.2337/diacare.24.11.1957; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; GOULDING ST, 1995, BRIT J ANAESTH, V75, P301, DOI 10.1093/bja/75.3.301; GRAY DS, 1991, J CLIN EPIDEMIOL, V44, P545, DOI 10.1016/0895-4356(91)90218-X; Guagnano MT, 2000, EUR J CLIN NUTR, V54, P356, DOI 10.1038/sj.ejcn.1600963; Gurrici S, 1998, EUR J CLIN NUTR, V52, P779, DOI 10.1038/sj.ejcn.1600637; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Harwell TS, 2001, AM J PREV MED, V20, P196, DOI 10.1016/S0749-3797(00)00312-3; Hauptman J, 2000, ARCH FAM MED, V9, P160, DOI 10.1001/archfami.9.2.160; Heiat A, 2001, ARCH INTERN MED, V161, P1194, DOI 10.1001/archinte.161.9.1194; Hill JO, 1999, AM J CLIN NUTR, V69, P1108; Hill JO, 1999, AM J CLIN NUTR, V69, P381; Holeczy P, 1999, OBES SURG, V9, P453, DOI 10.1381/096089299765552738; Hollander PA, 1998, DIABETES CARE, V21, P1288, DOI 10.2337/diacare.21.8.1288; Horchner R, 1999, OBES SURG, V9, P399, DOI 10.1381/096089299765553016; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; Hubbard, 1991, Obes Surg, V1, P257; JADAD A, 1998, RANDOMIZED CONTROLLE; Jakicic JM, 1999, JAMA-J AM MED ASSOC, V282, P1554, DOI 10.1001/jama.282.16.1554; James WPT, 2000, LANCET, V356, P2119, DOI 10.1016/S0140-6736(00)03491-7; Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074; Jeffery RW, 1997, INT J OBESITY, V21, P457, DOI 10.1038/sj.ijo.0800431; Jones DW, 1999, AM J HYPERTENS, V12, P1175, DOI 10.1016/S0895-7061(99)00123-5; Jones KB, 1998, OBES SURG, V8, P35, DOI 10.1381/096089298765555024; Juhaeri, 2002, INT J OBESITY, V26, P58, DOI 10.1038/sj.ijo.0801846; Karhunen L, 2000, INT J OBESITY, V24, P1567, DOI 10.1038/sj.ijo.0801443; Kim KS, 2000, ANN EPIDEMIOL, V10, P424, DOI 10.1016/S1047-2797(00)00065-X; KNOWLER WC, 1995, DIABETES, V44, P483, DOI 10.2337/diabetes.44.5.483; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KULLER L, 1993, ANN INTERN MED, V119, P630, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00015; Kuller LH, 2001, CIRCULATION, V103, P32; Laara E, 1996, J EPIDEMIOL COMMUN H, V50, P408, DOI 10.1136/jech.50.4.408; Lear SA, 2002, METABOLISM, V51, P1427, DOI 10.1053/meta.2002.34042; Leermakers EA, 1999, ADDICT BEHAV, V24, P219, DOI 10.1016/S0306-4603(98)00090-2; Liese AD, 1997, ANN EPIDEMIOL, V7, P407, DOI 10.1016/S1047-2797(97)00047-1; Lindgarde F, 2000, J INTERN MED, V248, P245, DOI 10.1046/j.1365-2796.2000.00720.x; LINDHOLM LH, 1995, BRIT MED J, V310, P1105, DOI 10.1136/bmj.310.6987.1105; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lovejoy JC, 1996, METABOLISM, V45, P1119, DOI 10.1016/S0026-0495(96)90011-6; Lundell L, 1997, EUR J SURG, V163, P525; Luque CA, 1999, ANN PHARMACOTHER, V33, P968, DOI 10.1345/aph.18319; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; McMahon FG, 2000, ARCH INTERN MED, V160, P2185, DOI 10.1001/archinte.160.14.2185; McNulty SJ, 2003, DIABETES CARE, V26, P125, DOI 10.2337/diacare.26.1.125; McTigue KM, 2002, ANN INTERN MED, V136, P857, DOI 10.7326/0003-4819-136-12-200206180-00006; Melissas J, 1998, SOUTHERN MED J, V91, P1143, DOI 10.1097/00007611-199812000-00009; Micic D, 1999, Med Pregl, V52, P323; Miles JM, 2002, DIABETES CARE, V25, P1123, DOI 10.2337/diacare.25.7.1123; Miller K, 1999, OBES SURG, V9, P183, DOI 10.1381/096089299765553467; Muls E, 2001, INT J OBESITY, V25, P1713, DOI 10.1038/sj.ijo.0801814; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Myers A, 1999, INT J OBESITY, V23, P221, DOI 10.1038/sj.ijo.0800765; *NAT CTR HLTH STAT, 2002, HLTH US 2002 CHARTB; *NAT CTR HLTH STAT, 2001, HLTH US 2001 URB RUR; Nguyen NT, 2000, J AM COLL SURGEONS, V191, P149, DOI 10.1016/S1072-7515(00)00276-3; Nilsen TIL, 2001, BRIT J CANCER, V84, P417, DOI 10.1054/bjoc.2000.1582; Nowara HA, 2001, OBES SURG, V11, P70, DOI 10.1381/096089201321454141; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Oh CH, 1997, OBES SURG, V7, P142, DOI 10.1381/096089297765556042; Olson MB, 2000, J AM COLL CARDIOL, V36, P1565, DOI 10.1016/S0735-1097(00)00901-3; Papakonstantinou A, 1998, OBES SURG, V8, P215, DOI 10.1381/096089298765554845; Park YW, 2001, OBES RES, V9, P381, DOI 10.1038/oby.2001.49; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Petersmarck KA, 1999, INT J OBESITY, V23, P1246, DOI 10.1038/sj.ijo.0801058; PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Reynolds MW, 1999, J AM GERIATR SOC, V47, P1409, DOI 10.1111/j.1532-5415.1999.tb01558.x; Rissanen P, 2001, INT J OBESITY, V25, P212, DOI 10.1038/sj.ijo.0801540; Roe D A, 1976, J Am Med Womens Assoc (1972), V31, P193; Rosengren A, 1999, EUR HEART J, V20, P269, DOI 10.1053/euhj.1998.1235; Rossner S, 2000, OBES RES, V8, P49, DOI 10.1038/oby.2000.8; Rothacker DQ, 2001, J AM DIET ASSOC, V101, P345, DOI 10.1016/S0002-8223(01)00089-X; Sbrocco T, 1999, J CONSULT CLIN PSYCH, V67, P260, DOI 10.1037/0022-006X.67.2.260; Schauer PR, 2000, ANN SURG, V232, P515, DOI 10.1097/00000658-200010000-00007; Scheen AJ, 1999, INT J OBESITY, V23, P47; Shaper AG, 1997, BRIT MED J, V314, P1311, DOI 10.1136/bmj.314.7090.1311; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Sjostrom CD, 1999, OBES RES, V7, P477; Sjostrom CD, 2001, OBES RES, V9, P188, DOI 10.1038/oby.2001.20; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; SJOSTROM L, 1992, INT J OBESITY, V16, P465; Sjostrom L, 2000, ENDOCRINE, V13, P213, DOI 10.1385/ENDO:13:2:213; Smith IG, 2001, J FAM PRACTICE, V50, P505; Song YM, 2001, EPIDEMIOLOGY, V12, P173, DOI 10.1097/00001648-200103000-00008; SORKIN JD, 1994, INT J OBESITY, V18, P752; Stevens J, 2002, AM J EPIDEMIOL, V156, P832, DOI 10.1093/aje/kwf114; Stevens J, 2000, NUTR REV, V58, P346, DOI 10.1111/j.1753-4887.2000.tb01832.x; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; Stoner J, 1997, OBES SURG, V7, P513, DOI 10.1381/096089297765555278; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; Suter M, 2000, SURG ENDOSC-ULTRAS, V14, P532, DOI 10.1007/s004640000114; Suter M, 1999, OBES SURG, V9, P374, DOI 10.1381/096089299765552963; Swinburn BA, 1999, J AM DIET ASSOC, V99, P1400, DOI 10.1016/S0002-8223(99)00339-9; Teachman BA, 2001, INT J OBESITY, V25, P1525, DOI 10.1038/sj.ijo.0801745; Thompson D, 1999, ARCH INTERN MED, V159, P2177, DOI 10.1001/archinte.159.18.2177; Torgerson JS, 2001, INT J OBESITY, V25, pS2, DOI 10.1038/sj.ijo.0801687; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US DEP HHS PUBL H, 1998, NIH PUBL; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P219; Van Gaal LF, 1998, EUR J CLIN PHARMACOL, V54, P125, DOI 10.1007/s002280050433; Wadden TA, 2001, ARCH INTERN MED, V161, P218, DOI 10.1001/archinte.161.2.218; Wajchenberg BL, 2002, HORM METAB RES, V34, P616, DOI 10.1055/s-2002-38256; WANG J, 1994, AM J CLIN NUTR, V60, P23, DOI 10.1093/ajcn/60.1.23; Wannamethee SG, 1998, ARCH INTERN MED, V158, P2433, DOI 10.1001/archinte.158.22.2433; Weiner R, 1999, OBES SURG, V9, P539, DOI 10.1381/096089299765552639; Weiner R, 2001, SURG ENDOSC-ULTRAS, V15, P63, DOI 10.1007/s004640000303; Weiss HG, 2002, OBES SURG, V12, P573, DOI 10.1381/096089202762252370; Wiesner W, 2000, RADIOLOGY, V216, P389, DOI 10.1148/radiology.216.2.r00au28389; WILLIAMSON DF, 1993, ANN INTERN MED, V119, P731, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00021; Williamson DF, 1996, J AM COLL NUTR, V15, P6; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; Wing RR, 1996, DIABETES CARE, V19, P409, DOI 10.2337/diacare.19.5.409; Wirth A, 2001, JAMA-J AM MED ASSOC, V286, P1331, DOI 10.1001/jama.286.11.1331; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907; Yashkov YI, 1997, OBES SURG, V7, P317, DOI 10.1381/096089297765555539; 1991, N ENGL J MED, V325, P1745; 1999, CAN FAM PHYSICIAN, V45, P2331; 2002, 2002 DRUG TOPICS RED	182	424	429	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					933	949		10.7326/0003-4819-139-11-200312020-00013	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00013			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644897				2022-12-28	WOS:000186884800008
J	Friis-Moller, N; Sabin, CA; Weber, R; Monforte, AD; El-Sadr, WM; Reiss, P; Thiebaut, R; Morfeldt, L; De Wit, S; Pradier, C; Calvo, G; Law, MG; Kirk, O; Phillips, AN; Lundgren, JD; Lundgren, JD; Weber, R; Monteforte, AD; Bartsch, G; Reiss, P; Dabis, F; Morfeldt, L; De Wit, S; Pradier, C; Calvo, G; Law, MG; Kirk, O; Phillips, AN; Houyez, F; Loeliger, E; Tressler, R; Weller, I; Friis-Moller, N; Sabin, CA; Sjol, A; Lundgren, JD; Sawitz, A; Rickenbach, M; Pezzotti, P; Krum, E; Meester, R; Lavignolle, V; Sundstrom, A; Poll, B; Fontas, E; Torres, F; Petoumenos, K; Kjaer, J; Hammer, S; Neaton, J; Sjol, A; de Wolf, F; van der Ven, E; Zaheri, S; Van Valkengoed, L; Meester, R; Bronsveld, W; Weigel, H; Brinkman, K; Frissen, P; ten Veen, J; Hillbrand, M; van Dam, P; Schieveld, S; Mulder, J; van Gorp, E; Meenhorst, P; van Eeden, A; Danner, S; Claessen, F; Perenboom, R; Schattenkerk, JKE; Godfried, M; Lange, J; Lowe, S; van der Meer, J; Nellen, F; Pogany, K; van der Poll, T; Prins, J; Reiss, R; Ruys, T; van der Valk, M; Wit, F; Richter, C; van Leusen, R; Vriesendorp, R; Jeurissen, F; Kauffmann, R; Koger, E; Brevenboer, B; ten Napel, C; Sprenger, HG; Law, G; ten Kate, RW; Leemhuis, M; Kroon, F; Schippers, E; Schrey, G; van der Geest, S; Verbon, A; Koopmans, P; Keuter, M; Telgt, D; van der Ven, A; van der Ende, M; Gyssens, I; de Marie, S; Juttmann, J; van der Heul, C; Schneider, M; Borleffs, J; Hoepelman, I; Jaspers, C; Matute, A; Schurink, C; Blok, W; Salamon, R; Beylot, J; Dupon, M; Le Bras, M; Pellegrin, JL; Ragnaud, JM; Dabis, F; Chene, G; Jacqmin-Gadda, H; Rhiebaut, R; Lawson-Ayayi, S; Lavignolle, V; Balestre, E; Blaizeau, MJ; Decoin, M; Formaggio, AM; Delveaux, S; Labarerre, S; Uwamaliya, B; Vimard, E; Merchadou, L; Palmer, G; Touchard, D; Dutoit, D; Pereira, F; Boulant, B; Beylot, J; Morlat, P; Bernard, N; Bonarek, M; Bonnet, F; Coadou, B; Gelie, P; Jaubert, D; Nouts, C; Lacoste, D; Dupon, M; Dutronc, H; Cipriano, G; Lafarie, S; Chossat, I; Lacut, JY; Leng, B; Pellegrin, JL; Mercie, P; Viallard, JF; Faure, I; Rispal, P; Cipriano, C; Tchamgoue, S; Le Bras, M; Djossou, F; Malvy, D; Pivetaud, JP; Ragnaud, JM; Chambon, D; De La Taille, C; Galperine, T; Lafarie, S; Neau, D; Ochoa, A; Beylot, C; Doutre, MS; Bezian, JH; Moreau, JF; Taupin, JL; Conri, C; Constans, J; Couzigou, P; Castera, L; Fleury, H; Lafon, ME; Masquelier, B; Pellegrin, I; Trimoulet, P; Moreau, F; Mestre, C; Series, C; Taytard, A; Law, M; Petoumenos, K; Anderson, J; Bal, J; Mijch, A; Watson, K; Roth, N; Wood, H; Austin, D; Gowers, A; Baker, B; McFarlane, R; Carr, A; Cooper, D; Chuah, J; Fankhauser, W; Mallal, S; Skett, J; Calvo, G; Torres, F; Mateau, S; Domingo, P; Sambeat, MA; Gatell, J; Del Cacho, E; Cadafalch, J; Fuster, M; Codina, C; Sirera, G; Vaque, A; Clumeck, N; De Wit, S; Gerard, M; Hildebrand, M; Kabeya, K; Konopnicki, D; Payen, MC; Poll, B; Van Laethem, Y; Neaton, J; Bartsch, G; El-Sadr, WM; Krum, E; Thompson, G; Wentworth, D; Luskin-Hawk, R; Telzak, E; El-Sadr, WM; Abrams, DI; Cohn, D; Markowitz, N; Arduino, R; Mushatt, D; Friedland, G; Perez, G; Tedaldi, E; Fisher, E; Gordin, F; Crane, LR; Sampson, J; Baxter, J; Kirk, O; Mocroft, A; Phillips, AN; Lundgren, JD; Vetter, N; Clumeck, N; Hermans, P; Colebunders, R; Machala, L; Nielsen, J; Benfield, T; Gerstoft, J; Katzenstein, T; Roge, B; Skinhoj, P; Pedersen, C; Katlama, C; Viard, JP; Saint-Marc, T; Vanhems, P; Pradier, C; Dietrich, M; Manegold, C; van Lunzen, J; Miller, V; Staszewski, S; Bieckel, M; Goebel, FD; Salzberger, B; Rockstroh, J; Kosmidis, J; Gargalianos, P; Sambatakou, H; Perdios, J; Panos, G; Karydis, I; Filandras, A; Banhegyi, D; Mulcahy, F; Yust, I; Turner, D; Pollack, S; Ben-Ishai, Z; Bentwich, Z; Maayan, S; Vella, S; Chiesi, A; Arici, C; Pristera, R; Mazzotta, F; Gabbuti, A; Esposito, R; Bedini, A; Chirianni, A; Montesarchio, E; Vullo, V; Santopadre, P; Narciso, P; Antinori, A; Franci, P; Zaccarelli, M; Lazzarin, A; Finazzi, R; Monforte, VO; Hemmer, R; Staub, T; Reiss, P; Bruun, J; Maeland, A; Ormaasen, V; Knysz, B; Gasiorowski, J; Horban, A; Prokopowicz, D; Boron-Kaczmarska, A; Pnyka, M; Beniowski, M; Trocha, H; Antunes, F; Mansinho, K; Proenca, R; Gonzalez-Lahoz, J; Diaz, B; Garcia-Benayas, T; Martin-Carbonero, L; Soriano, V; Clotet, B; Jou, A; Conejero, J; Tural, C; Gatell, JM; Miro, JM; Blaxhult, A; Heidemann, B; Pehrson, P; Ledergerber, B; Weber, R; Francioli, P; Telenti, A; Hirschel, B; Soravia-Dunand, V; Furrer, H; Fisher, M; Brettle, R; Barton, S; Johnson, AM; Mercey, D; Loveday, C; Johnson, MA; Pinching, A; Parkin, J; Weber, J; Scullard, G; Morfeldt, L; Thulin, G; Sunstrom, A; Akerlund, B; Koppel, K; Karlsson, A; Flamholc, L; Hakangard, C; Monforte, AD; Pezzotti, P; Moroni, M; Monforte, AD; Cargnel, A; Merli, S; Vigevani, GM; Pastecchia, C; Lazzarin, A; Novati, R; Caggese, L; Moioli, C; Mura, MS; Mannazzu, M; Suter, F; Arici, C; Manconi, PE; Piano, P; Mazzotta, F; Lo Caputo, S; Poggio, A; Bottari, G; Pagano, G; Alessandrini, A; Scasso, A; Vincenti, A; Abbadesse, V; Mancuso, S; Alberici, F; Ruggieri, A; Arlotti, M; Ortolani, P; De Lalla, F; Tositti, G; Piersantelli, N; Piscopo, R; Raise, E; Pasquinucci, S; Soscia, F; Tacconi, L; Tirelli, U; Nasti, G; Santoro, D; Pusterla, L; Carosi, G; Castelli, F; Cadeo, G; Vangi, D; Carnevale, G; Galloni, D; Filice, G; Bruno, R; Sinicco, A; Sciandra, M; Caramello, P; Gennero, L; Soranzo, ML; Bonasso, M; Rizzardini, G; Migliorino, G; Chiodo, F; Colangeli, V; Magnani, G; Ursitti, M; Menichetti, F; Martinelli, C; Esposito, R; Mussini, C; Ghinelli, F; Sighinolfi, L; Coronado, O; Zauli, T; Ballardini, G; Montroni, M; Zoli, A; Petrelli, E; Cioppi, A; Ortona, L; De Luca, A; Petrosillo, N; Noto, P; Narciso, P; Salcuni, P; Antinori, A; De Longis, P; Vullo, V; Lichtner, M; Pastore, G; Minafra, G; Chiriann, A; Loiacono, L; Piazza, M; Nappa, S; Abrescia, N; De Marco, M; Colomba, A; Prestileo, T; De Stefano, C; La Gala, A; Ferraro, T; Scerbo, A; Grima, P; Tundo, P; Pizzigallo, E; D'Alessandro, M; Grisorio, B; Ferrara, S; Pradier, C; Fontas, E; Caissotti, C; Dellamonica, P; Bentz, L; Bernard, E; Chaillou, S; De Salvador-Guillouet, F; Durant, J; Guttman, R; Heripret, L; Mondain-Miton, V; Perbost, I; Prouvost-Keller, B; Pugliese, P; Rahelinirina, V; Roger, PM; Vandenbos, F; Bernasconi, E; Bucher, H; Burgisser, P; Cattacin, S; Egger, M; Erb, P; Fierz, W; Fischer, M; Flepp, M; Fontana, A; Francioli, P; Furrer, HJ; Gorgievski, M; Hirschel, B; Kaiser, L; Kind, C; Klimkait, T; Ledergerber, B; Lauper, U; Opravil, M; Paccaud, F; Pantaleo, G; Perrin, L; Piffaretti, JC; Rickenbach, M; Rudin, C; Schupbach, J; Speck, R; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S				Friis-Moller, N; Sabin, CA; Weber, R; Monforte, AD; El-Sadr, WM; Reiss, P; Thiebaut, R; Morfeldt, L; De Wit, S; Pradier, C; Calvo, G; Law, MG; Kirk, O; Phillips, AN; Lundgren, JD; Lundgren, JD; Weber, R; Monteforte, AD; Bartsch, G; Reiss, P; Dabis, F; Morfeldt, L; De Wit, S; Pradier, C; Calvo, G; Law, MG; Kirk, O; Phillips, AN; Houyez, F; Loeliger, E; Tressler, R; Weller, I; Friis-Moller, N; Sabin, CA; Sjol, A; Lundgren, JD; Sawitz, A; Rickenbach, M; Pezzotti, P; Krum, E; Meester, R; Lavignolle, V; Sundstrom, A; Poll, B; Fontas, E; Torres, F; Petoumenos, K; Kjaer, J; Hammer, S; Neaton, J; Sjol, A; de Wolf, F; van der Ven, E; Zaheri, S; Van Valkengoed, L; Meester, R; Bronsveld, W; Weigel, H; Brinkman, K; Frissen, P; ten Veen, J; Hillbrand, M; van Dam, P; Schieveld, S; Mulder, J; van Gorp, E; Meenhorst, P; van Eeden, A; Danner, S; Claessen, F; Perenboom, R; Schattenkerk, JKE; Godfried, M; Lange, J; Lowe, S; van der Meer, J; Nellen, F; Pogany, K; van der Poll, T; Prins, J; Reiss, R; Ruys, T; van der Valk, M; Wit, F; Richter, C; van Leusen, R; Vriesendorp, R; Jeurissen, F; Kauffmann, R; Koger, E; Brevenboer, B; ten Napel, C; Sprenger, HG; Law, G; ten Kate, RW; Leemhuis, M; Kroon, F; Schippers, E; Schrey, G; van der Geest, S; Verbon, A; Koopmans, P; Keuter, M; Telgt, D; van der Ven, A; van der Ende, M; Gyssens, I; de Marie, S; Juttmann, J; van der Heul, C; Schneider, M; Borleffs, J; Hoepelman, I; Jaspers, C; Matute, A; Schurink, C; Blok, W; Salamon, R; Beylot, J; Dupon, M; Le Bras, M; Pellegrin, JL; Ragnaud, JM; Dabis, F; Chene, G; Jacqmin-Gadda, H; Rhiebaut, R; Lawson-Ayayi, S; Lavignolle, V; Balestre, E; Blaizeau, MJ; Decoin, M; Formaggio, AM; Delveaux, S; Labarerre, S; Uwamaliya, B; Vimard, E; Merchadou, L; Palmer, G; Touchard, D; Dutoit, D; Pereira, F; Boulant, B; Beylot, J; Morlat, P; Bernard, N; Bonarek, M; Bonnet, F; Coadou, B; Gelie, P; Jaubert, D; Nouts, C; Lacoste, D; Dupon, M; Dutronc, H; Cipriano, G; Lafarie, S; Chossat, I; Lacut, JY; Leng, B; Pellegrin, JL; Mercie, P; Viallard, JF; Faure, I; Rispal, P; Cipriano, C; Tchamgoue, S; Le Bras, M; Djossou, F; Malvy, D; Pivetaud, JP; Ragnaud, JM; Chambon, D; De La Taille, C; Galperine, T; Lafarie, S; Neau, D; Ochoa, A; Beylot, C; Doutre, MS; Bezian, JH; Moreau, JF; Taupin, JL; Conri, C; Constans, J; Couzigou, P; Castera, L; Fleury, H; Lafon, ME; Masquelier, B; Pellegrin, I; Trimoulet, P; Moreau, F; Mestre, C; Series, C; Taytard, A; Law, M; Petoumenos, K; Anderson, J; Bal, J; Mijch, A; Watson, K; Roth, N; Wood, H; Austin, D; Gowers, A; Baker, B; McFarlane, R; Carr, A; Cooper, D; Chuah, J; Fankhauser, W; Mallal, S; Skett, J; Calvo, G; Torres, F; Mateau, S; Domingo, P; Sambeat, MA; Gatell, J; Del Cacho, E; Cadafalch, J; Fuster, M; Codina, C; Sirera, G; Vaque, A; Clumeck, N; De Wit, S; Gerard, M; Hildebrand, M; Kabeya, K; Konopnicki, D; Payen, MC; Poll, B; Van Laethem, Y; Neaton, J; Bartsch, G; El-Sadr, WM; Krum, E; Thompson, G; Wentworth, D; Luskin-Hawk, R; Telzak, E; El-Sadr, WM; Abrams, DI; Cohn, D; Markowitz, N; Arduino, R; Mushatt, D; Friedland, G; Perez, G; Tedaldi, E; Fisher, E; Gordin, F; Crane, LR; Sampson, J; Baxter, J; Kirk, O; Mocroft, A; Phillips, AN; Lundgren, JD; Vetter, N; Clumeck, N; Hermans, P; Colebunders, R; Machala, L; Nielsen, J; Benfield, T; Gerstoft, J; Katzenstein, T; Roge, B; Skinhoj, P; Pedersen, C; Katlama, C; Viard, JP; Saint-Marc, T; Vanhems, P; Pradier, C; Dietrich, M; Manegold, C; van Lunzen, J; Miller, V; Staszewski, S; Bieckel, M; Goebel, FD; Salzberger, B; Rockstroh, J; Kosmidis, J; Gargalianos, P; Sambatakou, H; Perdios, J; Panos, G; Karydis, I; Filandras, A; Banhegyi, D; Mulcahy, F; Yust, I; Turner, D; Pollack, S; Ben-Ishai, Z; Bentwich, Z; Maayan, S; Vella, S; Chiesi, A; Arici, C; Pristera, R; Mazzotta, F; Gabbuti, A; Esposito, R; Bedini, A; Chirianni, A; Montesarchio, E; Vullo, V; Santopadre, P; Narciso, P; Antinori, A; Franci, P; Zaccarelli, M; Lazzarin, A; Finazzi, R; Monforte, VO; Hemmer, R; Staub, T; Reiss, P; Bruun, J; Maeland, A; Ormaasen, V; Knysz, B; Gasiorowski, J; Horban, A; Prokopowicz, D; Boron-Kaczmarska, A; Pnyka, M; Beniowski, M; Trocha, H; Antunes, F; Mansinho, K; Proenca, R; Gonzalez-Lahoz, J; Diaz, B; Garcia-Benayas, T; Martin-Carbonero, L; Soriano, V; Clotet, B; Jou, A; Conejero, J; Tural, C; Gatell, JM; Miro, JM; Blaxhult, A; Heidemann, B; Pehrson, P; Ledergerber, B; Weber, R; Francioli, P; Telenti, A; Hirschel, B; Soravia-Dunand, V; Furrer, H; Fisher, M; Brettle, R; Barton, S; Johnson, AM; Mercey, D; Loveday, C; Johnson, MA; Pinching, A; Parkin, J; Weber, J; Scullard, G; Morfeldt, L; Thulin, G; Sunstrom, A; Akerlund, B; Koppel, K; Karlsson, A; Flamholc, L; Hakangard, C; Monforte, AD; Pezzotti, P; Moroni, M; Monforte, AD; Cargnel, A; Merli, S; Vigevani, GM; Pastecchia, C; Lazzarin, A; Novati, R; Caggese, L; Moioli, C; Mura, MS; Mannazzu, M; Suter, F; Arici, C; Manconi, PE; Piano, P; Mazzotta, F; Lo Caputo, S; Poggio, A; Bottari, G; Pagano, G; Alessandrini, A; Scasso, A; Vincenti, A; Abbadesse, V; Mancuso, S; Alberici, F; Ruggieri, A; Arlotti, M; Ortolani, P; De Lalla, F; Tositti, G; Piersantelli, N; Piscopo, R; Raise, E; Pasquinucci, S; Soscia, F; Tacconi, L; Tirelli, U; Nasti, G; Santoro, D; Pusterla, L; Carosi, G; Castelli, F; Cadeo, G; Vangi, D; Carnevale, G; Galloni, D; Filice, G; Bruno, R; Sinicco, A; Sciandra, M; Caramello, P; Gennero, L; Soranzo, ML; Bonasso, M; Rizzardini, G; Migliorino, G; Chiodo, F; Colangeli, V; Magnani, G; Ursitti, M; Menichetti, F; Martinelli, C; Esposito, R; Mussini, C; Ghinelli, F; Sighinolfi, L; Coronado, O; Zauli, T; Ballardini, G; Montroni, M; Zoli, A; Petrelli, E; Cioppi, A; Ortona, L; De Luca, A; Petrosillo, N; Noto, P; Narciso, P; Salcuni, P; Antinori, A; De Longis, P; Vullo, V; Lichtner, M; Pastore, G; Minafra, G; Chiriann, A; Loiacono, L; Piazza, M; Nappa, S; Abrescia, N; De Marco, M; Colomba, A; Prestileo, T; De Stefano, C; La Gala, A; Ferraro, T; Scerbo, A; Grima, P; Tundo, P; Pizzigallo, E; D'Alessandro, M; Grisorio, B; Ferrara, S; Pradier, C; Fontas, E; Caissotti, C; Dellamonica, P; Bentz, L; Bernard, E; Chaillou, S; De Salvador-Guillouet, F; Durant, J; Guttman, R; Heripret, L; Mondain-Miton, V; Perbost, I; Prouvost-Keller, B; Pugliese, P; Rahelinirina, V; Roger, PM; Vandenbos, F; Bernasconi, E; Bucher, H; Burgisser, P; Cattacin, S; Egger, M; Erb, P; Fierz, W; Fischer, M; Flepp, M; Fontana, A; Francioli, P; Furrer, HJ; Gorgievski, M; Hirschel, B; Kaiser, L; Kind, C; Klimkait, T; Ledergerber, B; Lauper, U; Opravil, M; Paccaud, F; Pantaleo, G; Perrin, L; Piffaretti, JC; Rickenbach, M; Rudin, C; Schupbach, J; Speck, R; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S		DAD Study Grp	Combination antiretroviral therapy and the risk of myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; PROTEASE INHIBITORS; MONICA PROJECT; HEART-DISEASE; EVENT RATES; ASSOCIATION; LIPODYSTROPHY	Background: It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction. Methods: In this prospective observational study, we enrolled 23,468 patients from 11 previously established cohorts from December 1999 to April 2001 and collected follow-up data until February 2002. Data were collected on infection with the human immunodeficiency virus and on risk factors for and the incidence of myocardial infarction. Relative rates were calculated with Poisson regression models. Combination antiretroviral therapy was defined as any combination regimen of antiretroviral drugs that included a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor. Results: Over a period of 36,199 person-years, 126 patients had a myocardial infarction. The incidence of myocardial infarction increased with longer exposure to combination antiretroviral therapy (adjusted relative rate per year of exposure, 1.26 [95 percent confidence interval, 1.12 to 1.41]; P<0.001). Other factors significantly associated with myocardial infarction were older age, current or former smoking, previous cardiovascular disease, and male sex, but not a family history of coronary heart disease. A higher total serum cholesterol level, a higher triglyceride level, and the presence of diabetes were also associated with an increased incidence of myocardial infarction. Conclusions: Combination antiretroviral therapy was independently associated with a 26 percent relative increase in the rate of myocardial infarction per year of exposure during the first four to six years of use. However, the absolute risk of myocardial infarction was low and must be balanced against the marked benefits from antiretroviral treatment.	Hvidovre Univ Hosp, Sect 044, Copenhagen HIV Program, DAD Coordinating Ctr, DK-2650 Copenhagen, Denmark	University of Copenhagen	Lundgren, JD (corresponding author), Hvidovre Univ Hosp, Sect 044, Copenhagen HIV Program, DAD Coordinating Ctr, DK-2650 Copenhagen, Denmark.	jdl@cphiv.dk	Torres, Filipa/G-9742-2016; PEZZOTTI, PATRIZIO/C-6480-2016; Sighinolfi, Laura/AAH-1426-2020; Klimkait, Thomas/A-1057-2008; Wit, Ferdinand/AAC-3803-2019; chene, genevieve/H-8665-2014; Ledergerber, Bruno/B-5656-2009; Pradier, Christian/AAE-9669-2022; Lundgren, Jens/AAE-6876-2019; VELLA, STEFANO/V-8440-2019; Petrosillo, Nicola/AAZ-2095-2021; kirk, ole/ABB-4746-2021; Djossou, Felix/AAM-8640-2020; Mussini, Cristina/K-8672-2016; Gyssens, Inge C.J./L-4343-2015; DABIS, FRANCOIS/S-9298-2019; Phillips, Andrew N/B-4427-2008; Thiebaut, Rodolphe/T-6803-2019; VALLET, Yannick/F-9979-2011; Magnani, Giulia/AGM-1833-2022; Torres, Ferran/D-1296-2011; Castelli, Francesco/E-7045-2010; Antinori, Andrea/K-7125-2016; Domingo, Pere/AAP-7571-2021; Pradier, Christian/AFE-8255-2022; Gatell, Jose M/ABC-3607-2020; Telenti, Amalio/AAY-1674-2021; paccaud, fred/M-7516-2019; Furrer, Hansjakob/G-6768-2013; van Valkengoed, Irene G.M./B-2974-2013; Weber, Rainer/D-5175-2012; Bruno, Raffaele/AAB-9491-2022; Prins, Jan M./AAF-4945-2020; VELLA, STEFANO/ABI-3368-2020; MALVY, Denis/T-7930-2019; Bonnet, Fabrice/T-3254-2019; Panos, George/H-3944-2011; Gabbuti, Andrea/ABC-4907-2020; Domingo, Pere/CAF-3577-2022; Soriano, Vicente/O-5730-2018; Mallal, Simon Alexander/HDM-9561-2022; Vella, Stefano/GZM-0519-2022; Sabin, Caroline/C-2464-2008	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; chene, genevieve/0000-0002-8368-6460; Ledergerber, Bruno/0000-0002-6881-4401; VELLA, STEFANO/0000-0003-2347-5984; Mussini, Cristina/0000-0002-6615-4198; DABIS, FRANCOIS/0000-0002-1614-8857; Phillips, Andrew N/0000-0003-2384-4807; Thiebaut, Rodolphe/0000-0002-5235-3962; Magnani, Giulia/0000-0003-1090-0101; Torres, Ferran/0000-0002-7355-7913; Antinori, Andrea/0000-0003-2121-4684; Domingo, Pere/0000-0003-1138-5770; Furrer, Hansjakob/0000-0002-1375-3146; van Valkengoed, Irene G.M./0000-0002-9306-7831; Bruno, Raffaele/0000-0002-0235-9207; Soriano, Vicente/0000-0002-4624-5199; Mallal, Simon Alexander/0000-0002-7036-1309; Sabin, Caroline/0000-0001-5173-2760; Benfield, Thomas/0000-0003-0698-9385; Kaiser, Laurent/0000-0002-0857-2252; Law, Matthew/0000-0002-3540-8837; MARTIN CARBONERO, LUZ/0000-0001-8102-4079; Galperine, Tatiana Katerina/0000-0003-4125-1845; Friis-Moller, Nina/0000-0002-7449-7393; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100; Castelli, Francesco/0000-0001-9161-7804; Ruggieri, Anna/0000-0003-2987-3844	NIAID NIH HHS [5U01AI042170-10, 5U01AI046362-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI042170, U01AI046362] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Coplan PM, 2003, AIDS RES HUM RETROV, V19, P449, DOI 10.1089/088922203766774487; Currier J, 2002, ANTIVIR THER, V7, pL37; *D A D STUD, DAT COLL ADV EV ANT; Escaut L, 2003, INTENS CARE MED, V29, P969, DOI 10.1007/s00134-003-1740-0; Flynn TE, 1999, ANN INTERN MED, V131, P548, DOI 10.7326/0003-4819-131-7-199910050-00032; Friis-Moller N, 2003, AIDS, V17, P1179, DOI 10.1097/00002030-200305230-00010; Galli M, 2002, J ACQ IMMUN DEF SYND, V29, P21, DOI 10.1097/00126334-200201010-00003; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Karmochkine M, 1998, AIDS, V12, P2499; Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002; KLEIN D, 2003, 10 C RETR OPP INF BO; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; Law M, 2003, HIV Med, V4, P1, DOI 10.1046/j.1468-1293.2003.00138.x; MARYKRAUSE M, 2001, 8 C RETR OPP INF CHI; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MOORE RD, 2003, 10 C RETR OPP INF BO, P132; Tunstall-Pedoe H, 1998, LANCET, V351, P1425, DOI 10.1016/S0140-6736(97)11321-6; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Vergis EN, 2001, INT J STD AIDS, V12, P463, DOI 10.1258/0956462011923507; Vittecoq D, 1998, LANCET, V351, P1959, DOI 10.1016/S0140-6736(05)78644-X; Walli R, 1998, AIDS, V12, pF167, DOI 10.1097/00002030-199815000-00001; World Health Organization MONICA Project, MONICA MAN 4	30	1276	1322	2	83	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					1993	2003		10.1056/NEJMoa030218	http://dx.doi.org/10.1056/NEJMoa030218			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627784	Green Published			2022-12-28	WOS:000186642900003
J	Nef, S; Verma-Kurvari, S; Merenmies, J; Vassalli, JD; Efstratiadis, A; Accili, D; Parada, LF				Nef, S; Verma-Kurvari, S; Merenmies, J; Vassalli, JD; Efstratiadis, A; Accili, D; Parada, LF			Testis determination requires insulin receptor family function in mice	NATURE			English	Article							SEX DETERMINATION; SRY EXPRESSION; GENE; REVERSAL; PROLIFERATION; LACKING	In mice, gonads are formed shortly before embryonic day 10.5 by the thickening of the mesonephros and consist of somatic cells and migratory primordial germ cells(1). The male sex-determining process is set in motion by the sex-determining region of the Y chromosome (Sry), which triggers differentiation of the Sertoli cell lineage. In turn, Sertoli cells function as organizing centres and direct differentiation of the testis. In the absence of Sry expression, neither XX nor XY gonads develop testes(2), and alterations in Sry expression are often associated with abnormal sexual differentiation(3-8). The molecular signalling mechanisms by which Sry specifies the male pathway and models the undifferentiated gonad are unknown. Here we show that the insulin receptor tyrosine kinase family, comprising Ir, Igf1r and Irr, is required for the appearance of male gonads and thus for male sexual differentiation. XY mice that are mutant for all three receptors develop ovaries and show a completely female phenotype. Reduced expression of both Sry and the early testis-specific marker Sox9 indicates that the insulin signalling pathway is required for male sex determination.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75390 USA; Univ Geneva, Dept Morphol, Ctr Med Univ, CH-1211 Geneva 4, Switzerland; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Naomi Berrie Diabet Ctr, New York, NY 10032 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva; Columbia University; Columbia University; Columbia University	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	luis.parada@utsouthwestern.edu	Nef, Serge/AAV-6445-2020; Parada, luis F/B-9400-2014	Nef, Serge/0000-0001-5462-0676; 				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Albrecht KH, 2003, GENETICS, V164, P277; Burgoyne PS, 1993, GONADAL DEV FUNCTION, P17; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; Capel B, 2000, MECH DEVELOP, V92, P89, DOI 10.1016/S0925-4773(99)00327-5; Clarkson MJ, 2002, TRENDS ENDOCRIN MET, V13, P106, DOI 10.1016/S1043-2760(01)00541-0; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kitamura T, 2001, MOL CELL BIOL, V21, P5624, DOI 10.1128/MCB.21.16.5624-5630.2001; LEE CH, 1994, DEV BIOL, V165, P442, DOI 10.1006/dbio.1994.1266; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Nagamine CM, 1999, DEV BIOL, V216, P182, DOI 10.1006/dbio.1999.9436; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221; Scherer G, 1999, CELL MOL LIFE SCI, V55, P821, DOI 10.1007/s000180050335; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmahl J, 2003, DEV BIOL, V258, P264, DOI 10.1016/S0012-1606(03)00122-2; Soyal SM, 2000, DEVELOPMENT, V127, P4645; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Tevosian SG, 2002, DEVELOPMENT, V129, P4627; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Washburn LL, 2001, GENETICS, V158, P1675	27	202	210	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	2003	426	6964					291	295		10.1038/nature02059	http://dx.doi.org/10.1038/nature02059			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628051				2022-12-28	WOS:000186660800044
J	Yarar, D				Yarar, D			Cortical patches on the move	CELL			English	Editorial Material							ACTIN; ENDOCYTOSIS; CELLS	Endocytosis is the primary means by which eukaryotic cells internalize materials from the environment. However, while many components of the endocytic machinery are known, the timing of molecular events leading to endocytosis remains undefined. In this issue of Cell, Kaksonen et al. use real-time microscopy to define the temporal assembly of components of the endocytic machinery in the yeast S. cerevisiae. They also provide new insight into how the actin cytoskeleton is coordinated with the endocytic machinery.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Yarar, D (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.							Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111	6	3	3	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					373	375		10.1016/S0092-8674(03)00890-0	http://dx.doi.org/10.1016/S0092-8674(03)00890-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622592	Bronze			2022-12-28	WOS:000186627100004
J	Ntzani, EE; Ioannidis, JPA				Ntzani, EE; Ioannidis, JPA			Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment	LANCET			English	Article							CDNA MICROARRAYS; GENE-EXPRESSION; SCIENCE; STANDARDS; PITFALLS; MODEL	Background DNA microarrays are being used for many applications, including the prediction of cancer outcomes by simultaneous analysis of the expression of thousands of genes. We systematically assessed the predictive performance of this method for major clinical outcomes (death, metastasis, recurrence, response to therapy) and the correlation of gene profiling with other clinicopathological correlates of malignant disorders. Methods Eligible reports retrieved from MEDLINE (1995 to April, 2003) were assessed for features of study design, reported predictive performance, and consideration of other prognostic factors. We searched for study variables that increased the chances that a significant association with a clinical outcome or correlate would be found. Findings 84 eligible studies were identified, of which 30 addressed major clinical outcomes. A median of 25 (IQR 15-45) patients with cancer were included. Among the studies of major clinical outcomes, nine did cross-validation but it was complete in only two of them; six studies used independent validation of supervised predictive models. Smaller studies showed better sensitivity and specificity for clinical outcomes than larger studies. Only 11 studies addressing major clinical outcomes did subgroup or adjusted analyses for other prognostic factors. Across all 84 studies, significant associations were 3.5 (95% CI 1.5-8.0) times more likely per doubling of sample size and 9.7 (2.0-47.0) times more likely per ten-fold increase in microarray probes. Interpretation DNA microarrays addressing cancer outcomes show variable prognostic performance. Larger studies with appropriate clinical design, adjustment for known predictors, and proper validation are essential for this highly promising technology.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece; Fdn Res & Technol Hellas, Biomed Res Inst, GR-71110 Iraklion, Greece; Tufts Univ, Sch Med, Tufts New England Med Ctr, Div Clin Care Res, Boston, MA 02111 USA	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts Medical Center; Tufts University	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011; Ntzani, Evangelina E./K-1565-2019	Ntzani, Evangelia/0000-0003-3712-4181				Aitman TJ, 2001, BRIT MED J, V323, P611, DOI 10.1136/bmj.323.7313.611; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1919, DOI 10.1001/jama.281.20.1919; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Firestein GS, 2002, ARTHRITIS RHEUM, V46, P859, DOI 10.1002/art.10236; Golub TR, 2001, NEW ENGL J MED, V344, P601, DOI 10.1056/NEJM200102223440809; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; King HC, 2001, JAMA-J AM MED ASSOC, V286, P2280, DOI 10.1001/jama.286.18.2280; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029; Schumacher M, 1997, STAT MED, V16, P2813, DOI 10.1002/(SICI)1097-0258(19971230)16:24<2813::AID-SIM701>3.0.CO;2-Z; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Stoehr MU, 2002, CAN J FOREST RES, V32, P469, DOI 10.1139/X01-222; Wittes J, 1999, J NATL CANCER I, V91, P400, DOI 10.1093/jnci/91.5.400	21	243	261	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2003	362	9394					1439	1444		10.1016/S0140-6736(03)14686-7	http://dx.doi.org/10.1016/S0140-6736(03)14686-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602436				2022-12-28	WOS:000186356600008
J	Ham, C; York, N; Sutch, S; Shaw, R				Ham, C; York, N; Sutch, S; Shaw, R			Hospital bed utilisation in the NHS, Kaiser Permanente, and the US Medicare programme: analysis of routine data	BRITISH MEDICAL JOURNAL			English	Article								Objective To compare the utilisation of hospital beds in the NHS in England, Kaiser Permanente in California, and the Medicare programme in the United States and California. Design Analysis of routinely available data from 2000 and 2001 on inpatient admissions, lengths of stay, and bed days in populations aged over 65 for 11 leading causes of use of acute beds. Setting Comparison of NHS data with data from Kaiser Permanente in California and the Medicare programme in California and the United States; interviews with Kaiser Permanente staff and visits to Kaiser facilities. Results Bed day use in the NHS for the 11 leading causes is three and a half times that of Kaiser's standardised rate, almost twice that of the Medicare California's standardised rate, and more than 50% higher than the standardised rate in Medicare in the United States. Kaiser achieves these results through a combination of low admission rates and relatively short stays. The lower use of bed days in Medicare in California compared with Medicare in the United States suggests there is a "California effect" as well as a "Kaiser effect" in hospital utilisation. Conclusion The NHS can learn from Kaiser's integrated approach, the focus on chronic diseases and their effective management, the emphasis placed on self care, the role of intermediate care, and the leadership provided by doctors in developing and supporting this model of care.	Dept Hlth, Strategy Unit, London SW1A 2NS, England; Dept Hlth, Econ & Operat Res Div, Leeds LS2 7UE, W Yorkshire, England; NHS Informat Author, Winchester SO22 5DH, Hants, England		Ham, C (corresponding author), Dept Hlth, Strategy Unit, London SW1A 2NS, England.			Sutch, Stephen/0000-0003-3202-6718				[Anonymous], 2001, HOSP EP STAT 2000 20; *AUD COMM, 1992, LYING WAIT US MED BE; Berwick DM, 2002, BRIT MED J, V324, P142; Crosson FJ, 2003, BRIT MED J, V326, P654, DOI 10.1136/bmj.326.7390.654; Enthoven AC, 2002, BRIT MED J, V324, P143; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; GODDARD M, 2000, SHAPING FUTURE NHS L, P96; Hellinger FJ, 2000, MED CARE RES REV, V57, P405, DOI 10.1177/107755870005700402	8	122	123	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 29	2003	327	7426					1257	1260A		10.1136/bmj.327.7426.1257	http://dx.doi.org/10.1136/bmj.327.7426.1257			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749VD	14644968	Green Published, Bronze			2022-12-28	WOS:000186948800017
J	Lingel, A; Simon, B; Izaurralde, E; Sattler, M				Lingel, A; Simon, B; Izaurralde, E; Sattler, M			Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain	NATURE			English	Article							RNA INTERFERENCE; PROTEIN STRUCTURES; GENE; NMR; ATP; RECOGNITION; CLEAVAGE; PROGRAM; HOMOLOG; SYSTEM	RNA interference is a conserved mechanism that regulates gene expression in response to the presence of double-stranded (ds) RNAs1,2. The RNase III-like enzyme Dicer first cleaves dsRNA into 21-23-nucleotide small interfering RNAs (siR-NAs)(3-6). In the effector step, the multimeric RNA-induced silencing complex ( RISC) identifies messenger RNAs homologous to the siRNAs and promotes their degradation(3,7). The Argonaute 2 protein (Ago2) is a critical component of RISC8,9. Both Argonaute and Dicer family proteins contain a common PAZ domain whose function is unknown(10). Here we present the three-dimensional nuclear magnetic resonance structure of the Drosophila melanogaster Ago2 PAZ domain. This domain adopts a nucleic-acid-binding fold that is stabilized by conserved hydrophobic residues. The nucleic-acid-binding patch is located in a cleft between the surface of a central beta-barrel and a conserved module comprising strands beta3, beta4 and helix alpha3. Because critical structural residues and the binding surface are conserved, we suggest that PAZ domains in all members of the Argonaute and Dicer families adopt a similar fold with nucleic-acid binding function, and that this plays an important part in gene silencing.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Izaurralde, E (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Sattler, Michael/A-2407-2012; Lingel, Andreas/AAP-5078-2021; Sattler, Michael/C-1169-2010; Izaurralde, Elisa/G-3239-2012	Sattler, Michael/0000-0002-1594-0527; Simon, Bernd/0000-0003-0164-5516; Izaurralde, Elisa/0000-0001-7365-2649				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kataoka Y, 2001, GENES CELLS, V6, P313, DOI 10.1046/j.1365-2443.2001.00427.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; YAN KS, 2003, NATURE          1116; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	30	326	362	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 27	2003	426	6965					465	469		10.1038/nature02123	http://dx.doi.org/10.1038/nature02123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747JE	14615801				2022-12-28	WOS:000186800800043
J	Rayapureddi, JP; Kattamuri, C; Steinmetz, BD; Frankfort, BJ; Ostrin, EJ; Mardon, G; Hegde, RS				Rayapureddi, JP; Kattamuri, C; Steinmetz, BD; Frankfort, BJ; Ostrin, EJ; Mardon, G; Hegde, RS			Eyes absent represents a class of protein tyrosine phosphatases	NATURE			English	Article							P-TYPE ATPASE; DROSOPHILA EYE; GENE; DEHALOGENASE; SUBSTRATE; MUTATIONS; EYA1; SUPERFAMILY; ACTIVATION; COMPLEX	The Eyes absent proteins are members of a conserved regulatory network implicated in the development of the eye, muscle, kidney and ear(1-7). Mutations in the Eyes absent genes have been associated with several congenital disorders including the multi-organ disease bronchio-oto-renal syndrome(8), congenital cataracts(9) and late-onset deafness(10). On the basis of previous analyses it has been shown that Eyes absent is a nuclear transcription factor, acting through interaction with homeodomain-containing Sine oculis (also known as Six) proteins(11). Here we show that Eyes absent is also a protein tyrosine phosphatase. It does not resemble the classical tyrosine phosphatases that use cysteine as a nucleophile and proceed by means of a thiol-phosphate intermediate(12). Rather, Eyes absent is the prototype for a class of protein tyrosine phosphatases that use a nucleophilic aspartic acid in a metal-dependent reaction. Furthermore, the phosphatase activity of Eyes absent contributes to its ability to induce eye formation in Drosophila.	Cincinnati Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Neurosci & Program Dev Biol, Houston, TX 77030 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Hegde, RS (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL EYE INSTITUTE [R01EY014648, R01EY011232] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY014648] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdelhak S, 1997, HUM MOL GENET, V6, P2247, DOI 10.1093/hmg/6.13.2247; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Azuma N, 2000, HUM MOL GENET, V9, P363, DOI 10.1093/hmg/9.3.363; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Bui QT, 2000, GENETICS, V155, P709; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Desplan C, 1997, CELL, V91, P861, DOI 10.1016/S0092-8674(00)80475-4; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Pappu KS, 2003, DEVELOPMENT, V130, P3053, DOI 10.1242/dev.00534; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Wayne S, 2001, HUM MOL GENET, V10, P195, DOI 10.1093/hmg/10.3.195; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu PX, 1997, DEVELOPMENT, V124, P219; Xu PX, 2002, DEVELOPMENT, V129, P3033; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446	30	188	210	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 20	2003	426	6964					295	298		10.1038/nature02093	http://dx.doi.org/10.1038/nature02093			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	744YQ	14628052				2022-12-28	WOS:000186660800045
J	Dunn, DT; Gibb, DM; Duong, T; Babiker, AG; Bulterys, M; Gabiano, C; Galli, L; Giaquinto, C; Gray, L; Harris, DR; Hughes, M; McKinney, R; Mofenson, L; Moye, J; Newell, ML; Pahwa, S; Palumbo, P; Rudin, C; Schluchter, M; Sharland, M; Shearer, W; Thompson, B; Tookey, P				Dunn, DT; Gibb, DM; Duong, T; Babiker, AG; Bulterys, M; Gabiano, C; Galli, L; Giaquinto, C; Gray, L; Harris, DR; Hughes, M; McKinney, R; Mofenson, L; Moye, J; Newell, ML; Pahwa, S; Palumbo, P; Rudin, C; Schluchter, M; Sharland, M; Shearer, W; Thompson, B; Tookey, P		HIV Paediat Prognostic Markers Col	Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; INTRAVENOUS IMMUNE GLOBULIN; BACTERIAL-INFECTIONS; CONTROLLED TRIAL; VIRAL LOAD; HIV; TYPE-1; TRANSMISSION; PREVENTION; MORTALITY	Background Data on the short-term risk of disease progression in HIV-1-infected children are needed to address the question of when to begin combination antiretroviral therapy. We estimated 12-month risks of progression to AIDS and death, by age and most recent measurement of CD4 T-cell percentage (CD4%) or viral load, in children receiving no antiretroviral therapy or zidovudine monotherapy only. Methods We undertook a meta-analysis of individual longitudinal data for 3941 children from eight cohort studies and nine randomised trials in Europe and the USA. Estimates of risk were derived from parametric survival models. Findings 997 AIDS-defining events were recorded over 7297 person-years of follow-up in the analysis of CD4%, and 284 events over 2282 person-years in the viral load analysis, corresponding to 568 deaths (9087 person-years) and 129 deaths (2816 person-years), respectively. In children older than 2 years, risk of death increased sharply when CD4% was less than about 10%, or 15% for risk of AIDS, with a low and fairly stable risk at greater CD4%. Children younger than 2 years had worse outlook than older children with the same CD4%. Risk of progression increased when viral load exceeded about 10(5) copies per mL, although this association was more gradual compared with CD4%. Both markers had independent predictive value for disease progression; CD4% was the stronger predictor. Interpretation This information is important for paediatricians making decisions, and for researchers designing trials, about when to initiate or restart antiretroviral therapy.	MRC, Clin Trials Unit, London NW1 2DA, England; Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA; Univ Turin, Dept Pediat, I-10124 Turin, Italy; Univ Florence, Dept Pediat, Florence, Italy; Univ Padua, Dept Pediat, Padua, Italy; UCL, Inst Child Hlth, London WC1E 6BT, England; WESTAT Corp, Rockville, MD 20850 USA; NICHD, Intravenous Immunoglobulin Study Gr, Bethesda, MD USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Duke Univ, Med Ctr, Durham, NC USA; NICHHD, NIH, Rockville, MD USA; N Shore LIJ Res Inst, Manhasset, NY USA; UMDNJ, Sch Med, Newark, NJ USA; Univ Childrens Hosp, Basel, Switzerland; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; Baylor Coll Med, Houston, TX 77030 USA; Clin Trials & Surveys Corp, Baltimore, MD USA	Medical Research Council Clinical Trials Unit; Centers for Disease Control & Prevention - USA; University of Turin; University of Florence; University of Padua; University of London; University College London; Westat; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard T.H. Chan School of Public Health; Duke University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Northwell Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; Case Western Reserve University; St Georges University London; Baylor College of Medicine	Dunn, DT (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	d.dunn@ctu.mrc.ac.uk	Tookey, Pat A/G-2732-2010; Gray, Linsay/A-6741-2010; Giaquinto, Carlo/AAB-5016-2020; Mofenson, Lynne/P-9631-2019; VALLET, Yannick/F-9979-2011; Pahwa, Savita/AAA-4900-2019; Newell, Marie-Louise/AAE-8222-2019; Palma, Paolo/AAK-9275-2020; Chiappini, Elena/D-1118-2012	Tookey, Pat A/0000-0001-6258-0387; Mofenson, Lynne/0000-0002-2818-9808; Pahwa, Savita/0000-0002-4470-4216; Newell, Marie-Louise/0000-0002-1074-7699; Palma, Paolo/0000-0002-3066-4719; Chiappini, Elena/0000-0002-1476-4752; moye, john/0000-0001-9976-8586; Guarino, Alfredo/0000-0003-0199-0336; Castelli-Gattinara, Guido/0000-0002-3282-7462; Dunn, David/0000-0003-1836-4446				Aboulker JP, 2001, ARCH DIS CHILD, V84, P230, DOI 10.1136/adc.84.3.230; Aboulker JP, 1998, AIDS, V12, pF151; Babiker A, 2001, J ACQ IMMUN DEF SYND, V28, P158, DOI 10.1097/00126334-200110010-00008; Bakshi SS, 1997, J INFECT DIS, V175, P1039, DOI 10.1086/520351; Brady MT, 1996, J INFECT DIS, V173, P1097, DOI 10.1093/infdis/173.5.1097; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, pRR4; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Costain DJ, 2001, CANCER IMMUNOL IMMUN, V50, P293, DOI 10.1007/PL00006690; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Giaquinto C, 2002, AIDS, V16, P97, DOI 10.1097/00002030-200201040-00012; Gibb DM, 2003, BMJ-BRIT MED J, V327, P1019, DOI 10.1136/bmj.327.7422.1019; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; HUGHES MD, 1992, STAT MED, V11, P1731, DOI 10.1002/sim.4780111307; Kalish LA, 1999, J INFECT DIS, V180, P1514, DOI 10.1086/315064; Kattan M, 1996, J CLIN EPIDEMIOL, V49, P1285; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; Kline MW, 1998, PEDIATRICS, V101, P214, DOI 10.1542/peds.101.2.214; Lindsey JC, 2000, J INFECT DIS, V182, P1385, DOI 10.1086/315865; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; *PENTA, 1997, 6 EUR C CLIN ASP TRE; Phair JP, 2002, AIDS, V16, P2455, DOI 10.1097/00002030-200212060-00011; Sharland M, 2002, HIV Med, V3, P215, DOI 10.1046/j.1468-1293.2002.00120.x; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; SPECTOR SA, 1994, NEW ENGL J MED, V331, P1181, DOI 10.1056/NEJM199411033311802; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; WHO, 2003, SCAL ANT THER RES LT; *WORK GROUP ANT TH, GUID US ANT AG PED H	30	164	169	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1605	1611						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630440				2022-12-28	WOS:000186637400008
J	Kodama, S; Kuhtreiber, W; Fujimura, S; Dale, EA; Faustman, DL				Kodama, S; Kuhtreiber, W; Fujimura, S; Dale, EA; Faustman, DL			Islet regeneration during the reversal of autoimmune diabetes in NOD mice	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; IN-VIVO; ADULT MICE; DIFFERENTIATE; FUSION; HEPATOCYTES; BRAIN; PROGENITORS; EXPRESSION	Nonobese diabetic (NOD) mice are a model for type 1 diabetes in humans. Treatment of NOD mice with end-stage disease by injection of donor splenocytes and complete Freund's adjuvant eliminates autoimmunity and permanently restores normoglycemia. The return of endogenous insulin secretion is accompanied by the reappearance of pancreatic beta cells. We now show that live donor male or labeled splenocytes administered to diabetic NOD females contain cells that rapidly differentiate into islet and ductal epithelial cells within the pancreas. Treatment with irradiated splenocytes is also followed by islet regeneration, but at a slower rate. The islets generated in both instances are persistent, functional, and apparent in all NOD hosts with permanent disease reversal.	Massachusetts Gen Hosp, Immunobiol Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Faustman, DL (corresponding author), Massachusetts Gen Hosp, Immunobiol Lab, Bldg 149,13th St,Room 3602, Charlestown, MA 02129 USA.	faustman@helix.mgh.harvard.edu		Kuhtreiber, Willem/0000-0002-5717-5915	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057521] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK57521-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hayashi T, 1999, MOL CELL BIOL, V19, P8646; Hayashi T, 2000, NAT MED, V6, P1065, DOI 10.1038/80353; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ryu S, 2001, J CLIN INVEST, V108, P63, DOI 10.1172/JCI200112335; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Yang G, 1997, J IMMUNOL, V159, P3068; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	36	281	313	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1223	1227		10.1126/science.1088949	http://dx.doi.org/10.1126/science.1088949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615542				2022-12-28	WOS:000186544300058
J	Zhou, Y; Su, Y; Li, BL; Liu, F; Ryder, JW; Wu, X; Gonzalez-DeWhitt, PA; Gelfanova, V; Hale, JE; May, PC; Paul, SM; Ni, BH				Zhou, Y; Su, Y; Li, BL; Liu, F; Ryder, JW; Wu, X; Gonzalez-DeWhitt, PA; Gelfanova, V; Hale, JE; May, PC; Paul, SM; Ni, BH			Nonsteroidal anti-inflammatory drugs can lower amyloidogenic A beta(42) by inhibiting Rho	SCIENCE			English	Article							ALZHEIMERS-DISEASE; SULINDAC SULFIDE; RAS; PROTEIN	A subset of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to preferentially reduce the secretion of the highly amyloidogenic, 42-residue amyloid-beta peptide Abeta(42). We found that Rho and its effector, Rho-associated kinase, preferentially regulated the amount of Abeta(42) produced in vitro and that only those NSAIDs effective as Rho inhibitors lowered Abeta(42). Administration of Y-27632, a selective Rock inhibitor, also preferentially lowered brain levels of Abeta(42) in a transgenic mouse model of Alzheimer's disease. Thus, the Rho-Rock pathway may regulate amyloid precursor protein processing, and a subset of NSAIDs can reduce Abeta(42) through inhibition of Rho activity.	Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res & Biores Technol & Prot, Indianapolis, IN 46285 USA	Eli Lilly	Zhou, Y (corresponding author), Eli Lilly & Co, Lilly Res Labs, Neurosci Discovery Res & Biores Technol & Prot, Indianapolis, IN 46285 USA.	zhou_yan_yz@lilly.com; paul_steven_m@lilly.com	Paul, Steve/ABE-5400-2020					CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Gala M, 2002, CANCER LETT, V175, P89, DOI 10.1016/S0304-3835(01)00716-9; Gan XD, 2001, J BIOL CHEM, V276, P48702, DOI 10.1074/jbc.M109402200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Holstein SA, 2002, BIOCHEMISTRY-US, V41, P13698, DOI 10.1021/bi026251x; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Kuhn TB, 1998, J NEUROBIOL, V37, P524, DOI 10.1002/(SICI)1097-4695(199812)37:4<524::AID-NEU3>3.0.CO;2-H; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591	15	273	319	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1215	1217		10.1126/science.1090154	http://dx.doi.org/10.1126/science.1090154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615541				2022-12-28	WOS:000186544300056
J	di Fagagna, FD; Reaper, PM; Clay-Farrace, L; Fiegler, H; Carr, P; von Zglinicki, T; Saretzki, G; Carter, NP; Jackson, SP				di Fagagna, FD; Reaper, PM; Clay-Farrace, L; Fiegler, H; Carr, P; von Zglinicki, T; Saretzki, G; Carter, NP; Jackson, SP			A DNA damage checkpoint response in telomere-initiated senescence	NATURE			English	Article							IONIZING-RADIATION; S-CHECKPOINT; LIFE-SPAN; SENSITIVITY; GENOME; MDC1; ATM; APOPTOSIS; DISTINCT; KINASE	Most human somatic cells can undergo only a limited number of population doublings in vitro(1). This exhaustion of proliferative potential, called senescence, can be triggered when telomeres the ends of linear chromosomes-cannot fulfil their normal protective functions. Here we show that senescent human fibroblasts display molecular markers characteristic of cells bearing DNA double-strand breaks. These markers include nuclear foci of phosphorylated histone H2AX and their co-localization with DNA repair and DNA damage checkpoint factors such as 53BP1, MDC1 and NBS1. We also show that senescent cells contain activated forms of the DNA damage checkpoint kinases CHK1 and CHK2. Furthermore, by chromatin immunoprecipitation and whole-genome scanning approaches, we show that the chromosome ends of senescent cells directly contribute to the DNA damage response, and that uncapped telomeres directly associate with many, but not all, DNA damage response proteins. Finally, we show that inactivation of DNA damage checkpoint kinases in senescent cells can restore cell-cycle progression into S phase. Thus, we propose that telomere-initiated senescence reflects a DNA damage checkpoint response that is activated with a direct contribution from dysfunctional telomeres.	Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Newcastle Univ, Inst Ageing & Hlth, Henry Wellcome Lab Biogerontol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	University of Cambridge; Wellcome Trust Sanger Institute; Newcastle University - UK	Jackson, SP (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1QR, England.	dadda@ifom-firc.it; spj13@mole.bio.cam.ac.uk	d'Adda di Fagagna, Fabrizio/AAC-4683-2022; Dry, Kate/I-2328-2014; Saretzki, Gabriele Christine/I-7175-2019; Jackson, Stephen Philip/R-4548-2019	d'Adda di Fagagna, Fabrizio/0000-0002-9603-5966; Saretzki, Gabriele Christine/0000-0003-2100-8223; Jackson, Stephen Philip/0000-0001-9317-7937; DADDADIFAGAGNA, FABRIZIO/0000-0002-1976-3185; von Zglinicki, Thomas/0000-0002-5939-0248				Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stoeber K, 2001, J CELL SCI, V114, P2027; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	30	1187	1219	10	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	2003	426	6963					194	198		10.1038/nature02118	http://dx.doi.org/10.1038/nature02118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14608368				2022-12-28	WOS:000186517200047
J	Kunzig, R				Kunzig, R			Deep-sea biology: Living with the endless frontier	SCIENCE			English	Editorial Material																		Huxley T. H., 1909, AUTOBIOGRAPHY SELECT; LINKLATER E, 1972, VOYAGE CHALLENGER, P276; THOMSON CW, 1873, DEPTHS SEA, P49; 1855, LIT PAPERS LATE E FO	4	8	9	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					991	991		10.1126/science.1090808	http://dx.doi.org/10.1126/science.1090808			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605353				2022-12-28	WOS:000186396300028
J	Wentworth, P; Nieva, J; Takeuchi, C; Galve, R; Wentworth, AD; Dilley, RB; DeLaria, GA; Saven, A; Babior, BM; Janda, KD; Eschenmoser, A; Lerner, RA				Wentworth, P; Nieva, J; Takeuchi, C; Galve, R; Wentworth, AD; Dilley, RB; DeLaria, GA; Saven, A; Babior, BM; Janda, KD; Eschenmoser, A; Lerner, RA			Evidence for ozone formation in human atherosclerotic arteries	SCIENCE			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL; OZONIZATION; OXIDATION	Here, we report evidence for the production of ozone in human disease. Signature products unique to cholesterol ozonolysis are present within atherosclerotic tissue at the time of carotid endarterectomy, suggesting that ozone production occurred during lesion development. Furthermore, advanced atherosclerotic plaques generate ozone when the leukocytes within the diseased arteries are activated in vitro. The steroids produced by cholesterol ozonolysis cause effects that are thought to be critical to the pathogenesis of atherosclerosis, including cytotoxicity, lipid-loading in macrophages, and deformation of the apolipoprotein B-100 secondary structure. We propose the trivial designation "atheronals" for this previously unrecognized class of steroids.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Clin, Div Hematol & Oncol, La Jolla, CA 92037 USA; Scripps Clin, Div Cardiothorac & Vasc Surg, La Jolla, CA 92037 USA; ETH Honggerberg, Organ Chem Lab, CH-8093 Zurich, Switzerland; Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oxford	Wentworth, P (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Galve, Roger/I-3443-2017	Galve, Roger/0000-0001-6189-5037	NCI NIH HHS [P01CA27489] Funding Source: Medline; NIAID NIH HHS [5T32AI07606] Funding Source: Medline; NIGMS NIH HHS [GM 43858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043858, R29GM043858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babior BM, 2003, P NATL ACAD SCI USA, V100, P3031, DOI 10.1073/pnas.0530251100; CORNFORTH JW, 1953, BIOCHEM J, V54, P590, DOI 10.1042/bj0540590; GUMULKA J, 1983, J AM CHEM SOC, V105, P1972, DOI 10.1021/ja00345a052; GUMULKA J, 1982, LIPIDS, V17, P197, DOI 10.1007/BF02535103; HIETTER H, 1986, CANCER BIOCHEM BIOPH, V9, P75; JAWORSKI K, 1988, J ORG CHEM, V53, P545, DOI 10.1021/jo00238a014; LORENZO JL, 1987, FEBS LETT, V218, P77, DOI 10.1016/0014-5793(87)81022-0; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; PARYZEK Z, 1990, J CHEM SOC PERK T 1, P1222, DOI 10.1039/p19900001222; REYMOND JL, 1995, J ORG CHEM, V60, P6970, DOI 10.1021/jo00126a057; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SEVANIAN A, 1984, P NATL ACAD SCI-BIOL, V81, P4198, DOI 10.1073/pnas.81.13.4198; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; TAKEUCHI K, 1990, ANAL CHIM ACTA, V230, P183, DOI 10.1016/S0003-2670(00)82779-8; TAKEUCHI K, 1989, ANAL CHEM, V61, P619, DOI 10.1021/ac00181a025; WANG KY, 1993, STEROIDS, V58, P225, DOI 10.1016/0039-128X(93)90023-G; Wentworth AD, 2000, P NATL ACAD SCI USA, V97, P10930, DOI 10.1073/pnas.97.20.10930; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Wentworth P, 2003, P NATL ACAD SCI USA, V100, P1490, DOI 10.1073/pnas.0437831100	24	230	249	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1053	1056		10.1126/science.1089525	http://dx.doi.org/10.1126/science.1089525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605372				2022-12-28	WOS:000186396300051
J	Abmayr, SM; Workman, JL				Abmayr, SM; Workman, JL			Transcription factors prominently in Lasker Award to Roeder	CELL			English	Editorial Material							RNA-POLYMERASE-II; MAJOR LATE PROMOTER; ACCURATE TRANSCRIPTION; GENE-TRANSCRIPTION; MULTIPLE FACTORS; PREINITIATION COMPLEX; FUNCTIONAL-ANALYSIS; XENOPUS-LAEVIS; INITIATION; DNA		Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Workman, JL (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.							An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; LASSAR AB, 1985, MOL CELL BIOL, V5, P40, DOI 10.1128/MCB.5.1.40; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LUSE DS, 1981, NUCLEIC ACIDS RES, V9, P4339, DOI 10.1093/nar/9.17.4339; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NG SY, 1979, P NATL ACAD SCI USA, V76, P136, DOI 10.1073/pnas.76.1.136; PARKER CS, 1977, P NATL ACAD SCI USA, V74, P44, DOI 10.1073/pnas.74.1.44; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROEDER RG, 1969, NATURE, V224, P234, DOI 10.1038/224234a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROEDER RG, 1970, P NATL ACAD SCI USA, V65, P675, DOI 10.1073/pnas.65.3.675; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SKLAR VEF, 1975, P NATL ACAD SCI USA, V72, P348, DOI 10.1073/pnas.72.1.348; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WEIL PA, 1979, CELL, V18, P469; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P1790, DOI 10.1073/pnas.71.5.1790; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P3426, DOI 10.1073/pnas.71.9.3426; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X	34	0	0	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 31	2003	115	3					243	246		10.1016/S0092-8674(03)00846-8	http://dx.doi.org/10.1016/S0092-8674(03)00846-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636549	Bronze			2022-12-28	WOS:000186415000001
J	Changelian, PS; Flanagan, ME; Ball, DJ; Kent, CR; Magnuson, KS; Martin, WH; Rizzuti, BJ; Sawyer, PS; Perry, BD; Brissette, WH; McCurdy, SP; Kudlacz, EM; Conklyn, MJ; Elliott, EA; Koslov, ER; Fisher, MB; Strelevitz, TJ; Yoon, K; Whipple, DA; Sun, JM; Munchhof, MJ; Doty, JL; Casavant, JM; Blumenkopf, TA; Hines, M; Brown, MF; Lillie, BM; Subramanyam, C; Shang-Poa, C; Milici, AJ; Beckius, GE; Moyer, JD; Su, CY; Woodworth, TG; Gaweco, AS; Beals, CR; Littman, BH; Fisher, DA; Smith, JF; Zagouras, P; Magna, HA; Saltarelli, MJ; Johnson, KS; Nelms, LF; Des Etages, SG; Hayes, LS; Kawabata, TT; Finco-Kent, D; Baker, DL; Larson, M; Si, MS; Paniagua, R; Higgins, J; Holm, B; Reitz, B; Zhou, YJ; Morris, RE; O'Shea, JJ; Borie, DC				Changelian, PS; Flanagan, ME; Ball, DJ; Kent, CR; Magnuson, KS; Martin, WH; Rizzuti, BJ; Sawyer, PS; Perry, BD; Brissette, WH; McCurdy, SP; Kudlacz, EM; Conklyn, MJ; Elliott, EA; Koslov, ER; Fisher, MB; Strelevitz, TJ; Yoon, K; Whipple, DA; Sun, JM; Munchhof, MJ; Doty, JL; Casavant, JM; Blumenkopf, TA; Hines, M; Brown, MF; Lillie, BM; Subramanyam, C; Shang-Poa, C; Milici, AJ; Beckius, GE; Moyer, JD; Su, CY; Woodworth, TG; Gaweco, AS; Beals, CR; Littman, BH; Fisher, DA; Smith, JF; Zagouras, P; Magna, HA; Saltarelli, MJ; Johnson, KS; Nelms, LF; Des Etages, SG; Hayes, LS; Kawabata, TT; Finco-Kent, D; Baker, DL; Larson, M; Si, MS; Paniagua, R; Higgins, J; Holm, B; Reitz, B; Zhou, YJ; Morris, RE; O'Shea, JJ; Borie, DC			Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor	SCIENCE			English	Article							T-CELL HOMEOSTASIS; TRANSPLANTATION; LEUKEMIA; SURVIVAL; MICE; GENE; JAK3	Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinical immunosuppression. We report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants. CP-690,550 treatment was not associated with hypertension, hyperlipidemia, or lymphoproliferative disease. On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings.	Pfizer Global Res & Dev, Dept Antibacterials & Immunol, Immunol Grp, Groton, CT 06340 USA; Pfizer Global Res & Dev, Dept Drug Safety Evaluat, Groton, CT 06340 USA; Pfizer Global Res & Dev, Dept Pharmacokinet Dynam & Metab, Groton, CT 06340 USA; Pfizer Global Res & Dev, Dept Genom & Proteom Sci, Groton, CT 06340 USA; Stanford Univ, Sch Med, Transplantat Immunol Lab, Stanford, CA 94305 USA; NIH, Mol Immunol & Inflammat Branch, Bethesda, MD 20892 USA	Pfizer; Pfizer; Pfizer; Pfizer; Stanford University; National Institutes of Health (NIH) - USA	Changelian, PS (corresponding author), Pfizer Global Res & Dev, Dept Antibacterials & Immunol, Immunol Grp, Groton, CT 06340 USA.			Si, Ming-Sing/0000-0002-1927-420X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041106, Z01AR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Behbod F, 2001, J IMMUNOL, V166, P3724, DOI 10.4049/jimmunol.166.6.3724; Borie DC, 2002, J SURG RES, V107, P64, DOI 10.1006/jsre.2002.6499; CHANGELIAN PS, UNPUB; Christopher K, 2002, J IMMUNOL, V169, P522, DOI 10.4049/jimmunol.169.1.522; Colucci F, 2003, NAT REV IMMUNOL, V3, P413, DOI 10.1038/nri1088; COPELAND RA, ENZYMES PRACTICAL IN; CORRY RJ, 1973, TRANSPLANT P, V5, P733; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; El-Sawy T, 2002, CURR OPIN IMMUNOL, V14, P562, DOI 10.1016/S0952-7915(02)00382-5; Gozalo-Sanmillan S, 2001, J IMMUNOL, V166, P727, DOI 10.4049/jimmunol.166.2.727; Hausen B, 2001, TRANSPLANTATION, V72, P1128, DOI 10.1097/00007890-200109270-00025; Hong JC, 2000, SEMIN NEPHROL, V20, P108; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Nurse P, 2002, CHEMBIOCHEM, V3, P596, DOI 10.1002/1439-7633(20020703)3:7<596::AID-CBIC596>3.0.CO;2-U; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Saemann MD, 2003, TRANSPLANTATION, V75, P1864, DOI 10.1097/01.TP.0000065738.58742.A9; Saiura A, 2001, TRANSPLANTATION, V72, P320, DOI 10.1097/00007890-200107270-00027; Singer AL, 2002, SCIENCE, V296, P1639, DOI 10.1126/science.1071551; Sohn SJ, 1998, J IMMUNOL, V160, P2130; Stock PG, 2003, AM J TRANSPLANT, V3, P373, DOI 10.1034/j.1600-6143.2003.00115.x; Uckun FM, 2002, BLOOD, V99, P4192, DOI 10.1182/blood.V99.11.4192	24	530	646	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					875	878		10.1126/science.1087061	http://dx.doi.org/10.1126/science.1087061			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14593182				2022-12-28	WOS:000186258000052
J	Boysen, DA; Uda, T; Chisholm, CRI; Haile, SM				Boysen, DA; Uda, T; Chisholm, CRI; Haile, SM			High-performance solid acid fuel cells through humidity stabilization	SCIENCE			English	Article							CSH2PO4; AMBIENT	Although they hold the promise of clean energy, state-of-the-art fuel cells based on polymer electrolyte membrane fuel cells are inoperable above 100degreesC, require cumbersome humidification systems, and suffer from fuel permeation. These difficulties all arise from the hydrated nature of the electrolyte. In contrast, "solid acids" exhibit anhydrous proton transport and high-temperature stability. We demonstrate continuous, stable power generation for both H-2/O-2 and direct methanol fuel cells operated at similar to250degreesC using a humidity-stabilized solid acid CsH2PO4 electrolyte.	CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Haile, SM (corresponding author), CALTECH, Pasadena, CA 91125 USA.	smhaile@caltech.edu	Haile, Sossina M/I-3448-2015	Uda, Tetsuya/0000-0002-2484-4297				BARANOV AI, 1982, JETP LETT+, V36, P459; Boysen DA, 2003, CHEM MATER, V15, P727, DOI 10.1021/cm020138b; Haile SM, 2001, NATURE, V410, P910, DOI 10.1038/35073536; Merle RB, 2003, ENERG FUEL, V17, P210, DOI 10.1021/ef0201174; NIRSHA BM, 1980, RUSS J INORG CHEM, V27, P770; Otomo J, 2003, SOLID STATE IONICS, V156, P357, DOI 10.1016/S0167-2738(02)00746-4; RAPOPORT E, 1978, J SOLID STATE CHEM, V24, P423, DOI 10.1016/0022-4596(78)90035-X; Shukla AK, 2002, ELECTROCHIM ACTA, V47, P3401, DOI 10.1016/S0013-4686(02)00276-1; Thomas SC, 2002, ELECTROCHIM ACTA, V47, P3741, DOI 10.1016/S0013-4686(02)00344-4	9	397	412	11	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 2	2004	303	5654					68	70		10.1126/science.1090920	http://dx.doi.org/10.1126/science.1090920			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	758YU	14631049				2022-12-28	WOS:000187710600033
J	Wilcock, GK				Wilcock, GK			Dementia with Lewy bodies	LANCET			English	Editorial Material							INTERNATIONAL WORKSHOP; CONSENSUS CRITERIA; ALZHEIMERS-DISEASE; POPULATION; DIAGNOSIS; PREVALENCE; OLDER		Univ Bristol, Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England	University of Bristol	Wilcock, GK (corresponding author), Univ Bristol, Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; HANSEN L, 1990, NEUROLOGY, V40, P1; McKeith IG, 2000, NEUROLOGY, V54, P1050, DOI 10.1212/WNL.54.5.1050; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; Perry R H, 1989, Lancet, V1, P166; PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G; Rahkonen T, 2003, J NEUROL NEUROSUR PS, V74, P720, DOI 10.1136/jnnp.74.6.720; Stevens T, 2002, BRIT J PSYCHIAT, V180, P270, DOI 10.1192/bjp.180.3.270; Yamada T, 2002, PSYCHIAT CLIN NEUROS, V56, P71, DOI 10.1046/j.1440-1819.2002.00931.x; Yamada T, 2001, PSYCHIAT CLIN NEUROS, V55, P21, DOI 10.1046/j.1440-1819.2001.00779.x	11	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 22	2003	362	9397					1689	1690		10.1016/S0140-6736(03)14883-0	http://dx.doi.org/10.1016/S0140-6736(03)14883-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	746VE	14643115				2022-12-28	WOS:000186767700005
J	Jones, DT				Jones, DT			Learning to speak the language of proteins	SCIENCE			English	Editorial Material							DESIGN; SEQUENCES; FOLD		UCL, Dept Comp Sci, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Jones, DT (corresponding author), UCL, Dept Comp Sci, Mortimer St, London WC1E 6BT, England.	dtj@cs.ucl.ac.uk						Bolon DN, 2001, P NATL ACAD SCI USA, V98, P14274, DOI 10.1073/pnas.251555398; Bolon DN, 2002, CURR OPIN CHEM BIOL, V6, P125, DOI 10.1016/S1367-5931(02)00303-4; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Schonbrun J, 2002, CURR OPIN STRUC BIOL, V12, P348, DOI 10.1016/S0959-440X(02)00336-6; YUE K, 1992, P NATL ACAD SCI USA, V89, P4163, DOI 10.1073/pnas.89.9.4163	12	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1347	1348		10.1126/science.1092492	http://dx.doi.org/10.1126/science.1092492			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631028				2022-12-28	WOS:000186683500038
J	Matamala, R; Gonzalez-Meler, MA; Jastrow, JD; Norby, RJ; Schlesinger, WH				Matamala, R; Gonzalez-Meler, MA; Jastrow, JD; Norby, RJ; Schlesinger, WH			Impacts of fine root turnover on forest NPP and soil C sequestration potential	SCIENCE			English	Article							ELEVATED ATMOSPHERIC CO2; CARBON STORAGE; ECOSYSTEMS; BIOMASS; ENRICHMENT; MORTALITY; DYNAMICS; PATTERNS	Estimates of forest net primary production (NPP) demand accurate estimates of root production and turnover. We assessed root turnover with the use of an isotope tracer in two forest free-air carbon dioxide enrichment experiments. Growth at elevated carbon dioxide did not accelerate root turnover in either the pine or the hardwood forest. Turnover of fine root carbon varied from 1.2 to 9 years, depending on root diameter and dominant tree species. These long turnover times suggest that root production and turnover in forests have been overestimated and that sequestration of anthropogenic atmospheric carbon in forest soils may be lower than currently estimated.	Argonne Natl Lab, Div Environm Res, Argonne, IL 60439 USA; Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA; Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37831 USA; Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA	United States Department of Energy (DOE); Argonne National Laboratory; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; United States Department of Energy (DOE); Oak Ridge National Laboratory; Duke University	Matamala, R (corresponding author), Argonne Natl Lab, Div Environm Res, Argonne, IL 60439 USA.		Norby, Richard J/C-1773-2012; Jastrow, Julie D./AAX-1631-2020	Norby, Richard J/0000-0002-0238-9828; Jastrow, Julie D./0000-0001-7069-4560; Gonzalez-Meler, Miquel/0000-0001-5388-7969				ABER JD, 1985, OECOLOGIA, V66, P317, DOI 10.1007/BF00378292; DeLucia EH, 1999, SCIENCE, V284, P1177, DOI 10.1126/science.284.5417.1177; Eissenstat DM, 1997, ADV ECOL RES, V27, P1, DOI 10.1016/S0065-2504(08)60005-7; Ellsworth DS, 1999, PLANT CELL ENVIRON, V22, P461, DOI 10.1046/j.1365-3040.1999.00433.x; FARQUHAR GD, 1989, ANNU REV PLANT PHYS, V40, P503, DOI 10.1146/annurev.pp.40.060189.002443; Gaudinski JB, 2001, OECOLOGIA, V129, P420, DOI 10.1007/s004420100746; Gill RA, 2000, NEW PHYTOL, V147, P13, DOI 10.1046/j.1469-8137.2000.00681.x; GRIER CC, 1981, CAN J FOREST RES, V11, P155, DOI 10.1139/x81-021; HENDRICK RL, 1993, NATURE, V361, P59, DOI 10.1038/361059a0; Hendricks JJ, 1997, OECOLOGIA, V112, P300, DOI 10.1007/s004420050312; Jackson RB, 1997, P NATL ACAD SCI USA, V94, P7362, DOI 10.1073/pnas.94.14.7362; JASTROW JD, UNPUB; Langley JA, 2002, OECOLOGIA, V131, P542, DOI 10.1007/s00442-002-0932-6; Luo YQ, 2003, GLOBAL CHANGE BIOL, V9, P1118, DOI 10.1046/j.1365-2486.2003.00642.x; Matamala R, 2000, GLOB CHANGE BIOL, V6, P967, DOI 10.1046/j.1365-2486.2000.00374.x; MILCHUNAS DG, 1992, ECOLOGY, V73, P593, DOI 10.2307/1940765; Norby RJ, 2002, ECOL APPL, V12, P1261, DOI 10.1890/1051-0761(2002)012[1261:NPPOAC]2.0.CO;2; NORBY RJ, UNPUB; Pataki DE, 2003, BIOSCIENCE, V53, P805, DOI 10.1641/0006-3568(2003)053[0805:TCIEFU]2.0.CO;2; Pritchard SG, 2001, GLOBAL CHANGE BIOL, V7, P829, DOI 10.1046/j.1354-1013.2001.00457.x; SANTANTONIO D, 1987, CAN J FOREST RES, V17, P900, DOI 10.1139/x87-141; Schlesinger WH, 2001, NATURE, V411, P466, DOI 10.1038/35078060; Schoettle A.W., 1994, ECOL BULL, V43, P136, DOI DOI 10.2307/20113137	23	360	409	15	229	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1385	1387		10.1126/science.1089543	http://dx.doi.org/10.1126/science.1089543			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631037				2022-12-28	WOS:000186683500049
J	Stocking, MA				Stocking, MA			Tropical soils and food security: The next 50 years	SCIENCE			English	Article							QUALITY; FERTILITY; SYSTEMS; EROSION; TOOL	An appreciation of the dynamism of the links between soil resources and society provides a platform for examining food security over the next 50 years. Interventions to reverse declining trends in food security must recognize the variable resilience and sensitivity of major tropical soil types. In most agroecosystems, declining crop yield is exponentially related to loss of soil quality. For the majority smallholder (subsistence) farmers, investments to reverse degradation are primarily driven by private benefit, socially or financially. "Tragedy of the commons" scenarios can be averted by pragmatic local solutions that help farmers to help themselves.	Univ E Anglia, Sch Dev Studies, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Stocking, MA (corresponding author), Univ E Anglia, Sch Dev Studies, Norwich NR4 7TJ, Norfolk, England.							Andrews SS, 2001, ECOL APPL, V11, P1573, DOI 10.1890/1051-0761(2001)011[1573:DASQAT]2.0.CO;2; [Anonymous], 1999, WORLD HLTH REPORT 19; Boardman J, 2003, ENVIRON SCI POLICY, V6, P1, DOI 10.1016/S1462-9011(02)00120-X; Brookfield H., 2001, EXPLORING AGRODIVERS; *CIMMYT, 2003, GLOB WARM THREAT FOO; CROSSON P, 1995, SOIL EROSION ITS ON; Doran J. W., 1996, SSSA SPECIAL PUBLICA, V49; Dorward P, 2003, AGR SYST, V75, P97, DOI 10.1016/S0308-521X(02)00034-3; *FAO COMM WORLD FO, 2001, IMP HIV AIDS FOOD SE; Food and Agriculture Organization of the United Nations (FAO), SPEC PROGR FOOD SEC; Girvan MS, 2003, APPL ENVIRON MICROB, V69, P1800, DOI 10.1128/AEM.69.3.1800-1809.2003; Gordon Prain, 1999, BIOL CULTURAL DIVERS; GYASI EA, 2002, CULTIVATING BIODIVER, P245; HHIEMSTRA W, 1992, LET FARMERS JUDGE EX; *INT FOOD POL RES, 2002, REACH SUST FOOD SEC; KAHLHURA F, 2003, AGR BIODIVERSITY SMA; Karlen DL, 2003, GEODERMA, V114, P145, DOI 10.1016/S0016-7061(03)00039-9; KIOME RM, 1995, GLOBAL ENVIRON CHANG, V5, P281, DOI 10.1016/0959-3780(95)00063-T; LAL R, 1994, SOIL EROSION RES MET; Lutz E., 1994, 8 WORLD BANK; Mausback M.J., 1998, SOIL QUALITY AGR SUS, P33; MAZZUCATO V, 2000, TROPICAL RESOURCE MA, V32; Pretty J, 2001, WORLD DEV, V29, P209, DOI 10.1016/S0305-750X(00)00098-X; Pretty Jules, 1995, REGENERATING AGR POL; Renwick A, 2002, PHILOS T ROY SOC A, V360, P1721, DOI 10.1098/rsta.2002.1028; Sanchez PA, 2002, SCIENCE, V295, P2019, DOI 10.1126/science.1065256; Sanchez PA, 2003, GEODERMA, V114, P157, DOI 10.1016/S0016-7061(03)00040-5; Scherr S J, 1995, 14 INT FOOD POL RES; Seybold CA, 1998, ADV SOIL S, P387; Stocking M., 1988, Soil Technology, V1, P289, DOI 10.1016/0933-3630(88)90028-1; Stocking M., 2001, HDB FIELD ASSESSMENT; Stocking M., 2003, ENCY SOIL SCI; Stocking M., 2000, ENV SCI ENV MANAGEME, P287; STOCKING M, 1999, PUBLICATION AGL MISC, P91; STOCKING M, 2002, SUSTAINABLE USE MANA, V1, P178; Swift MJ, 1999, NATURE RESOUR, V35, P12; SWIFT MJ, 1998, CARBON NUTR DYNAMICS, P59; Tengberg A, 1998, ADV GEOECOL, V31, P355; Tengberg A, 2001, RESPONSE TO LAND DEGRADATION, P171; TENGBERG A, 1998, EXPT AGR, V34, P55; *UN DEV PROGR, 2001, ANN REP 2001; *UN DEV PROGR, 2003, MILL DEV GOALS; Versteeg MN, 1998, AGR SYST, V56, P269, DOI 10.1016/S0308-521X(97)00041-3; Whitbread AM, 2000, SOIL TILL RES, V54, P63, DOI 10.1016/S0167-1987(99)00112-9; *WORLD FOOD PROGR, WORLD FOOD PROGR GOA; 2003, DAILY NEWS      0617	46	155	170	3	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	2003	302	5649					1356	1359		10.1126/science.1088579	http://dx.doi.org/10.1126/science.1088579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745HP	14631030				2022-12-28	WOS:000186683500040
J	Svensson, M; Gustafsson, F; Galatius, S; Hildebrandt, PR; Atar, D				Svensson, M; Gustafsson, F; Galatius, S; Hildebrandt, PR; Atar, D			Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Aker Univ Hosp, Div Cardiol, Oslo, Norway; Frederiksberg Univ Hosp, Dept Cardiol & Endocrinol, DK-2000 Copenhagen, Denmark	University of Oslo	Atar, D (corresponding author), Aker Univ Hosp, Div Cardiol, Oslo, Norway.			Gustafsson, Finn/0000-0003-2144-341X				GALATIUS S, 2002, AM HEART J S, V144, pS2; GREENBERG B, 2002, J CARDIOVASC PHARM, V38, P59; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Remme WJ, 2002, EUR J HEART FAIL, V4, P11, DOI 10.1016/S1388-9842(01)00231-8	5	53	58	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1141	1142		10.1136/bmj.327.7424.1141	http://dx.doi.org/10.1136/bmj.327.7424.1141			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615339	Green Published, Bronze			2022-12-28	WOS:000186622100020
J	Kaksonen, M; Sun, Y; Drubin, DG				Kaksonen, M; Sun, Y; Drubin, DG			A pathway for association of receptors, adaptors, and actin during endocytic internalization	CELL			English	Article							ALDRICH-SYNDROME PROTEIN; CLATHRIN-COATED PITS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; IN-VIVO; MEDIATED ENDOCYTOSIS; FILAMENT TURNOVER; ARP2/3 COMPLEX; CYTOSKELETON; DYNAMICS	In budding yeast, many proteins involved in endocytic internalization, including adaptors and actin cytoskeletal proteins, are localized to cortical patches of differing protein composition. Using multicolor real-time fluorescence microscopy and particle tracking algorithms, we define an early endocytic pathway wherein an invariant sequence of changes in cortical patch protein composition correlates with changes in patch motility. Three Arp2/3 activators each showed a distinct behavior, suggesting distinct patch-related endocytic functions. Actin polymerization occurs late in the endocytic pathway and is required both for endocytic internalization and for patch disassembly. In cells lacking the highly conserved endocytic protein Sla2p, patch motility was arrested and actin comet tails associated with endocytic patch complexes. Fluorescence recovery after photobleaching of the actin comet tails revealed that endocytic complexes are nucleation sites for rapid actin polymerization. Attention is now focused on the mechanisms by which the order and timing of events in this endocytic pathway are achieved.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.			Sun, Yidi/0000-0002-2157-1983; Kaksonen, Marko/0000-0003-3645-7689	NIGMS NIH HHS [GM50399, GM42759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042759, R01GM050399, R01GM042759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Carlsson AE, 2002, BIOPHYS J, V82, P2333, DOI 10.1016/S0006-3495(02)75579-3; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; ENGQVISTGOLDSTE.AE, 2003, IN PRESS ANN REV CEL; Geli MI, 1998, J CELL SCI, V111, P1031; Goode BL, 2001, CURR OPIN MICROBIOL, V4, P703, DOI 10.1016/S1369-5274(01)00272-7; Gourlay CW, 2003, J CELL SCI, V116, P2551, DOI 10.1242/jcs.00454; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; KARPOVA TS, 1995, J CELL BIOL, V131, P1483, DOI 10.1083/jcb.131.6.1483; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Mulholland J, 1999, MOL BIOL CELL, V10, P799, DOI 10.1091/mbc.10.3.799; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Sekiya-Kawasaki M, 2003, J CELL BIOL, V162, P765, DOI 10.1083/jcb.200305077; Smith MG, 2001, J CELL SCI, V114, P1505; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; Warren DT, 2002, J CELL SCI, V115, P1703; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; Zeng GH, 2001, MOL BIOL CELL, V12, P3759, DOI 10.1091/mbc.12.12.3759	44	516	523	3	44	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					475	487		10.1016/S0092-8674(03)00883-3	http://dx.doi.org/10.1016/S0092-8674(03)00883-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622601	Bronze			2022-12-28	WOS:000186627100013
J	Bonke, M; Thitamadee, S; Mahonen, AP; Hauser, MT; Helariutta, Y				Bonke, M; Thitamadee, S; Mahonen, AP; Hauser, MT; Helariutta, Y			APL regulates vascular tissue identity in Arabidopsis	NATURE			English	Article							RADIAL ORGANIZATION; PATTERN-FORMATION; SIEVE ELEMENTS; ROOT; DIFFERENTIATION; CELL; MORPHOGENESIS; TRAFFICKING; MUTATIONS; PHLOEM	Vascular plants have a long-distance transport system consisting of two tissue types with elongated cell files, phloem and xylem(1). Phloem has two basic cell types, enucleate sieve elements and companion cells. Xylem has various lignified cell types, such as tracheary elements, the differentiation of which involves deposition of elaborate cell wall thickenings and programmed cell death(1-4). Until now, little has been known about the genetic control of phloem-xylem patterning. Here we identify the ALTERED PHLOEM DEVELOPMENT (APL) gene, which encodes a MYB coiled-coil-type transcription factor that is required for phloem identity in Arabidopsis. Phloem is established through asymmetric cell divisions and subsequent differentiation. We show that both processes are impaired by a recessive apl mutation. This is associated with the formation of cells that have xylem characteristics in the position of phloem. The APL expression profile is consistent with a key role in phloem development. Ectopic APL expression in the vascular bundle inhibits xylem development. Our studies suggest that APL has a dual role both in promoting phloem differentiation and in repressing xylem differentiation during vascular development.	Univ Helsinki, Inst Biotechnol, Plant Mol Biol Lab, FIN-00014 Helsinki, Finland; BOKU Univ Nat Resources & Appl Life Sci Vienna, Ctr Appl Genet, A-1190 Vienna, Austria	University of Helsinki; University of Natural Resources & Life Sciences, Vienna	Helariutta, Y (corresponding author), Univ Helsinki, Inst Biotechnol, Plant Mol Biol Lab, POB 56, FIN-00014 Helsinki, Finland.		Helariutta, Yrjo/AAE-8149-2020; Mähönen, Ari Pekka/B-9764-2015; Hauser, Marie-Theres/J-6029-2013	Helariutta, Yrjo/0000-0002-7287-8459; Mähönen, Ari Pekka/0000-0001-6051-866X; Hauser, Marie-Theres/0000-0001-8938-2460				ALONI R, 1987, ANNU REV PLANT PHYS, V38, P179, DOI 10.1146/annurev.pp.38.060187.001143; Baum SF, 2002, AM J BOT, V89, P908, DOI 10.3732/ajb.89.6.908; Carland FM, 1999, PLANT CELL, V11, P2123, DOI 10.1105/tpc.11.11.2123; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; Imlau A, 1999, PLANT CELL, V11, P309, DOI 10.1105/tpc.11.3.309; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; Lin Y, 2001, DEVELOPMENT, V128, P3697; Liu YG, 1999, P NATL ACAD SCI USA, V96, P6535, DOI 10.1073/pnas.96.11.6535; Mahonen AP, 2000, GENE DEV, V14, P2938, DOI 10.1101/gad.189200; McCann M, 1997, TRENDS PLANT SCI, V2, P333, DOI 10.1016/S1360-1385(97)84620-1; McConnell JR, 1998, DEVELOPMENT, V125, P2935; Oparka KJ, 1999, PLANT CELL, V11, P739, DOI 10.1105/tpc.11.4.739; Rubio V, 2001, GENE DEV, V15, P2122, DOI 10.1101/gad.204401; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHERES B, 1994, DEVELOPMENT, V120, P2475; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; WAITES R, 1995, DEVELOPMENT, V121, P2143; Wisman E, 1998, PLANT MOL BIOL, V37, P989, DOI 10.1023/A:1006082009151; Ye ZH, 2002, ANNU REV PLANT BIOL, V53, P183, DOI 10.1146/annurev.arplant.53.100301.135245; Yoshimura T, 1996, PLANT CELL PHYSIOL, V37, P1167, DOI 10.1093/oxfordjournals.pcp.a029068	25	323	353	7	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					181	186		10.1038/nature02100	http://dx.doi.org/10.1038/nature02100			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614507				2022-12-28	WOS:000186517200044
J	Freckleton, RP; Sutherland, WJ; Watkinson, AR				Freckleton, RP; Sutherland, WJ; Watkinson, AR			Deciding the future of GM crops in Europe	SCIENCE			English	Editorial Material							HERBICIDE-TOLERANT CROPS; BIODIVERSITY		Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ E Anglia, Sch Biol Sci, Ctr Ecol Evolut & Conservat, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Tyndall Ctr Climate Change Res, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England	University of Oxford; University of East Anglia; University of East Anglia; University of East Anglia	Freckleton, RP (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Freckleton, Rob P/B-6455-2013; Sutherland, William/B-1291-2013; Watkinson, Andrew R/N-1649-2013	Freckleton, Robert/0000-0002-8338-864X; Sutherland, William/0000-0002-6498-0437				Brooks DR, 2003, PHILOS T R SOC B, V358, P1847, DOI 10.1098/rstb.2003.1407; *CAB OFF, 2003, STRAT UN FIELD WORK; Campbell S, 2003, NATURE, V425, P559, DOI 10.1038/425559b; Champion GT, 2003, PHILOS T ROY SOC B, V358, P1801, DOI 10.1098/rstb.2003.1405; Dewar AM, 2003, P ROY SOC B-BIOL SCI, V270, P335, DOI 10.1098/rspb.2002.2248; Firbank LG, 2003, J APPL ECOL, V40, P2, DOI 10.1046/j.1365-2664.2003.00787.x; FRECKLETON RP, IN PRESS P R SOC B; *GM SCI REV PAN, 2003, 1 DEP TRAD IND GM SC; Hawes C, 2003, PHILOS T ROY SOC B, V358, P1899, DOI 10.1098/rstb.2003.1406; Heard MS, 2003, PHILOS T ROY SOC B, V358, P1833, DOI 10.1098/rstb.2003.1401; Heard MS, 2003, PHILOS T ROY SOC B, V358, P1819, DOI 10.1098/rstb.2003.1402; Krebs JR, 1999, NATURE, V400, P611, DOI 10.1038/23127; Robinson RA, 2002, J APPL ECOL, V39, P157, DOI 10.1046/j.1365-2664.2002.00695.x; Roy DB, 2003, PHILOS T ROY SOC B, V358, P1879, DOI 10.1098/rstb.2003.1404; Squire GR, 2003, PHILOS T R SOC B, V358, P1779, DOI 10.1098/rstb.2003.1403; Watkinson AR, 2000, SCIENCE, V289, P1554, DOI 10.1126/science.289.5484.1554; [No title captured]	17	19	20	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					994	996		10.1126/science.1092671	http://dx.doi.org/10.1126/science.1092671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605355				2022-12-28	WOS:000186396300030
J	Miller, AI; Foote, M				Miller, AI; Foote, M			Increased longevities of post-Paleozoic marine genera after mass extinctions	SCIENCE			English	Article							TAXONOMIC DIVERSITY; FOSSIL RECORD; END; RECOVERY; ORIGINATION; COMPONENTS; EVOLUTION	Cohorts of marine taxa that originated during recoveries from mass extinctions were commonly more widespread spatially than those originating at other times. Coupled with the recognition of a correlation between the geographic ranges and temporal longevities of marine taxa, this observation predicts that recovery taxa were unusually long-lived geologically. We analyzed this possibility by assessing the longevities of marine genus cohorts that originated in successive substages throughout the Phanerozoic. Results confirm that several mass extinction recovery cohorts were significantly longer lived than other cohorts, but this effect was limited to the post-Paleozoic, suggesting differences in the dynamics of Paleozoic versus post-Paleozoic diversification.	Univ Cincinnati, Dept Geol, Cincinnati, OH 45221 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Cincinnati; University of Chicago	Miller, AI (corresponding author), Univ Cincinnati, Dept Geol, POB 210013, Cincinnati, OH 45221 USA.							Adrain JM, 2000, SCIENCE, V289, P110, DOI 10.1126/science.289.5476.110; Droser ML, 2000, GEOLOGY, V28, P675, DOI 10.1130/0091-7613(2000)028<0675:DOTAES>2.3.CO;2; Erwin DH, 1998, SCIENCE, V279, P1324, DOI 10.1126/science.279.5355.1324; Erwin DH, 2001, P NATL ACAD SCI USA, V98, P5399, DOI 10.1073/pnas.091092698; Erwin DH, 1998, TRENDS ECOL EVOL, V13, P344, DOI 10.1016/S0169-5347(98)01436-0; Foote M, 2000, PALEOBIOLOGY, V26, P74, DOI 10.1666/0094-8373(2000)26[74:OAECOT]2.0.CO;2; Foote M, 2000, PALEOBIOLOGY, V26, P578, DOI 10.1666/0094-8373(2000)026<0578:OAECOT>2.0.CO;2; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; Jablonski D, 1998, SCIENCE, V279, P1327, DOI 10.1126/science.279.5355.1327; JABLONSKI D, 1991, SCIENCE, V253, P754, DOI 10.1126/science.253.5021.754; KENDALL DG, 1948, ANN MATH STAT, V19, P1, DOI 10.1214/aoms/1177730285; Kirchner JW, 2000, NATURE, V404, P177, DOI 10.1038/35004564; Kirchner JW, 2002, NATURE, V415, P65, DOI 10.1038/415065a; MARKOV AV, 2002, PALEONTOL J, V36, P121; Myers N, 2001, P NATL ACAD SCI USA, V98, P5389, DOI 10.1073/pnas.091092498; RAUP DM, 1985, PALEOBIOLOGY, V11, P42, DOI 10.1017/S0094837300011386; RAUP DM, 1986, SCIENCE, V231, P833, DOI 10.1126/science.11542060; RAUP DM, 1991, PALEOBIOLOGY, V17, P37, DOI 10.1017/S0094837300010332; Rodland DL, 2001, PALAIOS, V16, P95, DOI 10.2307/3515554; SCHUBERT JK, 1992, GEOLOGY, V20, P883, DOI 10.1130/0091-7613(1992)020<0883:ETSAPM>2.3.CO;2; Sepkoski J.J., 2002, B AM PALEONTOL, V363, P1; SHEEHAN P M, 1975, Paleobiology, V1, P205; Sheehan PM, 2001, ANNU REV EARTH PL SC, V29, P331, DOI 10.1146/annurev.earth.29.1.331; STANLEY SM, 1994, SCIENCE, V266, P1340, DOI 10.1126/science.266.5189.1340; Walker LJ, 2002, J GEOL, V110, P75, DOI 10.1086/324318	25	41	44	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1030	1032		10.1126/science.1089719	http://dx.doi.org/10.1126/science.1089719			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14605366				2022-12-28	WOS:000186396300043
J	Goldfine, AB; Kahn, CR				Goldfine, AB; Kahn, CR			Adiponectin: linking the fat cell to insulin sensitivity	LANCET			English	Editorial Material							ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE; RESISTANCE; OXIDATION; GENE		Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Joslin Diabet Ctr, Boston, MA 02215 USA.	C.Ronald.Kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Goldfine, Allison/0000-0002-0345-1048				Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Musi N, 2003, BIOCHEM SOC T, V31, P191, DOI 10.1042/bst0310191; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Stefan N, 2002, DIABETES, V51, P1884, DOI 10.2337/diabetes.51.6.1884; Stumvoll M, 2002, DIABETES, V51, P37, DOI 10.2337/diabetes.51.1.37; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Ukkola O, 2003, METABOLISM, V52, P881, DOI 10.1016/S0026-0495(03)00074-X; Vasseur F, 2003, INT CONGR SER, V1253, P37, DOI 10.1007/s11892-003-0039-4; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	19	89	94	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2003	362	9394					1431	1432		10.1016/S0140-6736(03)14727-7	http://dx.doi.org/10.1016/S0140-6736(03)14727-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602433				2022-12-28	WOS:000186356600005
J	Setty, BNY; Stuart, MJ; Dampier, C; Brodecki, D; Allen, JL				Setty, BNY; Stuart, MJ; Dampier, C; Brodecki, D; Allen, JL			Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology	LANCET			English	Article							ACUTE CHEST SYNDROME; LEUKOCYTE ADHESION; NITRIC-OXIDE; P-SELECTIN; ENDOTHELIUM; PLATELET; CHILDREN; ADOLESCENTS; ACTIVATION; SATURATION	Background Nocturnal oxyhaemoglobin desaturation might have a role in CNS complications related to sickle cell disease, and rates of painful crises. We attempted to examine the biological relations, and describe the haematological risk factors for oxyhaemoglobin desaturation. Methods The study population included children with sickle cell disease and controls. Cellular activation was assessed by measurement of soluble vascular cell adhesion molecule 1, P-selectin, L-selectin, and leukotriene B-4. Erythrocyte-endothelial adhesion and routine haematological variables were assessed. Oxygen saturation (SaO(2)) was measured by pulse oximetry while children were awake and asleep. Children with a mean sleeping SaO(2) of less than or equal to93% were identified as hypoxaemic. Children were divided into four groups: controls (ten children), HbSC (nine, all normoxic), HbSS normoxic (13), and HbSS hypoxaemic (15). Findings Among haematological variables, sleeping SaO(2) correlated only with packed-cell volume (r=0.7; p<0.0001). Inverse relations were noted between sleeping SaO(2) and adhesion (-0.45; p<0.01), and markers of white-cell (-0.51; p<0.01), platelet (-0.61; p<0.001), and endothelial activation (-0.46; p<0.01). In the HbSS group who had sleeping hypoxaemia, waking SaO(2) measurements showed continuing hypoxaemia, with similar correlation between SaO(2) and cell activation markers. Interpretation: Our adhesion-related findings suggest a potential mechanism for the increased occurrence of clinical vaso-occlusive crises in individuals with sickle cell disease who have oxyhaemoglobin desaturation. Release of cellular mediators in hypoxaemia, and the relation between anaemia and oxyhaemoglobin desaturation, suggest that risk factors for stroke, including anaemia, might have a role in CNS-vasculopathy through hypoxia-mediated pathways. Furthermore, hypoxaemia in the older child also occurs during the day; such mild untreated hypoxia could lead to an increased risk of vaso-occlusive episodes.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pediat, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Marian Anderson Sickle Cell Ctr Core Lab, Philadelphia, PA 19107 USA; St Christophers Hosp Children, Dept Pediat, Philadelphia, PA 19133 USA; St Christophers Hosp Children, Marian Anderson Sickle Cell Care & Res Ctr, Philadelphia, PA 19133 USA; Drexel Univ, MCP Hahnemann Sch Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; Drexel University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Stuart, MJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pediat, Med Coll Bldg,Suite 727,1025 Walnut St, Philadelphia, PA 19107 USA.	marie.stuart@jefferson.edu	Dampier, Carlton/Q-2967-2019	Dampier, Carlton/0000-0002-7738-2620	NHLBI NIH HHS [5R01-HL51493, P60HL62148] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051493, P60HL062148] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blann AD, 1997, ATHEROSCLEROSIS, V128, P135, DOI 10.1016/S0021-9150(96)05980-1; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; CARLOS TM, 1994, BLOOD, V84, P2068; Duits AJ, 1996, CLIN IMMUNOL IMMUNOP, V81, P96, DOI 10.1006/clin.1996.0163; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; Frenette PS, 2002, CURR OPIN HEMATOL, V9, P101, DOI 10.1097/00062752-200203000-00003; GEE BE, 1995, BLOOD, V85, P268, DOI 10.1182/blood.V85.1.268.bloodjournal851268; Gladwin MT, 1999, AM J RESP CRIT CARE, V159, P1368, DOI 10.1164/ajrccm.159.5.9810094; Hargrave DR, 2003, BLOOD, V101, P846, DOI 10.1182/blood-2002-05-1392; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Inwald DP, 2000, BRIT J HAEMATOL, V111, P474, DOI 10.1046/j.1365-2141.2000.02353.x; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; Kirkham FJ, 2001, LANCET, V357, P1656, DOI 10.1016/S0140-6736(00)04821-2; Lard LR, 1999, J LEUKOCYTE BIOL, V66, P411, DOI 10.1002/jlb.66.3.411; Loughlin GM, 1996, AM J RESP CRIT CARE, V153, P866; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; Needleman JP, 1999, PEDIATR PULM, V28, P423, DOI 10.1002/(SICI)1099-0496(199912)28:6<423::AID-PPUL7>3.0.CO;2-C; Needleman JP, 1999, PEDIATR PULM, V28, P418, DOI 10.1002/(SICI)1099-0496(199912)28:6<418::AID-PPUL6>3.0.CO;2-D; Ohene-Frempong K, 1998, BLOOD, V91, P288; Phelan MW, 1996, J CELL PHYSIOL, V167, P469, DOI 10.1002/(SICI)1097-4652(199606)167:3<469::AID-JCP11>3.3.CO;2-C; RACKOFF WR, 1993, BLOOD, V81, P3422; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P925, DOI 10.1136/adc.67.7.925; Setty BNY, 2002, J LAB CLIN MED, V139, P80, DOI 10.1067/mlc.2002.121200; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Shin YT, 2000, BLOOD, V95, P3232; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; Steen RG, 1999, ANN NEUROL, V45, P279, DOI 10.1002/1531-8249(199903)45:3<279::AID-ANA2>3.0.CO;2-7; Stuart MJ, 1999, BLOOD, V94, P1555, DOI 10.1182/blood.V94.5.1555.417k36_1555_1560	30	137	142	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2003	362	9394					1450	1455		10.1016/S0140-6736(03)14689-2	http://dx.doi.org/10.1016/S0140-6736(03)14689-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739PX	14602439				2022-12-28	WOS:000186356600011
J	Col, NF; Pauker, SG				Col, NF; Pauker, SG			The discrepancy between observational studies and randomized trials of menopausal hormone therapy: Did expectations shape experience?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNRECOGNIZED MYOCARDIAL-INFARCTION; ESTROGEN REPLACEMENT THERAPY; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR-DISEASE; PLUS PROGESTIN; PRIMARY PREVENTION; SEX-DIFFERENCES; CASE-FATALITY; PREVALENCE	Differences between observational and randomized studies of the effects of menopausal hormone therapy (HT) on coronary heart disease (CHD) have been attributed to the fact that women who choose to use HT tend to be healthier than those who do not. Although this bias should affect all clinical outcomes with modifiable risk factors, estimates for stroke and pulmonary embolism were unaffected. The authors sought possible explanations for this isolated discrepancy in CHD findings. Unlike the randomized Women's Health Initiative (WHI) trial, the observational Nurses' Health Study (NHS) did not try to detect silent myocardial infarctions. Many women present with atypical ischemic symptoms. Hormone therapy users who believe that HT reduces CHD risks might not interpret ischemic symptoms as related to CHD, might not seek medical attention, and might present differently to their physicians, all of which could lead to more unrecognized myocardial infarctions among HT users in the NHS. In addition, persons completing death certificates and NHS physicians interpreting death certificates were not blinded to the use of HT. If persons assigning cause of death knew the patient had used HT and believed that HT prevented CHD, they might have been more likely to assign a condition other than CHD as the cause of death. If HT users were 20% less likely to have their infarctions recognized and their deaths attributed to CHID, a true increase in CHD due to HT use would appear to be a reduction in CHD. Combining these reporting biases with socioeconomic differences between users and nonusers could explain discrepancies. Beliefs held by patients, clinicians, and investigators might have affected the ascertainment of CHD outcomes in observational studies.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Womens Hlth, Boston, MA 02120 USA; Tufts Univ New England Med Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center	Col, NF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Womens Hlth, 1620 Tremont St, Boston, MA 02120 USA.	ncol@partners.org	Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X	AHRQ HHS [R01 HS01332901] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BUTLER C, 1986, BRIT J CLIN PSYCHOL, V25, P173, DOI 10.1111/j.2044-8260.1986.tb00693.x; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; Campisi R, 2002, CIRCULATION, V105, P425, DOI 10.1161/hc0402.102860; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Flaten MA, 1999, PSYCHOSOM MED, V61, P250, DOI 10.1097/00006842-199903000-00018; Girdler SS, 1999, J WOMEN HEALTH GEN-B, V8, P637, DOI 10.1089/jwh.1.1999.8.637; Goldberg RJ, 1998, AM HEART J, V136, P189, DOI 10.1053/hj.1998.v136.88874; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRIMM RH, 1987, CIRCULATION, V75, P6; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Jonsdottir LS, 1998, EUR HEART J, V19, P1011, DOI 10.1053/euhj.1998.0980; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1990, ADV CARDIOL, V37, P202; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Kessler KM, 2001, ANN INTERN MED, V135, P1092, DOI 10.7326/0003-4819-135-12-200112180-00023; LINDBERG HA, 1960, ARCH INTERN MED, V106, P628, DOI 10.1001/archinte.1960.03820050040008; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; NADELMANN J, 1990, AM J CARDIOL, V66, P533, DOI 10.1016/0002-9149(90)90477-I; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; Peterson ED, 1998, AM HEART J, V136, P186, DOI 10.1053/hj.1998.v136.89736; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; Prandoni P, 2003, NEW ENGL J MED, V348, P1435, DOI 10.1056/NEJMoa022157; Qizilbash N, 1995, LANCET, V346, P1647; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; ROSENMAN RH, 1967, AM J CARDIOL, V19, P776, DOI 10.1016/0002-9149(67)90498-5; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sacco RL, 1999, NEUROLOGY, V53, pS15; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; SCHLESSELMAN JJ, 1992, J CLIN EPIDEMIOL, V45, P449, DOI 10.1016/0895-4356(92)90094-4; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sheifer SE, 2001, ANN INTERN MED, V135, P801, DOI 10.7326/0003-4819-135-9-200111060-00010; Sheifer SE, 2000, J AM COLL CARDIOL, V35, P119, DOI 10.1016/S0735-1097(99)00524-0; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; Simon J A, 2001, Climacteric, V4, P19, DOI 10.1080/713605032; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STERNBACH RA, 1964, PSYCHOPHYSIOLOGY, V1, P67; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; Tunstall-Pedoe H, 1998, HEART, V80, P112, DOI 10.1136/hrt.80.2.112; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1978, BRIT HEART J, V40, P510; Wagner KR, 1996, J RHEUMATOL, V23, P2079; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1973, JAMA, V226, P652; 1973, CIRCULATION S, V47, pI1; 1980, N ENGL J MED, V303, P1083	64	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2003	139	11					923	929		10.7326/0003-4819-139-11-200312020-00011	http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WW	14644895				2022-12-28	WOS:000186884800006
J	Sklar, P; Masur, H				Sklar, P; Masur, H			HIV infection and cardiovascular disease - Is there really a link?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORONARY-HEART-DISEASE; PROTEASE INHIBITORS; RISK		Drexel Univ, Coll Med, Div HIV AIDS Med, Philadelphia, PA 19104 USA; NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	Drexel University; National Institutes of Health (NIH) - USA	Sklar, P (corresponding author), Drexel Univ, Coll Med, Div HIV AIDS Med, Philadelphia, PA 19104 USA.							Bozzette SA, 2003, NEW ENGL J MED, V348, P702, DOI 10.1056/NEJMoa022048; Currier JS, 2003, JAIDS-J ACQ IMM DEF, V33, P506, DOI 10.1097/00126334-200308010-00012; DUBE MPS, 2002, 9 C RETR OPP INF SEA; FEINGOLD KR, 1993, J CLIN ENDOCR METAB, V76, P1423, DOI 10.1210/jc.76.6.1423; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Klein D, 2002, J ACQ IMMUN DEF SYND, V30, P471, DOI 10.1097/00126334-200208150-00002; MARYKRAUSE M, 2001, 8 C RETR OPP INF CHI; Riddler SA, 2003, JAMA-J AM MED ASSOC, V289, P2978, DOI 10.1001/jama.289.22.2978; WILSON PWF, 1987, AM J CARDIOL, V59, pG91, DOI 10.1016/0002-9149(87)90165-2; WILSON PWF, 1987, AM J CARDIOL, V60, pA11	11	39	40	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	2003	349	21					2065	2067		10.1056/NEJMe038158	http://dx.doi.org/10.1056/NEJMe038158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744QE	14627792				2022-12-28	WOS:000186642900012
J	El-Serag, H; Davila, JA; Petersen, NJ; McGlynn, KA				El-Serag, H; Davila, JA; Petersen, NJ; McGlynn, KA			The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-C-VIRUS; PRIMARY LIVER-CANCER; DIABETES-MELLITUS; RISING INCIDENCE; RISK-FACTORS; PREVALENCE; INFECTION; JAPAN	Background: The incidence of hepatocellular carcinoma was reported to be increasing in the United States. However, alternate explanations were diagnostic or reclassification bias and changes in the demographic features of the general population. Objective: To examine the temporal trends in the incidence of hepatocellular carcinoma. Design: Retrospective cohort study. Setting: Information collected by population-based registries of the Surveillance, Epidemiology, and End Results (SEER) program. Patients: Persons given a diagnosis of hepatocellular carcinoma between 1975 and 1998. Measurements: Linear Poisson multivariate regression model, controlling for differences in age, sex, race or ethnicity, and geographic region among patients with hepatocellular carcinoma and in the underlying population. Results: The overall age-adjusted incidence rates of hepatocellular carcinoma increased from 1.4 per 100 000 in 1975 to 1977 to 3.0 per 100 000 in 1996 to 1998. There was a 25% increase during the last 3 years of the study compared with the preceding 3 years (1993 to 1995). The increase affected most age groups above 40 years, with the greatest increase in the 45- to 49-year-old age group. White men had the greatest increase (31%) in the last time period (1996 to 1998) compared with 1993 to 1995. The Poisson regression model confirmed an almost 2-fold increase in the incidence rate ratio for hepatocellular carcinoma between 1975 to 1978 and 1996 to 1998. Conclusions: The incidence of hepatocellular carcinoma continues to increase rapidly in the United States, with rates increasing the fastest in white men 45 to 54 years of age. These findings are consistent with a true increase and could be explained by consequences of hepatitis C virus acquired during the 1960s and 1970s.	Houston Vet Affairs Med Ctr, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	El-Serag, H (corresponding author), Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.	hasheme@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [ZIACP010158, Z01CP010158] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami HO, 1996, J NATL CANCER I, V88, P1472, DOI 10.1093/jnci/88.20.1472; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332; COLOMBO M, 1989, LANCET, V2, P1006; Davila JA, 2003, J CLIN EPIDEMIOL, V56, P487, DOI 10.1016/S0895-4356(02)00605-4; El-Serag HB, 2000, ARCH INTERN MED, V160, P3227, DOI 10.1001/archinte.160.21.3227; El-Serag HB, 2001, AM J GASTROENTEROL, V96, P2462, DOI 10.1111/j.1572-0241.2001.04054.x; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Hassan MM, 2002, J CLIN GASTROENTEROL, V35, P266, DOI 10.1097/00004836-200209000-00013; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; Kaczynski J, 1999, NEW ENGL J MED, V341, P451; Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001; McCarthy EP, 2000, MED CARE, V38, P868, DOI 10.1097/00005650-200008000-00010; MCQUILLAN GM, 1989, AM J MED, V87, pS5; *NAT CANC I, 2001, SURV EP END RES SEER; OKUDA K, 1987, CANCER RES, V47, P4967; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P15584, DOI 10.1073/pnas.242608099; Warren JL, 2002, MED CARE S, V40; World Health Organization, 1976, INT CLASS DIS ONC	19	764	790	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 18	2003	139	10					817	823		10.7326/0003-4819-139-10-200311180-00009	http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744ZV	14623619				2022-12-28	WOS:000186663500005
J	Gupta, R; Sheikh, A; Strachan, D; Anderson, HR				Gupta, R; Sheikh, A; Strachan, D; Anderson, HR			Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions' data	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England	St Georges University London	Gupta, R (corresponding author), St George Hosp, Sch Med, Dept Community Hlth Sci, Cranmer Terrace, London SW17 0RE, England.		Anderson, Hugh R/A-7417-2016; Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056				*DEP HLTH, PRESCR COST AN; *DEP HLTH, 1991, HOSP EP STAT, V1; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; *UCB I ALL, 1997, EUR ALL WHIT PAP ALL; *WHO, 1977, INT CLASS DIS MAN IN	5	99	100	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 15	2003	327	7424					1142	1143		10.1136/bmj.327.7424.1142	http://dx.doi.org/10.1136/bmj.327.7424.1142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744HL	14615340	Green Published, Bronze			2022-12-28	WOS:000186622100021
J	Robinson, BWS; Creaney, J; Lake, R; Nowak, A; Musk, AW; de Klerk, N; Winzell, P; Hellstrom, KE; Hellstrom, I				Robinson, BWS; Creaney, J; Lake, R; Nowak, A; Musk, AW; de Klerk, N; Winzell, P; Hellstrom, KE; Hellstrom, I			Mesothelin-family proteins and diagnosis of mesothelioma	LANCET			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; MOLECULAR-CLONING; OVARIAN-CARCINOMA; GENE-THERAPY; CELL-LINE; CANCER; EXPRESSION; ANTIBODY; SERUM; CDNA	Background Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour. markers. Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals. Methods We assayed serum concentrations of soluble mesothelin-related proteins (SMR) using a double determinant (sandwich) ELISA in a blinded study of serum samples from 44 patients with histologically proven mesothelioma; 68 matched healthy controls, 40 of whom had been exposed to asbestos; and 160 patients with other inflammatory or malignant lung and pleural diseases. Findings 37 (84%) of 44 patients with mesothelioma had raised concentrations of SMR at a serum dilution of 1/80, compared with three (2%) of 160 patients with other cancers or other inflammatory lung or pleural diseases, and with none of 28 controls who had not been exposed to asbestos. SMR concentrations correlated with tumour size and increased during tumour progression. Seven of the 40 asbestos-exposed individuals had increased serum concentrations of SMR; three of those seven developed mesothelioma and one developed lung carcinoma within 1-5 years. None of the 33 asbestos-exposed participants whose serum samples had normal concentrations of SMR and who were followed up over 8 years developed mesothelioma. Interpretation Determination of SMR in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression. It might also prove helpful for screening asbestos-exposed individuals for early evidence of mesothelioma.	Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Med, Perth, WA 6009, Australia; Western Australian Inst Med Res, Perth, WA, Australia; Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia; Telethon Inst Child Hlth Res, Subiaco, WA, Australia; UWA Ctr Child Hlth Res, Subiaco, WA, Australia; Pacific NW Res Inst, Seattle, WA USA	University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia	Robinson, BWS (corresponding author), Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Med, 4th Floor,G Block, Perth, WA 6009, Australia.	bwsrobin@cyllene.uwa.edu.au	de Klerk, Nicholas H/D-8388-2016; Robinson, Bruce/N-1900-2014; Nowak, Anna K/B-2487-2013	de Klerk, Nicholas H/0000-0001-9223-0767; Nowak, Anna K/0000-0002-9317-9526	NATIONAL CANCER INSTITUTE [R01CA085780, R01CA079490, K22CA098008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98008, CA 85780, CA 79490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTMAN K, 1988, J CLIN ONCOL, V6, P147, DOI 10.1200/JCO.1988.6.1.147; Argani P, 2001, CLIN CANCER RES, V7, P3862; BATES SE, 1991, ANN INTERN MED, V115, P623, DOI 10.7326/0003-4819-115-8-623; Boutin C, 1998, EUR RESPIR J, V12, P972, DOI 10.1183/09031936.98.12040972; Byrne MJ, 1999, J CLIN ONCOL, V17, P25, DOI 10.1200/JCO.1999.17.1.25; Caminschi I, 1999, AM J RESP CELL MOL, V21, P347, DOI 10.1165/ajrcmb.21.3.3575; Carretta A, 2000, EUR J CARDIO-THORAC, V17, P377, DOI 10.1016/S1010-7940(00)00377-8; CHANG K, 1992, CANCER RES, V52, P181; CHANG K, 1994, INT J CANCER, V57, P90, DOI 10.1002/ijc.2910570117; Chowdhury PS, 1998, P NATL ACAD SCI USA, V95, P669, DOI 10.1073/pnas.95.2.669; CONAGHAN P, 1996, IMMUNOPATHOLOGY LUNG, P147; Henderson DW, 1998, AM J CLIN PATHOL, V110, P397, DOI 10.1093/ajcp/110.3.397; HILLERDAL G, 1991, CANCER, V67, P2410, DOI 10.1002/1097-0142(19910501)67:9<2410::AID-CNCR2820670933>3.0.CO;2-D; Ho L, 2001, Cancer Treat Res, V105, P327; Johnson P J, 2001, Clin Liver Dis, V5, P145, DOI 10.1016/S1089-3261(05)70158-6; Kagan E., 1996, IMMUNOPATHOLOGY LUNG, P421; KOJIMA T, 1995, J BIOL CHEM, V270, P21984, DOI 10.1074/jbc.270.37.21984; Marzo AL, 2000, J IMMUNOL, V165, P6047, DOI 10.4049/jimmunol.165.11.6047; McIntosh MW, 2002, CANCER EPIDEM BIOMAR, V11, P159; McLaren BR, 2000, CANCER CHEMOTH PHARM, V45, P502, DOI 10.1007/s002800051026; Musk AW, 1998, INT J CANCER, V75, P355, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;355::AID-IJC5&gt;3.0.CO;2-1; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Olt G, 1990, Obstet Gynecol Surv, V45, P570, DOI 10.1097/00006254-199009000-00002; Poteat HT, 2000, AM J CLIN PATHOL, V113, P421, DOI 10.1309/E11X-491Y-GUJH-EGGF; Robinson B., 1996, IMMUNOPATHOLOGY LUNG, P165; ROBINSON BWS, 1993, LUNG CANCER, V9, P413; Rothman KJ., 1986, MODERN EPIDEMIOLOGY; Rusch VW, 1999, ANN THORAC SURG, V68, P1799, DOI 10.1016/S0003-4975(99)01038-3; Scholler N, 1999, P NATL ACAD SCI USA, V96, P11531, DOI 10.1073/pnas.96.20.11531; Scott B., 2000, TXB LUNG CANC, P273; Spurzem J., 1996, IMMUNOPATHOLOGY LUNG, P119; Urwin Debra, 2000, Molecular Cell Biology Research Communications, V3, P26, DOI 10.1006/mcbr.2000.0181; Vauthey JN, 1996, DIGEST DIS, V14, P5, DOI 10.1159/000171535; YAMAGUCHI N, 1994, J BIOL CHEM, V269, P805; Zellos LS, 2002, SEMIN ONCOL, V29, P41, DOI 10.1053/sonc.2002.30230	35	427	444	1	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 15	2003	362	9396					1612	1616		10.1016/S0140-6736(03)14794-0	http://dx.doi.org/10.1016/S0140-6736(03)14794-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	744MZ	14630441				2022-12-28	WOS:000186637400009
J	Karoly, DJ; Braganza, K; Stott, PA; Arblaster, JM; Meehl, GA; Broccoli, AJ; Dixon, KW				Karoly, DJ; Braganza, K; Stott, PA; Arblaster, JM; Meehl, GA; Broccoli, AJ; Dixon, KW			Detection of a human influence on North American climate	SCIENCE			English	Article							20TH-CENTURY TEMPERATURE; SOLAR IRRADIANCE; SURFACE; VARIABILITY; INDEXES	Several indices of large-scale patterns of surface temperature variation were used to investigate climate change in North America over the 20th century. The observed variability of these indices was simulated well by a number of climate models. Comparison of index trends in observations and model simulations shows that North American temperature changes from 1950 to 1999 were unlikely to be due to natural climate variation alone. Observed trends over this period are consistent with simulations that include anthropogenic forcing from increasing atmospheric greenhouse gases and sulfate aerosols. However, most of the observed warming from 1900 to 1949 was likely due to natural climate variation.	Univ Oklahoma, Sch Meteorol, Norman, OK 73019 USA; Monash Univ, Sch Math Sci, Clayton, Vic 3800, Australia; Hadley Ctr, MetOff, Bracknell RG12 2SY, Berks, England; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA	University of Oklahoma System; University of Oklahoma - Norman; Monash University; Met Office - UK; Hadley Centre; National Center Atmospheric Research (NCAR) - USA; National Oceanic Atmospheric Admin (NOAA) - USA	Karoly, DJ (corresponding author), Univ Oklahoma, Sch Meteorol, Norman, OK 73019 USA.	dkaroly@ou.edu	Arblaster, Julie/C-1342-2010; Broccoli, Anthony J/D-9186-2014; Stott, Peter/N-1228-2016; Braganza, Karl/AAQ-1508-2020; Scott, Peter/GYA-5335-2022; Dixon, Keith W/L-7120-2015; Karoly, David J/C-8262-2011	Arblaster, Julie/0000-0002-4287-2363; Broccoli, Anthony J/0000-0003-2619-1434; Stott, Peter/0000-0003-4853-7686; Dixon, Keith W/0000-0003-3044-326X; Karoly, David J/0000-0002-8671-2994				Ammann CM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016875; Andronova NG, 1999, J GEOPHYS RES-ATMOS, V104, P16807, DOI 10.1029/1999JD900165; Bell J, 2000, GEOPHYS RES LETT, V27, P261, DOI 10.1029/1999GL006080; Braganza K, 2003, CLIM DYNAM, V20, P491, DOI 10.1007/s00382-002-0286-0; BROCCOLI AJ, UNPUB; Houghton J. T., 2001, CLIMATE CHANGE 2001; HOYT DV, 1993, J GEOPHYS RES-SPACE, V98, P18895, DOI 10.1029/93JA01944; Johns TC, 2003, CLIM DYNAM, V20, P583, DOI 10.1007/s00382-002-0296-y; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Karl TR, 1996, B AM METEOROL SOC, V77, P279, DOI 10.1175/1520-0477(1996)077<0279:IOCCFT>2.0.CO;2; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; Lean J, 2000, GEOPHYS RES LETT, V27, P2425, DOI 10.1029/2000GL000043; Meehl GA, 2003, J CLIMATE, V16, P426, DOI [10.1175/1520-0442(2003)016<0426:SAGGFA>2.0.CO;2, 10.1175/1520-0442(2003)016&lt;0426:SAGGFA&gt;2.0.CO;2]; Mitchell JFB, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P695; New M, 2000, J CLIMATE, V13, P2217, DOI 10.1175/1520-0442(2000)013<2217:RTCSTC>2.0.CO;2; Santer BD, 2003, SCIENCE, V301, P479, DOI 10.1126/science.1084123; SATO M, 1993, J GEOPHYS RES-ATMOS, V98, P22987, DOI 10.1029/93JD02553; Stott PA, 1998, J CLIMATE, V11, P3282, DOI 10.1175/1520-0442(1998)011<3282:SDDOCC>2.0.CO;2; Stott PA, 2000, SCIENCE, V290, P2133, DOI 10.1126/science.290.5499.2133; Stott PA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017324; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; Zwiers FW, 2003, J CLIMATE, V16, P793, DOI 10.1175/1520-0442(2003)016<0793:TRSCCD>2.0.CO;2	22	82	86	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1200	1203		10.1126/science.1089159	http://dx.doi.org/10.1126/science.1089159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615536				2022-12-28	WOS:000186544300051
J	Preston, LA; Creager, KC; Crosson, RS; Brocher, TM; Trehu, AM				Preston, LA; Creager, KC; Crosson, RS; Brocher, TM; Trehu, AM			Intraslab earthquakes: Dehydration of the Cascadia slab	SCIENCE			English	Article							SUBDUCTION ZONE; VELOCITY STRUCTURE; CRUSTAL STRUCTURE; SILENT SLIP; WASHINGTON; SERPENTINITE; PRESSURE; MARGIN; TREMOR; ARC	We simultaneously invert travel times of refracted and wide-angle reflected waves for three-dimensional compressional-wave velocity structure, earthquake locations, and reflector geometry in northwest Washington state. The reflector, interpreted to be the crust-mantle boundary (Moho) of the subducting Juan de Fuca plate, separates intraslab earthquakes into two groups, permitting a new understanding of the origins of intraslab earthquakes in Cascadia. Earthquakes up-dip of the Moho's 45-kilometer depth contour occur below the reflector, in the subducted oceanic mantle, consistent with serpentinite dehydration; earthquakes located down-dip occur primarily within the subducted crust, consistent with the basalt-to-eclogite transformation.	Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; US Geol Survey, Menlo Pk, CA 94025 USA; Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA	University of Washington; University of Washington Seattle; United States Department of the Interior; United States Geological Survey; Oregon State University	Preston, LA (corresponding author), Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA.	preston@ess.washington.edu		Brocher, Thomas/0000-0002-9740-839X				Brocher TM, 2003, GEOLOGY, V31, P267, DOI 10.1130/0091-7613(2003)031<0267:SEFWSF>2.0.CO;2; BROCHER TM, 1999, 99314 US GEOL SURV; CASSIDY JF, 1993, J GEOPHYS RES-SOL EA, V98, P4407, DOI 10.1029/92JB02696; CHOY GL, 2001, 010005 US GEOL SURV; CROSSON RS, 1976, J GEOPHYS RES, V81, P3047, DOI 10.1029/JB081i017p03047; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; GREEN HW, 1995, ANNU REV EARTH PL SC, V23, P169, DOI 10.1146/annurev.ea.23.050195.001125; Hacker BR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001129; Hacker BR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001127; HACKER BR, 2002, CASCADIA SUBDUCTION, P133; HOLE J, 1995, GEOPHYS J INT, V121; KIRBY SH, 1987, J GEOPHYS RES-SOLID, V92, P13789, DOI 10.1029/JB092iB13p13789; LUDWIN RS, 1991, NEOTECTONICS N AM DE, V1, P77; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Obara K, 2002, SCIENCE, V296, P1679, DOI 10.1126/science.1070378; Parsons T, 1998, GEOLOGY, V26, P199, DOI 10.1130/0091-7613(1998)026<0199:ANVITC>2.3.CO;2; PEACOCK SM, 2002, CASCADIA SUBDUCTION, P123; PRESTON LA, 2003, THESIS U WASHINGTON; RALEIGH CB, 1965, J GEOPHYS RES, V70, P3965, DOI 10.1029/JZ070i016p03965; Rogers G, 2003, SCIENCE, V300, P1942, DOI 10.1126/science.1084783; RUTTER EH, 1988, J GEOPHYS RES-SOLID, V93, P4907, DOI 10.1029/JB093iB05p04907; TREHU AM, 2002, CASCADIA SUBDUCTION, P25; Van Wagoner TM, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000710; VIDALE JE, 1990, GEOPHYSICS, V55, P521, DOI 10.1190/1.1442863	24	83	83	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1197	1200		10.1126/science.1090751	http://dx.doi.org/10.1126/science.1090751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14615535				2022-12-28	WOS:000186544300050
J	Schumacher, MA; Lau, AOT; Johnson, PJ				Schumacher, MA; Lau, AOT; Johnson, PJ			Structural basis of core promoter recognition in a primitive eukaryote	CELL			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; PROTEIN-CODING GENES; LARGEST-SUBUNIT; DNA-BINDING; CRYSTAL-STRUCTURE; ETS-DOMAIN; INITIATOR ELEMENT; CAPPING ENZYME; TRANSCRIPTION	Transcription start site selection in eukaryotes is mediated through combinations of the TATA, initiator (lnr), and downstream promoter elements (DPE). In Trichomonas vaginalis, a parabasalian flagellate thought to represent an ancient eukaryote lineage, the lnr appears to be solely responsible for start site selection and is recognized by the initiator binding protein 39 kDa (IBP39). IBP39 contains an N-terminal lnr binding domain (IBD) connected via a flexible linker to a C-terminal domain (C domain). Here we present crystal structures of the apoIBD and IBD-lnr complexes and the C domain. The 11313 structures reveal a winged-helix motif with prokaryotic and eukaryotic features and a scaffold similar to that of ETS-family proteins. The C domain structure and biochemical studies indicate that it interacts with the T. vaginalis RNAP 11 large subunit C-terminal domain. These data suggest that binding of IBP39 to the lnr directly recruits RNAP 11 and in this way initiates transcription.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Sch Med, Los Angeles, CA 90095 USA	Oregon Health & Science University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schumacher, MA (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.			Lau, Audrey/0000-0001-8212-0142	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI050359, R01AI030537] Funding Source: NIH RePORTER; NIAID NIH HHS [F32AI50359, AI30537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARKHIPOVA IR, 1995, GENETICS, V139, P1359; BARRONCASELLA E, 1992, J MOL EVOL, V35, P405, DOI 10.1007/BF00171818; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; Cramer P, 2002, CURR OPIN STRUC BIOL, V12, P89, DOI 10.1016/S0959-440X(02)00294-4; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EVERS R, 1989, NUCLEIC ACIDS RES, V17, P3403, DOI 10.1093/nar/17.9.3403; EVERS R, 1989, CELL, V56, P585, DOI 10.1016/0092-8674(89)90581-3; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadonaga JT, 2002, EXP MOL MED, V34, P259, DOI 10.1038/emm.2002.36; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Keeling PJ, 2000, NATURE, V405, P635, DOI 10.1038/35015167; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOWESTRA D, 1991, NATURE, V349, P178; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Liston DR, 2001, MOL CELL BIOL, V21, P7872, DOI 10.1128/MCB.21.22.7872-7882.2001; Litingtung Y, 1999, MOL GEN GENET, V261, P100, DOI 10.1007/s004380050946; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Myers JK, 2001, BIOCHEMISTRY-US, V40, P8479, DOI 10.1021/bi0027884; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; QUON DVK, 1994, P NATL ACAD SCI USA, V91, P4579, DOI 10.1073/pnas.91.10.4579; Quon DVK, 1996, J MOL EVOL, V43, P253, DOI 10.1007/PL00006084; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; WEMER MH, 1997, J BIOMOL NMR, V10, P317; WEST ML, 1995, GENETICS, V140, P1223; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514	56	50	51	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 14	2003	115	4					413	424		10.1016/S0092-8674(03)00887-0	http://dx.doi.org/10.1016/S0092-8674(03)00887-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	744KB	14622596	Bronze			2022-12-28	WOS:000186627100008
J	Huangfu, DW; Liu, AM; Rakeman, AS; Murcia, NS; Niswander, L; Anderson, KV				Huangfu, DW; Liu, AM; Rakeman, AS; Murcia, NS; Niswander, L; Anderson, KV			Hedgehog signalling in the mouse requires intraflagellar transport proteins	NATURE			English	Article							KINESIN-II; GENE; DISEASE; GLI3; MORPHOGENESIS; EXPRESSION; DELETION; PATHWAY; LACKING; MUTANTS	Intraflagellar transport (IFT) proteins were first identified as essential factors for the growth and maintenance of flagella in the single-celled alga Chlamydomonas reinhardtii(1). In a screen for embryonic patterning mutations induced by ethylnitrosourea, here we identify two mouse mutants, wimple (wim) and flexo (fxo), that lack ventral neural cell types and show other phenotypes characteristic of defects in Sonic hedgehog signalling. Both mutations disrupt IFT proteins: the wim mutation is an allele of the previously uncharacterized mouse homologue of IFT172; and fxo is a new hypomorphic allele of polaris, the mouse homologue of IFT88. Genetic analysis shows that Wim, Polaris and the IFT motor protein Kif3a are required for Hedgehog signalling at a step downstream of Patched1 ( the Hedgehog receptor) and upstream of direct targets of Hedgehog signalling. Our data show that IFT machinery has an essential and vertebrate-specific role in Hedgehog signal transduction.	Sloan Kettering Inst, Dev Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Mol Cell & Dev Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Neurosci Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Howard Hughes Med Inst, New York, NY 10021 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Anderson, KV (corresponding author), Sloan Kettering Inst, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA.	k-anderson@ski.mskcc.org	Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594; Huangfu, Danwei/0000-0002-1145-6199; Anderson, Kathryn/0000-0003-1657-2161				Bale AE, 2002, ANNU REV GENOM HUM G, V3, P47, DOI 10.1146/annurev.genom.3.022502.103031; Caspary T, 2002, CURR BIOL, V12, P1628, DOI 10.1016/S0960-9822(02)01147-8; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Eggenschwiler JT, 2000, DEV BIOL, V227, P648, DOI 10.1006/dbio.2000.9918; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; HAN Y, 1932, CURR BIOL, V13, P1679; Howard PW, 2000, J BIOL CHEM, V275, P13336, DOI 10.1074/jbc.275.18.13336; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Motoyama J, 2003, DEV BIOL, V259, P150, DOI 10.1016/S0012-1606(03)00159-3; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Ray K, 1999, J CELL BIOL, V147, P507, DOI 10.1083/jcb.147.3.507; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Schimenti JC, 2000, GENOME RES, V10, P1043, DOI 10.1101/gr.10.7.1043; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Sloboda RD, 2002, CELL MOTIL CYTOSKEL, V52, P1, DOI 10.1002/cm.10035; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Vetter DE, 2002, NAT GENET, V31, P363, DOI 10.1038/ng914; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; Ying LT, 2000, DEV DYNAM, V219, P143, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1050>3.3.CO;2-H; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916	30	1002	1026	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2003	426	6962					83	87		10.1038/nature02061	http://dx.doi.org/10.1038/nature02061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739WY	14603322				2022-12-28	WOS:000186370800046
J	Kodama, A; Karakesisoglou, L; Wong, E; Vaezi, A; Fuchs, E				Kodama, A; Karakesisoglou, L; Wong, E; Vaezi, A; Fuchs, E			ACF7: An essential integrator of microtubule dynamics	CELL			English	Article							ADENOMATOUS POLYPOSIS-COLI; CELL POLARITY; MITOTIC SPINDLE; FISSION YEAST; MIGRATING CELLS; RHO-GTPASES; PLUS-END; F-ACTIN; CYTOSKELETON; PROTEINS	ACF7 is a member of the spectraplakin family of cytoskeletal crosslinking proteins possessing actin and microtubule binding domains. Here, we show that ACF7 is an essential integrator of MT-actin dynamics. In endodermal cells, ACF7 binds along microtubules but concentrates at their distal ends and at cell borders when polarized. In ACF7's absence, microtubules still bind EB1 and CLIP170, but they no longer grow along polarized actin bundles, nor do they pause and tether to actin-rich cortical sites. The consequences are less stable, long microtubules with skewed cytoplasmic trajectories and altered dynamic instability. In response to wounding, ACF7 null cultures activate polarizing signals, but fail to maintain them and coordinate migration. Rescue of these defects requires ACF7's actin and microtubule binding domains. Thus, spectraplakins are important for controlling microtubule dynamics and reinforcing links between microtubules and polarized F-actin, so that cellular polarization and coordinated cell movements can be sustained.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA.		Fuchs, Elaine/G-1565-2016	Karakesisoglou, Iakowos (Akis)/0000-0002-8549-0728	NIAMS NIH HHS [R01 AR027883-28] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe K, 1996, EXP CELL RES, V229, P27, DOI 10.1006/excr.1996.0340; Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; Barth AIM, 2002, J CELL SCI, V115, P1583; Behrens R, 2002, J CELL BIOL, V157, P783, DOI 10.1083/jcb.200112027; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; GOTLIEB AI, 1981, J CELL BIOL, V91, P589, DOI 10.1083/jcb.91.2.589; GUNDERSEN GG, 1986, J CELL BIOL, V102, P1118, DOI 10.1083/jcb.102.3.1118; Gundersen GG, 2002, NAT REV MOL CELL BIO, V3, P296, DOI 10.1038/nrm777; Gupton SL, 2002, CURR BIOL, V12, P1891, DOI 10.1016/S0960-9822(02)01276-9; Hayles J, 2001, NAT REV MOL CELL BIO, V2, P647, DOI 10.1038/35089520; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karakesisoglou I, 2000, J CELL BIOL, V149, P195, DOI 10.1083/jcb.149.1.195; Kaverina I, 2002, J CELL SCI, V115, P2283; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kofron M, 2002, J CELL BIOL, V158, P695, DOI 10.1083/jcb.200202123; Komarova YA, 2002, J CELL SCI, V115, P3527; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lee S, 2002, DEVELOPMENT, V129, P1195; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; LIU JJ, 2003, IN PRESS J CELL BIOL; Magdalena J, 2003, J CELL SCI, V116, P743, DOI 10.1242/jcs.00288; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Reuter JE, 2003, DEVELOPMENT, V130, P1203, DOI 10.1242/dev.00319; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; Roper K, 2002, J CELL SCI, V115, P4215, DOI 10.1242/jcs.00157; Salmon WC, 2002, J CELL BIOL, V158, P31, DOI 10.1083/jcb.200203022; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Subramanian A, 2003, CURR BIOL, V13, P1086, DOI 10.1016/S0960-9822(03)00416-0; Sun DM, 2001, J CELL SCI, V114, P161; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; TIMAUER JS, 2002, MOL BIOL CELL, V13, P3614; Tirnauer JS, 2002, MOL BIOL CELL, V13, P4308, DOI 10.1091/mbc.e02-04-0236; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wittmann T, 2001, J CELL SCI, V114, P3795; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Yvon AMC, 2002, MOL BIOL CELL, V13, P1871, DOI 10.1091/mbc.01-11-0539; Zhou FQ, 2002, J CELL BIOL, V157, P839, DOI 10.1083/jcb.200112014	62	254	263	0	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 31	2003	115	3					343	354		10.1016/S0092-8674(03)00813-4	http://dx.doi.org/10.1016/S0092-8674(03)00813-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	740RH	14636561	Bronze			2022-12-28	WOS:000186415000013
J	Yoshimura, T; Yasuo, S; Watanabe, M; Iigo, M; Yamamura, T; Hirunagi, K; Ebihara, S				Yoshimura, T; Yasuo, S; Watanabe, M; Iigo, M; Yamamura, T; Hirunagi, K; Ebihara, S			Light-induced hormone conversion of T-4 to T-3 regulates photoperiodic response of gonads in birds	NATURE			English	Article							CIRCADIAN CLOCK GENES; JAPANESE-QUAIL; ELECTRICAL-STIMULATION; GONADOTROPHIN RELEASE; TUBERAL HYPOTHALAMUS; TESTICULAR GROWTH; THYROIDECTOMY; EXPRESSION; THYROXINE; RHYTHMICITY	Reproduction of many temperate zone birds is under photoperiodic control. The Japanese quail is an excellent model for studying the mechanism of photoperiodic time measurement because of its distinct and marked response to changing photoperiods. Studies on this animal have suggested that the mediobasal hypothalamus (MBH) is an important centre controlling photoperiodic time measurement(1-8). Here we report that expression in the MBH of the gene encoding type 2 iodothyronine deiodinase (Dio2), which catalyses the intracellular deiodination of thyroxine (T-4) prohormone to the active 3,5,3'-triiodothyronine (T-3), is induced by light in Japanese quail. Intracerebroventricular administration of T-3 mimics the photoperiodic response, whereas the Dio2 inhibitor iopanoic acid prevents gonadal growth. These findings demonstrate that light-induced Dio2 expression in the MBH may be involved in the photoperiodic response of gonads in Japanese quail.	Nagoya Univ, Grad Sch Bioagr Sci, Div Biomodeling, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ Museum, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Utsunomiya Univ, Fac Agr, Dept Appl Biol Chem, Utsunomiya, Tochigi 3218505, Japan	Nagoya University; Nagoya University; Utsunomiya University	Yoshimura, T (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Div Biomodeling, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.		Yoshimura, Takashi/C-8306-2012; Iigo, Masayuki/I-7110-2013	Yoshimura, Takashi/0000-0001-7018-9652; Iigo, Masayuki/0000-0001-8251-4141				Bernal J, 2002, J ENDOCRINOL INVEST, V25, P268, DOI 10.1007/BF03344003; Chopra I J, 1978, Recent Prog Horm Res, V34, P521; DAVIES DT, 1975, PROC R SOC SER B-BIO, V191, P303, DOI 10.1098/rspb.1975.0130; DAWSON A, 1993, J ENDOCRINOL, V139, P51, DOI 10.1677/joe.0.1390051; Dawson A, 1998, GEN COMP ENDOCR, V110, P196, DOI 10.1006/gcen.1998.7065; Dawson A, 2001, J BIOL RHYTHM, V16, P365, DOI 10.1177/074873001129002079; Dawson A., 2001, P141; FOLLETT BK, 1988, J COMP PHYSIOL B, V157, P829, DOI 10.1007/BF00691015; FOLLETT BK, 1988, J COMP PHYSIOL B, V157, P837, DOI 10.1007/BF00691016; FOLLETT BK, 1969, NATURE, V223, P968, DOI 10.1038/223968b0; FOLLETT BK, 1985, J ENDOCRINOL, V107, P211, DOI 10.1677/joe.0.1070211; FOLLETT BK, 1984, J EXP ZOOL, V232, P573, DOI 10.1002/jez.1402320325; IKUTA K, 1987, GEN COMP ENDOCR, V65, P99, DOI 10.1016/0016-6480(87)90228-0; JUSS TS, 1993, AVIAN ENDOCRINOLOGY, P47; KONISHI H, 1987, J COMP PHYSIOL A, V161, P315, DOI 10.1007/BF00615251; Kuenzel W.J., 1988, STEREOTAXIC ATLAS BR; Leonard JL, 1986, THYROID HORMONE META, P189; MEDDLE SL, 1995, J COMP PHYSIOL A, V176, P79; Meddle SL, 1997, J NEUROSCI, V17, P8909; NICHOLS DH, 1985, CLIN OBSTET GYNECOL, V28, P375, DOI 10.1097/00003081-198528020-00015; OHTA M, 1984, J COMP PHYSIOL, V154, P583, DOI 10.1007/BF00610171; OHTA M, 1987, GEN COMP ENDOCR, V68, P286, DOI 10.1016/0016-6480(87)90040-2; Prendergast BJ, 2002, P NATL ACAD SCI USA, V99, P16291, DOI 10.1073/pnas.232490799; SHARP PJ, 1969, NEUROENDOCRINOLOGY, V5, P205, DOI 10.1159/000121861; SILVER R, 1988, CELL TISSUE RES, V253, P189; TAGAWA M, 1987, GEN COMP ENDOCR, V68, P129, DOI 10.1016/0016-6480(87)90068-2; Yasuo S, 2003, ENDOCRINOLOGY, V144, P3742, DOI 10.1210/en.2003-0435; Yoshimura T, 2000, MOL BRAIN RES, V78, P207, DOI 10.1016/S0169-328X(00)00091-7	28	366	382	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	2003	426	6963					178	181		10.1038/nature02117	http://dx.doi.org/10.1038/nature02117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742LA	14614506				2022-12-28	WOS:000186517200043
